Naloxone	Chemical
reverses	O
the	O
antihypertensive	O
effect	O
of	O
clonidine	Chemical
.	O
In	O
unanesthetized,	O
spontaneously	O
hypertensive	Disease
rats	O
the	O
decrease	O
in	O
blood	O
pressure	O
and	O
heart	O
rate	O
produced	O
by	O
intravenous	O
clonidine	Chemical
,	O
5	O
to	O
20	O
micrograms/kg,	O
was	O
inhibited	O
or	O
reversed	O
by	O
nalozone	Chemical
,	O
0.2	O
to	O
2	O
mg/kg.	O
The	O
hypotensive	Disease
effect	O
of	O
100	O
mg/kg	O
alpha-methyldopa	Chemical
was	O
also	O
partially	O
reversed	O
by	O
naloxone	Chemical
.	O
Naloxone	Chemical
alone	O
did	O
not	O
affect	O
either	O
blood	O
pressure	O
or	O
heart	O
rate.	O
In	O
brain	O
membranes	O
from	O
spontaneously	O
hypertensive	Disease
rats	O
clonidine	Chemical
,	O
10(-8)	O
to	O
10(-5)	O
M,	O
did	O
not	O
influence	O
stereoselective	O
binding	O
of	O
[3H]-naloxone	Chemical
(8	O
nM),	O
and	O
naloxone	Chemical
,	O
10(-8)	O
to	O
10(-4)	O
M,	O
did	O
not	O
influence	O
clonidine	Chemical
-suppressible	O
binding	O
of	O
[3H]-dihydroergocryptine	Chemical
(1	O
nM).	O
These	O
findings	O
indicate	O
that	O
in	O
spontaneously	O
hypertensive	Disease
rats	O
the	O
effects	O
of	O
central	O
alpha-adrenoceptor	O
stimulation	O
involve	O
activation	O
of	O
opiate	O
receptors.	O
As	O
naloxone	Chemical
and	O
clonidine	Chemical
do	O
not	O
appear	O
to	O
interact	O
with	O
the	O
same	O
receptor	O
site,	O
the	O
observed	O
functional	O
antagonism	O
suggests	O
the	O
release	O
of	O
an	O
endogenous	O
opiate	O
by	O
clonidine	Chemical
or	O
alpha-methyldopa	Chemical


Lidocaine	Chemical
-induced	O
cardiac	Disease
asystole	Disease
.	O
Intravenous	O
administration	O
of	O
a	O
single	O
50-mg	O
bolus	O
of	O
lidocaine	Chemical
in	O
a	O
67-year-old	O
man	O
resulted	O
in	O
profound	O
depression	Disease
of	O
the	O
activity	O
of	O
the	O
sinoatrial	O
and	O
atrioventricular	O
nodal	O
pacemakers.	O
The	O
patient	O
had	O
no	O
apparent	O
associated	O
conditions	O
which	O
might	O
have	O
predisposed	O
him	O
to	O
the	O
development	O
of	O
bradyarrhythmias	Disease
;	O
and,	O
thus,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrasy	O
to	O
lidocaine	Chemical

Suxamethonium	Chemical
infusion	O
rate	O
and	O
observed	O
fasciculations	Disease
.	O
A	O
dose-response	O
study.	O
Suxamethonium	Chemical
chloride	Chemical
(	O
Sch	Chemical
)	O
was	O
administered	O
i.v.	O
to	O
36	O
adult	O
males	O
at	O
six	O
rates:	O
0.25	O
mg	O
s-1	O
to	O
20	O
mg	O
s-1.	O
The	O
infusion	O
was	O
discontinued	O
either	O
when	O
there	O
was	O
no	O
muscular	O
response	O
to	O
tetanic	Disease
stimulation	O
of	O
the	O
ulnar	O
nerve	O
or	O
when	O
Sch	Chemical
120	O
mg	O
was	O
exceeded.	O
Six	O
additional	O
patients	O
received	O
a	O
30-mg	O
i.v.	O
bolus	O
dose.	O
Fasciculations	Disease
in	O
six	O
areas	O
of	O
the	O
body	O
were	O
scored	O
from	O
0	O
to	O
3	O
and	O
summated	O
as	O
a	O
total	O
fasciculation	Disease
score.	O
The	O
times	O
to	O
first	O
fasciculation	Disease
,	O
twitch	Disease
suppression	O
and	O
tetanus	Disease
suppression	O
were	O
inversely	O
related	O
to	O
the	O
infusion	O
rates.	O
Fasciculations	Disease
in	O
the	O
six	O
areas	O
and	O
the	O
total	O
fasciculation	Disease
score	O
were	O
related	O
directly	O
to	O
the	O
rate	O
of	O
infusion.	O
Total	O
fasciculation	Disease

Galanthamine	Chemical
hydrobromide	Chemical
,	O
a	O
longer	O
acting	O
anticholinesterase	O
drug,	O
in	O
the	O
treatment	O
of	O
the	O
central	O
effects	O
of	O
scopolamine	Chemical
(	O
Hyoscine	Chemical
).	O
Galanthamine	Chemical
hydrobromide	Chemical
,	O
an	O
anticholinesterase	O
drug	O
capable	O
of	O
penetrating	O
the	O
blood-brain	O
barrier,	O
was	O
used	O
in	O
a	O
patient	O
demonstrating	O
central	O
effects	O
of	O
scopolamine	Chemical
(	O
hyoscine	Chemical
)	O
overdosage	Disease
.	O
It	O
is	O
longer	O
acting	O
than	O
physostigmine	Chemical
and	O
is	O
used	O
in	O
anaesthesia	O
to	O
reverse	O
the	O
non-depolarizing	O
neuromuscular	O
block.	O
However,	O
studies	O
into	O
the	O
dose	O
necessary	O
to	O
combating	O
scopolamine	Chemical

Effects	O
of	O
uninephrectomy	O
and	O
high	O
protein	O
feeding	O
on	O
lithium	Chemical
-induced	O
chronic	Disease
renal	Disease
failure	Disease
in	O
rats.	O
Rats	O
with	O
lithium	Chemical
-induced	O
nephropathy	Disease
were	O
subjected	O
to	O
high	O
protein	O
(HP)	O
feeding,	O
uninephrectomy	O
(NX)	O
or	O
a	O
combination	O
of	O
these,	O
in	O
an	O
attempt	O
to	O
induce	O
glomerular	O
hyperfiltration	O
and	O
further	O
progression	O
of	O
renal	Disease
failure	Disease
.	O
Newborn	O
female	O
Wistar	O
rats	O
were	O
fed	O
a	O
lithium	Chemical
-containing	O
diet	O
(50	O
mmol/kg)	O
for	O
8	O
weeks	O
and	O
then	O
randomized	O
to	O
normal	O
diet,	O
HP	O
diet	O
(40	O
vs.	O
19%),	O
NX	O
or	O
HP+NX	O
for	O
another	O
8	O
weeks.	O
Corresponding	O
non-	O
lithium	Chemical
pretreated	O
groups	O
were	O
generated.	O
When	O
comparing	O
all	O
lithium	Chemical
treated	O
versus	O
non-	O
lithium	Chemical
-treated	O
groups,	O
lithium	Chemical
caused	O
a	O
reduction	O
in	O
glomerular	O
filtration	O
rate	O
(GFR)	O
without	O
significant	O
changes	O
in	O
effective	O
renal	O
plasma	O
flow	O
(as	O
determined	O
by	O
a	O
marker	O
secreted	O
into	O
the	O
proximal	O
tubules)	O
or	O
lithium	Chemical
clearance.	O
Consequently,	O
lithium	Chemical
pretreatment	O
caused	O
a	O
fall	O
in	O
filtration	O
fraction	O
and	O
an	O
increase	O
in	O
fractional	O
Li	Chemical
excretion.	O
Lithium	Chemical
also	O
caused	O
proteinuria	Disease
and	O
systolic	O
hypertension	Disease
in	O
absence	O
of	O
glomerulosclerosis	Disease
.	O
HP	O
failed	O
to	O
accentuante	O
progression	O
of	O
renal	Disease
failure	Disease
and	O
in	O
fact	O
tended	O
to	O
increase	O
GFR	O
and	O
decrease	O
plasma	O
creatinine	Chemical
levels	O
in	O
lithium	Chemical
pretreated	O
rats.	O
NX	O
caused	O
an	O
additive	O
deterioration	O
in	O
GFR	O
which,	O
however,	O
was	O
ameliorated	O
by	O
HP.	O
NX+HP	O
caused	O
a	O
further	O
rise	O
in	O
blood	O
pressure	O
in	O
Li	Chemical
-pretreated	O
rats.	O
The	O
results	O
indicate	O
that	O
Li	Chemical
-induced	O
nephropathy	Disease
,	O
even	O
when	O
the	O
GFR	O
is	O
only	O
modestly	O
reduced,	O
is	O
associated	O
with	O
proteinuria	Disease
and	O
arterial	O
systolic	O
hypertension	Disease
.	O
In	O
this	O
model	O
of	O
chronic	Disease
renal	Disease
failure	Disease

Treatment	O
of	O
Crohn's	Disease
disease	Disease
with	O
fusidic	Chemical
acid	Chemical
:	O
an	O
antibiotic	O
with	O
immunosuppressive	O
properties	O
similar	O
to	O
cyclosporin	Chemical
.	O
Fusidic	O
acid	O
is	O
an	O
antibiotic	O
with	O
T-cell	O
specific	O
immunosuppressive	O
effects	O
similar	O
to	O
those	O
of	O
cyclosporin	Chemical
.	O
Because	O
of	O
the	O
need	O
for	O
the	O
development	O
of	O
new	O
treatments	O
for	O
Crohn's	Disease
disease	Disease
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	O
and	O
tolerability	O
of	O
fusidic	Chemical
acid	Chemical
treatment	O
in	O
chronic	O
active,	O
therapy-resistant	O
patients.	O
Eight	O
Crohn's	Disease
disease	Disease
patients	O
were	O
included.	O
Fusidic	Chemical
acid	Chemical
was	O
administered	O
orally	O
in	O
a	O
dose	O
of	O
500	O
mg	O
t.d.s.	O
and	O
the	O
treatment	O
was	O
planned	O
to	O
last	O
8	O
weeks.	O
The	O
disease	O
activity	O
was	O
primarily	O
measured	O
by	O
a	O
modified	O
individual	O
grading	O
score.	O
Five	O
of	O
8	O
patients	O
(63%)	O
improved	O
during	O
fusidic	Chemical
acid	Chemical
treatment:	O
3	O
at	O
two	O
weeks	O
and	O
2	O
after	O
four	O
weeks.	O
There	O
were	O
no	O
serious	O
clinical	O
side	O
effects,	O
but	O
dose	O
reduction	O
was	O
required	O
in	O
two	O
patients	O
because	O
of	O
nausea	Disease
.	O
Biochemically,	O
an	O
increase	O
in	O
alkaline	O
phosphatases	O
was	O
noted	O
in	O
5	O
of	O
8	O
cases	O
(63%),	O
and	O
the	O
greatest	O
increases	O
were	O
seen	O
in	O
those	O
who	O
had	O
elevated	O
levels	O
prior	O
to	O
treatment.	O
All	O
reversed	O
to	O
pre-treatment	O
levels	O
after	O
cessation	O
of	O
treatment.	O
The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	O
that	O
fusidic	Chemical
acid	Chemical
may	O
be	O
of	O
benefit	O
in	O
selected	O
chronic	O
active	O
Crohn's	Disease
disease	Disease
patients	O
in	O
whom	O
conventional	O
treatment	O
is	O
ineffective.	O
Because	O
there	O
seems	O
to	O
exist	O
a	O
scientific	O
rationale	O
for	O
the	O
use	O
of	O
fusidic	Chemical
acid	Chemical
at	O
the	O
cytokine	O
level	O
in	O
inflammatory	Disease
bowel	Disease
disease	Disease

Electrocardiographic	O
evidence	O
of	O
myocardial	Disease
injury	Disease
in	O
psychiatrically	O
hospitalized	O
cocaine	Chemical
abusers.	O
The	O
electrocardiograms	O
(ECG)	O
of	O
99	O
cocaine	Chemical
-abusing	O
patients	O
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	Disease
controls.	O
Eleven	O
of	O
the	O
cocaine	Chemical
abusers	O
and	O
none	O
of	O
the	O
controls	O
had	O
ECG	O
evidence	O
of	O
significant	O
myocardial	Disease
injury	Disease
defined	O
as	O
myocardial	Disease
infarction	Disease
,	O
ischemia	Disease
,	O
and	O
bundle	Disease
branch	Disease
block	Disease

Sulpiride	Chemical
-induced	O
tardive	Disease
dystonia	Disease
.	O
Sulpiride	Chemical
is	O
a	O
selective	O
D2-receptor	O
antagonist	O
with	O
antipsychotic	O
and	O
antidepressant	Chemical
properties.	O
Although	O
initially	O
thought	O
to	O
be	O
free	O
of	O
extrapyramidal	O
side	O
effects,	O
sulpiride	Chemical
-induced	O
tardive	Disease
dyskinesia	Disease
and	O
parkinsonism	Disease
have	O
been	O
reported	O
occasionally.	O
We	O
studied	O
a	O
37-year-old	O
man	O
who	O
developed	O
persistent	O
segmental	O
dystonia	Disease
within	O
2	O
months	O
after	O
starting	O
sulpiride	Chemical
therapy.	O
We	O
could	O
not	O
find	O
any	O
previous	O
reports	O
of	O
sulpiride	Chemical
-induced	O
tardive	Disease
dystonia	Disease

Ocular	Disease
and	Disease
auditory	Disease
toxicity	Disease
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	Chemical
.	O
During	O
an	O
18-month	O
period	O
of	O
study	O
41	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	Chemical
(10-40	O
mg/kg	O
BW/3	O
times	O
weekly)	O
for	O
the	O
first	O
time	O
were	O
monitored	O
for	O
detection	O
of	O
audiovisual	Disease
toxicity	Disease
.	O
6	O
patients	O
presented	O
clinical	O
symptoms	O
of	O
visual	Disease
or	Disease
auditory	Disease
toxicity	Disease
.	O
Moreover,	O
detailed	O
ophthalmologic	O
and	O
audiologic	O
studies	O
disclosed	O
abnormalities	O
in	O
7	O
more	O
asymptomatic	O
patients.	O
Visual	Disease
toxicity	Disease
was	O
of	O
retinal	O
origin	O
and	O
was	O
characterized	O
by	O
a	O
tritan-type	O
dyschromatopsy	Disease
,	O
sometimes	O
associated	O
with	O
a	Disease
loss	Disease
of	Disease
visual	Disease
acuity	Disease
and	O
pigmentary	Disease
retinal	Disease
deposits	Disease
.	O
Auditory	Disease
toxicity	Disease
was	O
characterized	O
by	O
a	O
mid-	O
to	O
high-frequency	O
neurosensorial	Disease
hearing	Disease
loss	Disease
and	O
the	O
lesion	O
was	O
of	O
the	O
cochlear	O
type.	O
Desferrioxamine	Chemical
withdrawal	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
visual	O
function	O
in	O
1	O
patient	O
and	O
partial	O
recovery	O
in	O
3,	O
and	O
a	O
complete	O
reversal	O
of	O
hearing	Disease
loss	Disease
in	O
3	O
patients	O
and	O
partial	O
recovery	O
in	O
3.	O
This	O
toxicity	Disease
appeared	O
in	O
patients	O
receiving	O
the	O
higher	O
doses	O
of	O
desferrioxamine	Chemical
or	O
coincided	O
with	O
the	O
normalization	O
of	O
ferritin	O
or	O
aluminium	Chemical
serum	O
levels.	O
The	O
data	O
indicate	O
that	O
audiovisual	Disease
toxicity	Disease
is	O
not	O
an	O
infrequent	O
complication	O
in	O
hemodialyzed	O
patients	O
receiving	O
desferrioxamine	Chemical

Myasthenia	Disease
gravis	Disease
presenting	O
as	O
weakness	O
after	O
magnesium	Chemical
administration.	O
We	O
studied	O
a	O
patient	O
with	O
no	O
prior	O
history	O
of	O
neuromuscular	Disease
disease	Disease
who	O
became	O
virtually	O
quadriplegic	Disease
after	O
parenteral	O
magnesium	Chemical
administration	O
for	O
preeclampsia	Disease
.	O
The	O
serum	O
magnesium	Chemical
concentration	O
was	O
3.0	O
mEq/L,	O
which	O
is	O
usually	O
well	O
tolerated.	O
The	O
magnesium	Chemical
was	O
stopped	O
and	O
she	O
recovered	O
over	O
a	O
few	O
days.	O
While	O
she	O
was	O
weak,	O
2-Hz	O
repetitive	O
stimulation	O
revealed	O
a	O
decrement	O
without	O
significant	O
facilitation	O
at	O
rapid	O
rates	O
or	O
after	O
exercise,	O
suggesting	O
postsynaptic	Disease
neuromuscular	Disease
blockade	Disease
.	O
After	O
her	O
strength	O
returned,	O
repetitive	O
stimulation	O
was	O
normal,	O
but	O
single	O
fiber	O
EMG	O
revealed	O
increased	O
jitter	O
and	O
blocking.	O
Her	O
acetylcholine	Chemical
receptor	O
antibody	O
level	O
was	O
markedly	O
elevated.	O
Although	O
paralysis	Disease
after	O
magnesium	Chemical
administration	O
has	O
been	O
described	O
in	O
patients	O
with	O
known	O
myasthenia	Disease
gravis	Disease
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
the	O
initial	O
or	O
only	O
manifestation	O
of	O
the	O
disease.	O
Patients	O
who	O
are	O
unusually	O
sensitive	O
to	O
the	O
neuromuscular	O
effects	O
of	O
magnesium	Chemical
should	O
be	O
suspected	O
of	O
having	O
an	O
underlying	O
disorder	Disease
of	Disease
neuromuscular	Disease
transmission	Disease

Chloroacetaldehyde	Chemical
and	O
its	O
contribution	O
to	O
urotoxicity	O
during	O
treatment	O
with	O
cyclophosphamide	Chemical
or	O
ifosfamide	Chemical
.	O
An	O
experimental	O
study/short	O
communication.	O
Based	O
on	O
clinical	O
data,	O
indicating	O
that	O
chloroacetaldehyde	Chemical
(	O
CAA	Chemical
)	O
is	O
an	O
important	O
metabolite	O
of	O
oxazaphosphorine	O
cytostatics,	O
an	O
experimental	O
study	O
was	O
carried	O
out	O
in	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
CAA	Chemical
in	O
the	O
development	O
of	O
hemorrhagic	Disease
cystitis	Disease
.	O
The	O
data	O
demonstrate	O
that	O
CAA	Chemical
after	O
i.v.	O
administration	O
does	O
not	O
contribute	O
to	O
bladder	Disease
damage	Disease
.	O
When	O
instilled	O
directly	O
into	O
the	O
bladder,	O
CAA	Chemical
exerts	O
urotoxic	O
effects,	O
it	O
is,	O
however,	O
susceptible	O
to	O
detoxification	O
with	O
mesna	Chemical

Source	O
of	O
pain	Disease
and	O
primitive	O
dysfunction	O
in	O
migraine	Disease
:	O
an	O
identical	O
site?	O
Twenty	O
common	O
migraine	Disease
patients	O
received	O
a	O
one	O
sided	O
frontotemporal	O
application	O
of	O
nitroglycerin	Chemical
(10	O
patients)	O
or	O
placebo	O
ointment	O
(10	O
patients)	O
in	O
a	O
double	O
blind	O
study.	O
Early	O
onset	O
migraine	Disease
attacks	O
were	O
induced	O
by	O
nitroglycerin	Chemical
in	O
seven	O
out	O
of	O
10	O
patients	O
versus	O
no	O
patient	O
in	O
the	O
placebo	O
group.	O
Subsequently	O
20	O
migraine	Disease
patients,	O
who	O
developed	O
an	O
early	O
onset	O
attack	O
with	O
frontotemporal	O
nitroglycerin	Chemical
,	O
received	O
the	O
drug	O
in	O
a	O
second	O
induction	O
test	O
at	O
other	O
body	O
areas.	O
No	O
early	O
onset	O
migraine	Disease
was	O
observed.	O
Thus	O
the	O
migraine	Disease
-inducing	O
effect	O
of	O
nitroglycerin	Chemical
seems	O
to	O
depend	O
on	O
direct	O
stimulation	O
of	O
the	O
habitual	O
site	O
of	O
pain	Disease
,	O
suggesting	O
that	O
the	O
frontotemporal	O
region	O
is	O
of	O
crucial	O
importance	O
in	O
the	O
development	O
of	O
a	O
migraine	Disease
crisis.	O
This	O
is	O
not	O
consistent	O
with	O
a	O
CNS	O
origin	O
of	O
migraine	Disease

Clotiazepam	Chemical
-induced	O
acute	O
hepatitis	Disease
.	O
We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
acute	O
hepatitis	Disease
with	O
extensive	Disease
hepatocellular	Disease
necrosis	Disease
,	O
7	O
months	O
after	O
the	O
onset	O
of	O
administration	O
of	O
clotiazepam	Chemical
,	O
a	O
thienodiazepine	Chemical
derivative.	O
Clotiazepam	Chemical
withdrawal	O
was	O
followed	O
by	O
prompt	O
recovery.	O
The	O
administration	O
of	O
several	O
benzodiazepines	Chemical
,	O
chemically	O
related	O
to	O
clotiazepam	Chemical
,	O
did	O
not	O
interfere	O
with	O
recovery	O
and	O
did	O
not	O
induce	O
any	O
relapse	O
of	O
hepatitis	Disease
.	O
This	O
observation	O
shows	O
that	O
clotiazepam	Chemical
can	O
induce	O
acute	O
hepatitis	Disease
and	O
suggests	O
that	O
there	O
is	O
no	O
cross	O
hepatotoxicity	Disease
between	O
clotiazepam	Chemical
and	O
several	O
benzodiazepines	Chemical

Arterial	O
hypertension	Disease
as	O
a	O
complication	O
of	O
prolonged	O
ketoconazole	Chemical
treatment.	O
Two	O
of	O
14	O
patients	O
with	O
Cushing's	Disease
syndrome	Disease
treated	O
on	O
a	O
long-term	O
basis	O
with	O
ketoconazole	Chemical
developed	O
sustained	O
hypertension	Disease
.	O
In	O
both	O
cases	O
normal	O
plasma	O
and	O
urinary	O
free	O
cortisol	Chemical
levels	O
had	O
been	O
achieved	O
following	O
ketoconazole	Chemical
therapy,	O
yet	O
continuous	O
blood	O
pressure	O
monitoring	O
demonstrated	O
hypertension	Disease
31	O
(patient	O
1)	O
and	O
52	O
weeks	O
(patient	O
2)	O
after	O
treatment.	O
In	O
patient	O
1,	O
plasma	O
levels	O
of	O
deoxycorticosterone	Chemical
and	O
11-deoxycortisol	Chemical
were	O
elevated.	O
In	O
patient	O
2,	O
in	O
addition	O
to	O
an	O
increase	O
in	O
both	O
deoxycorticosterone	Chemical
and	O
11-deoxycortisol	Chemical
levels,	O
plasma	O
aldosterone	Chemical
values	O
were	O
raised,	O
with	O
a	O
concomitant	O
suppression	O
of	O
renin	O
levels.	O
Our	O
findings	O
show	O
that	O
long-term	O
treatment	O
with	O
high	O
doses	O
of	O
ketoconazole	Chemical
may	O
induce	O
enzyme	O
blockade	O
leading	O
to	O
mineralocorticoid-related	O
hypertension	Disease

Effects	O
of	O
an	O
inhibitor	O
of	O
angiotensin	Chemical
converting	O
enzyme	O
(	O
Captopril	Chemical
)	O
on	O
pulmonary	Disease
and	Disease
renal	Disease
insufficiency	Disease
due	O
to	O
intravascular	Disease
coagulation	Disease
in	O
the	O
rat.	O
Induction	O
of	O
intravascular	Disease
coagulation	Disease
and	O
inhibition	O
of	O
fibrinolysis	O
by	O
injection	O
of	O
thrombin	O
and	O
tranexamic	Chemical
acid	Chemical
(	O
AMCA	Chemical
)	O
in	O
the	O
rat	O
gives	O
rise	O
to	O
pulmonary	Disease
and	Disease
renal	Disease
insufficiency	Disease
resembling	O
that	O
occurring	O
after	O
trauma	Disease
or	O
sepsis	Disease
in	O
man.	O
Injection	O
of	O
Captopril	Chemical
(1	O
mg/kg),	O
an	O
inhibitor	O
of	O
angiotensin	Chemical
converting	O
enzyme	O
(ACE),	O
reduced	O
both	O
pulmonary	Disease
and	Disease
renal	Disease
insufficiency	Disease
in	O
this	O
rat	O
model.	O
The	O
lung	O
weights	O
were	O
lower	O
and	O
PaO2	O
was	O
improved	O
in	O
rats	O
given	O
this	O
enzyme-blocking	O
agent.	O
The	O
contents	O
of	O
albumin	O
in	O
the	O
lungs	O
were	O
not	O
changed,	O
indicating	O
that	O
Captopril	Chemical
did	O
not	O
influence	O
the	O
extravasation	O
of	O
protein.	O
Renal	Disease
damage	Disease
as	O
reflected	O
by	O
an	O
increase	O
in	O
serum	O
urea	Chemical
and	O
in	O
kidney	O
weight	O
was	O
prevented	O
by	O
Captopril	Chemical
.	O
The	O
amount	O
of	O
fibrin	O
in	O
the	O
kidneys	O
was	O
also	O
considerably	O
lower	O
than	O
in	O
animals	O
which	O
received	O
thrombin	O
and	O
AMCA	Chemical
alone.	O
It	O
is	O
suggested	O
that	O
the	O
effects	O
of	O
Captopril	Chemical
on	O
the	O
lungs	O
may	O
be	O
attributable	O
to	O
a	O
vasodilatory	O
effect	O
due	O
to	O
a	O
reduction	O
in	O
the	O
circulating	O
level	O
of	O
Angiotension	Chemical
II	Chemical
and	O
an	O
increase	O
in	O
prostacyclin	Chemical
(secondary	O
to	O
an	O
increase	O
in	O
bradykinin	Chemical
).	O
Captopril	Chemical
may,	O
by	O
the	O
same	O
mechanism,	O
reduce	O
the	O
increase	O
in	O
glomerular	O
filtration	O
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
injection	O
of	O
thrombin,	O
thereby	O
diminishing	O
the	O
aggregation	O
of	O
fibrin	O
monomers	O
in	O
the	O
glomeruli,	O
with	O
the	O
result	O
that	O
less	O
fibrin	O
will	O
be	O
deposited	O
and	O
thus	O
less	O
kidney	Disease
damage	Disease

A	O
randomized	O
comparison	O
of	O
labetalol	Chemical
and	O
nitroprusside	Chemical
for	O
induced	O
hypotension	Disease
.	O
In	O
a	O
randomized	O
study,	O
labetalol	Chemical
-induced	O
hypotension	Disease
and	O
nitroprusside	Chemical
-induced	O
hypotension	Disease
were	O
compared	O
in	O
20	O
patients	O
(10	O
in	O
each	O
group)	O
scheduled	O
for	O
major	O
orthopedic	O
procedures.	O
Each	O
patient	O
was	O
subjected	O
to	O
an	O
identical	O
anesthetic	O
protocol	O
and	O
similar	O
drug-induced	O
reductions	Disease
in	Disease
mean	Disease
arterial	Disease
blood	Disease
pressure	Disease
(BP)	O
(50	O
to	O
55	O
mmHg).	O
Nitroprusside	O
infusion	O
was	O
associated	O
with	O
a	O
significant	O
(p	O
less	O
than	O
0.05)	O
increase	Disease
in	Disease
heart	Disease
rate	Disease
and	Disease
cardiac	Disease
output	Disease
;	O
rebound	O
hypertension	Disease
was	O
observed	O
in	O
three	O
patients	O
after	O
discontinuation	O
of	O
nitroprusside	Chemical
.	O
Labetalol	Chemical
administration	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
findings.	O
Arterial	O
PO2	Chemical
decreased	O
in	O
both	O
groups.	O
It	O
was	O
concluded	O
that	O
labetalol	Chemical
offers	O
advantages	O
over	O
nitroprusside	Chemical

Chronic	O
carbamazepine	Chemical
treatment	O
in	O
the	O
rat:	O
efficacy,	O
toxicity	Disease
,	O
and	O
effect	O
on	O
plasma	O
and	O
tissue	O
folate	Chemical
concentrations.	O
Folate	Chemical
depletion	O
has	O
often	O
been	O
a	O
problem	O
in	O
chronic	O
antiepileptic	O
drug	O
(AED)	O
therapy.	O
Carbamazepine	Chemical
(	O
CBZ	Chemical
),	O
a	O
commonly	O
used	O
AED,	O
has	O
been	O
implicated	O
in	O
some	O
clinical	O
studies.	O
A	O
rat	O
model	O
was	O
developed	O
to	O
examine	O
the	O
effects	O
of	O
chronic	O
CBZ	Chemical
treatment	O
on	O
folate	Chemical
concentrations	O
in	O
the	O
rat.	O
In	O
the	O
course	O
of	O
developing	O
this	O
model,	O
a	O
common	O
vehicle,	O
propylene	Chemical
glycol	Chemical
,	O
by	O
itself	O
in	O
high	O
doses,	O
was	O
found	O
to	O
exhibit	O
protective	O
properties	O
against	O
induced	O
seizures	Disease
and	O
inhibited	O
weight	Disease
gain	Disease
.	O
Seizures	Disease
induced	O
by	O
hexafluorodiethyl	Chemical
ether	Chemical
(	O
HFDE	Chemical
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitive	O
measure	O
of	O
protection	O
by	O
CBZ	Chemical
than	O
seizures	Disease
induced	O
by	O
maximal	O
electroshock	O
(MES).	O
Oral	O
administration	O
of	O
CBZ	Chemical
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	O
of	O
250	O
mg/kg	O
was	O
continuously	O
protective	O
against	O
HFDE	Chemical
-induced	O
seizures	Disease
and	O
was	O
minimally	O
toxic	O
as	O
measured	O
by	O
weight	Disease
gain	Disease
over	O
8	O
weeks	O
of	O
treatment.	O
The	O
CBZ	Chemical
levels	O
measured	O
in	O
plasma	O
and	O
brain	O
of	O
these	O
animals,	O
however,	O
were	O
below	O
those	O
normally	O
considered	O
protective.	O
This	O
treatment	O
with	O
CBZ	Chemical
had	O
no	O
apparent	O
adverse	O
effect	O
on	O
folate	Chemical
concentrations	O
in	O
the	O
rat,	O
and,	O
indeed,	O
the	O
folate	Chemical

Inhibition	O
of	O
sympathoadrenal	O
activity	O
by	O
atrial	O
natriuretic	O
factor	O
in	O
dogs.	O
In	O
six	O
conscious,	O
trained	O
dogs,	O
maintained	O
on	O
a	O
normal	O
sodium	Chemical
intake	O
of	O
2	O
to	O
4	O
mEq/kg/day,	O
sympathetic	O
activity	O
was	O
assessed	O
as	O
the	O
release	O
rate	O
of	O
norepinephrine	Chemical
and	O
epinephrine	Chemical
during	O
15-minute	O
i.v.	O
infusions	O
of	O
human	O
alpha-atrial	O
natriuretic	O
factor.	O
Mean	O
arterial	O
pressure	O
(as	O
a	O
percentage	O
of	O
control	O
+/-	O
SEM)	O
during	O
randomized	O
infusions	O
of	O
0.03,	O
0.1,	O
0.3,	O
or	O
1.0	O
microgram/kg/min	O
was	O
99	O
+/-	O
1,	O
95	O
+/-	O
1	O
(p	O
less	O
than	O
0.05),	O
93	O
+/-	O
1	O
(p	O
less	O
than	O
0.01),	O
or	O
79	O
+/-	O
6%	O
(p	O
less	O
than	O
0.001),	O
respectively,	O
but	O
no	O
tachycardia	Disease
and	O
no	O
augmentation	O
of	O
the	O
norepinephrine	Chemical
release	O
rate	O
(up	O
to	O
0.3	O
microgram/kg/min)	O
were	O
observed,	O
which	O
is	O
in	O
contrast	O
to	O
comparable	O
hypotension	Disease
induced	O
by	O
hydralazine	Chemical
or	O
nitroglycerin	Chemical
.	O
The	O
release	O
rate	O
of	O
epinephrine	Chemical

Death	Disease
from	O
chemotherapy	O
in	O
gestational	Disease
trophoblastic	Disease
disease	Disease
.	O
Multiple	O
cytotoxic	O
drug	O
administration	O
is	O
the	O
generally	O
accepted	O
treatment	O
of	O
patients	O
with	O
a	O
high-risk	O
stage	O
of	O
choriocarcinoma	Disease
.	O
Based	O
on	O
this	O
principle	O
a	O
27-year	O
old	O
woman,	O
classified	O
as	O
being	O
in	O
the	O
high-risk	O
group	O
(Goldstein	O
and	O
Berkowitz	O
score:	O
11),	O
was	O
treated	O
with	O
multiple	O
cytotoxic	O
drugs.	O
The	O
multiple	O
drug	O
schema	O
consisted	O
of:	O
Etoposide	Chemical
16.213,	O
Methotrexate	Chemical
,	O
Cyclophosphamide	Chemical
,	O
Actomycin-D	Chemical
,	O
and	O
Cisplatin	Chemical
.	O
On	O
the	O
first	O
day	O
of	O
the	O
schedule,	O
moderate	O
high	O
doses	O
of	O
Methotrexate	Chemical
,	O
Etoposide	Chemical
and	O
Cyclophosphamide	Chemical
were	O
administered.	O
Within	O
8	O
hours	O
after	O
initiation	O
of	O
therapy	O
the	O
patient	O
died	O
with	O
a	O
clinical	O
picture	O
resembling	O
massive	O
pulmonary	Disease
obstruction	Disease
due	O
to	O
choriocarcinomic	O
tissue	O
plugs,	O
probably	O
originating	O
from	O
the	O
uterus.	O
Formation	O
of	O
these	O
plugs	O
was	O
probably	O
due	O
to	O
extensive	O
tumor	Disease
	O
necrosis	Disease
at	O
the	O
level	O
of	O
the	O
walls	O
of	O
the	O
major	O
uterine	O
veins,	O
which	O
resulted	O
in	O
an	O
open	O
exchange	O
of	O
tumor	Disease
plugs	O
to	O
the	O
vascular	O
spaces;	O
decrease	O
in	O
tumor	Disease
tissue	O
coherence	O
secondary	O
to	O
chemotherapy	O
may	O
have	O
further	O
contributed	O
to	O
the	O
formation	O
of	O
tumor	Disease
emboli.	O
In	O
view	O
of	O
the	O
close	O
time	O
association	O
between	O
the	O
start	O
of	O
chemotherapy	O
and	O
the	O
acute	O
onset	O
of	O
massive	O
embolism	Disease
other	O
explanations,	O
such	O
as	O
spontaneous	O
necrosis	Disease
,	O
must	O
be	O
considered	O
less	O
likely.	O
Patients	O
with	O
large	O
pelvic	Disease
tumor	Disease

Sexual	Disease
dysfunction	Disease
among	O
patients	O
with	O
arthritis	Disease
.	O
The	O
relationship	O
of	O
arthritis	Disease
and	O
sexual	Disease
dysfunction	Disease
was	O
investigated	O
among	O
169	O
patients	O
with	O
rheumatoid	Disease
arthritis	Disease
,	O
osteoarthritis	Disease
and	O
spondyloarthropathy	Disease
,	O
130	O
of	O
whom	O
were	O
pair-matched	O
to	O
controls.	O
Assessments	O
of	O
marital	O
happiness	O
and	O
depressed	Disease
mood	Disease
were	O
also	O
made	O
using	O
the	O
CES-D	O
and	O
the	O
Azrin	O
Marital	O
Happiness	O
Scale	O
(AMHS).	O
Sexual	Disease
dysfunctions	Disease
were	O
found	O
to	O
be	O
common	O
among	O
patients	O
and	O
controls,	O
the	O
majority	O
in	O
both	O
groups	O
reporting	O
one	O
or	O
more	O
dysfunctions.	O
Impotence	Disease
was	O
more	O
common	O
among	O
male	O
patients	O
than	O
controls	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co-morbidity	O
and	O
the	O
taking	O
of	O
methotrexate	Chemical
.	O
Depressed	Disease
mood	Disease
was	O
more	O
common	O
among	O
patients	O
and	O
was	O
associated	O
with	O
certain	O
sexual	O
difficulties,	O
but	O
not	O
with	O
impotence	Disease
.	O
Marital	O
unhappiness,	O
as	O
indicated	O
by	O
AMHS	O
scores,	O
was	O
not	O
associated	O
with	O
arthritis	Disease
but	O
was	O
associated	O
with	O
sexual	Disease
dysfunction	Disease

Does	O
paracetamol	Chemical
cause	O
urothelial	Disease
cancer	Disease
or	O
renal	Disease
papillary	Disease
necrosis	Disease
?	O
The	O
risk	O
of	O
developing	O
renal	Disease
papillary	Disease
necrosis	Disease
or	O
cancer	Disease
of	Disease
the	Disease
renal	Disease
pelvis,	Disease
ureter	Disease
or	Disease
bladder	Disease
associated	O
with	O
consumption	O
of	O
either	O
phenacetin	Chemical
or	O
paracetamol	Chemical
was	O
calculated	O
from	O
data	O
acquired	O
by	O
questionnaire	O
from	O
381	O
cases	O
and	O
808	O
controls.	O
The	O
risk	O
of	O
renal	Disease
papillary	Disease
necrosis	Disease
was	O
increased	O
nearly	O
20-fold	O
by	O
consumption	O
of	O
phenacetin	Chemical
,	O
which	O
also	O
increased	O
the	O
risk	O
for	O
cancer	Disease
of	Disease
the	Disease
renal	Disease
pelvis	Disease
and	Disease
bladder	Disease
but	O
not	O
for	O
ureteric	Disease
cancer	Disease
.	O
By	O
contrast,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
increased	O
risk	O
from	O
paracetamol	Chemical
consumption	O
for	O
renal	Disease
papillary	Disease
necrosis	Disease
or	O
any	O
of	O
these	O
cancers	Disease
although	O
there	O
was	O
a	O
suggestion	O
of	O
an	O
association	O
with	O
cancer	Disease
of	Disease
the	Disease
ureter	Disease

Dapsone	Chemical
-associated	O
Heinz	O
body	O
hemolytic	Disease
anemia	Disease
in	O
a	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait.	O
A	O
Cambodian	O
woman	O
with	O
hemoglobin	O
E	O
trait	O
(AE)	O
and	O
leprosy	Disease
developed	O
a	O
Heinz	O
body	O
hemolytic	Disease
anemia	Disease
while	O
taking	O
a	O
dose	O
of	O
dapsone	Chemical
(50	O
mg/day)	O
not	O
usually	O
associated	O
with	O
clinical	O
hemolysis	Disease
.	O
Her	O
red	O
blood	O
cells	O
(RBCs)	O
had	O
increased	O
incubated	O
Heinz	O
body	O
formation,	O
decreased	O
reduced	O
glutathione	Chemical
(	O
GSH	Chemical
),	O
and	O
decreased	O
GSH	Chemical
stability.	O
The	O
pentose	Chemical
phosphate	Chemical
shunt	O
activity	O
of	O
the	O
dapsone	Chemical
-exposed	O
AE	O
RBCs	O
was	O
increased	O
compared	O
to	O
normal	O
RBCs.	O
Although	O
the	O
AE	O
RBCs	O
from	O
an	O
individual	O
not	O
taking	O
dapsone	Chemical
had	O
increased	O
incubated	O
Heinz	O
body	O
formation,	O
the	O
GSH	Chemical
content	O
and	O
GSH	Chemical
stability	O
were	O
normal.	O
The	O
pentose	Chemical
phosphate	Chemical
shunt	O
activity	O
of	O
the	O
non-	O
dapsone	Chemical
-exposed	O
AE	O
RBCs	O
was	O
decreased	O
compared	O
to	O
normal	O
RBCs.	O
Thus,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
increased	O
sensitivity	O
to	O
oxidant	O
stress	O
both	O
in	O
vitro	O
and	O
in	O
vivo,	O
since	O
dapsone	Chemical
does	O
not	O
cause	O
hemolytic	Disease
anemia	Disease
at	O
this	O
dose	O
in	O
hematologically	O
normal	O
individuals.	O
Given	O
the	O
influx	O
of	O
Southeast	O
Asians	O
into	O
the	O
United	O
States,	O
oxidant	O
medications	O
should	O
be	O
used	O
with	O
caution,	O
especially	O
if	O
an	O
infection	Disease

Severe	O
complications	O
of	O
antianginal	O
drug	O
therapy	O
in	O
a	O
patient	O
identified	O
as	O
a	O
poor	O
metabolizer	O
of	O
metoprolol	Chemical
,	O
propafenone	Chemical
,	O
diltiazem	Chemical
,	O
and	O
sparteine	Chemical
.	O
A	O
47-year-old	O
patient	O
suffering	O
from	O
coronary	Disease
artery	Disease
disease	Disease
was	O
admitted	O
to	O
the	O
CCU	O
in	O
shock	Disease
with	O
III.	O
AV	Disease
block	Disease
,	O
severe	O
hypotension	Disease
,	O
and	O
impairment	Disease
of	Disease
ventricular	Disease
function	Disease
.	O
One	O
week	O
prior	O
to	O
admission	O
a	O
therapy	O
with	O
standard	O
doses	O
of	O
metoprolol	Chemical
(100	O
mg	O
t.i.d.	O
and	O
then	O
100	O
mg	O
b.i.d.)	O
had	O
been	O
initiated.	O
Two	O
days	O
before	O
admission	O
diltiazem	Chemical
(60	O
mg	O
b.i.d.)	O
was	O
prescribed	O
in	O
addition.	O
Analyses	O
of	O
a	O
blood	O
sample	O
revealed	O
unusually	O
high	O
plasma	O
concentrations	O
of	O
metoprolol	Chemical
(greater	O
than	O
3000	O
ng/ml)	O
and	O
diltiazem	Chemical
(526	O
ng/ml).	O
The	O
patient	O
recovered	O
within	O
1	O
week	O
following	O
discontinuation	O
of	O
antianginal	O
therapy.	O
Three	O
months	O
later	O
the	O
patient	O
was	O
exposed	O
to	O
a	O
single	O
dose	O
of	O
metoprolol	Chemical
,	O
diltiazem	Chemical
,	O
propafenone	Chemical
(since	O
he	O
had	O
received	O
this	O
drug	O
in	O
the	O
past),	O
and	O
sparteine	Chemical
(as	O
a	O
probe	O
for	O
the	O
debrisoquine	Chemical
/	O
sparteine	Chemical
type	O
polymorphism	O
of	O
oxidative	O
drug	O
metabolism).	O
It	O
was	O
found	O
that	O
he	O
was	O
a	O
poor	O
metabolizer	O
of	O
all	O
four	O
drugs,	O
indicating	O
that	O
their	O
metabolism	O
is	O
under	O
the	O
same	O
genetic	O
control.	O
Therefore,	O
patients	O
belonging	O
to	O
the	O
poor-metabolizer	O
phenotype	O
of	O
sparteine	Chemical
/	O
debrisoquine	Chemical
polymorphism	O
in	O
drug	O
metabolism,	O
which	O
constitutes	O
6.4%	O
of	O
the	O
German	O
population,	O
may	O
experience	O
adverse	Disease
drug	Disease
reactions	Disease

Triazolam	Chemical
-induced	O
brief	O
episodes	O
of	O
secondary	O
mania	Disease
in	O
a	O
depressed	Disease
patient.	O
Large	O
doses	O
of	O
triazolam	Chemical
repeatedly	O
induced	O
brief	O
episodes	O
of	O
mania	Disease
in	O
a	O
depressed	Disease
elderly	O
woman.	O
Features	O
of	O
organic	Disease
mental	Disease
disorder	Disease
(	O
delirium	Disease
)	O
were	O
not	O
present.	O
Manic	Disease
excitement	O
was	O
coincident	O
with	O
the	O
duration	O
of	O
action	O
of	O
triazolam	Chemical
.	O
The	O
possible	O
contribution	O
of	O
the	O
triazolo	Chemical

On	O
the	O
mechanisms	O
of	O
the	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	Disease
rigidity	Disease
produced	O
by	O
morphine	Chemical
in	O
rats.	O
The	O
development	O
of	O
tolerance	O
to	O
the	O
muscular	Disease
rigidity	Disease
produced	O
by	O
morphine	Chemical
was	O
studied	O
in	O
rats.	O
Saline-pretreated	O
controls	O
given	O
a	O
test	O
dose	O
of	O
morphine	Chemical
(20	O
mg/kg	O
i.p.)	O
showed	O
a	O
pronounced	O
rigidity	Disease
recorded	O
as	O
tonic	O
activity	O
in	O
the	O
electromyogram.	O
Rats	O
treated	O
for	O
11	O
days	O
with	O
morphine	Chemical
and	O
withdrawn	O
for	O
36-40	O
h	O
showed	O
differences	O
in	O
the	O
development	O
of	O
tolerance:	O
about	O
half	O
of	O
the	O
animals	O
showed	O
a	O
rigidity	Disease
after	O
the	O
test	O
dose	O
of	O
morphine	Chemical
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
controls	O
and	O
were	O
akinetic	Disease
(A	O
group).	O
The	O
other	O
rats	O
showed	O
a	O
strong	O
decrease	O
in	O
the	O
rigidity	Disease
and	O
the	O
occurrence	O
of	O
stereotyped	O
(S)	O
licking	O
and/or	O
gnawing	O
in	O
presence	O
of	O
akinetic	Disease
or	O
hyperkinetic	Disease
(K)	O
behaviour	O
(AS/KS	O
group),	O
suggesting	O
signs	O
of	O
dopaminergic	O
activation.	O
The	O
rigidity	Disease
was	O
considerably	O
decreased	O
in	O
both	O
groups	O
after	O
20	O
days'	O
treatment.	O
In	O
a	O
further	O
series	O
of	O
experiments,	O
haloperidol	Chemical
(0.2	O
mg/kg	O
i.p.)	O
was	O
used	O
in	O
order	O
to	O
block	O
the	O
dopaminergic	O
activation	O
and	O
to	O
estimate	O
the	O
real	O
degree	O
of	O
the	O
tolerance	O
to	O
the	O
rigidity	Disease
without	O
any	O
dopaminergic	O
interference.	O
Haloperidol	Chemical
enhanced	O
the	O
rigidity	Disease
in	O
the	O
A	O
group.	O
However,	O
the	O
level	O
in	O
the	O
AS/KS	O
group	O
remained	O
considerably	O
lower	O
than	O
in	O
the	O
A	O
group.	O
The	O
results	O
suggest	O
that	O
rigidity	Disease
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
action	O
of	O
morphine	Chemical
in	O
the	O
striatum,	O
can	O
be	O
antagonized	O
by	O
another	O
process	O
leading	O
to	O
dopaminergic	O
activation	O
in	O
the	O
striatum.	O
Nevertheless,	O
there	O
occurs	O
some	O
real	O
tolerance	O
to	O
this	O
effect.	O
The	O
rapid	O
alternations	O
of	O
rigidity	Disease

Compression	Disease
neuropathy	Disease
of	Disease
the	Disease
radial	Disease
nerve	Disease
due	O
to	O
pentazocine	Chemical
-induced	O
fibrous	Disease
myopathy	Disease
.	O
Fibrous	Disease
myopathy	Disease
is	O
a	O
common,	O
well-known	O
side	O
effect	O
of	O
repeated	O
pentazocine	Chemical
injection.	O
However,	O
compression	Disease
neuropathy	Disease
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine	Chemical
-induced	O
myopathy	Disease
has	O
not	O
previously	O
been	O
reported.	O
In	O
a	O
37-year-old	O
woman	O
with	O
documented	O
pentazocine	Chemical
-induced	O
fibrous	Disease
myopathy	Disease
of	O
triceps	O
and	O
deltoid	O
muscles	O
bilaterally	O
and	O
a	O
three-week	O
history	O
of	O
right	O
wrist	O
drop,	O
electrodiagnostic	O
examination	O
showed	O
a	O
severe	O
but	O
partial	O
lesion	O
of	O
the	O
right	O
radial	O
nerve	O
distal	O
to	O
the	O
branches	O
to	O
the	O
triceps,	O
in	O
addition	O
to	O
the	O
fibrous	Disease
myopathy	Disease

Recurrent	O
reversible	O
acute	Disease
renal	Disease
failure	Disease
from	O
amphotericin	Chemical
.	O
A	O
patient	O
with	O
cryptogenic	O
cirrhosis	Disease
and	O
disseminated	O
sporotrichosis	Disease
developed	O
acute	Disease
renal	Disease
failure	Disease
immediately	O
following	O
the	O
administration	O
of	O
amphotericin	Chemical
B	Chemical
on	O
four	O
separate	O
occasions.	O
The	O
abruptness	O
of	O
the	O
renal	Disease
failure	Disease
and	O
its	O
reversibility	O
within	O
days	O
suggests	O
that	O
there	O
was	O
a	O
functional	O
component	O
to	O
the	O
renal	Disease
dysfunction	Disease
.	O
We	O
propose	O
that	O
amphotericin	Chemical
,	O
in	O
the	O
setting	O
of	O
reduced	O
effective	O
arterial	O
volume,	O
may	O
activate	O
tubuloglomerular	O
feedback,	O
thereby	O
contributing	O
to	O
acute	Disease
renal	Disease
failure	Disease

Pneumonitis	O
with	O
pleural	Disease
and	Disease
pericardial	Disease
effusion	Disease
and	O
neuropathy	Disease
during	O
amiodarone	Chemical
therapy.	O
A	O
patient	O
with	O
sinuatrial	Disease
disease	Disease
and	O
implanted	O
pacemaker	O
was	O
treated	O
with	O
amiodarone	Chemical
(maximum	O
dose	O
1000	O
mg,	O
maintenance	O
dose	O
800	O
mg	O
daily)	O
for	O
10	O
months,	O
for	O
control	O
of	O
supraventricular	Disease
tachyarrhythmias	Disease
.	O
He	O
developed	O
pneumonitis	Disease
,	O
pleural	Disease
and	Disease
pericardial	Disease
effusions	Disease
,	O
and	O
a	O
predominantly	O
proximal	Disease
motor	Disease
neuropathy	Disease
.	O
Immediate	O
but	O
gradual	O
improvement	O
followed	O
withdrawal	O
of	O
amiodarone	Chemical
and	O
treatment	O
with	O
prednisolone	Chemical
.	O
Review	O
of	O
this	O
and	O
previously	O
reported	O
cases	O
indicates	O
the	O
need	O
for	O
early	O
diagnosis	O
of	O
amiodarone	Chemical
	O
pneumonitis	Disease
,	O
immediate	O
withdrawal	O
of	O
amiodarone	Chemical
,	O
and	O
prompt	O
but	O
continued	O
steroid	Chemical

Indomethacin	Chemical
-induced	O
renal	Disease
insufficiency	Disease
:	O
recurrence	O
on	O
rechallenge.	O
We	O
have	O
reported	O
a	O
case	O
of	O
acute	O
oliguric	O
renal	Disease
failure	Disease
with	O
hyperkalemia	Disease
in	O
a	O
patient	O
with	O
cirrhosis	Disease
,	O
ascites	Disease
,	O
and	O
cor	Disease
pulmonale	Disease
after	O
indomethacin	Chemical
therapy.	O
Prompt	O
restoration	O
of	O
renal	O
function	O
followed	O
drug	O
withdrawal,	O
while	O
re-exposure	O
to	O
a	O
single	O
dose	O
of	O
indomethacin	Chemical
caused	O
recurrence	O
of	O
acute	O
reversible	O
oliguria	Disease
.	O
Our	O
case	O
supports	O
the	O
hypothesis	O
that	O
endogenous	O
renal	O
prostaglandins	Chemical
play	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
when	O
circulating	O
plasma	O
volume	O
is	O
diminished.	O
Since	O
nonsteroidal	O
anti-inflammatory	O
agents	O
interfere	O
with	O
this	O
compensatory	O
mechanism	O
and	O
may	O
cause	O
acute	Disease
renal	Disease
failure	Disease

Comparison	O
of	O
the	O
subjective	O
effects	O
and	O
plasma	O
concentrations	O
following	O
oral	O
and	O
i.m.	O
administration	O
of	O
flunitrazepam	Chemical
in	O
volunteers.	O
Flunitrazepam	Chemical
0.5,	O
1.0	O
or	O
2.0	O
mg	O
was	O
given	O
by	O
the	O
oral	O
or	O
i.m.	O
routes	O
to	O
groups	O
of	O
volunteers	O
and	O
its	O
effects	O
compared.	O
Plasma	O
concentrations	O
of	O
the	O
drug	O
were	O
estimated	O
by	O
gas-liquid	O
chromatography,	O
in	O
a	O
smaller	O
number	O
of	O
the	O
subjects.	O
The	O
most	O
striking	O
effect	O
was	O
sedation	O
which	O
increased	O
with	O
the	O
dose,	O
2	O
mg	O
producing	O
deep	O
sleep	O
although	O
the	O
subjects	O
could	O
still	O
be	O
aroused.	O
The	O
effects	O
of	O
i.m.	O
administration	O
were	O
apparent	O
earlier	O
and	O
sometimes	O
lasted	O
longer	O
than	O
those	O
following	O
oral	O
administration.	O
Dizziness	Disease
was	O
less	O
marked	O
than	O
sedation,	O
but	O
increased	O
with	O
the	O
dose.	O
There	O
was	O
pain	Disease
on	O
i.m.	O
injection	O
of	O
flunitrazepam	Chemical

Changes	O
in	O
heart	O
size	O
during	O
long-term	O
timolol	Chemical
treatment	O
after	O
myocardial	Disease
infarction	Disease
.	O
The	O
effect	O
of	O
long-term	O
timolol	Chemical
treatment	O
on	O
heart	O
size	O
after	O
myocardial	Disease
infarction	Disease
was	O
evaluated	O
by	O
X-ray	O
in	O
a	O
double-blind	O
study	O
including	O
241	O
patients	O
(placebo	O
126,	O
timolol	Chemical
115).	O
The	O
follow-up	O
period	O
was	O
12	O
months.	O
The	O
timolol	Chemical
-treated	O
patients	O
showed	O
a	O
small	O
but	O
significant	O
increase	O
in	O
heart	O
size	O
from	O
baseline	O
in	O
contrast	O
to	O
a	O
decrease	O
in	O
the	O
placebo	O
group.	O
These	O
differences	O
may	O
be	O
caused	O
by	O
timolol	Chemical
-induced	O
bradycardia	Disease
and	O
a	O
compensatory	O
increase	O
in	O
end-diastolic	O
volume.	O
The	O
timolol	Chemical
-related	O
increase	O
in	O
heart	O
size	O
was	O
observed	O
only	O
in	O
patients	O
with	O
normal	O
and	O
borderline	O
heart	O
size.	O
In	O
patients	O
with	O
cardiomegaly	Disease
,	O
the	O
increase	O
in	O
heart	O
size	O
was	O
similar	O
in	O
both	O
groups.	O
After	O
re-	O
infarction	Disease
,	O
heart	O
size	O
increased	O
in	O
the	O
placebo	O
group	O
and	O
remained	O
unchanged	O
in	O
the	O
timolol	Chemical

Vitamin	Chemical
D3	Chemical
	O
toxicity	Disease
in	O
dairy	O
cows.	O
Large	O
parenteral	O
doses	O
of	O
vitamin	Chemical
D3	Chemical
(15	O
to	O
17.5	O
x	O
10(6)	O
IU	O
vitamin	Chemical
D3	Chemical
)	O
were	O
associated	O
with	O
prolonged	O
hypercalcemia	Disease
,	O
hyperphosphatemia	Disease
,	O
and	O
large	O
increases	O
of	O
vitamin	Chemical
D3	Chemical
and	O
its	O
metabolites	O
in	O
the	O
blood	O
plasma	O
of	O
nonlactating	O
nonpregnant	O
and	O
pregnant	O
Jersey	O
cows.	O
Calcium	Chemical
concentrations	O
1	O
day	O
postpartum	O
were	O
higher	O
in	O
cows	O
treated	O
with	O
vitamin	Chemical
D3	Chemical
about	O
32	O
days	O
prepartum	O
(8.8	O
mg/100	O
ml)	O
than	O
in	O
control	O
cows	O
(5.5	O
mg/100	O
ml).	O
None	O
of	O
the	O
cows	O
treated	O
with	O
vitamin	Chemical
D3	Chemical
showed	O
signs	O
of	O
milk	Disease
fever	Disease
during	O
the	O
peripartal	O
period;	O
however,	O
22%	O
of	O
the	O
control	O
cows	O
developed	O
clinical	O
signs	O
of	O
milk	Disease
fever	Disease
during	O
this	O
period.	O
Signs	O
of	O
vitamin	Chemical
D3	Chemical
	O
toxicity	Disease
were	O
not	O
observed	O
in	O
nonlactating	O
nonpregnant	O
cows;	O
however,	O
pregnant	O
cows	O
commonly	O
developed	O
severe	O
signs	O
of	O
vitamin	Chemical
D3	Chemical
	O
toxicity	Disease
and	O
10	O
of	O
17	O
cows	O
died.	O
There	O
was	O
widespread	O
metastatic	O
calcification	O
in	O
the	O
cows	O
that	O
died.	O
Because	O
of	O
the	O
extreme	O
toxicity	Disease
of	O
vitamin	Chemical
D3	Chemical
in	O
pregnant	O
Jersey	O
cows	O
and	O
the	O
low	O
margin	O
of	O
safety	O
between	O
doses	O
of	O
vitamin	Chemical
D3	Chemical
that	O
prevent	O
milk	Disease
fever	Disease
and	O
doses	O
that	O
induce	O
milk	Disease
fever	Disease
,	O
we	O
concluded	O
that	O
vitamin	Chemical
D3	Chemical
cannot	O
be	O
used	O
practically	O
to	O
prevent	O
milk	Disease
fever	Disease

Diseases	Disease
of	Disease
peripheral	Disease
nerves	Disease
as	O
seen	O
in	O
the	O
Nigerian	O
African.	O
The	O
anatomical	O
and	O
aetiological	O
diagnoses	O
of	O
peripheral	Disease
nerve	Disease
disease	Disease
excluding	O
its	O
primary	O
benign	O
and	O
malignant	O
disorders,	O
as	O
seen	O
in	O
358	O
Nigerians	O
are	O
presented.	O
There	O
is	O
a	O
male	O
preponderance	O
and	O
the	O
peak	O
incidence	O
is	O
in	O
the	O
fourth	O
decade.	O
Sensori-motor	Disease
neuropathy	Disease
was	O
the	O
commonest	O
presentation	O
(50%).	O
Guillain-Barr	Disease
	Disease
	Disease
syndrome	Disease
was	O
the	O
commonest	O
identifiable	O
cause	O
(15.6%),	O
accounting	O
for	O
half	O
of	O
the	O
cases	O
with	O
motor	Disease
neuropathy	Disease
.	O
Peripheral	Disease
neuropathy	Disease
due	O
to	O
nutritional	Disease
deficiency	Disease
of	O
thiamine	Chemical
and	O
riboflavin	Chemical
was	O
common	O
(10.1%)	O
and	O
presented	O
mainly	O
as	O
sensory	O
and	O
sensori-motor	Disease
neuropathy	Disease
.	O
Diabetes	Disease
mellitus	Disease
was	O
the	O
major	O
cause	O
of	O
autonomic	Disease
neuropathy	Disease
.	O
Isoniazid	Chemical
was	O
the	O
most	O
frequent	O
agent	O
in	O
drug-induced	O
neuropathy	Disease
.	O
Migraine	Disease
(20%)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
cranial	Disease
neuropathy	Disease
although	O
malignancies	Disease
arising	O
from	O
the	O
reticuloendothelial	O
system	O
or	O
related	O
structures	O
of	O
the	O
head	O
and	O
neck	O
were	O
more	O
frequent	O
(26%).	O
In	O
26.5%	O
of	O
all	O
the	O
cases,	O
the	O
aetiology	O
of	O
the	O
neuropathy	Disease
was	O
undetermined.	O
Heredofamilial	O
and	O
connective	Disease
tissue	Disease
disorders	Disease
were	O
rare.	O
Some	O
of	O
the	O
factors	O
related	O
to	O
the	O
clinical	O
presentation	O
and	O
pathogenesis	O
of	O
the	O
neuropathies	Disease

A	O
double-blind	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
dothiepin	Chemical
hydrochloride	Chemical
in	O
the	O
treatment	O
of	O
major	O
depressive	Disease
disorder	Disease
.	O
In	O
a	O
6-week	O
double-blind	O
parallel	O
treatment	O
study,	O
dothiepin	Chemical
and	O
amitriptyline	Chemical
were	O
compared	O
to	O
placebo	O
in	O
the	O
treatment	O
of	O
33	O
depressed	Disease
outpatients.	O
Dothiepin	Chemical
and	O
amitriptyline	Chemical
were	O
equally	O
effective	O
in	O
alleviating	O
the	O
symptoms	O
of	O
depressive	Disease
illness	Disease
,	O
and	O
both	O
were	O
significantly	O
superior	O
to	O
placebo.	O
The	O
overall	O
incidence	O
of	O
side	O
effects	O
and	O
the	O
frequency	O
and	O
severity	O
of	O
blurred	Disease
vision	Disease
,	O
dry	Disease
mouth	Disease
,	O
and	O
drowsiness	O
were	O
significantly	O
less	O
with	O
dothiepin	Chemical
than	O
with	O
amitriptyline	Chemical
.	O
Dothiepin	Chemical
also	O
produced	O
fewer	O
CNS	O
and	O
cardiovascular	O
effects.	O
There	O
were	O
no	O
clinically	O
important	O
changes	O
in	O
laboratory	O
parameters.	O
Dothiepin	Chemical
thus	O
was	O
found	O
to	O
be	O
an	O
effective	O
antidepressant	Chemical
drug	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
amitriptyline	Chemical
in	O
the	O
treatment	O
of	O
depressed	Disease

Behavioral	O
effects	O
of	O
diazepam	Chemical
and	O
propranolol	Chemical
in	O
patients	O
with	O
panic	Disease
disorder	Disease
and	O
agoraphobia	Disease
.	O
The	O
effects	O
of	O
oral	O
doses	O
of	O
diazepam	Chemical
(single	O
dose	O
of	O
10	O
mg	O
and	O
a	O
median	O
dose	O
of	O
30	O
mg/day	O
for	O
2	O
weeks)	O
and	O
propranolol	Chemical
(single	O
dose	O
of	O
80	O
mg	O
and	O
a	O
median	O
dose	O
of	O
240	O
mg/day	O
for	O
2	O
weeks)	O
on	O
psychological	O
performance	O
of	O
patients	O
with	O
panic	Disease
disorders	Disease
and	O
agoraphobia	Disease
were	O
investigated	O
in	O
a	O
double-blind,	O
randomized	O
and	O
crossover	O
design.	O
Both	O
drugs	O
impaired	Disease
immediate	Disease
free	Disease
recall	Disease
but	O
the	O
decrease	O
was	O
greater	O
for	O
diazepam	Chemical
than	O
propranolol	Chemical
.	O
Delayed	Disease
free	Disease
recall	Disease
was	Disease
also	Disease
impaired	Disease
but	O
the	O
two	O
drugs	O
did	O
not	O
differ.	O
Patients	O
tapped	O
faster	O
after	O
propranolol	Chemical
than	O
diazepam	Chemical
and	O
they	O
were	O
more	O
sedated	O
after	O
diazepam	Chemical
than	O
propranolol	Chemical
.	O
After	O
2	O
weeks	O
of	O
treatment,	O
patients	O
tested	O
5-8	O
h	O
after	O
the	O
last	O
dose	O
of	O
medication	O
did	O
not	O
show	O
any	O
decrement	O
of	O
performance.	O
These	O
results	O
are	O
similar	O
to	O
those	O
previously	O
found	O
in	O
healthy	O
subjects.	O
Accumulation	O
of	O
drugs	O
was	O
not	O
reflected	O
in	O
prolonged	O
behavioral	Disease
impairment	Disease

Effect	O
of	O
aspirin	Chemical
on	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	Chemical
-induced	O
epithelial	O
proliferation	O
in	O
the	O
urinary	O
bladder	O
and	O
forestomach	O
of	O
the	O
rat.	O
The	O
co-administration	O
of	O
aspirin	Chemical
with	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	Chemical
(	O
FANFT	Chemical
)	O
to	O
rats	O
resulted	O
in	O
a	O
reduced	O
incidence	O
of	O
FANFT	Chemical
-induced	O
bladder	Disease
carcinomas	Disease
but	O
a	O
concomitant	O
induction	O
of	O
forestomach	Disease
tumors	Disease
.	O
An	O
autoradiographic	O
study	O
was	O
performed	O
on	O
male	O
F-344	O
rats	O
fed	O
diet	O
containing	O
FANFT	Chemical
at	O
a	O
level	O
of	O
0.2%	O
and/or	O
aspirin	Chemical
at	O
a	O
level	O
of	O
0.5%	O
to	O
evaluate	O
the	O
effect	O
of	O
aspirin	Chemical
on	O
the	O
increased	O
cell	O
proliferation	O
induced	O
by	O
FANFT	Chemical
in	O
the	O
forestomach	O
and	O
bladder.	O
FANFT	Chemical
-induced	O
cell	O
proliferation	O
in	O
the	O
bladder	O
was	O
significantly	O
suppressed	O
by	O
aspirin	Chemical
co-administration	O
after	O
4	O
weeks	O
but	O
not	O
after	O
12	O
weeks.	O
In	O
the	O
forestomach,	O
and	O
also	O
in	O
the	O
liver,	O
aspirin	Chemical
did	O
not	O
affect	O
the	O
FANFT	Chemical
-induced	O
increase	O
in	O
labeling	O
index.	O
The	O
present	O
results	O
are	O
consistent	O
with	O
the	O
carcinogenicity	O
experiment	O
suggesting	O
that	O
different	O
mechanisms	O
are	O
involved	O
in	O
FANFT	Chemical
	O
carcinogenesis	Disease
in	O
the	O
bladder	O
and	O
forestomach,	O
and	O
that	O
aspirin	Chemical
's	O
effect	O
on	O
FANFT	Chemical
in	O
the	O
forestomach	O
is	O
not	O
due	O
to	O
an	O
irritant	O
effect	O
associated	O
with	O
increased	O
cell	O
proliferation.	O
Also,	O
there	O
appears	O
to	O
be	O
an	O
adaptation	O
by	O
the	O
rats	O
to	O
the	O
chronic	O
ingestion	O
of	O
aspirin	Chemical

Provocation	O
of	O
postural	O
hypotension	Disease
by	O
nitroglycerin	Chemical
in	O
diabetic	Disease
autonomic	Disease
neuropathy	Disease
?	O
The	O
effect	O
of	O
nitroglycerin	Chemical
on	O
heart	O
rate	O
and	O
systolic	O
blood	O
pressure	O
was	O
compared	O
in	O
5	O
normal	O
subjects,	O
12	O
diabetic	Disease
subjects	O
without	O
autonomic	Disease
neuropathy	Disease
,	O
and	O
5	O
diabetic	Disease
subjects	O
with	O
autonomic	Disease
neuropathy	Disease
.	O
The	O
magnitude	O
and	O
time	O
course	O
of	O
the	O
increase	O
in	O
heart	O
rate	O
and	O
the	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
after	O
nitroglycerin	Chemical
were	O
similar	O
in	O
the	O
normal	O
and	O
diabetic	Disease
subjects	O
without	O
autonomic	Disease
neuropathy	Disease
,	O
whereas	O
a	O
lesser	O
increase	O
in	O
heart	O
rate	O
and	O
a	O
greater	O
decrease	O
in	O
systolic	O
blood	O
pressure	O
occurred	O
in	O
the	O
diabetic	Disease
subjects	O
with	O
autonomic	Disease
neuropathy	Disease
.	O
It	O
is	O
therefore	O
suggested	O
that	O
caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
vasodilator	O
drugs	O
in	O
diabetic	Disease
patients,	O
particularly	O
those	O
with	O
autonomic	Disease
neuropathy	Disease

Characterization	O
of	O
estrogen	Chemical
-induced	O
adenohypophyseal	Disease
tumors	Disease
in	O
the	O
Fischer	O
344	O
rat.	O
Pituitary	Disease
tumors	Disease
were	O
induced	O
in	O
F344	O
female	O
rats	O
by	O
chronic	O
treatment	O
with	O
diethylstilbestrol	Chemical
(	O
DES	Chemical
,	O
8-10	O
mg)	O
implanted	O
subcutaneously	O
in	O
silastic	O
capsules.	O
Over	O
a	O
range	O
of	O
1-150	O
days	O
of	O
DES	Chemical
treatment,	O
pairs	O
of	O
control	O
and	O
DES	Chemical
-treated	O
rats	O
were	O
sacrificed,	O
and	O
their	O
pituitaries	O
dissociated	O
enzymatically	O
into	O
single-cell	O
preparations.	O
The	O
cell	O
populations	O
were	O
examined	O
regarding	O
total	O
cell	O
recovery	O
correlated	O
with	O
gland	O
weight,	O
intracellular	O
prolactin	O
(PRL)	O
content	O
and	O
subsequent	O
release	O
in	O
primary	O
culture,	O
immunocytochemical	O
PRL	O
staining,	O
density	O
and/or	O
size	O
alterations	O
via	O
separation	O
on	O
Ficoll-Hypaque	O
and	O
by	O
unit	O
gravity	O
sedimentation,	O
and	O
cell	O
cycle	O
analysis,	O
after	O
acriflavine	Chemical
DNA	O
staining,	O
by	O
laser	O
flow	O
cytometry.	O
Total	O
cell	O
yields	O
from	O
DES	Chemical
-treated	O
pituitaries	O
increased	O
from	O
1.3	O
times	O
control	O
yields	O
at	O
8	O
days	O
of	O
treatment	O
to	O
58.9	O
times	O
control	O
values	O
by	O
day	O
150.	O
Intracellular	O
PRL	O
content	O
ranged	O
from	O
1.9	O
to	O
9.4	O
times	O
control	O
levels,	O
and	O
PRL	O
release	O
in	O
vitro	O
was	O
significantly	O
and	O
consistently	O
higher	O
than	O
controls,	O
after	O
at	O
least	O
8	O
days	O
of	O
DES	Chemical
exposure.	O
Beyond	O
8	O
days	O
of	O
DES	Chemical
exposure,	O
the	O
immunochemically	O
PRL-positive	O
proportion	O
of	O
cells	O
increased	O
to	O
over	O
50%	O
of	O
the	O
total	O
population.	O
Increased	O
density	O
and/or	O
size	O
and	O
PRL	O
content	O
were	O
indicated	O
for	O
the	O
majority	O
of	O
the	O
PRL	O
cell	O
population	O
in	O
both	O
types	O
of	O
separation	O
protocols.	O
All	O
these	O
effects	O
of	O
DES	Chemical
were	O
more	O
pronounced	O
among	O
previously	O
ovariectomized	O
animals.	O
The	O
data	O
extend	O
the	O
findings	O
of	O
other	O
investigators,	O
further	O
establishing	O
the	O
DES	Chemical
-induced	O
tumor	Disease

Triamterene	Chemical
	O
nephrolithiasis	Disease
complicating	O
dyazide	Chemical
therapy.	O
A	O
case	O
of	O
triamterene	Chemical
	O
nephrolithiasis	Disease
is	O
reported	O
in	O
a	O
man	O
after	O
4	O
years	O
of	O
hydrochlorothiazide-triamterene	Chemical
therapy	O
for	O
hypertension	Disease
.	O
The	O
stone	O
passed	O
spontaneously	O
and	O
was	O
found	O
to	O
contain	O
a	O
triamterene	Chemical
metabolite	O
admixed	O
with	O
uric	Chemical
acid	Chemical
salts	Chemical
.	O
Factors	O
affecting	O
triamterene	Chemical
	O
nephrolithiasis	Disease

Metabolic	O
involvement	O
in	O
adriamycin	Chemical
	O
cardiotoxicity	Disease
.	O
The	O
cardiotoxic	Disease
effects	O
of	O
adriamycin	Chemical
were	O
studied	O
in	O
mammalian	O
myocardial	O
cells	O
in	O
culture	O
as	O
a	O
model	O
system.	O
Adriamycin	Chemical
inhibited	O
cell	O
growth	O
and	O
the	O
rhythmic	O
contractions	O
characteristic	O
of	O
myocardial	O
cells	O
in	O
culture.	O
A	O
possible	O
involvement	O
of	O
energy	O
metabolism	O
was	O
suggested	O
previously,	O
and	O
in	O
this	O
study	O
the	O
adenylate	O
energy	O
charge	O
and	O
phosphorylcreatine	Chemical
mole	O
fraction	O
were	O
determined	O
in	O
the	O
adriamycin	Chemical
-treated	O
cells.	O
The	O
adenylate	O
energy	O
charge	O
was	O
found	O
to	O
be	O
significantly	O
decreased,	O
while	O
the	O
phophorylcreatine	Chemical
mole	O
fraction	O
was	O
unchanged.	O
Such	O
disparity	O
suggests	O
an	O
inhibition	O
of	O
creatine	Chemical
phosphokinase.	O
The	O
addition	O
of	O
1	O
mM	O
adenosine	Chemical
to	O
the	O
myocardial	O
cell	O
cultures	O
markedly	O
increases	O
the	O
ATP	Chemical
concentration	O
through	O
a	O
pathway	O
reportedly	O
leading	O
to	O
a	O
compartmentalized	O
ATP	Chemical
pool.	O
In	O
the	O
adriamycin	Chemical
-treated	O
cells,	O
the	O
addition	O
of	O
adenosine	Chemical

Age-dependent	O
sensitivity	O
of	O
the	O
rat	O
to	O
neurotoxic	Disease
effects	O
of	O
streptomycin	Chemical
.	O
Streptomycin	Chemical
sulfate	O
(300	O
mg/kg	O
s.c.)	O
was	O
injected	O
for	O
various	O
periods	O
into	O
preweanling	O
rats	O
and	O
for	O
3	O
weeks	O
into	O
weanling	O
rats.	O
Beginning	O
at	O
8	O
days	O
of	O
age,	O
body	O
movement	O
and	O
hearing	O
were	O
examined	O
for	O
6	O
and	O
up	O
to	O
17	O
weeks,	O
respectively.	O
Abnormal	Disease
movements	Disease
and	O
deafness	Disease
occurred	O
only	O
in	O
rats	O
treated	O
during	O
the	O
preweaning	O
period;	O
within	O
this	O
period	O
the	O
greatest	O
sensitivities	O
for	O
these	O
abnormalities	O
occurred	O
from	O
2	O
to	O
11-17	O
and	O
5	O
to	O
11	O
days	O
of	O
age,	O
respectively,	O
indicating	O
that	O
the	O
cochlea	O
is	O
more	O
sensitive	O
to	O
streptomycin	Chemical
than	O
the	O
site	O
(vestibular	O
or	O
central)	O
responsible	O
for	O
the	O
dyskinesias	Disease

Crescentic	O
fibrillary	O
glomerulonephritis	Disease
associated	O
with	O
intermittent	O
rifampin	Chemical
therapy	O
for	O
pulmonary	Disease
tuberculosis	Disease
.	O
This	O
case	O
study	O
reveals	O
an	O
unusual	O
finding	O
of	O
rapidly	O
proliferative	O
crescentic	O
glomerulonephritis	Disease
in	O
a	O
patient	O
treated	O
with	O
rifampin	Chemical
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	O
this	O
disease.	O
This	O
patient	O
underwent	O
a	O
10-month	O
regimen	O
of	O
rifampin	Chemical
and	O
isoniazid	Chemical
for	O
pulmonary	Disease
tuberculosis	Disease
and	O
was	O
discovered	O
to	O
have	O
developed	O
signs	O
of	O
severe	O
renal	Disease
failure	Disease
five	O
weeks	O
after	O
completion	O
of	O
therapy.	O
Renal	O
biopsy	O
revealed	O
severe	O
glomerulonephritis	Disease
with	O
crescents,	O
electron	O
dense	O
fibrillar	O
deposits	O
and	O
moderate	O
lymphocytic	O
interstitial	O
infiltrate.	O
Other	O
possible	O
causes	O
of	O
rapidly	O
progressive	O
glomerulonephritis	Disease
were	O
investigated	O
and	O
ruled	O
out.	O
This	O
report	O
documents	O
the	O
unusual	O
occurrence	O
of	O
rapidly	O
progressive	O
glomerulonephritis	Disease
with	O
crescents	O
and	O
fibrillar	O
glomerulonephritis	Disease
in	O
a	O
patient	O
treated	O
with	O
rifampin	Chemical

Time	O
course	O
of	O
lipid	O
peroxidation	O
in	O
puromycin	Chemical
aminonucleoside	Chemical
-induced	O
nephropathy	Disease
.	O
Reactive	O
oxygen	Chemical
species	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
acute	O
puromycin	Chemical
aminonucleoside	Chemical
(	O
PAN	Chemical
)-induced	O
nephropathy	Disease
,	O
with	O
antioxidants	O
significantly	O
reducing	O
the	O
proteinuria	Disease
.	O
The	O
temporal	O
relationship	O
between	O
lipid	O
peroxidation	O
in	O
the	O
kidney	O
and	O
proteinuria	Disease
was	O
examined	O
in	O
this	O
study.	O
Rats	O
were	O
treated	O
with	O
a	O
single	O
IV	O
injection	O
of	O
puromycin	Chemical
aminonucleoside	Chemical
,	O
(	O
PAN	Chemical
,	O
7.5	O
mg/kg)	O
and	O
24	O
hour	O
urine	O
samples	O
were	O
obtained	O
prior	O
to	O
sacrifice	O
on	O
days	O
3,5,7,10,17,27,41	O
(N	O
=	O
5-10	O
per	O
group).	O
The	O
kidneys	O
were	O
removed,	O
flushed	O
with	O
ice	O
cold	O
TRIS	O
buffer.	O
Kidney	O
cortices	O
from	O
each	O
animal	O
were	O
used	O
to	O
prepare	O
homogenates.	O
Tissue	O
lipid	O
peroxidation	O
was	O
measured	O
in	O
whole	O
homogenates	O
as	O
well	O
as	O
in	O
lipid	O
extracts	O
from	O
homogenates	O
as	O
thiobarbituric	Chemical
acid	Chemical
reactive	O
substances.	O
Proteinuria	Disease
was	O
evident	O
at	O
day	O
5,	O
peaked	O
at	O
day	O
7	O
and	O
persisted	O
to	O
day	O
27.	O
Lipid	O
peroxidation	O
in	O
homogenates	O
was	O
maximal	O
at	O
day	O
3	O
and	O
declined	O
rapidly	O
to	O
control	O
levels	O
by	O
day	O
17.	O
This	O
study	O
supports	O
the	O
role	O
of	O
lipid	O
peroxidation	O
in	O
mediating	O
the	O
proteinuric	Disease
injury	Disease
in	O
PAN	Chemical
	O
nephropathy	Disease

Clomipramine	Chemical
-induced	O
sleep	Disease
disturbance	Disease
does	O
not	O
impair	O
its	O
prolactin-releasing	O
action.	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
role	O
of	O
sleep	Disease
disturbance	Disease
,	O
induced	O
by	O
clomipramine	Chemical
administration,	O
on	O
the	O
secretory	O
rate	O
of	O
prolactin	O
(PRL)	O
in	O
addition	O
to	O
the	O
direct	O
drug	O
effect.	O
Two	O
groups	O
of	O
supine	O
subjects	O
were	O
studied	O
under	O
placebo-controlled	O
conditions,	O
one	O
during	O
the	O
night,	O
when	O
sleeping	O
(n	O
=	O
7)	O
and	O
the	O
other	O
at	O
daytime,	O
when	O
awake	O
(n	O
=	O
6).	O
Each	O
subject	O
received	O
a	O
single	O
50	O
mg	O
dose	O
of	O
clomipramine	Chemical
given	O
orally	O
2	O
hours	O
before	O
blood	O
collection.	O
Plasma	O
PRL	O
concentrations	O
were	O
analysed	O
at	O
10	O
min	O
intervals	O
and	O
underlying	O
secretory	O
rates	O
calculated	O
by	O
a	O
deconvolution	O
procedure.	O
For	O
both	O
experiments	O
the	O
drug	O
intake	O
led	O
to	O
significant	O
increases	O
in	O
PRL	O
secretion,	O
acting	O
preferentially	O
on	O
tonic	O
secretion	O
as	O
pulse	O
amplitude	O
and	O
frequency	O
did	O
not	O
differ	O
significantly	O
from	O
corresponding	O
control	O
values.	O
During	O
the	O
night	O
clomipramine	Chemical
ingestion	O
altered	O
the	O
complete	O
sleep	O
architecture	O
in	O
that	O
it	O
suppressed	O
REM	O
sleep	O
and	O
the	O
sleep	O
cycles	O
and	O
induced	O
increased	O
wakefulness.	O
As	O
the	O
relative	O
increase	O
in	O
PRL	O
secretion	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
mean	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
night	O
and	O
day	O
time	O
studies	O
(46	O
+/-	O
19%	O
vs	O
34	O
+/-	O
10%),	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	Disease
disturbance	Disease
did	O
not	O
interfere	O
with	O
the	O
drug	O
action	O
per	O
se.	O
The	O
presence	O
of	O
REM	O
sleep	O
was	O
shown	O
not	O
to	O
be	O
a	O
determining	O
factor	O
either	O
for	O
secretory	O
pulse	O
amplitude	O
and	O
frequency,	O
as,	O
for	O
both,	O
mean	O
nocturnal	O
values	O
were	O
similar	O
with	O
and	O
without	O
prior	O
clomipramine	Chemical

Angioedema	Disease
following	O
the	O
intravenous	O
administration	O
of	O
metoprolol	Chemical
.	O
A	O
72-year-old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
"flash"	O
pulmonary	Disease
edema	Disease
,	O
preceded	O
by	O
chest	Disease
pain	Disease
,	O
requiring	O
intubation.	O
Her	O
medical	O
history	O
included	O
coronary	Disease
artery	Disease
disease	Disease
with	O
previous	O
myocardial	Disease
infarctions	Disease
,	O
hypertension	Disease
,	O
and	O
diabetes	Disease
mellitus	Disease
.	O
A	O
history	O
of	O
angioedema	Disease
secondary	O
to	O
lisinopril	Chemical
therapy	O
was	O
elicited.	O
Current	O
medications	O
did	O
not	O
include	O
angiotensin	Chemical
-converting	O
enzyme	O
inhibitors	O
or	O
beta-blockers.	O
She	O
had	O
no	O
previous	O
beta-blocking	O
drug	O
exposure.	O
During	O
the	O
first	O
day	O
of	O
hospitalization	O
(while	O
intubated),	O
intravenous	O
metoprolol	Chemical
was	O
given,	O
resulting	O
in	O
severe	O
angioedema	Disease
.	O
The	O
angioedema	Disease
resolved	O
after	O
therapy	O
with	O
intravenous	O
steroids	Chemical
and	O
diphenhydramine	Chemical

Effect	O
of	O
coniine	Chemical
on	O
the	O
developing	O
chick	O
embryo.	O
Coniine	Chemical
,	O
an	O
alkaloid	O
from	O
Conium	O
maculatum	O
(poison	O
hemlock),	O
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
livestock.	O
The	O
major	O
teratogenic	O
outcome	O
is	O
arthrogryposis	Disease
,	O
presumably	O
due	O
to	O
nicotinic	O
receptor	O
blockade.	O
However,	O
coniine	Chemical
has	O
failed	O
to	O
produce	O
arthrogryposis	Disease
in	O
rats	O
or	O
mice	O
and	O
is	O
only	O
weakly	O
teratogenic	O
in	O
rabbits.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
effects	O
of	O
coniine	Chemical
and	O
nicotine	Chemical
in	O
the	O
developing	O
chick.	O
Concentrations	O
of	O
coniine	Chemical
and	O
nicotine	Chemical
sulfate	O
were	O
0.015%,	O
0.03%,	O
0.075%,	O
0.15%,	O
0.75%,	O
1.5%,	O
3%,	O
and	O
6%	O
and	O
1%,	O
5%,	O
and	O
10%,	O
respectively.	O
Both	O
compounds	O
caused	O
deformations	Disease
and	O
lethality	O
in	O
a	O
dose-dependent	O
manner.	O
All	O
concentrations	O
of	O
nicotine	Chemical
sulfate	O
caused	O
some	O
lethality	O
but	O
a	O
no	O
effect	O
level	O
for	O
coniine	Chemical
lethality	O
was	O
0.75%.	O
The	O
deformations	Disease
caused	O
by	O
both	O
coniine	Chemical
and	O
nicotine	Chemical
sulfate	O
were	O
excessive	Disease
flexion	Disease
or	Disease
extension	Disease
of	Disease
one	Disease
or	Disease
more	Disease
toes	Disease
.	O
No	O
histopathological	O
alterations	O
or	O
differences	O
in	O
bone	O
formation	O
were	O
seen	O
in	O
the	O
limbs	O
or	O
toes	O
of	O
any	O
chicks	O
from	O
any	O
group;	O
however,	O
extensive	O
cranial	Disease
hemorrhage	Disease
occurred	O
in	O
all	O
nicotine	Chemical
sulfate-treated	O
chicks.	O
There	O
was	O
a	O
statistically	O
significant	O
(P	O
<	O
or	O
=	O
0.01)	O
decrease	O
in	O
movement	O
in	O
coniine	Chemical
and	O
nicotine	Chemical
sulfate	O
treated	O
chicks	O
as	O
determined	O
by	O
ultrasound.	O
Control	O
chicks	O
were	O
in	O
motion	O
an	O
average	O
of	O
33.67%	O
of	O
the	O
time,	O
while	O
coniine	Chemical
-treated	O
chicks	O
were	O
only	O
moving	O
8.95%	O
of	O
a	O
5-min	O
interval,	O
and	O
no	O
movement	O
was	O
observed	O
for	O
nicotine	Chemical
sulfate	O
treated	O
chicks.	O
In	O
summary,	O
the	O
chick	O
embryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimental	O
animal	O
model	O
of	O
coniine	Chemical
-induced	O
arthrogryposis	Disease

Epidural	O
blood	O
flow	O
during	O
prostaglandin	Chemical
E1	Chemical
or	O
trimethaphan	Chemical
induced	O
hypotension	Disease
.	O
To	O
evaluate	O
the	O
effect	O
of	O
prostaglandin	Chemical
E1	Chemical
(	O
PGE1	Chemical
)	O
or	O
trimethaphan	Chemical
(	O
TMP	Chemical
)	O
induced	O
hypotension	Disease
on	O
epidural	O
blood	O
flow	O
(EBF)	O
during	O
spinal	O
surgery,	O
EBF	O
was	O
measured	O
using	O
the	O
heat	O
clearance	O
method	O
in	O
30	O
patients	O
who	O
underwent	O
postero-lateral	O
interbody	O
fusion	O
under	O
isoflurane	Chemical
anaesthesia.	O
An	O
initial	O
dose	O
of	O
0.1	O
microgram.kg-1.min-1	O
of	O
PGE1	Chemical
(15	O
patients),	O
or	O
10	O
micrograms.kg-1.min-1	O
of	O
TMP	Chemical
(15	O
patients)	O
was	O
administered	O
intravenously	O
after	O
the	O
dural	O
opening	O
and	O
the	O
dose	O
was	O
adjusted	O
to	O
maintain	O
the	O
mean	O
arterial	O
blood	O
pressure	O
(MAP)	O
at	O
about	O
60	O
mmHg.	O
The	O
hypotensive	Disease
drug	O
was	O
discontinued	O
at	O
the	O
completion	O
of	O
the	O
operative	O
procedure.	O
After	O
starting	O
PGE1	Chemical
or	O
TMP	Chemical
,	O
MAP	O
and	O
rate	O
pressure	O
product	O
(RPP)	O
decreased	O
significantly	O
compared	O
with	O
preinfusion	O
values	O
(P	O
<	O
0.01),	O
and	O
the	O
degree	O
of	O
hypotension	Disease
due	O
to	O
PGE1	Chemical
remained	O
constant	O
until	O
60	O
min	O
after	O
its	O
discontinuation.	O
Heart	O
rate	O
(HR)	O
did	O
not	O
change	O
in	O
either	O
group.	O
EBFF	O
did	O
not	O
change	O
during	O
PGE1	Chemical
infusion	O
whereas	O
in	O
the	O
TMP	Chemical
group,	O
EBF	O
decreased	O
significantly	O
at	O
30	O
and	O
60	O
min	O
after	O
the	O
start	O
of	O
TMP	Chemical
(preinfusion:	O
45.9	O
+/-	O
13.9	O
ml/100g/min.	O
30	O
min:	O
32.3	O
+/-	O
9.9	O
ml/100	O
g/min	O
(P	O
<	O
0.05).	O
60	O
min:	O
30	O
+/-	O
7.5	O
ml/100	O
g/min	O
(P	O
<	O
0.05)).	O
These	O
results	O
suggest	O
that	O
PGE1	Chemical
may	O
be	O
preferable	O
to	O
TMP	Chemical
for	O
hypotensive	Disease
anaesthesia	O
in	O
spinal	O
surgery	O
because	O
TMP	Chemical

Immunohistochemical	O
studies	O
with	O
antibodies	O
to	O
neurofilament	O
proteins	O
on	O
axonal	Disease
damage	Disease
in	O
experimental	O
focal	O
lesions	O
in	O
rat.	O
Immunohistochemistry	O
with	O
monoclonal	O
antibodies	O
against	O
neurofilament	O
(NF)	O
proteins	O
of	O
middle	O
and	O
high	O
molecular	O
weight	O
class,	O
NF-M	O
and	O
NF-H,	O
was	O
used	O
to	O
study	O
axonal	Disease
injury	Disease
in	O
the	O
borderzone	O
of	O
focal	O
lesions	O
in	O
rats.	O
Focal	O
injury	Disease
in	Disease
the	Disease
cortex	Disease
was	O
produced	O
by	O
infusion	O
of	O
lactate	Chemical
at	O
acid	O
pH	O
or	O
by	O
stab	O
caused	O
by	O
needle	O
insertion.	O
Infarcts	Disease
in	Disease
substantia	Disease
nigra	Disease
pars	Disease
reticulata	Disease
were	O
evoked	O
by	O
prolonged	O
pilocarpine	Chemical
-induced	O
status	Disease
epilepticus	Disease
.	O
Immunohistochemical	O
staining	O
for	O
NFs	O
showed	O
characteristic	O
terminal	O
clubs	O
of	O
axons	O
in	O
the	O
borderzone	O
of	O
lesions.	O
Differences	O
in	O
the	O
labelling	O
pattern	O
occurred	O
with	O
different	O
antibodies	O
which	O
apparently	O
depended	O
on	O
molecular	O
weight	O
class	O
of	O
NFs	O
and	O
phosphorylation	O
state.	O
These	O
immunohistochemical	O
changes	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marker	O
for	O
axonal	Disease
damage	Disease
in	O
various	O
experimental	O
traumatic	Disease

Increase	O
of	O
Parkinson	Disease
disability	Disease
after	O
fluoxetine	Chemical
medication.	O
Depression	Disease
is	O
a	O
major	O
clinical	O
feature	O
of	O
Parkinson's	Disease
disease	Disease
.	O
We	O
report	O
the	O
increased	O
amount	O
of	O
motor	Disease
disability	Disease
in	O
four	O
patients	O
with	O
idiopathic	Disease
Parkinson's	Disease
disease	Disease
after	O
exposure	O
to	O
the	O
antidepressant	Chemical
	O
fluoxetine	Chemical
.	O
The	O
possibility	O
of	O
a	O
clinically	O
relevant	O
dopamine	Chemical
-antagonistic	O
capacity	O
of	O
fluoxetine	Chemical
in	O
Parkinson's	Disease
disease	Disease

Acetaminophen	Chemical
-induced	O
hypotension	Disease
.	O
Through	O
30	O
years	O
of	O
widespread	O
use,	O
acetaminophen	Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
remarkably	O
safe	O
medication	O
in	O
therapeutic	O
dosages.	O
The	O
potential	O
for	O
acetaminophen	Chemical
to	O
produce	O
cardiovascular	Disease
toxicities	Disease
is	O
very	O
low.	O
However,	O
acetaminophen	Chemical
has	O
been	O
demonstrated	O
to	O
produce	O
symptoms	O
of	O
anaphylaxis	Disease
,	O
including	O
hypotension	Disease
,	O
in	O
sensitive	O
individuals.	O
This	O
article	O
describes	O
two	O
critically	Disease
ill	Disease
patients	O
in	O
whom	O
transient	O
episodes	O
of	O
hypotension	Disease
reproducibly	O
developed	O
after	O
administration	O
of	O
acetaminophen	Chemical
.	O
Other	O
symptoms	O
of	O
allergic	Disease
reactions	Disease
were	O
not	O
clinically	O
detectable.	O
The	O
hypotensive	Disease
episodes	O
were	O
severe	O
enough	O
to	O
require	O
vasopressor	O
administration.	O
The	O
reports	O
illustrate	O
the	O
need	O
for	O
clinicians	O
to	O
consider	O
acetaminophen	Chemical
in	O
patients	O
with	O
hypotension	Disease

Acute	O
hepatitis	Disease
,	O
autoimmune	Disease
hemolytic	Disease
anemia	Disease
,	O
and	O
erythroblastocytopenia	Disease
induced	O
by	O
ceftriaxone	Chemical
.	O
An	O
80-yr-old	O
man	O
developed	O
acute	O
hepatitis	Disease
shortly	O
after	O
ingesting	O
oral	O
ceftriaxone	Chemical
.	O
Although	O
the	O
transaminases	O
gradually	O
returned	O
to	O
baseline	O
after	O
withholding	O
the	O
beta	Chemical
lactam	Chemical
antibiotic,	O
there	O
was	O
a	O
gradual	O
increase	O
in	O
serum	O
bilirubin	Chemical
and	O
a	O
decrease	O
in	O
hemoglobin	O
concentration	O
caused	O
by	O
an	O
autoimmune	Disease
hemolytic	Disease
anemia	Disease
and	O
erythroblastocytopenia	Disease
.	O
These	O
responded	O
to	O
systemic	O
steroids	Chemical
and	O
immunoglobulins.	O
Despite	O
the	O
widespread	O
use	O
of	O
these	O
agents	O
this	O
triad	O
of	O
side	O
effects	O
has	O
not	O
previously	O
been	O
reported	O
in	O
connection	O
with	O
beta	Chemical
lactam	Chemical

Adverse	O
effects	O
of	O
the	O
atypical	O
antipsychotics.	O
Collaborative	O
Working	O
Group	O
on	O
Clinical	O
Trial	O
Evaluations.	O
Adverse	O
effects	O
of	O
antipsychotics	O
often	O
lead	O
to	O
noncompliance.	O
Thus,	O
clinicians	O
should	O
address	O
patients'	O
concerns	O
about	O
adverse	O
effects	O
and	O
attempt	O
to	O
choose	O
medications	O
that	O
will	O
improve	O
their	O
patients'	O
quality	O
of	O
life	O
as	O
well	O
as	O
overall	O
health.	O
The	O
side	O
effect	O
profiles	O
of	O
the	O
atypical	O
antipsychotics	O
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
conventional	O
neuroleptics.	O
Conventional	O
agents	O
are	O
associated	O
with	O
unwanted	O
central	O
nervous	O
system	O
effects,	O
including	O
extrapyramidal	Disease
symptoms	Disease
(	O
EPS	Disease
),	O
tardive	Disease
dyskinesia	Disease
,	O
sedation,	O
and	O
possible	O
impairment	O
of	O
some	O
cognitive	O
measures,	O
as	O
well	O
as	O
cardiac	O
effects,	O
orthostatic	Disease
hypotension	Disease
,	O
hepatic	O
changes,	O
anticholinergic	O
side	O
effects,	O
sexual	Disease
dysfunction	Disease
,	O
and	O
weight	Disease
gain	Disease
.	O
The	O
newer	O
atypical	O
agents	O
have	O
a	O
lower	O
risk	O
of	O
EPS	Disease
,	O
but	O
are	O
associated	O
in	O
varying	O
degrees	O
with	O
sedation,	O
cardiovascular	O
effects,	O
anticholinergic	O
effects,	O
weight	Disease
gain	Disease
,	O
sexual	Disease
dysfunction	Disease
,	O
hepatic	O
effects,	O
lowered	O
seizure	Disease
threshold	O
(primarily	O
clozapine	Chemical
),	O
and	O
agranulocytosis	Disease
(	O
clozapine	Chemical

Effects	O
of	O
tetrandrine	Chemical
and	O
fangchinoline	Chemical
on	O
experimental	O
thrombosis	Disease
in	O
mice	O
and	O
human	O
platelet	Disease
aggregation	Disease
.	O
Tetrandrine	Chemical
(	O
TET	Chemical
)	O
and	O
fangchinoline	Chemical
(	O
FAN	Chemical
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	Chemical
structure.	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	Chemical
and	O
FAN	Chemical
on	O
the	O
experimental	O
thrombosis	Disease
induced	O
by	O
collagen	O
plus	O
epinephrine	Chemical
(	O
EP	Chemical
)	O
in	O
mice,	O
and	O
platelet	Disease
aggregation	Disease
and	O
blood	Disease
coagulation	Disease
in	O
vitro.	O
In	O
the	O
in	O
vivo	O
study,	O
the	O
administration	O
(50	O
mg/kg,	O
i.p.)	O
of	O
TET	Chemical
and	O
FAN	Chemical
in	O
mice	O
showed	O
the	O
inhibition	O
of	O
thrombosis	Disease
by	O
55%	O
and	O
35%,	O
respectively,	O
while	O
acetylsalicylic	Chemical
acid	Chemical
(	O
ASA	Chemical
,	O
50	O
mg/kg,	O
i.p.),	O
a	O
positive	O
control,	O
showed	O
only	O
30%	O
inhibition.	O
In	O
the	O
vitro	O
human	O
platelet	Disease
aggregations	Disease
induced	O
by	O
the	O
agonists	O
used	O
in	O
tests,	O
TET	Chemical
and	O
FAN	Chemical
showed	O
the	O
inhibitions	O
dose	O
dependently.	O
In	O
addition,	O
neither	O
TET	Chemical
nor	O
FAN	Chemical
showed	O
any	O
anticoagulation	O
activities	O
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(APTT),	O
prothrombin	O
time	O
(PT)	O
and	O
thrombin	O
time	O
(TT)	O
using	O
human-citrated	O
plasma.	O
These	O
results	O
suggest	O
that	O
antithrombosis	O
of	O
TET	Chemical
and	O
FAN	Chemical

Gemcitabine	Chemical
plus	O
vinorelbine	Chemical
in	O
nonsmall	Disease
cell	Disease
lung	Disease
carcinoma	Disease
patients	O
age	O
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
cannot	O
receive	O
cisplatin	Chemical
.	O
Oncopaz	O
Cooperative	O
Group.	O
BACKGROUND:	O
Although	O
the	O
prevalence	O
of	O
nonsmall	Disease
cell	Disease
lung	Disease
carcinoma	Disease
(	O
NSCLC	Disease
)	O
is	O
high	O
among	O
elderly	O
patients,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	Disease
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients.	O
Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	Chemical
(	O
VNB	Chemical
)	O
or	O
gemcitabine	Chemical
(	O
GEM	Chemical
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
20-30%	O
in	O
elderly	O
patients,	O
with	O
acceptable	O
toxicity	Disease
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life.	O
In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	Disease
of	O
the	O
combination	O
of	O
GEM	Chemical
and	O
VNB	Chemical
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	Disease
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	Chemical
were	O
assessed.	O
METHODS:	O
Forty-nine	O
patients	O
with	O
advanced	O
NSCLC	Disease
were	O
included,	O
38	O
of	O
whom	O
were	O
age	O
>/=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	Chemical
.	O
All	O
patients	O
were	O
evaluable	O
for	O
response	O
and	O
toxicity	Disease
.	O
Treatment	O
was	O
comprised	O
of	O
VNB	Chemical
,	O
25	O
mg/m(2),	O
plus	O
GEM	Chemical
,	O
1000	O
mg/m(2),	O
both	O
on	O
Days	O
1,	O
8,	O
and	O
15	O
every	O
28	O
days.	O
Patients	O
received	O
a	O
minimum	O
of	O
three	O
courses	O
unless	O
progressive	O
disease	O
was	O
detected.	O
RESULTS:	O
One	O
hundred	O
sixty-five	O
courses	O
were	O
administered,	O
with	O
a	O
median	O
of	O
3.	O
6	O
courses	O
per	O
patient.	O
The	O
overall	O
response	O
rate	O
was	O
26%	O
(95%	O
confidence	O
interval,	O
15-41%).	O
Two	O
patients	O
attained	O
a	O
complete	O
response	O
(4%)	O
and	O
11	O
patients	O
(22%)	O
achieved	O
a	O
partial	O
response.	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
improved	O
in	O
35%	O
of	O
those	O
patients	O
with	O
an	O
initial	O
value	O
>	O
0,	O
whereas	O
relief	O
of	O
at	O
least	O
1	O
symptom	O
without	O
worsening	O
of	O
other	O
symptoms	O
was	O
noted	O
in	O
27	O
patients	O
(55%).	O
The	O
median	O
time	O
to	O
progression	O
was	O
16	O
weeks	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
33%.	O
Toxicity	Disease
was	O
mild.	O
Six	O
patients	O
(12%)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3-4	O
neutropenia	Disease
,	O
2	O
patients	O
(4%)	O
had	O
Grade	O
3-4	O
thrombocytopenia	Disease
,	O
and	O
2	O
patients	O
(4%)	O
had	O
Grade	O
3	O
neurotoxicity	Disease
.	O
Three	O
patients	O
with	O
severe	O
neutropenia	Disease
(6%)	O
died	O
of	O
sepsis	Disease
.	O
The	O
median	O
age	O
of	O
those	O
patients	O
developing	O
Grade	O
3-4	O
neutropenia	Disease
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
remaining	O
patients	O
(75	O
years	O
vs.	O
72	O
years;	O
P	O
=	O
0.047).	O
CONCLUSIONS:	O
The	O
combination	O
of	O
GEM	Chemical
and	O
VNB	Chemical
is	O
moderately	O
active	O
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>/=	O
75	O
years.	O
This	O
age	O
group	O
had	O
an	O
increased	O
risk	O
of	O
myelosuppression	Disease
.	O
Therefore	O
the	O
prophylactic	O
use	O
of	O
granulocyte-colony	O
stimulating	O
factor	O
should	O
be	O
considered	O
with	O
this	O
treatment.	O
New	O
chemotherapy	O
combinations	O
with	O
higher	O
activity	O
and	O
lower	O
toxicity	Disease
are	O
needed	O
for	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	Disease

Warfarin	Chemical
-induced	O
artery	Disease
calcification	Disease
is	O
accelerated	O
by	O
growth	O
and	O
vitamin	Chemical
D	Chemical
.	O
The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	Chemical
D	Chemical
treatment	O
enhance	O
the	O
extent	O
of	O
artery	Disease
calcification	Disease
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	Chemical
to	O
inhibit	O
gamma-carboxylation	O
of	O
matrix	O
Gla	O
protein,	O
a	O
calcification	Disease
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall.	O
The	O
first	O
series	O
of	O
experiments	O
examined	O
the	O
influence	O
of	O
age	O
and	O
growth	O
status	O
on	O
artery	Disease
calcification	Disease
in	O
Warfarin	Chemical
-treated	O
rats.	O
Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	Chemical
caused	O
massive	O
focal	O
calcification	Disease
of	Disease
the	Disease
artery	Disease
media	O
in	O
20-day-old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	Disease
in	O
42-day-old	O
rats.	O
In	O
contrast,	O
no	O
artery	Disease
calcification	Disease
could	O
be	O
detected	O
in	O
10-month-old	O
adult	O
rats	O
even	O
after	O
4	O
weeks	O
of	O
Warfarin	Chemical
treatment.	O
To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin	Chemical
-induced	O
artery	Disease
calcification	Disease
in	O
animals	O
of	O
the	O
same	O
age,	O
20-day-old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6-g/d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth.	O
Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	Chemical
produced	O
massive	O
focal	O
calcification	Disease
of	Disease
the	Disease
artery	Disease
media	O
in	O
the	O
ad	O
libitum-fed	O
rats	O
but	O
no	O
detectable	O
artery	Disease
calcification	Disease
in	O
the	O
restricted-diet,	O
growth-inhibited	O
group.	O
Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	Disease
calcification	Disease
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	Chemical
and	O
susceptibility	O
to	O
artery	Disease
calcification	Disease
,	O
with	O
30%	O
higher	O
levels	O
of	O
serum	O
phosphate	Chemical
in	O
young,	O
ad	O
libitum-fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	Chemical
-induced	O
artery	Disease
calcification	Disease
,	O
ie,	O
the	O
10-month-old	O
rats	O
and	O
the	O
restricted-diet,	O
growth-inhibited	O
young	O
rats.	O
This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	O
to	O
Warfarin	Chemical
-induced	O
artery	Disease
calcification	Disease
could	O
be	O
related	O
to	O
higher	O
serum	O
phosphate	Chemical
levels.	O
The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	O
between	O
vitamin	Chemical
D	Chemical
and	O
Warfarin	Chemical
in	O
artery	Disease
calcification	Disease
.	O
High	O
doses	O
of	O
vitamin	Chemical
D	Chemical
are	O
known	O
to	O
cause	O
calcification	Disease
of	Disease
the	Disease
artery	Disease
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days.	O
High	O
doses	O
of	O
the	O
vitamin	Chemical
K	Chemical
antagonist	O
Warfarin	Chemical
are	O
also	O
known	O
to	O
cause	O
calcification	Disease
of	Disease
the	Disease
artery	Disease
media,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week.	O
In	O
the	O
current	O
study,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	Chemical
administration	O
dramatically	O
increased	O
the	O
extent	O
of	O
calcification	Disease
in	O
the	O
media	O
of	O
vitamin	Chemical
D	Chemical
-treated	O
rats	O
at	O
3	O
and	O
4	O
days.	O
There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	Chemical
D	Chemical
dose	O
on	O
artery	Disease
calcification	Disease
and	O
the	O
effect	O
of	O
vitamin	Chemical
D	Chemical
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	Chemical
,	O
which	O
suggests	O
that	O
vitamin	Chemical
D	Chemical
may	O
induce	O
artery	Disease
calcification	Disease
through	O
its	O
effect	O
on	O
serum	O
calcium	Chemical
.	O
Because	O
Warfarin	Chemical
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	Chemical
produced	O
by	O
vitamin	Chemical
D	Chemical
,	O
the	O
synergy	O
between	O
Warfarin	Chemical
and	O
vitamin	Chemical
D	Chemical
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	Chemical
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	Disease
inhibitor.	O
High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	Disease
calcification	Disease
in	O
rats	O
treated	O
with	O
vitamin	Chemical
D	Chemical
plus	O
Warfarin	Chemical
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma-carboxylated	Chemical
.	O
These	O
observations	O
indicate	O
that	O
although	O
the	O
gamma-carboxyglutamate	Chemical
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	O
as	O
a	O
calcification	Disease
inhibitor,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	Disease

Antidepressant	Chemical
-induced	O
mania	Disease
in	O
bipolar	Disease
patients:	O
identification	O
of	O
risk	O
factors.	O
BACKGROUND:	O
Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	Disease
associated	O
with	O
antidepressants	Chemical
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	O
paradigm	O
for	O
bipolar	Disease
depression	Disease
.	O
METHOD:	O
The	O
response	O
of	O
44	O
patients	O
meeting	O
DSM-IV	O
criteria	O
for	O
bipolar	Disease
disorder	Disease
to	O
naturalistic	O
treatment	O
was	O
assessed	O
for	O
at	O
least	O
6	O
weeks	O
using	O
the	O
Montgomery-Asberg	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Bech-Rafaelson	O
Mania	O
Rating	O
Scale.	O
Patients	O
who	O
experienced	O
a	O
manic	Disease
or	O
hypomanic	Disease
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age,	O
sex,	O
diagnosis	O
(	O
DSM-IV	Disease
bipolar	Disease
I	Disease
vs.	O
bipolar	Disease
II	Disease
),	O
number	O
of	O
previous	O
manic	Disease
episodes,	O
type	O
of	O
antidepressant	Chemical
therapy	O
used	O
(electroconvulsive	O
therapy	O
vs.	O
antidepressant	Chemical
drugs	O
and,	O
more	O
particularly,	O
selective	O
serotonin	Chemical
reuptake	Chemical
inhibitors	Chemical
[	O
SSRIs	Chemical
]),	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	Chemical
vs.	O
anticonvulsants),	O
and	O
temperament	O
of	O
the	O
patient,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi-structured	O
Affective	O
Temperament	O
Interview.	O
RESULTS:	O
Switches	O
to	O
hypomania	Disease
or	O
mania	Disease
occurred	O
in	O
27%	O
of	O
all	O
patients	O
(N	O
=	O
12)	O
(and	O
in	O
24%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	Chemical
[8/33]);	O
16%	O
(N	O
=	O
7)	O
experienced	O
manic	Disease
episodes,	O
and	O
11%	O
(N	O
=	O
5)	O
experienced	O
hypomanic	Disease
episodes.	O
Sex,	O
age,	O
diagnosis	O
(	O
bipolar	Disease
I	Disease
vs.	O
bipolar	Disease
II	Disease
),	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching.	O
The	O
incidence	O
of	O
mood	O
switches	O
seemed	O
not	O
to	O
differ	O
between	O
patients	O
receiving	O
an	O
anticonvulsant	O
and	O
those	O
receiving	O
no	O
mood	O
stabilizer.	O
In	O
contrast,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	O
receiving	O
lithium	Chemical
(15%,	O
4/26)	O
than	O
in	O
patients	O
not	O
treated	O
with	O
lithium	Chemical
(44%,	O
8/18;	O
p	O
=	O
.04).	O
The	O
number	O
of	O
previous	O
manic	Disease
episodes	O
did	O
not	O
affect	O
the	O
probability	O
of	O
switching,	O
whereas	O
a	O
high	O
score	O
on	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semistructured	O
Affective	O
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
switching	O
(p	O
=	O
.008).	O
CONCLUSION:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	O
with	O
acute	O
antidepressant	Chemical
therapy	O
may	O
be	O
reduced	O
by	O
lithium	Chemical

Caffeine	Chemical
-induced	O
cardiac	Disease
arrhythmia	Disease
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products.	O
We	O
describe	O
a	O
25-year-old	O
woman	O
with	O
pre-existing	O
mitral	Disease
valve	Disease
prolapse	Disease
who	O
developed	O
intractable	O
ventricular	Disease
fibrillation	Disease
after	O
consuming	O
a	O
"natural	O
energy"	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	Chemical

Bladder	O
retention	Disease
of	Disease
urine	Disease
as	O
a	O
result	O
of	O
continuous	O
intravenous	O
infusion	O
of	O
fentanyl	Chemical
:	O
2	O
case	O
reports.	O
Sedation	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonate	O
to	O
decrease	O
the	O
stress	O
and	O
pain	Disease
from	O
the	O
noxious	O
stimuli	O
and	O
invasive	O
procedures	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit,	O
as	O
well	O
as	O
to	O
facilitate	O
synchrony	O
between	O
ventilator	O
and	O
spontaneous	O
breaths.	O
Fentanyl	Chemical
,	O
an	O
opioid	O
analgesic,	O
is	O
frequently	O
used	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
setting	O
for	O
these	O
very	O
purposes.	O
Various	O
reported	O
side	O
effects	O
of	O
fentanyl	Chemical
administration	O
include	O
chest	Disease
wall	Disease
rigidity	Disease
,	O
hypotension	Disease
,	O
respiratory	Disease
depression	Disease
,	O
and	O
bradycardia	Disease
.	O
Here,	O
2	O
cases	O
of	O
urinary	Disease
bladder	Disease
retention	Disease
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	Disease
as	O
a	O
result	O
of	O
continuous	O
infusion	O
of	O
fentanyl	Chemical

Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	Disease
and	O
elevates	O
plasma	O
lactate	Chemical
in	O
transgenic	O
AIDS	Disease
mice.	O
Highly	O
active	O
antiretroviral	O
therapy	O
(HAART)	O
is	O
implicated	O
in	O
cardiomyopathy	Disease
(	O
CM	Disease
)	O
and	O
in	O
elevated	O
plasma	O
lactate	Chemical
(	O
LA	Chemical
)	O
in	O
AIDS	Disease
through	O
mechanisms	O
of	O
mitochondrial	Disease
dysfunction	Disease
.	O
To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo,	O
8-week-old	O
hemizygous	O
transgenic	O
AIDS	Disease
mice	O
(NL4-3Delta	O
gag/pol;	O
TG)	O
and	O
wild-type	O
FVB/n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	O
of	O
zidovudine	Chemical
,	O
lamivudine	Chemical
,	O
and	O
indinavir	Chemical
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days.	O
At	O
termination	O
of	O
the	O
experiments,	O
mice	O
underwent	O
echocardiography,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	Disease
(ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[ANF]	O
and	O
sarcoplasmic	O
calcium	Chemical
ATPase	O
[SERCA2]),	O
and	O
determination	O
of	O
plasma	O
LA	Chemical
.	O
Myocardial	O
histologic	O
features	O
were	O
analyzed	O
semiquantitatively	O
and	O
results	O
were	O
confirmed	O
by	O
transmission	O
electron	O
microscopy.	O
After	O
35	O
days	O
in	O
the	O
TG	O
+	O
HAART	O
cohort,	O
left	O
ventricular	O
mass	O
increased	O
160%	O
by	O
echocardiography.	O
Molecularly,	O
ANF	O
mRNA	O
increased	O
250%	O
and	O
SERCA2	O
mRNA	O
decreased	O
57%.	O
Biochemically,	O
LA	Chemical
was	O
elevated	O
(8.5	O
+/-	O
2.0	O
mM).	O
Pathologically,	O
granular	O
cytoplasmic	O
changes	O
were	O
found	O
in	O
cardiac	O
myocytes,	O
indicating	O
enlarged,	O
damaged	O
mitochondria.	O
Findings	O
were	O
confirmed	O
ultrastructurally.	O
No	O
changes	O
were	O
found	O
in	O
other	O
cohorts.	O
After	O
10	O
days,	O
only	O
ANF	O
was	O
elevated,	O
and	O
only	O
in	O
the	O
TG	O
+	O
HAART	O
cohort.	O
Results	O
show	O
that	O
cumulative	O
HAART	O
caused	O
mitochondrial	O
CM	Disease
with	O
elevated	O
LA	Chemical
in	O
AIDS	Disease

Oral	Chemical
contraceptives	Chemical
and	O
the	O
risk	O
of	O
myocardial	Disease
infarction	Disease
.	O
BACKGROUND:	O
An	O
association	O
between	O
the	O
use	O
of	O
oral	Chemical
contraceptives	Chemical
and	O
the	O
risk	O
of	O
myocardial	Disease
infarction	Disease
has	O
been	O
found	O
in	O
some,	O
but	O
not	O
all,	O
studies.	O
We	O
investigated	O
this	O
association,	O
according	O
to	O
the	O
type	O
of	O
progestagen	Chemical
included	O
in	O
third-generation	O
(i.e.,	O
desogestrel	Chemical
or	O
gestodene	Chemical
)	O
and	O
second-generation	O
(i.e.,	O
levonorgestrel	Chemical
)	O
oral	Chemical
contraceptives	Chemical
,	O
the	O
dose	O
of	O
estrogen	Chemical
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS:	O
In	O
a	O
nationwide,	O
population-based,	O
case-control	O
study,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	Disease
infarction	Disease
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	Disease
infarction	Disease
and	O
who	O
were	O
matched	O
for	O
age,	O
calendar	O
year	O
of	O
the	O
index	O
event,	O
and	O
area	O
of	O
residence.	O
Subjects	O
supplied	O
information	O
on	O
oral-contraceptive	Chemical
use	O
and	O
major	O
cardiovascular	O
risk	O
factors.	O
An	O
analysis	O
for	O
factor	O
V	O
Leiden	O
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	O
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS:	O
The	O
odds	O
ratio	O
for	O
myocardial	Disease
infarction	Disease
among	O
women	O
who	O
used	O
any	O
type	O
of	O
combined	O
oral	Chemical
contraceptive	Chemical
,	O
as	O
compared	O
with	O
nonusers,	O
was	O
2.0	O
(95	O
percent	O
confidence	O
interval,	O
1.5	O
to	O
2.8).	O
The	O
adjusted	O
odds	O
ratio	O
was	O
2.5	O
(95	O
percent	O
confidence	O
interval,	O
1.5	O
to	O
4.1)	O
among	O
women	O
who	O
used	O
second-generation	O
oral	Chemical
contraceptives	Chemical
and	O
1.3	O
(95	O
percent	O
confidence	O
interval,	O
0.7	O
to	O
2.5)	O
among	O
those	O
who	O
used	O
third-generation	O
oral	Chemical
contraceptives	Chemical
.	O
Among	O
women	O
who	O
used	O
oral	Chemical
contraceptives	Chemical
,	O
the	O
odds	O
ratio	O
was	O
2.1	O
(95	O
percent	O
confidence	O
interval,	O
1.5	O
to	O
3.0)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1.9	O
(95	O
percent	O
confidence	O
interval,	O
0.6	O
to	O
5.5)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS:	O
The	O
risk	O
of	O
myocardial	Disease
infarction	Disease
was	O
increased	O
among	O
women	O
who	O
used	O
second-generation	O
oral	Chemical
contraceptives	Chemical
.	O
The	O
results	O
with	O
respect	O
to	O
the	O
use	O
of	O
third-generation	O
oral	Chemical
contraceptives	Chemical
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	O
with	O
second-generation	O
oral	Chemical
contraceptives	Chemical
.	O
The	O
risk	O
of	O
myocardial	Disease
infarction	Disease
was	O
similar	O
among	O
women	O
who	O
used	O
oral	Chemical
contraceptives	Chemical

Effects	O
of	O
5-HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbal	O
shell	O
or	O
core	O
on	O
the	O
cocaine	Chemical
-induced	O
locomotor	Disease
hyperactivity	Disease
in	O
rats.	O
The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5-HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(the	O
shell	O
and	O
the	O
core)	O
on	O
the	O
locomotor	Disease
hyperactivity	Disease
induced	O
by	O
cocaine	Chemical
in	O
rats.	O
Male	O
Wistar	O
rats	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core,	O
and	O
then	O
were	O
locally	O
injected	O
with	O
GR	Chemical
55562	Chemical
(an	O
antagonist	O
of	O
5-HT1B	O
receptors)	O
or	O
CP	Chemical
93129	Chemical
(an	O
agonist	O
of	O
5-HT1B	O
receptors).	O
Given	O
alone	O
to	O
any	O
accumbal	O
subregion,	O
GR	Chemical
55562	Chemical
(0.1-10	O
microg/side)	O
or	O
CP	Chemical
93129	Chemical
(0.1-10	O
microg/side)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity.	O
Systemic	O
cocaine	Chemical
(10	O
mg/kg)	O
significantly	O
increased	O
the	O
locomotor	O
activity	O
of	O
rats.	O
GR	Chemical
55562	Chemical
(0.1-10	O
microg/side),	O
administered	O
intra-accumbens	O
shell	O
prior	O
to	O
cocaine	Chemical
,	O
dose-dependently	O
attenuated	O
the	O
psychostimulant-induced	O
locomotor	Disease
hyperactivity	Disease
.	O
Such	O
attenuation	O
was	O
not	O
found	O
in	O
animals	O
which	O
had	O
been	O
injected	O
with	O
GR	Chemical
55562	Chemical
into	O
the	O
accumbens	O
core.	O
When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(but	O
not	O
the	O
core)	O
before	O
cocaine	Chemical
,	O
CP	Chemical
93129	Chemical
(0.1-10	O
microg/side)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	Chemical
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg/side	O
of	O
the	O
agonist.	O
The	O
later	O
enhancement	O
was	O
attenuated	O
after	O
intra-accumbens	O
shell	O
treatment	O
with	O
GR	Chemical
55562	Chemical
(1	O
microg/side).	O
Our	O
findings	O
indicate	O
that	O
cocaine	Chemical
induced	O
hyperlocomotion	Disease
is	O
modified	O
by	O
5-HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell,	O
but	O
not	O
core,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5-HT1B	O
receptor	O
antagonist	O
(	O
GR	Chemical
55562	Chemical
)	O
and	O
agonist	O
(	O
CP	Chemical
93129	Chemical

Ticlopidine	Chemical
-induced	O
cholestatic	Disease
hepatitis	Disease
.	O
OBJECTIVE:	O
To	O
report	O
2	O
cases	O
of	O
ticlopidine	Chemical
-induced	O
cholestatic	Disease
hepatitis	Disease
,	O
investigate	O
its	O
mechanism,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases.	O
CASE	O
SUMMARIES:	O
Two	O
patients	O
developed	O
prolonged	O
cholestatic	Disease
hepatitis	Disease
after	O
receiving	O
ticlopidine	Chemical
following	O
percutaneous	O
coronary	O
angioplasty,	O
with	O
complete	O
remission	O
during	O
the	O
follow-up	O
period.	O
T-cell	O
stimulation	O
by	O
therapeutic	O
concentration	O
of	O
ticlopidine	Chemical
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patients,	O
but	O
not	O
in	O
healthy	O
controls.	O
DISCUSSION:	O
Cholestatic	Disease
hepatitis	Disease
is	O
a	O
rare	O
complication	O
of	O
the	O
antiplatelet	O
agent	O
ticlopidine	Chemical
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature.	O
Our	O
patients	O
developed	O
jaundice	Disease
following	O
treatment	O
with	O
ticlopidine	Chemical
and	O
showed	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	Disease
hepatitis	Disease
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug.	O
Hepatitis	Disease
may	O
develop	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	O
and	O
may	O
run	O
a	O
prolonged	O
course,	O
but	O
complete	O
remission	O
was	O
observed	O
in	O
all	O
reported	O
cases.	O
An	O
objective	O
causality	O
assessment	O
revealed	O
that	O
the	O
adverse	O
drug	O
event	O
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopidine	Chemical
.	O
The	O
mechanisms	O
of	O
this	O
ticlopidine	Chemical
-induced	O
cholestasis	Disease
are	O
unclear.	O
Immune	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
drug's	O
hepatotoxicity	Disease
,	O
as	O
suggested	O
by	O
the	O
T-cell	O
stimulation	O
study	O
reported	O
here.	O
CONCLUSIONS:	O
Cholestatic	Disease
hepatitis	Disease
is	O
a	O
rare	O
adverse	O
effect	O
of	O
ticlopidine	Chemical
that	O
may	O
be	O
immune	O
mediated.	O
Patients	O
receiving	O
the	O
drug	O
should	O
be	O
monitored	O
with	O
liver	O
function	O
tests	O
along	O
with	O
complete	O
blood	O
cell	O
counts.	O
This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	Chemical
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	O
clopidogrel	Chemical

Epithelial	O
sodium	Chemical
channel	O
(ENaC)	O
subunit	O
mRNA	O
and	O
protein	O
expression	O
in	O
rats	O
with	O
puromycin	Chemical
aminonucleoside	Chemical
-induced	O
nephrotic	Disease
syndrome	Disease
.	O
In	O
experimental	O
nephrotic	Disease
syndrome	Disease
,	O
urinary	O
sodium	Chemical
excretion	O
is	O
decreased	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease.	O
The	O
molecular	O
mechanism(s)	O
leading	O
to	O
salt	O
retention	O
has	O
not	O
been	O
completely	O
elucidated.	O
The	O
rate-limiting	O
constituent	O
of	O
collecting	O
duct	O
sodium	Chemical
transport	O
is	O
the	O
epithelial	O
sodium	Chemical
channel	O
(ENaC).	O
We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	Chemical
aminonucleoside	Chemical
(	O
PAN	Chemical
)-induced	O
nephrotic	Disease
syndrome	Disease
.	O
The	O
time	O
courses	O
of	O
urinary	O
sodium	Chemical
excretion,	O
plasma	O
aldosterone	Chemical
concentration	O
and	O
proteinuria	Disease
were	O
studied	O
in	O
male	O
Sprague-Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	Chemical
or	O
vehicle.	O
The	O
relative	O
amounts	O
of	O
alphaENaC,	O
betaENaC	O
and	O
gammaENaC	O
mRNAs	O
were	O
determined	O
in	O
kidneys	O
from	O
these	O
rats	O
by	O
real-time	O
quantitative	O
TaqMan	O
PCR,	O
and	O
the	O
amounts	O
of	O
proteins	O
by	O
Western	O
blot.	O
The	O
kinetics	O
of	O
urinary	O
sodium	Chemical
excretion	O
and	O
the	O
appearance	O
of	O
proteinuria	Disease
were	O
comparable	O
with	O
those	O
reported	O
previously.	O
Sodium	Chemical
retention	O
occurred	O
on	O
days	O
2,	O
3	O
and	O
6	O
after	O
PAN	Chemical
injection.	O
A	O
significant	O
up-regulation	O
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	O
abundance	O
on	O
days	O
1	O
and	O
2	O
preceded	O
sodium	Chemical
retention	O
on	O
days	O
2	O
and	O
3.	O
Conversely,	O
down-regulation	O
of	O
alphaENaC,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	O
of	O
high	O
aldosterone	Chemical
concentrations,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodium	Chemical
excretion	O
to	O
control	O
values.	O
The	O
amounts	O
of	O
alphaENaC,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	O
during	O
PAN	Chemical
-induced	O
sodium	Chemical
retention.	O
In	O
conclusion,	O
ENaC	O
mRNA	O
expression,	O
especially	O
alphaENaC,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	O
of	O
PAN	Chemical
-induced	O
nephrotic	Disease
syndrome	Disease
in	O
rats,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	O
by	O
aldosterone	Chemical

NO	Chemical
-induced	O
migraine	Disease
attack:	O
strong	O
increase	O
in	O
plasma	O
calcitonin	Chemical
gene-related	Chemical
peptide	Chemical
(	O
CGRP	Chemical
)	O
concentration	O
and	O
negative	O
correlation	O
with	O
platelet	O
serotonin	Chemical
release.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
in	O
the	O
plasma	O
calcitonin	Chemical
gene-related	Chemical
peptide	Chemical
(	O
CGRP	Chemical
)	O
concentration	O
and	O
platelet	O
serotonin	Chemical
(	O
5-hydroxytriptamine	Chemical
,	O
5-HT	Chemical
)	O
content	O
during	O
the	O
immediate	O
headache	Disease
and	O
the	O
delayed	O
genuine	O
migraine	Disease
attack	O
provoked	O
by	O
nitroglycerin	Chemical
.	O
Fifteen	O
female	O
migraineurs	Disease
(without	Disease
aura)	Disease
and	O
eight	O
controls	O
participated	O
in	O
the	O
study.	O
Sublingual	O
nitroglycerin	Chemical
(0.5	O
mg)	O
was	O
administered.	O
Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
four	O
times:	O
60	O
min	O
before	O
and	O
after	O
the	O
nitroglycerin	Chemical
application,	O
and	O
60	O
and	O
120	O
min	O
after	O
the	O
beginning	O
of	O
the	O
migraine	Disease
attack	O
(mean	O
344	O
and	O
404	O
min;	O
12	O
subjects).	O
In	O
those	O
subjects	O
who	O
had	O
no	O
migraine	Disease
attack	O
(11	O
subjects)	O
a	O
similar	O
time	O
schedule	O
was	O
used.	O
Plasma	O
CGRP	Chemical
concentration	O
increased	O
significantly	O
(P<0.01)	O
during	O
the	O
migraine	Disease
attack	O
and	O
returned	O
to	O
baseline	O
after	O
the	O
cessation	O
of	O
the	O
migraine	Disease
.	O
In	O
addition,	O
both	O
change	O
and	O
peak,	O
showed	O
significant	O
positive	O
correlations	O
with	O
migraine	Disease
	O
headache	Disease
intensity	O
(P<0.001).	O
However,	O
plasma	O
CGRP	Chemical
concentrations	O
failed	O
to	O
change	O
during	O
immediate	O
headache	Disease
and	O
in	O
the	O
subjects	O
with	O
no	O
migraine	Disease
attack.	O
Basal	O
CGRP	Chemical
concentration	O
was	O
significantly	O
higher	O
and	O
platelet	O
5-HT	Chemical
content	O
tended	O
to	O
be	O
lower	O
in	O
subjects	O
who	O
experienced	O
a	O
migraine	Disease
attack.	O
Platelet	O
serotonin	Chemical
content	O
decreased	O
significantly	O
(P<0.01)	O
after	O
nitroglycerin	Chemical
in	O
subjects	O
with	O
no	O
migraine	Disease
attack	O
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	Disease
attack.	O
In	O
conclusion,	O
the	O
fact	O
that	O
plasma	O
CGRP	Chemical
concentration	O
correlates	O
with	O
the	O
timing	O
and	O
severity	O
of	O
a	O
migraine	Disease
	O
headache	Disease
suggests	O
a	O
direct	O
relationship	O
between	O
CGRP	Chemical
and	O
migraine	Disease
.	O
In	O
contrast,	O
serotonin	Chemical
release	O
from	O
platelets	O
does	O
not	O
provoke	O
migraine	Disease
,	O
it	O
may	O
even	O
counteract	O
the	O
headache	Disease
and	O
the	O
concomitant	O
CGRP	Chemical

Coronary	Disease
aneurysm	Disease
after	O
implantation	O
of	O
a	O
paclitaxel	Chemical
-eluting	O
stent.	O
Formation	O
of	O
coronary	Disease
aneurysm	Disease
is	O
a	O
rare	O
complication	O
of	O
stenting	O
with	O
bare	O
metal	O
stents,	O
but	O
based	O
on	O
experimental	O
studies	O
drug-eluting	O
stents	O
may	O
induce	O
toxic	O
effects	O
on	O
the	O
vessel	O
wall	O
with	O
incomplete	O
stent	O
apposition,	O
aneurysm	Disease
formation	O
and	O
with	O
the	O
potential	O
of	O
stent	O
thrombosis	Disease
or	O
vessel	Disease
rupture	Disease
.	O
We	O
present	O
a	O
43-year-old	O
man	O
who	O
developed	O
a	O
coronary	Disease
aneurysm	Disease
in	O
the	O
right	O
coronary	O
artery	O
6	O
months	O
after	O
receiving	O
a	O
paclitaxel	Chemical
-eluting	O
stent.	O
The	O
patient	O
was	O
asymptomatic	O
and	O
the	O
aneurysm	Disease
was	O
detected	O
in	O
a	O
routine	O
control.	O
Angiography	O
and	O
intracoronary	O
ultrasound	O
demonstrated	O
lack	O
of	O
contact	O
between	O
stent	O
and	O
vessel	O
wall	O
in	O
a	O
15-mm	O
long	O
segment	O
with	O
maximal	O
aneurysm	Disease

Behavioral	O
effects	O
of	O
urotensin-II	Chemical
centrally	O
administered	O
in	O
mice.	O
Urotensin-II	Chemical
(	O
U-II	Chemical
)	O
receptors	O
are	O
widely	O
distributed	O
in	O
the	O
central	O
nervous	O
system.	O
Intracerebroventricular	O
(i.c.v.)	O
injection	O
of	O
U-II	Chemical
causes	O
hypertension	Disease
and	O
bradycardia	Disease
and	O
stimulates	O
prolactin	O
and	O
thyrotropin	O
secretion.	O
However,	O
the	O
behavioral	O
effects	O
of	O
centrally	O
administered	O
U-II	Chemical
have	O
received	O
little	O
attention.	O
In	O
the	O
present	O
study,	O
we	O
tested	O
the	O
effects	O
of	O
i.c.v.	O
injections	O
of	O
U-II	Chemical
on	O
behavioral,	O
metabolic,	O
and	O
endocrine	O
responses	O
in	O
mice.	O
Administration	O
of	O
graded	O
doses	O
of	O
U-II	Chemical
(1-10,000	O
ng/mouse)	O
provoked:	O
(1)	O
a	O
dose-dependent	O
reduction	O
in	O
the	O
number	O
of	O
head	O
dips	O
in	O
the	O
hole-board	O
test;	O
(2)	O
a	O
dose-dependent	O
reduction	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
white	O
chamber	O
in	O
the	O
black-and-white	O
compartment	O
test,	O
and	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
central	O
platform	O
and	O
open	O
arms	O
in	O
the	O
plus-maze	O
test;	O
and	O
(3)	O
a	O
dose-dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
the	O
forced-swimming	O
test	O
and	O
tail	O
suspension	O
test.	O
Intracerebroventricular	O
injection	O
of	O
U-II	Chemical
also	O
caused	O
an	O
increase	O
in:	O
food	O
intake	O
at	O
doses	O
of	O
100	O
and	O
1,000	O
ng/mouse,	O
water	O
intake	O
at	O
doses	O
of	O
100-10,000	O
ng/mouse,	O
and	O
horizontal	O
locomotion	O
activity	O
at	O
a	O
dose	O
of	O
10,000	O
ng/mouse.	O
Whatever	O
was	O
the	O
dose,	O
the	O
central	O
administration	O
of	O
U-II	Chemical
had	O
no	O
effect	O
on	O
body	O
temperature,	O
nociception,	O
apomorphine	Chemical
-induced	O
penile	Disease
erection	Disease
and	O
climbing	O
behavior,	O
and	O
stress-induced	O
plasma	O
corticosterone	Chemical
level.	O
Taken	O
together,	O
the	O
present	O
study	O
demonstrates	O
that	O
the	O
central	O
injection	O
of	O
U-II	Chemical
at	O
doses	O
of	O
1-10,000	O
ng/mouse	O
induces	O
anxiogenic-	O
and	O
depressant-like	O
effects	O
in	O
mouse.	O
These	O
data	O
suggest	O
that	O
U-II	Chemical
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiatric	Disease
disorders	Disease

Recurrent	O
dysphonia	Disease
and	O
acitretin	Chemical
.	O
We	O
report	O
the	O
case	O
of	O
a	O
woman	O
complaining	O
of	O
dysphonia	Disease
while	O
she	O
was	O
treated	O
by	O
acitretin	Chemical
.	O
Her	O
symptoms	O
totally	O
regressed	O
after	O
drug	O
withdrawal	O
and	O
reappeared	O
when	O
acitretin	Chemical
was	O
reintroduced.	O
To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
case	O
of	O
acitretin	Chemical
-induced	O
dysphonia	Disease

Pharmacological	O
modulation	O
of	O
pain	Disease
-related	O
brain	O
activity	O
during	O
normal	O
and	O
central	O
sensitization	O
states	O
in	O
humans.	O
Abnormal	O
processing	O
of	O
somatosensory	O
inputs	O
in	O
the	O
central	O
nervous	O
system	O
(central	O
sensitization)	O
is	O
the	O
mechanism	O
accounting	O
for	O
the	O
enhanced	O
pain	Disease
sensitivity	O
in	O
the	O
skin	O
surrounding	O
tissue	Disease
injury	Disease
(	O
secondary	Disease
hyperalgesia	Disease
).	O
Secondary	Disease
hyperalgesia	Disease
shares	O
clinical	O
characteristics	O
with	O
neurogenic	Disease
hyperalgesia	Disease
in	O
patients	O
with	O
neuropathic	Disease
pain	Disease
.	O
Abnormal	O
brain	O
responses	O
to	O
somatosensory	O
stimuli	O
have	O
been	O
found	O
in	O
patients	O
with	O
hyperalgesia	Disease
as	O
well	O
as	O
in	O
normal	O
subjects	O
during	O
experimental	O
central	O
sensitization.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
gabapentin	Chemical
,	O
a	O
drug	O
effective	O
in	O
neuropathic	Disease
pain	Disease
patients,	O
on	O
brain	O
processing	O
of	O
nociceptive	O
information	O
in	O
normal	O
and	O
central	O
sensitization	O
states.	O
Using	O
functional	O
magnetic	O
resonance	O
imaging	O
(fMRI)	O
in	O
normal	O
volunteers,	O
we	O
studied	O
the	O
gabapentin	Chemical
-induced	O
modulation	O
of	O
brain	O
activity	O
in	O
response	O
to	O
nociceptive	O
mechanical	O
stimulation	O
of	O
normal	O
skin	O
and	O
capsaicin	Chemical
-induced	O
secondary	Disease
hyperalgesia	Disease
.	O
The	O
dose	O
of	O
gabapentin	Chemical
was	O
1,800	O
mg	O
per	O
os,	O
in	O
a	O
single	O
administration.	O
We	O
found	O
that	O
(i)	O
gabapentin	Chemical
reduced	O
the	O
activations	O
in	O
the	O
bilateral	O
operculoinsular	O
cortex,	O
independently	O
of	O
the	O
presence	O
of	O
central	O
sensitization;	O
(ii)	O
gabapentin	Chemical
reduced	O
the	O
activation	O
in	O
the	O
brainstem,	O
only	O
during	O
central	O
sensitization;	O
(iii)	O
gabapentin	Chemical
suppressed	O
stimulus-induced	O
deactivations,	O
only	O
during	O
central	O
sensitization;	O
this	O
effect	O
was	O
more	O
robust	O
than	O
the	O
effect	O
on	O
brain	O
activation.	O
The	O
observed	O
drug-induced	O
effects	O
were	O
not	O
due	O
to	O
changes	O
in	O
the	O
baseline	O
fMRI	O
signal.	O
These	O
findings	O
indicate	O
that	O
gabapentin	Chemical
has	O
a	O
measurable	O
antinociceptive	O
effect	O
and	O
a	O
stronger	O
antihyperalgesic	O
effect	O
most	O
evident	O
in	O
the	O
brain	O
areas	O
undergoing	O
deactivation,	O
thus	O
supporting	O
the	O
concept	O
that	O
gabapentin	Chemical

MDMA	Chemical
polydrug	O
users	O
show	O
process-specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	Disease
social	Disease
and	Disease
emotional	Disease
judgement	Disease
processes	Disease
.	O
In	O
recent	O
years	O
working	O
memory	Disease
deficits	Disease
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	Chemical
(	O
3,4-methylenedioxymethamphetamine	Chemical
,	O
ecstasy	Chemical
).	O
The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	Chemical
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(set	O
shifting,	O
inhibition	O
and	O
memory	O
updating)	O
and	O
also	O
on	O
"prefrontal"	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes.	O
Fifteen	O
polydrug	O
ecstasy	Chemical
users	O
and	O
15	O
polydrug	O
non-	O
ecstasy	Chemical
user	O
controls	O
completed	O
a	O
general	O
drug	O
use	O
questionnaire,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(set	O
shifting),	O
Backward	O
Digit	O
Span	O
procedure	O
(memory	O
updating),	O
Inhibition	O
of	O
Return	O
(inhibition),	O
an	O
emotional	O
intelligence	O
scale,	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(DEX).	O
Compared	O
with	O
MDMA	Chemical
-free	O
polydrug	O
controls,	O
MDMA	Chemical
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating,	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes.	O
The	O
latter	O
two	O
deficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drug	O
use.	O
These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	Chemical

Severe	O
citrate	Chemical
	O
toxicity	Disease
complicating	O
volunteer	O
apheresis	O
platelet	O
donation.	O
We	O
report	O
a	O
case	O
of	O
severe	O
citrate	Chemical
	O
toxicity	Disease
during	O
volunteer	O
donor	O
apheresis	O
platelet	O
collection.	O
The	O
donor	O
was	O
a	O
40-year-old	O
female,	O
first-time	O
apheresis	O
platelet	O
donor.	O
Past	O
medical	O
history	O
was	O
remarkable	O
for	O
hypertension	Disease
,	O
hyperlipidemia	Disease
,	O
and	O
depression	Disease
.	O
Reported	O
medications	O
included	O
bumetanide	Chemical
,	O
pravastatin	Chemical
,	O
and	O
paroxetine	Chemical
.	O
Thirty	O
minutes	O
from	O
the	O
start	O
of	O
the	O
procedure,	O
the	O
donor	O
noted	O
tingling	O
around	O
the	O
mouth,	O
hands,	O
and	O
feet.	O
She	O
then	O
very	O
rapidly	O
developed	O
acute	O
onset	O
of	O
severe	O
facial	O
and	O
extremity	O
tetany	Disease
.	O
Empirical	O
treatment	O
with	O
intravenous	O
calcium	Chemical
gluconate	Chemical
was	O
initiated,	O
and	O
muscle	Disease
contractions	Disease
slowly	O
subsided	O
over	O
approximately	O
10	O
to	O
15	O
minutes.	O
The	O
events	O
are	O
consistent	O
with	O
a	O
severe	O
reaction	O
to	O
calcium	Chemical
chelation	O
by	O
sodium	Chemical
citrate	Chemical
anticoagulant	O
resulting	O
in	O
symptomatic	O
systemic	O
hypocalcemia	Disease
.	O
Upon	O
additional	O
retrospective	O
analysis,	O
it	O
was	O
noted	O
that	O
bumetanide	Chemical
is	O
a	O
loop	Chemical
diuretic	Chemical
that	O
may	O
cause	O
significant	O
hypocalcemia	Disease
.	O
We	O
conclude	O
that	O
careful	O
screening	O
for	O
medications	O
and	O
underlying	O
conditions	O
predisposing	O
to	O
hypocalcemia	Disease
is	O
recommended	O
to	O
help	O
prevent	O
severe	O
reactions	O
due	O
to	O
citrate	Chemical
	O
toxicity	Disease
.	O
Laboratory	O
measurement	O
of	O
pre-procedure	O
serum	O
calcium	Chemical

Proteinuria	Disease
after	O
conversion	O
to	O
sirolimus	Chemical
in	O
renal	O
transplant	O
recipients.	O
Sirolimus	Chemical
(	O
SRL	Chemical
)	O
is	O
a	O
new,	O
potent	O
immunosuppressive	O
agent.	O
More	O
recently,	O
proteinuria	Disease
has	O
been	O
reported	O
as	O
a	O
consequence	O
of	O
sirolimus	Chemical
therapy,	O
although	O
the	O
mechanism	O
has	O
remained	O
unclear.	O
We	O
retrospectively	O
examined	O
the	O
records	O
of	O
25	O
renal	O
transplant	O
patients,	O
who	O
developed	O
or	O
displayed	O
increased	O
proteinuria	Disease
after	O
SRL	Chemical
conversion.	O
The	O
patient	O
cohort	O
(14	O
men,	O
11	O
women)	O
was	O
treated	O
with	O
SRL	Chemical
as	O
conversion	O
therapy,	O
due	O
to	O
chronic	Disease
allograft	Disease
nephropathy	Disease
(	O
CAN	Disease
)	O
(n	O
=	O
15)	O
neoplasia	Disease
(n	O
=	O
8);	O
Kaposi's	Disease
sarcoma	Disease
,	O
Four	O
skin	Disease
cancers	Disease
,	O
One	O
intestinal	Disease
tumors	Disease
,	O
One	O
renal	Disease
cell	Disease
carsinom	Disease
)	O
or	O
BK	O
virus	O
nephropathy	Disease
(n	O
=	O
2).	O
SRL	Chemical
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+/-	O
42	O
(15	O
to	O
163)	O
months	O
after	O
transplantation.	O
Mean	O
follow-up	O
on	O
SRL	Chemical
therapy	O
was	O
20	O
+/-	O
12	O
(6	O
to	O
43)	O
months.	O
Proteinuria	Disease
increased	O
from	O
0.445	O
(0	O
to	O
1.5)	O
g/d	O
before	O
conversion	O
to	O
3.2	O
g/dL	O
(0.2	O
to	O
12)	O
after	O
conversion	O
(P	O
=	O
0.001).	O
Before	O
conversion	O
8	O
(32%)	O
patients	O
had	O
no	O
proteinuria	Disease
,	O
whereas	O
afterwards	O
all	O
patients	O
had	O
proteinuria	Disease
.	O
In	O
28%	O
of	O
patients	O
proteinuria	Disease
remained	O
unchanged,	O
whereas	O
it	O
increased	O
in	O
68%	O
of	O
patients.	O
In	O
40%	O
it	O
increased	O
by	O
more	O
than	O
100%.	O
Twenty-eight	O
percent	O
of	O
patients	O
showed	O
increased	O
proteinuria	Disease
to	O
the	O
nephrotic	Disease
range.	O
Biopsies	O
performed	O
in	O
five	O
patients	O
revealed	O
new	O
pathological	O
changes:	O
One	O
membranoproliferative	Disease
glomerulopathy	Disease
and	O
interstitial	Disease
nephritis	Disease
.	O
These	O
patients	O
showed	O
persistently	O
good	O
graft	O
function.	O
Serum	O
creatinine	Chemical
values	O
did	O
not	O
change	O
significantly:	O
1.98	O
+/-	O
0.8	O
mg/dL	O
before	O
SRL	Chemical
therapy	O
and	O
2.53	O
+/-	O
1.9	O
mg/dL	O
at	O
last	O
follow-up	O
(P	O
=	O
.14).	O
Five	O
grafts	O
were	O
lost	O
and	O
the	O
patients	O
returned	O
to	O
dialysis.	O
Five	O
patients	O
displayed	O
CAN	Disease
and	O
Kaposi's	Disease
sarcoma	Disease
.	O
Mean	O
urinary	O
protein	O
of	O
patients	O
who	O
returned	O
to	O
dialysis	O
was	O
1.26	O
(0.5	O
to	O
3.5)	O
g/d	O
before	O
and	O
4.7	O
(3	O
to	O
12)	O
g/d	O
after	O
conversion	O
(P	O
=	O
.01).	O
Mean	O
serum	O
creatinine	Chemical
level	O
before	O
conversion	O
was	O
2.21	O
mg/dL	O
and	O
thereafter,	O
4.93	O
mg/dL	O
(P	O
=	O
.02).	O
Heavy	O
proteinuria	Disease
was	O
common	O
after	O
the	O
use	O
of	O
SRL	Chemical
as	O
rescue	O
therapy	O
for	O
renal	O
transplantation.	O
Therefore,	O
conversion	O
should	O
be	O
considered	O
for	O
patients	O
who	O
have	O
not	O
developed	O
advanced	O
CAN	Disease
and	O
proteinuria	Disease
.	O
The	O
possibility	O
of	O
de	O
novo	O
glomerular	O
pathology	O
under	O
SRL	Chemical

In	O
vitro	O
characterization	O
of	O
parasympathetic	O
and	O
sympathetic	O
responses	O
in	O
cyclophosphamide	Chemical
-induced	O
cystitis	Disease
in	O
the	O
rat.	O
In	O
cyclophosphamide	Chemical
-induced	O
cystitis	Disease
in	O
the	O
rat,	O
detrusor	O
function	O
is	O
impaired	O
and	O
the	O
expression	O
and	O
effects	O
of	O
muscarinic	O
receptors	O
altered.	O
Whether	O
or	O
not	O
the	O
neuronal	O
transmission	O
may	O
be	O
affected	O
by	O
cystitis	Disease
was	O
presently	O
investigated.	O
Responses	O
of	O
urinary	O
strip	O
preparations	O
from	O
control	O
and	O
cyclophosphamide	Chemical
-pretreated	O
rats	O
to	O
electrical	O
field	O
stimulation	O
and	O
to	O
agonists	O
were	O
assessed	O
in	O
the	O
absence	O
and	O
presence	O
of	O
muscarinic,	O
adrenergic	O
and	O
purinergic	O
receptor	O
antagonists.	O
Generally,	O
atropine	Chemical
reduced	O
contractions,	O
but	O
in	O
contrast	O
to	O
controls,	O
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(1-5	O
Hz)	O
in	O
inflamed	O
preparations.	O
In	O
both	O
types,	O
purinoceptor	O
desensitization	O
with	O
alpha,beta-methylene	Chemical
adenosine-5'-triphosphate	Chemical
(	O
alpha,beta-meATP	Chemical
)	O
caused	O
further	O
reductions	O
at	O
low	O
frequencies	O
(<10	O
Hz).	O
The	O
muscarinic	O
receptor	O
antagonists	O
atropine	Chemical
,	O
4-diphenylacetoxy-N-methylpiperidine	Chemical
(	O
4-DAMP	Chemical
)	O
('M(1)/M(3)/M(5)-selective'),	O
methoctramine	Chemical
('M(2)-selective')	O
and	O
pirenzepine	Chemical
('M(1)-selective')	O
antagonized	O
the	O
tonic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation-evoked	O
contractile	O
response	O
more	O
potently	O
than	O
the	O
phasic	O
component.	O
4-DAMP	Chemical
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	Chemical
and	O
pirenzepine	Chemical
.	O
In	O
inflamed	O
preparations,	O
the	O
muscarinic	O
receptor	O
antagonism	O
on	O
the	O
phasic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation-evoked	O
contraction	O
was	O
decreased	O
and	O
the	O
pirenzepine	Chemical
and	O
4-DAMP	Chemical
antagonism	O
on	O
the	O
tonic	O
component	O
was	O
much	O
less	O
efficient	O
than	O
in	O
controls.	O
In	O
contrast	O
to	O
controls,	O
methoctramine	Chemical
increased	O
--	O
instead	O
of	O
decreased	O
--	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies.	O
While	O
contractions	O
to	O
carbachol	Chemical
and	O
ATP	Chemical
were	O
the	O
same	O
in	O
inflamed	O
and	O
in	O
control	O
strips	O
when	O
related	O
to	O
a	O
reference	O
potassium	Chemical
response,	O
isoprenaline	Chemical
-induced	O
relaxations	O
were	O
smaller	O
in	O
inflamed	O
strips.	O
Thus,	O
in	O
cystitis	Disease

Associations	O
between	O
use	O
of	O
benzodiazepines	Chemical
or	O
related	O
drugs	O
and	O
health,	O
physical	O
abilities	O
and	O
cognitive	O
function:	O
a	O
non-randomised	O
clinical	O
study	O
in	O
the	O
elderly.	O
OBJECTIVE:	O
To	O
describe	O
associations	O
between	O
the	O
use	O
of	O
benzodiazepines	Chemical
or	O
related	O
drugs	O
(	O
BZDs	Chemical
/RDs)	O
and	O
health,	O
functional	O
abilities	O
and	O
cognitive	O
function	O
in	O
the	O
elderly.	O
METHODS:	O
A	O
non-randomised	O
clinical	O
study	O
of	O
patients	O
aged	O
>	O
or	O
=65	O
years	O
admitted	O
to	O
acute	O
hospital	O
wards	O
during	O
1	O
month.	O
164	O
patients	O
(mean	O
age	O
+/-	O
standard	O
deviation	O
[SD]	O
81.6	O
+/-	O
6.8	O
years)	O
were	O
admitted.	O
Of	O
these,	O
nearly	O
half	O
(n	O
=	O
78)	O
had	O
used	O
BZDs	Chemical
/RDs	O
before	O
admission,	O
and	O
the	O
remainder	O
(n	O
=	O
86)	O
were	O
non-users.	O
Cognitive	O
ability	O
was	O
assessed	O
by	O
the	O
Mini-Mental	O
State	O
Examination	O
(MMSE).	O
Patients	O
scoring	O
>	O
or	O
=20	O
MMSE	O
sum	O
points	O
were	O
interviewed	O
(n	O
=	O
79)	O
and	O
questioned	O
regarding	O
symptoms	O
and	O
functional	O
abilities	O
during	O
the	O
week	O
prior	O
to	O
admission.	O
Data	O
on	O
use	O
of	O
BZDs	Chemical
/RDs	O
before	O
admission,	O
current	O
medications	O
and	O
discharge	O
diagnoses	O
were	O
collected	O
from	O
medical	O
records.	O
Health,	O
physical	O
abilities	O
and	O
cognitive	O
function	O
were	O
compared	O
between	O
BZD/RD	O
users	O
and	O
non-users,	O
and	O
adjustments	O
were	O
made	O
for	O
confounding	O
variables.	O
The	O
residual	O
serum	O
concentrations	O
of	O
oxazepam	Chemical
,	O
temazepam	Chemical
and	O
zopiclone	Chemical
were	O
analysed.	O
RESULTS:	O
The	O
mean	O
+/-	O
SD	O
duration	O
of	O
BZD/RD	O
use	O
was	O
7	O
+/-	O
7	O
years	O
(range	O
1-31).	O
Two	O
or	O
three	O
BZDs	Chemical
/RDs	O
were	O
concomitantly	O
taken	O
by	O
26%	O
of	O
users	O
(n	O
=	O
20).	O
Long-term	O
use	O
of	O
these	O
drugs	O
was	O
associated	O
with	O
female	O
sex	O
and	O
use	O
of	O
a	O
higher	O
number	O
of	O
drugs	O
with	O
effects	O
on	O
the	O
CNS,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diagnosed	O
dementia	Disease
.	O
After	O
adjustment	O
for	O
these	O
variables	O
as	O
confounders,	O
use	O
of	O
BZDs	Chemical
/RDs	O
was	O
not	O
associated	O
with	O
cognitive	O
function	O
as	O
measured	O
by	O
the	O
MMSE.	O
However,	O
use	O
of	O
BZDs	Chemical
/RDs	O
was	O
associated	O
with	O
dizziness	Disease
,	O
inability	Disease
to	Disease
sleep	Disease
after	O
awaking	O
at	O
night	O
and	O
tiredness	Disease
in	O
the	O
mornings	O
during	O
the	O
week	O
prior	O
to	O
admission	O
and	O
with	O
stronger	O
depressive	Disease
symptoms	Disease
measured	O
at	O
the	O
beginning	O
of	O
the	O
hospital	O
stay.	O
Use	O
of	O
BZDs	Chemical
/RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
ability	O
to	O
walk	O
and	O
shorter	O
night-time	O
sleep	O
during	O
the	O
week	O
prior	O
to	O
admission.	O
A	O
higher	O
residual	O
serum	O
concentration	O
of	O
temazepam	Chemical

Acute	O
vocal	Disease
fold	Disease
palsy	Disease
after	O
acute	O
disulfiram	Chemical
intoxication.	O
Acute	O
peripheral	Disease
neuropathy	Disease
caused	O
by	O
a	O
disulfiram	Chemical
	O
overdose	Disease
is	O
very	O
rare	O
and	O
there	O
is	O
no	O
report	O
of	O
it	O
leading	O
to	O
vocal	Disease
fold	Disease
palsy	Disease
.	O
A	O
49-year-old	O
woman	O
was	O
transferred	O
to	O
our	O
department	O
because	O
of	O
quadriparesis	Disease
,	O
lancinating	O
pain	Disease
,	O
sensory	Disease
loss	Disease
,	O
and	O
paresthesia	Disease
of	O
the	O
distal	O
limbs.	O
One	O
month	O
previously,	O
she	O
had	O
taken	O
a	O
single	O
high	O
dose	O
of	O
disulfiram	Chemical
(130	O
tablets	O
of	O
ALCOHOL	Chemical
STOP	O
TAB,	O
Shin-Poong	O
Pharm.	O
Co.,	O
Ansan,	O
Korea)	O
in	O
a	O
suicide	O
attempt.	O
She	O
was	O
not	O
an	O
alcoholic.	O
For	O
the	O
first	O
few	O
days	O
after	O
ingestion,	O
she	O
was	O
in	O
a	O
confused	O
state	O
and	O
had	O
mild	O
to	O
moderate	O
ataxia	Disease
and	O
giddiness	Disease
.	O
She	O
noticed	O
hoarseness	Disease
and	O
distally	O
accentuated	O
motor	O
and	O
sensory	O
dysfunction	O
after	O
she	O
had	O
recovered	O
from	O
this	O
state.	O
A	O
nerve	O
conduction	O
study	O
was	O
consistent	O
with	O
severe	O
sensorimotor	O
axonal	O
polyneuropathy	Disease
.	O
Laryngeal	O
electromyography	O
(thyroarytenoid	O
muscle)	O
showed	O
ample	O
denervation	O
potentials.	O
Laryngoscopy	O
revealed	O
asymmetric	O
vocal	O
fold	O
movements	O
during	O
phonation.	O
Her	O
vocal	O
change	O
and	O
weakness	O
began	O
to	O
improve	O
spontaneously	O
about	O
3	O
weeks	O
after	O
transfer.	O
This	O
was	O
a	O
case	O
of	O
acute	O
palsy	Disease
of	O
the	O
recurrent	O
laryngeal	O
nerve	O
and	O
superimposed	O
severe	O
acute	O
sensorimotor	O
axonal	O
polyneuropathy	Disease
caused	O
by	O
high-dose	O
disulfiram	Chemical

Higher	O
optical	O
density	O
of	O
an	O
antigen	O
assay	O
predicts	O
thrombosis	Disease
in	O
patients	O
with	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
.	O
OBJECTIVES:	O
To	O
correlate	O
optical	O
density	O
and	O
percent	O
inhibition	O
of	O
a	O
two-step	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
(	O
HIT	Disease
)	O
antigen	O
assay	O
with	O
thrombosis	Disease
;	O
the	O
assay	O
utilizes	O
reaction	O
inhibition	O
characteristics	O
of	O
a	O
high	O
heparin	Chemical
concentration.	O
PATIENTS	O
AND	O
METHODS:	O
Patients	O
with	O
more	O
than	O
50%	O
decrease	O
in	O
platelet	O
count	O
or	O
thrombocytopenia	Disease
(<150	O
x	O
10(9)/L)	O
after	O
exposure	O
to	O
heparin	Chemical
,	O
who	O
had	O
a	O
positive	O
two-step	O
antigen	O
assay	O
[optical	O
density	O
(OD)	O
>0.4	O
and	O
>50	O
inhibition	O
with	O
high	O
concentration	O
of	O
heparin	Chemical
]	O
were	O
included	O
in	O
the	O
study.	O
RESULTS:	O
Forty	O
of	O
94	O
HIT	Disease
patients	O
had	O
thrombosis	Disease
at	O
diagnosis;	O
54/94	O
had	O
isolated-	O
HIT	Disease
without	O
thrombosis	Disease
.	O
Eight	O
of	O
the	O
isolated-	O
HIT	Disease
patients	O
developed	O
thrombosis	Disease
within	O
the	O
next	O
30	O
d;	O
thus,	O
a	O
total	O
of	O
48	O
patients	O
had	O
thrombosis	Disease
at	O
day	O
30.	O
At	O
diagnosis	O
there	O
was	O
no	O
significant	O
difference	O
in	O
OD	O
between	O
HIT	Disease
patients	O
with	O
thrombosis	Disease
and	O
those	O
with	O
isolated-	O
HIT	Disease
.	O
However,	O
OD	O
was	O
significantly	O
higher	O
in	O
all	O
patients	O
with	O
thrombosis	Disease
(n	O
=	O
48,	O
1.34	O
+/-	O
0.89),	O
including	O
isolated-	O
HIT	Disease
patients	O
who	O
later	O
developed	O
thrombosis	Disease
within	O
30	O
d	O
(n	O
=	O
8,	O
1.84	O
+/-	O
0.64)	O
as	O
compared	O
to	O
isolated-	O
HIT	Disease
patients	O
who	O
did	O
not	O
develop	O
thrombosis	Disease
(0.96	O
+/-	O
0.75;	O
P	O
=	O
0.011	O
and	O
P	O
=	O
0.008).	O
The	O
Receiver	O
Operative	O
Characteristic	O
Curve	O
showed	O
that	O
OD	O
>1.27	O
in	O
the	O
isolated-	O
HIT	Disease
group	O
had	O
a	O
significantly	O
higher	O
chance	O
of	O
developing	O
thrombosis	Disease
by	O
day	O
30.	O
None	O
of	O
these	O
groups	O
showed	O
significant	O
difference	O
in	O
percent	O
inhibition.	O
Multivariate	O
analysis	O
showed	O
a	O
2.8-fold	O
increased	O
risk	O
of	O
thrombosis	Disease
in	O
females.	O
Similarly,	O
thrombotic	Disease
risk	O
increased	O
with	O
age	O
and	O
OD	O
values.	O
CONCLUSION:	O
Higher	O
OD	O
is	O
associated	O
with	O
significant	O
risk	O
of	O
subsequent	O
thrombosis	Disease
in	O
patients	O
with	O
isolated-	O
HIT	Disease

Central	O
retinal	Disease
vein	Disease
occlusion	Disease
associated	O
with	O
clomiphene	Chemical
-induced	O
ovulation.	O
OBJECTIVE:	O
To	O
report	O
a	O
case	O
of	O
central	O
retinal	Disease
vein	Disease
occlusion	Disease
associated	O
with	O
clomiphene	Chemical
citrate	Chemical
(	O
CC	Chemical
).	O
DESIGN:	O
Case	O
study.	O
SETTING:	O
Ophthalmology	O
clinic	O
of	O
an	O
academic	O
hospital.	O
PATIENT(S):	O
A	O
36-year-old	O
woman	O
referred	O
from	O
the	O
infertility	Disease
clinic	O
for	O
blurred	Disease
vision	Disease
.	O
INTERVENTION(S):	O
Ophthalmic	O
examination	O
after	O
CC	Chemical
therapy.	O
MAIN	O
OUTCOME	O
MEASURE(S):	O
Central	O
retinal	Disease
vein	Disease
occlusion	Disease
after	O
ovulation	O
induction	O
with	O
CC	Chemical
.	O
RESULT(S):	O
A	O
36-year-old	O
Chinese	O
woman	O
developed	O
central	O
retinal	Disease
vein	Disease
occlusion	Disease
after	O
eight	O
courses	O
of	O
CC	Chemical
.	O
A	O
search	O
of	O
the	O
literature	O
on	O
the	O
thromboembolic	Disease
complications	O
of	O
CC	Chemical
does	O
not	O
include	O
this	O
severe	O
ophthalmic	O
complication,	O
although	O
mild	O
visual	Disease
disturbance	Disease
after	O
CC	Chemical
intake	O
is	O
not	O
uncommon.	O
CONCLUSION(S):	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	O
retinal	Disease
vein	Disease
occlusion	Disease
after	O
treatment	O
with	O
CC	Chemical
.	O
Extra	O
caution	O
is	O
warranted	O
in	O
treating	O
infertility	Disease
patients	O
with	O
CC	Chemical

Nicotine	Chemical
-induced	O
nystagmus	Disease
correlates	O
with	O
midpontine	O
activation.	O
The	O
pathomechanism	O
of	O
nicotine	Chemical
-induced	O
nystagmus	Disease
(	O
NIN	Disease
)	O
is	O
unknown.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
delineate	O
brain	O
structures	O
that	O
are	O
involved	O
in	O
NIN	Disease
generation.	O
Eight	O
healthy	O
volunteers	O
inhaled	O
nicotine	Chemical
in	O
darkness	O
during	O
a	O
functional	O
magnetic	O
resonance	O
imaging	O
(fMRI)	O
experiment;	O
eye	O
movements	O
were	O
registered	O
using	O
video-oculography.	O
NIN	Disease
correlated	O
with	O
blood	O
oxygen	Chemical
level-dependent	O
(BOLD)	O
activity	O
levels	O
in	O
a	O
midpontine	O
site	O
in	O
the	O
posterior	O
basis	O
pontis.	O
NIN	Disease

Protective	O
effect	O
of	O
verapamil	Chemical
on	O
gastric	Disease
hemorrhagic	Disease
	O
ulcers	Disease
in	O
severe	O
atherosclerotic	Disease
rats.	O
Studies	O
concerning	O
with	O
pathogenesis	O
of	O
gastric	Disease
hemorrhage	Disease
and	O
mucosal	O
ulceration	O
produced	O
in	O
atherosclerotic	Disease
rats	O
are	O
lacking.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
role	O
of	O
gastric	O
acid	O
back-diffusion,	O
mast	O
cell	O
histamine	Chemical
release,	O
lipid	O
peroxide	O
(LPO)	O
generation	O
and	O
mucosal	O
microvascular	O
permeability	O
in	O
modulating	O
gastric	Disease
hemorrhage	Disease
and	O
ulcer	Disease
in	O
rats	O
with	O
atherosclerosis	Disease
induced	O
by	O
coadministration	O
of	O
vitamin	Chemical
D2	Chemical
and	O
cholesterol	Chemical
.	O
Additionally,	O
the	O
protective	O
effect	O
of	O
verapamil	Chemical
on	O
this	O
ulcer	Disease
model	O
was	O
evaluated.	O
Male	O
Wistar	O
rats	O
were	O
challenged	O
intragastrically	O
once	O
daily	O
for	O
9	O
days	O
with	O
1.0	O
ml/kg	O
of	O
corn	O
oil	O
containing	O
vitamin	Chemical
D2	Chemical
and	O
cholesterol	Chemical
to	O
induce	O
atherosclerosis	Disease
.	O
Control	O
rats	O
received	O
corn	O
oil	O
only.	O
After	O
gastric	O
surgery,	O
rat	O
stomachs	O
were	O
irrigated	O
for	O
3	O
h	O
with	O
either	O
simulated	O
gastric	O
juice	O
or	O
normal	O
saline.	O
Gastric	O
acid	O
back-diffusion,	O
mucosal	O
LPO	O
generation,	O
histamine	Chemical
concentration,	O
microvascular	O
permeability,	O
luminal	Chemical
hemoglobin	O
content	O
and	O
ulcer	Disease
areas	O
were	O
determined.	O
Elevated	O
atherosclerotic	Disease
parameters,	O
such	O
as	O
serum	O
calcium	Chemical
,	O
total	O
cholesterol	Chemical
and	O
low-density	O
lipoprotein	O
concentration	O
were	O
obtained	O
in	O
atherosclerotic	Disease
rats.	O
Severe	O
gastric	O
ulcers	Disease
accompanied	O
with	O
increased	O
ulcerogenic	O
factors,	O
including	O
gastric	O
acid	O
back-diffusion,	O
histamine	Chemical
release,	O
LPO	O
generation	O
and	O
luminal	Chemical
hemoglobin	O
content	O
were	O
also	O
observed	O
in	O
these	O
rats.	O
Moreover,	O
a	O
positive	O
correlation	O
of	O
histamine	Chemical
to	O
gastric	Disease
hemorrhage	Disease
and	O
to	O
ulcer	Disease
was	O
found	O
in	O
those	O
atherosclerotic	Disease
rats.	O
This	O
hemorrhagic	Disease
	O
ulcer	Disease
and	O
various	O
ulcerogenic	O
parameters	O
were	O
dose-dependently	O
ameliorated	O
by	O
daily	O
intragastric	O
verapamil	Chemical
.	O
Atherosclerosis	Disease
could	O
produce	O
gastric	Disease
hemorrhagic	Disease
	O
ulcer	Disease
via	O
aggravation	O
of	O
gastric	O
acid	O
back-diffusion,	O
LPO	O
generation,	O
histamine	Chemical
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	Chemical

Adriamycin	Chemical
-induced	O
autophagic	O
cardiomyocyte	O
death	Disease
plays	O
a	O
pathogenic	O
role	O
in	O
a	O
rat	O
model	O
of	O
heart	Disease
failure	Disease
.	O
BACKGROUND:	O
The	O
mechanisms	O
underlying	O
heart	Disease
failure	Disease
induced	O
by	O
adriamycin	Chemical
are	O
very	O
complicated	O
and	O
still	O
unclear.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
autophagy	O
was	O
involved	O
in	O
the	O
progression	O
of	O
heart	Disease
failure	Disease
induced	O
by	O
adriamycin	Chemical
,	O
so	O
that	O
we	O
can	O
develop	O
a	O
novel	O
treatment	O
strategy	O
for	O
heart	Disease
failure	Disease
.	O
METHODS:	O
3-methyladenine	Chemical
(	O
3MA	Chemical
),	O
a	O
specific	O
inhibitor	O
on	O
autophagy	O
was	O
used	O
in	O
a	O
heart	Disease
failure	Disease
model	O
of	O
rats	O
induced	O
by	O
adriamycin	Chemical
.	O
Neonatal	O
cardiomyocytes	O
were	O
isolated	O
from	O
Sprague-Dawley	O
rat	O
hearts	O
and	O
randomly	O
divided	O
into	O
controls,	O
an	O
adriamycin	Chemical
-treated	O
group,	O
and	O
a	O
3MA	Chemical
plus	O
adriamycin	Chemical
-treated	O
group.	O
We	O
then	O
examined	O
the	O
morphology,	O
expression	O
of	O
beclin	O
1	O
gene,	O
mitochondrial	O
permeability	O
transition	O
(MPT),	O
and	O
Na+-	O
K	Chemical
+	O
ATPase	O
activity	O
in	O
vivo.	O
We	O
also	O
assessed	O
cell	O
viability,	O
mitochondrial	O
membrane	O
potential	O
changes	O
and	O
counted	O
autophagic	O
vacuoles	O
in	O
cultured	O
cardiomyocytes.	O
In	O
addition,	O
we	O
analyzed	O
the	O
expression	O
of	O
autophagy	O
associated	O
gene,	O
beclin	O
1	O
using	O
RT-PCR	O
and	O
Western	O
blotting	O
in	O
an	O
animal	O
model.	O
RESULTS:	O
3MA	Chemical
significantly	O
improved	O
cardiac	O
function	O
and	O
reduced	O
mitochondrial	O
injury.	O
Furthermore,	O
adriamycin	Chemical
induced	O
the	O
formation	O
of	O
autophagic	O
vacuoles,	O
and	O
3MA	Chemical
strongly	O
downregulated	O
the	O
expression	O
of	O
beclin	O
1	O
in	O
adriamycin	Chemical
-induced	O
failing	O
heart	O
and	O
inhibited	O
the	O
formation	O
of	O
autophagic	O
vacuoles.	O
CONCLUSION:	O
Autophagic	O
cardiomyocyte	O
death	Disease
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
heart	Disease
failure	Disease
in	O
rats	O
induced	O
by	O
adriamycin	Chemical
.	O
Mitochondrial	O
injury	O
may	O
be	O
involved	O
in	O
the	O
progression	O
of	O
heart	Disease
failure	Disease
caused	O
by	O
adriamycin	Chemical

Confusion	Disease
,	O
a	O
rather	O
serious	O
adverse	O
drug	O
reaction	O
with	O
valproic	Chemical
acid	Chemical
:	O
a	O
review	O
of	O
the	O
French	O
Pharmacovigilance	O
database.	O
INTRODUCTION:	O
Confusion	Disease
is	O
an	O
adverse	O
drug	O
reaction	O
frequently	O
observed	O
with	O
valproic	Chemical
acid	Chemical
.	O
Some	O
case	O
reports	O
are	O
published	O
in	O
the	O
literature	O
but	O
no	O
systematic	O
study	O
from	O
a	O
sample	O
of	O
patients	O
has	O
been	O
published.	O
We	O
performed	O
this	O
study	O
in	O
order	O
to	O
describe	O
the	O
main	O
characteristics	O
of	O
this	O
adverse	O
drug	O
reaction.	O
METHODS:	O
Using	O
the	O
French	O
Pharmacovigilance	O
database,	O
we	O
selected	O
the	O
cases	O
of	O
confusion	Disease
reported	O
since	O
1985	O
with	O
valproic	Chemical
acid	Chemical
.	O
RESULTS:	O
272	O
cases	O
of	O
confusion	Disease
were	O
reported	O
with	O
valproic	Chemical
acid	Chemical
:	O
153	O
women	O
and	O
119	O
men.	O
Confusion	Disease
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
valproic	Chemical
acid	Chemical
exposure	O
(39.7%).	O
It	O
was	O
"serious"	O
for	O
almost	O
2/3	O
of	O
the	O
patients	O
(62.5%)	O
and	O
its	O
outcome	O
favourable	O
in	O
most	O
of	O
the	O
cases	O
(82%).	O
The	O
occurrence	O
of	O
this	O
ADR	O
was	O
more	O
frequent	O
in	O
patients	O
aged	O
between	O
61	O
and	O
80	O
years.	O
CONCLUSION:	O
This	O
work	O
shows	O
that	O
confusion	Disease
with	O
valproic	Chemical
acid	Chemical

Learning	Disease
and	Disease
memory	Disease
deficits	Disease
in	O
ecstasy	Chemical
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face-learning	O
task.	O
It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	Chemical
users	O
display	O
impairments	Disease
in	Disease
learning	Disease
and	Disease
memory	Disease
performance.	O
In	O
addition,	O
working	O
memory	O
processing	O
in	O
ecstasy	Chemical
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and/or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(fMRI).	O
Using	O
functional	O
imaging	O
and	O
a	O
face-learning	O
task,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face-name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	Chemical
and	O
20	O
controls.	O
To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	Chemical
use	O
of	O
the	O
ecstasy	Chemical
using	O
group,	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	Chemical
users	O
(Nestor,	O
L.,	O
Roberts,	O
G.,	O
Garavan,	O
H.,	O
Hester,	O
R.,	O
2008.	O
Deficits	Disease
in	Disease
learning	Disease
and	Disease
memory	Disease
:	O
parahippocampal	O
hyperactivity	Disease
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	Chemical
users.	O
Neuroimage	O
40,	O
1328-1339).	O
Ecstasy	Chemical
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	Chemical
users.	O
A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	Chemical
-specific	O
hyperactivity	Disease
in	O
bilateral	O
frontal	O
regions,	O
left	O
temporal,	O
right	O
parietal,	O
bilateral	O
temporal,	O
and	O
bilateral	O
occipital	O
brain	O
regions.	O
Ecstasy	Chemical
-specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(ACC)	O
and	O
left	O
posterior	O
cingulated	O
cortex.	O
In	O
both	O
ecstasy	Chemical
and	O
cannabis	Chemical
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus,	O
left	O
parahippocampal	O
gyrus,	O
left	O
dorsal	O
cingulate	O
gyrus,	O
and	O
left	O
caudate.	O
These	O
results	O
elucidated	O
ecstasy	Chemical
-related	O
deficits,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	Chemical
use.	O
These	O
ecstasy	Chemical
-specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	O
to	O
the	O
neurotoxic	Disease
effects	O
of	O
ecstasy	Chemical

Prolonged	O
elevation	O
of	O
plasma	O
argatroban	Chemical
in	O
a	O
cardiac	O
transplant	O
patient	O
with	O
a	O
suspected	O
history	O
of	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
with	O
thrombosis	Disease
.	O
BACKGROUND:	O
Direct	O
thrombin	O
inhibitors	O
(DTIs)	O
provide	O
an	O
alternative	O
method	O
of	O
anticoagulation	O
for	O
patients	O
with	O
a	O
history	O
of	O
heparin	Chemical
-induced	O
thrombocytopenia	Disease
(	O
HIT	Disease
)	O
or	O
HIT	Disease
with	O
thrombosis	Disease
(	O
HITT	Disease
)	O
undergoing	O
cardiopulmonary	O
bypass	O
(CPB).	O
In	O
the	O
following	O
report,	O
a	O
65-year-old	O
critically	Disease
ill	Disease
patient	O
with	O
a	O
suspected	O
history	O
of	O
HITT	Disease
was	O
administered	O
argatroban	Chemical
for	O
anticoagulation	O
on	O
bypass	O
during	O
heart	O
transplantation.	O
The	O
patient	O
required	O
massive	O
transfusion	O
support	O
(55	O
units	O
of	O
red	O
blood	O
cells,	O
42	O
units	O
of	O
fresh-frozen	O
plasma,	O
40	O
units	O
of	O
cryoprecipitate,	O
40	O
units	O
of	O
platelets,	O
and	O
three	O
doses	O
of	O
recombinant	O
Factor	O
VIIa)	O
for	O
severe	O
intraoperative	Disease
and	Disease
postoperative	Disease
bleeding	Disease
.	O
STUDY	O
DESIGN	O
AND	O
METHODS:	O
Plasma	O
samples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analyzed	O
postoperatively	O
for	O
argatroban	Chemical
concentration	O
using	O
a	O
modified	O
ecarin	O
clotting	O
time	O
(ECT)	O
assay.	O
RESULTS:	O
Unexpectedly	O
high	O
concentrations	O
of	O
argatroban	Chemical
were	O
measured	O
in	O
these	O
samples	O
(range,	O
0-32	O
microg/mL),	O
and	O
a	O
prolonged	O
plasma	O
argatroban	Chemical
half	O
life	O
(t(1/2))	O
of	O
514	O
minutes	O
was	O
observed	O
(published	O
elimination	O
t(1/2)	O
is	O
39-51	O
minutes	O
[<	O
or	O
=	O
181	O
minutes	O
with	O
hepatic	Disease
impairment	Disease
]).	O
CONCLUSIONS:	O
Correlation	O
of	O
plasma	O
argatroban	Chemical
concentration	O
versus	O
the	O
patient's	O
coagulation	O
variables	O
and	O
clinical	O
course	O
suggest	O
that	O
prolonged	O
elevated	O
levels	O
of	O
plasma	O
argatroban	Chemical
may	O
have	O
contributed	O
to	O
the	O
patient's	O
extended	O
coagulopathy	Disease
.	O
Because	O
DTIs	O
do	O
not	O
have	O
reversal	O
agents,	O
surgical	O
teams	O
and	O
transfusion	O
services	O
should	O
remain	O
aware	O
of	O
the	O
possibility	O
of	O
massive	O
transfusion	O
events	O
during	O
anticoagulation	O
with	O
these	O
agents.	O
This	O
is	O
the	O
first	O
report	O
to	O
measure	O
plasma	O
argatroban	Chemical
concentration	O
in	O
the	O
context	O
of	O
CPB	O
and	O
extended	O
coagulopathy	Disease

Antituberculosis	Chemical
therapy-induced	O
acute	Disease
liver	Disease
failure	Disease
:	O
magnitude,	O
profile,	O
prognosis,	O
and	O
predictors	O
of	O
outcome.	O
Antituberculosis	Chemical
therapy	O
(ATT)-associated	O
acute	Disease
liver	Disease
failure	Disease
(ATT-	O
ALF	Disease
)	O
is	O
the	O
commonest	O
drug-induced	O
ALF	Disease
in	O
South	O
Asia.	O
Prospective	O
studies	O
on	O
ATT-	O
ALF	Disease
are	O
lacking.	O
The	O
current	O
study	O
prospectively	O
evaluated	O
the	O
magnitude,	O
clinical	O
course,	O
outcome,	O
and	O
prognostic	O
factors	O
in	O
ATT-	O
ALF	Disease
.	O
From	O
January	O
1986	O
to	O
January	O
2009,	O
1223	O
consecutive	O
ALF	Disease
patients	O
were	O
evaluated:	O
ATT	O
alone	O
was	O
the	O
cause	O
in	O
70	O
(5.7%)	O
patients.	O
Another	O
15	O
(1.2%)	O
had	O
ATT	O
and	O
simultaneous	O
hepatitis	Disease
virus	Disease
infection	Disease
.	O
In	O
44	O
(62.8%)	O
patients,	O
ATT	O
was	O
prescribed	O
empirically	O
without	O
definitive	O
evidence	O
of	O
tuberculosis	Disease
.	O
ATT-	O
ALF	Disease
patients	O
were	O
younger	O
(32.87	O
[+/-15.8]	O
years),	O
and	O
49	O
(70%)	O
of	O
them	O
were	O
women.	O
Most	O
had	O
hyperacute	O
presentation;	O
the	O
median	O
icterus	Disease
	O
encephalopathy	Disease
interval	O
was	O
4.5	O
(0-30)	O
days.	O
The	O
median	O
duration	O
of	O
ATT	O
before	O
ALF	Disease
was	O
30	O
(7-350)	O
days.	O
At	O
presentation,	O
advanced	O
encephalopathy	Disease
and	O
cerebral	Disease
edema	Disease
were	O
present	O
in	O
51	O
(76%)	O
and	O
29	O
(41.4%)	O
patients,	O
respectively.	O
Gastrointestinal	Disease
bleed	Disease
,	O
seizures	Disease
,	O
infection	Disease
,	O
and	O
acute	Disease
renal	Disease
failure	Disease
were	O
documented	O
in	O
seven	O
(10%),	O
five	O
(7.1%),	O
26	O
(37.1%),	O
and	O
seven	O
(10%)	O
patients,	O
respectively.	O
Compared	O
with	O
hepatitis	Disease
E	Disease
virus	O
(HEV)	O
and	O
non-A	O
non-E-induced	O
ALF	Disease
,	O
ATT-	O
ALF	Disease
patients	O
had	O
nearly	O
similar	O
presentations	O
except	O
for	O
older	O
age	O
and	O
less	O
elevation	O
of	O
liver	O
enzymes.	O
The	O
mortality	O
rate	O
among	O
patients	O
with	O
ATT-	O
ALF	Disease
was	O
high	O
(67.1%,	O
n	O
=	O
47),	O
and	O
only	O
23	O
(32.9%)	O
patients	O
recovered	O
with	O
medical	O
treatment.	O
In	O
multivariate	O
analysis,	O
three	O
factors	O
independently	O
predicted	O
mortality:	O
serum	O
bilirubin	Chemical
(>or=10.8	O
mg/dL),	O
prothrombin	O
time	O
(PT)	O
prolongation	O
(>or=26	O
seconds),	O
and	O
grade	O
III/IV	O
encephalopathy	Disease
at	O
presentation.	O
CONCLUSION:	O
ATT-	O
ALF	Disease
constituted	O
5.7%	O
of	O
ALF	Disease

Central	Disease
nervous	Disease
system	Disease
complications	Disease
during	O
treatment	O
of	O
acute	Disease
lymphoblastic	Disease
leukemia	Disease
in	O
a	O
single	O
pediatric	O
institution.	O
Central	Disease
nervous	Disease
system	Disease
(CNS)	Disease
complications	Disease
during	O
treatment	O
of	O
childhood	O
acute	Disease
lymphoblastic	Disease
leukemia	Disease
(	O
ALL	Disease
)	O
remain	O
a	O
challenging	O
clinical	O
problem.	O
Outcome	O
improvement	O
with	O
more	O
intensive	O
chemotherapy	O
has	O
significantly	O
increased	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
events.	O
This	O
study	O
analyzed	O
the	O
incidence	O
of	O
neurological	Disease
complications	Disease
during	O
ALL	Disease
treatment	O
in	O
a	O
single	O
pediatric	O
institution,	O
focusing	O
on	O
clinical,	O
radiological,	O
and	O
electrophysiological	O
findings.	O
Exclusion	O
criteria	O
included	O
CNS	O
leukemic	Disease
infiltration	Disease
at	O
diagnosis,	O
therapy-related	O
peripheral	Disease
neuropathy	Disease
,	O
late-onset	O
encephalopathy	Disease
,	O
or	O
long-term	O
neurocognitive	Disease
defects	Disease
.	O
During	O
a	O
9-year	O
period,	O
we	O
retrospectively	O
collected	O
27	O
neurological	O
events	O
(11%)	O
in	O
as	O
many	O
patients,	O
from	O
253	O
children	O
enrolled	O
in	O
the	O
ALL	Disease
front-line	O
protocol.	O
CNS	O
complications	O
included	O
posterior	O
reversible	O
leukoencephalopathy	Disease
syndrome	O
(n	O
=	O
10),	O
stroke	Disease
(n	O
=	O
5),	O
temporal	Disease
lobe	Disease
epilepsy	Disease
(n	O
=	O
2),	O
high-dose	O
methotrexate	Chemical
	O
toxicity	Disease
(n	O
=	O
2),	O
syndrome	O
of	O
inappropriate	Disease
antidiuretic	Disease
hormone	Disease
secretion	Disease
(n	O
=	O
1),	O
and	O
other	O
unclassified	O
events	O
(n	O
=	O
7).	O
In	O
conclusion,	O
CNS	O
complications	O
are	O
frequent	O
events	O
during	O
ALL	Disease

Safety	O
of	O
capecitabine	Chemical
:	O
a	O
review.	O
IMPORTANCE	O
OF	O
THE	O
FIELD:	O
Fluoropyrimidines	Chemical
,	O
in	O
particular	O
5-fluorouracil	Chemical
(	O
5-FU	Chemical
),	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	Disease
,	O
including	O
colorectal,	Disease
breast	Disease
and	Disease
head	Disease
and	Disease
neck	Disease
cancers	Disease
,	O
for	O
>	O
40	O
years.	O
AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW:	O
This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	Chemical
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety.	O
WHAT	O
THE	O
READER	O
WILL	O
GAIN:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	Chemical
in	O
special	O
populations	O
such	O
as	O
patients	O
with	O
advanced	O
age,	O
renal	Disease
and	Disease
kidney	Disease
disease	Disease
.	O
We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	Chemical
administration.	O
TAKE	O
HOME	O
MESSAGE:	O
Capecitabine	Chemical
is	O
an	O
oral	O
prodrug	O
of	O
5-FU	Chemical
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety/efficacy	O
profile.	O
It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal,	Disease
breast,	Disease
pancreaticobiliary,	Disease
gastric,	Disease
renal	Disease
cell	Disease
and	Disease
head	Disease
and	Disease
neck	Disease
cancers	Disease
.	O
The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	Chemical
are	O
diarrhea	Disease
,	O
nausea	Disease
,	O
vomiting	Disease
,	O
stomatitis	Disease
and	O
hand-foot	Disease
syndrome	Disease
.	O
Capecitabine	Chemical
has	O
a	O
well-established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age,	O
hepatic	Disease
and	Disease
renal	Disease
dysfunctions	Disease

Effects	O
of	O
pallidal	O
neurotensin	Chemical
on	O
haloperidol	Chemical
-induced	O
parkinsonian	Disease
catalepsy	Disease
:	O
behavioral	O
and	O
electrophysiological	O
studies.	O
OBJECTIVE:	O
The	O
globus	O
pallidus	O
plays	O
a	O
critical	O
role	O
in	O
movement	O
regulation.	O
Previous	O
studies	O
have	O
indicated	O
that	O
the	O
globus	O
pallidus	O
receives	O
neurotensinergic	O
innervation	O
from	O
the	O
striatum,	O
and	O
systemic	O
administration	O
of	O
a	O
neurotensin	Chemical
analog	O
could	O
produce	O
antiparkinsonian	O
effects.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
pallidal	O
neurotensin	Chemical
on	O
haloperidol	Chemical
-induced	O
parkinsonian	Disease
symptoms	Disease
.	O
METHODS:	O
Behavioral	O
experiments	O
and	O
electrophysiological	O
recordings	O
were	O
performed	O
in	O
the	O
present	O
study.	O
RESULTS:	O
Bilateral	O
infusions	O
of	O
neurotensin	Chemical
into	O
the	O
globus	O
pallidus	O
reversed	O
haloperidol	Chemical
-induced	O
parkinsonian	Disease
catalepsy	Disease
in	O
rats.	O
Electrophysiological	O
recordings	O
showed	O
that	O
microinjection	O
of	O
neurotensin	Chemical
induced	O
excitation	O
of	O
pallidal	O
neurons	O
in	O
the	O
presence	O
of	O
systemic	O
haloperidol	Chemical
administration.	O
The	O
neurotensin	Chemical
type-1	Chemical
receptor	Chemical
antagonist	Chemical
	O
SR48692	Chemical
blocked	O
both	O
the	O
behavioral	O
and	O
the	O
electrophysiological	O
effects	O
induced	O
by	O
neurotensin	Chemical
.	O
CONCLUSION:	O
Activation	O
of	O
pallidal	O
neurotensin	Chemical
receptors	O
may	O
be	O
involved	O
in	O
neurotensin	Chemical

Antihypertensive	O
drugs	O
and	O
depression	Disease
:	O
a	O
reappraisal.	O
Eighty-nine	O
new	O
referral	O
hypertensive	Disease
out-patients	O
and	O
46	O
new	O
referral	O
non-	O
hypertensive	Disease
chronically	O
physically	O
ill	O
out-patients	O
completed	O
a	O
mood	O
rating	O
scale	O
at	O
regular	O
intervals	O
for	O
one	O
year.	O
The	O
results	O
showed	O
a	O
high	O
prevalence	O
of	O
depression	Disease
in	O
both	O
groups	O
of	O
patients,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertensive	Disease
group.	O
Hypertensive	Disease
patients	O
with	O
psychiatric	Disease
histories	O
had	O
a	O
higher	O
prevalence	O
of	O
depression	Disease
than	O
the	O
comparison	O
patients.	O
This	O
was	O
accounted	O
for	O
by	O
a	O
significant	O
number	O
of	O
depressions	Disease
occurring	O
in	O
methyl	Chemical
dopa	Chemical
treated	O
patients	O
with	O
psychiatric	Disease

Pulmonary	O
shunt	O
and	O
cardiovascular	O
responses	O
to	O
CPAP	O
during	O
nitroprusside	Chemical
-induced	O
hypotension	Disease
.	O
The	O
effects	O
of	O
continuous	O
positive	O
airway	O
pressure	O
(CPAP)	O
on	O
cardiovascular	O
dynamics	O
and	O
pulmonary	O
shunt	O
(QS/QT)	O
were	O
investigated	O
in	O
12	O
dogs	O
before	O
and	O
during	O
sodium	Chemical
nitroprusside	Chemical
infusion	O
that	O
decreased	O
mean	O
arterial	O
blood	O
pressure	O
40-50	O
per	O
cent.	O
Before	O
nitroprusside	Chemical
infusion,	O
5	O
cm	O
H2O	Chemical
CPAP	O
significantly,	O
P	O
less	O
than	O
.05,	O
decreased	O
arterial	O
blood	O
pressure,	O
but	O
did	O
not	O
significantly	O
alter	O
heart	O
rate,	O
cardiac	O
output,	O
systemic	O
vascular	O
resistance,	O
or	O
QS/QT.	O
Ten	O
cm	O
H2O	Chemical
CPAP	O
before	O
nitroprusside	Chemical
infusion	O
produced	O
a	O
further	O
decrease	Disease
in	Disease
arterial	Disease
blood	Disease
pressure	Disease
and	O
significantly	O
increased	O
heart	O
rate	O
and	O
decreased	Disease
cardiac	Disease
output	Disease
and	O
QS/QT.	O
Nitroprusside	Chemical
caused	O
significant	O
decreases	Disease
in	Disease
arterial	Disease
blood	Disease
pressure	Disease
and	O
systemic	O
vascular	O
resistance	O
and	O
increases	O
in	O
heart	O
rate,	O
but	O
did	O
not	O
change	O
cardiac	O
output	O
or	O
QS/QT.	O
Five	O
cm	O
H2O	Chemical
CPAP	O
during	O
nitroprusside	Chemical
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above-mentioned	O
variables.	O
However,	O
10	O
cm	O
H2O	Chemical
CPAP	O
decreased	O
arterial	O
blood	O
pressure,	O
cardiac	O
output,	O
and	O
QS/QT.	O
These	O
data	O
indicate	O
that	O
nitroprusside	Chemical
infusion	O
rates	O
that	O
decrease	O
mean	O
arterial	O
blood	O
pressure	O
by	O
40-50	O
per	O
cent	O
do	O
not	O
change	O
cardiac	O
output	O
or	O
QS/QT.	O
During	O
nitroprusside	Chemical
infusion	O
low	O
levels	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiovascular	O
dynamics,	O
but	O
high	O
levels	O
of	O
CPAP	O
(10	O
cm	O
H2O	Chemical
),	O
while	O
decreasing	O
QS/QT,	O
produce	O
marked	O
decreases	Disease
in	Disease
arterial	Disease
blood	Disease
pressure	Disease
and	Disease
cardiac	Disease
output	Disease

Mediation	O
of	O
enhanced	O
reflex	O
vagal	O
bradycardia	Disease
by	O
L-dopa	Chemical
via	O
central	O
dopamine	Chemical
formation	O
in	O
dogs.	O
L-Dopa	Chemical
(5	O
mg/kg	O
i.v.)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
after	O
extracerebral	O
decarboxylase	O
inhibition	O
with	O
MK-486	Chemical
(25	O
mg/kg	O
i.v.)	O
in	O
anesthetize	O
MAO	Chemical
-inhibited	O
dogs.	O
In	O
addition,	O
reflex	O
bradycardia	Disease
caused	O
by	O
injected	O
norepinephrine	Chemical
was	O
significantly	O
enhanced	O
by	O
L-dopa	Chemical
,	O
DL-Threo-dihydroxyphenylserine	Chemical
had	O
no	O
effect	O
on	O
blood	O
pressure,	O
heart	O
rate	O
or	O
reflex	O
responses	O
to	O
norepinephrine	Chemical
.	O
FLA-63	Chemical
,	O
a	O
dopamine	Chemical
-beta-oxidase	O
inhibitor,	O
did	O
not	O
have	O
any	O
effect	O
on	O
the	O
hypotension	Disease
,	O
bradycardia	Disease
or	O
reflex-enhancing	O
effect	O
of	O
L-dopa	Chemical
.	O
Pimozide	Chemical
did	O
not	O
affect	O
the	O
actions	O
of	O
L-dopa	Chemical
on	O
blood	O
pressure	O
and	O
heart	O
rate	O
but	O
completely	O
blocked	O
the	O
enhancement	O
of	O
reflexes.	O
Removal	O
of	O
the	O
carotid	O
sinuses	O
caused	O
an	O
elevation	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
abolished	O
the	O
negative	O
chronotropic	O
effect	O
of	O
norepinephrine	Chemical
.	O
However,	O
L-dopa	Chemical
restored	O
the	O
bradycardia	Disease
caused	O
by	O
norepinephrine	Chemical
in	O
addition	O
to	O
decreasing	O
blood	O
pressure	O
and	O
heart	O
rate.	O
5-HTP	Chemical
(5	O
mg/kg	O
i.v.)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
and	O
decreased	O
the	O
reflex	O
bradycardia	Disease
to	O
norepinephrine	Chemical
.	O
It	O
is	O
concluded	O
that	O
L-dopa	Chemical
enhances	O
reflex	O
bradycardia	Disease
through	O
central	O
alpha-receptor	O
stimulation.	O
Furthermore,	O
the	O
effects	O
are	O
mediated	O
through	O
dopamine	Chemical
rather	O
than	O
norepinephrine	Chemical

Cocaine	Chemical
-induced	O
myocardial	Disease
infarction	Disease
:	O
clinical	O
observations	O
and	O
pathogenetic	O
considerations.	O
Clinical	O
and	O
experimental	O
data	O
published	O
to	O
date	O
suggest	O
several	O
possible	O
mechanisms	O
by	O
which	O
cocaine	Chemical
may	O
result	O
in	O
acute	Disease
myocardial	Disease
infarction	Disease
.	O
In	O
individuals	O
with	O
preexisting,	O
high-grade	O
coronary	O
arterial	O
narrowing,	O
acute	Disease
myocardial	Disease
infarction	Disease
may	O
result	O
from	O
an	O
increase	O
in	O
myocardial	O
oxygen	Chemical
demand	O
associated	O
with	O
cocaine	Chemical
-induced	O
increase	O
in	O
rate-pressure	O
product.	O
In	O
other	O
individuals	O
with	O
no	O
underlying	O
atherosclerotic	Disease
obstruction	Disease
,	O
coronary	Disease
occlusion	Disease
may	O
be	O
due	O
to	O
spasm	Disease
,	O
thrombus	Disease
,	O
or	O
both.	O
With	O
regard	O
to	O
spasm	Disease
,	O
the	O
clinical	O
findings	O
are	O
largely	O
circumstantial,	O
and	O
the	O
locus	O
of	O
cocaine	Chemical
-induced	O
vasoconstriction	O
remains	O
speculative.	O
Although	O
certain	O
clinical	O
and	O
experimental	O
findings	O
support	O
the	O
hypothesis	O
that	O
spasm	Disease
involves	O
the	O
epicardial,	O
medium-size	O
vessels,	O
other	O
data	O
suggest	O
intramural	O
vasoconstriction.	O
Diffuse	O
intramural	O
vasoconstriction	O
is	O
not	O
consistent	O
with	O
reports	O
of	O
segmental,	O
discrete	O
infarction	Disease
.	O
Whereas	O
certain	O
in	O
vivo	O
data	O
suggest	O
that	O
these	O
effects	O
are	O
alpha-mediated,	O
other	O
in	O
vitro	O
data	O
suggest	O
the	O
opposite.	O
The	O
finding	O
of	O
cocaine	Chemical
-induced	O
vasoconstriction	O
in	O
segments	O
of	O
(noninnervated)	O
human	O
umbilical	O
artery	O
suggests	O
that	O
the	O
presence	O
or	O
absence	O
of	O
intact	O
innervation	O
is	O
not	O
sufficient	O
to	O
explain	O
the	O
discrepant	O
data	O
involving	O
the	O
possibility	O
of	O
alpha-mediated	O
effects.	O
Finally,	O
the	O
contribution	O
of	O
a	O
primary,	O
thrombotic	Disease
effect	O
of	O
cocaine	Chemical

Rabbit	Disease
syndrome	Disease
,	O
antidepressant	Chemical
use,	O
and	O
cerebral	O
perfusion	O
SPECT	O
scan	O
findings.	O
The	O
rabbit	Disease
syndrome	Disease
is	O
an	O
extrapyramidal	O
side	O
effect	O
associated	O
with	O
chronic	O
neuroleptic	O
therapy.	O
Its	O
occurrence	O
in	O
a	O
patient	O
being	O
treated	O
with	O
imipramine	Chemical
is	O
described,	O
representing	O
the	O
first	O
reported	O
case	O
of	O
this	O
syndrome	O
in	O
conjunction	O
with	O
antidepressants	Chemical
.	O
Repeated	O
cerebral	O
perfusion	O
SPECT	O
scans	O
revealed	O
decreased	Disease
basal	Disease
ganglia	Disease
perfusion	Disease
while	O
the	O
movement	Disease
disorder	Disease
was	O
present,	O
and	O
a	O
return	O
to	O
normal	O
perfusion	O
when	O
the	O
rabbit	Disease
syndrome	Disease

Acute	O
bronchodilating	O
effects	O
of	O
ipratropium	Chemical
bromide	Chemical
and	O
theophylline	Chemical
in	O
chronic	Disease
obstructive	Disease
pulmonary	Disease
disease	Disease
.	O
The	O
bronchodilator	O
effects	O
of	O
a	O
single	O
dose	O
of	O
ipratropium	Chemical
bromide	Chemical
aerosol	O
(36	O
micrograms)	O
and	O
short-acting	O
theophylline	Chemical
tablets	O
(dose	O
titrated	O
to	O
produce	O
serum	O
levels	O
of	O
10-20	O
micrograms/mL)	O
were	O
compared	O
in	O
a	O
double-blind,	O
placebo-controlled	O
crossover	O
study	O
in	O
21	O
patients	O
with	O
stable,	O
chronic	Disease
obstructive	Disease
pulmonary	Disease
disease	Disease
.	O
Mean	O
peak	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
(FEV1)	O
increases	O
over	O
baseline	O
and	O
the	O
proportion	O
of	O
patients	O
attaining	O
at	O
least	O
a	O
15%	O
increase	O
in	O
the	O
FEV1	O
(responders)	O
were	O
31%	O
and	O
90%,	O
respectively,	O
for	O
ipratropium	Chemical
and	O
17%	O
and	O
50%,	O
respectively,	O
for	O
theophylline	Chemical
.	O
The	O
average	O
FEV1	O
increases	O
during	O
the	O
6-hour	O
observation	O
period	O
were	O
18%	O
for	O
ipratropium	Chemical
and	O
8%	O
for	O
theophylline	Chemical
.	O
The	O
mean	O
duration	O
of	O
action	O
was	O
3.8	O
hours	O
with	O
ipratropium	Chemical
and	O
2.4	O
hours	O
with	O
theophylline	Chemical
.	O
While	O
side	O
effects	O
were	O
rare,	O
those	O
experienced	O
after	O
theophylline	Chemical
use	O
did	O
involve	O
the	O
cardiovascular	Disease
and	Disease
gastrointestinal	Disease
systems	Disease
.	O
These	O
results	O
show	O
that	O
ipratropium	Chemical
is	O
a	O
more	O
potent	O
bronchodilator	O
than	O
oral	O
theophylline	Chemical
in	O
patients	O
with	O
chronic	Disease
airflow	Disease
obstruction	Disease

Irreversible	O
damage	O
to	O
the	O
medullary	O
interstitium	O
in	O
experimental	O
analgesic	O
nephropathy	Disease
in	O
F344	O
rats.	O
Renal	Disease
papillary	Disease
necrosis	Disease
(	O
RPN	Disease
)	O
and	O
a	O
decreased	O
urinary	O
concentrating	O
ability	O
developed	O
during	O
continuous	O
long-term	O
treatment	O
with	O
aspirin	Chemical
and	O
paracetamol	Chemical
in	O
female	O
Fischer	O
344	O
rats.	O
Renal	O
structure	O
and	O
concentrating	O
ability	O
were	O
examined	O
after	O
a	O
recovery	O
period	O
of	O
up	O
to	O
18	O
weeks,	O
when	O
no	O
analgesics	O
were	O
given,	O
to	O
investigate	O
whether	O
the	O
analgesic-induced	O
changes	O
were	O
reversible.	O
There	O
was	O
no	O
evidence	O
of	O
repair	O
to	O
the	O
damaged	O
medullary	O
interstitial	O
matrix,	O
or	O
proliferation	O
of	O
remaining	O
undamaged	O
type	O
1	O
medullary	O
interstitial	O
cells	O
after	O
the	O
recovery	O
period	O
following	O
analgesic	O
treatment.	O
The	O
recovery	O
of	O
urinary	O
concentrating	O
ability	O
was	O
related	O
to	O
the	O
length	O
of	O
analgesic	O
treatment	O
and	O
the	O
extent	O
of	O
the	O
resulting	O
inner	O
medullary	O
structural	O
damage.	O
During	O
the	O
early	O
stages	O
of	O
analgesic	O
treatment,	O
the	O
changes	O
in	O
urinary	O
concentrating	O
ability	O
were	O
reversible,	O
but	O
after	O
prolonged	O
analgesic	O
treatment,	O
maximum	O
urinary	O
concentrating	O
ability	O
failed	O
to	O
recover.	O
This	O
study	O
shows	O
that	O
prolonged	O
analgesic	O
treatment	O
in	O
Fischer	O
344	O
rats	O
causes	O
progressive	O
and	O
irreversible	O
damage	O
to	O
the	O
interstitial	O
matrix	O
and	O
type	O
1	O
interstitial	O
cells	O
leading	O
to	O
RPN	Disease

Less	O
frequent	O
lithium	Chemical
administration	O
and	O
lower	O
urine	O
volume.	O
OBJECTIVE:	O
This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
patients	O
maintained	O
on	O
a	O
regimen	O
of	O
lithium	Chemical
on	O
a	O
once-per-day	O
schedule	O
have	O
lower	O
urine	O
volumes	O
than	O
do	O
patients	O
receiving	O
multiple	O
doses	O
per	O
day.	O
METHOD:	O
This	O
was	O
a	O
cross-sectional	O
study	O
of	O
85	O
patients	O
from	O
a	O
lithium	Chemical
clinic	O
who	O
received	O
different	O
dose	O
schedules.	O
Patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
measurement	O
of	O
lithium	Chemical
level,	O
creatinine	Chemical
clearance,	O
urine	O
volume,	O
and	O
maximum	O
osmolality.	O
RESULTS:	O
Multiple	O
daily	O
doses	O
of	O
lithium	Chemical
were	O
associated	O
with	O
higher	O
urine	O
volumes.	O
The	O
dosing	O
schedule,	O
duration	O
of	O
lithium	Chemical
treatment,	O
and	O
daily	O
dose	O
of	O
lithium	Chemical
did	O
not	O
affect	O
maximum	O
osmolality	O
or	O
creatinine	Chemical
clearance.	O
CONCLUSIONS:	O
Urine	O
volume	O
can	O
be	O
reduced	O
by	O
giving	O
lithium	Chemical
once	O
daily	O
and/or	O
by	O
lowering	O
the	O
total	O
daily	O
dose.	O
Lithium	Chemical
-induced	O
polyuria	Disease

Effect	O
of	O
adriamycin	Chemical
combined	O
with	O
whole	O
body	O
hyperthermia	Disease
on	O
tumor	Disease
and	O
normal	O
tissues.	O
Thermal	O
enhancement	O
of	O
Adriamycin	Chemical
-mediated	O
antitumor	O
activity	O
and	O
normal	O
tissue	O
toxicities	Disease
by	O
whole	O
body	O
hyperthermia	Disease
were	O
compared	O
using	O
a	O
F344	O
rat	O
model.	O
Antitumor	O
activity	O
was	O
studied	O
using	O
a	O
tumor	Disease
growth	O
delay	O
assay.	O
Acute	O
normal	O
tissue	O
toxicities	Disease
(i.e.,	O
leukopenia	Disease
and	O
thrombocytopenia	Disease
)	O
and	O
late	O
normal	O
tissue	O
toxicities	Disease
(i.e.,	O
myocardial	Disease
and	Disease
kidney	Disease
injury	Disease
)	O
were	O
evaluated	O
by	O
functional/physiological	O
assays	O
and	O
by	O
morphological	O
techniques.	O
Whole	O
body	O
hyperthermia	Disease
(120	O
min	O
at	O
41.5	O
degrees	O
C)	O
enhanced	O
both	O
Adriamycin	Chemical
-mediated	O
antitumor	O
activity	O
and	O
toxic	O
side	O
effects.	O
The	O
thermal	O
enhancement	O
ratio	O
calculated	O
for	O
antitumor	O
activity	O
was	O
1.6.	O
Thermal	O
enhancement	O
ratios	O
estimated	O
for	O
"acute"	O
hematological	O
changes	O
were	O
1.3,	O
whereas	O
those	O
estimated	O
for	O
"late"	O
damage	O
(based	O
on	O
morphological	O
cardiac	Disease
and	Disease
renal	Disease
lesions	Disease
)	O
varied	O
between	O
2.4	O
and	O
4.3.	O
Thus,	O
while	O
whole	O
body	O
hyperthermia	Disease
enhances	O
Adriamycin	Chemical
-mediated	O
antitumor	O
effect,	O
normal	O
tissue	O
toxicity	Disease

Prazosin	Chemical
-induced	O
stress	Disease
incontinence	Disease
.	O
A	O
case	O
of	O
genuine	O
stress	Disease
incontinence	Disease
due	O
to	O
prazosin	Chemical
,	O
a	O
common	O
antihypertensive	O
drug,	O
is	O
presented.	O
Prazosin	Chemical
exerts	O
its	O
antihypertensive	O
effects	O
through	O
vasodilatation	O
caused	O
by	O
selective	O
blockade	O
of	O
postsynaptic	O
alpha-1	O
adrenergic	O
receptors.	O
As	O
an	O
alpha-blocker,	O
it	O
also	O
exerts	O
a	O
significant	O
relaxant	O
effect	O
on	O
the	O
bladder	O
neck	O
and	O
urethra.	O
The	O
patient's	O
clinical	O
course	O
is	O
described	O
and	O
correlated	O
with	O
initial	O
urodynamic	O
studies	O
while	O
on	O
prazosin	Chemical
and	O
subsequent	O
studies	O
while	O
taking	O
verapamil	Chemical
.	O
Her	O
incontinence	Disease
resolved	O
with	O
the	O
change	O
of	O
medication.	O
The	O
restoration	O
of	O
continence	O
was	O
accompanied	O
by	O
a	O
substantial	O
rise	O
in	O
maximum	O
urethral	O
pressure,	O
maximum	O
urethral	O
closure	O
pressure,	O
and	O
functional	O
urethral	O
length.	O
Patients	O
who	O
present	O
with	O
stress	Disease
incontinence	Disease
while	O
taking	O
prazosin	Chemical
should	O
change	O
their	O
antihypertensive	O
medication	O
before	O
considering	O
surgery,	O
because	O
their	O
incontinence	Disease

Myocardial	Disease
infarction	Disease
following	O
sublingual	O
administration	O
of	O
isosorbide	Chemical
dinitrate	Chemical
.	O
A	O
78-year-old	O
with	O
healed	O
septal	O
necrosis	Disease
suffered	O
a	O
recurrent	O
myocardial	Disease
infarction	Disease
of	O
the	O
anterior	O
wall	O
following	O
the	O
administration	O
of	O
isosorbide	Chemical
dinitrate	Chemical
5	O
mg	O
sublingually.	O
After	O
detailing	O
the	O
course	O
of	O
events,	O
we	O
discuss	O
the	O
role	O
of	O
paradoxical	O
coronary	O
spasm	Disease
and	O
hypotension	Disease
-mediated	O
myocardial	Disease
ischemia	Disease
occurring	O
downstream	O
to	O
significant	O
coronary	Disease
arterial	Disease
stenosis	Disease
in	O
the	O
pathophysiology	O
of	O
acute	Disease
coronary	Disease
insufficiency	Disease

Fluoxetine	Chemical
-induced	O
akathisia	Disease
:	O
clinical	O
and	O
theoretical	O
implications.	O
Five	O
patients	O
receiving	O
fluoxetine	Chemical
for	O
the	O
treatment	O
of	O
obsessive	Disease
compulsive	Disease
disorder	Disease
or	O
major	Disease
depression	Disease
developed	O
akathisia	Disease
.	O
The	O
typical	O
fluoxetine	Chemical
-induced	O
symptoms	O
of	O
restlessness,	O
constant	O
pacing,	O
purposeless	O
movements	O
of	O
the	O
feet	O
and	O
legs,	O
and	O
marked	O
anxiety	Disease
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic-induced	O
akathisia	Disease
.	O
Three	O
patients	O
who	O
had	O
experienced	O
neuroleptic-induced	O
akathisia	Disease
in	O
the	O
past	O
reported	O
that	O
the	O
symptoms	O
of	O
fluoxetine	Chemical
-induced	O
akathisia	Disease
were	O
identical,	O
although	O
somewhat	O
milder.	O
Akathisia	Disease
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxetine	Chemical
and	O
generally	O
responded	O
well	O
to	O
treatment	O
with	O
the	O
beta-adrenergic	O
antagonist	O
propranolol	Chemical
,	O
dose	O
reduction,	O
or	O
both.	O
The	O
authors	O
suggest	O
that	O
fluoxetine	Chemical
-induced	O
akathisia	Disease
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	O
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine	Chemical
-induced	O
akathisia	Disease
and	O
tricyclic	O
antidepressant	Chemical

Chronic	Disease
active	Disease
hepatitis	Disease
associated	O
with	O
diclofenac	Chemical
sodium	Chemical
therapy.	O
Diclofenac	Chemical
sodium	Chemical
(	O
Voltarol	Chemical
,	O
Geigy	O
Pharmaceuticals)	O
is	O
a	O
non-steroidal	O
anti-inflammatory	O
derivative	O
of	O
phenylacetic	Chemical
acid	Chemical
.	O
Although	O
generally	O
well-tolerated,	O
asymptomatic	O
abnormalities	Disease
of	Disease
liver	Disease
function	Disease
have	O
been	O
recorded	O
and,	O
less	O
commonly,	O
severe	O
hepatitis	Disease
induced	O
by	O
diclofenac	Chemical
.	O
The	O
patient	O
described	O
developed	O
chronic	Disease
active	Disease
hepatitis	Disease
after	O
six	O
months	O
therapy	O
with	O
diclofenac	Chemical
sodium	Chemical

Stroke	Disease
associated	O
with	O
cocaine	Chemical
use.	O
We	O
describe	O
eight	O
patients	O
in	O
whom	O
cocaine	Chemical
use	O
was	O
related	O
to	O
stroke	Disease
and	O
review	O
39	O
cases	O
from	O
the	O
literature.	O
Among	O
these	O
47	O
patients	O
the	O
mean	O
(+/-	O
SD)	O
age	O
was	O
32.5	O
+/-	O
12.1	O
years;	O
76%	O
(34/45)	O
were	O
men.	O
Stroke	Disease
followed	O
cocaine	Chemical
use	O
by	O
inhalation,	O
intranasal,	O
intravenous,	O
and	O
intramuscular	O
routes.	O
Intracranial	Disease
aneurysms	Disease
or	O
arteriovenous	Disease
malformations	Disease
were	O
present	O
in	O
17	O
of	O
32	O
patients	O
studied	O
angiographically	O
or	O
at	O
autopsy;	O
cerebral	Disease
vasculitis	Disease
was	O
present	O
in	O
two	O
patients.	O
Cerebral	Disease
infarction	Disease
occurred	O
in	O
10	O
patients	O
(22%),	O
intracerebral	Disease
hemorrhage	Disease
in	O
22	O
(49%),	O
and	O
subarachnoid	Disease
hemorrhage	Disease
in	O
13	O
(29%).	O
These	O
data	O
indicate	O
that	O
(1)	O
the	O
apparent	O
incidence	O
of	O
stroke	Disease
related	O
to	O
cocaine	Chemical
use	O
is	O
increasing;	O
(2)	O
cocaine	Chemical
-associated	O
stroke	Disease
occurs	O
primarily	O
in	O
young	O
adults;	O
(3)	O
stroke	Disease
may	O
follow	O
any	O
route	O
of	O
cocaine	Chemical
administration;	O
(4)	O
stroke	Disease
after	O
cocaine	Chemical
use	O
is	O
frequently	O
associated	O
with	O
intracranial	Disease
aneurysms	Disease
and	O
arteriovenous	Disease
malformations	Disease
;	O
and	O
(5)	O
in	O
cocaine	Chemical
-associated	O
stroke	Disease
,	O
the	O
frequency	O
of	O
intracranial	Disease
hemorrhage	Disease
exceeds	O
that	O
of	O
cerebral	Disease
infarction	Disease

Glyburide	Chemical
-induced	O
hepatitis	Disease
.	O
Drug-induced	O
hepatotoxicity	Disease
,	O
although	O
common,	O
has	O
been	O
reported	O
only	O
infrequently	O
with	O
sulfonylureas	Chemical
.	O
For	O
glyburide	Chemical
,	O
a	O
second-generation	O
sulfonylurea	Chemical
,	O
only	O
two	O
brief	O
reports	O
of	O
hepatotoxicity	Disease
exist.	O
Two	O
patients	O
with	O
type	Disease
II	Disease
diabetes	Disease
mellitus	Disease
developed	O
an	O
acute	Disease
hepatitis-like	Disease
syndrome	Disease
soon	O
after	O
initiation	O
of	O
glyburide	Chemical
therapy.	O
There	O
was	O
no	O
serologic	O
evidence	O
of	O
viral	Disease
infection	Disease
,	O
and	O
a	O
liver	O
biopsy	O
sample	O
showed	O
a	O
histologic	O
pattern	O
consistent	O
with	O
drug-induced	Disease
hepatitis	Disease
.	O
Both	O
patients	O
recovered	O
quickly	O
after	O
stopping	O
glyburide	Chemical
therapy	O
and	O
have	O
remained	O
well	O
for	O
a	O
follow-up	O
period	O
of	O
1	O
year.	O
Glyburide	Chemical
can	O
produce	O
an	O
acute	Disease
hepatitis-like	Disease
illness	Disease

Systolic	O
pressure	O
variation	O
is	O
greater	O
during	O
hemorrhage	Disease
than	O
during	O
sodium	Chemical
nitroprusside	Chemical
-induced	O
hypotension	Disease
in	O
ventilated	O
dogs.	O
The	O
systolic	O
pressure	O
variation	O
(SPV),	O
which	O
is	O
the	O
difference	O
between	O
the	O
maximal	O
and	O
minimal	O
values	O
of	O
the	O
systolic	O
blood	O
pressure	O
(SBP)	O
after	O
one	O
positive-pressure	O
breath,	O
was	O
studied	O
in	O
ventilated	O
dogs	O
subjected	O
to	O
hypotension	Disease
.	O
Mean	O
arterial	O
pressure	O
was	O
decreased	O
to	O
50	O
mm	O
Hg	O
for	O
30	O
minutes	O
either	O
by	O
hemorrhage	Disease
(	O
HEM	Disease
,	O
n	O
=	O
7)	O
or	O
by	O
continuous	O
infusion	O
of	O
sodium	Chemical
nitroprusside	Chemical
(	O
SNP	Chemical
,	O
n	O
=	O
7).	O
During	O
HEM	Disease
-induced	O
hypotension	Disease
the	O
cardiac	O
output	O
was	O
significantly	O
lower	O
and	O
systemic	O
vascular	O
resistance	O
higher	O
compared	O
with	O
that	O
in	O
the	O
SNP	Chemical
group.	O
The	O
systemic,	O
central	O
venous,	O
pulmonary	O
capillary	O
wedge	O
pressures,	O
and	O
heart	O
rates,	O
were	O
similar	O
in	O
the	O
two	O
groups.	O
Analysis	O
of	O
the	O
respiratory	O
changes	O
in	O
the	O
arterial	O
pressure	O
waveform	O
enabled	O
differentiation	O
between	O
the	O
two	O
groups.	O
The	O
SPV	O
during	O
hypotension	Disease
was	O
15.7	O
+/-	O
6.7	O
mm	O
Hg	O
in	O
the	O
HEM	Disease
group,	O
compared	O
with	O
9.1	O
+/-	O
2.0	O
mm	O
Hg	O
in	O
the	O
SNP	Chemical
group	O
(P	O
less	O
than	O
0.02).	O
The	O
delta	O
down,	O
which	O
is	O
the	O
measure	O
of	O
decrease	O
of	O
SBP	O
after	O
a	O
mechanical	O
breath,	O
was	O
20.3	O
+/-	O
8.4	O
and	O
10.1	O
+/-	O
3.8	O
mm	O
Hg	O
in	O
the	O
HEM	Disease
and	O
SNP	Chemical
groups,	O
respectively,	O
during	O
hypotension	Disease
(P	O
less	O
than	O
0.02).	O
It	O
is	O
concluded	O
that	O
increases	O
in	O
the	O
SPV	O
and	O
the	O
delta	O
down	O
are	O
characteristic	O
of	O
a	O
hypotensive	Disease
state	O
due	O
to	O
a	O
predominant	O
decrease	O
in	O
preload.	O
They	O
are	O
thus	O
more	O
important	O
during	O
absolute	O
hypovolemia	Disease
than	O
during	O
deliberate	O
hypotension	Disease

Drug-induced	O
arterial	O
spasm	Disease
relieved	O
by	O
lidocaine	Chemical
.	O
Case	O
report.	O
Following	O
major	O
intracranial	O
surgery	O
in	O
a	O
35-year-old	O
man,	O
sodium	Chemical
pentothal	Chemical
was	O
intravenously	O
infused	O
to	O
minimize	O
cerebral	Disease
ischaemia	Disease
.	O
Intense	O
vasospasm	Disease
with	O
threatened	O
gangrene	Disease
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusion.	O
Since	O
the	O
cranial	O
condition	O
precluded	O
use	O
of	O
more	O
usual	O
methods,	O
lidocaine	Chemical
was	O
given	O
intra-arterially,	O
with	O
careful	O
cardiovascular	O
monitoring,	O
to	O
counteract	O
the	O
vasospasm	Disease

Cerebral	O
blood	O
flow	O
and	O
metabolism	O
during	O
isoflurane	Chemical
-induced	O
hypotension	Disease
in	O
patients	O
subjected	O
to	O
surgery	O
for	O
cerebral	Disease
aneurysms	Disease
.	O
Cerebral	O
blood	O
flow	O
and	O
cerebral	O
metabolic	O
rate	O
for	O
oxygen	Chemical
were	O
measured	O
during	O
isoflurane	Chemical
-induced	O
hypotension	Disease
in	O
10	O
patients	O
subjected	O
to	O
craniotomy	O
for	O
clipping	O
of	O
a	O
cerebral	Disease
aneurysm	Disease
.	O
Flow	O
and	O
metabolism	O
were	O
measured	O
5-13	O
days	O
after	O
the	O
subarachnoid	Disease
haemorrhage	Disease
by	O
a	O
modification	O
of	O
the	O
classical	O
Kety-Schmidt	O
technique	O
using	O
xenon	Chemical
-133	O
i.v.	O
Anaesthesia	O
was	O
maintained	O
with	O
an	O
inspired	O
isoflurane	Chemical
concentration	O
of	O
0.75%	O
(plus	O
67%	O
nitrous	Chemical
oxide	Chemical
in	O
oxygen	Chemical
),	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34.3	O
+/-	O
2.1	O
ml/100	O
g	O
min-1	O
and	O
2.32	O
+/-	O
0.16	O
ml/100	O
g	O
min-1	O
at	O
PaCO2	O
4.1	O
+/-	O
0.1	O
kPa	O
(mean	O
+/-	O
SEM).	O
Controlled	O
hypotension	Disease
to	O
an	O
average	O
MAP	O
of	O
50-55	O
mm	O
Hg	Chemical
was	O
induced	O
by	O
increasing	O
the	O
dose	O
of	O
isoflurane	Chemical
,	O
and	O
maintained	O
at	O
an	O
inspired	O
concentration	O
of	O
2.2	O
+/-	O
0.2%.	O
This	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
CMRO2	O
(to	O
1.73	O
+/-	O
0.16	O
ml/100	O
g	O
min-1),	O
while	O
CBF	O
was	O
unchanged.	O
After	O
the	O
clipping	O
of	O
the	O
aneurysm	Disease
the	O
isoflurane	Chemical
concentration	O
was	O
reduced	O
to	O
0.75%.	O
There	O
was	O
a	O
significant	O
increase	O
in	O
CBF,	O
although	O
CMRO2	O
was	O
unchanged,	O
compared	O
with	O
pre-	O
hypotensive	Disease
values.	O
These	O
changes	O
might	O
offer	O
protection	O
to	O
brain	O
tissue	O
during	O
periods	O
of	O
induced	O
hypotension	Disease

Allergic	Disease
reaction	Disease
to	O
5-fluorouracil	Chemical
infusion.	O
An	O
allergic	Disease
reaction	Disease
consisting	O
of	O
angioneurotic	Disease
edema	Disease
secondary	O
to	O
continuous	O
infusion	O
5-fluorouracil	Chemical
occurred	O
in	O
a	O
patient	O
with	O
recurrent	O
carcinoma	Disease
of	Disease
the	Disease
oral	Disease
cavity	Disease
,	O
cirrhosis	Disease
,	O
and	O
cisplatin	Chemical
-induced	O
impaired	Disease
renal	Disease
function	Disease
.	O
This	O
reaction	O
occurred	O
during	O
the	O
sixth	O
and	O
seventh	O
courses	O
of	O
infusional	O
chemotherapy.	O
Oral	O
diphenhydramine	Chemical
and	O
prednisone	Chemical
were	O
ineffective	O
in	O
preventing	O
the	O
recurrence	O
of	O
the	O
allergic	Disease
reaction	Disease

Amiodarone	Chemical
-induced	O
sinoatrial	Disease
block	Disease
.	O
We	O
observed	O
sinoatrial	Disease
block	Disease
due	O
to	O
chronic	O
amiodarone	Chemical
administration	O
in	O
a	O
5-year-old	O
boy	O
with	O
primary	Disease
cardiomyopathy	Disease
,	O
Wolff-Parkinson-White	Disease
syndrome	Disease
and	O
supraventricular	Disease
tachycardia	Disease
.	O
Reduction	O
in	O
the	O
dosage	O
of	O
amiodarone	Chemical
resulted	O
in	O
the	O
disappearance	O
of	O
the	O
sinoatrial	Disease
block	Disease
and	O
the	O
persistence	O
of	O
asymptomatic	O
sinus	Disease
bradycardia	Disease

Possible	O
teratogenicity	O
of	O
sulphasalazine	Chemical
.	O
Three	O
infants,	O
born	O
of	O
two	O
mothers	O
with	O
inflammatory	Disease
bowel	Disease
disease	Disease
who	O
received	O
treatment	O
with	O
sulphasalazine	Chemical
throughout	O
pregnancy,	O
were	O
found	O
to	O
have	O
major	O
congenital	Disease
anomalies	Disease
.	O
In	O
the	O
singleton	O
pregnancy,	O
the	O
mother	O
had	O
ulcerative	Disease
colitis	Disease
,	O
and	O
the	O
infant,	O
a	O
male,	O
had	O
coarctation	Disease
of	Disease
the	Disease
aorta	Disease
and	O
a	O
ventricular	Disease
septal	Disease
defect	Disease
.	O
In	O
the	O
twin	O
pregnancy,	O
the	O
mother	O
had	O
Crohn's	Disease
disease	Disease
.	O
The	O
first	O
twin,	O
a	O
female,	O
had	O
a	O
left	O
Potter-type	Disease
IIa	Disease
polycystic	Disease
kidney	Disease
and	O
a	O
rudimentary	Disease
left	Disease
uterine	Disease
cornu	Disease
.	O
The	O
second	O
twin,	O
a	O
male,	O
had	O
some	O
features	O
of	O
Potter's	Disease
facies	Disease
,	O
hypoplastic	Disease
lungs	Disease
,	O
absent	Disease
kidneys	Disease
and	Disease
ureters	Disease
,	O
and	O
talipes	Disease
equinovarus	Disease
.	O
Despite	O
reports	O
to	O
the	O
contrary,	O
it	O
is	O
suggested	O
that	O
sulphasalazine	Chemical

Veno-occlusive	Disease
liver	Disease
disease	Disease
after	O
dacarbazine	Chemical
therapy	O
(	O
DTIC	Chemical
)	O
for	O
melanoma	Disease
.	O
A	O
case	O
of	O
veno-occlusive	Disease
disease	Disease
of	Disease
the	Disease
liver	Disease
with	O
fatal	O
outcome	O
after	O
dacarbazine	Chemical
(	O
DTIC	Chemical
)	O
therapy	O
for	O
melanoma	Disease
is	O
reported.	O
There	O
was	O
a	O
fulminant	O
clinical	O
course	O
from	O
start	O
of	O
symptoms	O
until	O
death	Disease
.	O
At	O
autopsy	O
the	O
liver	O
was	O
enlarged	O
and	O
firm	O
with	O
signs	O
of	O
venous	Disease
congestion	Disease
.	O
Small-	O
and	O
medium-sized	O
hepatic	O
veins	O
were	O
blocked	O
by	O
thrombosis	Disease

A	O
case	O
of	O
tardive	Disease
dyskinesia	Disease
caused	O
by	O
metoclopramide	Chemical
.	O
Abnormal	Disease
involuntary	Disease
movements	Disease
appeared	O
in	O
the	O
mouth,	O
tongue,	O
neck	O
and	O
abdomen	O
of	O
a	O
64-year-old	O
male	O
patient	O
after	O
he	O
took	O
metoclopramide	Chemical
for	O
gastrointestinal	Disease
disorder	Disease
in	O
a	O
regimen	O
of	O
30	O
mg	O
per	O
day	O
for	O
a	O
total	O
of	O
about	O
260	O
days.	O
The	O
symptoms	O
exacerbated	O
to	O
a	O
maximum	O
in	O
a	O
month.	O
When	O
the	O
metoclopramide	Chemical
administration	O
was	O
discontinued,	O
the	O
abnormal	Disease
movements	Disease
gradually	O
improved	O
to	O
a	O
considerable	O
extent.	O
Attention	O
to	O
the	O
possible	O
induction	O
of	O
specific	O
tardive	Disease
dyskinesia	Disease

Further	O
observations	O
on	O
the	O
electrophysiologic	O
effects	O
of	O
oral	O
amiodarone	Chemical
therapy.	O
A	O
case	O
is	O
presented	O
of	O
a	O
reversible	O
intra-Hisian	Disease
block	Disease
occurring	O
under	O
amiodarone	Chemical
treatment	O
for	O
atrial	Disease
tachycardia	Disease
in	O
a	O
patient	O
without	O
clear	O
intraventricular	Disease
conduction	Disease
abnormalities	Disease
.	O
His	O
bundle	O
recordings	O
showed	O
an	O
atrial	Disease
tachycardia	Disease
with	O
intermittent	O
exit	O
block	O
and	O
greatly	O
prolonged	O
BH	O
and	O
HV	O
intervals	O
(40	O
and	O
100	O
msec,	O
respectively).	O
Thirty	O
days	O
after	O
amiodarone	Chemical
discontinuation,	O
His	O
bundle	O
electrograms	O
showed	O
atrial	Disease
flutter	Disease
without	O
intra-Hisian	O
or	O
infra-Hisian	O
delay.	O
Amiodarone	Chemical

Busulfan	Chemical
-induced	O
hemorrhagic	Disease
cystitis	Disease
.	O
A	O
case	O
of	O
a	O
busulfan	Chemical
-induced	O
hemorrhage	Disease
cystitis	Disease
is	O
reported.	O
Spontaneous	O
resolution	O
occurred	O
following	O
cessation	O
of	O
the	O
drug.	O
The	O
similarity	O
between	O
the	O
histologic	O
appearances	O
of	O
busulfan	Chemical
	O
cystitis	Disease
and	O
both	O
radiation	O
and	O
cyclophosphamide	Chemical
-induced	O
cystitis	Disease
is	O
discussed	O
and	O
the	O
world	O
literature	O
reviewed.	O
In	O
view	O
of	O
the	O
known	O
tendency	O
of	O
busulfan	Chemical
to	O
induce	O
cellular	O
atypia	O
and	O
carcinoma	Disease

Rebound	O
hypertensive	Disease
after	O
sodium	Chemical
nitroprusside	Chemical
prevented	O
by	O
saralasin	Chemical
in	O
rats.	O
The	O
role	O
of	O
the	O
renin--	O
angiotensin	Chemical
system	O
in	O
the	O
maintenance	O
of	O
blood	O
pressure	O
during	O
halothane	Chemical
anesthesia	O
and	O
sodium	Chemical
nitroprusside	Chemical
(	O
SNP	Chemical
)-induced	O
hypotension	Disease
was	O
evaluated.	O
Control	O
rats	O
received	O
halothane	Chemical
anesthesia	O
(1	O
MAC)	O
for	O
one	O
hour,	O
followed	O
by	O
SNP	Chemical
infusion,	O
40	O
microgram/kg/min,	O
for	O
30	O
min,	O
followed	O
by	O
a	O
30-min	O
recovery	O
period.	O
A	O
second	O
group	O
of	O
rats	O
was	O
treated	O
identically	O
and,	O
in	O
addition,	O
received	O
an	O
infusion	O
of	O
saralasin	Chemical
(a	O
competitive	O
inhibitor	O
of	O
angiotensin	Chemical
II	Chemical
)	O
throughout	O
the	O
experimental	O
period.	O
In	O
each	O
group,	O
SNP	Chemical
infusion	O
resulted	O
in	O
an	O
initial	O
decrease	O
in	O
blood	O
pressure	O
from	O
86	O
torr	O
and	O
83	O
torr,	O
respectively,	O
to	O
48	O
torr.	O
During	O
the	O
SNP	Chemical
infusion	O
the	O
control	O
animals	O
demonstrated	O
a	O
progressive	O
increase	Disease
in	Disease
blood	Disease
pressure	Disease
to	O
61	O
torr,	O
whereas	O
the	O
saralasin	Chemical
-treated	O
animals	O
showed	O
no	O
change.	O
Following	O
discontinuation	O
of	O
SNP	Chemical
,	O
blood	O
pressure	O
in	O
the	O
control	O
animals	O
rebounded	O
to	O
94	O
torr,	O
as	O
compared	O
with	O
78	O
torr	O
in	O
the	O
saralasin	Chemical
-treated	O
rats.	O
This	O
study	O
indicates	O
that	O
with	O
stable	O
halothane	Chemical
anesthesia,	O
the	O
partial	O
recovery	O
of	O
blood	O
pressure	O
during	O
SNP	Chemical
infusion	O
and	O
the	O
post-	O
SNP	Chemical
rebound	O
of	O
blood	O
pressure	O
can	O
be	O
completely	O
blocked	O
by	O
saralasin	Chemical
.	O
This	O
demonstrates	O
the	O
participation	O
of	O
the	O
renin--	O
angiotensin	Chemical
system	O
in	O
antagonizing	O
the	O
combined	O
hypotensive	Disease
effects	O
of	O
halothane	Chemical
and	O
SNP	Chemical

Toxic	Disease
hepatitis	Disease
induced	O
by	O
antithyroid	O
drugs:	O
four	O
cases	O
including	O
one	O
with	O
cross-reactivity	O
between	O
carbimazole	Chemical
and	O
benzylthiouracil	Chemical
.	O
OBJECTIVE:	O
This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
occurrence	O
of	O
hepatic	Disease
adverse	Disease
effects	Disease
encountered	O
with	O
antithyroid	O
drugs.	O
METHODS:	O
Retrospective	O
review	O
of	O
medical	O
records	O
of	O
236	O
patients	O
with	O
hyperthyroidism	Disease
admitted	O
in	O
our	O
department	O
(in-	O
or	O
out-patients)	O
from	O
1986	O
to	O
1992.	O
RESULTS:	O
Four	O
patients	O
(1.7%)	O
were	O
identified	O
with	O
toxic	Disease
hepatitis	Disease
which	O
could	O
reasonably	O
be	O
attributed	O
to	O
the	O
use	O
of	O
antithyroid	O
agent.	O
Two	O
patients	O
had	O
a	O
cholestatic	Disease
hepatitis	Disease
induced	O
by	O
carbimazole	Chemical
(	O
N	Chemical
	Chemical
omercazole	Chemical
).	O
Two	O
others	O
had	O
a	O
mixed	O
(	O
cholestatic	Disease
and	O
cytolytic)	O
hepatitis	Disease
following	O
carbimazole	Chemical
.	O
One	O
of	O
the	O
latter	O
two	O
patients	O
further	O
experienced	O
a	O
cytolytic	O
hepatitis	Disease
which	O
appeared	O
after	O
Benzylthiouracil	Chemical
(	O
Basd	Chemical
	Chemical
ne	Chemical
)	O
had	O
replaced	O
carbimazole	Chemical
.	O
Biological	O
features	O
of	O
hepatitis	Disease
disappeared	O
in	O
all	O
cases	O
after	O
cessation	O
of	O
the	O
incriminated	O
drug,	O
while	O
biliary,	O
viral	O
and	O
immunological	O
searches	O
were	O
negative.	O
Only	O
2	O
patients	O
of	O
our	O
retrospective	O
study	O
experienced	O
a	O
mild	O
or	O
severe	O
neutropenia	Disease
.	O
CONCLUSION:	O
Toxic	Disease
hepatitis	Disease
is	O
a	O
potential	O
adverse	O
effect	O
of	O
antithyroid	O
drugs	O
which	O
warrants,	O
as	O
for	O
haematological	O
disturbances,	O
a	O
pre-therapeutic	O
determination	O
and	O
a	O
careful	O
follow-up	O
of	O
relevant	O
biological	O
markers.	O
Moreover,	O
hepatotoxicity	Disease

Study	O
of	O
the	O
role	O
of	O
vitamin	Chemical
B12	Chemical
and	O
folinic	Chemical
acid	Chemical
supplementation	O
in	O
preventing	O
hematologic	O
toxicity	Disease
of	O
zidovudine	Chemical
.	O
A	O
prospective,	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
role	O
of	O
vitamin	Chemical
B12	Chemical
and	O
folinic	Chemical
acid	Chemical
supplementation	O
in	O
preventing	O
zidovudine	Chemical
(	O
ZDV	Chemical
)-induced	O
bone	Disease
marrow	Disease
suppression	Disease
.	O
Seventy-five	O
human	Disease
immunodeficiency	Disease
virus	Disease
(HIV)-infected	Disease
patients	O
with	O
CD4+	O
cell	O
counts	O
<	O
500/mm3	O
were	O
randomized	O
to	O
receive	O
either	O
ZDV	Chemical
(500	O
mg	O
daily)	O
alone	O
(group	O
I,	O
n	O
=	O
38)	O
or	O
in	O
combination	O
with	O
folinic	Chemical
acid	Chemical
(15	O
mg	O
daily)	O
and	O
intramascular	O
vitamin	Chemical
B12	Chemical
(1000	O
micrograms	O
monthly)	O
(group	O
II,	O
n	O
=	O
37).	O
Finally,	O
15	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
(noncompliance	O
14,	O
death	Disease
1);	O
thus,	O
60	O
patients	O
(31	O
in	O
group	O
I	O
and	O
29	O
in	O
group	O
II)	O
were	O
eligible	O
for	O
analysis.	O
No	O
significant	O
differences	O
between	O
groups	O
were	O
found	O
at	O
enrollment.	O
During	O
the	O
study,	O
vitamin	Chemical
B12	Chemical
and	O
folate	Chemical
levels	O
were	O
significantly	O
higher	O
in	O
group	O
II	O
patients;	O
however,	O
no	O
differences	O
in	O
hemoglobin,	O
hematocrit,	O
mean	O
corpuscular	O
volume,	O
and	O
white-cell,	O
neutrophil	O
and	O
platelet	O
counts	O
were	O
observed	O
between	O
groups	O
at	O
3,	O
6,	O
9	O
and	O
12	O
months.	O
Severe	O
hematologic	O
toxicity	Disease
(neutrophil	O
count	O
<	O
1000/mm3	O
and/or	O
hemoglobin	O
<	O
8	O
g/dl)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II.	O
There	O
was	O
no	O
correlation	O
between	O
vitamin	Chemical
B12	Chemical
or	O
folate	Chemical
levels	O
and	O
development	O
of	O
myelosuppression	Disease
.	O
Vitamin	Chemical
B12	Chemical
and	O
folinic	Chemical
acid	Chemical
supplementation	O
of	O
ZDV	Chemical
therapy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
reducing	O
ZDV	Chemical
-induced	O
myelotoxicity	Disease

Acute	O
confusion	Disease
induced	O
by	O
a	O
high-dose	O
infusion	O
of	O
5-fluorouracil	Chemical
and	O
folinic	Chemical
acid	Chemical
.	O
A	O
61-year-old	O
man	O
was	O
treated	O
with	O
combination	O
chemotherapy	O
incorporating	O
cisplatinum	Chemical
,	O
etoposide	Chemical
,	O
high-dose	O
5-fluorouracil	Chemical
(2,250	O
mg/m2/24	O
hours)	O
and	O
folinic	Chemical
acid	Chemical
for	O
an	O
inoperable	O
gastric	Disease
adenocarcinoma	Disease
.	O
He	O
developed	O
acute	O
neurologic	O
symptoms	O
of	O
mental	O
confusion	Disease
,	O
disorientation	Disease
and	O
irritability	Disease
,	O
and	O
then	O
lapsed	O
into	O
a	O
deep	O
coma	Disease
,	O
lasting	O
for	O
approximately	O
40	O
hours	O
during	O
the	O
first	O
dose	O
(day	O
2)	O
of	O
5-fluorouracil	Chemical
and	O
folinic	Chemical
acid	Chemical
infusion.	O
This	O
complication	O
reappeared	O
on	O
day	O
25	O
during	O
the	O
second	O
dose	O
of	O
5-fluorouracil	Chemical
and	O
folinic	Chemical
acid	Chemical
,	O
which	O
were	O
then	O
the	O
only	O
drugs	O
given.	O
Because	O
folinic	Chemical
acid	Chemical
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
condition,	O
neurotoxicity	Disease
due	O
to	O
high-dose	O
5-fluorouracil	Chemical
was	O
highly	O
suspected.	O
The	O
pathogenesis	O
of	O
5-fluorouracil	Chemical
	O
neurotoxicity	Disease
may	O
be	O
due	O
to	O
a	O
Krebs	O
cycle	O
blockade	O
by	O
fluoroacetate	Chemical
and	O
fluorocitrate	Chemical
,	O
thiamine	Chemical
deficiency,	O
or	O
dihydrouracil	Chemical
dehydrogenase	O
deficiency.	O
High-dose	O
5-fluorouracil	Chemical
/	O
folinic	Chemical
acid	Chemical
infusion	O
therapy	O
has	O
recently	O
become	O
a	O
popular	O
regimen	O
for	O
various	O
cancers	Disease

Effect	O
of	O
switching	O
carbamazepine	Chemical
to	O
oxcarbazepine	Chemical
on	O
the	O
plasma	O
levels	O
of	O
neuroleptics.	O
A	O
case	O
report.	O
Carbamazepine	Chemical
was	O
switched	O
to	O
its	O
10-keto	O
analogue	O
oxcarbazepine	Chemical
among	O
six	O
difficult-to-treat	O
schizophrenic	Disease
or	O
organic	Disease
psychotic	Disease
patients	O
using	O
concomitantly	O
haloperidol	Chemical
,	O
chlorpromazine	Chemical
or	O
clozapine	Chemical
.	O
This	O
change	O
resulted	O
within	O
2-4	O
weeks	O
in	O
the	O
50-200%	O
increase	O
in	O
the	O
plasma	O
levels	O
of	O
these	O
neuroleptics	O
and	O
the	O
appearance	O
of	O
extrapyramidal	Disease
symptoms	Disease
.	O
None	O
of	O
the	O
patients	O
showed	O
any	O
clinical	O
deteriotation	O
during	O
the	O
following	O
3-6	O
months.	O
The	O
results	O
of	O
this	O
case	O
report	O
support	O
the	O
idea	O
that	O
in	O
contrast	O
with	O
carbamazepine	Chemical
	O
oxcarbazepine	Chemical

Erythema	Disease
multiforme	Disease
and	O
hypersensitivity	Disease
myocarditis	Disease
caused	O
by	O
ampicillin	Chemical
.	O
OBJECTIVE:	O
To	O
report	O
a	O
case	O
of	O
erythema	Disease
multiforme	Disease
and	O
hypersensitivity	Disease
myocarditis	Disease
caused	O
by	O
ampicillin	Chemical
.	O
CASE	O
SUMMARY:	O
A	O
13-year-old	O
boy	O
was	O
treated	O
with	O
ampicillin	Chemical
and	O
gentamicin	Chemical
because	O
of	O
suspected	O
septicemia	Disease
.	O
Medications	O
were	O
discontinued	O
when	O
erythema	Disease
multiforme	Disease
and	O
congestive	Disease
heart	Disease
failure	Disease
caused	O
by	O
myocarditis	Disease
occurred.	O
The	O
patient	O
was	O
treated	O
with	O
methylprednisolone	Chemical
and	O
gradually	O
improved.	O
Macrophage-migration	O
inhibition	O
(MIF)	O
test	O
with	O
ampicillin	Chemical
was	O
positive.	O
DISCUSSION:	O
After	O
most	O
infections	Disease
causing	O
erythema	Disease
multiforme	Disease
and	O
myocarditis	Disease
were	O
ruled	O
out,	O
a	O
drug-induced	Disease
allergic	Disease
reaction	Disease
was	O
suspected.	O
Positive	O
MIF	O
test	O
for	O
ampicillin	Chemical
showed	O
sensitization	O
of	O
the	O
patient's	O
lymphocytes	O
to	O
ampicillin	Chemical
.	O
CONCLUSIONS:	O
Hypersensitivity	Disease
myocarditis	Disease
is	O
a	O
rare	O
and	O
dangerous	O
manifestation	O
of	O
allergy	Disease
to	O
penicillins	Chemical

Immediate	O
allergic	Disease
reactions	Disease
to	O
amoxicillin	Chemical
.	O
A	O
large	O
group	O
of	O
patients	O
with	O
suspected	O
allergic	Disease
reactions	Disease
to	O
beta-lactam	Chemical
antibiotics	O
was	O
evaluated.	O
A	O
detailed	O
clinical	O
history,	O
together	O
with	O
skin	O
tests,	O
RAST	O
(radioallergosorbent	O
test),	O
and	O
controlled	O
challenge	O
tests,	O
was	O
used	O
to	O
establish	O
whether	O
patients	O
allergic	Disease
to	O
beta-lactam	Chemical
antibiotics	O
had	O
selective	O
immediate	O
allergic	Disease
responses	O
to	O
amoxicillin	Chemical
(	O
AX	Chemical
)	O
or	O
were	O
cross-reacting	O
with	O
other	O
penicillin	Chemical
derivatives.	O
Skin	O
tests	O
were	O
performed	O
with	O
benzylpenicilloyl-poly-L-lysine	Chemical
(	O
BPO-PLL	Chemical
),	O
benzylpenicilloate	Chemical
,	O
benzylpenicillin	Chemical
(	O
PG	Chemical
),	O
ampicillin	Chemical
(	O
AMP	Chemical
),	O
and	O
AX	Chemical
.	O
RAST	O
for	O
BPO-PLL	Chemical
and	O
AX	Chemical
-PLL	O
was	O
done.	O
When	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
BPO	Chemical
were	O
negative,	O
single-blind,	O
placebo-controlled	O
challenge	O
tests	O
were	O
done	O
to	O
ensure	O
tolerance	O
of	O
PG	Chemical
or	O
sensitivity	O
to	O
AX	Chemical
.	O
A	O
total	O
of	O
177	O
patients	O
were	O
diagnosed	O
as	O
allergic	Disease
to	O
beta-lactam	Chemical
antibiotics.	O
We	O
selected	O
the	O
54	O
(30.5%)	O
cases	O
of	O
immediate	O
AX	Chemical
	O
allergy	Disease
with	O
good	O
tolerance	O
of	O
PG	Chemical
.	O
Anaphylaxis	Disease
was	O
seen	O
in	O
37	O
patients	O
(69%),	O
the	O
other	O
17	O
(31%)	O
having	O
urticaria	Disease
and/or	O
angioedema	Disease
.	O
All	O
the	O
patients	O
were	O
skin	O
test	O
negative	O
to	O
BPO	Chemical
;	O
49	O
of	O
51	O
(96%)	O
were	O
also	O
negative	O
to	O
MDM	Disease
,	O
and	O
44	O
of	O
46	O
(96%)	O
to	O
PG	Chemical
.	O
Skin	O
tests	O
with	O
AX	Chemical
were	O
positive	O
in	O
34	O
(63%)	O
patients.	O
RAST	O
was	O
positive	O
for	O
AX	Chemical
in	O
22	O
patients	O
(41%)	O
and	O
to	O
BPO	Chemical
in	O
just	O
5	O
(9%).	O
None	O
of	O
the	O
sera	O
with	O
negative	O
RAST	O
for	O
AX	Chemical
were	O
positive	O
to	O
BPO	Chemical
.	O
Challenge	O
tests	O
with	O
AX	Chemical
were	O
performed	O
in	O
23	O
subjects	O
(43%)	O
to	O
establish	O
the	O
diagnosis	O
of	O
immediate	O
allergic	Disease
reaction	Disease
to	O
AX	Chemical
,	O
and	O
in	O
15	O
cases	O
(28%)	O
both	O
skin	O
test	O
and	O
RAST	O
for	O
AX	Chemical
were	O
negative.	O
PG	Chemical
was	O
well	O
tolerated	O
by	O
all	O
54	O
patients.	O
We	O
describe	O
the	O
largest	O
group	O
of	O
AX	Chemical
-	O
allergic	Disease
patients	O
who	O
have	O
tolerated	O
PG	Chemical
reported	O
so	O
far.	O
Diagnosis	O
of	O
these	O
patients	O
can	O
be	O
achieved	O
only	O
if	O
specific	O
AX	Chemical

Persistent	O
paralysis	Disease
after	O
prolonged	O
use	O
of	O
atracurium	Chemical
in	O
the	O
absence	O
of	O
corticosteroids.	O
Neuromuscular	O
blocking	O
agents	O
(NMBAs)	O
are	O
often	O
used	O
for	O
patients	O
requiring	O
prolonged	O
mechanical	O
ventilation.	O
Reports	O
of	O
persistent	O
paralysis	Disease
after	O
the	O
discontinuance	O
of	O
these	O
drugs	O
have	O
most	O
often	O
involved	O
aminosteroid-based	O
NMBAs	O
such	O
as	O
vecuronium	Chemical
bromide	Chemical
,	O
especially	O
when	O
used	O
in	O
conjunction	O
with	O
corticosteroids.	O
Atracurium	Chemical
besylate	Chemical
,	O
a	O
short-acting	O
benzylisoquinolinium	Chemical
NMBA	O
that	O
is	O
eliminated	O
independently	O
of	O
renal	O
or	O
hepatic	O
function,	O
has	O
also	O
been	O
associated	O
with	O
persistent	O
paralysis	Disease
,	O
but	O
only	O
when	O
used	O
with	O
corticosteroids.	O
We	O
report	O
a	O
case	O
of	O
atracurium	Chemical
-related	O
paralysis	Disease

Habitual	O
use	O
of	O
acetaminophen	Chemical
as	O
a	O
risk	O
factor	O
for	O
chronic	Disease
renal	Disease
failure	Disease
:	O
a	O
comparison	O
with	O
phenacetin	Chemical
.	O
Six	O
epidemiologic	O
studies	O
in	O
the	O
United	O
States	O
and	O
Europe	O
indicate	O
that	O
habitual	O
use	O
of	O
phenacetin	Chemical
is	O
associated	O
with	O
the	O
development	O
of	O
chronic	Disease
renal	Disease
failure	Disease
and	O
end-stage	Disease
renal	Disease
disease	Disease
(	O
ESRD	Disease
),	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
4	O
to	O
19.	O
As	O
a	O
result	O
of	O
these	O
and	O
other	O
studies,	O
phenacetin	Chemical
has	O
now	O
been	O
withdrawn	O
from	O
the	O
market	O
in	O
most	O
countries.	O
However,	O
three	O
case	O
control	O
studies,	O
one	O
each	O
in	O
North	O
Carolina,	O
northern	O
Maryland,	O
and	O
West	O
Berlin,	O
Germany,	O
showed	O
that	O
habitual	O
use	O
of	O
acetaminophen	Chemical
is	O
also	O
associated	O
with	O
chronic	Disease
renal	Disease
failure	Disease
and	O
ESRD	Disease
,	O
with	O
a	O
relative	O
risk	O
in	O
the	O
range	O
of	O
2	O
to	O
4.	O
These	O
studies	O
suggest	O
that	O
both	O
phenacetin	Chemical
and	O
acetaminophen	Chemical
may	O
contribute	O
to	O
the	O
burden	O
of	O
ESRD	Disease
,	O
with	O
the	O
risk	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former.	O
This	O
apparent	O
difference	O
in	O
risk	O
may	O
not	O
be	O
due	O
to	O
differences	O
in	O
nephrotoxic	Disease
potential	O
of	O
the	O
drugs	O
themselves.	O
A	O
lower	O
relative	O
risk	O
would	O
be	O
expected	O
for	O
acetaminophen	Chemical
if	O
the	O
risk	O
of	O
both	O
drugs	O
in	O
combination	O
with	O
other	O
analgesics	O
was	O
higher	O
than	O
the	O
risk	O
of	O
either	O
agent	O
alone.	O
Thus,	O
acetaminophen	Chemical
has	O
been	O
used	O
both	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
other	O
analgesics,	O
whereas	O
phenacetin	Chemical
was	O
available	O
only	O
in	O
combinations.	O
The	O
possibility	O
that	O
habitual	O
use	O
of	O
acetaminophen	Chemical
alone	O
increases	O
the	O
risk	O
of	O
ESRD	Disease

Reduction	O
of	O
heparan	Chemical
sulphate	Chemical
-associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
of	O
rats	O
with	O
streptozotocin	Chemical
-induced	O
diabetic	Disease
nephropathy	Disease
.	O
Heparan	Chemical
sulphate	Chemical
-associated	O
anionic	O
sites	O
in	O
the	O
glomerular	O
basement	O
membrane	O
were	O
studied	O
in	O
rats	O
8	O
months	O
after	O
induction	O
of	O
diabetes	Disease
by	O
streptozotocin	Chemical
and	O
in	O
age-	O
adn	O
sex-matched	O
control	O
rats,	O
employing	O
the	O
cationic	O
dye	O
cuprolinic	Chemical
blue	Chemical
.	O
Morphometric	O
analysis	O
at	O
the	O
ultrastructural	O
level	O
was	O
performed	O
using	O
a	O
computerized	O
image	O
processor.	O
The	O
heparan	Chemical
sulphate	Chemical
specificity	O
of	O
the	O
cuprolinic	Chemical
blue	Chemical
staining	O
was	O
demonstrated	O
by	O
glycosaminoglycan	Chemical
-degrading	O
enzymes,	O
showing	O
that	O
pretreatment	O
of	O
the	O
sections	O
with	O
heparitinase	O
abolished	O
all	O
staining,	O
whereas	O
chondroitinase	O
ABC	O
had	O
no	O
effect.	O
The	O
majority	O
of	O
anionic	O
sites	O
(74%	O
in	O
diabetic	Disease
and	O
81%	O
in	O
control	O
rats)	O
were	O
found	O
within	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane.	O
A	O
minority	O
of	O
anionic	O
sites	O
were	O
scattered	O
throughout	O
the	O
lamina	O
densa	O
and	O
lamina	O
rara	O
interna,	O
and	O
were	O
significantly	O
smaller	O
than	O
those	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(p<0.001	O
and	O
p<0.01	O
for	O
diabetic	Disease
and	O
control	O
rats,	O
respectively).	O
Diabetic	Disease
rats	O
progressively	O
developed	O
albuminuria	Disease
reaching	O
40.3	O
(32.2-62.0)	O
mg/24	O
h	O
after	O
8	O
months	O
in	O
contrast	O
to	O
the	O
control	O
animals	O
(0.8	O
(0.2-0.9)	O
mg/24	O
h,	O
p<0.002).	O
At	O
the	O
same	O
time,	O
the	O
number	O
of	O
heparan	Chemical
sulphate	Chemical
anionic	O
sites	O
and	O
the	O
total	O
anionic	O
site	O
surface	O
(number	O
of	O
anionic	O
sites	O
x	O
mean	O
anionic	O
site	O
surface)	O
in	O
the	O
lamina	O
rara	O
externa	O
of	O
the	O
glomerular	O
basement	O
membrane	O
was	O
reduced	O
by	O
19%	O
(p<0.021)	O
and	O
by	O
26%	O
(p<0.02),	O
respectively.	O
Number	O
and	O
total	O
anionic	O
site	O
surface	O
in	O
the	O
remaining	O
part	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(lamina	O
densa	O
and	O
lamina	O
rara	O
interna)	O
were	O
not	O
significantly	O
changed.	O
We	O
conclude	O
that	O
in	O
streptozotocin	Chemical
-	O
diabetic	Disease
rats	O
with	O
an	O
increased	O
urinary	O
albumin	O
excretion,	O
a	O
reduced	O
heparan	Chemical
sulphate	Chemical

Effect	O
of	O
some	O
anticancer	O
drugs	O
and	O
combined	O
chemotherapy	O
on	O
renal	Disease
toxicity	Disease
.	O
The	O
nephrotoxic	Disease
action	O
of	O
anticancer	O
drugs	O
such	O
as	O
nitrogranulogen	Chemical
(	O
NG	Chemical
),	O
methotrexate	Chemical
(	O
MTX	Chemical
),	O
5-fluorouracil	Chemical
(	O
5-FU	Chemical
)	O
and	O
cyclophosphamide	Chemical
(	O
CY	Chemical
)	O
administered	O
alone	O
or	O
in	O
combination	O
[	O
MTX	Chemical
+	O
5-FU	Chemical
+	O
CY	Chemical
(CMF)]	O
was	O
evaluated	O
in	O
experiments	O
on	O
Wistar	O
rats.	O
After	O
drug	O
administration,	O
creatinine	Chemical
concentrations	O
in	O
the	O
plasma	O
and	O
in	O
the	O
urine	O
of	O
the	O
rats	O
were	O
determined,	O
as	O
well	O
as	O
creatinine	Chemical
clearance.	O
Histopathologic	O
evaluation	O
of	O
the	O
kidneys	O
was	O
also	O
performed.	O
After	O
MTX	Chemical
administration	O
a	O
significant	O
increase	O
(p	O
=	O
0.0228)	O
in	O
the	O
plasma	O
creatinine	Chemical
concentration	O
and	O
a	O
significant	O
(p	O
=	O
0.0001)	O
decrease	O
in	O
creatinine	Chemical
clearance	O
was	O
noted	O
compared	O
to	O
controls.	O
After	O
the	O
administration	O
of	O
NG	Chemical
,	O
5-FU	Chemical
and	O
CY	Chemical
neither	O
a	O
statistically	O
significant	O
increase	O
in	O
creatinine	Chemical
concentration	O
nor	O
an	O
increase	O
in	O
creatinine	Chemical
clearance	O
was	O
observed	O
compared	O
to	O
the	O
group	O
receiving	O
no	O
cytostatics.	O
Following	O
polytherapy	O
according	O
to	O
the	O
CMF	O
regimen,	O
a	O
statistically	O
significant	O
decrease	O
(p	O
=	O
0.0343)	O
in	O
creatinine	Chemical
clearance	O
was	O
found,	O
but	O
creatinine	Chemical
concentration	O
did	O
not	O
increase	O
significantly	O
compared	O
to	O
controls.	O
CY	Chemical
caused	O
hemorrhagic	Disease
cystitis	Disease
in	O
40%	O
of	O
rats,	O
but	O
it	O
did	O
not	O
cause	O
this	O
complication	O
when	O
combined	O
with	O
5-FU	Chemical
and	O
MTX	Chemical
.	O
Histologic	O
changes	O
were	O
found	O
in	O
rat	O
kidneys	O
after	O
administration	O
of	O
MTX	Chemical
,	O
CY	Chemical
and	O
NG	Chemical
,	O
while	O
no	O
such	O
change	O
was	O
observed	O
after	O
5-FU	Chemical
and	O
joint	O
administration	O
of	O
MTX	Chemical
+	O
5-FU	Chemical
+	O
CY	Chemical
compared	O
to	O
controls.	O
Our	O
studies	O
indicate	O
that	O
nephrotoxicity	Disease
of	O
MTX	Chemical
+	O
5-FU	Chemical
+	O
CY	Chemical

Lithium	Chemical
-associated	O
cognitive	Disease
and	Disease
functional	Disease
deficits	Disease
reduced	O
by	O
a	O
switch	O
to	O
divalproex	Chemical
sodium	Chemical
:	O
a	O
case	O
series.	O
BACKGROUND:	O
Lithium	Chemical
remains	O
a	O
first-line	O
treatment	O
for	O
the	O
acute	O
and	O
maintenance	O
treatment	O
of	O
bipolar	Disease
disorder	Disease
.	O
Although	O
much	O
has	O
been	O
written	O
about	O
the	O
management	O
of	O
the	O
more	O
common	O
adverse	O
effects	O
of	O
lithium	Chemical
,	O
such	O
as	O
polyuria	Disease
and	O
tremor	Disease
,	O
more	O
subtle	O
lithium	Chemical
side	O
effects	O
such	O
as	O
cognitive	Disease
deficits	Disease
,	O
loss	Disease
of	Disease
creativity	Disease
,	O
and	O
functional	Disease
impairments	Disease
remain	O
understudied.	O
This	O
report	O
summarizes	O
our	O
experience	O
in	O
switching	O
bipolar	Disease
patients	O
from	O
lithium	Chemical
to	O
divalproex	Chemical
sodium	Chemical
to	O
alleviate	O
such	O
cognitive	Disease
and	Disease
functional	Disease
impairments	Disease
.	O
METHOD:	O
Open,	O
case	O
series	O
design.	O
RESULTS:	O
We	O
report	O
seven	O
cases	O
where	O
substitution	O
of	O
lithium	Chemical
,	O
either	O
fully	O
or	O
partially,	O
with	O
divalproex	Chemical
sodium	Chemical
was	O
extremely	O
helpful	O
in	O
reducing	O
the	O
cognitive,	Disease
motivational,	Disease
or	Disease
creative	Disease
deficits	Disease
attributed	O
to	O
lithium	Chemical
in	O
our	O
bipolar	Disease
patients.	O
CONCLUSION:	O
In	O
this	O
preliminary	O
report,	O
divalproex	Chemical
sodium	Chemical
was	O
a	O
superior	O
alternative	O
to	O
lithium	Chemical
in	O
bipolar	Disease
patients	O
experiencing	O
cognitive	Disease
deficits	Disease
,	O
loss	Disease
of	Disease
creativity	Disease
,	O
and	O
functional	Disease
impairments	Disease

Treatment	O
of	O
previously	O
treated	O
metastatic	O
breast	Disease
cancer	Disease
by	O
mitoxantrone	Chemical
and	O
48-hour	O
continuous	O
infusion	O
of	O
high-dose	O
5-FU	Chemical
and	O
leucovorin	Chemical
(	O
MFL	Chemical
):	O
low	O
palliative	O
benefit	O
and	O
high	O
treatment-related	O
toxicity	Disease
.	O
For	O
previously	O
treated	O
advanced	O
breast	Disease
cancer	Disease
,	O
there	O
is	O
no	O
standard	O
second-line	O
therapy.	O
Combination	O
chemotherapy	O
with	O
mitoxantrone	Chemical
,	O
high-dose	O
5-fluorouracil	Chemical
(	O
5-FU	Chemical
)	O
and	O
leucovorin	Chemical
(	O
MFL	Chemical
regimen	Chemical
)	O
had	O
been	O
reported	O
as	O
an	O
effective	O
and	O
well	O
tolerated	O
regimen.	O
From	O
October	O
1993	O
to	O
November	O
1995,	O
we	O
treated	O
13	O
patients	O
with	O
previously	O
chemotherapy-treated	O
metastatic	O
breast	Disease
cancer	Disease
by	O
mitoxantrone	Chemical
,	O
12	O
mg/m2,	O
on	O
day	O
1	O
and	O
continuous	O
infusion	O
of	O
5-FU	Chemical
,	O
3000	O
mg/m2,	O
together	O
with	O
leucovorin	Chemical
,	O
300	O
mg/m2,	O
for	O
48	O
h	O
from	O
day	O
1	O
to	O
2.	O
Each	O
course	O
of	O
chemotherapy	O
was	O
given	O
every	O
4	O
weeks.	O
Most	O
of	O
these	O
patients	O
had	O
more	O
than	O
two	O
metastatic	O
sites,	O
with	O
lung	O
metastasis	O
predominant.	O
Seven	O
patients	O
had	O
been	O
treated	O
with	O
anthracycline	Chemical
.	O
Seven	O
patients	O
had	O
previously	O
received	O
radiotherapy	O
and	O
seven	O
had	O
received	O
hormone	O
therapy.	O
Median	O
number	O
of	O
courses	O
of	O
MFL	Chemical
regimen	Chemical
given	O
was	O
six	O
and	O
the	O
median	O
cumulative	O
dose	O
of	O
mitoxantrone	Chemical
was	O
68.35	O
mg/m2.	O
One	O
patient	O
had	O
complete	O
response,	O
seven	O
had	O
stable	O
disease,	O
none	O
had	O
partial	O
response	O
and	O
five	O
had	O
progressive	O
disease.	O
The	O
overall	O
objective	O
response	O
rate	O
was	O
7.6%.	O
The	O
median	O
follow-up	O
period	O
was	O
14	O
months.	O
Median	O
survival	O
was	O
16	O
months.	O
Median	O
progression-free	O
survival	O
was	O
5	O
months.	O
A	O
complete	O
responder	O
had	O
relapse-free	O
survival	O
up	O
to	O
17	O
months.	O
Major	O
toxicities	Disease
were	O
cardiotoxicity	Disease
and	O
leukopenia	Disease
.	O
Eight	O
patients	O
were	O
dead	O
in	O
the	O
last	O
follow-up;	O
two	O
of	O
them	O
died	O
of	O
treatment-related	O
toxicity	Disease
.	O
The	O
MFL	Chemical
regimen	Chemical
achieves	O
little	O
palliative	O
benefit	O
and	O
induces	O
severe	O
toxicity	Disease
at	O
a	O
fairly	O
high	O
rate.	O
Administration	O
of	O
this	O
regimen	O
to	O
breast	Disease
cancer	Disease
patients	O
who	O
have	O
been	O
treated	O
by	O
chemotherapy	O
and	O
those	O
with	O
impaired	Disease
heart	Disease
function	Disease

Upregulation	O
of	O
the	O
expression	O
of	O
vasopressin	Chemical
gene	O
in	O
the	O
paraventricular	O
and	O
supraoptic	O
nuclei	O
of	O
the	O
lithium	Chemical
-induced	O
diabetes	Disease
insipidus	Disease
rat.	O
The	O
expression	O
of	O
arginine	Chemical
vasopressin	Chemical
(	O
AVP	Chemical
)	O
gene	O
in	O
the	O
paraventricular	O
(PVN)	O
and	O
supraoptic	O
nuclei	O
(SON)	O
was	O
investigated	O
in	O
rats	O
with	O
lithium	Chemical
(	O
Li	Chemical
)-induced	O
polyuria	Disease
,	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
and	O
radioimmunoassay.	O
The	O
male	O
Wistar	O
rats	O
consuming	O
a	O
diet	O
that	O
contained	O
LiCl	Chemical
(60	O
mmol/kg)	O
for	O
4	O
weeks	O
developed	O
marked	O
polyuria	Disease
.	O
The	O
Li	Chemical
-treated	O
rats	O
produced	O
a	O
large	O
volume	O
of	O
hypotonic	O
urine	O
with	O
low	O
ionic	O
concentrations.	O
Plasma	O
sodium	Chemical
concentrations	O
were	O
found	O
to	O
be	O
slightly	O
increased	O
in	O
the	O
Li	Chemical
-treated	O
rats	O
compared	O
with	O
those	O
in	O
controls.	O
Plasma	O
concentration	O
of	O
AVP	Chemical
and	O
transcripts	O
of	O
AVP	Chemical
gene	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
increased	O
in	O
the	O
Li	Chemical
-treated	O
rats	O
compared	O
with	O
controls.	O
These	O
results	O
suggest	O
that	O
dehydration	Disease
and/or	O
the	O
activation	O
of	O
visceral	O
afferent	O
inputs	O
may	O
contribute	O
to	O
the	O
elevation	O
of	O
plasma	O
AVP	Chemical
and	O
the	O
upregulation	O
of	O
AVP	Chemical
gene	O
expression	O
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li	Chemical
-induced	O
diabetes	Disease
insipidus	Disease

Suxamethonium	Chemical
-induced	O
cardiac	Disease
arrest	Disease
and	O
death	Disease
following	O
5	O
days	O
of	O
immobilization.	O
The	O
present	O
report	O
describes	O
a	O
case	O
of	O
cardiac	Disease
arrest	Disease
and	O
subsequent	O
death	Disease
as	O
a	O
result	O
of	O
hyperkalaemia	Disease
following	O
the	O
use	O
of	O
suxamethonium	Chemical
in	O
a	O
23-year-old	O
Malawian	O
woman.	O
Five	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
of	O
meningitis	Disease
,	O
the	O
patient	O
aspirated	O
stomach	O
contents	O
and	O
needed	O
endotracheal	O
intubation.	O
Forty	O
seconds	O
after	O
injection	O
of	O
suxamethonium	Chemical
,	O
bradycardia	Disease
and	O
cardiac	Disease
arrest	Disease
occurred.	O
Attempts	O
to	O
resuscitate	O
the	O
patient	O
were	O
not	O
successful.	O
The	O
serum	O
level	O
of	O
potassium	Chemical
was	O
observed	O
to	O
be	O
8.4	O
mequiv	O
L-1.	O
Apart	O
from	O
the	O
reduction	O
in	O
the	O
patient's	O
level	O
of	O
consciousness,	O
there	O
were	O
no	O
signs	O
of	O
motor	O
neurone	O
damage	O
or	O
of	O
any	O
of	O
the	O
other	O
known	O
predisposing	O
conditions	O
for	O
hyperkalaemia	Disease
following	O
the	O
administration	O
of	O
suxamethonium	Chemical
.	O
It	O
is	O
postulated	O
that	O
her	O
death	Disease
was	O
caused	O
by	O
hypersensitivity	Disease
to	O
suxamethonium	Chemical

An	O
unusual	O
toxic	O
reaction	O
to	O
axillary	O
block	O
by	O
mepivacaine	Chemical
with	O
adrenaline	Chemical
.	O
An	O
increase	Disease
in	Disease
blood	Disease
pressure	Disease
,	O
accompanied	O
by	O
atrial	Disease
fibrillation	Disease
,	O
agitation	Disease
,	O
incomprehensible	Disease
shouts	Disease
and	O
loss	Disease
of	Disease
consciousness	Disease
,	O
was	O
observed	O
in	O
an	O
elderly,	O
ASA	O
classification	O
group	O
II,	O
cardiovascularly	O
medicated	O
male,	O
12	O
min	O
after	O
performance	O
of	O
axillary	O
block	O
with	O
mepivacaine	Chemical
850	O
mg	O
containing	O
adrenaline	Chemical
0.225	O
mg,	O
for	O
correction	O
of	O
Dupuytren's	Disease
contracture	Disease
.	O
After	O
intravenous	O
administration	O
of	O
labetalol	Chemical
,	O
metoprolol	Chemical
and	O
midazolam	Chemical
the	O
patient's	O
condition	O
improved,	O
and	O
15	O
min	O
later	O
he	O
woke	O
up.	O
The	O
block	O
was	O
successful	O
and	O
surgery	O
was	O
conducted	O
as	O
scheduled	O
despite	O
persisting	O
atrial	Disease
fibrillation	Disease
.	O
Postoperatively,	O
the	O
patient	O
refused	O
DC	O
cardioversion	O
and	O
was	O
treated	O
medically.	O
Both	O
the	O
temporal	O
relationship	O
of	O
events	O
and	O
the	O
response	O
to	O
treatment	O
suggest	O
that	O
a	O
rapid	O
systemic	O
absorption	O
of	O
mepivacaine	Chemical
with	O
adrenaline	Chemical

Clinical	O
and	O
histopathologic	O
examination	O
of	O
renal	O
allografts	O
treated	O
with	O
tacrolimus	Chemical
(	O
FK506	Chemical
)	O
for	O
at	O
least	O
one	O
year.	O
BACKGROUND:	O
We	O
clinically	O
and	O
pathologically	O
analyzed	O
renal	O
allografts	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
treated	O
with	O
tacrolimus	Chemical
(	O
FK506	Chemical
)	O
for	O
more	O
than	O
1	O
year.	O
METHODS:	O
Twenty-six	O
renal	O
allograft	O
biopsy	O
specimens	O
from	O
1	O
9	O
renal	O
transplant	O
patients	O
who	O
underwent	O
transplantations	O
between	O
1991	O
and	O
1993	O
were	O
evaluated.	O
Thirteen	O
biopsies	O
were	O
performed	O
from	O
stable	O
functioning	O
renal	O
allografts	O
with	O
informed	O
consent	O
(nonepisode	O
biopsy)	O
and	O
the	O
other	O
13	O
were	O
from	O
dysfunctional	O
renal	O
allografts	O
with	O
a	O
clinical	O
indication	O
for	O
biopsy	O
(episode	O
biopsy).	O
RESULTS:	O
The	O
main	O
pathologic	O
diagnoses	O
(some	O
overlap)	O
were	O
acute	O
rejection	O
(AR;	O
n	O
=	O
4),	O
chronic	O
rejection	O
(CR;	O
n=5),	O
AR+CR	O
(n	O
=4),	O
recurrent	O
IgA	Disease
nephropathy	Disease
(n	O
=5),	O
normal	O
findings	O
(n	O
=2),	O
minimal-type	O
chronic	O
FK506	Chemical
	O
nephropathy	Disease
(n	O
=	O
9),	O
and	O
mild-type	O
FK506	Chemical
	O
nephropathy	Disease
(n	O
=	O
11).	O
Of	O
the	O
nonepisode	O
biopsies,	O
7	O
and	O
4	O
biopsies	O
showed	O
minimal-type	O
and	O
mild-type	O
chronic	O
FK506	Chemical
	O
nephropathy	Disease
,	O
respectively.	O
Chronic	O
FK506	Chemical
	O
nephropathy	Disease
consisted	O
of	O
rough	O
and	O
foamy	O
tubular	O
vacuolization	O
(5	O
biopsies),	O
arteriolopathy	O
(angiodegeneration	O
of	O
the	O
arteriolar	O
wall;	O
20	O
biopsies),	O
focal	Disease
segmental	Disease
glomerulosclerosis	Disease
(4	O
biopsies)	O
and	O
the	O
striped	O
form	O
of	O
interstitial	Disease
fibrosis	Disease
(11	O
biopsies).	O
The	O
serum	O
creatinine	Chemical
levels	O
of	O
patients	O
in	O
the	O
mild-type	O
chronic	O
FK506	Chemical
	O
nephropathy	Disease
group,	O
which	O
included	O
7	O
episode	O
biopsies,	O
were	O
statistically	O
higher	O
than	O
those	O
in	O
the	O
minimum-type	O
chronic	O
FK506	Chemical
-	O
nephropathy	Disease
group	O
(P<	O
0.001).	O
CONCLUSIONS:	O
This	O
study	O
demonstrates	O
that	O
chronic	O
FK506	Chemical
	O
nephropathy	Disease
consists	O
primarily	O
of	O
arteriolopathy	O
manifesting	O
as	O
insudative	O
hyalinosis	O
of	O
the	O
arteriolar	O
wall,	O
and	O
suggests	O
that	O
mild-type	O
chronic	O
FK506	Chemical
	O
nephropathy	Disease

Memory	O
facilitation	O
and	O
stimulation	O
of	O
endogenous	O
nerve	O
growth	O
factor	O
synthesis	O
by	O
the	O
acetylcholine	Chemical
releaser	O
PG-9	Chemical
.	O
The	O
effects	O
of	O
PG-9	Chemical
(	O
3alpha-tropyl	Chemical
2-(p-bromophenyl)propionate	Chemical
),	O
the	O
acetylcholine	Chemical
releaser,	O
on	O
memory	O
processes	O
and	O
nerve	O
growth	O
factor	O
(NGF)	O
synthesis	O
were	O
evaluated.	O
In	O
the	O
mouse	O
passive-avoidance	O
test,	O
PG-9	Chemical
(10-30	O
mg/kg,	O
i.p.),	O
administered	O
20	O
min	O
before	O
the	O
training	O
session,	O
prevented	O
amnesia	Disease
induced	O
by	O
both	O
the	O
non	O
selective	O
antimuscarinic	O
drug	O
scopolamine	Chemical
and	O
the	O
M1-selective	O
antagonist	O
S-(-)-ET-126	Chemical
.	O
In	O
the	O
same	O
experimental	O
conditions,	O
PG-9	Chemical
(5-20	O
microg	O
per	O
mouse,	O
i.c.v.)	O
was	O
also	O
able	O
to	O
prevent	O
antimuscarine-induced	O
amnesia	Disease
,	O
demonstrating	O
a	O
central	O
localization	O
of	O
the	O
activity.	O
At	O
the	O
highest	O
effective	O
doses,	O
PG-9	Chemical
did	O
not	O
produce	O
any	O
collateral	O
symptoms	O
as	O
revealed	O
by	O
the	O
Irwin	O
test,	O
and	O
it	O
did	O
not	O
modify	O
spontaneous	O
motility	O
and	O
inspection	O
activity,	O
as	O
revealed	O
by	O
the	O
hole-board	O
test.	O
PG-9	Chemical
was	O
also	O
able	O
to	O
increase	O
the	O
amount	O
of	O
NGF	O
secreted	O
in	O
vitro	O
by	O
astrocytes	O
in	O
a	O
dose-dependent	O
manner.	O
The	O
maximal	O
NGF	O
contents	O
obtained	O
by	O
PG-9	Chemical
were	O
17.6-fold	O
of	O
the	O
control	O
value.	O
During	O
culture,	O
no	O
morphological	O
changes	O
were	O
found	O
at	O
effective	O
concentrations	O
of	O
PG-9	Chemical
.	O
The	O
current	O
work	O
indicates	O
the	O
ability	O
of	O
PG-9	Chemical
to	O
induce	O
beneficial	O
effects	O
on	O
cognitive	O
processes	O
and	O
stimulate	O
activity	O
of	O
NGF	O
synthesis	O
in	O
astroglial	O
cells.	O
Therefore,	O
PG-9	Chemical

Angioedema	Disease
due	O
to	O
ACE	Chemical
inhibitors	Chemical
:	O
common	O
and	O
inadequately	O
diagnosed.	O
The	O
estimated	O
incidence	O
of	O
angioedema	Disease
during	O
angiotensin-converting	Chemical
enzyme	Chemical
(ACE)	Chemical
inhibitor	Chemical

Recurarization	O
in	O
the	O
recovery	O
room.	O
A	O
case	O
of	O
recurarization	O
in	O
the	O
recovery	O
room	O
is	O
reported.	O
Accumulation	O
of	O
atracurium	Chemical
in	O
the	O
intravenous	O
line	O
led	O
to	O
recurarization	O
after	O
flushing	O
the	O
line	O
in	O
the	O
recovery	O
room.	O
A	O
respiratory	Disease
arrest	Disease
with	O
severe	O
desaturation	Disease
and	O
bradycardia	Disease
occurred.	O
Circumstances	O
leading	O
to	O
this	O
event	O
and	O
the	O
mechanisms	O
enabling	O
a	O
neuromuscular	Disease
blockade	Disease

Recurrent	O
use	O
of	O
newer	O
oral	Chemical
contraceptives	Chemical
and	O
the	O
risk	O
of	O
venous	Disease
thromboembolism	Disease
.	O
The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	Disease
thromboembolism	Disease
(	O
VTE	Disease
)	O
associated	O
with	O
newer	O
oral	Chemical
contraceptives	Chemical
(	O
OC	Chemical
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	Chemical
use,	O
namely	O
first-time	O
users,	O
repeaters	O
and	O
switchers.	O
Data	O
from	O
a	O
Transnational	O
case-control	O
study	O
were	O
used	O
to	O
assess	O
the	O
risk	O
of	O
VTE	Disease
for	O
the	O
latter	O
patterns	O
of	O
use,	O
while	O
accounting	O
for	O
duration	O
of	O
use.	O
Over	O
the	O
period	O
1993-1996,	O
551	O
cases	O
of	O
VTE	Disease
were	O
identified	O
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls.	O
Totals	O
of	O
128	O
cases	O
and	O
650	O
controls	O
were	O
analysed	O
for	O
repeat	O
use	O
and	O
135	O
cases	O
and	O
622	O
controls	O
for	O
switching	O
patterns.	O
The	O
adjusted	O
rate	O
ratio	O
of	O
VTE	Disease
for	O
repeat	O
users	O
of	O
third	O
generation	O
OC	Chemical
was	O
0.6	O
(95%	O
CI:0.3-1.2)	O
relative	O
to	O
repeat	O
users	O
of	O
second	O
generation	O
pills,	O
whereas	O
it	O
was	O
1.3	O
(95%	O
CI:0.7-2.4)	O
for	O
switchers	O
from	O
second	O
to	O
third	O
generation	O
pills	O
relative	O
to	O
switchers	O
from	O
third	O
to	O
second	O
generation	O
pills.	O
We	O
conclude	O
that	O
second	O
and	O
third	O
generation	O
agents	O
are	O
associated	O
with	O
equivalent	O
risks	O
of	O
VTE	Disease
when	O
the	O
same	O
agent	O
is	O
used	O
repeatedly	O
after	O
interruption	O
periods	O
or	O
when	O
users	O
are	O
switched	O
between	O
the	O
two	O
generations	O
of	O
pills.	O
These	O
analyses	O
suggest	O
that	O
the	O
higher	O
risk	O
observed	O
for	O
the	O
newer	O
OC	Chemical

Development	O
of	O
apomorphine	Chemical
-induced	O
aggressive	Disease
behavior	Disease
:	O
comparison	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats.	O
The	O
development	O
of	O
apomorphine	Chemical
-induced	O
(1.0	O
mg/kg	O
s.c.	O
once	O
daily)	O
aggressive	Disease
behavior	Disease
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets.	O
In	O
male	O
animals,	O
repeated	O
apomorphine	Chemical
treatment	O
induced	O
a	O
gradual	O
development	O
of	O
aggressive	Disease
behavior	Disease
as	O
evidenced	O
by	O
the	O
increased	O
intensity	O
of	O
aggressiveness	Disease
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent.	O
In	O
female	O
rats,	O
only	O
a	O
weak	O
tendency	O
toward	O
aggressiveness	Disease
was	O
found.	O
In	O
conclusion,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	O
in	O
the	O
development	O
of	O
the	O
apomorphine	Chemical
-induced	O
aggressive	Disease
behavior	Disease

Serotonergic	Chemical
antidepressants	Chemical
and	O
urinary	Disease
incontinence	Disease
.	O
Many	O
new	O
serotonergic	Chemical
antidepressants	Chemical
have	O
been	O
introduced	O
over	O
the	O
past	O
decade.	O
Although	O
urinary	Disease
incontinence	Disease
is	O
listed	O
as	O
one	O
side	O
effect	O
of	O
these	O
drugs	O
in	O
their	O
package	O
inserts	O
there	O
is	O
only	O
one	O
report	O
in	O
the	O
literature.	O
This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	O
incontinence	Disease
while	O
taking	O
venlafaxine	Chemical
.	O
In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	Disease
secondary	O
to	O
the	O
selective	O
serotonin	Chemical
reuptake	O
inhibitors	O
paroxetine	Chemical
and	O
sertraline	Chemical
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	Chemical
.	O
In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	O
lithium	Chemical
carbonate	Chemical
and	O
beta-blockers,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontinence	Disease
.	O
Animal	O
studies	O
suggest	O
that	O
incontinence	Disease
secondary	O
to	O
serotonergic	Chemical
antidepressants	Chemical

Hypotension	Disease
following	O
the	O
initiation	O
of	O
tizanidine	Chemical
in	O
a	O
patient	O
treated	O
with	O
an	O
angiotensin	Chemical
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	Disease
.	O
Centrally	O
acting	O
alpha-2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
spasticity	Disease
related	O
to	O
disorders	Disease
of	Disease
the	Disease
central	Disease
nervous	Disease
system	Disease
.	O
In	O
addition	O
to	O
their	O
effects	O
on	O
spasticity	Disease
,	O
certain	O
adverse	O
cardiorespiratory	O
effects	O
have	O
been	O
reported.	O
Adults	O
chronically	O
treated	O
with	O
angiotensin	Chemical
converting	O
enzyme	O
inhibitors	O
may	O
have	O
a	O
limited	O
ability	O
to	O
respond	O
to	O
hypotension	Disease
when	O
the	O
sympathetic	O
response	O
is	O
simultaneously	O
blocked.	O
The	O
authors	O
present	O
a	O
10-year-old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	Chemical
,	O
an	O
angiotensin	Chemical
converting	O
enzyme	O
inhibitor,	O
to	O
control	O
hypertension	Disease
who	O
developed	O
hypotension	Disease
following	O
the	O
addition	O
of	O
tizanidine	Chemical
,	O
an	O
alpha-2	O
agonist,	O
for	O
the	O
treatment	O
of	O
spasticity	Disease
.	O
The	O
possible	O
interaction	O
of	O
tizanidine	Chemical
and	O
other	O
antihypertensive	O
agents	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	O
either	O
hypertension	Disease
or	O
spasticity	Disease

Peritubular	O
capillary	O
basement	O
membrane	O
reduplication	O
in	O
allografts	O
and	O
native	O
kidney	Disease
disease	Disease
:	O
a	O
clinicopathologic	O
study	O
of	O
278	O
consecutive	O
renal	O
specimens.	O
BACKGROUND:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	Disease
glomerulopathy	Disease
(	O
TG	Disease
)	O
and	O
reduplication	O
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(PTCR).	O
Although	O
such	O
an	O
association	O
is	O
of	O
practical	O
and	O
theoretical	O
importance,	O
only	O
one	O
prospective	O
study	O
has	O
tried	O
to	O
confirm	O
it.	O
METHODS:	O
We	O
examined	O
278	O
consecutive	O
renal	O
specimens	O
(from	O
135	O
transplants	O
and	O
143	O
native	O
kidneys)	O
for	O
ultrastructural	O
evidence	O
of	O
PTCR.	O
In	O
addition	O
to	O
renal	O
allografts	O
with	O
TG	Disease
,	O
we	O
also	O
examined	O
grafts	O
with	O
acute	O
rejection,	O
recurrent	O
glomerulonephritis	Disease
,	O
chronic	Disease
allograft	Disease
nephropathy	Disease
and	O
stable	O
grafts	O
("protocol	O
biopsies").	O
Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	Disease
as	O
well	O
as	O
cases	O
of	O
thrombotic	Disease
microangiopathy	Disease
,	O
malignant	Disease
hypertension	Disease
,	O
acute	O
interstitial	Disease
nephritis	Disease
,	O
and	O
acute	Disease
tubular	Disease
necrosis	Disease
.	O
RESULTS:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	O
TG	Disease
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	O
without	O
TG	Disease
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens.	O
These	O
13	O
included	O
cases	O
of	O
malignant	Disease
hypertension	Disease
,	O
thrombotic	Disease
microangiopathy	Disease
,	O
lupus	Disease
nephritis	Disease
,	O
Henoch-Schonlein	Disease
nephritis	Disease
,	O
crescentic	O
glomerulonephritis	Disease
,	O
and	O
cocaine	Chemical
-related	O
acute	Disease
renal	Disease
failure	Disease
.	O
Mild	O
PTCR	O
in	O
allografts	O
without	O
TG	Disease
did	O
not	O
predict	O
renal	Disease
failure	Disease
or	O
significant	O
proteinuria	Disease
after	O
follow-up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year.	O
CONCLUSIONS:	O
We	O
conclude	O
that	O
in	O
transplants,	O
there	O
is	O
a	O
strong	O
association	O
between	O
well-developed	O
PTCR	O
and	O
TG	Disease
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	O
value	O
in	O
the	O
absence	O
of	O
TG	Disease
is	O
unclear.	O
PTCR	O
also	O
occurs	O
in	O
certain	O
native	O
kidney	Disease
diseases	Disease
,	O
though	O
the	O
association	O
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	Disease
.	O
We	O
suggest	O
that	O
repeated	O
endothelial	Disease
injury	Disease
,	O
including	O
immunologic	Disease
injury	Disease

Conformationally	O
restricted	O
analogs	O
of	O
BD1008	Chemical
and	O
an	O
antisense	O
oligodeoxynucleotide	Chemical
targeting	O
sigma1	O
receptors	O
produce	O
anti-	O
cocaine	Chemical
effects	O
in	O
mice.	O
Cocaine	Chemical
's	O
ability	O
to	O
interact	O
with	O
sigma	O
receptors	O
suggests	O
that	O
these	O
proteins	O
mediate	O
some	O
of	O
its	O
behavioral	O
effects.	O
Therefore,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice:	O
BD1018	Chemical
(	O
3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	Chemical
),	O
BD1063	Chemical
(	O
1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine	Chemical
),	O
and	O
LR132	Chemical
(1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).	O
Competition	O
binding	O
assays	O
demonstrated	O
that	O
all	O
three	O
compounds	O
have	O
high	O
affinities	O
for	O
sigma1	O
receptors.	O
The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	O
negligible	O
affinities	O
for	O
dopamine	Chemical
,	O
opioid,	O
GABA	Chemical
(A)	O
and	O
NMDA	Chemical
receptors.	O
In	O
behavioral	O
studies,	O
pre-treatment	O
of	O
mice	O
with	O
BD1018	Chemical
,	O
BD1063	Chemical
,	O
or	O
LR132	Chemical
significantly	O
attenuated	O
cocaine	Chemical
-induced	O
convulsions	Disease
and	O
lethality.	O
Moreover,	O
post-treatment	O
with	O
LR132	Chemical
prevented	O
cocaine	Chemical
-induced	O
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals.	O
In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists,	O
the	O
well-characterized	O
sigma	O
receptor	O
agonist	O
di-o-tolylguanidine	Chemical
(	O
DTG	Chemical
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	Chemical
(	O
3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	Chemical
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	Disease
of	O
cocaine	Chemical
.	O
At	O
doses	O
where	O
alone,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion,	O
BD1018	Chemical
,	O
BD1063	Chemical
and	O
LR132	Chemical
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	Chemical
.	O
To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti-	O
cocaine	Chemical
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors,	O
an	O
antisense	O
oligodeoxynucleotide	Chemical
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	O
the	O
convulsive	Disease
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	Chemical
.	O
Together,	O
the	O
data	O
suggests	O
that	O
functional	O
antagonism	O
of	O
sigma	O
receptors	O
is	O
capable	O
of	O
attenuating	O
a	O
number	O
of	O
cocaine	Chemical

Pharmacokinetic/pharmacodynamic	O
assessment	O
of	O
the	O
effects	O
of	O
E4031	Chemical
,	O
cisapride	Chemical
,	O
terfenadine	Chemical
and	O
terodiline	Chemical
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog.	O
1.	O
Torsades	Disease
de	Disease
pointes	Disease
(	O
TDP	Disease
)	O
is	O
a	O
potentially	O
fatal	O
ventricular	Disease
tachycardia	Disease
associated	O
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(MAPD).	O
TDP	Disease
is	O
a	O
side-effect	O
that	O
has	O
led	O
to	O
withdrawal	O
of	O
several	O
drugs	O
from	O
the	O
market	O
(e.g.	O
terfenadine	Chemical
and	O
terodiline	Chemical
).	O
2.	O
The	O
potential	O
of	O
compounds	O
to	O
cause	O
TDP	Disease
was	O
evaluated	O
by	O
monitoring	O
their	O
effects	O
on	O
MAPD	O
in	O
dog.	O
Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	Disease
were	O
investigated:	O
terfenadine	Chemical
,	O
terodiline	Chemical
,	O
cisapride	Chemical
and	O
E4031	Chemical
.	O
On	O
the	O
basis	O
that	O
only	O
free	O
drug	O
in	O
the	O
systemic	O
circulation	O
will	O
elicit	O
a	O
pharmacological	O
response	O
target,	O
free	O
concentrations	O
in	O
plasma	O
were	O
selected	O
to	O
mimic	O
the	O
free	O
drug	O
exposures	O
in	O
man.	O
Infusion	O
regimens	O
were	O
designed	O
that	O
rapidly	O
achieved	O
and	O
maintained	O
target-free	O
concentrations	O
of	O
these	O
drugs	O
in	O
plasma	O
and	O
data	O
on	O
the	O
relationship	O
between	O
free	O
concentration	O
and	O
changes	O
in	O
MAPD	O
were	O
obtained	O
for	O
these	O
compounds.	O
3.	O
These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	Chemical
(1.9	O
nM),	O
terodiline	Chemical
(76	O
nM),	O
cisapride	Chemical
(11	O
nM)	O
and	O
E4031	Chemical
(1.9	O
nM)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects.	O
For	O
compounds	O
that	O
have	O
shown	O
TDP	Disease
in	O
the	O
clinic	O
(	O
terfenadine	Chemical
,	O
terodiline	Chemical
,	O
cisapride	Chemical
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(<	O
10-fold)	O
reflecting	O
their	O
limited	O
safety	O
margins.	O
These	O
data	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
therapeutic	O
ratio	O
with	O
respect	O
to	O
TDP	Disease

Fatal	O
myeloencephalopathy	Disease
due	O
to	O
accidental	O
intrathecal	O
vincristin	Chemical
administration:	O
a	O
report	O
of	O
two	O
cases.	O
We	O
report	O
on	O
two	O
fatal	O
cases	O
of	O
accidental	O
intrathecal	O
vincristine	Chemical
instillation	O
in	O
a	O
5-year	O
old	O
girl	O
with	O
recurrent	O
acute	Disease
lymphoblastic	Disease
leucemia	Disease
and	O
a	O
57-year	O
old	O
man	O
with	O
lymphoblastic	Disease
lymphoma	Disease
.	O
The	O
girl	O
died	O
seven	O
days,	O
the	O
man	O
four	O
weeks	O
after	O
intrathecal	O
injection	O
of	O
vincristine	Chemical
.	O
Clinically,	O
the	O
onset	O
was	O
characterized	O
by	O
the	O
signs	O
of	O
opistothonus,	Disease
sensory	Disease
and	Disease
motor	Disease
dysfunction	Disease
and	O
ascending	O
paralysis	Disease
.	O
Histological	O
and	O
immunohistochemical	O
investigations	O
(HE-LFB,	O
CD-68,	O
Neurofilament)	O
revealed	O
degeneration	Disease
of	Disease
myelin	Disease
and	Disease
axons	Disease
as	O
well	O
as	O
pseudocystic	Disease
transformation	Disease
in	O
areas	O
exposed	O
to	O
vincristine	Chemical
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages.	O
The	O
clinical	O
course	O
and	O
histopathological	O
results	O
of	O
the	O
two	O
cases	O
are	O
presented.	O
A	O
review	O
of	O
all	O
reported	O
cases	O
in	O
the	O
literature	O
is	O
given.	O
A	O
better	O
controlled	O
regimen	O
for	O
administering	O
vincristine	Chemical

Intravenous	O
administration	O
of	O
prochlorperazine	Chemical
by	O
15-minute	O
infusion	O
versus	O
2-minute	O
bolus	O
does	O
not	O
affect	O
the	O
incidence	O
of	O
akathisia	Disease
:	O
a	O
prospective,	O
randomized,	O
controlled	O
trial.	O
STUDY	O
OBJECTIVE:	O
We	O
sought	O
to	O
compare	O
the	O
rate	O
of	O
akathisia	Disease
after	O
administration	O
of	O
intravenous	O
prochlorperazine	Chemical
as	O
a	O
2-minute	O
bolus	O
or	O
15-minute	O
infusion.	O
METHODS:	O
We	O
conducted	O
a	O
prospective,	O
randomized,	O
double-blind	O
study	O
in	O
the	O
emergency	O
department	O
of	O
a	O
central-city	O
teaching	O
hospital.	O
Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	O
with	O
prochlorperazine	Chemical
for	O
headache	Disease
,	O
nausea	Disease
,	O
or	O
vomiting	Disease
were	O
eligible	O
for	O
inclusion.	O
Study	O
participants	O
were	O
randomized	O
to	O
receive	O
10	O
mg	O
of	O
prochlorperazine	Chemical
administered	O
intravenously	O
by	O
means	O
of	O
2-minute	O
push	O
(bolus	O
group)	O
or	O
10	O
mg	O
diluted	O
in	O
50	O
mL	O
of	O
normal	O
saline	O
solution	O
administered	O
by	O
means	O
of	O
intravenous	O
infusion	O
during	O
a	O
15-minute	O
period	O
(infusion	O
group).	O
The	O
main	O
outcome	O
was	O
the	O
number	O
of	O
study	O
participants	O
experiencing	O
akathisia	Disease
within	O
60	O
minutes	O
of	O
administration.	O
Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	Disease
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient-reported	O
akathisia	Disease
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator-observed	O
akathisia	Disease
rating	O
scale.	O
The	O
intensity	O
of	O
headache	Disease
and	O
nausea	Disease
was	O
measured	O
with	O
a	O
100-mm	O
visual	O
analog	O
scale.	O
RESULTS:	O
One	O
hundred	O
patients	O
were	O
enrolled.	O
One	O
study	O
participant	O
was	O
excluded	O
after	O
protocol	O
violation.	O
Seventy-three	O
percent	O
(73/99)	O
of	O
the	O
study	O
participants	O
were	O
treated	O
for	O
headache	Disease
and	O
70%	O
(70/99)	O
for	O
nausea	Disease
.	O
In	O
the	O
bolus	O
group,	O
26.0%	O
(13/50)	O
had	O
akathisia	Disease
compared	O
with	O
32.7%	O
(16/49)	O
in	O
the	O
infusion	O
group	O
(Delta=-6.7%;	O
95%	O
confidence	O
interval	O
[CI]	O
-24.6%	O
to	O
11.2%).	O
The	O
difference	O
between	O
the	O
bolus	O
and	O
infusion	O
groups	O
in	O
the	O
percentage	O
of	O
participants	O
who	O
saw	O
a	O
50%	O
reduction	O
in	O
their	O
headache	Disease
intensity	O
within	O
30	O
minutes	O
was	O
11.8%	O
(95%	O
CI	O
-9.6%	O
to	O
33.3%).	O
The	O
difference	O
in	O
the	O
percentage	O
of	O
patients	O
with	O
a	O
50%	O
reduction	O
in	O
their	O
nausea	Disease
was	O
12.6%	O
(95%	O
CI	O
-4.6%	O
to	O
29.8%).	O
CONCLUSION:	O
A	O
50%	O
reduction	O
in	O
the	O
incidence	O
of	O
akathisia	Disease
when	O
prochlorperazine	Chemical
was	O
administered	O
by	O
means	O
of	O
15-minute	O
intravenous	O
infusion	O
versus	O
a	O
2-minute	O
intravenous	O
push	O
was	O
not	O
detected.	O
The	O
efficacy	O
of	O
prochlorperazine	Chemical
in	O
the	O
treatment	O
of	O
headache	Disease
and	O
nausea	Disease

Antithymocyte	Chemical
globulin	Chemical
in	O
the	O
treatment	O
of	O
D-penicillamine	Chemical
-induced	O
aplastic	Disease
anemia	Disease
.	O
A	O
patient	O
who	O
received	O
antithymocyte	Chemical
globulin	Chemical
therapy	O
for	O
aplastic	Disease
anemia	Disease
due	O
to	O
D-penicillamine	Chemical
therapy	O
is	O
described.	O
Bone	O
marrow	O
recovery	O
and	O
peripheral	O
blood	O
recovery	O
were	O
complete	O
1	O
month	O
and	O
3	O
months,	O
respectively,	O
after	O
treatment,	O
and	O
blood	O
transfusion	O
or	O
other	O
therapies	O
were	O
not	O
necessary	O
in	O
a	O
follow-up	O
period	O
of	O
more	O
than	O
2	O
years.	O
Use	O
of	O
antithymocyte	Chemical
globulin	Chemical
may	O
be	O
the	O
optimal	O
treatment	O
of	O
D-penicillamine	Chemical
-induced	O
aplastic	Disease
anemia	Disease

The	O
relationship	O
between	O
hippocampal	O
acetylcholine	Chemical
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	O
withdrawal	O
seizure	Disease
-prone	O
and	O
withdrawal	O
seizure	Disease
-resistant	O
selected	O
mouse	O
lines.	O
BACKGROUND:	O
The	O
septo-hippocampal	O
cholinergic	O
pathway	O
has	O
been	O
implicated	O
in	O
epileptogenesis,	O
and	O
genetic	O
factors	O
influence	O
the	O
response	O
to	O
cholinergic	O
agents,	O
but	O
limited	O
data	O
are	O
available	O
on	O
cholinergic	O
involvement	O
in	O
alcohol	Chemical
withdrawal	O
severity.	O
Thus,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	O
and	O
alcohol	Chemical
withdrawal	O
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	Chemical
withdrawal	O
severity.	O
METHODS:	O
Cholinergic	O
convulsant	O
sensitivity	O
was	O
examined	O
in	O
alcohol	Chemical
-na	O
	O
ve	O
Withdrawal	O
Seizure	Disease
-Prone	O
(WSP)	O
and-Resistant	O
(WSR)	O
mice.	O
Animals	O
were	O
administered	O
nicotine	Chemical
,	O
carbachol	Chemical
,	O
or	O
neostigmine	Chemical
via	O
timed	O
tail	O
vein	O
infusion,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	Disease
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose.	O
We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	O
and	O
potassium	Chemical
-stimulated	O
acetylcholine	Chemical
(	O
ACh	Chemical
)	O
release	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus.	O
Potassium	Chemical
was	O
applied	O
by	O
reverse	O
dialysis	O
twice,	O
separated	O
by	O
75	O
min.	O
Hippocampal	O
ACh	Chemical
also	O
was	O
measured	O
during	O
testing	O
for	O
handling-induced	O
convulsions	Disease
.	O
RESULTS:	O
Sensitivity	O
to	O
several	O
convulsion	Disease
endpoints	O
induced	O
by	O
nicotine	Chemical
,	O
carbachol	Chemical
,	O
and	O
neostigmine	Chemical
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice.	O
In	O
microdialysis	O
experiments,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	O
release	O
of	O
ACh	Chemical
,	O
and	O
50	O
mM	O
KCl	Chemical
increased	O
ACh	Chemical
output	O
in	O
both	O
lines	O
of	O
mice.	O
However,	O
the	O
increase	O
in	O
release	O
of	O
ACh	Chemical
produced	O
by	O
the	O
first	O
application	O
of	O
KCl	Chemical
was	O
2-fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice.	O
When	O
hippocampal	O
ACh	Chemical
was	O
measured	O
during	O
testing	O
for	O
handling-induced	O
convulsions	Disease
,	O
extracellular	O
ACh	Chemical
was	O
significantly	O
elevated	O
(192%)	O
in	O
WSP	O
mice,	O
but	O
was	O
nonsignificantly	O
elevated	O
(59%)	O
in	O
WSR	O
mice.	O
CONCLUSIONS:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	O
convulsants	Disease
may	O
be	O
associated	O
with	O
ethanol	Chemical
withdrawal	O
severity	O
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	Chemical
withdrawal.	O
Specifically,	O
WSP	O
mice	O
may	O
have	O
lower	O
sensitivity	O
to	O
cholinergic	O
convulsants	Disease

Prenatal	O
dexamethasone	Chemical
programs	O
hypertension	Disease
and	O
renal	Disease
injury	Disease
in	O
the	O
rat.	O
Dexamethasone	O
is	O
frequently	O
administered	O
to	O
the	O
developing	O
fetus	O
to	O
accelerate	O
pulmonary	O
development.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	O
dexamethasone	Chemical
programmed	O
a	O
progressive	O
increase	Disease
in	Disease
blood	Disease
pressure	Disease
and	O
renal	Disease
injury	Disease
in	O
rats.	O
Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	Chemical
(0.2	O
mg/kg	O
body	O
weight)	O
on	O
gestational	O
days	O
11	O
and	O
12,	O
13	O
and	O
14,	O
15	O
and	O
16,	O
17	O
and	O
18,	O
or	O
19	O
and	O
20.	O
Offspring	O
of	O
rats	O
administered	O
dexamethasone	Chemical
on	O
days	O
15	O
and	O
16	O
gestation	O
had	O
a	O
20%	O
reduction	Disease
in	Disease
glomerular	Disease
number	Disease
compared	O
with	O
control	O
at	O
6	O
to	O
9	O
months	O
of	O
age	O
(22	O
527+/-509	O
versus	O
28	O
050+/-561,	O
P<0.05),	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduction	O
in	O
glomeruli	O
measured	O
at	O
3	O
weeks	O
of	O
age.	O
Six-	O
to	O
9-month	O
old	O
rats	O
receiving	O
prenatal	O
dexamethasone	Chemical
on	O
days	O
17	O
and	O
18	O
of	O
gestation	O
had	O
a	O
17%	O
reduction	O
in	O
glomeruli	O
(23	O
380+/-587)	O
compared	O
with	O
control	O
rats	O
(P<0.05).	O
Male	O
rats	O
that	O
received	O
prenatal	O
dexamethasone	Chemical
on	O
days	O
15	O
and	O
16,	O
17	O
and	O
18,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	Disease
blood	Disease
pressures	Disease
at	O
6	O
months	O
of	O
age;	O
the	O
latter	O
group	O
did	O
not	O
have	O
a	O
reduction	Disease
in	Disease
glomerular	Disease
number	Disease
.	O
Adult	O
rats	O
given	O
dexamethasone	Chemical
on	O
days	O
15	O
and	O
16	O
of	O
gestation	O
had	O
more	O
glomeruli	O
with	O
glomerulosclerosis	Disease
than	O
control	O
rats.	O
This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	Chemical
in	O
rats	O
results	O
in	O
a	O
reduction	Disease
in	Disease
glomerular	Disease
number	Disease
,	O
glomerulosclerosis	Disease
,	O
and	O
hypertension	Disease
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation.	O
Hypertension	Disease
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	Disease
in	Disease
glomerular	Disease
number	Disease
,	O
suggesting	O
that	O
a	O
reduction	Disease
in	Disease
glomerular	Disease
number	Disease
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	O
of	O
hypertension	Disease

The	O
risk	O
of	O
venous	Disease
thromboembolism	Disease
in	O
women	O
prescribed	O
cyproterone	Chemical
acetate	Chemical
in	O
combination	O
with	O
ethinyl	Chemical
estradiol	Chemical
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case-control	O
study.	O
BACKGROUND:	O
Cyproterone	Chemical
acetate	Chemical
combined	O
with	O
ethinyl	Chemical
estradiol	Chemical
(	O
CPA	Chemical
/	O
EE	Chemical
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	Disease
and	O
hirsutism	Disease
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	Disease
ovary	Disease
syndrome	Disease
(	O
PCOS	Disease
).	O
Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	Disease
thromboembolism	Disease
(	O
VTE	Disease
)	O
associated	O
with	O
CPA	Chemical
/	O
EE	Chemical
compared	O
with	O
conventional	O
combined	O
oral	Chemical
contraceptives	Chemical
(COCs).	O
We	O
believe	O
the	O
results	O
of	O
those	O
studies	O
may	O
have	O
been	O
affected	O
by	O
residual	O
confounding.	O
METHODS:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case-control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	Disease
,	O
hirsutism	Disease
or	O
PCOS	Disease
to	O
estimate	O
the	O
risk	O
of	O
VTE	Disease
associated	O
with	O
CPA	Chemical
/	O
EE	Chemical
.	O
RESULTS:	O
The	O
age-adjusted	O
incidence	O
rate	O
ratio	O
for	O
CPA	Chemical
/	O
EE	Chemical
versus	O
conventional	O
COCs	O
was	O
2.20	O
[95%	O
confidence	O
interval	O
(CI)	O
1.35-3.58].	O
Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms,	O
the	O
case-control	O
analysis	O
gave	O
an	O
adjusted	O
odds	O
ratio	O
(OR(adj))	O
of	O
7.44	O
(95%	O
CI	O
3.67-15.08)	O
for	O
CPA	Chemical
/	O
EE	Chemical
use	O
compared	O
with	O
an	O
OR(adj)	O
of	O
2.58	O
(95%	O
CI	O
1.60-4.18)	O
for	O
use	O
of	O
conventional	O
COCs.	O
CONCLUSIONS:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	Disease
associated	O
with	O
the	O
use	O
of	O
CPA	Chemical
/	O
EE	Chemical
in	O
women	O
with	O
acne	Disease
,	O
hirsutism	Disease
or	O
PCOS	Disease

Pseudoacromegaly	Disease
induced	O
by	O
the	O
long-term	O
use	O
of	O
minoxidil	Chemical
.	O
Acromegaly	Disease
is	O
an	O
endocrine	Disease
disorder	Disease
caused	O
by	O
chronic	O
excessive	O
growth	O
hormone	O
secretion	O
from	O
the	O
anterior	O
pituitary	O
gland.	O
Significant	O
disfiguring	O
changes	O
occur	O
as	O
a	O
result	O
of	O
bone,	O
cartilage,	O
and	O
soft	O
tissue	O
hypertrophy	Disease
,	O
including	O
the	O
thickening	O
of	O
the	O
skin,	O
coarsening	O
of	O
facial	O
features,	O
and	O
cutis	Disease
verticis	Disease
gyrata	Disease
.	O
Pseudoacromegaly	Disease
,	O
on	O
the	O
other	O
hand,	O
is	O
the	O
presence	O
of	O
similar	O
acromegaloid	O
features	O
in	O
the	O
absence	O
of	O
elevated	O
growth	O
hormone	O
or	O
insulin-like	O
growth	O
factor	O
levels.	O
We	O
present	O
a	O
patient	O
with	O
pseudoacromegaly	Disease
that	O
resulted	O
from	O
the	O
long-term	O
use	O
of	O
minoxidil	Chemical
at	O
an	O
unusually	O
high	O
dose.	O
This	O
is	O
the	O
first	O
case	O
report	O
of	O
pseudoacromegaly	Disease
as	O
a	O
side	O
effect	O
of	O
minoxidil	Chemical

Combined	O
androgen	O
blockade-induced	O
anemia	Disease
in	O
prostate	Disease
cancer	Disease
patients	O
without	O
bone	O
involvement.	O
BACKGROUND:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combined	O
androgen	O
blockade	O
(CAB)-induced	O
anemia	Disease
in	O
prostate	Disease
cancer	Disease
patients	O
without	O
bone	O
involvement.	O
PATIENTS	O
AND	O
METHODS:	O
Forty-two	O
patients	O
with	O
biopsy-proven	O
prostatic	Disease
adenocarcinoma	Disease
[26	O
with	O
stage	O
C	O
(T3N0M0)	O
and	O
16	O
with	O
stage	O
D1	O
(T3N1M0)]	O
were	O
included	O
in	O
this	O
study.	O
All	O
patients	O
received	O
CAB	O
[	O
leuprolide	Chemical
acetate	Chemical
(	O
LHRH-A	Chemical
)	O
3.75	O
mg,	O
intramuscularly,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	Chemical
,	O
tid,	O
per	O
Os]	O
and	O
were	O
evaluated	O
for	O
anemia	Disease
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(1,	O
2,	O
3	O
and	O
6	O
months	O
post-CAB).	O
Hb,	O
PSA	O
and	O
Testosterone	Chemical
measurements	O
were	O
recorded.	O
Patients	O
with	O
stage	O
D2-3	O
disease,	O
abnormal	O
hemoglobin	O
level	O
or	O
renal	O
and	O
liver	O
function	O
tests	O
that	O
were	O
higher	O
than	O
the	O
upper	O
limits	O
were	O
excluded	O
from	O
the	O
study.	O
The	O
duration	O
of	O
the	O
study	O
was	O
six	O
months.	O
RESULTS:	O
The	O
mean	O
hemoglobin	O
(Hb)	O
levels	O
were	O
significantly	O
declined	O
in	O
all	O
patients	O
from	O
baseline	O
of	O
14.2	O
g/dl	O
to	O
14.0	O
g/dl,	O
13.5	O
g/dl,	O
13.2	O
g/dl	O
and	O
12.7	O
g/dl	O
at	O
1,	O
2,	O
3	O
and	O
6	O
months	O
post-CAB,	O
respectively.	O
Severe	O
and	O
clinically	O
evident	O
anemia	Disease
of	O
Hb	O
<	O
11	O
g/dl	O
with	O
clinical	O
symptoms	O
was	O
detected	O
in	O
6	O
patients	O
(14.3%).	O
This	O
CAB-induced	O
anemia	Disease
was	O
normochromic	O
and	O
normocytic.	O
At	O
six	O
months	O
post-CAB,	O
patients	O
with	O
severe	O
anemia	Disease
had	O
a	O
Hb	O
mean	O
value	O
of	O
10.2	O
+/-	O
0.1	O
g/dl	O
(X	O
+/-	O
SE),	O
whereas	O
the	O
other	O
patients	O
had	O
mild	O
anemia	Disease
with	O
Hb	O
mean	O
value	O
of	O
13.2	O
+/-	O
0.17	O
(X	O
+/-	O
SE).	O
The	O
development	O
of	O
severe	O
anemia	Disease
at	O
6	O
months	O
post-CAB	O
was	O
predictable	O
by	O
the	O
reduction	O
of	O
Hb	O
baseline	O
value	O
of	O
more	O
than	O
2.5	O
g/dl	O
after	O
3	O
months	O
of	O
CAB	O
(p	O
=	O
0.01).	O
The	O
development	O
of	O
severe	O
CAB-induced	O
anemia	Disease
in	O
prostate	Disease
cancer	Disease
patients	O
did	O
not	O
correlate	O
with	O
T	O
baseline	O
values	O
(T	O
<	O
3	O
ng/ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng/ml),	O
with	O
age	O
(<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs),	O
and	O
clinical	O
stage	O
(stage	O
C	O
versus	O
stage	O
D1).	O
Severe	O
and	O
clinically	O
evident	O
anemia	Disease
was	O
easily	O
corrected	O
by	O
subcutaneous	O
injections	O
(3	O
times/week	O
for	O
1	O
month)	O
of	O
recombinant	O
erythropoietin	O
(rHuEPO-beta).	O
CONCLUSION:	O
Our	O
data	O
suggest	O
that	O
rHuEPO-beta	O
correctable	O
CAB-induced	O
anemia	Disease
occurs	O
in	O
14.3%	O
of	O
prostate	Disease
cancer	Disease

Reversible	O
dilated	Disease
cardiomyopathy	Disease
related	O
to	O
amphotericin	Chemical
B	Chemical
therapy.	O
We	O
describe	O
a	O
patient	O
who	O
developed	O
dilated	Disease
cardiomyopathy	Disease
and	O
clinical	O
congestive	O
heart	Disease
failure	Disease
after	O
2	O
months	O
of	O
therapy	O
with	O
amphotericin	Chemical
B	Chemical
(	O
AmB	Chemical
)	O
for	O
disseminated	O
coccidioidomycosis	Disease
.	O
His	O
echocardiographic	O
abnormalities	O
and	O
heart	Disease
failure	Disease
resolved	O
after	O
posaconazole	Chemical
was	O
substituted	O
for	O
AmB	Chemical
.	O
It	O
is	O
important	O
to	O
recognize	O
the	O
rare	O
and	O
potentially	O
reversible	O
toxicity	Disease
of	O
AmB	Chemical

Risks	O
of	O
the	O
consumption	O
of	O
beverages	O
containing	O
quinine	Chemical
.	O
Although	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
banned	O
its	O
use	O
for	O
nocturnal	Disease
leg	Disease
cramps	Disease
due	O
to	O
lack	O
of	O
safety	O
and	O
efficacy,	O
quinine	Chemical
is	O
widely	O
available	O
in	O
beverages	O
including	O
tonic	O
water	O
and	O
bitter	O
lemon.	O
Numerous	O
anecdotal	O
reports	O
suggest	O
that	O
products	O
containing	O
quinine	Chemical
may	O
produce	O
neurological	Disease
complications	Disease
,	O
including	O
confusion	Disease
,	O
altered	O
mental	O
status,	O
seizures	Disease
,	O
and	O
coma	Disease
,	O
particularly	O
in	O
older	O
women.	O
Psychologists	O
need	O
to	O
inquire	O
about	O
consumption	O
of	O
quinine	Chemical

Organophosphate	Chemical
-induced	O
convulsions	Disease
and	O
prevention	O
of	O
neuropathological	Disease
damages	Disease
.	O
Such	O
organophosphorus	Chemical
(	O
OP	Chemical
)	O
compounds	O
as	O
diisopropylfluorophosphate	Chemical
(	O
DFP	Chemical
),	O
sarin	Chemical
and	O
soman	Chemical
are	O
potent	O
inhibitors	O
of	O
acetylcholinesterases	O
(AChEs)	O
and	O
butyrylcholinesterases	O
(BChEs).	O
The	O
acute	O
toxicity	Disease
of	O
OPs	Chemical
is	O
the	O
result	O
of	O
their	O
irreversible	O
binding	O
with	O
AChEs	O
in	O
the	O
central	O
nervous	O
system	O
(CNS),	O
which	O
elevates	O
acetylcholine	Chemical
(	O
ACh	Chemical
)	O
levels.	O
The	O
protective	O
action	O
of	O
subcutaneously	O
(SC)	O
administered	O
antidotes	O
or	O
their	O
combinations	O
in	O
DFP	Chemical
(2.0	O
mg/kg	O
BW)	O
intoxication	O
was	O
studied	O
in	O
9-10-weeks-old	O
Han-Wistar	O
male	O
rats.	O
The	O
rats	O
received	O
AChE	O
reactivator	O
pralidoxime-2-chloride	Chemical
(	O
2PAM	Chemical
)	O
(30.0	O
mg/kg	O
BW),	O
anticonvulsant	O
diazepam	Chemical
(2.0	O
mg/kg	O
BW),	O
A(1)-	O
adenosine	Chemical
receptor	O
agonist	O
N(6)-cyclopentyl	Chemical
adenosine	Chemical
(	O
CPA	Chemical
)	O
(2.0	O
mg/kg	O
BW),	O
NMDA	Chemical
-receptor	O
antagonist	O
dizocilpine	Chemical
maleate	Chemical
(+-MK801	O
hydrogen	O
maleate)	O
(2.0	O
mg/kg	O
BW)	O
or	O
their	O
combinations	O
with	O
cholinolytic	O
drug	O
atropine	Chemical
sulfate	Chemical
(50.0	O
mg/kg	O
BW)	O
immediately	O
or	O
30	O
min	O
after	O
the	O
single	O
SC	O
injection	O
of	O
DFP	Chemical
.	O
The	O
control	O
rats	O
received	O
atropine	Chemical
sulfate	Chemical
,	O
but	O
also	O
saline	O
and	O
olive	O
oil	O
instead	O
of	O
other	O
antidotes	O
and	O
DFP	Chemical
,	O
respectively.	O
All	O
rats	O
were	O
terminated	O
either	O
24	O
h	O
or	O
3	O
weeks	O
after	O
the	O
DFP	Chemical
injection.	O
The	O
rats	O
treated	O
with	O
DFP	Chemical
-	O
atropine	Chemical
showed	O
severe	O
typical	O
OP	Chemical
-induced	O
toxicity	Disease
signs.	O
When	O
CPA	Chemical
,	O
diazepam	Chemical
or	O
2PAM	Chemical
was	O
given	O
immediately	O
after	O
DFP	Chemical
-	O
atropine	Chemical
,	O
these	O
treatments	O
prevented,	O
delayed	O
or	O
shortened	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	Disease
.	O
Atropine	Chemical
-	O
MK801	Chemical
did	O
not	O
offer	O
any	O
additional	O
protection	O
against	O
DFP	Chemical
	O
toxicity	Disease
.	O
In	O
conclusion,	O
CPA	Chemical
,	O
diazepam	Chemical
and	O
2PAM	Chemical
in	O
combination	O
with	O
atropine	Chemical
prevented	O
the	O
occurrence	O
of	O
serious	O
signs	O
of	O
poisoning	Disease
and	O
thus	O
reduced	O
the	O
toxicity	Disease
of	O
DFP	Chemical

Differential	O
modulation	O
by	O
estrogen	Chemical
of	O
alpha2-adrenergic	O
and	O
I1-	O
imidazoline	Chemical
receptor-mediated	O
hypotension	Disease
in	O
female	O
rats.	O
We	O
have	O
recently	O
shown	O
that	O
estrogen	Chemical
negatively	O
modulates	O
the	O
hypotensive	Disease
effect	O
of	O
clonidine	Chemical
(mixed	O
alpha2-/I1-receptor	O
agonist)	O
in	O
female	O
rats	O
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction.	O
The	O
present	O
study	O
investigated	O
whether	O
this	O
effect	O
of	O
estrogen	Chemical
involves	O
interaction	O
with	O
alpha2-	O
and/or	O
I1-receptors.	O
Changes	O
evoked	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
rilmenidine	Chemical
(600	O
microg/kg)	O
or	O
alpha-methyldopa	Chemical
(100	O
mg/kg),	O
selective	O
I1-	O
and	O
alpha2-receptor	O
agonists,	O
respectively,	O
in	O
blood	O
pressure,	O
hemodynamic	O
variability,	O
and	O
locomotor	O
activity	O
were	O
assessed	O
in	O
radiotelemetered	O
sham-operated	O
and	O
ovariectomized	O
(Ovx)	O
Sprague-Dawley	O
female	O
rats	O
with	O
or	O
without	O
12-wk	O
estrogen	Chemical
replacement.	O
Three	O
time	O
domain	O
indexes	O
of	O
hemodynamic	O
variability	O
were	O
employed:	O
the	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
as	O
a	O
measure	O
of	O
blood	O
pressure	O
variability	O
and	O
the	O
standard	O
deviation	O
of	O
beat-to-beat	O
intervals	O
(SDRR)	O
and	O
the	O
root	O
mean	O
square	O
of	O
successive	O
differences	O
in	O
R-wave-to-R-wave	O
intervals	O
as	O
measures	O
of	O
heart	O
rate	O
variability.	O
In	O
sham-operated	O
rats,	O
rilmenidine	Chemical
or	O
alpha-methyldopa	Chemical
elicited	O
similar	O
hypotension	Disease
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure.	O
SDRR	O
was	O
reduced	O
only	O
by	O
alpha-methyldopa	Chemical
.	O
Ovx	O
significantly	O
enhanced	O
the	O
hypotensive	Disease
response	O
to	O
alpha-methyldopa	Chemical
,	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmenidine	Chemical
	O
hypotension	Disease
.	O
The	O
enhanced	O
alpha-methyldopa	Chemical
	O
hypotension	Disease
in	O
Ovx	O
rats	O
was	O
paralleled	O
with	O
further	O
reduction	O
in	O
SDRR	O
and	O
a	Disease
reduced	Disease
locomotor	Disease
activity	Disease
.	O
Estrogen	O
replacement	O
(	O
17beta-estradiol	Chemical
subcutaneous	O
pellet,	O
14.2	O
microg/day,	O
12	O
wk)	O
of	O
Ovx	O
rats	O
restored	O
the	O
hemodynamic	O
and	O
locomotor	O
effects	O
of	O
alpha-methyldopa	Chemical
to	O
sham-operated	O
levels.	O
These	O
findings	O
suggest	O
that	O
estrogen	Chemical
downregulates	O
alpha2-	O
but	O
not	O
I1-receptor-mediated	O
hypotension	Disease
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha-methyldopa	Chemical
-	O
estrogen	Chemical

Cardioprotective	O
effect	O
of	O
tincture	Chemical
of	Chemical
Crataegus	Chemical
on	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
infarction	Disease
in	O
rats.	O
Tincture	Chemical
of	Chemical
Crataegus	Chemical
(	O
TCR	Chemical
),	O
an	O
alcoholic	Chemical
extract	Chemical
of	Chemical
the	Chemical
berries	Chemical
of	Chemical
hawthorn	Chemical
(	O
Crataegus	Chemical
oxycantha	Chemical
),	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine.	O
The	O
present	O
study	O
was	O
done	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
TCR	Chemical
on	O
experimentally	O
induced	O
myocardial	Disease
infarction	Disease
in	O
rats.	O
Pretreatment	O
of	O
TCR	Chemical
,	O
at	O
a	O
dose	O
of	O
0.5	O
mL/100	O
g	O
bodyweight	O
per	O
day,	O
orally	O
for	O
30	O
days,	O
prevented	O
the	O
increase	O
in	O
lipid	O
peroxidation	O
and	O
activity	O
of	O
marker	O
enzymes	O
observed	O
in	O
isoproterenol	Chemical
-induced	O
rats	O
(85	O
mg	O
kg(-1)	O
s.	O
c.	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h).	O
TCR	Chemical
prevented	O
the	O
isoproterenol	Chemical
-induced	O
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP	Chemical
-stimulated	O
oxygen	Chemical
uptake	O
and	O
respiratory	O
coupling	O
ratio.	O
TCR	Chemical
protected	O
against	O
pathological	O
changes	O
induced	O
by	O
isoproterenol	Chemical
in	O
rat	O
heart.	O
The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	Chemical
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	O
induced	O
by	O
isoproterenol	Chemical

Safety	O
and	O
adverse	O
effects	O
associated	O
with	O
raloxifene	Chemical
:	O
multiple	O
outcomes	O
of	O
raloxifene	Chemical
evaluation.	O
OBJECTIVE:	O
To	O
examine	O
the	O
effect	O
of	O
raloxifene	Chemical
on	O
major	O
adverse	O
events	O
that	O
occur	O
with	O
postmenopausal	O
estrogen	Chemical
therapy	O
or	O
tamoxifen	Chemical
.	O
METHODS:	O
The	O
Multiple	O
Outcomes	O
of	O
Raloxifene	Chemical
Evaluation,	O
a	O
multicenter,	O
randomized,	O
double-blind	O
trial,	O
enrolled	O
7,705	O
postmenopausal	O
women	O
with	O
osteoporosis	Disease
.	O
Women	O
were	O
randomly	O
assigned	O
to	O
raloxifene	Chemical
60	O
mg/d	O
or	O
120	O
mg/d	O
or	O
placebo.	O
Outcomes	O
included	O
venous	Disease
thromboembolism	Disease
,	O
cataracts	Disease
,	O
gallbladder	Disease
disease	Disease
,	O
and	O
endometrial	Disease
hyperplasia	Disease
or	Disease
cancer	Disease
.	O
RESULTS:	O
During	O
a	O
mean	O
follow-up	O
of	O
3.3	O
years,	O
raloxifene	Chemical
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	Disease
thromboembolism	Disease
(relative	O
risk	O
[RR]	O
2.1;	O
95%	O
confidence	O
interval	O
[CI]	O
1.2-3.8).	O
The	O
excess	O
event	O
rate	O
was	O
1.8	O
per	O
1,000	O
woman-years	O
(95%	O
CI	O
-0.5-4.1),	O
and	O
the	O
number	O
needed	O
to	O
treat	O
to	O
cause	O
1	O
event	O
was	O
170	O
(95%	O
CI	O
100-582)	O
over	O
3.3	O
years.	O
Risk	O
in	O
the	O
raloxifene	Chemical
group	O
was	O
higher	O
than	O
in	O
the	O
placebo	O
group	O
for	O
the	O
first	O
2	O
years,	O
but	O
decreased	O
to	O
about	O
the	O
same	O
rate	O
as	O
in	O
the	O
placebo	O
group	O
thereafter.	O
Raloxifene	Chemical
did	O
not	O
increase	O
risk	O
for	O
cataracts	Disease
(RR	O
0.9;	O
95%	O
CI	O
0.8-1.1),	O
gallbladder	Disease
disease	Disease
(RR	O
1.0;	O
95%	O
CI	O
0.7-1.3),	O
endometrial	Disease
hyperplasia	Disease
(RR	O
1.3;	O
95%	O
CI	O
0.4-5.1),	O
or	O
endometrial	Disease
cancer	Disease
(RR	O
0.9;	O
95%	O
CI	O
0.3-2.7).	O
CONCLUSION:	O
Raloxifene	Chemical
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	Disease
thromboembolism	Disease
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
cataracts	Disease
,	O
gallbladder	Disease
disease	Disease
,	O
endometrial	Disease
hyperplasia	Disease
,	O
or	O
endometrial	Disease
cancer	Disease

Ceftriaxone	Chemical
-associated	O
biliary	Disease
pseudolithiasis	Disease
in	O
paediatric	O
surgical	O
patients.	O
It	O
is	O
well	O
known	O
that	O
ceftriaxone	Chemical
leads	O
to	O
pseudolithiasis	Disease
in	O
some	O
patients.	O
Clinical	O
and	O
experimental	O
studies	O
also	O
suggest	O
that	O
situations	O
causing	O
gallbladder	Disease
dysfunction	Disease
,	O
such	O
as	O
fasting,	O
may	O
have	O
a	O
role	O
for	O
the	O
development	O
of	O
pseudolithiasis	Disease
.	O
In	O
this	O
study,	O
we	O
prospectively	O
evaluated	O
the	O
incidence	O
and	O
clinical	O
importance	O
of	O
pseudolithiasis	Disease
in	O
paediatric	O
surgical	O
patients	O
receiving	O
ceftriaxone	Chemical
treatment,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
post-operative	O
period.	O
Fifty	O
children	O
who	O
were	O
given	O
ceftriaxone	Chemical
were	O
evaluated	O
by	O
serial	O
abdominal	O
sonograms.	O
Of	O
those,	O
13	O
(26%)	O
developed	O
biliary	O
pathology.	O
Comparison	O
of	O
the	O
patients	O
with	O
or	O
without	O
pseudolithiasis	Disease
revealed	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
age,	O
sex,	O
duration	O
of	O
the	O
treatment	O
and	O
starvation	O
variables.	O
After	O
cessation	O
of	O
the	O
treatment,	O
pseudolithiasis	Disease
resolved	O
spontaneously	O
within	O
a	O
short	O
period.	O
The	O
incidence	O
of	O
pseudolithiasis	Disease

Evaluation	O
of	O
the	O
anticocaine	O
monoclonal	O
antibody	O
GNC92H2	Chemical
as	O
an	O
immunotherapy	O
for	O
cocaine	Disease
overdose	Disease
.	O
The	O
illicit	O
use	O
of	O
cocaine	Chemical
continues	O
in	O
epidemic	O
proportions	O
and	O
treatment	O
for	O
cocaine	Disease
overdose	Disease
remains	O
elusive.	O
Current	O
protein-based	O
technology	O
offers	O
a	O
new	O
therapeutic	O
venue	O
by	O
which	O
antibodies	O
bind	O
the	O
drug	O
in	O
the	O
blood	O
stream,	O
inactivating	O
its	O
toxic	O
effects.	O
The	O
therapeutic	O
potential	O
of	O
the	O
anticocaine	O
antibody	O
GNC92H2	Chemical
was	O
examined	O
using	O
a	O
model	O
of	O
cocaine	Disease
overdose	Disease
.	O
Swiss	O
albino	O
mice	O
prepared	O
with	O
intrajugular	O
catheters	O
were	O
tested	O
in	O
photocell	O
cages	O
after	O
administration	O
of	O
93	O
mg/kg	O
(LD50)	O
of	O
cocaine	Chemical
and	O
GNC92H2	Chemical
infusions	O
ranging	O
from	O
30	O
to	O
190	O
mg/kg.	O
GNC92H2	Chemical
was	O
delivered	O
30	O
min	O
before,	O
concomitantly	O
or	O
3	O
min	O
after	O
cocaine	Chemical
treatment.	O
Significant	O
blockade	O
of	O
cocaine	Chemical
	O
toxicity	Disease
was	O
observed	O
with	O
the	O
higher	O
dose	O
of	O
GNC92H2	Chemical
(190	O
mg/kg),	O
where	O
premorbid	O
behaviors	O
were	O
reduced	O
up	O
to	O
40%,	O
seizures	Disease
up	O
to	O
77%	O
and	O
death	Disease
by	O
72%.	O
Importantly,	O
GNC92H2	Chemical
prevented	O
death	Disease
even	O
post-	O
cocaine	Chemical
injection.	O
The	O
results	O
support	O
the	O
important	O
potential	O
of	O
GNC92H2	Chemical
as	O
a	O
therapeutic	O
tool	O
against	O
cocaine	Disease
overdose	Disease

The	O
effects	O
of	O
short-term	O
raloxifene	Chemical
therapy	O
on	O
fibrinolysis	O
markers:	O
TAFI,	O
tPA,	O
and	O
PAI-1.	O
BACKGROUND:	O
Markers	O
of	O
fibrinolysis,	O
thrombin-activatable	O
fibrinolysis	O
inhibitor	O
(TAFI),	O
tissue-type	O
plasminogen	O
activator	O
(tPA),	O
and	O
plasminogen	O
activator	O
inhibitor-1	O
(PAI-1)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short-term	O
effects	O
of	O
raloxifene	Chemical
administration	O
in	O
postmenopausal	O
women.	O
METHODS:	O
Thirty-nine	O
postmenopausal	O
women	O
with	O
osteopenia	Disease
or	O
osteoporosis	Disease
were	O
included	O
in	O
this	O
prospective,	O
controlled	O
clinical	O
study.	O
Twenty-five	O
women	O
were	O
given	O
raloxifene	Chemical
hydrochloride	Chemical
(60	O
mg/day)	O
plus	O
calcium	Chemical
(500	O
mg/day).	O
Age-matched	O
controls	O
(n	O
=	O
14)	O
were	O
given	O
only	O
calcium	Chemical
.	O
Plasma	O
TAFI,	O
tPA,	O
and	O
PAI-1	O
antigen	O
levels	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
3	O
months	O
of	O
treatment	O
by	O
commercially	O
available	O
ELISA	O
kits.	O
Variations	O
of	O
individuals	O
were	O
assessed	O
by	O
Wilcoxon's	O
test.	O
Relationship	O
between	O
those	O
markers	O
and	O
demographic	O
characteristics	O
were	O
investigated.	O
RESULTS:	O
Three	O
months	O
of	O
raloxifene	Chemical
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	O
antigen	O
concentrations	O
(16%	O
change,	O
P	O
<	O
0.01),	O
and	O
a	O
significant	O
increase	O
in	O
tPA	O
antigen	O
concentrations	O
(25%	O
change,	O
P	O
<	O
0.05).	O
A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	O
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	Disease
(P	O
<	O
0.05;	O
r	O
=	O
0.33).	O
CONCLUSION:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	Disease
thromboembolism	Disease
due	O
to	O
raloxifene	Chemical

Ketoconazole	Chemical
induced	O
torsades	Disease
de	Disease
pointes	Disease
without	O
concomitant	O
use	O
of	O
QT	O
interval-prolonging	O
drug.	O
Ketoconazole	Chemical
is	O
not	O
known	O
to	O
be	O
proarrhythmic	O
without	O
concomitant	O
use	O
of	O
QT	O
interval-prolonging	O
drugs.	O
We	O
report	O
a	O
woman	O
with	O
coronary	Disease
artery	Disease
disease	Disease
who	O
developed	O
a	O
markedly	O
prolonged	Disease
QT	Disease
interval	Disease
and	O
torsades	Disease
de	Disease
pointes	Disease
(	O
TdP	Disease
)	O
after	O
taking	O
ketoconazole	Chemical
for	O
treatment	O
of	O
fungal	Disease
infection	Disease
.	O
Her	O
QT	O
interval	O
returned	O
to	O
normal	O
upon	O
withdrawal	O
of	O
ketoconazole	Chemical
.	O
Genetic	O
study	O
did	O
not	O
find	O
any	O
mutation	O
in	O
her	O
genes	O
that	O
encode	O
cardiac	O
IKr	O
channel	O
proteins.	O
We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blocking	O
action	O
on	O
IKr,	O
ketoconazole	Chemical
alone	O
may	O
prolong	O
QT	O
interval	O
and	O
induce	O
TdP	Disease
.	O
This	O
calls	O
for	O
attention	O
when	O
ketoconazole	Chemical
is	O
administered	O
to	O
patients	O
with	O
risk	O
factors	O
for	O
acquired	O
long	Disease
QT	Disease
syndrome	Disease

Pharmacological	O
evidence	O
for	O
the	O
potential	O
of	O
Daucus	O
carota	O
in	O
the	O
management	O
of	O
cognitive	Disease
dysfunctions	Disease
.	O
The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
effects	O
of	O
Daucus	O
carota	O
seeds	O
on	O
cognitive	O
functions,	O
total	O
serum	O
cholesterol	Chemical
levels	O
and	O
brain	O
cholinesterase	O
activity	O
in	O
mice.	O
The	O
ethanolic	O
extract	Chemical
of	Chemical
Daucus	Chemical
carota	Chemical
seeds	Chemical
(	O
DCE	Chemical
)	O
was	O
administered	O
orally	O
in	O
three	O
doses	O
(100,	O
200,	O
400	O
mg/kg)	O
for	O
seven	O
successive	O
days	O
to	O
different	O
groups	O
of	O
young	O
and	O
aged	O
mice.	O
Elevated	O
plus	O
maze	O
and	O
passive	O
avoidance	O
apparatus	O
served	O
as	O
the	O
exteroceptive	O
behavioral	O
models	O
for	O
testing	O
memory.	O
Diazepam	Chemical
-,	O
scopolamine	Chemical
-	O
and	O
ageing-induced	O
amnesia	Disease
served	O
as	O
the	O
interoceptive	O
behavioral	O
models.	O
DCE	Chemical
(200,	O
400	O
mg/kg,	O
p.o.)	O
showed	O
significant	O
improvement	O
in	O
memory	O
scores	O
of	O
young	O
and	O
aged	O
mice.	O
The	O
extent	O
of	O
memory	O
improvement	O
evoked	O
by	O
DCE	Chemical
was	O
23%	O
at	O
the	O
dose	O
of	O
200	O
mg/kg	O
and	O
35%	O
at	O
the	O
dose	O
of	O
400	O
mg/kg	O
in	O
young	O
mice	O
using	O
elevated	O
plus	O
maze.	O
Similarly,	O
significant	O
improvements	O
in	O
memory	O
scores	O
were	O
observed	O
using	O
passive	O
avoidance	O
apparatus	O
and	O
aged	O
mice.	O
Furthermore,	O
DCE	Chemical
reversed	O
the	O
amnesia	Disease
induced	O
by	O
scopolamine	Chemical
(0.4	O
mg/kg,	O
i.p.)	O
and	O
diazepam	Chemical
(1	O
mg/kg,	O
i.p.).	O
Daucus	Chemical
carota	Chemical
extract	Chemical
(200,	O
400	O
mg/kg,	O
p.o.)	O
reduced	O
significantly	O
the	O
brain	O
acetylcholinesterase	O
activity	O
and	O
cholesterol	Chemical
levels	O
in	O
young	O
and	O
aged	O
mice.	O
The	O
extent	O
of	O
inhibition	O
of	O
brain	O
cholinesterase	O
activity	O
evoked	O
by	O
DCE	Chemical
at	O
the	O
dose	O
of	O
400	O
mg/kg	O
was	O
22%	O
in	O
young	O
and	O
19%	O
in	O
aged	O
mice.	O
There	O
was	O
a	O
remarkable	O
reduction	O
in	O
total	O
cholesterol	Chemical
level	O
as	O
well,	O
to	O
the	O
extent	O
of	O
23%	O
in	O
young	O
and	O
21%	O
in	O
aged	O
animals	O
with	O
this	O
dose	O
of	O
DCE	Chemical
.	O
Therefore,	O
DCE	Chemical
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
management	O
of	O
cognitive	Disease
dysfunctions	Disease
on	O
account	O
of	O
its	O
multifarious	O
beneficial	O
effects	O
such	O
as,	O
memory	O
improving	O
property,	O
cholesterol	Chemical

Cauda	Disease
equina	Disease
syndrome	Disease
after	O
epidural	O
steroid	Chemical
injection:	O
a	O
case	O
report.	O
OBJECTIVE:	O
Conventional	O
treatment	O
methods	O
of	O
lumbusacral	O
radiculopathy	Disease
are	O
physical	O
therapy,	O
epidural	O
steroid	Chemical
injections,	O
oral	O
medications,	O
and	O
spinal	O
manipulative	O
therapy.	O
Cauda	Disease
equina	Disease
syndrome	Disease
is	O
a	O
rare	O
complication	O
of	O
epidural	O
anesthesia.	O
The	O
following	O
case	O
is	O
a	O
report	O
of	O
cauda	Disease
equina	Disease
syndrome	Disease
possibly	O
caused	O
by	O
epidural	O
injection	O
of	O
triamcinolone	Chemical
and	O
bupivacaine	Chemical
.	O
CLINICAL	O
FEATURES:	O
A	O
50-year-old	O
woman	O
with	O
low	Disease
back	Disease
and	Disease
right	Disease
leg	Disease
pain	Disease
was	O
scheduled	O
for	O
epidural	O
steroid	Chemical
injection.	O
INTERVENTION	O
AND	O
OUTCOME:	O
An	O
18-gauge	O
Touhy	O
needle	O
was	O
inserted	O
until	O
loss	O
of	O
resistance	O
occurred	O
at	O
the	O
L4-5	O
level.	O
Spread	O
of	O
the	O
contrast	O
medium	O
within	O
the	O
epidural	O
space	O
was	O
determined	O
by	O
radiographic	O
imaging.	O
After	O
verifying	O
the	O
epidural	O
space,	O
bupivacaine	Chemical
and	O
triamcinolone	Chemical
diacetate	Chemical
were	O
injected.	O
After	O
the	O
injection,	O
there	O
was	O
a	O
reduction	O
in	O
radicular	O
symptoms.	O
Three	O
hours	O
later,	O
she	O
complained	O
of	O
perineal	O
numbness	Disease
and	O
lower	Disease
extremity	Disease
weakness	Disease
.	O
The	O
neurologic	O
evaluation	O
revealed	O
loss	Disease
of	Disease
sensation	Disease
in	O
the	O
saddle	O
area	O
and	O
medial	O
aspect	O
of	O
her	O
right	O
leg.	O
There	O
was	O
a	O
decrease	O
in	O
the	O
perception	O
of	O
pinprick	O
test.	O
Deep-tendon	O
reflexes	O
were	O
decreased	O
especially	O
in	O
the	O
right	O
leg.	O
She	O
was	O
unable	O
to	O
urinate.	O
The	O
patient's	O
symptoms	O
improved	O
slightly	O
over	O
the	O
next	O
few	O
hours.	O
She	O
had	O
a	O
gradual	O
return	O
of	O
motor	O
function	O
and	O
ability	O
of	O
feeling	O
Foley	O
catheter.	O
All	O
of	O
the	O
symptoms	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours.	O
CONCLUSION:	O
Complications	O
associated	O
with	O
epidural	O
steroid	Chemical
injections	O
are	O
rare.	O
Clinical	O
examination	O
and	O
continued	O
vigilance	O
for	O
neurologic	Disease
deterioration	Disease
after	O
epidural	O
steroid	Chemical

High-dose	O
testosterone	Chemical
is	O
associated	O
with	O
atherosclerosis	Disease
in	O
postmenopausal	O
women.	O
OBJECTIVES:	O
To	O
study	O
the	O
long-term	O
effects	O
of	O
androgen	O
treatment	O
on	O
atherosclerosis	Disease
in	O
postmenopausal	O
women.	O
METHODS:	O
In	O
a	O
population-based	O
study	O
in	O
513	O
naturally	O
postmenopausal	O
women	O
aged	O
54-67	O
years,	O
we	O
studied	O
the	O
association	O
between	O
self-reported	O
intramuscularly	O
administered	O
high-dose	O
estrogen	Chemical
-	O
testosterone	Chemical
therapy	O
(	O
estradiol-	Chemical
and	Chemical
testosterone	Chemical
esters	Chemical
)	O
and	O
aortic	O
atherosclerosis	Disease
.	O
Aortic	O
atherosclerosis	Disease
was	O
diagnosed	O
by	O
radiographic	O
detection	O
of	O
calcified	O
deposits	O
in	O
the	O
abdominal	O
aorta,	O
which	O
have	O
been	O
shown	O
to	O
reflect	O
intima	O
atherosclerosis	Disease
.	O
Hormone	O
therapy	O
users	O
were	O
compared	O
with	O
never	O
users.	O
RESULTS:	O
Intramuscular	O
hormone	O
therapy	O
use	O
for	O
1	O
year	O
or	O
longer	O
was	O
reported	O
by	O
25	O
women.	O
In	O
almost	O
half	O
of	O
these	O
women	O
severe	O
atherosclerosis	Disease
of	O
the	O
aorta	O
was	O
present	O
(n=11),	O
while	O
in	O
women	O
without	O
hormone	O
use	O
severe	O
atherosclerosis	Disease
of	O
the	O
aorta	O
was	O
present	O
in	O
less	O
than	O
20%	O
(OR	O
3.1;	O
95%	O
CI,	O
1.1-8.5,	O
adjusted	O
for	O
age,	O
years	O
since	O
menopause,	O
smoking,	O
and	O
body	O
mass	O
index).	O
The	O
association	O
remained	O
after	O
additional	O
adjustment	O
for	O
diabetes	Disease
,	O
cholesterol	Chemical
level,	O
systolic	O
blood	O
pressure,	O
or	O
alcohol	Chemical
use.	O
No	O
association	O
was	O
found	O
for	O
hormone	O
use	O
less	O
than	O
1	O
year.	O
CONCLUSION:	O
Our	O
results	O
suggest	O
that	O
high-dose	O
testosterone	Chemical
therapy	O
may	O
adversely	O
affect	O
atherosclerosis	Disease

Sirolimus	Chemical
-associated	O
proteinuria	Disease
and	O
renal	Disease
dysfunction	Disease
.	O
Sirolimus	Chemical
is	O
a	O
novel	O
immunosuppressant	O
with	O
potent	O
antiproliferative	O
actions	O
through	O
its	O
ability	O
to	O
inhibit	O
the	O
raptor-containing	O
mammalian	O
target	O
of	O
rapamycin	Chemical
protein	O
kinase.	O
Sirolimus	Chemical
represents	O
a	O
major	O
therapeutic	O
advance	O
in	O
the	O
prevention	O
of	O
acute	O
renal	O
allograft	O
rejection	O
and	O
chronic	O
allograft	O
nephropathy	Disease
.	O
Its	O
role	O
in	O
the	O
therapy	O
of	O
glomerulonephritis	Disease
,	O
autoimmunity	Disease
,	O
cystic	Disease
renal	Disease
diseases	Disease
and	O
renal	Disease
cancer	Disease
is	O
under	O
investigation.	O
Because	O
sirolimus	Chemical
does	O
not	O
share	O
the	O
vasomotor	O
renal	O
adverse	O
effects	O
exhibited	O
by	O
calcineurin	O
inhibitors,	O
it	O
has	O
been	O
designated	O
a	O
'non-	O
nephrotoxic	Disease
drug'.	O
However,	O
clinical	O
reports	O
suggest	O
that,	O
under	O
some	O
circumstances,	O
sirolimus	Chemical
is	O
associated	O
with	O
proteinuria	Disease
and	O
acute	Disease
renal	Disease
dysfunction	Disease
.	O
A	O
common	O
risk	O
factor	O
appears	O
to	O
be	O
presence	O
of	O
pre-existing	O
chronic	Disease
renal	Disease
damage	Disease
.	O
The	O
mechanisms	O
of	O
sirolimus	Chemical
-associated	O
proteinuria	Disease
are	O
multifactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
glomerular	O
capillary	O
pressure	O
following	O
calcineurin	O
inhibitor	O
withdrawal.	O
It	O
has	O
also	O
been	O
suggested	O
that	O
sirolimus	Chemical
directly	O
causes	O
increased	O
glomerular	O
permeability/injury,	O
but	O
evidence	O
for	O
this	O
mechanism	O
is	O
currently	O
inconclusive.	O
The	O
acute	Disease
renal	Disease
dysfunction	Disease
associated	O
with	O
sirolimus	Chemical
(such	O
as	O
in	O
delayed	O
graft	O
function)	O
may	O
be	O
due	O
to	O
suppression	O
of	O
compensatory	O
renal	O
cell	O
proliferation	O
and	O
survival/repair	O
processes.	O
Although	O
these	O
adverse	O
effects	O
occur	O
in	O
some	O
patients,	O
their	O
occurrence	O
could	O
be	O
minimised	O
by	O
knowledge	O
of	O
the	O
molecular	O
effects	O
of	O
sirolimus	Chemical
on	O
the	O
kidney,	O
the	O
use	O
of	O
sirolimus	Chemical
in	O
appropriate	O
patient	O
populations,	O
close	O
monitoring	O
of	O
proteinuria	Disease
and	O
renal	O
function,	O
use	O
of	O
angiotensin	Chemical
-converting	O
enzyme	O
inhibitors	O
or	O
angiotensin	Chemical
II	Chemical
receptor	O
blockers	O
if	O
proteinuria	Disease
occurs	O
and	O
withdrawal	O
if	O
needed.	O
Further	O
long-term	O
analysis	O
of	O
renal	O
allograft	O
studies	O
using	O
sirolimus	Chemical

Progressive	O
myopathy	Disease
with	O
up-regulation	O
of	O
MHC-I	O
associated	O
with	O
statin	Chemical
therapy.	O
Statins	Chemical
can	O
cause	O
a	O
necrotizing	O
myopathy	Disease
and	O
hyperCKaemia	Disease
which	O
is	O
reversible	O
on	O
cessation	O
of	O
the	O
drug.	O
What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenomenon	O
whereby	O
statins	Chemical
may	O
induce	O
a	O
myopathy	Disease
,	O
which	O
persists	O
or	O
may	O
progress	O
after	O
stopping	O
the	O
drug.	O
We	O
investigated	O
the	O
muscle	O
pathology	O
in	O
8	O
such	O
cases.	O
All	O
had	O
myofibre	O
necrosis	Disease
but	O
only	O
3	O
had	O
an	O
inflammatory	O
infiltrate.	O
In	O
all	O
cases	O
there	O
was	O
diffuse	O
or	O
multifocal	O
up-regulation	O
of	O
MHC-I	O
expression	O
even	O
in	O
non-	O
necrotic	Disease
fibres.	O
Progressive	O
improvement	O
occurred	O
in	O
7	O
cases	O
after	O
commencement	O
of	O
prednisolone	Chemical
and	O
methotrexate	Chemical
,	O
and	O
in	O
one	O
case	O
spontaneously.	O
These	O
observations	O
suggest	O
that	O
statins	Chemical
may	O
initiate	O
an	O
immune-mediated	O
myopathy	Disease
that	O
persists	O
after	O
withdrawal	O
of	O
the	O
drug	O
and	O
responds	O
to	O
immunosuppressive	O
therapy.	O
The	O
mechanism	O
of	O
this	O
myopathy	Disease
is	O
uncertain	O
but	O
may	O
involve	O
the	O
induction	O
by	O
statins	Chemical

Direct	O
inhibition	O
of	O
cardiac	O
hyperpolarization-activated	O
cyclic	Chemical
nucleotide	Chemical
-gated	O
pacemaker	O
channels	O
by	O
clonidine	Chemical
.	O
BACKGROUND:	O
Inhibition	O
of	O
cardiac	O
sympathetic	O
tone	O
represents	O
an	O
important	O
strategy	O
for	O
treatment	O
of	O
cardiovascular	Disease
disease	Disease
,	O
including	O
arrhythmia	Disease
,	O
coronary	Disease
heart	Disease
disease	Disease
,	O
and	O
chronic	O
heart	Disease
failure	Disease
.	O
Activation	O
of	O
presynaptic	O
alpha2-adrenoceptors	O
is	O
the	O
most	O
widely	O
accepted	O
mechanism	O
of	O
action	O
of	O
the	O
antisympathetic	O
drug	O
clonidine	Chemical
;	O
however,	O
other	O
target	O
proteins	O
have	O
been	O
postulated	O
to	O
contribute	O
to	O
the	O
in	O
vivo	O
actions	O
of	O
clonidine	Chemical
.	O
METHODS	O
AND	O
RESULTS:	O
To	O
test	O
whether	O
clonidine	Chemical
elicits	O
pharmacological	O
effects	O
independent	O
of	O
alpha2-adrenoceptors,	O
we	O
have	O
generated	O
mice	O
with	O
a	O
targeted	O
deletion	O
of	O
all	O
3	O
alpha2-adrenoceptor	O
subtypes	O
(alpha2ABC-/-).	O
Alpha2ABC-/-	O
mice	O
were	O
completely	O
unresponsive	O
to	O
the	O
analgesic	O
and	O
hypnotic	O
effects	O
of	O
clonidine	Chemical
;	O
however,	O
clonidine	Chemical
significantly	O
lowered	O
heart	O
rate	O
in	O
alpha2ABC-/-	O
mice	O
by	O
up	O
to	O
150	O
bpm.	O
Clonidine	Chemical
-induced	O
bradycardia	Disease
in	O
conscious	O
alpha2ABC-/-	O
mice	O
was	O
32.3%	O
(10	O
microg/kg)	O
and	O
26.6%	O
(100	O
microg/kg)	O
of	O
the	O
effect	O
in	O
wild-type	O
mice.	O
A	O
similar	O
bradycardic	O
effect	O
of	O
clonidine	Chemical
was	O
observed	O
in	O
isolated	O
spontaneously	O
beating	O
right	O
atria	O
from	O
alpha2ABC-knockout	O
and	O
wild-type	O
mice.	O
Clonidine	Chemical
inhibited	O
the	O
native	O
pacemaker	O
current	O
(I(f))	O
in	O
isolated	O
sinoatrial	O
node	O
pacemaker	O
cells	O
and	O
the	O
I(f)-generating	O
hyperpolarization-activated	O
cyclic	Chemical
nucleotide	Chemical
-gated	O
(HCN)	O
2	O
and	O
HCN4	O
channels	O
in	O
transfected	O
HEK293	O
cells.	O
As	O
a	O
consequence	O
of	O
blocking	O
I(f),	O
clonidine	Chemical
reduced	O
the	O
slope	O
of	O
the	O
diastolic	O
depolarization	O
and	O
the	O
frequency	O
of	O
pacemaker	O
potentials	O
in	O
sinoatrial	O
node	O
cells	O
from	O
wild-type	O
and	O
alpha2ABC-knockout	O
mice.	O
CONCLUSIONS:	O
Direct	O
inhibition	O
of	O
cardiac	O
HCN	O
pacemaker	O
channels	O
contributes	O
to	O
the	O
bradycardic	O
effects	O
of	O
clonidine	Chemical
gene-targeted	O
mice	O
in	O
vivo,	O
and	O
thus,	O
clonidine	Chemical

Influence	O
of	O
smoking	Chemical
on	O
developing	O
cochlea.	O
Does	O
smoking	Chemical
during	O
pregnancy	O
affect	O
the	O
amplitudes	O
of	O
transient	O
evoked	O
otoacoustic	O
emissions	O
in	O
newborns?	O
OBJECTIVE:	O
Maternal	O
tobacco	O
smoking	Chemical
has	O
negative	O
effects	O
on	O
fetal	O
growth.	O
The	O
influence	O
of	O
smoking	Chemical
during	O
pregnancy	O
on	O
the	O
developing	O
cochlea	O
has	O
not	O
been	O
estimated,	O
although	O
smoking	Chemical
has	O
been	O
positively	O
associated	O
with	O
hearing	Disease
loss	Disease
in	O
adults.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
maternal	O
smoking	Chemical
on	O
transient	O
evoked	O
otoacoustic	O
emissions	O
(TEOAEs)	O
of	O
healthy	O
neonates.	O
METHODS:	O
This	O
study	O
was	O
undertaken	O
as	O
part	O
of	O
neonatal	O
screening	O
for	O
hearing	Disease
impairment	Disease
and	O
involved	O
both	O
ears	O
of	O
200	O
newborns.	O
Newborns	O
whose	O
mothers	O
reported	O
smoking	Chemical
during	O
pregnancy	O
(n=200	O
ears)	O
were	O
compared	O
to	O
a	O
control	O
group	O
of	O
newborns	O
(n=200	O
ears),	O
whose	O
mothers	O
were	O
non-smokers.	O
Exposure	O
to	O
tobacco	O
was	O
characterized	O
as	O
low	O
(<5	O
cigarettes	O
per	O
day,	O
n=88	O
ears),	O
moderate	O
(5<	O
or	O
=cigarettes	O
per	O
day<10,	O
n=76)	O
or	O
high	O
(>	O
or	O
=10	O
cigarettes	O
per	O
day,	O
n=36).	O
RESULTS:	O
In	O
exposed	O
neonates,	O
TEOAEs	O
mean	O
response	O
(across	O
frequency)	O
and	O
mean	O
amplitude	O
at	O
4000Hz	O
was	O
significantly	O
lower	O
than	O
in	O
non-exposed	O
neonates.	O
Comparisons	O
between	O
exposed	O
newborns'	O
subgroups	O
revealed	O
no	O
significant	O
differences.	O
However,	O
by	O
comparing	O
each	O
subgroup	O
to	O
control	O
group,	O
we	O
found	O
statistically	O
significant	O
decreases	Disease
of	Disease
TEOAEs	Disease
amplitudes	Disease
at	O
4000Hz	O
for	O
all	O
three	O
groups.	O
Mean	O
TEOAEs	O
responses	O
of	O
highly	O
exposed	O
newborns	O
were	O
also	O
significantly	O
lower	O
in	O
comparison	O
to	O
our	O
control	O
group.	O
CONCLUSION:	O
In	O
utero,	O
exposure	O
to	O
tobacco	O
smoking	Chemical
seems	O
to	O
have	O
a	O
small	O
impact	O
on	O
outer	O
hair	O
cells.	O
These	O
effects	O
seem	O
to	O
be	O
equally	O
true	O
for	O
all	O
exposed	O
newborns,	O
regardless	O
of	O
the	O
degree	O
of	O
exposure.	O
Further	O
studies	O
are	O
needed	O
in	O
order	O
to	O
establish	O
a	O
potential	O
negative	O
effect	O
of	O
maternal	O
smoking	Chemical

Neuroinflammation	Disease
and	O
behavioral	Disease
abnormalities	Disease
after	O
neonatal	O
terbutaline	Chemical
treatment	O
in	O
rats:	O
implications	O
for	O
autism	Disease
.	O
Autism	Disease
is	O
a	O
neurodevelopmental	Disease
disorder	Disease
presenting	O
before	O
3	O
years	O
of	O
age	O
with	O
deficits	Disease
in	Disease
communication	Disease
and	Disease
social	Disease
skills	Disease
and	O
repetitive	Disease
behaviors	Disease
.	O
In	O
addition	O
to	O
genetic	O
influences,	O
recent	O
studies	O
suggest	O
that	O
prenatal	O
drug	O
or	O
chemical	O
exposures	O
are	O
risk	O
factors	O
for	O
autism	Disease
.	O
Terbutaline	Chemical
,	O
a	O
beta2-adrenoceptor	O
agonist	O
used	O
to	O
arrest	O
preterm	Disease
labor	Disease
,	O
has	O
been	O
associated	O
with	O
increased	O
concordance	O
for	O
autism	Disease
in	O
dizygotic	O
twins.	O
We	O
studied	O
the	O
effects	O
of	O
terbutaline	Chemical
on	O
microglial	O
activation	O
in	O
different	O
brain	O
regions	O
and	O
behavioral	O
outcomes	O
in	O
developing	O
rats.	O
Newborn	O
rats	O
were	O
given	O
terbutaline	Chemical
(10	O
mg/kg)	O
daily	O
on	O
postnatal	O
days	O
(PN)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	O
24	O
h	O
after	O
the	O
last	O
dose	O
and	O
at	O
PN	O
30.	O
Immunohistochemical	O
studies	O
showed	O
that	O
administration	O
of	O
terbutaline	Chemical
on	O
PN	O
2	O
to	O
5	O
produced	O
a	O
robust	O
increase	O
in	O
microglial	O
activation	O
on	O
PN	O
30	O
in	O
the	O
cerebral	O
cortex,	O
as	O
well	O
as	O
in	O
cerebellar	O
and	O
cerebrocortical	O
white	O
matter.	O
None	O
of	O
these	O
effects	O
occurred	O
in	O
animals	O
given	O
terbutaline	Chemical
on	O
PN	O
11	O
to	O
14.	O
In	O
behavioral	O
tests,	O
animals	O
treated	O
with	O
terbutaline	Chemical
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	O
patterns	O
of	O
hyper-reactivity	O
to	O
novelty	O
and	O
aversive	O
stimuli	O
when	O
assessed	O
in	O
a	O
novel	O
open	O
field,	O
as	O
well	O
as	O
in	O
the	O
acoustic	O
startle	O
response	O
test.	O
Our	O
findings	O
indicate	O
that	O
beta2-adrenoceptor	O
overstimulation	O
during	O
an	O
early	O
critical	O
period	O
results	O
in	O
microglial	O
activation	O
associated	O
with	O
innate	O
neuroinflammatory	O
pathways	O
and	O
behavioral	Disease
abnormalities	Disease
,	O
similar	O
to	O
those	O
described	O
in	O
autism	Disease
.	O
This	O
study	O
provides	O
a	O
useful	O
animal	O
model	O
for	O
understanding	O
the	O
neuropathological	O
processes	O
underlying	O
autism	Disease
spectrum	Disease
disorders	Disease

Acute	O
myocarditis	Disease
associated	O
with	O
clozapine	Chemical
.	O
OBJECTIVE:	O
A	O
case	O
of	O
acute	O
myocarditis	Disease
associated	O
with	O
the	O
commencement	O
of	O
clozapine	Chemical
is	O
described,	O
highlighting	O
the	O
onset,	O
course	O
and	O
possible	O
contributing	O
factors.	O
There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
about	O
this	O
potentially	O
fatal	O
complication	O
of	O
clozapine	Chemical
use.	O
RESULTS:	O
A	O
20-year-old	O
male	O
with	O
schizophrenia	Disease
developed	O
a	O
sudden	O
onset	O
of	O
myocarditis	Disease
after	O
commencement	O
of	O
clozapine	Chemical
.	O
The	O
patient	O
recovered	O
with	O
intensive	O
medical	O
support.	O
The	O
symptoms	O
occurred	O
around	O
2	O
weeks	O
after	O
starting	O
clozapine	Chemical
in	O
an	O
inpatient	O
setting.	O
Possible	O
contributing	O
factors	O
may	O
have	O
been	O
concomitant	O
antidepressant	Chemical
use	O
and	O
unaccustomed	O
physical	O
activity.	O
CONCLUSIONS:	O
Myocarditis	Disease
is	O
an	O
increasingly	O
recognized	O
complication	O
associated	O
with	O
the	O
use	O
of	O
clozapine	Chemical
.	O
It	O
can	O
be	O
fatal	O
if	O
not	O
recognized	O
and	O
treated	O
early.	O
Considering	O
that	O
clozapine	Chemical
remains	O
the	O
gold	O
standard	O
in	O
treatment	O
of	O
resistant	O
psychosis	Disease
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
among	O
medical	O
and	O
paramedical	O
staff	O
involved	O
in	O
the	O
care	O
of	O
these	O
patients.	O
There	O
are	O
also	O
implications	O
for	O
recommendations	O
and	O
regulations	O
regarding	O
the	O
use	O
of	O
clozapine	Chemical

Encephalopathy	Disease
induced	O
by	O
levetiracetam	Chemical
added	O
to	O
valproate	Chemical
.	O
BACKGROUND:	O
We	O
report	O
on	O
the	O
manifestation	O
of	O
a	O
levetiracetam	Chemical
(	O
LEV	Chemical
)-induced	O
encephalopathy	Disease
.	O
FINDINGS:	O
A	O
28-year-old	O
man	O
suffering	O
from	O
idiopathic	Disease
epilepsy	Disease
with	O
generalized	O
seizures	Disease
was	O
treated	O
with	O
LEV	Chemical
(3000	O
mg)	O
added	O
to	O
valproate	Chemical
(	O
VPA	Chemical
)	O
(2000	O
mg).	O
Frequency	O
of	O
generalized	O
tonic-clonic	Disease
seizures	Disease
increased	O
from	O
one	O
per	O
6	O
months	O
to	O
two	O
per	O
month.	O
Neuropsychological	O
testing	O
showed	O
impaired	Disease
word	Disease
fluency,	Disease
psychomotor	Disease
speed	Disease
and	Disease
working	Disease
memory	Disease
.	O
The	O
interictal	O
electroencephalogram	O
(EEG)	O
showed	O
a	O
generalized	O
slowing	O
to	O
5	O
per	O
second	O
theta	O
rhythms	O
with	O
bilateral	O
generalized	O
high-amplitude	O
discharges.	O
OUTCOME:	O
Following	O
discontinuation	O
of	O
LEV	Chemical
,	O
EEG	O
and	O
neuropsychological	O
findings	O
improved	O
and	O
seizure	Disease

Norepinephrine	Chemical
signaling	O
through	O
beta-adrenergic	O
receptors	O
is	O
critical	O
for	O
expression	O
of	O
cocaine	Chemical
-induced	O
anxiety	Disease
.	O
BACKGROUND:	O
Cocaine	Chemical
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties.	O
While	O
the	O
mechanisms	O
underlying	O
cocaine	Chemical
's	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively,	O
less	O
attention	O
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	O
states	O
induced	O
by	O
cocaine	Chemical
,	O
such	O
as	O
anxiety	Disease
.	O
METHODS:	O
In	O
this	O
study,	O
we	O
evaluated	O
the	O
performance	O
of	O
dopamine	Chemical
beta-hydroxylase	O
knockout	O
(Dbh	O
-/-)	O
mice,	O
which	O
lack	O
norepinephrine	Chemical
(	O
NE	Chemical
),	O
in	O
the	O
elevated	O
plus	O
maze	O
(EPM)	O
to	O
examine	O
the	O
contribution	O
of	O
noradrenergic	O
signaling	O
to	O
cocaine	Chemical
-induced	O
anxiety	Disease
.	O
RESULTS:	O
We	O
found	O
that	O
cocaine	Chemical
dose-dependently	O
increased	O
anxiety	Disease
-like	O
behavior	O
in	O
control	O
(Dbh	O
+/-)	O
mice,	O
as	O
measured	O
by	O
a	O
decrease	O
in	O
open	O
arm	O
exploration.	O
The	O
Dbh	O
-/-	O
mice	O
had	O
normal	O
baseline	O
performance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistant	O
to	O
the	O
anxiogenic	O
effects	O
of	O
cocaine	Chemical
.	O
Cocaine	Chemical
-induced	O
anxiety	Disease
was	O
also	O
attenuated	O
in	O
Dbh	O
+/-	O
mice	O
following	O
administration	O
of	O
disulfiram	Chemical
,	O
a	O
dopamine	Chemical
beta-hydroxylase	O
(DBH)	O
inhibitor.	O
In	O
experiments	O
using	O
specific	O
adrenergic	O
antagonists,	O
we	O
found	O
that	O
pretreatment	O
with	O
the	O
beta-adrenergic	O
receptor	O
antagonist	O
propranolol	Chemical
blocked	O
cocaine	Chemical
-induced	O
anxiety	Disease
-like	O
behavior	O
in	O
Dbh	O
+/-	O
and	O
wild-type	O
C57BL6/J	O
mice,	O
while	O
the	O
alpha(1)	O
antagonist	O
prazosin	Chemical
and	O
the	O
alpha(2)	O
antagonist	O
yohimbine	Chemical
had	O
no	O
effect.	O
CONCLUSIONS:	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
signaling	O
via	O
beta-adrenergic	O
receptors	O
is	O
required	O
for	O
cocaine	Chemical
-induced	O
anxiety	Disease

Clonidine	Chemical
for	O
attention-deficit/hyperactivity	Disease
disorder	Disease
:	O
II.	O
ECG	O
changes	O
and	O
adverse	O
events	O
analysis.	O
OBJECTIVE:	O
To	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
clonidine	Chemical
used	O
alone	O
or	O
with	O
methylphenidate	Chemical
in	O
children	O
with	O
attention-deficit/hyperactivity	Disease
disorder	Disease
(	O
ADHD	Disease
).	O
METHOD:	O
In	O
a	O
16-week	O
multicenter,	O
double-blind	O
trial,	O
122	O
children	O
with	O
ADHD	Disease
were	O
randomly	O
assigned	O
to	O
clonidine	Chemical
(n	O
=	O
31),	O
methylphenidate	Chemical
(n	O
=	O
29),	O
clonidine	Chemical
and	O
methylphenidate	Chemical
(n	O
=	O
32),	O
or	O
placebo	O
(n	O
=	O
30).	O
Doses	O
were	O
flexibly	O
titrated	O
up	O
to	O
0.6	O
mg/day	O
for	O
clonidine	Chemical
and	O
60	O
mg/day	O
for	O
methylphenidate	Chemical
(both	O
with	O
divided	O
dosing).	O
Groups	O
were	O
compared	O
regarding	O
adverse	O
events	O
and	O
changes	O
from	O
baseline	O
to	O
week	O
16	O
in	O
electrocardiograms	O
and	O
vital	O
signs.	O
RESULTS:	O
There	O
were	O
more	O
incidents	O
of	O
bradycardia	Disease
in	O
subjects	O
treated	O
with	O
clonidine	Chemical
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	Chemical
(17.5%	O
versus	O
3.4%;	O
p	O
=.02),	O
but	O
no	O
other	O
significant	O
group	O
differences	O
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	O
outcomes.	O
There	O
were	O
no	O
suggestions	O
of	O
interactions	O
between	O
clonidine	Chemical
and	O
methylphenidate	Chemical
regarding	O
cardiovascular	O
outcomes.	O
Moderate	O
or	O
severe	O
adverse	O
events	O
were	O
more	O
common	O
in	O
subjects	O
on	O
clonidine	Chemical
(79.4%	O
versus	O
49.2%;	O
p	O
=.0006)	O
but	O
not	O
associated	O
with	O
higher	O
rates	O
of	O
early	O
study	O
withdrawal.	O
Drowsiness	Disease
was	O
common	O
on	O
clonidine	Chemical
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
weeks.	O
CONCLUSIONS:	O
Clonidine	Chemical
,	O
used	O
alone	O
or	O
with	O
methylphenidate	Chemical
,	O
appears	O
safe	O
and	O
well	O
tolerated	O
in	O
childhood	O
ADHD	Disease
.	O
Physicians	O
prescribing	O
clonidine	Chemical
should	O
monitor	O
for	O
bradycardia	Disease
and	O
advise	O
patients	O
about	O
the	O
high	O
likelihood	O
of	O
initial	O
drowsiness	Disease

Thalidomide	Chemical
has	O
limited	O
single-agent	O
activity	O
in	O
relapsed	O
or	O
refractory	O
indolent	O
non-Hodgkin	Disease
lymphomas	Disease
:	O
a	O
phase	O
II	O
trial	O
of	O
the	O
Cancer	Disease
and	O
Leukemia	Disease
Group	O
B.	O
Thalidomide	Chemical
is	O
an	O
immunomodulatory	O
agent	O
with	O
demonstrated	O
activity	O
in	O
multiple	Disease
myeloma	Disease
,	O
mantle	Disease
cell	Disease
lymphoma	Disease
and	O
lymphoplasmacytic	Disease
lymphoma	Disease
.	O
Its	O
activity	O
is	O
believed	O
to	O
be	O
due	O
modulation	O
of	O
the	O
tumour	Disease
milieu,	O
including	O
downregulation	O
of	O
angiogenesis	O
and	O
inflammatory	O
cytokines.	O
Between	O
July	O
2001	O
and	O
April	O
2004,	O
24	O
patients	O
with	O
relapsed/refractory	O
indolent	O
lymphomas	Disease
received	O
thalidomide	Chemical
200	O
mg	O
daily	O
with	O
escalation	O
by	O
100	O
mg	O
daily	O
every	O
1-2	O
weeks	O
as	O
tolerated,	O
up	O
to	O
a	O
maximum	O
of	O
800	O
mg	O
daily.	O
Patients	O
had	O
received	O
a	O
median	O
of	O
2	O
(range,	O
1-4)	O
prior	O
regimens.	O
Of	O
24	O
evaluable	O
patients,	O
two	O
achieved	O
a	O
complete	O
remission	O
and	O
one	O
achieved	O
a	O
partial	O
remission	O
for	O
an	O
overall	O
response	O
rate	O
of	O
12.5%	O
(95%	O
confidence	O
interval:	O
2.6-32.4%).	O
Eleven	O
patients	O
progressed	O
during	O
therapy.	O
Grade	O
3-4	O
adverse	O
effects	O
included	O
myelosuppression	Disease
,	O
fatigue	Disease
,	O
somnolence	Disease
/	O
depressed	Disease
mood	Disease
,	O
neuropathy	Disease
and	O
dyspnea	Disease
.	O
Of	O
concern	O
was	O
the	O
occurrence	O
of	O
four	O
thromboembolic	Disease
events.	O
Our	O
results	O
failed	O
to	O
demonstrate	O
an	O
important	O
response	O
rate	O
to	O
single	O
agent	O
thalidomide	Chemical
in	O
indolent	O
lymphomas	Disease
and	O
contrast	O
with	O
the	O
higher	O
activity	O
level	O
reported	O
with	O
the	O
second	O
generation	O
immunomodulatory	O
agent,	O
lenalidomide	Chemical

Intracavernous	O
epinephrine	Chemical
:	O
a	O
minimally	O
invasive	O
treatment	O
for	O
priapism	Disease
in	O
the	O
emergency	O
department.	O
Priapism	Disease
is	O
the	O
prolonged	O
erection	O
of	O
the	O
penis	O
in	O
the	O
absence	O
of	O
sexual	O
arousal.	O
A	O
45-year-old	O
man,	O
an	O
admitted	O
frequent	O
cocaine	Chemical
user,	O
presented	O
to	O
the	O
Emergency	O
Department	O
(ED)	O
on	O
two	O
separate	O
occasions	O
with	O
a	O
history	O
of	O
priapism	Disease
after	O
cocaine	Chemical
use.	O
The	O
management	O
options	O
in	O
the	O
ED,	O
as	O
exemplified	O
by	O
four	O
individual	O
case	O
reports,	O
in	O
particular	O
the	O
use	O
of	O
a	O
minimally	O
invasive	O
method	O
of	O
intracorporal	O
epinephrine	Chemical

Effect	O
of	O
green	Chemical
tea	Chemical
and	O
vitamin	Chemical
E	Chemical
combination	O
in	O
isoproterenol	Chemical
induced	O
myocardial	Disease
infarction	Disease
in	O
rats.	O
The	O
present	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
green	Chemical
tea	Chemical
and	O
vitamin	Chemical
E	Chemical
on	O
heart	O
weight,	O
body	O
weight,	O
serum	O
marker	O
enzymes,	O
lipid	O
peroxidation,	O
endogenous	O
antioxidants	O
and	O
membrane	O
bound	O
ATPases	O
in	O
isoproterenol	Chemical
(	O
ISO	Chemical
)-induced	O
myocardial	Disease
infarction	Disease
in	O
rats.	O
Adult	O
male	O
albino	O
rats,	O
treated	O
with	O
ISO	Chemical
(200	O
mg/kg,	O
s.c.)	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(P<0.05)	O
elevation	O
of	O
heart	O
weight,	O
serum	O
marker	O
enzymes,	O
lipid	O
peroxidation	O
and	O
Ca	Chemical
+2	O
ATPase	O
level	O
whereas	O
there	O
was	O
a	O
significant	O
(P<0.05)	O
decrease	O
in	O
body	O
weight,	O
endogenous	O
antioxidants,	O
Na	Chemical
+/	O
K	Chemical
+	O
ATPase	O
and	O
Mg	Chemical
+2	O
ATPase	O
levels.	O
Administration	O
of	O
green	Chemical
tea	Chemical
(100	O
mg/kg/day,	O
p.o.)	O
and	O
vitamin	Chemical
E	Chemical
(100	O
mg/kg/day,	O
p.o.)	O
together	O
for	O
30	O
consecutive	O
days	O
and	O
challenged	O
with	O
ISO	Chemical
on	O
the	O
day	O
29th	O
and	O
30th,	O
showed	O
a	O
significant	O
(P<0.05)	O
decrease	O
in	O
heart	O
weight,	O
serum	O
marker	O
enzymes,	O
lipid	O
peroxidation,	O
Ca	Chemical
+2	O
ATPase	O
and	O
a	O
significant	O
increase	O
in	O
the	O
body	O
weight,	O
endogenous	O
antioxidants,	O
Na	Chemical
+/	O
K	Chemical
+	O
ATPase	O
and	O
Mg	Chemical
+2	O
ATPase	O
when	O
compared	O
with	O
ISO	Chemical
treated	O
group	O
and	O
green	Chemical
tea	Chemical
or	O
vitamin	Chemical
E	Chemical
alone	O
treated	O
groups.	O
These	O
findings	O
indicate	O
the	O
synergistic	O
protective	O
effect	O
of	O
green	Chemical
tea	Chemical
and	O
vitamin	Chemical
E	Chemical
during	O
ISO	Chemical
induced	O
myocardial	Disease
infarction	Disease

Development	O
of	O
ocular	Disease
myasthenia	Disease
during	O
pegylated	Chemical
interferon	Chemical
and	O
ribavirin	Chemical
treatment	O
for	O
chronic	Disease
hepatitis	Disease
C	Disease
.	O
A	O
63-year-old	O
male	O
experienced	O
sudden	O
diplopia	Disease
after	O
9	O
weeks	O
of	O
administration	O
of	O
pegylated	Chemical
interferon	Chemical
(IFN)	Chemical
alpha-2b	Chemical
and	O
ribavirin	Chemical
for	O
chronic	Disease
hepatitis	Disease
C	Disease
(	O
CHC	Disease
).	O
Ophthalmologic	O
examinations	O
showed	O
ptosis	Disease
on	Disease
the	Disease
right	Disease
upper	Disease
lid	Disease
and	O
restricted	Disease
right	Disease
eye	Disease
movement	Disease
without	O
any	O
other	O
neurological	O
signs.	O
A	O
brain	O
imaging	O
study	O
and	O
repetitive	O
nerve	O
stimulation	O
test	O
indicated	O
no	O
abnormality.	O
The	O
acetylcholine	Chemical
receptor	O
antibody	O
titer	O
and	O
response	O
to	O
acetylcholinesterase	O
inhibitors	O
were	O
negative,	O
and	O
the	O
results	O
of	O
thyroid	O
function	O
tests	O
were	O
normal.	O
The	O
patient's	O
ophthalmological	O
symptoms	O
improved	O
rapidly	O
3	O
weeks	O
after	O
discontinuation	O
of	O
pegylated	Chemical
IFN	Chemical
alpha-2b	Chemical
and	O
ribavirin	Chemical
.	O
The	O
ocular	Disease
myasthenia	Disease
associated	O
with	O
combination	O
therapy	O
of	O
pegylated	Chemical
IFN	Chemical
alpha-2b	Chemical
and	O
ribavirin	Chemical
for	O
CHC	Disease
is	O
very	O
rarely	O
reported;	O
therefore,	O
we	O
present	O
this	O
case	O
with	O
a	O
review	O
of	O
the	O
various	O
eye	O
complications	O
of	O
IFN	Chemical

The	O
glycine	Chemical
transporter-1	O
inhibitor	O
SSR103800	Chemical
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic-like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice.	O
Schizophrenia	Disease
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	Chemical
neurotransmission.	O
However,	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	Chemical
	O
N-methyl-D-aspartate	Chemical
(	O
NMDA	Chemical
)	O
receptor	O
produce	O
schizophrenic	Disease
-like	O
symptoms	O
in	O
humans	O
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	Chemical
receptor.	O
As	O
a	O
result,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	Chemical
receptor.	O
Among	O
them	O
are	O
glycine	Chemical
transporter-1	O
(GlyT1)	O
inhibitors	O
such	O
as	O
SSR103800	Chemical
,	O
which	O
indirectly	O
enhance	O
NMDA	Chemical
receptor	O
function	O
by	O
increasing	O
the	O
glycine	Chemical
(a	O
co-agonist	O
for	O
the	O
NMDA	Chemical
receptor)	O
levels	O
in	O
the	O
synapse.	O
This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic-like	O
properties	O
of	O
SSR103800	Chemical
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	Disease
,	O
involving	O
either	O
drug	O
challenge	O
(ie,	O
amphetamine	Chemical
and	O
MK-801	Chemical
)	O
or	O
transgenic	O
mice	O
(ie,	O
NMDA	Chemical
Nr1(neo-/-)	O
and	O
DAT(-/-)).	O
Results	O
showed	O
that	O
SSR103800	Chemical
(10-30	O
mg/kg	O
p.o.)	O
blocked	O
hyperactivity	Disease
induced	O
by	O
the	O
non-competitive	O
NMDA	Chemical
receptor	O
antagonist,	O
MK-801	Chemical
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	Disease
of	O
NMDA	Chemical
Nr1(neo-/-)	O
mice.	O
In	O
contrast,	O
SSR103800	Chemical
failed	O
to	O
affect	O
hyperactivity	Disease
induced	O
by	O
amphetamine	Chemical
or	O
naturally	O
observed	O
in	O
dopamine	Chemical
transporter	O
(DAT(-/-))	O
knockout	O
mice	O
(10-30	O
mg/kg	O
p.o.).	O
Importantly,	O
both	O
classical	O
(	O
haloperidol	Chemical
)	O
and	O
atypical	O
(	O
olanzapine	Chemical
,	O
clozapine	Chemical
and	O
aripiprazole	Chemical
)	O
antipsychotics	O
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	Disease
.	O
However,	O
unlike	O
these	O
latter,	O
SSR103800	Chemical
did	O
not	O
produce	O
catalepsy	Disease
(retention	O
on	O
the	O
bar	O
test)	O
up	O
to	O
30	O
mg/kg	O
p.o.	O
Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	O
inhibitor,	O
SSR103800	Chemical

Phenylephrine	Chemical
but	O
not	O
ephedrine	Chemical
	O
reduces	Disease
frontal	Disease
lobe	Disease
oxygenation	Disease
following	O
anesthesia-induced	O
hypotension	Disease
.	O
BACKGROUND:	O
Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia-induced	O
hypotension	Disease
.	O
We	O
describe	O
the	O
effect	O
of	O
phenylephrine	Chemical
and	O
ephedrine	Chemical
on	O
frontal	O
lobe	O
oxygenation	O
(S(c)O(2))	O
following	O
anesthesia-induced	O
hypotension	Disease
.	O
METHODS:	O
Following	O
induction	O
of	O
anesthesia	O
by	O
fentanyl	Chemical
(0.15	O
mg	O
kg(-1))	O
and	O
propofol	Chemical
(2.0	O
mg	O
kg(-1)),	O
13	O
patients	O
received	O
phenylephrine	Chemical
(0.1	O
mg	O
iv)	O
and	O
12	O
patients	O
received	O
ephedrine	Chemical
(10	O
mg	O
iv)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(MAP).	O
Heart	O
rate	O
(HR),	O
MAP,	O
stroke	Disease
volume	O
(SV),	O
cardiac	O
output	O
(CO),	O
and	O
frontal	O
lobe	O
oxygenation	O
(S(c)O(2))	O
were	O
registered.	O
RESULTS:	O
Induction	O
of	O
anesthesia	O
was	O
followed	O
by	O
a	Disease
decrease	Disease
in	Disease
MAP,	Disease
HR,	Disease
SV,	Disease
and	Disease
CO	Disease
concomitant	O
with	O
an	O
elevation	O
in	O
S(c)O(2).	O
After	O
administration	O
of	O
phenylephrine	Chemical
,	O
MAP	O
increased	O
(51	O
+/-	O
12	O
to	O
81	O
+/-	O
13	O
mmHg;	O
P	O
<	O
0.001;	O
mean	O
+/-	O
SD).	O
However,	O
a	O
14%	O
(from	O
70	O
+/-	O
8%	O
to	O
60	O
+/-	O
7%)	O
reduction	O
in	O
S(c)O(2)	O
(P	O
<	O
0.05)	O
followed	O
with	O
no	O
change	O
in	O
CO	O
(3.7	O
+/-	O
1.1	O
to	O
3.4	O
+/-	O
0.9	O
l	O
min(-1)).	O
The	O
administration	O
of	O
ephedrine	Chemical
led	O
to	O
a	O
similar	O
increase	O
in	O
MAP	O
(53	O
+/-	O
9	O
to	O
79	O
+/-	O
8	O
mmHg;	O
P	O
<	O
0.001),	O
restored	O
CO	O
(3.2	O
+/-	O
1.2	O
to	O
5.0	O
+/-	O
1.3	O
l	O
min(-1)),	O
and	O
preserved	O
S(c)O(2).	O
CONCLUSIONS:	O
The	O
utilization	O
of	O
phenylephrine	Chemical
to	O
correct	O
hypotension	Disease
induced	O
by	O
anesthesia	O
has	O
a	O
negative	O
impact	O
on	O
S(c)O(2)	O
while	O
ephedrine	Chemical

A	O
novel,	O
multiple	O
symptom	O
model	O
of	O
obsessive-compulsive-like	Disease
behaviors	Disease
in	O
animals.	O
BACKGROUND:	O
Current	O
animal	O
models	O
of	O
obsessive-compulsive	Disease
disorder	Disease
(	O
OCD	Disease
)	O
typically	O
involve	O
acute,	O
drug-induced	O
symptom	O
provocation	O
or	O
a	O
genetic	O
association	O
with	O
stereotypies	O
or	O
anxiety	Disease
.	O
None	O
of	O
these	O
current	O
models	O
demonstrate	O
multiple	O
OCD	Disease
-like	O
behaviors.	O
METHODS:	O
Neonatal	O
rats	O
were	O
treated	O
with	O
the	O
tricyclic	O
antidepressant	Chemical
	O
clomipramine	Chemical
or	O
vehicle	O
between	O
days	O
9	O
and	O
16	O
twice	O
daily	O
and	O
behaviorally	O
tested	O
in	O
adulthood.	O
RESULTS:	O
Clomipramine	Chemical
exposure	O
in	O
immature	O
rats	O
produced	O
significant	O
behavioral	O
and	O
biochemical	O
changes	O
that	O
include	O
enhanced	O
anxiety	Disease
(elevated	O
plus	O
maze	O
and	O
marble	O
burying),	O
behavioral	Disease
inflexibility	Disease
(perseveration	O
in	O
the	O
spontaneous	O
alternation	O
task	O
and	O
impaired	O
reversal	O
learning),	O
working	O
memory	Disease
impairment	Disease
(e.g.,	O
win-shift	O
paradigm),	O
hoarding	Disease
,	O
and	O
corticostriatal	Disease
dysfunction	Disease
.	O
Dopamine	Chemical
D2	O
receptors	O
were	O
elevated	O
in	O
the	O
striatum,	O
whereas	O
serotonin	Chemical
2C,	O
but	O
not	O
serotonin	Chemical
1A,	O
receptors	O
were	O
elevated	O
in	O
the	O
orbital	O
frontal	O
cortex.	O
CONCLUSIONS:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
multiple	O
symptoms	O
consistent	O
with	O
an	O
OCD	Disease
-like	O
profile	O
in	O
animals.	O
Moreover,	O
these	O
behaviors	O
are	O
accompanied	O
by	O
biochemical	O
changes	O
in	O
brain	O
regions	O
previously	O
identified	O
as	O
relevant	O
to	O
OCD	Disease
.	O
This	O
novel	O
model	O
of	O
OCD	Disease
demonstrates	O
that	O
drug	O
exposure	O
during	O
a	O
sensitive	O
period	O
can	O
program	O
disease-like	O
systems	O
permanently,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeutic	O
strategies	O
for	O
this	O
and	O
other	O
psychiatric	Disease
disorders	Disease

Late	O
recovery	O
of	O
renal	O
function	O
in	O
a	O
woman	O
with	O
the	O
hemolytic	Disease
uremic	Disease
syndrome	Disease
.	O
A	O
case	O
is	O
reported	O
of	O
the	O
hemolytic	Disease
uremic	Disease
syndrome	Disease
(	O
HUS	Disease
)	O
in	O
a	O
woman	O
taking	O
oral	Chemical
contraceptives	Chemical
.	O
She	O
was	O
treated	O
with	O
heparin	Chemical
,	O
dipyridamole	Chemical
and	O
hemodialysis;	O
and	O
after	O
more	O
than	O
three	O
months,	O
her	O
urinary	O
output	O
rose	O
above	O
500	O
ml;	O
and	O
six	O
months	O
after	O
the	O
onset	O
of	O
anuria	Disease
,	O
dialysis	O
treatment	O
was	O
stopped.	O
This	O
case	O
emphasizes	O
the	O
possibility	O
that	O
HUS	Disease
in	O
adults	O
is	O
not	O
invariably	O
irreversible	O
and	O
that,	O
despite	O
prolonged	O
oliguria	Disease
,	O
recovery	O
of	O
renal	O
function	O
can	O
be	O
obtained.	O
Therefore,	O
in	O
adult	O
patients	O
affected	O
by	O
HUS	Disease
,	O
dialysis	O
should	O
not	O
be	O
discontinued	O
prematurely;	O
moreover,	O
bilateral	O
nephrectomy,	O
for	O
treatment	O
of	O
severe	O
hypertension	Disease
and	O
microangiopathic	Disease
hemolytic	Disease
anemia	Disease

Effects	O
of	O
acetylsalicylic	Chemical
acid	Chemical
,	O
dipyridamole	Chemical
,	O
and	O
hydrocortisone	Chemical
on	O
epinephrine	Chemical
-induced	O
myocardial	Disease
injury	Disease
in	O
dogs.	O
A	O
reproducible	O
model	O
for	O
producing	O
diffuse	O
myocardial	Disease
injury	Disease
(	O
epinephrine	Chemical
infusion)	O
has	O
been	O
developed	O
to	O
study	O
the	O
cardioprotective	O
effects	O
of	O
agents	O
or	O
maneuvers	O
which	O
might	O
alter	O
the	O
evolution	O
of	O
acute	O
myocardial	Disease
infarction	Disease
.	O
Infusions	O
of	O
epinephrine	Chemical
(4	O
mug	O
per	O
kilogram	O
per	O
minute	O
for	O
6	O
hours)	O
increased	O
radiocalcium	Chemical
uptakes	O
into	O
intact	O
myocardium	O
and	O
each	O
of	O
its	O
subcellular	O
components	O
with	O
the	O
mitochondrial	O
fraction	O
showing	O
the	O
most	O
consistent	O
changes	O
when	O
compared	O
to	O
saline-infused	O
control	O
animals	O
(4,957	O
vs.	O
827	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
tissue	O
or	O
fraction).	O
Myocardial	O
concentrations	O
of	O
calcium	Chemical
also	O
increased	O
significantly	O
(12.0	O
vs.	O
5.0	O
mg.per	O
100	O
Gm.	O
of	O
fat-free	O
dry	O
weight).	O
Infusions	O
of	O
calcium	Chemical
chloride	Chemical
sufficient	O
to	O
raise	O
serum	O
calcium	Chemical
concentrations	O
2	O
mEq.	O
per	O
liter	O
failed	O
to	O
increase	O
calcium	Chemical
influx	O
into	O
the	O
myocardial	O
cell.	O
Mitochondrial	O
radiocalcium	Chemical
uptakes	O
were	O
significantly	O
decreased	O
in	O
animals	O
pretreated	O
with	O
acetylsalicylic	Chemical
acid	Chemical
or	O
dipyridamole	Chemical
or	O
when	O
hydrocortisone	Chemical
was	O
added	O
to	O
the	O
epinephrine	Chemical
infusion	O
(2,682,2,803,	O
and	O
3,424	O
counts	O
per	O
minute	O
per	O
gram	O
of	O
dried	O
fraction,	O
respectively).	O
Myocardial	O
calcium	Chemical
concentrations	O
also	O
were	O
decreased	O
(11.2,	O
8.3,	O
and	O
8.9	O
mg.	O
per	O
100	O
Gm.	O
of	O
fat-free	O
dry	O
weight,	O
respectively)	O
in	O
the	O
three	O
treatment	O
groups,	O
being	O
significantly	O
decreased	O
only	O
in	O
the	O
last	O
two.	O
Evidence	O
of	O
microscopic	O
damage	O
was	O
graded	O
as	O
less	O
severe	O
in	O
the	O
three	O
treatment	O
groups.	O
Acetylsalicylic	Chemical
acid	Chemical
,	O
dipyridamole	Chemical
,	O
and	O
hydrocortisone	Chemical

Changes	O
in	O
depressive	Disease
status	O
associated	O
with	O
topical	O
beta-blockers.	O
Depression	Disease
and	O
sexual	Disease
dysfunction	Disease
have	O
been	O
related	O
to	O
side	O
effects	O
of	O
topical	O
beta-blockers.	O
We	O
performed	O
a	O
preliminary	O
study	O
in	O
order	O
to	O
determine	O
any	O
difference	O
between	O
a	O
non	O
selective	O
beta-blocker	O
(	O
timolol	Chemical
)	O
and	O
a	O
selective	O
beta-blocker	O
(	O
betaxolol	Chemical
)	O
regarding	O
CNS	O
side	O
effects.	O
Eight	O
glaucomatous	Disease
patients	O
chronically	O
treated	O
with	O
timolol	Chemical
0.5%/12h,	O
suffering	O
from	O
depression	Disease
diagnosed	O
through	O
DMS-III-R	O
criteria,	O
were	O
included	O
in	O
the	O
study.	O
During	O
the	O
six-month	O
follow	O
up,	O
depression	Disease
was	O
quantified	O
through	O
the	O
Beck	O
and	O
Zung-Conde	O
scales	O
every	O
two	O
months.	O
In	O
a	O
double	O
blind	O
cross-over	O
study	O
with	O
control	O
group,	O
the	O
patients	O
under	O
timolol	Chemical
treatment	O
presented	O
higher	O
depression	Disease
values	O
measured	O
through	O
the	O
Beck	O
and	O
the	O
Zung-Conde	O
scales	O
(p	O
<	O
0.001	O
vs	O
control).	O
These	O
results	O
suggest	O
that	O
betaxolol	Chemical
could	O
be	O
less	O
of	O
a	O
depression	Disease
-inducer	O
than	O
timolol	Chemical

Long-term	O
follow-up	O
of	O
ifosfamide	Chemical
	O
renal	Disease
toxicity	Disease
in	O
children	O
treated	O
for	O
malignant	Disease
mesenchymal	Disease
tumors	Disease
:	O
an	O
International	O
Society	O
of	O
Pediatric	O
Oncology	O
report.	O
The	O
renal	O
function	O
of	O
74	O
children	O
with	O
malignant	Disease
mesenchymal	Disease
tumors	Disease
in	O
complete	O
remission	O
and	O
who	O
have	O
received	O
the	O
same	O
ifosfamide	Chemical
chemotherapy	O
protocol	O
(International	O
Society	O
of	O
Pediatric	O
Oncology	O
Malignant	Disease
Mesenchymal	Disease
Tumor	Disease
Study	O
84	O
[SIOP	O
MMT	O
84])	O
were	O
studied	O
1	O
year	O
after	O
the	O
completion	O
of	O
treatment.	O
Total	O
cumulative	O
doses	O
were	O
36	O
or	O
60	O
g/m2	O
of	O
ifosfamide	Chemical
(six	O
or	O
10	O
cycles	O
of	O
ifosfamide,	Chemical
vincristine,	Chemical
and	Chemical
dactinomycin	Chemical
[	O
IVA	Chemical
]).	O
None	O
of	O
them	O
had	O
received	O
cisplatin	Chemical
chemotherapy.	O
Ages	O
ranged	O
from	O
4	O
months	O
to	O
17	O
years;	O
58	O
patients	O
were	O
males	O
and	O
42	O
females.	O
The	O
most	O
common	O
primary	O
tumor	Disease
site	O
was	O
the	O
head	O
and	O
neck.	O
Renal	O
function	O
was	O
investigated	O
by	O
measuring	O
plasma	O
and	O
urinary	O
electrolytes,	O
glucosuria	Disease
,	O
proteinuria	Disease
,	O
aminoaciduria	Disease
,	O
urinary	O
pH,	O
osmolarity,	O
creatinine	Chemical
clearance,	O
phosphate	Chemical
tubular	O
reabsorption,	O
beta	O
2	O
microglobulinuria,	O
and	O
lysozymuria.	O
Fifty-eight	O
patients	O
(78%)	O
had	O
normal	O
renal	O
tests,	O
whereas	O
16	O
patients	O
(22%)	O
had	O
renal	Disease
abnormalities	Disease
.	O
Two	O
subsets	O
of	O
patients	O
were	O
identified	O
from	O
this	O
latter	O
group:	O
the	O
first	O
included	O
four	O
patients	O
(5%	O
of	O
the	O
total	O
population)	O
who	O
developed	O
major	O
toxicity	Disease
resulting	O
in	O
Fanconi's	Disease
syndrome	Disease
(	O
TDFS	Disease
);	O
and	O
the	O
second	O
group	O
included	O
five	O
patients	O
with	O
elevated	O
beta	O
2	O
microglobulinuria	O
and	O
low	O
phosphate	Chemical
reabsorption.	O
The	O
remaining	O
seven	O
patients	O
had	O
isolated	O
beta	O
2	O
microglobulinuria.	O
Severe	O
toxicity	Disease
was	O
correlated	O
with	O
the	O
higher	O
cumulative	O
dose	O
of	O
60	O
g/m2	O
of	O
ifosfamide	Chemical
,	O
a	O
younger	O
age	O
(less	O
than	O
2	O
1/2	O
years	O
old),	O
and	O
a	O
predominance	O
of	O
vesicoprostatic	O
tumor	Disease
involvement.	O
This	O
low	O
percentage	O
(5%)	O
of	O
TDFS	O
must	O
be	O
evaluated	O
with	O
respect	O
to	O
the	O
efficacy	O
of	O
ifosfamide	Chemical
in	O
the	O
treatment	O
of	O
mesenchymal	Disease
tumors	Disease

Evidence	O
for	O
an	O
involvement	O
of	O
D1	O
and	O
D2	O
dopamine	Chemical
receptors	O
in	O
mediating	O
nicotine	Chemical
-induced	O
hyperactivity	Disease
in	O
rats.	O
Previous	O
studies	O
have	O
suggested	O
that	O
repeated	O
exposure	O
of	O
rats	O
to	O
the	O
drug	O
or	O
to	O
the	O
experimental	O
environment	O
is	O
necessary	O
to	O
observe	O
nicotine	Chemical
-induced	O
locomotor	O
stimulation.	O
In	O
the	O
present	O
study	O
the	O
role	O
of	O
habituation	O
to	O
the	O
experimental	O
environment	O
on	O
the	O
stimulant	O
effect	O
of	O
nicotine	Chemical
in	O
rats	O
was	O
examined.	O
In	O
addition,	O
the	O
role	O
of	O
dopamine	Chemical
receptors	O
in	O
mediating	O
nicotine	Chemical
-induced	O
locomotor	O
stimulation	O
was	O
investigated	O
by	O
examining	O
the	O
effects	O
of	O
selective	O
D1	O
and	O
D2	O
dopamine	Chemical
receptor	O
antagonists	O
on	O
activity	O
induced	O
by	O
nicotine	Chemical
.	O
Locomotor	O
activity	O
was	O
assessed	O
in	O
male	O
Sprague-Dawley	O
rats	O
tested	O
in	O
photocell	O
cages.	O
Nicotine	Chemical
(1.0	O
mg/kg)	O
caused	O
a	O
significant	O
increase	Disease
in	Disease
locomotor	Disease
activity	Disease
in	O
rats	O
that	O
were	O
habituated	O
to	O
the	O
test	O
environment,	O
but	O
had	O
only	O
a	O
weak	O
and	O
delayed	O
stimulant	O
action	O
in	O
rats	O
that	O
were	O
unfamiliar	O
with	O
the	O
test	O
environment.	O
The	O
stimulant	O
action	O
of	O
nicotine	Chemical
was	O
blocked	O
by	O
the	O
central	O
nicotinic	O
antagonist	O
mecamylamine	Chemical
but	O
not	O
by	O
the	O
peripheral	O
nicotinic	O
blocker	O
hexamethonium	Chemical
,	O
indicating	O
that	O
the	O
response	O
is	O
probably	O
mediated	O
by	O
central	O
nicotinic	O
receptors.	O
Nicotine	Chemical
-induced	O
hyperactivity	Disease
was	O
blocked	O
by	O
the	O
selective	O
D1	O
antagonist	O
SCH	Chemical
23390	Chemical
,	O
the	O
selective	O
D2	O
antagonist	O
raclopride	Chemical
and	O
the	O
D1/D2	O
antagonist	O
fluphenazine	Chemical
.	O
Pretreatment	O
with	O
the	O
D2	O
agonist	O
PHNO	Chemical
enhanced	O
nicotine	Chemical
-induced	O
hyperactivity	Disease
,	O
whereas	O
the	O
D1	O
agonist	O
SKF	Chemical
38393	Chemical
had	O
no	O
effect.	O
The	O
results	O
indicate	O
that	O
acute	O
nicotine	Chemical
injection	O
induces	O
a	O
pronounced	O
hyperactivity	Disease
in	O
rats	O
habituated	O
to	O
the	O
test	O
environment.	O
The	O
effect	O
appears	O
to	O
be	O
mediated	O
by	O
central	O
nicotine	Chemical
receptors,	O
possibly	O
located	O
on	O
dopaminergic	O
neurons,	O
and	O
also	O
requires	O
the	O
activation	O
of	O
both	O
D1	O
and	O
D2	O
dopamine	Chemical

Neuropsychiatric	O
side	O
effects	O
after	O
the	O
use	O
of	O
mefloquine	Chemical
.	O
This	O
study	O
describes	O
neuropsychiatric	O
side	O
effects	O
in	O
patients	O
after	O
treatment	O
with	O
mefloquine	Chemical
.	O
Reactions	O
consisted	O
mainly	O
of	O
seizures	Disease
,	O
acute	O
psychoses	Disease
,	O
anxiety	Disease
neurosis	Disease
,	O
and	O
major	O
disturbances	Disease
of	Disease
sleep-wake	Disease
rhythm	Disease
.	O
Side	O
effects	O
occurred	O
after	O
both	O
therapeutic	O
and	O
prophylactic	O
intake	O
and	O
were	O
graded	O
from	O
moderate	O
to	O
severe.	O
In	O
a	O
risk	O
analysis	O
of	O
neuropsychiatric	O
side	O
effects	O
in	O
Germany,	O
it	O
is	O
estimated	O
that	O
one	O
of	O
8,000	O
mefloquine	Chemical
users	O
suffers	O
from	O
such	O
reactions.	O
The	O
incidence	O
calculation	O
revealed	O
that	O
one	O
of	O
215	O
therapeutic	O
users	O
had	O
reactions,	O
compared	O
with	O
one	O
of	O
13,000	O
in	O
the	O
prophylaxis	O
group,	O
making	O
the	O
risk	O
of	O
neuropsychiatric	O
reactions	O
after	O
mefloquine	Chemical
treatment	O
60	O
times	O
higher	O
than	O
after	O
prophylaxis.	O
Therefore,	O
certain	O
limitations	O
for	O
malaria	Disease
prophylaxis	O
and	O
treatment	O
with	O
mefloquine	Chemical

Reduction	O
in	O
injection	O
pain	Disease
using	O
buffered	O
lidocaine	Chemical
as	O
a	O
local	O
anesthetic	O
before	O
cardiac	O
catheterization.	O
Previous	O
reports	O
have	O
suggested	O
that	O
pain	Disease
associated	O
with	O
the	O
injection	O
of	O
lidocaine	Chemical
is	O
related	O
to	O
the	O
acidic	O
pH	O
of	O
the	O
solution.	O
To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buffering	O
solution	O
to	O
adjust	O
the	O
pH	O
of	O
lidocaine	Chemical
into	O
the	O
physiologic	O
range	O
would	O
reduce	O
pain	Disease
during	O
injection,	O
we	O
performed	O
a	O
blinded	O
randomized	O
study	O
in	O
patients	O
undergoing	O
cardiac	O
catheterization.	O
Twenty	O
patients	O
were	O
asked	O
to	O
quantify	O
the	O
severity	O
of	O
pain	Disease
after	O
receiving	O
standard	O
lidocaine	Chemical
in	O
one	O
femoral	O
area	O
and	O
buffered	O
lidocaine	Chemical
in	O
the	O
opposite	O
femoral	O
area.	O
The	O
mean	O
pain	Disease
score	O
for	O
buffered	O
lidocaine	Chemical
was	O
significantly	O
lower	O
than	O
the	O
mean	O
score	O
for	O
standard	O
lidocaine	Chemical
(2.7	O
+/-	O
1.9	O
vs.	O
3.8	O
+/-	O
2.2,	O
P	O
=	O
0.03).	O
The	O
pH	O
adjustment	O
of	O
standard	O
lidocaine	Chemical
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterization	O
laboratory	O
before	O
injection	O
and	O
results	O
in	O
a	O
reduction	O
of	O
the	O
pain	Disease

Randomized,	O
double-blind	O
trial	O
of	O
mazindol	Chemical
in	O
Duchenne	Disease
dystrophy	Disease
.	O
There	O
is	O
evidence	O
that	O
growth	O
hormone	O
may	O
be	O
related	O
to	O
the	O
progression	O
of	O
weakness	Disease
in	O
Duchenne	Disease
dystrophy	Disease
.	O
We	O
conducted	O
a	O
12-month	O
controlled	O
trial	O
of	O
mazindol	Chemical
,	O
a	O
putative	O
growth	O
hormone	O
secretion	O
inhibitor,	O
in	O
83	O
boys	O
with	O
Duchenne	Disease
dystrophy	Disease
.	O
Muscle	O
strength,	O
contractures,	O
functional	O
ability	O
and	O
pulmonary	O
function	O
were	O
tested	O
at	O
baseline,	O
and	O
6	O
and	O
12	O
months	O
after	O
treatment	O
with	O
mazindol	Chemical
(3	O
mg/d)	O
or	O
placebo.	O
The	O
study	O
was	O
designed	O
to	O
have	O
a	O
power	O
of	O
greater	O
than	O
0.90	O
to	O
detect	O
a	O
slowing	O
to	O
25%	O
of	O
the	O
expected	O
rate	O
of	O
progression	O
of	O
weakness	Disease
at	O
P	O
less	O
than	O
0.05.	O
Mazindol	Chemical
did	O
not	O
benefit	O
strength	O
at	O
any	O
point	O
in	O
the	O
study.	O
Side	O
effects	O
attributable	O
to	O
mazindol	Chemical
included	O
decreased	Disease
appetite	Disease
(36%),	O
dry	Disease
mouth	Disease
(10%),	O
behavioral	O
change	O
(22%),	O
and	O
gastrointestinal	Disease
symptoms	Disease
(18%);	O
mazindol	Chemical
dosage	O
was	O
reduced	O
in	O
43%	O
of	O
patients.	O
The	O
effect	O
of	O
mazindol	Chemical
on	O
GH	O
secretion	O
was	O
estimated	O
indirectly	O
by	O
comparing	O
the	O
postabsorptive	O
IGF-I	O
levels	O
obtained	O
following	O
3,	O
6,	O
9,	O
and	O
12	O
months	O
in	O
the	O
mazindol	Chemical
treated	O
to	O
those	O
in	O
the	O
placebo	O
groups.	O
Although	O
mazindol	Chemical
-treated	O
patients	O
gained	O
less	O
weight	O
and	O
height	O
than	O
placebo-treated	O
patients,	O
no	O
significant	O
effect	O
on	O
IGF-I	O
levels	O
was	O
observed.	O
Mazindol	Chemical
doses	O
not	O
slow	O
the	O
progression	O
of	O
weakness	Disease
in	O
Duchenne	Disease
dystrophy	Disease

Pentoxifylline	Chemical
(	O
Trental	Chemical
)	O
does	O
not	O
inhibit	O
dipyridamole	Chemical
-induced	O
coronary	O
hyperemia	Disease
:	O
implications	O
for	O
dipyridamole	Chemical
-	O
thallium	Chemical
-201	O
myocardial	O
imaging.	O
Dipyridamole	Chemical
-	O
thallium	Chemical
-201	O
imaging	O
is	O
often	O
performed	O
in	O
patients	O
unable	O
to	O
exercise	O
because	O
of	O
peripheral	Disease
vascular	Disease
disease	Disease
.	O
Many	O
of	O
these	O
patients	O
are	O
taking	O
pentoxifylline	Chemical
(	O
Trental	Chemical
),	O
a	O
methylxanthine	Chemical
derivative	O
which	O
may	O
improve	O
intermittent	Disease
claudication	Disease
.	O
Whether	O
pentoxifylline	Chemical
inhibits	O
dipyridamole	Chemical
-induced	O
coronary	O
hyperemia	Disease
like	O
other	O
methylxanthines	Chemical
such	O
as	O
theophylline	Chemical
and	O
should	O
be	O
stopped	O
prior	O
to	O
dipyridamole	Chemical
-	O
thallium	Chemical
-201	O
imaging	O
is	O
unknown.	O
Therefore,	O
we	O
studied	O
the	O
hyperemic	O
response	O
to	O
dipyridamole	Chemical
in	O
seven	O
open-chest	O
anesthetized	O
dogs	O
after	O
pretreatment	O
with	O
either	O
pentoxifylline	Chemical
(0,	O
7.5,	O
or	O
15	O
mg/kg	O
i.v.)	O
or	O
theophylline	Chemical
(3	O
mg/kg	O
i.v.).	O
Baseline	O
circumflex	O
coronary	O
blood	O
flows	O
did	O
not	O
differ	O
significantly	O
among	O
treatment	O
groups.	O
Dipyridamole	Chemical
significantly	O
increased	O
coronary	O
blood	O
flow	O
before	O
and	O
after	O
7.5	O
or	O
15	O
mm/kg	O
i.v.	O
pentoxifylline	Chemical
(p	O
less	O
than	O
0.002).	O
Neither	O
dose	O
of	O
pentoxifylline	Chemical
significantly	O
decreased	O
the	O
dipyridamole	Chemical
-induced	O
hyperemia	Disease
,	O
while	O
peak	O
coronary	O
blood	O
flow	O
was	O
significantly	O
lower	O
after	O
theophylline	Chemical
(p	O
less	O
than	O
0.01).	O
We	O
conclude	O
that	O
pentoxyifylline	Chemical
does	O
not	O
inhibit	O
dipyridamole	Chemical
-induced	O
coronary	O
hyperemia	Disease

Cause	O
of	O
death	Disease
among	O
patients	O
with	O
Parkinson's	Disease
disease	Disease
:	O
a	O
rare	O
mortality	O
due	O
to	O
cerebral	Disease
haemorrhage	Disease
.	O
Causes	O
of	O
death	Disease
,	O
with	O
special	O
reference	O
to	O
cerebral	Disease
haemorrhage	Disease
,	O
among	O
240	O
patients	O
with	O
pathologically	O
verified	O
Parkinson's	Disease
disease	Disease
were	O
investigated	O
using	O
the	O
Annuals	O
of	O
the	O
Pathological	O
Autopsy	O
Cases	O
in	O
Japan	O
from	O
1981	O
to	O
1985.	O
The	O
leading	O
causes	O
of	O
death	Disease
were	O
pneumonia	Disease
and	O
bronchitis	Disease
(44.1%),	O
malignant	O
neoplasms	Disease
(11.6%),	O
heart	Disease
diseases	Disease
(4.1%),	O
cerebral	Disease
infarction	Disease
(3.7%)	O
and	O
septicaemia	Disease
(3.3%).	O
Cerebral	Disease
haemorrhage	Disease
was	O
the	O
11th	O
most	O
frequent	O
cause	O
of	O
death	Disease
,	O
accounting	O
for	O
only	O
0.8%	O
of	O
deaths	Disease
among	O
the	O
patients,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	O
cause	O
of	O
death	Disease
among	O
the	O
Japanese	O
general	O
population	O
in	O
1985.	O
The	O
low	O
incidence	O
of	O
cerebral	Disease
haemorrhage	Disease
as	O
a	O
cause	O
of	O
death	Disease
in	O
patients	O
with	O
Parkinson's	Disease
disease	Disease
may	O
reflect	O
the	O
hypotensive	Disease
effect	O
of	O
levodopa	Chemical
and	O
a	O
hypotensive	Disease
mechanism	O
due	O
to	O
reduced	O
noradrenaline	Chemical
levels	O
in	O
the	O
parkinsonian	Disease

Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	Chemical
in	O
patients	O
with	O
Argentine	Disease
hemorrhagic	Disease
fever	Disease
.	O
Tolerance	O
and	O
antiviral	O
effect	O
of	O
ribavirin	Chemical
was	O
studied	O
in	O
6	O
patients	O
with	O
Argentine	Disease
hemorrhagic	Disease
fever	Disease
(	O
AHF	Disease
)	O
of	O
more	O
than	O
8	O
days	O
of	O
evolution.	O
Administration	O
of	O
ribavirin	Chemical
resulted	O
in	O
a	O
neutralization	O
of	O
viremia	Disease
and	O
a	O
drop	O
of	O
endogenous	O
interferon	O
titers.	O
The	O
average	O
time	O
of	O
death	Disease
was	O
delayed.	O
A	O
reversible	O
anemia	Disease
was	O
the	O
only	O
adverse	O
effect	O
observed.	O
From	O
these	O
results,	O
we	O
conclude	O
that	O
ribavirin	Chemical
has	O
an	O
antiviral	O
effect	O
in	O
advanced	O
cases	O
of	O
AHF	Disease
,	O
and	O
that	O
anemia	Disease
,	O
the	O
only	O
secondary	O
reaction	O
observed,	O
can	O
be	O
easily	O
managed.	O
The	O
possible	O
beneficial	O
effect	O
of	O
ribavirin	Chemical
during	O
the	O
initial	O
days	O
of	O
AHF	Disease

Dipyridamole	Chemical
-induced	O
myocardial	Disease
ischemia	Disease
.	O
Angina	Disease
and	O
ischemic	O
electrocardiographic	O
changes	O
occurred	O
after	O
administration	O
of	O
oral	O
dipyridamole	Chemical
in	O
four	O
patients	O
awaiting	O
urgent	O
myocardial	O
revascularization	O
procedures.	O
To	O
our	O
knowledge,	O
this	O
has	O
not	O
previously	O
been	O
reported	O
as	O
a	O
side	O
effect	O
of	O
preoperative	O
dipyridamole	Chemical
therapy,	O
although	O
dipyridamole	Chemical
-induced	O
myocardial	Disease
ischemia	Disease
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
animals	O
and	O
humans	O
with	O
coronary	Disease
artery	Disease
disease	Disease
.	O
Epicardial	O
coronary	O
collateral	O
vessels	O
were	O
demonstrated	O
in	O
all	O
four	O
patients;	O
a	O
coronary	O
"steal"	O
phenomenon	O
may	O
be	O
the	O
mechanism	O
of	O
the	O
dipyridamole	Chemical
-induced	O
ischemia	Disease

Inhibition	O
of	O
immunoreactive	O
corticotropin-releasing	O
factor	O
secretion	O
into	O
the	O
hypophysial-portal	O
circulation	O
by	O
delayed	O
glucocorticoid	O
feedback.	O
Nitroprusside	Chemical
-induced	O
hypotension	Disease
evokes	O
ACTH	O
secretion	O
which	O
is	O
primarily	O
mediated	O
by	O
enhanced	O
secretion	O
of	O
immunoreactive	O
corticotropin-releasing	O
factor	O
(irCRF)	O
into	O
the	O
hypophysial-portal	O
circulation.	O
Portal	O
plasma	O
concentrations	O
of	O
neither	O
arginine	Chemical
vasopressin	Chemical
nor	O
oxytocin	Chemical
are	O
significantly	O
altered	O
in	O
this	O
paradigm.	O
Application	O
of	O
a	O
delayed	O
feedback	O
signal,	O
in	O
the	O
form	O
of	O
a	O
2-h	O
systemic	O
corticosterone	Chemical
infusion	O
in	O
urethane	Chemical
-anesthetized	O
rats	O
with	O
pharmacological	O
blockade	O
of	O
glucocorticoid	O
synthesis,	O
is	O
without	O
effect	O
on	O
the	O
resting	O
secretion	O
of	O
arginine	Chemical
vasopressin	Chemical
and	O
oxytocin	Chemical
at	O
any	O
corticosterone	Chemical
feedback	O
dose	O
tested.	O
Resting	O
irCRF	O
levels	O
are	O
suppressed	O
only	O
at	O
the	O
highest	O
corticosterone	Chemical
infusion	O
rate,	O
which	O
resulted	O
in	O
systemic	O
corticosterone	Chemical
levels	O
of	O
40	O
micrograms/dl.	O
Suppression	O
of	O
irCRF	O
secretion	O
in	O
response	O
to	O
nitroprusside	Chemical
-induced	O
hypotension	Disease
is	O
observed	O
and	O
occurs	O
at	O
a	O
plasma	O
corticosterone	Chemical

Noradrenergic	O
involvement	O
in	O
catalepsy	Disease
induced	O
by	O
delta	Chemical
9-tetrahydrocannabinol	Chemical
.	O
In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholaminergic	O
system	O
in	O
the	O
cataleptogenic	O
effect	O
of	O
delta	Chemical
9-tetrahydrocannabinol	Chemical
(	O
THC	Chemical
),	O
the	O
effect	O
of	O
pretreatment	O
with	O
6-hydroxydopamine	Chemical
(	O
6-OHDA	Chemical
)	O
or	O
with	O
desipramine	Chemical
and	O
6-OHDA	Chemical
and	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
were	O
investigated	O
in	O
rats.	O
The	O
cataleptogenic	O
effect	O
of	O
THC	Chemical
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
6-OHDA	Chemical
and	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
but	O
not	O
in	O
rats	O
treated	O
with	O
desipramine	Chemical
and	O
6-OHDA	Chemical
,	O
as	O
compared	O
with	O
control	O
rats.	O
On	O
the	O
contrary,	O
the	O
cataleptogenic	O
effect	O
of	O
haloperidol	Chemical
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
desipramine	Chemical
and	O
6-OHDA	Chemical
but	O
not	O
in	O
rats	O
treated	O
with	O
6-OHDA	Chemical
or	O
in	O
rats	O
with	O
lesions	O
of	O
the	O
locus	O
coeruleus.	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
neurons	O
have	O
an	O
important	O
role	O
in	O
the	O
manifestation	O
of	O
catalepsy	Disease
induced	O
by	O
THC	Chemical
,	O
whereas	O
dopaminergic	O
neurons	O
are	O
important	O
in	O
catalepsy	Disease
induced	O
by	O
haloperidol	Chemical

Intracranial	O
pressure	O
increases	O
during	O
alfentanil	Chemical
-induced	O
rigidity	Disease
.	O
Intracranial	O
pressure	O
(ICP)	O
was	O
measured	O
during	O
alfentanil	Chemical
-induced	O
rigidity	Disease
in	O
rats.	O
Ten	O
rats	O
had	O
arterial,	O
central	O
venous	O
(CVP),	O
and	O
subdural	O
cannulae	O
inserted	O
under	O
halothane	Chemical
anesthesia.	O
The	O
animals	O
were	O
mechanically	O
ventilated	O
to	O
achieve	O
normocarbia	O
(PCO2	O
=	O
42	O
+/-	O
1	O
mmHg,	O
mean	O
+/-	O
SE).	O
Following	O
instrumentation,	O
halothane	Chemical
was	O
discontinued	O
and	O
alfentanil	Chemical
(125	O
mu/kg)	O
administered	O
iv	O
during	O
emergence	O
from	O
halothane	Chemical
anesthesia.	O
In	O
the	O
five	O
rats	O
that	O
developed	O
somatic	Disease
rigidity	Disease
,	O
ICP	O
and	O
CVP	O
increased	O
significantly	O
above	O
baseline	O
(delta	O
ICP	O
7.5	O
+/-	O
1.0	O
mmHg,	O
delta	O
CVP	O
5.9	O
+/-	O
1.3	O
mmHg).	O
These	O
variables	O
returned	O
to	O
baseline	O
when	O
rigidity	Disease
was	O
abolished	O
with	O
metocurine	Chemical
.	O
In	O
five	O
rats	O
that	O
did	O
not	O
become	O
rigid,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	O
following	O
alfentanil	Chemical
.	O
These	O
observations	O
suggest	O
that	O
rigidity	Disease
should	O
be	O
prevented	O
when	O
alfentanil	Chemical

Adverse	O
cardiac	O
effects	O
during	O
induction	O
chemotherapy	O
treatment	O
with	O
cis-platin	Chemical
and	O
5-fluorouracil	Chemical
.	O
Survival	O
for	O
patients	O
with	O
advanced	O
head	Disease
and	Disease
neck	Disease
carcinoma	Disease
and	O
esophageal	Disease
carcinoma	Disease
is	O
poor	O
with	O
radiotherapy	O
and/or	O
surgery.	O
Obviously,	O
there	O
is	O
a	O
need	O
for	O
effective	O
chemotherapy.	O
In	O
the	O
present	O
study,	O
cis-platin	Chemical
(80-120	O
mg/m2BSA)	O
and	O
5-FU	Chemical
(1000	O
mg/m2BSA	O
daily	O
as	O
a	O
continuous	O
infusion	O
during	O
5	O
days)	O
were	O
given	O
to	O
76	O
patients	O
before	O
radiotherapy	O
and	O
surgery.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
clarify	O
the	O
incidence	O
and	O
severity	O
of	O
adverse	O
cardiac	O
effects	O
to	O
this	O
treatment.	O
Before	O
treatment	O
all	O
patients	O
had	O
a	O
cardiac	O
evaluation	O
and	O
during	O
treatment	O
serial	O
ECG	O
recordings	O
were	O
performed.	O
In	O
the	O
pre-treatment	O
evaluation,	O
signs	O
of	O
cardiovascular	Disease
disease	Disease
were	O
found	O
in	O
33	O
patients	O
(43%).	O
During	O
treatment,	O
adverse	O
cardiac	O
effects	O
were	O
observed	O
in	O
14	O
patients	O
(18%).	O
The	O
mean	O
age	O
of	O
these	O
patients	O
was	O
the	O
same	O
as	O
for	O
the	O
entire	O
group,	O
64	O
years.	O
The	O
incidence	O
of	O
cardiotoxicity	Disease
was	O
not	O
higher	O
in	O
patients	O
with	O
signs	O
of	O
cardiovascular	Disease
disease	Disease
than	O
in	O
those	O
without	O
in	O
the	O
pre-treatment	O
evaluation.	O
The	O
most	O
common	O
signs	O
of	O
cardiotoxicity	Disease
were	O
chest	Disease
pain	Disease
,	O
ST-T	O
wave	O
changes	O
and	O
atrial	Disease
fibrillation	Disease
.	O
This	O
was	O
followed	O
by	O
ventricular	Disease
fibrillation	Disease
in	O
one	O
patient	O
and	O
sudden	Disease
death	Disease
in	O
another.	O
It	O
is	O
concluded	O
that	O
patients	O
on	O
5-FU	Chemical
treatment	O
should	O
be	O
under	O
close	O
supervision	O
and	O
that	O
the	O
treatment	O
should	O
be	O
discontinued	O
if	O
chest	Disease
pain	Disease
or	O
tachyarrhythmia	Disease

Verapamil	Chemical
-induced	O
carbamazepine	Chemical
	O
neurotoxicity	Disease
.	O
A	O
report	O
of	O
two	O
cases.	O
Two	O
patients	O
with	O
signs	O
of	O
carbamazepine	Chemical
	O
neurotoxicity	Disease
after	O
combined	O
treatment	O
with	O
verapamil	Chemical
showed	O
complete	O
recovery	O
after	O
discontinuation	O
of	O
the	O
calcium	Chemical
entry	O
blocker.	O
Use	O
of	O
verapamil	Chemical
in	O
combination	O
with	O
carbamazepine	Chemical
should	O
either	O
be	O
avoided	O
or	O
prescribed	O
only	O
with	O
appropriate	O
adjustment	O
of	O
the	O
carbamazepine	Chemical
dose	O
(usually	O
reduction	O
of	O
the	O
carbamazepine	Chemical

Serial	O
studies	O
of	O
auditory	Disease
neurotoxicity	Disease
in	O
patients	O
receiving	O
deferoxamine	Chemical
therapy.	O
Visual	Disease
and	Disease
auditory	Disease
neurotoxicity	Disease
was	O
previously	O
documented	O
in	O
42	O
of	O
89	O
patients	O
with	O
transfusion-dependent	O
anemia	Disease
who	O
were	O
receiving	O
iron	Chemical
chelation	O
therapy	O
with	O
daily	O
subcutaneous	O
deferoxamine	Chemical
.	O
Twenty-two	O
patients	O
in	O
the	O
affected	O
group	O
had	O
abnormal	Disease
audiograms	Disease
with	Disease
deficits	Disease
mostly	Disease
in	Disease
the	Disease
high	Disease
frequency	Disease
range	Disease
of	Disease
4,000	Disease
to	Disease
8,000	Disease
Hz	Disease
and	O
in	O
the	O
hearing	O
threshold	O
levels	O
of	O
30	O
to	O
100	O
decibels.	O
When	O
deferoxamine	Chemical
therapy	O
was	O
discontinued	O
and	O
serial	O
studies	O
were	O
performed,	O
audiograms	O
in	O
seven	O
cases	O
reverted	O
to	O
normal	O
or	O
near	O
normal	O
within	O
two	O
to	O
three	O
weeks,	O
and	O
nine	O
of	O
13	O
patients	O
with	O
symptoms	O
became	O
asymptomatic.	O
Audiograms	O
from	O
15	O
patients	O
remained	O
abnormal	O
and	O
four	O
patients	O
required	O
hearing	O
aids	O
because	O
of	O
permanent	Disease
disability	Disease
.	O
Since	O
18	O
of	O
the	O
22	O
patients	O
were	O
initially	O
receiving	O
deferoxamine	Chemical
doses	O
in	O
excess	O
of	O
the	O
commonly	O
recommended	O
50	O
mg/kg	O
per	O
dose,	O
therapy	O
was	O
restarted	O
with	O
lower	O
doses,	O
usually	O
50	O
mg/kg	O
per	O
dose	O
or	O
less	O
depending	O
on	O
the	O
degree	O
of	O
auditory	Disease
abnormality	Disease
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cases	O
no	O
further	O
toxicity	Disease
was	O
demonstrated.	O
Auditory	O
deterioration	O
and	O
improvement,	O
demonstrated	O
serially	O
in	O
individual	O
patients	O
receiving	O
and	O
not	O
receiving	O
deferoxamine	Chemical
,	O
respectively,	O
provided	O
convincing	O
evidence	O
for	O
a	O
cause-and-effect	O
relation	O
between	O
deferoxamine	Chemical
administration	O
and	O
ototoxicity	Disease
.	O
Based	O
on	O
these	O
data,	O
a	O
plan	O
of	O
management	O
was	O
developed	O
that	O
allows	O
effective	O
yet	O
safe	O
administration	O
of	O
deferoxamine	Chemical
.	O
A	O
dose	O
of	O
50	O
mg/kg	O
is	O
recommended	O
in	O
those	O
without	O
audiogram	O
abnormalities.	O
With	O
mild	O
toxicity	Disease
,	O
a	O
reduction	O
to	O
30	O
or	O
40	O
mg/kg	O
per	O
dose	O
should	O
result	O
in	O
a	O
reversal	O
of	O
the	O
abnormal	O
results	O
to	O
normal	O
within	O
four	O
weeks.	O
Moderate	O
abnormalities	O
require	O
a	O
reduction	O
of	O
deferoxamine	Chemical
to	O
25	O
mg/kg	O
per	O
dose	O
with	O
careful	O
monitoring.	O
In	O
those	O
with	O
symptoms	O
of	O
hearing	Disease
loss	Disease
,	O
the	O
drug	O
should	O
be	O
stopped	O
for	O
four	O
weeks,	O
and	O
when	O
the	O
audiogram	O
is	O
stable	O
or	O
improved,	O
therapy	O
should	O
be	O
restarted	O
at	O
10	O
to	O
25	O
mg/kg	O
per	O
dose.	O
Serial	O
audiograms	O
should	O
be	O
performed	O
every	O
six	O
months	O
in	O
those	O
without	O
problems	O
and	O
more	O
frequently	O
in	O
young	O
patients	O
with	O
normal	O
serum	O
ferritin	O
values	O
and	O
in	O
those	O
with	O
auditory	Disease
dysfunction	Disease

Flurbiprofen	Chemical
in	O
the	O
treatment	O
of	O
juvenile	Disease
rheumatoid	Disease
arthritis	Disease
.	O
Thirty-four	O
patients	O
with	O
juvenile	Disease
rheumatoid	Disease
arthritis	Disease
,	O
who	O
were	O
treated	O
with	O
flurbiprofen	Chemical
at	O
a	O
maximum	O
dose	O
of	O
4	O
mg/kg/day,	O
had	O
statistically	O
significant	O
decreases	O
from	O
baseline	O
in	O
6	O
arthritis	Disease
indices	O
after	O
12	O
weeks	O
of	O
treatment.	O
Improvements	O
were	O
seen	O
in	O
the	O
number	O
of	O
tender	Disease
joints	Disease
,	O
the	O
severity	O
of	O
swelling	Disease
and	O
tenderness	Disease
,	O
the	O
time	O
of	O
walk	O
50	O
feet,	O
the	O
duration	O
of	O
morning	Disease
stiffness	Disease
and	O
the	O
circumference	O
of	O
the	O
left	O
knee.	O
The	O
most	O
frequently	O
observed	O
side	O
effect	O
was	O
fecal	Disease
occult	Disease
blood	Disease
(25%	O
of	O
patients);	O
however,	O
there	O
was	O
no	O
other	O
evidence	O
of	O
gastrointestinal	Disease
(GI)	Disease
bleeding	Disease
in	O
these	O
patients.	O
One	O
patient	O
was	O
prematurely	O
discontinued	O
from	O
the	O
study	O
for	O
severe	O
headache	Disease
and	O
abdominal	Disease
pain	Disease

The	O
correlation	O
between	O
neurotoxic	Disease
esterase	O
inhibition	O
and	O
mipafox	Chemical
-induced	O
neuropathic	Disease
damage	Disease
in	O
rats.	O
The	O
correlation	O
between	O
neuropathic	Disease
damage	Disease
and	O
inhibition	O
of	O
neurotoxic	Disease
esterase	O
or	O
neuropathy	Disease
target	O
enzyme	O
(NTE)	O
was	O
examined	O
in	O
rats	O
acutely	O
exposed	O
to	O
Mipafox	Chemical
(	O
N,	Chemical
N'-diisopropylphosphorodiamidofluoridate	Chemical
),	O
a	O
neurotoxic	Disease
	O
organophosphate	Chemical
.	O
Brain	O
and	O
spinal	O
cord	O
NTE	O
activities	O
were	O
measured	O
in	O
Long-Evans	O
male	O
rats	O
1	O
hr	O
post-exposure	O
to	O
various	O
dosages	O
of	O
Mipafox	Chemical
(ip,	O
1-15	O
mg/kg).	O
These	O
data	O
were	O
correlated	O
with	O
histologically	O
scored	O
cervical	O
cord	Disease
damage	Disease
in	O
a	O
separate	O
group	O
of	O
similarly	O
dosed	O
rats	O
sampled	O
14-21	O
days	O
post-exposure.	O
Those	O
dosages	O
(greater	O
than	O
or	O
equal	O
to	O
10	O
mg/kg)	O
that	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
the	O
spinal	O
cord	O
greater	O
than	O
or	O
equal	O
to	O
73%	O
and	O
brain	O
greater	O
than	O
or	O
equal	O
to	O
67%	O
of	O
control	O
values	O
produced	O
severe	O
(greater	O
than	O
or	O
equal	O
to	O
3)	O
cervical	O
cord	O
pathology	O
in	O
85%	O
of	O
the	O
rats.	O
In	O
contrast,	O
dosages	O
of	O
Mipafox	Chemical
(less	O
than	O
or	O
equal	O
to	O
5	O
mg/kg)	O
which	O
inhibited	O
mean	O
NTE	O
activity	O
in	O
spinal	O
cord	O
less	O
than	O
or	O
equal	O
to	O
61%	O
and	O
brain	O
less	O
than	O
or	O
equal	O
to	O
60%	O
produced	O
this	O
degree	O
of	O
cord	Disease
damage	Disease
in	O
only	O
9%	O
of	O
the	O
animals.	O
These	O
data	O
indicate	O
that	O
a	O
critical	O
percentage	O
of	O
NTE	O
inhibition	O
in	O
brain	O
and	O
spinal	O
cord	O
sampled	O
shortly	O
after	O
Mipafox	Chemical
exposure	O
can	O
predict	O
neuropathic	Disease
damage	Disease

Cerebral	Disease
infarction	Disease
with	O
a	O
single	O
oral	O
dose	O
of	O
phenylpropanolamine	Chemical
.	O
Phenylpropanolamine	Chemical
(	O
PPA	Chemical
),	O
a	O
synthetic	O
sympathomimetic	O
that	O
is	O
structurally	O
similar	O
to	O
amphetamine	Chemical
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorectics,	O
nasal	O
congestants,	O
and	O
cold	O
preparations.	O
Its	O
prolonged	O
use	O
or	O
overuse	O
has	O
been	O
associated	O
with	O
seizures	Disease
,	O
intracerebral	Disease
hemorrhage	Disease
,	O
neuropsychiatric	Disease
symptoms	Disease
,	O
and	O
nonhemorrhagic	O
cerebral	Disease
infarction	Disease
.	O
We	O
report	O
the	O
case	O
of	O
a	O
young	O
woman	O
who	O
suffered	O
a	O
cerebral	Disease
infarction	Disease
after	O
taking	O
a	O
single	O
oral	O
dose	O
of	O
PPA	Chemical

Treatment	O
of	O
psoriasis	Disease
with	O
azathioprine	Chemical
.	O
Azathioprine	Chemical
treatment	O
benefited	O
19	O
(66%)	O
out	O
of	O
29	O
patients	O
suffering	O
from	O
severe	O
psoriasis	Disease
.	O
Haematological	O
complications	O
were	O
not	O
troublesome	O
and	O
results	O
of	O
biochemical	O
liver	O
function	O
tests	O
remained	O
normal.	O
Minimal	O
cholestasis	Disease
was	O
seen	O
in	O
two	O
cases	O
and	O
portal	O
fibrosis	Disease
of	O
a	O
reversible	O
degree	O
in	O
eight.	O
Liver	O
biopsies	O
should	O
be	O
undertaken	O
at	O
regular	O
intervals	O
if	O
azathioprine	Chemical
therapy	O
is	O
continued	O
so	O
that	O
structural	O
liver	Disease
damage	Disease

Maternal	O
lithium	Chemical
and	O
neonatal	O
Ebstein's	Disease
anomaly	Disease
:	O
evaluation	O
with	O
cross-sectional	O
echocardiography.	O
Cross-sectional	O
echocardiography	O
was	O
used	O
to	O
evaluate	O
two	O
neonates	O
whose	O
mothers	O
ingested	O
lithium	Chemical
during	O
pregnancy.	O
In	O
one	O
infant,	O
Ebstein's	Disease
anomaly	Disease
of	O
the	O
tricuspid	O
valve	O
was	O
identified.	O
In	O
the	O
other	O
infant	O
cross-sectional	O
echocardiography	O
provided	O
reassurance	O
that	O
the	O
infant	O
did	O
not	O
have	O
Ebstein's	Disease
anomaly	Disease
.	O
Cross-sectional	O
echocardiographic	O
screening	O
of	O
newborns	O
exposed	O
to	O
lithium	Chemical
during	O
gestation	O
can	O
provide	O
highly	O
accurate,	O
noninvasive	O
assessment	O
of	O
the	O
presence	O
or	O
absence	O
of	O
lithium	Chemical
-induced	O
cardiac	Disease
malformations	Disease

Effects	O
of	O
training	O
on	O
the	O
extent	O
of	O
experimental	O
myocardial	Disease
infarction	Disease
in	O
aging	O
rats.	O
The	O
effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
infarction	Disease
were	O
studied	O
in	O
female	O
albino	O
rats	O
of	O
20,40,60	O
and	O
80	O
weeks	O
of	O
age.	O
The	O
rats	O
were	O
trained	O
to	O
swim	O
for	O
a	O
specific	O
duration	O
and	O
for	O
a	O
particular	O
period.	O
The	O
occurrence	O
of	O
infarcts	Disease
were	O
confirmed	O
by	O
histological	O
methods.	O
Elevations	O
in	O
the	O
serum	O
GOT	O
and	O
GPT	O
were	O
maximum	O
in	O
the	O
sedentary-	O
isoproterenols	Chemical
and	O
minimum	O
in	O
the	O
exercise-controls.	O
These	O
changes	O
in	O
the	O
serum	O
transaminases	O
were	O
associated	O
with	O
corresponding	O
depletions	O
in	O
the	O
cardiac	O
GOT	O
and	O
GPT.	O
However,	O
age	O
was	O
seen	O
to	O
interfere	O
with	O
the	O
responses	O
exhibited	O
by	O
the	O
young	O
and	O
old	O
rats.	O
Studies	O
dealing	O
with	O
myocardial	Disease
infarction	Disease

Effect	O
of	O
polyethylene	Chemical
glycol	Chemical
400	Chemical
on	O
adriamycin	Chemical
	O
toxicity	Disease
in	O
mice.	O
The	O
effect	O
of	O
a	O
widely	O
used	O
organic	O
solvent,	O
polyethylene	Chemical
glycol	Chemical
400	Chemical
(	O
PEG	Chemical
400	Chemical
),	O
on	O
the	O
toxic	O
action	O
of	O
an	O
acute	O
or	O
chronic	O
treatment	O
with	O
adriamycin	Chemical
(	O
ADR	Chemical
)	O
was	O
evaluated	O
in	O
mice.	O
PEG	Chemical
400	Chemical
impressively	O
decreased	O
both	O
acute	O
high-dose	O
and	O
chronic	O
low-dose-	O
ADR	Chemical
-associated	O
lethality.	O
Light	O
microscopic	O
analysis	O
showed	O
a	O
significant	O
protection	O
against	O
ADR	Chemical
-induced	O
cardiac	Disease
morphological	Disease
alterations	Disease
.	O
Such	O
treatment	O
did	O
not	O
diminish	O
the	O
ADR	Chemical
antitumor	O
activity	O
in	O
L1210	Disease
leukemia	Disease
and	O
in	O
Ehrlich	Disease
ascites	Disease
tumor	Disease

Intra-arterial	O
BCNU	Chemical
chemotherapy	O
for	O
treatment	O
of	O
malignant	Disease
gliomas	Disease
of	O
the	O
central	O
nervous	O
system.	O
Because	O
of	O
the	O
rapid	O
systemic	O
clearance	O
of	O
BCNU	Chemical
(	O
1,3-bis-(2-chloroethyl)-1-nitrosourea	Chemical
),	O
intra-arterial	O
administration	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
intravenous	O
administration	O
for	O
the	O
treatment	O
of	O
malignant	Disease
gliomas	Disease
.	O
Thirty-six	O
patients	O
were	O
treated	O
with	O
BCNU	Chemical
every	O
6	O
to	O
8	O
weeks,	O
either	O
by	O
transfemoral	O
catheterization	O
of	O
the	O
internal	O
carotid	O
or	O
vertebral	O
artery	O
or	O
through	O
a	O
fully	O
implantable	O
intracarotid	O
drug	O
delivery	O
system,	O
beginning	O
with	O
a	O
dose	O
of	O
200	O
mg/sq	O
m	O
body	O
surface	O
area.	O
Twelve	O
patients	O
with	O
Grade	O
III	O
or	O
IV	O
astrocytomas	Disease
were	O
treated	O
after	O
partial	O
resection	O
of	O
the	O
tumor	Disease
without	O
prior	O
radiation	O
therapy.	O
After	O
two	O
to	O
seven	O
cycles	O
of	O
chemotherapy,	O
nine	O
patients	O
showed	O
a	O
decrease	O
in	O
tumor	Disease
size	O
and	O
surrounding	O
edema	Disease
on	O
contrast-enhanced	O
computerized	O
tomography	O
scans.	O
In	O
the	O
nine	O
responders,	O
median	O
duration	O
of	O
chemotherapy	O
response	O
from	O
the	O
time	O
of	O
operation	O
was	O
25	O
weeks	O
(range	O
12	O
to	O
more	O
than	O
91	O
weeks).	O
The	O
median	O
duration	O
of	O
survival	O
in	O
the	O
12	O
patients	O
was	O
54	O
weeks	O
(range	O
21	O
to	O
more	O
than	O
156	O
weeks),	O
with	O
an	O
18-month	O
survival	O
rate	O
of	O
42%.	O
Twenty-four	O
patients	O
with	O
recurrent	O
Grade	O
I	O
to	O
IV	O
astrocytomas	Disease
,	O
whose	O
resection	O
and	O
irradiation	O
therapy	O
had	O
failed,	O
received	O
two	O
to	O
eight	O
courses	O
of	O
intra-arterial	O
BCNU	Chemical
therapy.	O
Seventeen	O
of	O
these	O
had	O
a	O
response	O
or	O
were	O
stable	O
for	O
a	O
median	O
of	O
20	O
weeks	O
(range	O
6	O
to	O
more	O
than	O
66	O
weeks).	O
The	O
catheterization	O
procedure	O
is	O
safe,	O
with	O
no	O
immediate	O
complication	O
in	O
111	O
infusions	O
of	O
BCNU	Chemical
.	O
A	O
delayed	O
complication	O
in	O
nine	O
patients	O
has	O
been	O
unilateral	O
loss	Disease
of	Disease
vision	Disease
secondary	O
to	O
a	O
retinal	Disease
vasculitis	Disease
.	O
The	O
frequency	O
of	O
visual	Disease
loss	Disease
decreased	O
after	O
the	O
concentration	O
of	O
the	O
ethanol	Chemical

Blood	O
pressure	O
response	O
to	O
chronic	O
low-dose	O
intrarenal	O
noradrenaline	Chemical
infusion	O
in	O
conscious	O
rats.	O
Sodium	Chemical
chloride	Chemical
solution	O
(0.9%)	O
or	O
noradrenaline	Chemical
in	O
doses	O
of	O
4,	O
12	O
and	O
36	O
micrograms	O
h-1	O
kg-1	O
was	O
infused	O
for	O
five	O
consecutive	O
days,	O
either	O
intrarenally	O
(by	O
a	O
new	O
technique)	O
or	O
intravenously	O
into	O
rats	O
with	O
one	O
kidney	O
removed.	O
Intrarenal	O
infusion	O
of	O
noradrenaline	Chemical
caused	O
hypertension	Disease
at	O
doses	O
which	O
did	O
not	O
do	O
so	O
when	O
infused	O
intravenously.	O
Intrarenal	O
compared	O
with	O
intravenous	O
infusion	O
of	O
noradrenaline	Chemical
caused	O
higher	O
plasma	O
noradrenaline	Chemical
concentrations	O
and	O
a	O
shift	O
of	O
the	O
plasma	O
noradrenaline	Chemical
concentration-blood	O
pressure	O
effect	O
curve	O
towards	O
lower	O
plasma	O
noradrenaline	Chemical
levels.	O
These	O
results	O
suggest	O
that	O
hypertension	Disease
after	O
chronic	O
intrarenal	O
noradrenaline	Chemical
infusion	O
is	O
produced	O
by	O
relatively	O
higher	O
levels	O
of	O
circulating	O
noradrenaline	Chemical

Age	O
and	O
renal	O
clearance	O
of	O
cimetidine	Chemical
.	O
In	O
35	O
patients	O
(ages	O
20	O
to	O
86	O
yr)	O
receiving	O
cimetidine	Chemical
therapeutically	O
two	O
serum	O
samples	O
and	O
all	O
urine	O
formed	O
in	O
the	O
interim	O
were	O
collected	O
for	O
analysis	O
of	O
cimetidine	Chemical
by	O
high-pressure	O
liquid	O
chromatography	O
and	O
for	O
creatinine	Chemical
.	O
Cimetidine	Chemical
clearance	O
decreased	O
with	O
age.	O
The	O
extrapolated	O
6-hr	O
serum	O
concentration	O
of	O
cimetidine	Chemical
per	O
unit	O
dose,	O
after	O
intravenous	O
cimetidine	Chemical
,	O
increased	O
with	O
age	O
of	O
the	O
patients.	O
The	O
ratio	O
of	O
cimetidine	Chemical
clearance	O
to	O
creatinine	Chemical
clearance	O
(Rc)	O
averaged	O
4.8	O
+/-	O
2.0,	O
indicating	O
net	O
tubular	O
secretion	O
for	O
cimetidine	Chemical
.	O
Rc	O
seemed	O
to	O
be	O
independent	O
of	O
age	O
and	O
decreased	O
with	O
increasing	O
serum	O
concentration	O
of	O
cimetidine	Chemical
,	O
suggesting	O
that	O
secretion	O
of	O
cimetidine	Chemical
is	O
a	O
saturable	O
process.	O
There	O
was	O
only	O
one	O
case	O
of	O
dementia	Disease
possibly	O
due	O
to	O
cimetidine	Chemical
(with	O
a	O
drug	O
level	O
of	O
1.9	O
microgram/ml	O
6	O
hr	O
after	O
a	O
dose)	O
in	O
a	O
group	O
of	O
13	O
patients	O
without	O
liver	Disease
or	Disease
kidney	Disease
disease	Disease
who	O
had	O
cimetidine	Chemical
levels	O
above	O
1.25	O
microgram/ml.	O
Thus,	O
high	O
cimetidine	Chemical
levels	O
alone	O
do	O
not	O
always	O
induce	O
dementia	Disease

Development	O
of	O
clear	Disease
cell	Disease
adenocarcinoma	Disease
in	O
DES	Chemical
-exposed	O
offspring	O
under	O
observation.	O
Two	O
cases	O
of	O
clear	Disease
cell	Disease
adenocarcinoma	Disease
of	Disease
the	Disease
vagina	Disease
detected	O
at	O
follow-up	O
in	O
young	O
women	O
exposed	O
in	O
utero	O
to	O
diethylstilbestrol	Chemical
are	O
reported.	O
One	O
patient,	O
aged	O
23,	O
had	O
been	O
followed	O
for	O
2	O
years	O
before	O
carcinoma	Disease
was	O
diagnosed;	O
the	O
second	O
patient,	O
aged	O
22,	O
had	O
been	O
seen	O
on	O
a	O
regular	O
basis	O
for	O
5	O
years,	O
8	O
months.	O
In	O
both	O
instances,	O
suspicion	O
of	O
the	O
presence	O
of	O
carcinoma	Disease

Phenobarbitone	Chemical
-induced	O
enlargement	Disease
of	Disease
the	Disease
liver	Disease
in	O
the	O
rat:	O
its	O
relationship	O
to	O
carbon	Chemical
tetrachloride	Chemical
-induced	O
cirrhosis	Disease
.	O
The	O
yield	O
of	O
severe	O
cirrhosis	Disease
of	Disease
the	Disease
liver	Disease
(defined	O
as	O
a	O
shrunken	O
finely	O
nodular	O
liver	O
with	O
micronodular	O
histology,	O
ascites	Disease
greater	O
than	O
30	O
ml,	O
plasma	O
albumin	O
less	O
than	O
2.2	O
g/dl,	O
splenomegaly	Disease
2-3	O
times	O
normal,	O
and	O
testicular	O
atrophy	Disease
approximately	O
half	O
normal	O
weight)	O
after	O
12	O
doses	O
of	O
carbon	Chemical
tetrachloride	Chemical
given	O
intragastrically	O
in	O
the	O
phenobarbitone	Chemical
-primed	O
rat	O
was	O
increased	O
from	O
25%	O
to	O
56%	O
by	O
giving	O
the	O
initial	O
"calibrating"	O
dose	O
of	O
carbon	Chemical
tetrachloride	Chemical
at	O
the	O
peak	O
of	O
the	O
phenobarbitone	Chemical
-induced	O
enlargement	Disease
of	Disease
the	Disease
liver	Disease
.	O
At	O
this	O
point	O
it	O
was	O
assumed	O
that	O
the	O
cytochrome	O
P450/	O
CCl4	Chemical
toxic	O
state	O
was	O
both	O
maximal	O
and	O
stable.	O
The	O
optimal	O
rat	O
size	O
to	O
begin	O
phenobarbitone	Chemical
was	O
determined	O
as	O
100	O
g,	O
and	O
this	O
size	O
as	O
a	O
group	O
had	O
a	O
mean	O
maximum	O
relative	O
liver	O
weight	O
increase	O
47%	O
greater	O
than	O
normal	O
rats	O
of	O
the	O
same	O
body	O
weight.	O
The	O
optimal	O
time	O
for	O
the	O
initial	O
dose	O
of	O
carbon	Chemical
tetrachloride	Chemical
was	O
after	O
14	O
days	O
on	O
phenobarbitone	Chemical

Attenuation	O
of	O
the	O
lithium	Chemical
-induced	O
diabetes-insipidus-like	Disease
syndrome	Disease
by	O
amiloride	Chemical
in	O
rats.	O
The	O
effect	O
of	O
amiloride	Chemical
on	O
lithium	Chemical
-induced	O
polydipsia	Disease
and	O
polyuria	Disease
and	O
on	O
the	O
lithium	Chemical
concentration	O
in	O
the	O
plasma,	O
brain,	O
kidney,	O
thyroid	O
and	O
red	O
blood	O
cells	O
was	O
investigated	O
in	O
rats,	O
chronically	O
treated	O
with	O
LiCl	Chemical
.	O
Amiloride	Chemical
reduced	O
the	O
drinking	O
and	O
urine	O
volume	O
of	O
rats	O
in	O
an	O
acute	O
(6	O
or	O
12	O
h)	O
and	O
a	O
subacute	O
(3	O
days)	O
experiment.	O
6	O
h	O
after	O
the	O
administration	O
of	O
amiloride	Chemical
,	O
a	O
reduction	O
was	O
observed	O
in	O
the	O
lithium	Chemical
content	O
of	O
the	O
renal	O
medulla	O
but	O
not	O
in	O
the	O
other	O
organs	O
studied.	O
At	O
12	O
h,	O
all	O
the	O
tissues	O
showed	O
a	O
slight	O
increase	O
in	O
lithium	Chemical
levels.	O
After	O
3	O
days	O
of	O
combined	O
treatment,	O
a	O
marked	O
elevation	O
in	O
plasma	O
and	O
tissue	O
lithium	Chemical
levels	O
accompanied	O
a	O
reduction	O
in	O
water	O
intake.	O
In	O
all	O
the	O
experiments,	O
the	O
attenuation	O
of	O
the	O
lithium	Chemical
-induced	O
diabetes-insipidus-like	Disease
syndrome	Disease
by	O
amiloride	Chemical
was	O
accompanied	O
by	O
a	O
reduction	O
of	O
the	O
ratio	O
between	O
the	O
lithium	Chemical
concentration	O
in	O
the	O
renal	O
medulla	O
and	O
its	O
levels	O
in	O
the	O
blood	O
and	O
an	O
elevation	O
in	O
the	O
plasma	O
potassium	Chemical
level.	O
It	O
is	O
concluded	O
that	O
acute	O
amiloride	Chemical
administration	O
to	O
lithium	Chemical
-treated	O
patients	O
suffering	O
from	O
polydipsia	Disease
and	O
polyuria	Disease
might	O
relieve	O
these	O
patients	O
but	O
prolonged	O
amiloride	Chemical
supplementation	O
would	O
result	O
in	O
elevated	O
lithium	Chemical

Safety	O
and	O
side-effects	O
of	O
alprazolam	Chemical
.	O
Controlled	O
study	O
in	O
agoraphobia	Disease
with	O
panic	Disease
disorder	Disease
.	O
BACKGROUND:	O
The	O
widespread	O
use	O
of	O
benzodiazepines	Chemical
has	O
led	O
to	O
increasing	O
recognition	O
of	O
their	O
unwanted	O
effects.	O
The	O
efficacy	O
of	O
alprazolam	Chemical
and	O
placebo	O
in	O
panic	Disease
disorder	Disease
with	O
agoraphobia	Disease
,	O
and	O
the	O
side-effect	O
and	O
adverse	O
effect	O
profiles	O
of	O
both	O
drug	O
groups	O
were	O
measured.	O
METHOD:	O
In	O
London	O
and	O
Toronto	O
154	O
patients	O
who	O
met	O
DSM-III	O
criteria	O
for	O
panic	Disease
disorder	Disease
with	O
agoraphobia	Disease
were	O
randomised	O
to	O
alprazolam	Chemical
or	O
placebo.	O
Subjects	O
in	O
each	O
drug	O
group	O
also	O
received	O
either	O
exposure	O
or	O
relaxation.	O
Treatment	O
was	O
from	O
weeks	O
0	O
to	O
8	O
and	O
was	O
then	O
tapered	O
from	O
weeks	O
8	O
to	O
16.	O
RESULTS:	O
Mean	O
alprazolam	Chemical
dose	O
was	O
5	O
mg	O
daily.	O
Compared	O
with	O
placebo	O
subjects,	O
alprazolam	Chemical
patients	O
developed	O
more	O
adverse	O
reactions	O
(21%	O
v.	O
0%)	O
of	O
depression	Disease
,	O
enuresis	Disease
,	O
disinhibition	O
and	O
aggression	Disease
;	O
and	O
more	O
side-effects,	O
particularly	O
sedation,	O
irritability	Disease
,	O
impaired	Disease
memory	Disease
,	O
weight	Disease
loss	Disease
and	O
ataxia	Disease
.	O
Side-effects	O
tended	O
to	O
diminish	O
during	O
treatment	O
but	O
remained	O
significant	O
at	O
week	O
8.	O
Despite	O
this,	O
the	O
drop-out	O
rate	O
was	O
low.	O
CONCLUSIONS:	O
Alprazolam	Chemical

Dup	Chemical
753	Chemical
prevents	O
the	O
development	O
of	O
puromycin	Chemical
aminonucleoside	Chemical
-induced	O
nephrosis	Disease
.	O
The	O
appearance	O
of	O
nephrotic	Disease
syndromes	Disease
such	O
as	O
proteinuria	Disease
,	O
hypoalbuminemia	Disease
,	O
hypercholesterolemia	Disease
and	O
increase	O
in	O
blood	Chemical
nitrogen	Chemical
urea	Chemical
,	O
induced	O
in	O
rats	O
by	O
injection	O
of	O
puromycin	Chemical
aminonucleoside	Chemical
was	O
markedly	O
inhibited	O
by	O
oral	O
administration	O
of	O
Dup	Chemical
753	Chemical
(	O
losartan	Chemical
),	O
a	O
novel	O
angiotensin	Chemical
II	Chemical
receptor	O
antagonist,	O
at	O
a	O
dose	O
of	O
1	O
or	O
2	O
mg/kg	O
per	O
day.	O
The	O
results	O
suggest	O
a	O
possible	O
involvement	O
of	O
the	O
renin-	O
angiotensin	Chemical
system	O
in	O
the	O
development	O
of	O
puromycin	Chemical
aminonucleoside	Chemical
-induced	O
nephrosis	Disease

Sodium	Chemical
bicarbonate	Chemical
alleviates	O
penile	Disease
pain	Disease
induced	O
by	O
intracavernous	O
injections	O
for	O
erectile	Disease
dysfunction	Disease
.	O
In	O
an	O
attempt	O
to	O
determine	O
whether	O
penile	Disease
pain	Disease
associated	O
with	O
intracorporeal	O
injections	O
could	O
be	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication,	O
we	O
performed	O
a	O
randomized	O
study	O
comparing	O
the	O
incidence	O
of	O
penile	Disease
pain	Disease
following	O
intracorporeal	O
injections	O
with	O
or	O
without	O
the	O
addition	O
of	O
sodium	Chemical
bicarbonate	Chemical
to	O
the	O
intracorporeal	O
medications.	O
A	O
total	O
of	O
38	O
consecutive	O
patients	O
who	O
presented	O
to	O
our	O
clinic	O
with	O
impotence	Disease
received	O
0.2	O
ml.	O
of	O
a	O
combination	O
of	O
3	O
drugs:	O
6	O
mg.	O
papaverine	Chemical
,	O
100	O
micrograms.	O
phentolamine	Chemical
and	O
10	O
micrograms.	O
prostaglandin	Chemical
E1	Chemical
with	O
(pH	O
7.05)	O
or	O
without	O
(pH	O
4.17)	O
the	O
addition	O
of	O
sodium	Chemical
bicarbonate	Chemical
(0.03	O
mEq.).	O
Of	O
the	O
19	O
patients	O
without	O
sodium	Chemical
bicarbonate	Chemical
added	O
to	O
the	O
medication	O
11	O
(58%)	O
complained	O
of	O
penile	Disease
pain	Disease
due	O
to	O
the	O
medication,	O
while	O
only	O
1	O
of	O
the	O
19	O
men	O
(5%)	O
who	O
received	O
sodium	Chemical
bicarbonate	Chemical
complained	O
of	O
penile	Disease
pain	Disease
.	O
From	O
these	O
data	O
we	O
conclude	O
that	O
the	O
penile	Disease
pain	Disease

Prospective	O
study	O
of	O
the	O
long-term	O
effects	O
of	O
somatostatin	O
analog	O
(	O
octreotide	Chemical
)	O
on	O
gallbladder	O
function	O
and	O
gallstone	Disease
formation	O
in	O
Chinese	O
acromegalic	Disease
patients.	O
This	O
article	O
reports	O
the	O
changes	O
in	O
gallbladder	O
function	O
examined	O
by	O
ultrasonography	O
in	O
20	O
Chinese	O
patients	O
with	O
active	O
acromegaly	Disease
treated	O
with	O
sc	O
injection	O
of	O
the	O
somatostatin	O
analog	O
octreotide	Chemical
in	O
dosages	O
of	O
300-1500	O
micrograms/day	O
for	O
a	O
mean	O
of	O
24.2	O
+/-	O
13.9	O
months.	O
During	O
treatment	O
with	O
octreotide	Chemical
,	O
17	O
patients	O
developed	O
sludge,	O
10	O
had	O
gallstones	Disease
,	O
and	O
1	O
developed	O
acute	Disease
cholecystitis	Disease
requiring	O
surgery.	O
In	O
all	O
of	O
7	O
patients	O
examined	O
acutely,	O
gallbladder	O
contractility	O
was	O
inhibited	O
after	O
a	O
single	O
100-micrograms	O
injection.	O
In	O
8	O
patients	O
followed	O
for	O
24	O
weeks,	O
gallbladder	O
contractility	O
remained	O
depressed	Disease
throughout	O
therapy.	O
After	O
withdrawal	O
of	O
octreotide	Chemical
in	O
10	O
patients	O
without	O
gallstones	Disease
,	O
8	O
patients	O
assessed	O
had	O
return	O
of	O
normal	O
gallbladder	O
contractility	O
within	O
1	O
month.	O
In	O
8	O
of	O
the	O
remaining	O
10	O
patients	O
who	O
developed	O
gallstones	Disease
during	O
treatment,	O
gallbladder	O
contractility	O
normalized	O
in	O
5	O
patients	O
(3	O
of	O
whom	O
has	O
disappearance	O
of	O
their	O
stones	O
within	O
3	O
weeks),	O
and	O
remained	O
depressed	Disease
in	O
3	O
(2	O
of	O
whom	O
had	O
stones	O
present	O
at	O
6	O
months).	O
Our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
gallbladder	O
contractility	O
is	O
the	O
cause	O
of	O
the	O
successive	O
formation	O
of	O
bile	O
sludge,	O
gallstones	Disease
,	O
and	O
cholecystitis	Disease
during	O
octreotide	Chemical
therapy	O
in	O
Chinese	O
acromegalic	Disease
patients.	O
It	O
is	O
therefore	O
very	O
important	O
to	O
follow	O
the	O
changes	O
of	O
gallbladder	O
function	O
during	O
long-term	O
octreotide	Chemical
therapy	O
of	O
acromegalic	Disease

Improvement	O
of	O
levodopa	Chemical
-induced	O
dyskinesia	Disease
by	O
propranolol	Chemical
in	O
Parkinson's	Disease
disease	Disease
.	O
Seven	O
patients	O
suffering	O
from	O
Parkinson's	Disease
disease	Disease
(	O
PD	Disease
)	O
with	O
severely	O
disabling	O
dyskinesia	Disease
received	O
low-dose	O
propranolol	Chemical
as	O
an	O
adjunct	O
to	O
the	O
currently	O
used	O
medical	O
treatment.	O
There	O
was	O
a	O
significant	O
40%	O
improvement	O
in	O
the	O
dyskinesia	Disease
score	O
without	O
increase	O
of	O
parkinsonian	Disease
	O
motor	Disease
disability	Disease
.	O
Ballistic	O
and	O
choreic	O
dyskinesia	Disease
were	O
markedly	O
ameliorated,	O
whereas	O
dystonia	Disease
was	O
not.	O
This	O
study	O
suggests	O
that	O
administration	O
of	O
low	O
doses	O
of	O
beta-blockers	O
may	O
improve	O
levodopa	Chemical
-induced	O
ballistic	O
and	O
choreic	O
dyskinesia	Disease
in	O
PD	Disease

Morphological	O
features	O
of	O
encephalopathy	Disease
after	O
chronic	O
administration	O
of	O
the	O
antiepileptic	O
drug	O
valproate	Chemical
to	O
rats.	O
A	O
transmission	O
electron	O
microscopic	O
study	O
of	O
capillaries	O
in	O
the	O
cerebellar	O
cortex.	O
Long-term	O
intragastric	O
application	O
of	O
the	O
antiepileptic	O
drug	O
sodium	Chemical
valproate	Chemical
(Vupral	O
"Polfa")	O
at	O
the	O
effective	O
dose	O
of	O
200	O
mg/kg	O
b.	O
w.	O
once	O
daily	O
to	O
rats	O
for	O
1,	O
3,	O
6,	O
9	O
and	O
12	O
months	O
revealed	O
neurological	Disease
disorders	Disease
indicating	O
cerebellum	Disease
damage	Disease
("	O
valproate	Chemical
	O
encephalopathy	Disease
").	O
The	O
first	O
ultrastructural	O
changes	O
in	O
structural	O
elements	O
of	O
the	O
blood-brain-barrier	O
(BBB)	O
in	O
the	O
cerebellar	O
cortex	O
were	O
detectable	O
after	O
3	O
months	O
of	O
the	O
experiment.	O
They	O
became	O
more	O
severe	O
in	O
the	O
later	O
months	O
of	O
the	O
experiment,	O
and	O
were	O
most	O
severe	O
after	O
12	O
months,	O
located	O
mainly	O
in	O
the	O
molecular	O
layer	O
of	O
the	O
cerebellar	O
cortex.	O
Lesions	O
of	O
the	O
capillary	O
included	O
necrosis	Disease
of	O
endothelial	O
cells.	O
Organelles	O
of	O
these	O
cells,	O
in	O
particular	O
the	O
mitochondria	O
(increased	O
number	O
and	O
size,	O
distinct	O
degeneration	O
of	O
their	O
matrix	O
and	O
cristae)	O
and	O
Golgi	O
apparatus	O
were	O
altered.	O
Reduced	O
size	O
of	O
capillary	O
lumen	O
and	O
occlusion	O
were	O
caused	O
by	O
swollen	O
endothelial	O
cells	O
which	O
had	O
luminal	Chemical
protrusions	O
and	O
swollen	O
microvilli.	O
Pressure	O
on	O
the	O
vessel	O
wall	O
was	O
produced	O
by	O
enlarged	O
perivascular	O
astrocytic	O
processes.	O
Fragments	O
of	O
necrotic	Disease
endothelial	O
cells	O
were	O
in	O
the	O
vascular	O
lumens	O
and	O
in	O
these	O
there	O
was	O
loosening	O
and	O
breaking	O
of	O
tight	O
cellular	O
junctions.	O
Damage	O
to	O
the	O
vascular	O
basement	O
lamina	O
was	O
also	O
observed.	O
Damage	O
to	O
the	O
capillary	O
was	O
accompanied	O
by	O
marked	O
damage	O
to	O
neuroglial	O
cells,	O
mainly	O
to	O
perivascular	O
processes	O
of	O
astrocytes.	O
The	O
proliferation	O
of	O
astrocytes	O
(Bergmann's	O
in	O
particular)	O
and	O
occasionally	O
of	O
oligodendrocytes	O
was	O
found.	O
Alterations	O
in	O
the	O
structural	O
elements	O
of	O
the	O
BBB	O
coexisted	O
with	O
marked	O
lesions	O
of	O
neurons	O
of	O
the	O
cerebellum	O
(Purkinje	O
cells	O
are	O
earliest).	O
In	O
electron	O
micrographs	O
both	O
luminal	Chemical
and	O
antiluminal	O
sides	O
of	O
the	O
BBB	O
of	O
the	O
cerebellar	O
cortex	O
had	O
similar	O
lesions.	O
The	O
possible	O
influence	O
of	O
the	O
hepatic	Disease
damage	Disease
,	O
mainly	O
hyperammonemia	Disease
,	O
upon	O
the	O
development	O
of	O
valproate	Chemical
	O
encephalopathy	Disease

Macula	O
toxicity	Disease
after	O
intravitreal	O
amikacin	Chemical
.	O
BACKGROUND:	O
Although	O
intravitreal	O
aminoglycosides	Chemical
have	O
substantially	O
improved	O
visual	O
prognosis	O
in	O
endophthalmitis	Disease
,	O
macular	O
infarction	Disease
may	O
impair	O
full	O
visual	O
recovery.	O
METHODS:	O
We	O
present	O
a	O
case	O
of	O
presumed	O
amikacin	Chemical
	O
retinal	Disease
toxicity	Disease
following	O
treatment	O
with	O
amikacin	Chemical
and	O
vancomycin	Chemical
for	O
alpha-haemolytic	O
streptococcal	Disease
endophthalmitis	Disease
.	O
RESULTS:	O
Endophthalmitis	Disease
resolved	O
with	O
improvement	O
in	O
visual	O
acuity	O
to	O
6/24	O
at	O
three	O
months.	O
Fundus	O
fluorescein	Chemical
angiography	O
confirmed	O
macular	O
capillary	O
closure	O
and	O
telangiectasis	Disease
.	O
CONCLUSIONS:	O
Currently	O
accepted	O
intravitreal	O
antibiotic	O
regimens	O
may	O
cause	O
retinal	Disease
toxicity	Disease
and	O
macular	O
ischaemia	Disease
.	O
Treatment	O
strategies	O
aimed	O
at	O
avoiding	O
retinal	Disease
toxicity	Disease

Iatrogenically	O
induced	O
intractable	O
atrioventricular	Disease
reentrant	Disease
tachycardia	Disease
after	O
verapamil	Chemical
and	O
catheter	O
ablation	O
in	O
a	O
patient	O
with	O
Wolff-Parkinson-White	Disease
syndrome	Disease
and	O
idiopathic	Disease
dilated	Disease
cardiomyopathy	Disease
.	O
In	O
a	O
patient	O
with	O
WPW	Disease
syndrome	Disease
and	O
idiopathic	Disease
dilated	Disease
cardiomyopathy	Disease
,	O
intractable	O
atrioventricular	Disease
reentrant	Disease
tachycardia	Disease
(	O
AVRT	Disease
)	O
was	O
iatrogenically	O
induced.	O
QRS	O
without	O
preexcitation,	O
caused	O
by	O
junctional	O
escape	O
beats	O
after	O
verapamil	Chemical
or	O
unidirectional	O
antegrade	O
block	O
of	O
accessory	O
pathway	O
after	O
catheter	O
ablation,	O
established	O
frequent	O
AVRT	Disease

Epidemic	O
of	O
liver	Disease
disease	Disease
caused	O
by	O
hydrochlorofluorocarbons	Chemical
used	O
as	O
ozone	Chemical
-sparing	O
substitutes	O
of	O
chlorofluorocarbons	Chemical
.	O
BACKGROUND:	O
Hydrochlorofluorocarbons	Chemical
(	O
HCFCs	Chemical
)	O
are	O
used	O
increasingly	O
in	O
industry	O
as	O
substitutes	O
for	O
ozone	Chemical
-depleting	O
chlorofluorocarbons	Chemical
(	O
CFCs	Chemical
).	O
Limited	O
studies	O
in	O
animals	O
indicate	O
potential	O
hepatotoxicity	Disease
of	O
some	O
of	O
these	O
compounds.	O
We	O
investigated	O
an	O
epidemic	O
of	O
liver	Disease
disease	Disease
in	O
nine	O
industrial	O
workers	O
who	O
had	O
had	O
repeated	O
accidental	O
exposure	O
to	O
a	O
mixture	O
of	O
1,1-dichloro-2,2,2-trifluoroethane	Chemical
(	O
HCFC	Chemical
123	Chemical
)	O
and	O
1-chloro-1,2,2,2-tetrafluoroethane	Chemical
(	O
HCFC	Chemical
124	Chemical
).	O
All	O
nine	O
exposed	O
workers	O
were	O
affected	O
to	O
various	O
degrees.	O
Both	O
compounds	O
are	O
metabolised	O
in	O
the	O
same	O
way	O
as	O
1-bromo-1-chloro-2,2,2-trifluoroethane	Chemical
(	O
halothane	Chemical
)	O
to	O
form	O
reactive	O
trifluoroacetyl	Chemical
halide	O
intermediates,	O
which	O
have	O
been	O
implicated	O
in	O
the	O
hepatotoxicity	Disease
of	O
halothane	Chemical
.	O
We	O
aimed	O
to	O
test	O
whether	O
HCFCs	Chemical
123	Chemical
and	Chemical
124	Chemical
can	O
result	O
in	O
serious	O
liver	Disease
disease	Disease
.	O
METHODS:	O
For	O
one	O
severely	O
affected	O
worker	O
liver	O
biopsy	O
and	O
immunohistochemical	O
stainings	O
for	O
the	O
presence	O
of	O
trifluoroacetyl	Chemical
protein	O
adducts	O
were	O
done.	O
The	O
serum	O
of	O
six	O
affected	O
workers	O
and	O
five	O
controls	O
was	O
tested	O
for	O
autoantibodies	O
that	O
react	O
with	O
human	O
liver	O
cytochrome-P450	O
2E1	O
(P450	O
2E1)	O
and	O
P58	O
protein	O
disulphide	O
isomerase	O
isoform	O
(P58).	O
FINDINGS:	O
The	O
liver	O
biopsy	O
sample	O
showed	O
hepatocellular	O
necrosis	Disease
which	O
was	O
prominent	O
in	O
perivenular	O
zone	O
three	O
and	O
extended	O
focally	O
from	O
portal	O
tracts	O
to	O
portal	O
tracts	O
and	O
centrilobular	O
areas	O
(bridging	O
necrosis	Disease
).	O
Trifluoroacetyl	Chemical
-adducted	O
proteins	O
were	O
detected	O
in	O
surviving	O
hepatocytes.	O
Autoantibodies	O
against	O
P450	O
2E1	O
or	O
P58,	O
previously	O
associated	O
with	O
halothane	Disease
hepatitis	Disease
,	O
were	O
detected	O
in	O
the	O
serum	O
of	O
five	O
affected	O
workers.	O
INTERPRETATION:	O
Repeated	O
exposure	O
of	O
human	O
beings	O
to	O
HCFCs	Chemical
123	Chemical
and	Chemical
124	Chemical
can	O
result	O
in	O
serious	O
liver	Disease
injury	Disease
in	O
a	O
large	O
proportion	O
of	O
the	O
exposed	O
population.	O
Although	O
the	O
exact	O
mechanism	O
of	O
hepatotoxicity	Disease
of	O
these	O
agents	O
is	O
not	O
known,	O
the	O
results	O
suggest	O
that	O
trifluoroacetyl	Chemical

The	O
effect	O
of	O
different	O
anaesthetic	O
agents	O
in	O
hearing	Disease
loss	Disease
following	O
spinal	O
anaesthesia.	O
The	O
cause	O
of	O
hearing	Disease
loss	Disease
after	O
spinal	O
anaesthesia	O
is	O
unknown.	O
Up	O
until	O
now,	O
the	O
only	O
factor	O
studied	O
has	O
been	O
the	O
effect	O
of	O
the	O
diameter	O
of	O
the	O
spinal	O
needle	O
on	O
post-operative	O
sensorineural	Disease
hearing	Disease
loss	Disease
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
this	O
hearing	Disease
loss	Disease
and	O
to	O
investigate	O
other	O
factors	O
influencing	O
the	O
degree	O
of	O
hearing	Disease
loss	Disease
.	O
Two	O
groups	O
of	O
22	O
similar	O
patients	O
were	O
studied:	O
one	O
group	O
received	O
6	O
mL	O
prilocaine	Chemical
2%;	O
and	O
the	O
other	O
received	O
3	O
mL	O
bupivacaine	Chemical
0.5%.	O
Patients	O
given	O
prilocaine	Chemical
were	O
more	O
likely	O
to	O
develop	O
hearing	Disease
loss	Disease
(10	O
out	O
of	O
22)	O
than	O
those	O
given	O
bupivacaine	Chemical
(4	O
out	O
of	O
22)	O
(P	O
<	O
0.05).	O
The	O
average	O
hearing	Disease
loss	Disease
for	O
speech	O
frequencies	O
was	O
about	O
10	O
dB	O
after	O
prilocaine	Chemical
and	O
15	O
dB	O
after	O
bupivacaine	Chemical
.	O
None	O
of	O
the	O
patients	O
complained	O
of	O
subjective	O
hearing	Disease
loss	Disease

A	O
transient	O
neurological	Disease
deficit	Disease
following	O
intrathecal	O
injection	O
of	O
1%	O
hyperbaric	O
bupivacaine	Chemical
for	O
unilateral	O
spinal	O
anaesthesia.	O
We	O
describe	O
a	O
case	O
of	O
transient	O
neurological	Disease
deficit	Disease
that	O
occurred	O
after	O
unilateral	O
spinal	O
anaesthesia	O
with	O
8	O
mg	O
of	O
1%	O
hyperbaric	O
bupivacaine	Chemical
slowly	O
injected	O
through	O
a	O
25-gauge	O
pencil-point	O
spinal	O
needle.	O
The	O
surgery	O
and	O
anaesthesia	O
were	O
uneventful,	O
but	O
3	O
days	O
after	O
surgery,	O
the	O
patient	O
reported	O
an	O
area	O
of	O
hypoaesthesia	O
over	O
L3-L4	O
dermatomes	O
of	O
the	O
leg	O
which	O
had	O
been	O
operated	O
on	O
(	O
loss	Disease
of	Disease
pinprick	Disease
sensation	Disease
)	O
without	O
reduction	O
in	O
muscular	O
strength.	O
Sensation	O
in	O
this	O
area	O
returned	O
to	O
normal	O
over	O
the	O
following	O
2	O
weeks.	O
Prospective	O
multicentre	O
studies	O
with	O
a	O
large	O
population	O
and	O
a	O
long	O
follow-up	O
should	O
be	O
performed	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
of	O
this	O
unusual	O
side	O
effect.	O
However,	O
we	O
suggest	O
that	O
a	O
low	O
solution	O
concentration	O
should	O
be	O
preferred	O
for	O
unilateral	O
spinal	O
anaesthesia	O
with	O
a	O
hyperbaric	O
anaesthetic	O
solution	O
(if	O
pencil-point	O
needle	O
and	O
slow	O
injection	O
rate	O
are	O
employed),	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
a	O
localized	O
high	O
peak	O
anaesthetic	O
concentration,	O
which	O
might	O
lead	O
to	O
a	O
transient	O
neurological	Disease
deficit	Disease

Pethidine	Chemical
-associated	O
seizure	Disease
in	O
a	O
healthy	O
adolescent	O
receiving	O
pethidine	Chemical
for	O
postoperative	Disease
pain	Disease
control.	O
A	O
healthy	O
17-year-old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	Chemical
via	O
a	O
patient-controlled	O
analgesia	O
(PCA)	O
pump	O
for	O
management	O
of	O
postoperative	Disease
pain	Disease
control.	O
Twenty-three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self-limited	O
seizure	Disease
.	O
Both	O
plasma	O
pethidine	Chemical
and	O
norpethidine	Chemical
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	O
excitation.	O
No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	Disease
were	O
identified.	O
This	O
method	O
allowed	O
frequent	O
self-dosing	O
of	O
pethidine	Chemical
at	O
short	O
time	O
intervals	O
and	O
rapid	O
accumulation	O
of	O
pethidine	Chemical
and	O
norpethidine	Chemical
.	O
The	O
routine	O
use	O
of	O
pethidine	Chemical

Drug-associated	O
acute-onset	O
vanishing	Disease
bile	Disease
duct	Disease
and	O
Stevens-Johnson	Disease
syndromes	Disease
in	O
a	O
child.	O
Acute	O
vanishing	Disease
bile	Disease
duct	Disease
syndrome	O
is	O
a	O
rare	O
but	O
established	O
cause	O
of	O
progressive	O
cholestasis	Disease
in	O
adults,	O
is	O
most	O
often	O
drug	O
or	O
toxin	O
related,	O
and	O
is	O
of	O
unknown	O
pathogenesis.	O
It	O
has	O
not	O
been	O
reported	O
previously	O
in	O
children.	O
Stevens-Johnson	Disease
syndrome	Disease
is	O
a	O
well-recognized	O
immune	O
complex-mediated	O
hypersensitivity	Disease
reaction	O
that	O
affects	O
all	O
age	O
groups,	O
is	O
drug	O
or	O
infection	Disease
induced,	O
and	O
has	O
classic	O
systemic,	O
mucosal,	O
and	O
dermatologic	O
manifestations.	O
A	O
previously	O
healthy	O
child	O
who	O
developed	O
acute,	O
severe,	O
rapidly	O
progressive	O
vanishing	Disease
bile	Disease
duct	Disease
syndrome	Disease
shortly	O
after	O
Stevens-Johnson	Disease
syndrome	Disease
is	O
described;	O
this	O
was	O
temporally	O
associated	O
with	O
ibuprofen	Chemical
use.	O
Despite	O
therapy	O
with	O
ursodeoxycholic	Chemical
acid	Chemical
,	O
prednisone	Chemical
,	O
and	O
then	O
tacrolimus	Chemical
,	O
her	O
cholestatic	Disease
disease	Disease
was	O
unrelenting,	O
with	O
cirrhosis	Disease
shown	O
by	O
biopsy	O
6	O
months	O
after	O
presentation.	O
This	O
case	O
documents	O
acute	O
drug-related	O
vanishing	Disease
bile	Disease
duct	Disease
syndrome	Disease
in	O
the	O
pediatric	O
age	O
group	O
and	O
suggests	O
shared	O
immune	O
mechanisms	O
in	O
the	O
pathogenesis	O
of	O
both	O
Stevens-Johnson	Disease
syndrome	Disease
and	O
vanishing	Disease
bile	Disease
duct	Disease
syndrome	Disease

High	O
incidence	O
of	O
primary	Disease
pulmonary	Disease
hypertension	Disease
associated	O
with	O
appetite	Chemical
suppressants	Chemical
in	O
Belgium.	O
Primary	Disease
pulmonary	Disease
hypertension	Disease
is	O
a	O
rare,	O
progressive	O
and	O
incurable	O
disease,	O
which	O
has	O
been	O
associated	O
with	O
the	O
intake	O
of	O
appetite	Chemical
suppressant	Chemical
drugs.	O
The	O
importance	O
of	O
this	O
association	O
was	O
evaluated	O
in	O
Belgium	O
while	O
this	O
country	O
still	O
had	O
no	O
restriction	O
on	O
the	O
prescription	O
of	O
appetite	Chemical
suppressants	Chemical
.	O
Thirty-five	O
patients	O
with	O
primary	Disease
pulmonary	Disease
hypertension	Disease
and	O
85	O
matched	O
controls	O
were	O
recruited	O
over	O
32	O
months	O
(1992-1994)	O
in	O
Belgium.	O
Exposure	O
to	O
appetite-suppressants	Chemical
was	O
assessed	O
on	O
the	O
basis	O
of	O
hospital	O
records	O
and	O
standardized	O
interview.	O
Twenty-three	O
of	O
the	O
patients	O
had	O
previously	O
taken	O
appetite	Chemical
suppressants	Chemical
,	O
mainly	O
fenfluramines	Chemical
,	O
as	O
compared	O
with	O
only	O
5	O
of	O
the	O
controls	O
(66	O
versus	O
6%,	O
p<0.0001).	O
Five	O
patients	O
died	O
before	O
the	O
interview,	O
all	O
of	O
them	O
had	O
taken	O
appetite	Chemical
suppressants	Chemical
.	O
In	O
8	O
patients	O
the	O
diagnosis	O
of	O
primary	Disease
pulmonary	Disease
hypertension	Disease
was	O
uncertain,	O
5	O
of	O
them	O
had	O
taken	O
appetite	Chemical
suppressants	Chemical
.	O
The	O
patients	O
who	O
had	O
been	O
exposed	O
to	O
appetite	Chemical
suppressants	Chemical
tended	O
to	O
be	O
on	O
average	O
more	O
severely	O
ill,	O
and	O
to	O
have	O
a	O
shorter	O
median	O
delay	O
between	O
onset	O
of	O
symptoms	O
and	O
diagnosis.	O
A	O
policy	O
of	O
unrestricted	O
prescription	O
of	O
appetite	Chemical
suppressants	Chemical
may	O
lead	O
to	O
a	O
high	O
incidence	O
of	O
associated	O
primary	Disease
pulmonary	Disease
hypertension	Disease
.	O
Intake	O
of	O
appetite	Chemical
suppressants	Chemical

Choreoathetoid	Disease
movements	Disease
associated	O
with	O
rapid	O
adjustment	O
to	O
methadone	Chemical
.	O
Choreatiform	Disease
hyperkinesias	Disease
are	O
known	O
to	O
be	O
occasional	O
movement	Disease
abnormalities	Disease
during	O
intoxications	O
with	O
cocaine	Chemical
but	O
not	O
opiates.	O
This	O
is	O
a	O
case	O
report	O
of	O
euphoria	O
and	O
choreoathetoid	Disease
movements	Disease
both	O
transiently	O
induced	O
by	O
rapid	O
adjustment	O
to	O
the	O
selective	O
mu-opioid	O
receptor	O
agonist	O
methadone	Chemical
in	O
an	O
inpatient	O
previously	O
abusing	O
heroine	Chemical
and	O
cocaine	Chemical

Cocaine	Chemical
-induced	O
mood	Disease
disorder	Disease
:	O
prevalence	O
rates	O
and	O
psychiatric	Disease
symptoms	O
in	O
an	O
outpatient	O
cocaine	Chemical
-dependent	O
sample.	O
This	O
paper	O
attempts	O
to	O
examine	O
and	O
compare	O
prevalence	O
rates	O
and	O
symptom	O
patterns	O
of	O
DSM	O
substance-induced	O
and	O
other	O
mood	Disease
disorders	Disease
.	O
243	O
cocaine	Chemical
-dependent	O
outpatients	O
with	O
cocaine	Chemical
-induced	O
mood	Disease
disorder	Disease
(	O
CIMD	Disease
),	O
other	O
mood	Disease
disorders	Disease
,	O
or	O
no	O
mood	Disease
disorder	Disease
were	O
compared	O
on	O
measures	O
of	O
psychiatric	Disease
symptoms.	O
The	O
prevalence	O
rate	O
for	O
CIMD	Disease
was	O
12%	O
at	O
baseline.	O
Introduction	O
of	O
the	O
DSM-IV	O
diagnosis	O
of	O
CIMD	Disease
did	O
not	O
substantially	O
affect	O
rates	O
of	O
the	O
other	O
depressive	Disease
disorders	Disease
.	O
Patients	O
with	O
CIMD	Disease
had	O
symptom	O
severity	O
levels	O
between	O
those	O
of	O
patients	O
with	O
and	O
without	O
a	O
mood	Disease
disorder	Disease
.	O
These	O
findings	O
suggest	O
some	O
validity	O
for	O
the	O
new	O
DSM-IV	O
diagnosis	O
of	O
CIMD	Disease

Hemolysis	Disease
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	Chemical
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure.	O
Tamoxifen	Chemical
(	O
TAM	Chemical
),	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	Disease
cancer	Disease
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	Disease
anemia	Disease
.	O
This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	Chemical
on	O
isolated	O
human	O
erythrocytes,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM	Chemical
-induced	O
hemolytic	Disease
anemia	Disease
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms.	O
TAM	Chemical
induces	O
hemolysis	Disease
of	O
erythrocytes	O
as	O
a	O
function	O
of	O
concentration.	O
The	O
extension	O
of	O
hemolysis	Disease
is	O
variable	O
with	O
erythrocyte	O
samples,	O
but	O
12.5	O
microM	O
TAM	Chemical
induces	O
total	O
hemolysis	Disease
of	O
all	O
tested	O
suspensions.	O
Despite	O
inducing	O
extensive	O
erythrocyte	O
lysis,	O
TAM	Chemical
does	O
not	O
shift	O
the	O
osmotic	O
fragility	O
curves	O
of	O
erythrocytes.	O
The	O
hemolytic	Disease
effect	O
of	O
TAM	Chemical
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha-tocopherol	Chemical
(	O
alpha-T	Chemical
)	O
and	O
alpha-tocopherol	Chemical
acetate	Chemical
(	O
alpha-TAc	Chemical
)	O
(inactivated	O
functional	O
hydroxyl	Chemical
)	O
indicating	O
that	O
TAM	Chemical
-induced	O
hemolysis	Disease
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage.	O
This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	Chemical
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	Chemical
-induced	O
hemolysis	Disease
.	O
Furthermore,	O
it	O
was	O
observed	O
that	O
TAM	Chemical
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	Chemical
,	O
thus	O
ruling	O
out	O
TAM	Chemical
-induced	O
cell	O
oxidative	O
stress.	O
Hemolysis	Disease
caused	O
by	O
TAM	Chemical
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K	Chemical
(+)	O
from	O
the	O
cells,	O
also	O
excluding	O
a	O
colloid-osmotic	O
type	O
mechanism	O
of	O
hemolysis	Disease
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves.	O
However,	O
TAM	Chemical
induces	O
release	O
of	O
peripheral	O
proteins	O
of	O
membrane-cytoskeleton	O
and	O
cytosol	O
proteins	O
essentially	O
bound	O
to	O
band	O
3.	O
Either	O
alpha-T	Chemical
or	O
alpha-TAc	Chemical
increases	O
membrane	O
packing	O
and	O
prevents	O
TAM	Chemical
partition	O
into	O
model	O
membranes.	O
These	O
effects	O
suggest	O
that	O
the	O
protection	O
from	O
hemolysis	Disease
by	O
tocopherols	Chemical
is	O
related	O
to	O
a	O
decreased	O
TAM	Chemical
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided.	O
Therefore,	O
TAM	Chemical
-induced	O
hemolysis	Disease
results	O
from	O
a	O
structural	O
perturbation	O
of	O
red	O
cell	O
membrane,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	O
by	O
its	O
high	O
partition	O
in	O
the	O
membrane.	O
These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	O
by	O
TAM	Chemical
,	O
resulting	O
in	O
hemolytic	Disease
anemia	Disease
.	O
Additionally,	O
since	O
membrane	O
leakage	O
is	O
a	O
final	O
stage	O
of	O
cytotoxicity,	O
the	O
disruption	O
of	O
the	O
structural	O
characteristics	O
of	O
biomembranes	O
by	O
TAM	Chemical

Changes	O
of	O
sodium	Chemical
and	O
ATP	Chemical
affinities	O
of	O
the	O
cardiac	O
(	O
Na	Chemical
,	O
K	Chemical
)-ATPase	O
during	O
and	O
after	O
nitric	Chemical
oxide	Chemical
deficient	O
hypertension	Disease
.	O
In	O
the	O
cardiovascular	O
system,	O
NO	Chemical
is	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
functions.	O
Inhibition	O
of	O
NO	Chemical
synthesis	O
induces	O
sustained	O
hypertension	Disease
.	O
In	O
several	O
models	O
of	O
hypertension	Disease
,	O
elevation	O
of	O
intracellular	O
sodium	Chemical
level	O
was	O
documented	O
in	O
cardiac	O
tissue.	O
To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	Chemical
+,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	Chemical
,	O
K	Chemical
)-ATPase	O
to	O
NO	Chemical
-deficient	O
hypertension	Disease
induced	O
in	O
rats	O
by	O
NO	Chemical
-synthase	O
inhibition	O
with	O
40	O
mg/kg/day	O
N(G)-nitro-L-arginine	Chemical
methyl	Chemical
ester	Chemical
(	O
L-NAME	Chemical
)	O
for	O
4	O
four	O
weeks.	O
After	O
4-week	O
administration	O
of	O
L-NAME	Chemical
,	O
the	O
systolic	O
blood	O
pressure	O
(SBP)	O
increased	O
by	O
36%.	O
Two	O
weeks	O
after	O
terminating	O
the	O
treatment,	O
the	O
SBP	O
recovered	O
to	O
control	O
value.	O
When	O
activating	O
the	O
(	O
Na	Chemical
,	O
K	Chemical
)-ATPase	O
with	O
its	O
substrate	O
ATP	Chemical
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	Chemical
-deficient	O
rats.	O
During	O
activation	O
with	O
Na	Chemical
+,	O
the	O
Vmax	O
remained	O
unchanged,	O
however	O
the	O
K	Chemical
(	O
Na	Chemical
)	O
increased	O
by	O
50%,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	Chemical
+-binding	O
site	O
in	O
NO	Chemical
-deficient	O
rats.	O
After	O
recovery	O
from	O
hypertension	Disease
,	O
the	O
activity	O
of	O
(	O
Na	Chemical
,	O
K	Chemical
)-ATPase	O
increased,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	Chemical
-binding	O
site,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	Chemical
.	O
The	O
K	Chemical
(	O
Na	Chemical
)	O
value	O
for	O
Na	Chemical
+	O
returned	O
to	O
control	O
value.	O
Inhibition	O
of	O
NO	Chemical
-synthase	O
induced	O
a	O
reversible	O
hypertension	Disease
accompanied	O
by	O
depressed	Disease
	O
Na	Chemical
+-extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	Chemical
+-binding	O
properties	O
of	O
the	O
(	O
Na	Chemical
,	O
K	Chemical
)-ATPase.	O
After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values,	O
the	O
extrusion	O
of	O
Na	Chemical
+	O
from	O
cardiac	O
cells	O
was	O
normalized,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	Chemical
,	O
K	Chemical

Effects	O
of	O
long-term	O
pretreatment	O
with	O
isoproterenol	Chemical
on	O
bromocriptine	Chemical
-induced	O
tachycardia	Disease
in	O
conscious	O
rats.	O
It	O
has	O
been	O
shown	O
that	O
bromocriptine	Chemical
-induced	O
tachycardia	Disease
,	O
which	O
persisted	O
after	O
adrenalectomy,	O
is	O
(i)	O
mediated	O
by	O
central	O
dopamine	Chemical
D2	O
receptor	O
activation	O
and	O
(ii)	O
reduced	O
by	O
5-day	O
isoproterenol	Chemical
pretreatment,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart.	O
This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	O
with	O
isoproterenol	Chemical
could	O
abolish	O
bromocriptine	Chemical
-induced	O
tachycardia	Disease
in	O
conscious	O
rats.	O
Isoproterenol	Chemical
pretreatment	O
for	O
15	O
days	O
caused	O
cardiac	Disease
hypertrophy	Disease
without	O
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate.	O
In	O
control	O
rats,	O
intravenous	O
bromocriptine	Chemical
(150	O
microg/kg)	O
induced	O
significant	O
hypotension	Disease
and	O
tachycardia	Disease
.	O
Bromocriptine	Chemical
-induced	O
hypotension	Disease
was	O
unaffected	O
by	O
isoproterenol	Chemical
pretreatment,	O
while	O
tachycardia	Disease
was	O
reversed	O
to	O
significant	O
bradycardia	Disease
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i.v.	O
domperidone	Chemical
(0.5	O
mg/kg).	O
Neither	O
cardiac	O
vagal	O
nor	O
sympathetic	O
tone	O
was	O
altered	O
by	O
isoproterenol	Chemical
pretreatment.	O
In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	Chemical
-pretreated	O
rats,	O
the	O
isoproterenol	Chemical
-induced	O
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced,	O
compared	O
with	O
saline-pretreated	O
rats	O
(the	O
EC50	O
of	O
the	O
isoproterenol	Chemical
-induced	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22-fold).	O
These	O
results	O
show	O
that	O
15-day	O
isoproterenol	Chemical
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	Chemical
-induced	O
tachycardia	Disease
to	O
bradycardia	Disease
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta-adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart.	O
They	O
suggest	O
that,	O
in	O
normal	O
conscious	O
rats,	O
the	O
central	O
tachycardia	Disease
of	O
bromocriptine	Chemical
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	Disease
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	Chemical

A	O
developmental	O
analysis	O
of	O
clonidine	Chemical
's	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
in	O
infant	O
rats.	O
Under	O
controlled	O
conditions,	O
infant	O
rats	O
emit	O
ultrasonic	O
vocalizations	O
during	O
extreme	O
cold	O
exposure	O
and	O
after	O
administration	O
of	O
the	O
alpha(2)	O
adrenoceptor	O
agonist,	O
clonidine	Chemical
.	O
Previous	O
investigations	O
have	O
determined	O
that,	O
in	O
response	O
to	O
clonidine	Chemical
,	O
ultrasound	O
production	O
increases	O
through	O
the	O
2nd-week	O
postpartum	O
and	O
decreases	O
thereafter.	O
Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern,	O
and	O
given	O
that	O
clonidine	Chemical
induces	O
sympathetic	O
withdrawal	O
and	O
bradycardia	Disease
,	O
we	O
hypothesized	O
that	O
clonidine	Chemical
's	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other.	O
Therefore,	O
in	O
the	O
present	O
experiment,	O
the	O
effects	O
of	O
clonidine	Chemical
administration	O
(0.5	O
mg/kg)	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
were	O
examined	O
in	O
2-,	O
8-,	O
15-,	O
and	O
20-day-old	O
rats.	O
Age-related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	O
in	O
cardiovascular	O
variables,	O
including	O
baseline	O
cardiac	O
rate	O
and	O
clonidine	Chemical
-induced	O
bradycardia	Disease
.	O
This	O
experiment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypothesis	O
that	O
ultrasound	O
production	O
is	O
the	O
acoustic	O
by-product	O
of	O
a	O
physiological	O
maneuver	O
that	O
compensates	O
for	O
clonidine	Chemical

Differential	O
effects	O
of	O
systemically	O
administered	O
ketamine	Chemical
and	O
lidocaine	Chemical
on	O
dynamic	O
and	O
static	O
hyperalgesia	Disease
induced	O
by	O
intradermal	O
capsaicin	Chemical
in	O
humans.	O
We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	Chemical
and	O
lidocaine	Chemical
on	O
brush-evoked	O
(dynamic)	O
pain	Disease
and	O
punctate-evoked	O
(static)	O
hyperalgesia	Disease
induced	O
by	O
capsaicin	Chemical
.	O
In	O
a	O
randomized,	O
double-blind,	O
placebo-controlled,	O
crossover	O
study,	O
we	O
studied	O
12	O
volunteers	O
in	O
three	O
experiments.	O
Capsaicin	Chemical
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i.v.	O
infusion	O
of	O
ketamine	Chemical
(bolus	O
0.1	O
mg	O
kg-1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg-1	O
min-1),	O
lidocaine	Chemical
5	O
mg	O
kg-1	O
or	O
saline	O
for	O
50	O
min.	O
Infusion	O
started	O
15	O
min	O
after	O
injection	O
of	O
capsaicin	Chemical
.	O
The	O
following	O
were	O
measured:	O
spontaneous	O
pain	Disease
,	O
pain	Disease
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	O
(VAS),	O
and	O
areas	O
of	O
brush-evoked	O
and	O
punctate-evoked	O
hyperalgesia	Disease
.	O
Ketamine	Chemical
reduced	O
both	O
the	O
area	O
of	O
brush-evoked	O
and	O
punctate-evoked	O
hyperalgesia	Disease
significantly	O
and	O
it	O
tended	O
to	O
reduce	O
brush-evoked	O
pain	Disease
.	O
Lidocaine	Chemical
reduced	O
the	O
area	O
of	O
punctate-evoked	O
hyperalgesia	Disease
significantly.	O
It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	O
pain	Disease
but	O
had	O
no	O
effect	O
on	O
evoked	O
pain	Disease
.	O
The	O
differential	O
effects	O
of	O
ketamine	Chemical
and	O
lidocaine	Chemical
on	O
static	O
and	O
dynamic	O
hyperalgesia	Disease
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	Disease

Cyclosporine	Chemical
and	O
tacrolimus	Chemical
-associated	O
thrombotic	Disease
microangiopathy	Disease
.	O
The	O
development	O
of	O
thrombotic	Disease
microangiopathy	Disease
(	O
TMA	Disease
)	O
associated	O
with	O
the	O
use	O
of	O
cyclosporine	Chemical
has	O
been	O
well	O
documented.	O
Treatments	O
have	O
included	O
discontinuation	O
or	O
reduction	O
of	O
cyclosporine	Chemical
dose	O
with	O
or	O
without	O
concurrent	O
plasma	O
exchange,	O
plasma	O
infusion,	O
anticoagulation,	O
and	O
intravenous	O
immunoglobulin	O
G	O
infusion.	O
However,	O
for	O
recipients	O
of	O
organ	O
transplantation,	O
removing	O
the	O
inciting	O
agent	O
is	O
not	O
without	O
the	O
attendant	O
risk	O
of	O
precipitating	O
acute	O
rejection	O
and	O
graft	O
loss.	O
The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
tacrolimus	Chemical
as	O
a	O
potent	O
immunosuppressive	O
agent	O
with	O
mechanisms	O
of	O
action	O
virtually	O
identical	O
to	O
those	O
of	O
cyclosporine	Chemical
.	O
As	O
a	O
result,	O
switching	O
to	O
tacrolimus	Chemical
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclosporine	Chemical
-induced	O
TMA	Disease
.	O
With	O
the	O
more	O
widespread	O
application	O
of	O
tacrolimus	Chemical
in	O
organ	O
transplantation,	O
tacrolimus	Chemical
-associated	O
TMA	Disease
has	O
also	O
been	O
recognized.	O
However,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	O
of	O
TMA	Disease
in	O
patients	O
exposed	O
sequentially	O
to	O
cyclosporine	Chemical
and	O
tacrolimus	Chemical
is	O
limited.	O
We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine	Chemical
-induced	O
TMA	Disease
that	O
responded	O
to	O
the	O
withdrawal	O
of	O
cyclosporine	Chemical
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy.	O
Introduction	O
of	O
tacrolimus	Chemical
as	O
an	O
alternative	O
immunosuppressive	O
agent	O
resulted	O
in	O
the	O
recurrence	O
of	O
TMA	Disease
and	O
the	O
subsequent	O
loss	O
of	O
the	O
renal	O
allograft.	O
Patients	O
who	O
are	O
switched	O
from	O
cyclosporine	Chemical
to	O
tacrolimus	Chemical
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
recurrent	O
TMA	Disease

Repeated	O
transient	O
anuria	Disease
following	O
losartan	Chemical
administration	O
in	O
a	O
patient	O
with	O
a	O
solitary	O
kidney.	O
We	O
report	O
the	O
case	O
of	O
a	O
70-year-old	O
hypertensive	Disease
man	O
with	O
a	O
solitary	O
kidney	O
and	O
chronic	Disease
renal	Disease
insufficiency	Disease
who	O
developed	O
two	O
episodes	O
of	O
transient	O
anuria	Disease
after	O
losartan	Chemical
administration.	O
He	O
was	O
hospitalized	O
for	O
a	O
myocardial	Disease
infarction	Disease
with	O
pulmonary	Disease
edema	Disease
,	O
treated	O
with	O
high-dose	O
diuretics.	O
Due	O
to	O
severe	O
systolic	Disease
dysfunction	Disease
	O
losartan	Chemical
was	O
prescribed.	O
Surprisingly,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	Chemical
resulted	O
in	O
a	O
sudden	O
anuria	Disease
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high-dose	O
furosemide	Chemical
and	O
amine	Chemical
infusion.	O
One	O
week	O
later,	O
by	O
mistake,	O
losartan	Chemical
was	O
prescribed	O
again	O
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg,	O
the	O
patient	O
developed	O
a	O
second	O
episode	O
of	O
transient	O
anuria	Disease
lasting	O
10	O
hours.	O
During	O
these	O
two	O
episodes,	O
his	O
blood	O
pressure	O
diminished	O
but	O
no	O
severe	O
hypotension	Disease
was	O
noted.	O
Ultimately,	O
an	O
arteriography	O
showed	O
a	O
70-80%	O
renal	Disease
artery	Disease
stenosis	Disease
.	O
In	O
this	O
patient,	O
renal	Disease
artery	Disease
stenosis	Disease
combined	O
with	O
heart	Disease
failure	Disease
and	O
diuretic	O
therapy	O
certainly	O
resulted	O
in	O
a	O
strong	O
activation	O
of	O
the	O
renin-	O
angiotensin	Chemical
system	O
(RAS).	O
Under	O
such	O
conditions,	O
angiotensin	Chemical
II	Chemical
receptor	O
blockade	O
by	O
losartan	Chemical
probably	O
induced	O
a	O
critical	O
fall	O
in	O
glomerular	O
filtration	O
pressure.	O
This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	Chemical
II	Chemical
receptor	O
antagonist	O
losartan	Chemical
can	O
cause	O
serious	O
unexpected	O
complications	O
in	O
patients	O
with	O
renovascular	Disease
disease	Disease

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	Disease
cell	O
deaths	O
during	O
acetaminophen	Chemical
-induced	O
nephrotoxicity	Disease
,	O
amiodarone	Chemical
-induced	O
lung	Disease
toxicity	Disease
and	O
doxorubicin	Chemical
-induced	O
cardiotoxicity	Disease
by	O
a	O
novel	O
IH636	Chemical
grape	Chemical
seed	Chemical
proanthocyanidin	Chemical
extract	Chemical
.	O
Grape	Chemical
seed	Chemical
extract	Chemical
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyanidins	Chemical
,	O
has	O
been	O
shown	O
to	O
modulate	O
a	O
wide-range	O
of	O
biological,	O
pharmacological	O
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective.	O
This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	Chemical
grape	Chemical
seed	Chemical
proanthocyanidin	Chemical
extract	Chemical
(	O
GSPE	Chemical
)	O
to	O
prevent	O
acetaminophen	Chemical
(	O
AAP	Chemical
)-induced	O
nephrotoxicity	Disease
,	O
amiodarone	Chemical
(	O
AMI	Chemical
)-induced	O
lung	Disease
toxicity	Disease
,	O
and	O
doxorubicin	Chemical
(	O
DOX	Chemical
)-induced	O
cardiotoxicity	Disease
in	O
mice.	O
Experimental	O
design	O
consisted	O
of	O
four	O
groups:	O
control	O
(vehicle	O
alone),	O
GSPE	Chemical
alone,	O
drug	O
alone	O
and	O
GSPE	Chemical
+drug.	O
For	O
the	O
cytoprotection	O
study,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg/Kg	O
GSPE	Chemical
for	O
7-10	O
days	O
followed	O
by	O
i.p.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	Chemical
:	O
500	O
mg/Kg	O
for	O
24	O
h;	O
AMI	Chemical
:	O
50	O
mg/Kg/day	O
for	O
four	O
days;	O
DOX	Chemical
:	O
20	O
mg/Kg	O
for	O
48	O
h).	O
Parameters	O
of	O
study	O
included	O
analysis	O
of	O
serum	O
chemistry	O
(ALT,	O
BUN	O
and	O
CPK),	O
and	O
orderly	O
fragmentation	O
of	O
genomic	O
DNA	O
(both	O
endonuclease-dependent	O
and	O
independent)	O
in	O
addition	O
to	O
microscopic	O
evaluation	O
of	O
damage	O
and/or	O
protection	O
in	O
corresponding	O
PAS	O
stained	O
tissues.	O
Results	O
indicate	O
that	O
GSPE	Chemical
preexposure	O
prior	O
to	O
AAP	Chemical
,	O
AMI	Chemical
and	O
DOX	Chemical
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(ALT,	O
BUN	O
and	O
CPK),	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation.	O
Histopathological	O
examination	O
of	O
kidney,	O
heart	O
and	O
lung	O
sections	O
revealed	O
moderate	O
to	O
massive	O
tissue	Disease
damage	Disease
with	O
a	O
variety	O
of	O
morphological	O
aberrations	O
by	O
all	O
the	O
three	O
drugs	O
in	O
the	O
absence	O
of	O
GSPE	Chemical
preexposure	O
than	O
in	O
its	O
presence.	O
GSPE	Chemical
+drug	O
exposed	O
tissues	O
exhibited	O
minor	O
residual	O
damage	O
or	O
near	O
total	O
recovery.	O
Additionally,	O
histopathological	O
alterations	O
mirrored	O
both	O
serum	O
chemistry	O
changes	O
and	O
the	O
pattern	O
of	O
DNA	O
fragmentation.	O
Interestingly,	O
all	O
the	O
drugs,	O
such	O
as,	O
AAP	Chemical
,	O
AMI	Chemical
and	O
DOX	Chemical
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	Disease
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	Chemical
.	O
Since	O
AAP	Chemical
,	O
AMI	Chemical
and	O
DOX	Chemical
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo,	O
the	O
protection	O
by	O
GSPE	Chemical
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and/or	O
detoxification	O
of	O
cytotoxic	O
radicals.	O
In	O
addition,	O
its'	O
presumed	O
contribution	O
to	O
DNA	O
repair	O
may	O
be	O
another	O
important	O
attribute,	O
which	O
played	O
a	O
role	O
in	O
the	O
chemoprevention	O
process.	O
Additionally,	O
this	O
may	O
have	O
been	O
the	O
first	O
report	O
on	O
AMI	Chemical
-induced	O
apoptotic	O
death	O
in	O
the	O
lung	O
tissue.	O
Taken	O
together,	O
these	O
events	O
undoubtedly	O
establish	O
GSPE	Chemical

Palpebral	Disease
twitching	Disease
in	O
a	O
depressed	Disease
adolescent	O
on	O
citalopram	Chemical
.	O
Current	O
estimates	O
suggest	O
that	O
between	O
0.4%	O
and	O
8.3%	O
of	O
children	O
and	O
adolescents	O
are	O
affected	O
by	O
major	Disease
depression	Disease
.	O
We	O
report	O
a	O
favorable	O
response	O
to	O
treatment	O
with	O
citalopram	Chemical
by	O
a	O
15-year-old	O
boy	O
with	O
major	Disease
depression	Disease
who	O
exhibited	O
palpebral	Disease
twitching	Disease
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment.	O
This	O
may	O
have	O
been	O
a	O
side	O
effect	O
of	O
citalopram	Chemical

Metamizol	Chemical
potentiates	O
morphine	Chemical
antinociception	O
but	O
not	O
constipation	Disease
after	O
chronic	O
treatment.	O
This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	Disease
effects	O
of	O
the	O
combination	O
of	O
3.2	O
mg/kg	O
s.c.	O
morphine	Chemical
with	O
177.8	O
mg/kg	O
s.c.	O
metamizol	Chemical
in	O
acutely	O
and	O
chronically	O
treated	O
(once	O
a	O
day	O
for	O
12	O
days)	O
rats.	O
On	O
the	O
13th	O
day,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception,	O
pain	Disease
-induced	O
functional	O
impairment	O
model,	O
and	O
the	O
charcoal	Chemical
meal	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit.	O
Simultaneous	O
administration	O
of	O
morphine	Chemical
with	O
metamizol	Chemical
resulted	O
in	O
a	O
markedly	O
antinociceptive	O
potentiation	O
and	O
an	O
increasing	O
of	O
the	O
duration	O
of	O
action	O
after	O
a	O
single	O
(298+/-7	O
vs.	O
139+/-36	O
units	O
area	O
(ua);	O
P<0.001)	O
and	O
repeated	O
administration	O
(280+/-17	O
vs.	O
131+/-22	O
ua;	O
P<0.001).	O
Antinociceptive	O
effect	O
of	O
morphine	Chemical
was	O
reduced	O
in	O
chronically	O
treated	O
rats	O
(39+/-10	O
vs.	O
18+/-5	O
au)	O
while	O
the	O
combination-induced	O
antinociception	O
was	O
remained	O
similar	O
as	O
an	O
acute	O
treatment	O
(298+/-7	O
vs.	O
280+/-17	O
au).	O
Acute	O
antinociceptive	O
effects	O
of	O
the	O
combination	O
were	O
partially	O
prevented	O
by	O
3.2	O
mg/kg	O
naloxone	Chemical
s.c.	O
(P<0.05),	O
suggesting	O
the	O
partial	O
involvement	O
of	O
the	O
opioidergic	O
system	O
in	O
the	O
synergism	O
observed.	O
In	O
independent	O
groups,	O
morphine	Chemical
inhibited	O
the	O
intestinal	O
transit	O
in	O
48+/-4%	O
and	O
38+/-4%	O
after	O
acute	O
and	O
chronic	O
treatment,	O
respectively,	O
suggesting	O
that	O
tolerance	O
did	O
not	O
develop	O
to	O
the	O
constipating	Disease
effects.	O
The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	Chemical
regardless	O
of	O
the	O
time	O
of	O
treatment,	O
suggesting	O
that	O
metamizol	Chemical
did	O
not	O
potentiate	O
morphine	Chemical
-induced	O
constipation	Disease
.	O
These	O
findings	O
show	O
a	O
significant	O
interaction	O
between	O
morphine	Chemical
and	O
metamizol	Chemical
in	O
chronically	O
treated	O
rats,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	Disease
pain	Disease

Ifosfamide	Chemical
	O
encephalopathy	Disease
presenting	O
with	O
asterixis	Disease
.	O
CNS	O
toxic	O
effects	O
of	O
the	O
antineoplastic	O
agent	O
ifosfamide	Chemical
(	O
IFX	Chemical
)	O
are	O
frequent	O
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	O
drug	O
use.	O
We	O
report	O
a	O
case	O
of	O
a	O
51-year-old	O
man	O
who	O
developed	O
severe,	O
disabling	O
negative	O
myoclonus	Disease
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	O
of	O
ifosfamide	Chemical
for	O
plasmacytoma	Disease
.	O
He	O
was	O
awake,	O
revealed	O
no	O
changes	O
of	O
mental	O
status	O
and	O
at	O
rest	O
there	O
were	O
no	O
further	O
motor	O
symptoms.	O
Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	O
failed	O
to	O
reveal	O
structural	Disease
lesions	Disease
of	Disease
the	Disease
brain	Disease
and	O
metabolic	Disease
abnormalities	Disease
.	O
An	O
electroencephalogram	O
showed	O
continuous,	O
generalized	O
irregular	O
slowing	O
with	O
admixed	O
periodic	O
triphasic	O
waves	O
indicating	O
symptomatic	O
encephalopathy	Disease
.	O
The	O
administration	O
of	O
ifosfamide	Chemical
was	O
discontinued	O
and	O
within	O
12	O
h	O
the	O
asterixis	Disease
resolved	O
completely.	O
In	O
the	O
patient	O
described,	O
the	O
presence	O
of	O
asterixis	Disease
during	O
infusion	O
of	O
ifosfamide	Chemical
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	Disease
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	Chemical

Sub-chronic	O
low	O
dose	O
gamma-vinyl	Chemical
GABA	Chemical
(	O
vigabatrin	Chemical
)	O
inhibits	O
cocaine	Chemical
-induced	O
increases	O
in	O
nucleus	O
accumbens	O
dopamine	Chemical
.	O
RATIONALE:	O
gamma-Vinyl	Chemical
GABA	Chemical
(	O
GVG	Chemical
)	O
irreversibly	O
inhibits	O
GABA	Chemical
-transaminase.	O
This	O
non-receptor	O
mediated	O
inhibition	O
requires	O
de	O
novo	O
synthesis	O
for	O
restoration	O
of	O
functional	O
GABA	Chemical
catabolism.	O
OBJECTIVES:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	Disease
abuse	Disease
and	O
the	O
increased	O
risk	O
of	O
visual	Disease
field	Disease
defects	Disease
(	O
VFD	Disease
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure,	O
we	O
explored	O
the	O
effects	O
of	O
sub-chronic	O
low	O
dose	O
GVG	Chemical
on	O
cocaine	Chemical
-induced	O
increases	O
in	O
nucleus	O
accumbens	O
(NAcc)	O
dopamine	Chemical
(	O
DA	Chemical
).	O
METHODS:	O
Using	O
in	O
vivo	O
microdialysis,	O
we	O
compared	O
acute	O
exposure	O
(450	O
mg/kg)	O
to	O
an	O
identical	O
sub-chronic	O
exposure	O
(150	O
mg/kg	O
per	O
day	O
for	O
3	O
days),	O
followed	O
by	O
1-	O
or	O
3-day	O
washout.	O
Finally,	O
we	O
examined	O
the	O
low	O
dose	O
of	O
150	O
mg/kg	O
(50	O
mg/kg	O
per	O
day)	O
using	O
a	O
similar	O
washout	O
period.	O
RESULTS:	O
Sub-chronic	O
GVG	Chemical
exposure	O
inhibited	O
the	O
effect	O
of	O
cocaine	Chemical
for	O
3	O
days,	O
which	O
exceeded	O
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose.	O
CONCLUSIONS:	O
Sub-chronic	O
low	O
dose	O
GVG	Chemical
potentiates	O
and	O
extends	O
the	O
inhibition	O
of	O
cocaine	Chemical
-induced	O
increases	O
in	O
dopamine	Chemical

Amount	O
of	O
bleeding	Disease
and	O
hematoma	Disease
size	O
in	O
the	O
collagenase-induced	O
intracerebral	Disease
hemorrhage	Disease
rat	O
model.	O
The	O
aggravated	O
risk	O
on	O
intracerebral	Disease
hemorrhage	Disease
(	O
ICH	Disease
)	O
with	O
drugs	O
used	O
for	O
stroke	Disease
patients	O
should	O
be	O
estimated	O
carefully.	O
We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	O
a	O
rat	O
ICH	Disease
model	O
for	O
detection	O
of	O
ICH	Disease
deterioration.	O
In	O
ICH	Disease
intrastriatally	O
induced	O
by	O
0.014-unit,	O
0.070-unit,	O
and	O
0.350-unit	O
collagenase,	O
the	O
amount	O
of	O
bleeding	Disease
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	Disease
volume.	O
The	O
blood	O
amounts	O
and	O
hematoma	Disease
volumes	O
were	O
significantly	O
correlated,	O
and	O
the	O
hematoma	Disease
induced	O
by	O
0.014-unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	Disease
deterioration.	O
In	O
ICH	Disease
induction	O
using	O
0.014-unit	O
collagenase,	O
heparin	Chemical
enhanced	O
the	O
hematoma	Disease
volume	O
3.4-fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	Disease
animals	O
and	O
the	O
bleeding	Disease
7.6-fold.	O
Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	Disease
detection,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	Disease
induced	O
with	O
a	O
low-dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	O
affect	O
ICH	Disease

Estradiol	Chemical
reduces	O
seizure	Disease
-induced	O
hippocampal	Disease
injury	Disease
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats.	O
Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	Disease
injury	Disease
induced	O
by	O
kainic	Chemical
acid	Chemical
-induced	O
status	Disease
epilepticus	Disease
(	O
SE	Disease
).	O
We	O
compared	O
the	O
effects	O
of	O
17beta-estradiol	Chemical
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium	Chemical
-	O
pilocarpine	Chemical
-induced	O
SE	Disease
.	O
Rats	O
received	O
subcutaneous	O
injections	O
of	O
17beta-estradiol	Chemical
(2	O
microg/rat)	O
or	O
oil	O
once	O
daily	O
for	O
four	O
consecutive	O
days.	O
SE	Disease
was	O
induced	O
20	O
h	O
following	O
the	O
second	O
injection	O
and	O
terminated	O
3	O
h	O
later.	O
The	O
extent	O
of	O
silver	Chemical
-stained	O
CA3	O
and	O
CA1	O
hippocampal	O
neurons	O
was	O
evaluated	O
2	O
days	O
after	O
SE	Disease
.	O
17beta-Estradiol	Chemical
did	O
not	O
alter	O
the	O
onset	O
of	O
first	O
clonus	O
in	O
ovariectomized	O
rats	O
but	O
accelerated	O
it	O
in	O
males.	O
17beta-Estradiol	Chemical
reduced	O
the	O
argyrophilic	O
neurons	O
in	O
the	O
CA1	O
and	O
CA3-C	O
sectors	O
of	O
ovariectomized	O
rats.	O
In	O
males,	O
estradiol	Chemical
increased	O
the	O
total	O
damage	O
score.	O
These	O
findings	O
suggest	O
that	O
the	O
effects	O
of	O
estradiol	Chemical
on	O
seizure	Disease

Delirium	Disease
during	O
clozapine	Chemical
treatment:	O
incidence	O
and	O
associated	O
risk	O
factors.	O
BACKGROUND:	O
Incidence	O
and	O
risk	O
factors	O
for	O
delirium	Disease
during	O
clozapine	Chemical
treatment	O
require	O
further	O
clarification.	O
METHODS:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	Disease
inpatients	O
treated	O
with	O
clozapine	Chemical
(1995-96),	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	O
and	O
severity	O
of	O
delirium	Disease
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors.	O
RESULTS:	O
Subjects	O
(n	O
=	O
139)	O
were	O
72	O
women	O
and	O
67	O
men,	O
aged	O
40.8	O
+/-	O
12.1	O
years,	O
hospitalized	O
for	O
24.9	O
+/-	O
23.3	O
days,	O
and	O
given	O
clozapine	Chemical
,	O
gradually	O
increased	O
to	O
an	O
average	O
daily	O
dose	O
of	O
282	O
+/-	O
203	O
mg	O
(3.45	O
+/-	O
2.45	O
mg/kg)	O
for	O
18.9	O
+/-	O
16.4	O
days.	O
Delirium	Disease
was	O
diagnosed	O
in	O
14	O
(10.1	O
%	O
incidence,	O
or	O
1.48	O
cases/person-years	O
of	O
exposure);	O
71.4	O
%	O
of	O
cases	O
were	O
moderate	O
or	O
severe.	O
Associated	O
factors	O
were	O
co-treatment	O
with	O
other	O
centrally	O
antimuscarinic	O
agents,	O
poor	O
clinical	O
outcome,	O
older	O
age,	O
and	O
longer	O
hospitalization	O
(by	O
17.5	O
days,	O
increasing	O
cost);	O
sex,	O
diagnosis	O
or	O
medical	O
co-morbidity,	O
and	O
daily	O
clozapine	Chemical
dose,	O
which	O
fell	O
with	O
age,	O
were	O
unrelated.	O
CONCLUSIONS:	O
Delirium	Disease
was	O
found	O
in	O
10	O
%	O
of	O
clozapine	Chemical
-treated	O
inpatients,	O
particularly	O
in	O
older	O
patients	O
exposed	O
to	O
other	O
central	O
anticholinergics.	O
Delirium	Disease

Ketoconazole	Chemical
-induced	O
neurologic	Disease
sequelae	Disease
.	O
A	O
77-y-old	O
patient	O
developed	O
weakness	Disease
of	Disease
extremities	Disease
,	O
legs	Disease
paralysis	Disease
,	O
dysarthria	Disease
and	O
tremor	Disease
1	O
h	O
after	O
ingestion	O
of	O
200	O
mg	O
ketoconazole	Chemical
for	O
the	O
first	O
time	O
in	O
his	O
life.	O
All	O
complaints	O
faded	O
away	O
within	O
24	O
h.	O
Few	O
days	O
later,	O
the	O
patient	O
used	O
another	O
200	O
mg	O
ketoconazole	Chemical
tablet,	O
and	O
within	O
an	O
hour	O
experienced	O
a	O
similar	O
clinical	O
picture,	O
which	O
resolved	O
again	O
spontaneously	O
within	O
hours.	O
Laboratory	O
evaluations,	O
including	O
head	O
CT	O
scan,	O
were	O
normal.	O
This	O
case	O
illustrates	O
the	O
need	O
for	O
close	O
vigilance	O
in	O
adverse	Disease
drug	Disease
reactions	Disease

Noxious	O
chemical	O
stimulation	O
of	O
rat	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
through	O
a	O
trigemino-parasympathetic	O
reflex--an	O
experimental	O
model	O
for	O
vascular	Disease
dysfunctions	Disease
in	O
cluster	Disease
headache	Disease
.	O
Cluster	Disease
headache	Disease
is	O
characterized	O
by	O
typical	O
autonomic	O
dysfunctions	O
including	O
facial	O
and	O
intracranial	Disease
vascular	Disease
disturbances	Disease
.	O
Both	O
the	O
trigeminal	O
and	O
the	O
cranial	O
parasympathetic	O
systems	O
may	O
be	O
involved	O
in	O
mediating	O
these	O
dysfunctions.	O
An	O
experimental	O
model	O
was	O
developed	O
in	O
the	O
rat	O
to	O
measure	O
changes	O
in	O
lacrimation	O
and	O
intracranial	O
blood	O
flow	O
following	O
noxious	O
chemical	O
stimulation	O
of	O
facial	O
mucosa.	O
Blood	O
flow	O
was	O
monitored	O
in	O
arteries	O
of	O
the	O
exposed	O
cranial	O
dura	O
mater	O
and	O
the	O
parietal	O
cortex	O
using	O
laser	O
Doppler	O
flowmetry.	O
Capsaicin	Chemical
(0.01-1	O
mm)	O
applied	O
to	O
oral	O
or	O
nasal	O
mucosa	O
induced	O
increases	Disease
in	Disease
dural	Disease
and	Disease
cortical	Disease
blood	Disease
flow	Disease
and	O
provoked	O
lacrimation.	O
These	O
responses	O
were	O
blocked	O
by	O
systemic	O
pre-administration	O
of	O
hexamethonium	Chemical
chloride	Chemical
(20	O
mg/kg).	O
The	O
evoked	O
increases	Disease
in	Disease
dural	Disease
blood	Disease
flow	Disease
were	O
also	O
abolished	O
by	O
topical	O
pre-administration	O
of	O
atropine	Chemical
(1	O
mm)	O
and	O
[Lys1,	O
Pro2,5,	O
Arg3,4,	O
Tyr6]-VIP	O
(0.1	O
mm),	O
a	O
vasoactive	O
intestinal	O
polypeptide	O
(VIP)	O
antagonist,	O
onto	O
the	O
exposed	O
dura	O
mater.	O
We	O
conclude	O
that	O
noxious	O
stimulation	O
of	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
and	O
lacrimation	O
via	O
a	O
trigemino-parasympathetic	O
reflex.	O
The	O
blood	O
flow	O
responses	O
seem	O
to	O
be	O
mediated	O
by	O
the	O
release	O
of	O
acetylcholine	Chemical
and	O
VIP	O
within	O
the	O
meninges.	O
Similar	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
cluster	Disease
headache	Disease

Recurrent	O
excitation	O
in	O
the	O
dentate	O
gyrus	O
of	O
a	O
murine	O
model	O
of	O
temporal	Disease
lobe	Disease
epilepsy	Disease
.	O
Similar	O
to	O
rats,	O
systemic	O
pilocarpine	Chemical
injection	O
causes	O
status	Disease
epilepticus	Disease
(	O
SE	Disease
)	O
and	O
the	O
eventual	O
development	O
of	O
spontaneous	O
seizures	Disease
and	O
mossy	O
fiber	O
sprouting	O
in	O
C57BL/6	O
and	O
CD1	O
mice,	O
but	O
the	O
physiological	O
correlates	O
of	O
these	O
events	O
have	O
not	O
been	O
identified	O
in	O
mice.	O
Population	O
responses	O
in	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
examined	O
in	O
transverse	O
slices	O
of	O
the	O
ventral	O
hippocampus	O
from	O
pilocarpine	Chemical
-treated	O
and	O
untreated	O
mice.	O
In	O
Mg	Chemical
(2+)-free	O
bathing	O
medium	O
containing	O
bicuculline	Chemical
,	O
conditions	O
designed	O
to	O
increase	O
excitability	O
in	O
the	O
slices,	O
electrical	O
stimulation	O
of	O
the	O
hilus	O
resulted	O
in	O
a	O
single	O
population	O
spike	O
in	O
granule	O
cells	O
from	O
control	O
mice	O
and	O
pilocarpine	Chemical
-treated	O
mice	O
that	O
did	O
not	O
experience	O
SE	Disease
.	O
In	O
SE	Disease
survivors,	O
similar	O
stimulation	O
resulted	O
in	O
a	O
population	O
spike	O
followed,	O
at	O
a	O
variable	O
latency,	O
by	O
negative	O
DC	O
shifts	O
and	O
repetitive	O
afterdischarges	O
of	O
3-60	O
s	O
duration,	O
which	O
were	O
blocked	O
by	O
ionotropic	O
glutamate	Chemical
receptor	O
antagonists.	O
Focal	O
glutamate	Chemical
photostimulation	O
of	O
the	O
granule	O
cell	O
layer	O
at	O
sites	O
distant	O
from	O
the	O
recording	O
pipette	O
resulted	O
in	O
population	O
responses	O
of	O
1-30	O
s	O
duration	O
in	O
slices	O
from	O
SE	Disease
survivors	O
but	O
not	O
other	O
groups.	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
SE	Disease
-induced	O
mossy	O
fiber	O
sprouting	O
and	O
synaptic	O
reorganization	O
are	O
relevant	O
characteristics	O
of	O
seizure	Disease
development	O
in	O
these	O
murine	O
strains,	O
resembling	O
rat	O
models	O
of	O
human	O
temporal	Disease
lobe	Disease
epilepsy	Disease

The	O
alpha3	O
and	O
beta4	O
nicotinic	O
acetylcholine	Chemical
receptor	O
subunits	O
are	O
necessary	O
for	O
nicotine	Chemical
-induced	O
seizures	Disease
and	O
hypolocomotion	Disease
in	O
mice.	O
Binding	O
of	O
nicotine	Chemical
to	O
nicotinic	O
acetylcholine	Chemical
receptors	O
(nAChRs)	O
elicits	O
a	O
series	O
of	O
dose-dependent	O
behaviors	O
that	O
go	O
from	O
altered	O
exploration,	O
sedation,	O
and	O
tremors	Disease
,	O
to	O
seizures	Disease
and	O
death	Disease
.	O
nAChRs	O
are	O
pentameric	O
ion	O
channels	O
usually	O
composed	O
of	O
alpha	O
and	O
beta	O
subunits.	O
A	O
gene	O
cluster	O
comprises	O
the	O
alpha3,	O
alpha5	O
and	O
beta4	O
subunits,	O
which	O
coassemble	O
to	O
form	O
functional	O
receptors.	O
We	O
examined	O
the	O
role	O
of	O
the	O
beta4	O
subunits	O
in	O
nicotine	Chemical
-induced	O
seizures	Disease
and	O
hypolocomotion	Disease
in	O
beta4	O
homozygous	O
null	O
(beta4	O
-/-)	O
and	O
alpha3	O
heterozygous	O
(+/-)	O
mice.	O
beta4	O
-/-	O
mice	O
were	O
less	O
sensitive	O
to	O
the	O
effects	O
of	O
nicotine	Chemical
both	O
at	O
low	O
doses,	O
measured	O
as	O
decreased	O
exploration	O
in	O
an	O
open	O
field,	O
and	O
at	O
high	O
doses,	O
measured	O
as	O
sensitivity	O
to	O
nicotine	Chemical
-induced	O
seizures	Disease
.	O
Using	O
in	O
situ	O
hybridization	O
probes	O
for	O
the	O
alpha3	O
and	O
alpha5	O
subunits,	O
we	O
showed	O
that	O
alpha5	O
mRNA	O
levels	O
are	O
unchanged,	O
whereas	O
alpha3	O
mRNA	O
levels	O
are	O
selectively	O
decreased	O
in	O
the	O
mitral	O
cell	O
layer	O
of	O
the	O
olfactory	O
bulb,	O
and	O
the	O
inferior	O
and	O
the	O
superior	O
colliculus	O
of	O
beta4	O
-/-	O
brains.	O
alpha3	O
+/-	O
mice	O
were	O
partially	O
resistant	O
to	O
nicotine	Chemical
-induced	O
seizures	Disease
when	O
compared	O
to	O
wild-type	O
littermates.	O
mRNA	O
levels	O
for	O
the	O
alpha5	O
and	O
the	O
beta4	O
subunits	O
were	O
unchanged	O
in	O
alpha3	O
+/-	O
brains.	O
Together,	O
these	O
results	O
suggest	O
that	O
the	O
beta4	O
and	O
the	O
alpha3	O
subunits	O
are	O
mediators	O
of	O
nicotine	Chemical
-induced	O
seizures	Disease
and	O
hypolocomotion	Disease

Recurrent	O
acute	O
interstitial	Disease
nephritis	Disease
induced	O
by	O
azithromycin	Chemical
.	O
A	O
14-year-old	O
girl	O
is	O
reported	O
with	O
recurrent,	O
azithromycin	Chemical
-induced,	O
acute	O
interstitial	Disease
nephritis	Disease
.	O
The	O
second	O
episode	O
was	O
more	O
severe	O
than	O
the	O
first;	O
and	O
although	O
both	O
were	O
treated	O
with	O
intensive	O
corticosteroid	O
therapy,	O
renal	O
function	O
remained	O
impaired.	O
Although	O
most	O
cases	O
of	O
antibiotic	O
induced	O
acute	O
interstitial	Disease
nephritis	Disease
are	O
benign	O
and	O
self-limited,	O
some	O
patients	O
are	O
at	O
risk	O
for	O
permanent	O
renal	Disease
injury	Disease

Valproate	Chemical
-induced	O
encephalopathy	Disease
.	O
Valproate	Chemical
-induced	O
encephalopathy	Disease
is	O
a	O
rare	O
syndrome	O
that	O
may	O
manifest	O
in	O
otherwise	O
normal	O
epileptic	Disease
individuals.	O
It	O
may	O
even	O
present	O
in	O
patients	O
who	O
have	O
tolerated	O
this	O
medicine	O
well	O
in	O
the	O
past.	O
It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperammonemia	Disease
.	O
The	O
EEG	O
shows	O
characteristic	O
triphasic	O
waves	O
in	O
most	O
patients	O
with	O
this	O
complication.	O
A	O
case	O
of	O
valproate	Chemical
-induced	O
encephalopathy	Disease

Nitro-L-arginine	Chemical
methyl	Chemical
ester	Chemical
:	O
a	O
potential	O
protector	O
against	O
gentamicin	Chemical
	O
ototoxicity	Disease
.	O
The	O
nitric	Chemical
oxide	Chemical
(	O
NO	Chemical
)	O
inhibitor	O
nitro-L-arginine	Chemical
methyl	Chemical
ester	Chemical
(	O
L-NAME	Chemical
)	O
may	O
act	O
as	O
an	O
otoprotectant	O
against	O
high-frequency	Disease
hearing	Disease
loss	Disease
caused	O
by	O
gentamicin	Chemical
,	O
but	O
further	O
studies	O
are	O
needed	O
to	O
confirm	O
this.	O
Aminoglycoside	Chemical
antibiotics	O
are	O
still	O
widely	O
used	O
by	O
virtue	O
of	O
their	O
efficacy	O
and	O
low	O
cost.	O
Their	O
ototoxicity	Disease
is	O
a	O
serious	O
health	O
problem	O
and,	O
as	O
their	O
ototoxic	Disease
mechanism	O
involves	O
the	O
production	O
of	O
NO	Chemical
,	O
we	O
need	O
to	O
assess	O
the	O
use	O
of	O
NO	Chemical
inhibitors	O
for	O
the	O
prevention	O
of	O
aminoglycoside	Chemical
-induced	O
sensorineural	Disease
hearing	Disease
loss	Disease
.	O
In	O
this	O
experimental	O
study	O
we	O
used	O
30	O
Sprague-Dawley	O
rats,	O
27	O
of	O
which	O
had	O
gentamicin	Chemical
instilled	O
into	O
the	O
middle	O
ear.	O
The	O
otoprotectant	O
L-NAME	Chemical
was	O
administered	O
topically	O
to	O
12/27	O
animals.	O
Its	O
effect	O
was	O
determined	O
in	O
terms	O
of	O
attenuation	O
of	O
hearing	Disease
loss	Disease
,	O
measured	O
by	O
shifts	O
in	O
the	O
auditory	O
brainstem	O
response	O
threshold.	O
L-NAME	Chemical
reduced	O
gentamicin	Chemical
-induced	O
hearing	Disease
loss	Disease

Cerebral	Disease
vasculitis	Disease
following	O
oral	O
methylphenidate	Chemical
intake	O
in	O
an	O
adult:	O
a	O
case	O
report.	O
Methylphenidate	Chemical
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
amphetamine	Chemical
.	O
Cerebral	Disease
vasculitis	Disease
associated	O
with	O
amphetamine	Disease
abuse	Disease
is	O
well	O
documented,	O
and	O
in	O
rare	O
cases	O
ischaemic	Disease
stroke	Disease
has	O
been	O
reported	O
after	O
methylphenidate	Chemical
intake	O
in	O
children.	O
We	O
report	O
the	O
case	O
of	O
a	O
63-year-old	O
female	O
who	O
was	O
treated	O
with	O
methylphenidate	Chemical
due	O
to	O
hyperactivity	Disease
and	O
suffered	O
from	O
multiple	O
ischaemic	Disease
strokes	Disease
.	O
We	O
consider	O
drug-induced	O
cerebral	Disease
vasculitis	Disease
as	O
the	O
most	O
likely	O
cause	O
of	O
recurrent	O
ischaemic	Disease
strokes	Disease
in	O
the	O
absence	O
of	O
any	O
pathological	O
findings	O
during	O
the	O
diagnostic	O
work-up.	O
We	O
conclude	O
that	O
methylphenidate	Chemical
mediated	O
vasculitis	Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
neurological	O
symptoms	O
and	O
a	O
history	O
of	O
methylphenidate	Chemical
therapy.	O
This	O
potential	O
side-effect,	O
though	O
very	O
rare,	O
represents	O
one	O
more	O
reason	O
to	O
be	O
very	O
restrictive	O
in	O
the	O
use	O
of	O
methylphenidate	Chemical

Cerebral	Disease
haemorrhage	Disease
induced	O
by	O
warfarin	Chemical
-	O
the	O
influence	O
of	O
drug-drug	O
interactions.	O
PURPOSE:	O
To	O
evaluate	O
the	O
frequency,	O
severity	O
and	O
preventability	O
of	O
warfarin	Chemical
-induced	O
cerebral	Disease
haemorrhages	Disease
due	O
to	O
warfarin	Chemical
and	O
warfarin	Chemical
-drug	O
interactions	O
in	O
patients	O
living	O
in	O
the	O
county	O
of	O
Osterg	O
	O
tland,	O
Sweden.	O
METHODS:	O
All	O
patients	O
with	O
a	O
diagnosed	O
cerebral	Disease
haemorrhage	Disease
at	O
three	O
hospitals	O
during	O
the	O
period	O
2000-2002	O
were	O
identified.	O
Medical	O
records	O
were	O
studied	O
retrospectively	O
to	O
evaluate	O
whether	O
warfarin	Chemical
and	O
warfarin	Chemical
-drug	O
interactions	O
could	O
have	O
caused	O
the	O
cerebral	Disease
haemorrhage	Disease
.	O
The	O
proportion	O
of	O
possibly	O
avoidable	O
cases	O
due	O
to	O
drug	O
interactions	O
was	O
estimated.	O
RESULTS:	O
Among	O
593	O
patients	O
with	O
cerebral	Disease
haemorrhage	Disease
,	O
59	O
(10%)	O
were	O
assessed	O
as	O
related	O
to	O
warfarin	Chemical
treatment.	O
This	O
imply	O
an	O
incidence	O
of	O
1.7/100,000	O
treatment	O
years.	O
Of	O
the	O
59	O
cases,	O
26	O
(44%)	O
had	O
a	O
fatal	O
outcome,	O
compared	O
to	O
136	O
(25%)	O
among	O
the	O
non-	O
warfarin	Chemical
patients	O
(p	O
<	O
0.01).	O
A	O
warfarin	Chemical
-drug	O
interaction	O
could	O
have	O
contributed	O
to	O
the	O
haemorrhage	Disease
in	O
24	O
(41%)	O
of	O
the	O
warfarin	Chemical
patients	O
and	O
in	O
7	O
of	O
these	O
(12%)	O
the	O
bleeding	Disease
complication	O
was	O
considered	O
being	O
possible	O
to	O
avoid.	O
CONCLUSIONS:	O
Warfarin	Chemical
-induced	O
cerebral	Disease
haemorrhages	Disease
are	O
a	O
major	O
clinical	O
problem	O
with	O
a	O
high	O
fatality	O
rate.	O
Almost	O
half	O
of	O
the	O
cases	O
was	O
related	O
to	O
a	O
warfarin	Chemical
-drug	O
interaction.	O
A	O
significant	O
proportion	O
of	O
warfarin	Chemical
-related	O
cerebral	Disease
haemorrhages	Disease
might	O
have	O
been	O
prevented	O
if	O
greater	O
caution	O
had	O
been	O
taken	O
when	O
prescribing	O
drugs	O
known	O
to	O
interact	O
with	O
warfarin	Chemical

Side	O
effects	O
of	O
postoperative	O
administration	O
of	O
methylprednisolone	Chemical
and	O
gentamicin	Chemical
into	O
the	O
posterior	O
sub-Tenon's	O
space.	O
PURPOSE:	O
To	O
assess	O
the	O
incidence	O
of	O
postoperative	O
emetic	O
side	O
effects	O
after	O
the	O
administration	O
of	O
methylprednisolone	Chemical
and	O
gentamicin	Chemical
into	O
the	O
posterior	O
sub-Tenon's	O
space	O
at	O
the	O
end	O
of	O
routine	O
cataract	Disease
surgery.	O
SETTING:	O
St.	O
Luke's	O
Hospital,	O
Gwardamangia,	O
Malta.	O
METHODS:	O
A	O
double-blind	O
double-armed	O
prospective	O
study	O
comprised	O
40	O
patients	O
who	O
had	O
uneventful	O
sutureless	O
phacoemulsification	O
under	O
sub-Tenon's	O
local	O
infiltration	O
of	O
3	O
mL	O
of	O
plain	O
lignocaine	Chemical
.	O
At	O
the	O
end	O
of	O
the	O
procedure,	O
Group	O
A	O
(n	O
=	O
20)	O
had	O
20	O
mg/0.5	O
mL	O
of	O
methylprednisolone	Chemical
and	O
10	O
mg/0.5	O
mL	O
of	O
gentamicin	Chemical
injected	O
into	O
the	O
posterior	O
sub-Tenon's	O
space	O
and	O
Group	O
B	O
(n	O
=	O
20)	O
had	O
the	O
same	O
combination	O
injected	O
into	O
the	O
anterior	O
sub-Tenon's	O
space.	O
Postoperatively,	O
all	O
patients	O
were	O
assessed	O
for	O
symptoms	O
of	O
nausea,	Disease
vomiting	Disease
,	O
and	O
headache	Disease
.	O
A	O
chi-square	O
test	O
was	O
used	O
to	O
assess	O
the	O
statistical	O
significance	O
of	O
results.	O
RESULTS:	O
Sixty	O
percent	O
in	O
Group	O
A	O
developed	O
postoperative	Disease
emetic	Disease
symptoms	Disease
,	O
headache	Disease
,	O
or	O
both;	O
1	O
patient	O
in	O
Group	O
B	O
developed	O
symptoms.	O
CONCLUSIONS:	O
The	O
administration	O
of	O
methylprednisolone	Chemical
and	O
gentamicin	Chemical
in	O
the	O
posterior	O
sub-Tenon's	O
space	O
was	O
related	O
to	O
a	O
high	O
incidence	O
of	O
side	O
effects	O
including	O
nausea,	Disease
vomiting	Disease
,	O
and	O
headache	Disease

Cardiac	O
Angiography	O
in	O
Renally	O
Impaired	O
Patients	O
(CARE)	O
study:	O
a	O
randomized	O
double-blind	O
trial	O
of	O
contrast-induced	O
nephropathy	Disease
in	O
patients	O
with	O
chronic	Disease
kidney	Disease
disease	Disease
.	O
BACKGROUND:	O
No	O
direct	O
comparisons	O
exist	O
of	O
the	O
renal	O
tolerability	O
of	O
the	O
low-osmolality	O
contrast	Chemical
medium	Chemical
	O
iopamidol	Chemical
with	O
that	O
of	O
the	O
iso-osmolality	O
contrast	Chemical
medium	Chemical
	O
iodixanol	Chemical
in	O
high-risk	O
patients.	O
METHODS	O
AND	O
RESULTS:	O
The	O
present	O
study	O
is	O
a	O
multicenter,	O
randomized,	O
double-blind	O
comparison	O
of	O
iopamidol	Chemical
and	O
iodixanol	Chemical
in	O
patients	O
with	O
chronic	Disease
kidney	Disease
disease	Disease
(estimated	O
glomerular	O
filtration	O
rate,	O
20	O
to	O
59	O
mL/min)	O
who	O
underwent	O
cardiac	O
angiography	O
or	O
percutaneous	O
coronary	O
interventions.	O
Serum	O
creatinine	Chemical
(SCr)	O
levels	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
assessed	O
at	O
baseline	O
and	O
2	O
to	O
5	O
days	O
after	O
receiving	O
medications.	O
The	O
primary	O
outcome	O
was	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
0.5	O
mg/dL	O
(44.2	O
micromol/L)	O
over	O
baseline.	O
Secondary	O
outcomes	O
were	O
a	O
postdose	O
SCr	O
increase	O
>	O
or	O
=	O
25%,	O
a	O
postdose	O
estimated	O
glomerular	O
filtration	O
rate	O
decrease	O
of	O
>	O
or	O
=	O
25%,	O
and	O
the	O
mean	O
peak	O
change	O
in	O
SCr.	O
In	O
414	O
patients,	O
contrast	O
volume,	O
presence	O
of	O
diabetes	Disease
mellitus	Disease
,	O
use	O
of	O
N-acetylcysteine	Chemical
,	O
mean	O
baseline	O
SCr,	O
and	O
estimated	O
glomerular	O
filtration	O
rate	O
were	O
comparable	O
in	O
the	O
2	O
groups.	O
SCr	O
increases	O
>	O
or	O
=	O
0.5	O
mg/dL	O
occurred	O
in	O
4.4%	O
(9	O
of	O
204	O
patients)	O
after	O
iopamidol	Chemical
and	O
6.7%	O
(14	O
of	O
210	O
patients)	O
after	O
iodixanol	Chemical
(P=0.39),	O
whereas	O
rates	O
of	O
SCr	O
increases	O
>	O
or	O
=	O
25%	O
were	O
9.8%	O
and	O
12.4%,	O
respectively	O
(P=0.44).	O
In	O
patients	O
with	O
diabetes	Disease
,	O
SCr	O
increases	O
>	O
or	O
=	O
0.5	O
mg/dL	O
were	O
5.1%	O
(4	O
of	O
78	O
patients)	O
with	O
iopamidol	Chemical
and	O
13.0%	O
(12	O
of	O
92	O
patients)	O
with	O
iodixanol	Chemical
(P=0.11),	O
whereas	O
SCr	O
increases	O
>	O
or	O
=	O
25%	O
were	O
10.3%	O
and	O
15.2%,	O
respectively	O
(P=0.37).	O
Mean	O
post-SCr	O
increases	O
were	O
significantly	O
less	O
with	O
iopamidol	Chemical
(all	O
patients:	O
0.07	O
versus	O
0.12	O
mg/dL,	O
6.2	O
versus	O
10.6	O
micromol/L,	O
P=0.03;	O
patients	O
with	O
diabetes	Disease
:	O
0.07	O
versus	O
0.16	O
mg/dL,	O
6.2	O
versus	O
14.1	O
micromol/L,	O
P=0.01).	O
CONCLUSIONS:	O
The	O
rate	O
of	O
contrast-induced	O
nephropathy	Disease
,	O
defined	O
by	O
multiple	O
end	O
points,	O
is	O
not	O
statistically	O
different	O
after	O
the	O
intraarterial	O
administration	O
of	O
iopamidol	Chemical
or	O
iodixanol	Chemical
to	O
high-risk	O
patients,	O
with	O
or	O
without	O
diabetes	Disease
mellitus	Disease

A	O
novel	O
compound,	O
maltolyl	Chemical
p-coumarate	Chemical
,	O
attenuates	O
cognitive	Disease
deficits	Disease
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	Disease
models.	O
To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	O
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection,	O
we	O
newly	O
synthesized	O
maltolyl	Chemical
p-coumarate	Chemical
by	O
the	O
esterification	O
of	O
maltol	Chemical
and	O
p-coumaric	Chemical
acid	Chemical
.	O
In	O
the	O
present	O
study,	O
we	O
investigated	O
whether	O
maltolyl	Chemical
p-coumarate	Chemical
could	O
improve	O
cognitive	Disease
decline	Disease
in	O
scopolamine	Chemical
-injected	O
rats	O
and	O
in	O
amyloid	Chemical
beta	Chemical
peptide(1-42)	Chemical
-infused	O
rats.	O
Maltolyl	Chemical
p-coumarate	Chemical
was	O
found	O
to	O
attenuate	O
cognitive	Disease
deficits	Disease
in	O
both	O
rat	O
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	O
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	Chemical
beta	Chemical
peptide(1-42)	Chemical
-infused	O
rats.	O
We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	Chemical
p-coumarate	Chemical
in	O
vitro	O
using	O
SH-SY5Y	O
cells.	O
Cells	O
were	O
pretreated	O
with	O
maltolyl	Chemical
p-coumarate	Chemical
,	O
before	O
exposed	O
to	O
amyloid	Chemical
beta	Chemical
peptide(1-42)	Chemical
,	O
glutamate	Chemical
or	O
H2O2	Chemical
.	O
We	O
found	O
that	O
maltolyl	Chemical
p-coumarate	Chemical
significantly	O
decreased	O
apoptotic	O
cell	O
death	O
and	O
reduced	O
reactive	O
oxygen	O
species,	O
cytochrome	O
c	O
release,	O
and	O
caspase	O
3	O
activation.	O
Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together,	O
our	O
study	O
suggests	O
that	O
maltolyl	Chemical
p-coumarate	Chemical
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer's	Disease
disease	Disease
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	Disease
death	Disease
and	O
progressive	O
decline	Disease
of	Disease
cognitive	Disease
function	Disease

Interaction	O
between	O
warfarin	Chemical
and	O
levofloxacin	Chemical
:	O
case	O
series.	O
Warfarin	Chemical
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	O
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions.	O
Levofloxacin	Chemical
,	O
a	O
fluoroquinolone	Chemical
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribed	O
antibiotics	O
in	O
clinical	O
practice	O
and	O
is	O
effective	O
against	O
Gram-positive,	O
Gram-negative,	O
and	O
atypical	O
bacteria.	O
While	O
small	O
prospective	O
studies	O
have	O
not	O
revealed	O
any	O
significant	O
drug-drug	O
interaction	O
between	O
warfarin	Chemical
and	O
levofloxacin	Chemical
,	O
several	O
case	O
reports	O
have	O
indicated	O
that	O
levofloxacin	Chemical
may	O
significantly	O
potentiate	O
the	O
anticoagulation	O
effect	O
of	O
warfarin	Chemical
.	O
We	O
report	O
3	O
cases	O
of	O
serious	O
bleeding	Disease
complications	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
warfarin	Chemical
and	O
levofloxacin	Chemical
.	O
Physicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
interaction	O
and	O
use	O
caution	O
when	O
prescribing	O
levofloxacin	Chemical
to	O
patients	O
taking	O
warfarin	Chemical

Mutations	O
associated	O
with	O
lamivudine	Chemical
-resistance	O
in	O
therapy-	O
na	Chemical
ve	O
hepatitis	Disease
B	Disease
virus	Disease
(HBV)	Disease
infected	Disease
patients	O
with	O
and	O
without	O
HIV	Disease
co-infection	Disease
:	O
implications	O
for	O
antiretroviral	O
therapy	O
in	O
HBV	Disease
and	Disease
HIV	Disease
co-infected	Disease
South	O
African	O
patients.	O
This	O
was	O
an	O
exploratory	O
study	O
to	O
investigate	O
lamivudine	Chemical
-resistant	O
hepatitis	Disease
B	Disease
virus	O
(HBV)	O
strains	O
in	O
selected	O
lamivudine	Chemical
-	O
na	Chemical
ve	O
HBV	O
carriers	O
with	O
and	O
without	O
human	Disease
immunodeficiency	Disease
virus	Disease
(HIV)	Disease
co-infection	Disease
in	O
South	O
African	O
patients.	O
Thirty-five	O
lamivudine	Chemical
-	O
na	Chemical
ve	O
HBV	Disease
infected	Disease
patients	O
with	O
or	O
without	O
HIV	Disease
co-infection	Disease
were	O
studied:	O
15	O
chronic	O
HBV	Disease
mono-infected	Disease
patients	O
and	O
20	O
HBV-HIV	Disease
co-infected	Disease
patients.	O
The	O
latter	O
group	O
was	O
further	O
sub-divided	O
into	O
13	O
occult	O
HBV	O
(	O
HBsAg	Chemical
-negative)	O
and	O
7	O
overt	O
HBV	O
(	O
HBsAg	Chemical
-	O
positive)	O
patients.	O
HBsAg	Chemical
,	O
anti-HBs,	O
anti-HBc,	O
and	O
anti-HIV	O
1/2	O
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(Abbott	O
Laboratories,	O
North	O
Chicago,	O
IL).	O
Serum	O
samples	O
were	O
PCR	O
amplified	O
with	O
HBV	O
reverse	O
transcriptase	O
(RT)	O
primers,	O
followed	O
by	O
direct	O
sequencing	O
across	O
the	O
tyrosine	Chemical
-	O
methionine	Chemical
-	O
aspartate	Chemical
-	O
aspartate	Chemical
(YMDD)	O
motif	O
of	O
the	O
major	O
catalytic	O
region	O
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	O
RT	O
enzyme.	O
HBV	O
viral	O
load	O
was	O
performed	O
with	O
Amplicor	O
HBV	O
Monitor	O
test	O
v2.0	O
(Roche	O
Diagnostics,	O
Penzberg,	O
Germany).	O
HBV	O
lamivudine	Chemical
-resistant	O
strains	O
were	O
detected	O
in	O
3	O
of	O
15	O
mono-infected	O
chronic	O
hepatitis	Disease
B	Disease
patients	O
and	O
10	O
of	O
20	O
HBV-HIV	Disease
co-infected	Disease
patients.	O
To	O
the	O
best	O
of	O
our	O
knowledge,	O
this	O
constitutes	O
the	O
first	O
report	O
of	O
HBV	O
lamivudine	Chemical
-resistant	O
strains	O
in	O
therapy-	O
na	Chemical
ve	O
HBV-HIV	Disease
co-infected	Disease
patients.	O
The	O
HBV	O
viral	O
loads	O
for	O
mono-infected	O
and	O
co-infected	O
patients	O
ranged	O
from	O
3.32	O
x	O
10(2)	O
to	O
3.82	O
x	O
10(7)	O
and	O
<200	O
to	O
4.40	O
x	O
10(3)	O
copies/ml,	O
respectively.	O
It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre-existing	O
antiviral	O
mutations	O
could	O
result	O
in	O
widespread	O
emergence	O
of	O
HBV	O
resistant	O
strains	O
when	O
lamivudine	Chemical
-containing	O
highly	O
active	O
antiretroviral	O
(ARV)	O
treatment	O
(HAART)	O
regimens	O
become	O
widely	O
applied	O
in	O
South	O
Africa,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	O
implications	O
in	O
the	O
management	O
of	O
HBV-HIV	Disease
co-infected	Disease

Sex	O
differences	O
in	O
NMDA	Chemical
antagonist	O
enhancement	O
of	O
morphine	Chemical
antihyperalgesia	O
in	O
a	O
capsaicin	Chemical
model	O
of	O
persistent	O
pain	Disease
:	O
comparisons	O
to	O
two	O
models	O
of	O
acute	Disease
pain	Disease
.	O
In	O
acute	Disease
pain	Disease
models,	O
N-methyl-D-aspartate	Chemical
(	O
NMDA	Chemical
)	O
antagonists	O
enhance	O
the	O
antinociceptive	O
effects	O
of	O
morphine	Chemical
to	O
a	O
greater	O
extent	O
in	O
males	O
than	O
females.	O
The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
extend	O
these	O
findings	O
to	O
a	O
persistent	O
pain	Disease
model	O
which	O
could	O
be	O
distinguished	O
from	O
acute	Disease
pain	Disease
models	O
on	O
the	O
basis	O
of	O
the	O
nociceptive	O
fibers	O
activated,	O
neurochemical	O
substrates,	O
and	O
duration	O
of	O
the	O
nociceptive	O
stimulus.	O
To	O
this	O
end,	O
persistent	O
hyperalgesia	Disease
was	O
induced	O
by	O
administration	O
of	O
capsaicin	Chemical
in	O
the	O
tail	O
of	O
gonadally	O
intact	O
F344	O
rats,	O
following	O
which	O
the	O
tail	O
was	O
immersed	O
in	O
a	O
mildly	O
noxious	O
thermal	O
stimulus,	O
and	O
tail-withdrawal	O
latencies	O
measured.	O
For	O
comparison,	O
tests	O
were	O
conducted	O
in	O
two	O
acute	Disease
pain	Disease
models,	O
the	O
hotplate	O
and	O
warm	O
water	O
tail-withdrawal	O
procedures.	O
In	O
males,	O
the	O
non-competitive	O
NMDA	Chemical
antagonist	O
dextromethorphan	Chemical
enhanced	O
the	O
antihyperalgesic	O
effect	O
of	O
low	O
to	O
moderate	O
doses	O
of	O
morphine	Chemical
in	O
a	O
dose-and	O
time-dependent	O
manner.	O
Across	O
the	O
doses	O
and	O
pretreatment	O
times	O
examined,	O
enhancement	O
was	O
not	O
observed	O
in	O
females.	O
Enhancement	O
of	O
morphine	Chemical
antinociception	O
by	O
dextromethorphan	Chemical
was	O
seen	O
in	O
both	O
males	O
and	O
females	O
in	O
the	O
acute	Disease
pain	Disease
models,	O
with	O
the	O
magnitude	O
of	O
this	O
effect	O
being	O
greater	O
in	O
males.	O
These	O
findings	O
demonstrate	O
a	O
sexually-dimorphic	O
interaction	O
between	O
NMDA	Chemical
antagonists	O
and	O
morphine	Chemical
in	O
a	O
persistent	O
pain	Disease
model	O
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
acute	Disease
pain	Disease

Development	O
of	O
proteinuria	Disease
after	O
switch	O
to	O
sirolimus	Chemical
-based	O
immunosuppression	O
in	O
long-term	O
cardiac	O
transplant	O
patients.	O
Calcineurin-inhibitor	O
therapy	O
can	O
lead	O
to	O
renal	Disease
dysfunction	Disease
in	O
heart	O
transplantation	O
patients.	O
The	O
novel	O
immunosuppressive	O
(IS)	O
drug	O
sirolmus	Chemical
(	O
Srl	Chemical
)	O
lacks	O
nephrotoxic	Disease
effects;	O
however,	O
proteinuria	Disease
associated	O
with	O
Srl	Chemical
has	O
been	O
reported	O
following	O
renal	O
transplantation.	O
In	O
cardiac	O
transplantation,	O
the	O
incidence	O
of	O
proteinuria	Disease
associated	O
with	O
Srl	Chemical
is	O
unknown.	O
In	O
this	O
study,	O
long-term	O
cardiac	O
transplant	O
patients	O
were	O
switched	O
from	O
cyclosporine	Chemical
to	O
Srl	Chemical
-based	O
IS.	O
Concomitant	O
IS	O
consisted	O
of	O
mycophenolate	Chemical
mofetil	Chemical
+/-	O
steroids	Chemical
.	O
Proteinuria	O
increased	O
significantly	O
from	O
a	O
median	O
of	O
0.13	O
g/day	O
(range	O
0-5.7)	O
preswitch	O
to	O
0.23	O
g/day	O
(0-9.88)	O
at	O
24	O
months	O
postswitch	O
(p	O
=	O
0.0024).	O
Before	O
the	O
switch,	O
11.5%	O
of	O
patients	O
had	O
high-grade	O
proteinuria	Disease
(>1.0	O
g/day);	O
this	O
increased	O
to	O
22.9%	O
postswitch	O
(p	O
=	O
0.006).	O
ACE	Chemical
inhibitor	Chemical
and	O
angiotensin-releasing	Chemical
blocker	Chemical
(	O
ARB	Chemical
)	O
therapy	O
reduced	O
proteinuria	Disease
development.	O
Patients	O
without	O
proteinuria	Disease
had	O
increased	O
renal	O
function	O
(median	O
42.5	O
vs.	O
64.1,	O
p	O
=	O
0.25),	O
whereas	O
patients	O
who	O
developed	O
high-grade	O
proteinuria	Disease
showed	O
decreased	O
renal	O
function	O
at	O
the	O
end	O
of	O
follow-up	O
(median	O
39.6	O
vs.	O
29.2,	O
p	O
=	O
0.125).	O
Thus,	O
proteinuria	Disease
may	O
develop	O
in	O
cardiac	O
transplant	O
patients	O
after	O
switch	O
to	O
Srl	Chemical
,	O
which	O
may	O
have	O
an	O
adverse	O
effect	O
on	O
renal	O
function	O
in	O
these	O
patients.	O
Srl	Chemical
should	O
be	O
used	O
with	O
ACEi	Chemical
/	O
ARB	Chemical
therapy	O
and	O
patients	O
monitored	O
for	O
proteinuria	Disease
and	O
increased	O
renal	Disease
dysfunction	Disease

Synthesis	O
of	O
N-pyrimidinyl-2-phenoxyacetamides	Chemical
as	O
adenosine	Chemical
A2A	O
receptor	O
antagonists.	O
A	O
series	O
of	O
N-pyrimidinyl-2-phenoxyacetamide	Chemical
	O
adenosine	Chemical
A(2A)	O
antagonists	O
is	O
described.	O
SAR	O
studies	O
led	O
to	O
compound	O
14	O
with	O
excellent	O
potency	O
(K(i)	O
=	O
0.4	O
nM),	O
selectivity	O
(A(1)/A(2A)	O
>	O
100),	O
and	O
efficacy	O
(MED	O
10	O
mg/kg	O
p.o.)	O
in	O
the	O
rat	O
haloperidol	Chemical
-induced	O
catalepsy	Disease
model	O
for	O
Parkinson's	Disease
disease	Disease

Methamphetamine	Chemical
-induced	O
neurotoxicity	Disease
and	O
microglial	O
activation	O
are	O
not	O
mediated	O
by	O
fractalkine	O
receptor	O
signaling.	O
Methamphetamine	Chemical
(	O
METH	Chemical
)	O
damages	O
dopamine	Chemical
(	O
DA	Chemical
)	O
nerve	O
endings	O
by	O
a	O
process	O
that	O
has	O
been	O
linked	O
to	O
microglial	O
activation	O
but	O
the	O
signaling	O
pathways	O
that	O
mediate	O
this	O
response	O
have	O
not	O
yet	O
been	O
delineated.	O
Cardona	O
et	O
al.	O
[Nat.	O
Neurosci.	O
9	O
(2006),	O
917]	O
recently	O
identified	O
the	O
microglial-specific	O
fractalkine	O
receptor	O
(CX3CR1)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP	Chemical
-induced	O
neurodegeneration	Disease
of	O
DA	Chemical
neurons.	O
Because	O
the	O
CNS	Disease
damage	Disease
caused	O
by	O
METH	Chemical
and	O
MPTP	Chemical
is	O
highly	O
selective	O
for	O
the	O
DA	Chemical
neuronal	O
system	O
in	O
mouse	O
models	O
of	O
neurotoxicity	Disease
,	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH	Chemical
-induced	O
neurotoxicity	Disease
and	O
microglial	O
activation.	O
Mice	O
in	O
which	O
the	O
CX3CR1	O
gene	O
has	O
been	O
deleted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(eGFP)	O
were	O
treated	O
with	O
METH	Chemical
and	O
examined	O
for	O
striatal	O
neurotoxicity	Disease
.	O
METH	Chemical
depleted	O
DA	Chemical
,	O
caused	O
microglial	O
activation,	O
and	O
increased	O
body	O
temperature	O
in	O
CX3CR1	O
knockout	O
mice	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
time	O
course	O
seen	O
in	O
wild-type	O
controls.	O
The	O
effects	O
of	O
METH	Chemical
in	O
CX3CR1	O
knockout	O
mice	O
were	O
not	O
gender-dependent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum.	O
Striatal	O
microglia	O
expressing	O
eGFP	O
constitutively	O
show	O
morphological	O
changes	O
after	O
METH	Chemical
that	O
are	O
characteristic	O
of	O
activation.	O
This	O
response	O
was	O
restricted	O
to	O
the	O
striatum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP-microglia	O
in	O
surrounding	O
brain	O
areas	O
that	O
are	O
not	O
damaged	O
by	O
METH	Chemical
.	O
We	O
conclude	O
from	O
these	O
studies	O
that	O
CX3CR1	O
signaling	O
does	O
not	O
modulate	O
METH	Chemical
	O
neurotoxicity	Disease
or	O
microglial	O
activation.	O
Furthermore,	O
it	O
appears	O
that	O
striatal-resident	O
microglia	O
respond	O
to	O
METH	Chemical

Recovery	O
of	O
tacrolimus	Chemical
-associated	O
brachial	Disease
neuritis	Disease
after	O
conversion	O
to	O
everolimus	Chemical
in	O
a	O
pediatric	O
renal	O
transplant	O
recipient--case	O
report	O
and	O
review	O
of	O
the	O
literature.	O
TAC	Chemical
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agent	O
for	O
solid	O
organ	O
transplantation	O
in	O
pediatrics.	O
Neurotoxicity	Disease
is	O
a	O
potentially	O
serious	O
toxic	O
effect.	O
It	O
is	O
characterized	O
by	O
encephalopathy	Disease
,	O
headaches	Disease
,	O
seizures	Disease
,	O
or	O
neurological	Disease
deficits	Disease
.	O
Here,	O
we	O
describe	O
an	O
eight-and-a-half-yr-old	O
male	O
renal	O
transplant	O
recipient	O
with	O
right	O
BN.	O
MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	Disease
and	O
right	O
brachial	Disease
plexitis	Disease
.	O
Symptoms	O
persisted	O
for	O
three	O
months	O
despite	O
TAC	Chemical
dose	O
reduction,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	O
of	O
methylprednisolone	Chemical
pulse	O
therapy.	O
Improvement	O
and	O
eventually	O
full	O
recovery	O
only	O
occurred	O
after	O
TAC	Chemical
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	Chemical

Valvular	Disease
heart	Disease
disease	Disease
in	O
patients	O
with	O
Parkinson's	Disease
disease	Disease
treated	O
with	O
pergolide	Chemical
.	O
Course	O
following	O
treatment	O
modifications.	O
Valvular	Disease
heart	Disease
abnormalities	Disease
have	O
been	O
reported	O
in	O
patients	O
with	O
Parkinson's	Disease
disease	Disease
(	O
PD	Disease
)	O
treated	O
with	O
pergolide	Chemical
.	O
However,	O
the	O
incidence	O
and	O
severity	O
of	O
these	O
abnormalities	O
vary	O
from	O
study	O
to	O
study	O
and	O
their	O
course	O
after	O
drug	O
withdrawal	O
has	O
not	O
been	O
systematically	O
assessed.	O
OBJECTIVES:	O
To	O
estimate	O
the	O
frequency	O
and	O
severity	O
of	O
valvular	Disease
heart	Disease
abnormality	Disease
and	O
its	O
possible	O
reversibility	O
after	O
drug	O
withdrawal	O
in	O
a	O
case-control	O
study.	O
METHODS:	O
All	O
PD	Disease
patients	O
in	O
the	O
Amiens	O
area	O
treated	O
with	O
pergolide	Chemical
were	O
invited	O
to	O
attend	O
a	O
cardiologic	O
assessment	O
including	O
transthoracic	O
echocardiography.	O
Thirty	O
PD	Disease
patients	O
participated	O
in	O
the	O
study.	O
A	O
second	O
echocardiography	O
was	O
performed	O
(median	O
interval:	O
13	O
months)	O
after	O
pergolide	Chemical
withdrawal	O
(n=10	O
patients).	O
Controls	O
were	O
age-	O
and	O
sex-matched	O
non-	O
PD	Disease
patients	O
referred	O
to	O
the	O
cardiology	O
department.	O
RESULTS:	O
Compared	O
to	O
controls,	O
aortic	Disease
regurgitation	Disease
(OR:	O
3.1;	O
95%	O
IC:	O
1.1-8.8)	O
and	O
mitral	Disease
regurgitation	Disease
(OR:	O
10.7;	O
95%	O
IC:	O
2.1-53)	O
were	O
more	O
frequent	O
in	O
PD	Disease
patients	O
(tricuspid:	O
NS).	O
The	O
number	O
of	O
affected	O
valves	O
(n=2.4+/-0.7)	O
and	O
the	O
sum	O
of	O
regurgitation	O
grades	O
(n=2.8+/-1.09)	O
were	O
higher	O
(p=0.008	O
and	O
p=0.006,	O
respectively)	O
in	O
the	O
pergolide	Chemical
group.	O
Severity	O
of	O
regurgitation	O
was	O
not	O
correlated	O
with	O
pergolide	Chemical
cumulative	O
dose.	O
A	O
restrictive	O
pattern	O
of	O
valvular	Disease
regurgitation	Disease
,	O
suggestive	O
of	O
the	O
role	O
of	O
pergolide	Chemical
,	O
was	O
observed	O
in	O
12/30	O
(40%)	O
patients	O
including	O
two	O
with	O
heart	Disease
failure	Disease
.	O
Pergolide	Chemical
was	O
discontinued	O
in	O
10	O
patients	O
with	O
valvular	Disease
heart	Disease
disease	Disease
,	O
resulting	O
in	O
a	O
lower	O
regurgitation	O
grade	O
(p=0.01)	O
at	O
the	O
second	O
transthoracic	O
echocardiography	O
and	O
the	O
two	O
patients	O
with	O
heart	Disease
failure	Disease
returned	O
to	O
nearly	O
normal	O
clinical	O
examination.	O
This	O
study	O
supports	O
the	O
high	O
frequency	O
of	O
restrictive	O
valve	Disease
regurgitation	Disease
in	O
PD	Disease
patients	O
treated	O
with	O
pergolide	Chemical
and	O
reveals	O
that	O
a	O
significant	O
improvement	O
is	O
usual	O
when	O
the	O
treatment	O
is	O
converted	O
to	O
non-ergot	O
dopamine	Chemical

Adverse	O
effects	O
of	O
topical	O
papaverine	Chemical
on	O
auditory	O
nerve	O
function.	O
BACKGROUND:	O
Papaverine	Chemical
hydrochloride	Chemical
is	O
a	O
direct-acting	O
vasodilator	O
used	O
to	O
manage	O
vasospasm	Disease
during	O
various	O
neurosurgical	O
operations.	O
Transient	O
cranial	Disease
nerve	Disease
dysfunction	Disease
has	O
been	O
described	O
in	O
a	O
few	O
cases	O
with	O
topical	O
papaverine	Chemical
.	O
This	O
study	O
supports	O
previous	O
reports	O
and	O
provides	O
neurophysiological	O
evidence	O
of	O
an	O
adverse	O
effect	O
on	O
the	O
auditory	O
nerve.	O
METHODS:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
70	O
consecutive	O
microvascular	O
decompression	O
operations	O
and	O
studied	O
those	O
patients	O
who	O
received	O
topical	O
papaverine	Chemical
for	O
vasospasm	Disease
.	O
Topical	O
papaverine	Chemical
was	O
used	O
as	O
a	O
direct	O
therapeutic	O
action	O
to	O
manage	O
vasospasm	Disease
in	O
a	O
total	O
of	O
11	O
patients.	O
The	O
timing	O
of	O
papaverine	Chemical
application	O
and	O
ongoing	O
operative	O
events	O
was	O
reviewed	O
relative	O
to	O
changes	O
in	O
neurophysiological	O
recordings.	O
Brainstem	O
auditory	O
evoked	O
potentials	O
(BAEPs)	O
were	O
routinely	O
used	O
to	O
monitor	O
cochlear	O
nerve	O
function	O
during	O
these	O
operations.	O
FINDINGS:	O
A	O
temporal	O
relationship	O
was	O
found	O
between	O
topical	O
papaverine	Chemical
and	O
BAEP	O
changes	O
leading	O
to	O
complete	O
waveform	O
loss.	O
The	O
average	O
temporal	O
delay	O
between	O
papaverine	Chemical
and	O
the	O
onset	O
of	O
an	O
adverse	O
BAEP	O
change	O
was	O
5	O
min.	O
In	O
10	O
of	O
11	O
patients,	O
BAEP	O
waves	O
II/III-V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	O
after	O
papaverine	Chemical
.	O
Eight	O
of	O
these	O
10	O
patients	O
had	O
complete	O
loss	O
of	O
BAEP	O
waveforms	O
within	O
10	O
min.	O
One	O
patient	O
showed	O
no	O
recovery	O
of	O
later	O
waves	O
and	O
a	O
delayed	O
profound	O
sensorineural	Disease
hearing	Disease
loss	Disease
.	O
The	O
average	O
recovery	O
time	O
of	O
BAEP	O
waveforms	O
to	O
pre-	O
papaverine	Chemical
baseline	O
values	O
was	O
39	O
min.	O
CONCLUSIONS:	O
Topical	O
papaverine	Chemical
for	O
the	O
treatment	O
of	O
vasospasm	Disease
was	O
associated	O
with	O
the	O
onset	O
of	O
a	O
transient	O
disturbance	O
in	O
neurophysiological	O
function	O
of	O
the	O
ascending	O
auditory	O
brainstem	O
pathway.	O
The	O
complete	O
disappearance	O
of	O
BAEP	O
waveforms	O
with	O
a	O
consistent	O
temporal	O
delay	O
suggests	O
a	O
possible	O
adverse	Disease
effect	Disease
on	Disease
the	Disease
proximal	Disease
eighth	Disease
nerve	Disease
.	O
Recommendations	O
to	O
avoid	O
potential	O
cranial	Disease
nerve	Disease
deficits	Disease
from	O
papaverine	Chemical

Massive	O
proteinuria	Disease
and	O
acute	Disease
renal	Disease
failure	Disease
after	O
oral	O
bisphosphonate	Chemical
(	O
alendronate	Chemical
)	O
administration	O
in	O
a	O
patient	O
with	O
focal	Disease
segmental	Disease
glomerulosclerosis	Disease
.	O
A	O
61-year-old	O
Japanese	O
man	O
with	O
nephrotic	Disease
syndrome	Disease
due	O
to	O
focal	Disease
segmental	Disease
glomerulosclerosis	Disease
was	O
initially	O
responding	O
well	O
to	O
steroid	Chemical
therapy.	O
The	O
amount	O
of	O
daily	O
urinary	O
protein	O
decreased	O
from	O
15.6	O
to	O
2.8	O
g.	O
Within	O
14	O
days	O
of	O
the	O
oral	O
bisphosphonate	Chemical
(	O
alendronate	Chemical
sodium	Chemical
)	O
administration,	O
the	O
amount	O
of	O
daily	O
urinary	O
protein	O
increased	O
rapidly	O
up	O
to	O
12.8	O
g	O
with	O
acute	Disease
renal	Disease
failure	Disease
.	O
After	O
discontinuing	O
the	O
oral	O
alendronate	Chemical
,	O
the	O
patient	O
underwent	O
six	O
cycles	O
of	O
hemodialysis	O
and	O
four	O
cycles	O
of	O
LDL	O
apheresis.	O
Urinary	O
volume	O
and	O
serum	O
creatinine	Chemical
levels	O
recovered	O
to	O
the	O
normal	O
range,	O
with	O
urinary	O
protein	O
disappearing	O
completely	O
within	O
40	O
days.	O
This	O
report	O
demonstrates	O
that	O
not	O
only	O
intravenous,	O
but	O
also	O
oral	O
bisphosphonates	Chemical
can	O
aggravate	O
proteinuria	Disease
and	O
acute	Disease
renal	Disease
failure	Disease

Serum-	O
and	O
glucocorticoid-inducible	O
kinase	O
1	O
in	O
doxorubicin	Chemical
-induced	O
nephrotic	Disease
syndrome	Disease
.	O
Doxorubicin	Chemical
-induced	O
nephropathy	Disease
leads	O
to	O
epithelial	O
sodium	Chemical
channel	O
(ENaC)-dependent	O
volume	Disease
retention	Disease
and	O
renal	O
fibrosis	Disease
.	O
The	O
aldosterone	Chemical
-sensitive	O
serum-	O
and	O
glucocorticoid-inducible	O
kinase	O
SGK1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
stimulation	O
of	O
ENaC	O
and	O
to	O
mediate	O
renal	O
fibrosis	Disease
following	O
mineralocorticoid	O
and	O
salt	O
excess.	O
The	O
present	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	O
in	O
the	O
volume	Disease
retention	Disease
and	O
fibrosis	Disease
during	O
nephrotic	Disease
syndrome	Disease
.	O
To	O
this	O
end,	O
doxorubicin	Chemical
(15	O
mug/g	O
body	O
wt)	O
was	O
injected	O
intravenously	O
into	O
gene-targeted	O
mice	O
lacking	O
SGK1	O
(sgk1(-/-))	O
and	O
their	O
wild-type	O
littermates	O
(sgk1(+/+)).	O
Doxorubicin	Chemical
treatment	O
resulted	O
in	O
heavy	O
proteinuria	Disease
(>100	O
mg	O
protein/mg	O
crea)	O
in	O
15/44	O
of	O
sgk1(+/+)	O
and	O
15/44	O
of	O
sgk1(-/-)	O
mice	O
leading	O
to	O
severe	O
nephrotic	Disease
syndrome	Disease
with	O
ascites	Disease
,	O
lipidemia	Disease
,	O
and	O
hypoalbuminemia	Disease
in	O
both	O
genotypes.	O
Plasma	O
aldosterone	Chemical
levels	O
increased	O
in	O
nephrotic	Disease
mice	O
of	O
both	O
genotypes	O
and	O
was	O
followed	O
by	O
increased	O
SGK1	O
protein	O
expression	O
in	O
sgk1(+/+)	O
mice.	O
Urinary	O
sodium	Chemical
excretion	O
reached	O
signficantly	O
lower	O
values	O
in	O
sgk1(+/+)	O
mice	O
(15	O
+/-	O
5	O
mumol/mg	O
crea)	O
than	O
in	O
sgk1(-/-)	O
mice	O
(35	O
+/-	O
5	O
mumol/mg	O
crea)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
body	O
weight	Disease
gain	Disease
in	O
sgk1(+/+)	O
compared	O
with	O
sgk1(-/-)	O
mice	O
(+6.6	O
+/-	O
0.7	O
vs.	O
+4.1	O
+/-	O
0.8	O
g).	O
During	O
the	O
course	O
of	O
nephrotic	Disease
syndrome	Disease
,	O
serum	O
urea	Chemical
concentrations	O
increased	O
significantly	O
faster	O
in	O
sgk1(-/-)	O
mice	O
than	O
in	O
sgk1(+/+)	O
mice	O
leading	O
to	O
uremia	Disease
and	O
a	O
reduced	O
median	O
survival	O
in	O
sgk1(-/-)	O
mice	O
(29	O
vs.	O
40	O
days	O
in	O
sgk1(+/+)	O
mice).	O
In	O
conclusion,	O
gene-targeted	O
mice	O
lacking	O
SGK1	O
showed	O
blunted	O
volume	Disease
retention	Disease
,	O
yet	O
were	O
not	O
protected	O
against	O
renal	O
fibrosis	Disease
during	O
experimental	O
nephrotic	Disease
syndrome	Disease

Severe	O
and	O
long	O
lasting	O
cholestasis	Disease
after	O
high-dose	O
co-trimoxazole	Chemical
treatment	O
for	O
Pneumocystis	Disease
pneumonia	Disease
in	O
HIV-infected	Disease
patients--a	O
report	O
of	O
two	O
cases.	O
Pneumocystis	Disease
pneumonia	Disease
(	O
PCP	Disease
),	O
a	O
common	O
opportunistic	Disease
infection	Disease
in	O
HIV-infected	Disease
individuals,	O
is	O
generally	O
treated	O
with	O
high	O
doses	O
of	O
co-trimoxazole	Chemical
.	O
However,	O
treatment	O
is	O
often	O
limited	O
by	O
adverse	O
effects.	O
Here,	O
we	O
report	O
two	O
cases	O
of	O
severely	O
immunocompromised	O
HIV-infected	Disease
patients	O
who	O
developed	O
severe	O
intrahepatic	Disease
cholestasis	Disease
,	O
and	O
in	O
one	O
patient	O
lesions	O
mimicking	O
liver	Disease
abscess	Disease
formation	O
on	O
radiologic	O
exams,	O
during	O
co-trimoxazole	Chemical
treatment	O
for	O
PCP	Disease
.	O
Whereas	O
patient	O
1	O
showed	O
lesions	O
of	O
up	O
to	O
1	O
cm	O
readily	O
detectable	O
on	O
magnetic	O
resonance	O
imaging	O
under	O
prolonged	O
co-trimoxazole	Chemical

Clinically	O
significant	O
proteinuria	Disease
following	O
the	O
administration	O
of	O
sirolimus	Chemical
to	O
renal	O
transplant	O
recipients.	O
BACKGROUND:	O
Sirolimus	Chemical
is	O
the	O
latest	O
immunosuppressive	O
agent	O
used	O
to	O
prevent	O
rejection,	O
and	O
may	O
have	O
less	O
nephrotoxicity	Disease
than	O
calcineurin	O
inhibitor	O
(CNI)-based	O
regimens.	O
To	O
date	O
there	O
has	O
been	O
little	O
documentation	O
of	O
clinically	O
significant	O
proteinuria	Disease
linked	O
with	O
the	O
use	O
of	O
sirolimus	Chemical
.	O
We	O
have	O
encountered	O
several	O
patients	O
who	O
developed	O
substantial	O
proteinuria	Disease
associated	O
with	O
sirolimus	Chemical
use.	O
In	O
each	O
patient,	O
the	O
close	O
temporal	O
association	O
between	O
the	O
commencement	O
of	O
sirolimus	Chemical
therapy	O
and	O
proteinuria	Disease
implicated	O
sirolimus	Chemical
as	O
the	O
most	O
likely	O
etiology	O
of	O
the	O
proteinuria	Disease
.	O
METHODS:	O
We	O
analyzed	O
the	O
clinical	O
and	O
laboratory	O
information	O
available	O
for	O
all	O
119	O
patients	O
transplanted	O
at	O
the	O
Washington	O
Hospital	O
Center	O
between	O
1999-2003	O
for	O
whom	O
sirolimus	Chemical
was	O
a	O
component	O
of	O
their	O
immunosuppressant	O
regimen.	O
In	O
these	O
patients,	O
the	O
magnitude	O
of	O
proteinuria	Disease
was	O
assessed	O
on	O
morning	O
urine	O
samples	O
by	O
turbidometric	O
measurement	O
or	O
random	O
urine	O
protein:	O
creatinine	Chemical
ratios,	O
an	O
estimate	O
of	O
grams	O
of	O
proteinuria	Disease
/day.	O
Laboratory	O
results	O
were	O
compared	O
between	O
prior,	O
during	O
and	O
following	O
sirolimus	Chemical
use.	O
RESULTS:	O
Twenty-eight	O
patients	O
(24%)	O
developed	O
increased	O
proteinuria	Disease
from	O
baseline	O
during	O
their	O
post-transplantation	O
course.	O
In	O
21	O
patients	O
an	O
alternative	O
cause	O
of	O
proteinuria	Disease
was	O
either	O
obvious	O
or	O
insufficient	O
data	O
was	O
available	O
to	O
be	O
conclusive.	O
In	O
7	O
of	O
the	O
28	O
patients	O
there	O
was	O
a	O
striking	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
sirolimus	Chemical
and	O
the	O
development	O
of	O
nephrotic	Disease
-range	O
proteinuria	Disease
.	O
Proteinuria	Disease
correlated	O
most	O
strongly	O
with	O
sirolimus	Chemical
therapy	O
when	O
compared	O
to	O
other	O
demographic	O
and	O
clinical	O
variables.	O
In	O
most	O
patients,	O
discontinuation	O
of	O
sirolimus	Chemical
resulted	O
in	O
a	O
decrease,	O
but	O
not	O
resolution,	O
of	O
proteinuria	Disease
.	O
CONCLUSIONS:	O
Sirolimus	Chemical
induces	O
or	O
aggravates	O
pre-existing	O
proteinuria	Disease
in	O
an	O
unpredictable	O
subset	O
of	O
renal	O
allograft	O
recipients.	O
Proteinuria	Disease
may	O
improve,	O
but	O
does	O
not	O
resolve,	O
when	O
sirolimus	Chemical

Comparative	O
cognitive	O
and	O
subjective	O
side	O
effects	O
of	O
immediate-release	O
oxycodone	Chemical
in	O
healthy	O
middle-aged	O
and	O
older	O
adults.	O
This	O
study	O
measured	O
the	O
objective	O
and	O
subjective	O
neurocognitive	O
effects	O
of	O
a	O
single	O
10-mg	O
dose	O
of	O
immediate-release	O
oxycodone	Chemical
in	O
healthy,	O
older	O
(>	O
65	O
years),	O
and	O
middle-aged	O
(35	O
to	O
55	O
years)	O
adults	O
who	O
were	O
not	O
suffering	O
from	O
chronic	O
or	O
significant	O
daily	O
pain	Disease
.	O
Seventy-one	O
participants	O
completed	O
2	O
separate	O
study	O
days	O
and	O
were	O
blind	O
to	O
medication	O
condition	O
(placebo,	O
10-mg	O
oxycodone	Chemical
).	O
Plasma	O
oxycodone	Chemical
concentration	O
peaked	O
between	O
60	O
and	O
90	O
minutes	O
postdose	O
(P	O
<	O
.01)	O
and	O
pupil	O
size,	O
an	O
indication	O
of	O
physiological	O
effects	O
of	O
the	O
medication,	O
peaked	O
at	O
approximately	O
90	O
to	O
120	O
minutes	O
postdose	O
(P	O
<	O
.01).	O
Significant	O
declines	Disease
in	Disease
simple	Disease
and	Disease
sustained	Disease
attention,	Disease
working	Disease
memory,	Disease
and	Disease
verbal	Disease
memory	Disease
were	O
observed	O
at	O
1	O
hour	O
postdose	O
compared	O
to	O
baseline	O
for	O
both	O
age	O
groups	O
with	O
a	O
trend	O
toward	O
return	O
to	O
baseline	O
by	O
5	O
hours	O
postdose.	O
For	O
almost	O
all	O
cognitive	O
measures,	O
there	O
were	O
no	O
medication	O
by	O
age-interaction	O
effects,	O
which	O
indicates	O
that	O
the	O
2	O
age	O
groups	O
exhibited	O
similar	O
responses	O
to	O
the	O
medication	O
challenge.	O
This	O
study	O
suggests	O
that	O
for	O
healthy	O
older	O
adults	O
who	O
are	O
not	O
suffering	O
from	O
chronic	Disease
pain	Disease
,	O
neurocognitive	O
and	O
pharmacodynamic	O
changes	O
in	O
response	O
to	O
a	O
10-mg	O
dose	O
of	O
immediate-release	O
oxycodone	Chemical
are	O
similar	O
to	O
those	O
observed	O
for	O
middle-aged	O
adults.	O
PERSPECTIVE:	O
Study	O
findings	O
indicate	O
that	O
the	O
metabolism,	O
neurocognitive	O
effects,	O
and	O
physical	O
side	O
effects	O
of	O
oral	O
oxycodone	Chemical

Normalizing	O
effects	O
of	O
modafinil	Chemical
on	O
sleep	O
in	O
chronic	O
cocaine	Chemical
users.	O
OBJECTIVE:	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
morning-dosed	O
modafinil	Chemical
on	O
sleep	O
and	O
daytime	Disease
sleepiness	Disease
in	O
chronic	O
cocaine	Chemical
users.	O
METHOD:	O
Twenty	O
cocaine	Chemical
-dependent	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modafinil	Chemical
,	O
400	O
mg	O
(N=10),	O
or	O
placebo	O
(N=10)	O
every	O
morning	O
at	O
7:30	O
a.m.	O
for	O
16	O
days	O
in	O
an	O
inpatient,	O
double-blind	O
randomized	O
trial.	O
Participants	O
underwent	O
polysomnographic	O
sleep	O
recordings	O
on	O
days	O
1	O
to	O
3,	O
7	O
to	O
9,	O
and	O
14	O
to	O
16	O
(first,	O
second,	O
and	O
third	O
weeks	O
of	O
abstinence).	O
The	O
Multiple	O
Sleep	O
Latency	O
Test	O
was	O
performed	O
at	O
11:30	O
a.m.,	O
2:00	O
p.m.,	O
and	O
4:30	O
p.m.	O
on	O
days	O
2,	O
8,	O
and	O
15.	O
For	O
comparison	O
of	O
sleep	O
architecture	O
variables,	O
12	O
healthy	O
comparison	O
participants	O
underwent	O
a	O
single	O
night	O
of	O
experimental	O
polysomnography	O
that	O
followed	O
1	O
night	O
of	O
accommodation	O
polysomnography.	O
RESULTS:	O
Progressive	O
abstinence	O
from	O
cocaine	Chemical
was	O
associated	O
with	O
worsening	O
of	O
all	O
measured	O
polysomnographic	O
sleep	O
outcomes.	O
Compared	O
with	O
placebo,	O
modafinil	Chemical
decreased	O
nighttime	O
sleep	O
latency	O
and	O
increased	O
slow-wave	O
sleep	O
time	O
in	O
cocaine	Chemical
-dependent	O
participants.	O
The	O
effect	O
of	O
modafinil	Chemical
interacted	O
with	O
the	O
abstinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
time	O
and	O
shorter	O
REM	O
sleep	O
latency	O
in	O
the	O
third	O
week	O
of	O
abstinence.	O
Comparison	O
of	O
slow-wave	O
sleep	O
time,	O
total	O
sleep	O
time,	O
and	O
sleep	O
latency	O
in	O
cocaine	Chemical
-dependent	O
and	O
healthy	O
participants	O
revealed	O
a	O
normalizing	O
effect	O
of	O
modafinil	Chemical
in	O
cocaine	Chemical
-dependent	O
participants.	O
Modafinil	Chemical
was	O
associated	O
with	O
increased	O
daytime	O
sleep	O
latency,	O
as	O
measured	O
by	O
the	O
Multiple	O
Sleep	O
Latency	O
Test,	O
and	O
a	O
nearly	O
significant	O
decrease	O
in	O
subjective	O
daytime	Disease
sleepiness	Disease
.	O
CONCLUSIONS:	O
Morning-dosed	O
modafinil	Chemical
promotes	O
nocturnal	O
sleep,	O
normalizes	O
sleep	O
architecture,	O
and	O
decreases	O
daytime	Disease
sleepiness	Disease
in	O
abstinent	O
cocaine	Chemical
users.	O
These	O
effects	O
may	O
be	O
relevant	O
in	O
the	O
treatment	O
of	O
cocaine	Chemical

Efficacy	O
and	O
safety	O
of	O
asenapine	Chemical
in	O
a	O
placebo-	O
and	O
haloperidol	Chemical
-controlled	O
trial	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
schizophrenia	Disease
.	O
Asenapine	Chemical
is	O
approved	O
by	O
the	O
Food	O
and	O
Drugs	O
Administration	O
in	O
adults	O
for	O
acute	O
treatment	O
of	O
schizophrenia	Disease
or	O
of	O
manic	Disease
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	Disease
I	Disease
disorder	Disease
with	O
or	O
without	O
psychotic	Disease
features.	O
In	O
a	O
double-blind	O
6-week	O
trial,	O
458	O
patients	O
with	O
acute	O
schizophrenia	Disease
were	O
randomly	O
assigned	O
to	O
fixed-dose	O
treatment	O
with	O
asenapine	Chemical
at	O
5	O
mg	O
twice	O
daily	O
(BID),	O
asenapine	Chemical
at	O
10	O
mg	O
BID,	O
placebo,	O
or	O
haloperidol	Chemical
at	O
4	O
mg	O
BID	O
(to	O
verify	O
assay	O
sensitivity).	O
With	O
last	O
observations	O
carried	O
forward	O
(LOCF),	O
mean	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
total	O
score	O
reductions	O
from	O
baseline	O
to	O
endpoint	O
were	O
significantly	O
greater	O
with	O
asenapine	Chemical
at	O
5	O
mg	O
BID	O
(-16.2)	O
and	O
haloperidol	Chemical
(-15.4)	O
than	O
placebo	O
(-10.7;	O
both	O
P	O
<	O
0.05);	O
using	O
mixed	O
model	O
for	O
repeated	O
measures	O
(MMRM),	O
changes	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
asenapine	Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
(-21.3	O
and	O
-19.4,	O
respectively)	O
and	O
haloperidol	Chemical
(-20.0)	O
than	O
placebo	O
(-14.6;	O
all	O
P	O
<	O
0.05).	O
On	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
positive	O
subscale,	O
all	O
treatments	O
were	O
superior	O
to	O
placebo	O
with	O
LOCF	O
and	O
MMRM;	O
asenapine	Chemical
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
negative	O
subscale	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopathology	O
subscale	O
with	O
LOCF	O
and	O
MMRM.	O
Treatment-related	O
adverse	O
events	O
(AEs)	O
occurred	O
in	O
44%	O
and	O
52%,	O
57%,	O
and	O
41%	O
of	O
the	O
asenapine	Chemical
at	O
5	O
and	O
10	O
mg	O
BID,	O
haloperidol	Chemical
,	O
and	O
placebo	O
groups,	O
respectively.	O
Extrapyramidal	Disease
symptoms	Disease
reported	O
as	O
AEs	O
occurred	O
in	O
15%	O
and	O
18%,	O
34%,	O
and	O
10%	O
of	O
the	O
asenapine	Chemical
at	O
5	O
and	O
10	O
mg	O
BID,	O
haloperidol	Chemical
,	O
and	O
placebo	O
groups,	O
respectively.	O
Across	O
all	O
groups,	O
no	O
more	O
than	O
5%	O
of	O
patients	O
had	O
clinically	O
significant	O
weight	O
change.	O
Post	O
hoc	O
analyses	O
indicated	O
that	O
efficacy	O
was	O
similar	O
with	O
asenapine	Chemical
and	O
haloperidol	Chemical
;	O
greater	O
contrasts	O
were	O
seen	O
in	O
AEs,	O
especially	O
extrapyramidal	Disease
symptoms	Disease

Permeability,	O
ultrastructural	O
changes,	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	Chemical
aminonucleoside	Chemical
	O
nephrosis	Disease
.	O
BACKGROUND/AIMS:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	Disease
starts.	O
Using	O
puromycin	Chemical
aminonucleoside	Chemical
	O
nephrosis	Disease
(PAN)	O
rats,	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte-associated	O
molecules	O
nephrin,	O
a-actinin,	O
dendrin,	O
and	O
plekhh2,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes.	O
METHODS:	O
Using	O
immune	O
stainings,	O
semiquantitative	O
measurement	O
was	O
performed	O
under	O
the	O
electron	O
microscope.	O
Permeability	O
was	O
assessed	O
using	O
isolated	O
kidney	O
perfusion	O
with	O
tracers.	O
Possible	O
effects	O
of	O
ACE	O
inhibition	O
were	O
tested.	O
RESULTS:	O
By	O
day	O
2,	O
some	O
patchy	O
foot	O
process	O
effacement,	O
but	O
no	O
proteinuria	Disease
,	O
appeared.	O
The	O
amount	O
of	O
nephrin	O
was	O
reduced	O
in	O
both	O
diseased	O
and	O
normal	O
areas.	O
The	O
other	O
proteins	O
showed	O
few	O
changes,	O
which	O
were	O
limited	O
to	O
diseased	O
areas.	O
By	O
day	O
4,	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	Disease
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage.	O
Nephrin	O
decreased	O
further,	O
while	O
dendrin	O
and	O
plekhh2	O
also	O
decreased	O
but	O
a-actinin	O
remained	O
unchanged.	O
ACE	O
inhibition	O
had	O
no	O
significant	O
protective	O
effect.	O
CONCLUSIONS:	O
PAN	O
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4,	O
despite	O
relatively	O
mild	O
proteinuria	Disease

Twin	O
preterm	O
neonates	O
with	O
cardiac	Disease
toxicity	Disease
related	O
to	O
lopinavir/ritonavir	Chemical
therapy.	O
We	O
report	O
twin	O
neonates	O
who	O
were	O
born	O
prematurely	O
at	O
32	O
weeks	O
of	O
gestation	O
to	O
a	O
mother	O
with	O
human	Disease
immunodeficiency	Disease
virus	Disease
infection	Disease
.	O
One	O
of	O
the	O
twins	O
developed	O
complete	O
heart	Disease
block	Disease
and	O
dilated	Disease
cardiomyopathy	Disease
related	O
to	O
lopinavir/ritonavir	Chemical
therapy,	O
a	O
boosted	O
protease-inhibitor	O
agent,	O
while	O
the	O
other	O
twin	O
developed	O
mild	O
bradycardia	Disease
.	O
We	O
recommend	O
caution	O
in	O
the	O
use	O
of	O
lopinavir/ritonavir	Chemical

Learning	O
of	O
rats	O
under	O
amnesia	Disease
caused	O
by	O
pentobarbital	Chemical
.	O
Dissociated	O
learning	O
of	O
rats	O
in	O
the	O
normal	O
state	O
and	O
the	O
state	O
of	O
amnesia	Disease
produced	O
by	O
pentobarbital	Chemical
(15	O
mg/kg,	O
ip)	O
was	O
carried	O
out.	O
Rats	O
were	O
trained	O
to	O
approach	O
a	O
shelf	O
where	O
they	O
received	O
food	O
reinforcement.	O
In	O
Group	O
1	O
the	O
rats	O
were	O
trained	O
under	O
the	O
influence	O
of	O
pentobarbital	Chemical
to	O
run	O
to	O
the	O
same	O
shelf	O
as	O
in	O
the	O
normal	O
state.	O
In	O
Group	O
2	O
the	O
rats	O
were	O
trained	O
to	O
approach	O
different	O
shelves	O
in	O
different	O
drug	O
states.	O
It	O
was	O
shown	O
that	O
memory	Disease
dissociation	Disease
occurred	O
in	O
both	O
groups.	O
Differences	O
in	O
the	O
parameters	O
of	O
training	O
under	O
the	O
influence	O
of	O
pentobarbital	Chemical
between	O
Groups	O
1	O
and	O
2	O
were	O
revealed.	O
These	O
findings	O
show	O
that	O
the	O
brain-dissociated	O
state	O
induced	O
by	O
pentobarbital	Chemical

Angiosarcoma	Disease
of	Disease
the	Disease
liver	Disease
associated	O
with	O
diethylstilbestrol	Chemical
.	O
Angiosarcoma	Disease
of	Disease
the	Disease
liver	Disease
occurred	O
in	O
a	O
76-year-old	O
man	O
who	O
had	O
been	O
treated	O
for	O
a	O
well-differentiated	O
adenocarcinoma	Disease
of	Disease
the	Disease
liver	Disease
with	O
diethylstilbestrol	Chemical
for	O
13	O
years.	O
Angiosarcoma	Disease
was	O
also	O
present	O
within	O
pulmonary	O
and	O
renal	O
arteries.	O
The	O
possibility	O
that	O
the	O
intraarterial	Disease
lesions	Disease
might	O
represent	O
independent	O
primary	O
tumors	Disease

Role	O
of	O
xanthine	Chemical
oxidase	O
in	O
dexamethasone	Chemical
-induced	O
hypertension	Disease
in	O
rats.	O
1.	O
Glucocorticoid-induced	O
hypertension	Disease
(GC-	O
HT	Disease
)	O
in	O
the	O
rat	O
is	O
associated	O
with	O
nitric	Chemical
oxide	Chemical
-redox	O
imbalance.	O
2.	O
We	O
studied	O
the	O
role	O
of	O
xanthine	Chemical
oxidase	O
(XO),	O
which	O
is	O
implicated	O
in	O
the	O
production	O
of	O
reactive	O
oxygen	O
species,	O
in	O
dexamethasone	Chemical
-induced	O
hypertension	Disease
(	O
dex	Chemical
-	O
HT	Disease
).	O
3.	O
Thirty	O
male	O
Sprague-Dawley	O
rats	O
were	O
divided	O
randomly	O
into	O
four	O
treatment	O
groups:	O
saline,	O
dexamethasone	Chemical
(	O
dex	Chemical
),	O
allopurinol	Chemical
plus	O
saline,	O
and	O
allopurinol	Chemical
plus	O
dex	Chemical
.	O
4.	O
Systolic	O
blood	O
pressures	O
(SBP)	O
and	O
bodyweights	O
were	O
recorded	O
each	O
alternate	O
day.	O
Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity,	O
and	O
serum	O
urate	Chemical
to	O
assess	O
XO	O
inhibition.	O
5.	O
Dex	Chemical
	O
increased	Disease
SBP	Disease
(110	O
+/-	O
2-126	O
+/-	O
3	O
mmHg;	O
P	O
<	O
0.001)	O
and	O
decreased	Disease
thymus	Disease
(P	Disease
<	Disease
0.001)	Disease
and	Disease
bodyweights	Disease
(P"	O
<	O
0.01).	O
Allopurinol	Chemical
decreased	O
serum	O
urate	Chemical
from	O
76	O
+/-	O
5	O
to	O
30	O
+/-	O
3	O
micromol/L	O
(P	O
<	O
0.001)	O
in	O
saline	O
and	O
from	O
84	O
+/-	O
13	O
to	O
28	O
+/-	O
2	O
micromol/L	O
in	O
dex	Chemical
-treated	O
(P	O
<	O
0.01)	O
groups.	O
6.	O
Allopurinol	Chemical
did	O
not	O
prevent	O
dex	Chemical
-	O
HT	Disease
.	O
This,	O
together	O
with	O
our	O
previous	O
findings	O
that	O
allopurinol	Chemical
failed	O
to	O
prevent	O
adrenocorticotrophic	O
hormone	O
induced	O
hypertension	Disease
,	O
suggests	O
that	O
XO	O
activity	O
is	O
not	O
a	O
major	O
determinant	O
of	O
GC-	O
HT	Disease

Extrapyramidal	O
side	O
effects	O
with	O
risperidone	Chemical
and	O
haloperidol	Chemical
at	O
comparable	O
D2	O
receptor	O
occupancy	O
levels.	O
Risperidone	Chemical
is	O
an	O
antipsychotic	O
drug	O
with	O
high	O
affinity	O
at	O
dopamine	Chemical
D2	O
and	O
serotonin	Chemical
5-HT2	Chemical
receptors.	O
Previous	O
clinical	O
studies	O
have	O
proposed	O
that	O
risperidone	Chemical
's	O
pharmacologic	O
profile	O
may	O
produce	O
improved	O
efficacy	O
for	O
negative	O
psychotic	Disease
symptoms	Disease
and	O
decreased	O
propensity	O
for	O
extrapyramidal	O
side	O
effects;	O
features	O
shared	O
by	O
so-called	O
'atypical'	O
neuroleptics.	O
To	O
determine	O
if	O
routine	O
risperidone	Chemical
treatment	O
is	O
associated	O
with	O
a	O
unique	O
degree	O
of	O
D2	O
receptor	O
occupancy	O
and	O
pattern	O
of	O
clinical	O
effects,	O
we	O
used	O
[123I]IBZM	O
SPECT	O
to	O
determine	O
D2	O
occupancy	O
in	O
subjects	O
treated	O
with	O
routine	O
clinical	O
doses	O
of	O
risperidone	Chemical
(n	O
=	O
12)	O
or	O
haloperidol	Chemical
(n	O
=	O
7).	O
Both	O
risperidone	Chemical
and	O
haloperidol	Chemical
produced	O
D2	O
occupancy	O
levels	O
between	O
approximately	O
60	O
and	O
90%	O
at	O
standard	O
clinical	O
doses.	O
There	O
was	O
no	O
significant	O
difference	O
between	O
occupancy	O
levels	O
obtained	O
with	O
haloperidol	Chemical
or	O
risperidone	Chemical
.	O
Drug-induced	Disease
parkinsonism	Disease
was	O
observed	O
in	O
subjects	O
treated	O
with	O
risperidone	Chemical
(42%)	O
and	O
haloperidol	Chemical
(29%)	O
and	O
was	O
observed	O
at	O
occupancy	O
levels	O
above	O
60%.	O
Based	O
on	O
these	O
observations,	O
it	O
is	O
concluded	O
that	O
5-HT2	O
blockade	O
obtained	O
with	O
risperidone	Chemical

Simvastatin-ezetimibe	Chemical
-induced	O
hepatic	Disease
failure	Disease
necessitating	O
liver	O
transplantation.	O
Abstract	O
Serum	O
aminotransferase	O
elevations	O
are	O
a	O
commonly	O
known	O
adverse	O
effect	O
of	O
3-hydroxy-3-methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitor	O
(	O
statin	Chemical
)	O
therapy.	O
However,	O
hepatotoxic	Disease
events	O
have	O
not	O
been	O
widely	O
published	O
with	O
ezetimibe	Chemical
or	O
the	O
combination	O
agent	O
simvastatin-ezetimibe	Chemical
.	O
We	O
describe	O
a	O
70-year-old	O
Hispanic	O
woman	O
who	O
developed	O
fulminant	Disease
hepatic	Disease
failure	Disease
necessitating	O
liver	O
transplantation	O
10	O
weeks	O
after	O
conversion	O
from	O
simvastatin	Chemical
40	O
mg/day	O
to	O
simvastatin	Chemical
10	Chemical
mg-ezetimibe	Chemical
40	Chemical
mg	Chemical
/day.	O
The	O
patient's	O
lipid	O
panel	O
had	O
been	O
maintained	O
with	O
simvastatin	Chemical
for	O
18	O
months	O
before	O
the	O
conversion	O
without	O
evidence	O
of	O
hepatotoxicity	Disease
.	O
A	O
routine	O
laboratory	O
work-up	O
10	O
weeks	O
after	O
conversion	O
revealed	O
elevated	O
serum	O
aminotransferase	O
levels.	O
Simvastatinezetimibe	Chemical
and	O
escitalopram	Chemical
(which	O
she	O
was	O
taking	O
for	O
depression	Disease
)	O
were	O
discontinued,	O
and	O
other	O
potential	O
causes	O
of	O
hepatotoxicity	Disease
were	O
excluded.	O
A	O
repeat	O
work-up	O
revealed	O
further	O
elevations	O
in	O
aminotransferase	O
levels,	O
and	O
liver	O
biopsy	O
revealed	O
evidence	O
of	O
moderate-to-severe	O
drug	Disease
toxicity	Disease
.	O
She	O
underwent	O
liver	O
transplantation	O
with	O
an	O
uneventful	O
postoperative	O
course.	O
Her	O
aminotransferase	O
levels	O
returned	O
to	O
normal	O
by	O
postoperative	O
day	O
23,	O
and	O
her	O
2-year	O
follow-up	O
showed	O
no	O
adverse	O
events.	O
Ezetimibe	Chemical
undergoes	O
extensive	O
glucuronidation	O
by	O
uridine	Chemical
diphosphate	Chemical
glucoronosyltransferases	O
(UGT)	O
in	O
the	O
intestine	O
and	O
liver	O
and	O
may	O
have	O
inhibited	O
the	O
glucuronidation	O
of	O
simvastatin	Chemical
hydroxy	Chemical
acid	Chemical
,	O
resulting	O
in	O
increased	O
simvastatin	Chemical
exposure	O
and	O
subsequent	O
hepatotoxicity	Disease
.	O
To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
simvastatin-ezetimibe	Chemical
-induced	O
liver	Disease
failure	Disease
that	O
resulted	O
in	O
liver	O
transplantation.	O
We	O
postulate	O
that	O
the	O
mechanism	O
of	O
the	O
simvastatinezetimibe	Chemical
-induced	O
hepatotoxicity	Disease
is	O
the	O
increased	O
simvastatin	Chemical
exposure	O
by	O
ezetimibe	Chemical
inhibition	O
of	O
UGT	O
enzymes.	O
Clinicians	O
should	O
be	O
aware	O
of	O
potential	O
hepatotoxicity	Disease
with	O
simvastatin-ezetimibe	Chemical

Oral	O
manifestations	O
of	O
"	O
meth	Disease
mouth	Disease
":	O
a	O
case	O
report.	O
AIM:	O
The	O
aim	O
of	O
the	O
documentation	O
of	O
this	O
clinical	O
case	O
is	O
to	O
make	O
clinicians	O
aware	O
of	O
"	O
meth	Disease
mouth	Disease
"	O
and	O
the	O
medical	O
risks	O
associated	O
with	O
this	O
serious	O
condition.	O
BACKGROUND:	O
Methamphetamine	Chemical
is	O
a	O
very	O
addictive,	O
powerful	O
stimulant	O
that	O
increases	O
wakefulness	O
and	O
physical	O
activity	O
and	O
can	O
produce	O
other	O
effects	O
such	O
as	O
cardiac	Disease
dysrhythmias	Disease
,	O
hypertension	Disease
,	O
hallucinations	Disease
,	O
and	O
violent	Disease
behavior	Disease
.	O
Dental	O
patients	O
abusing	O
methamphetamine	Chemical
can	O
present	O
with	O
poor	O
oral	O
hygiene,	O
xerostomia	Disease
,	O
rampant	O
caries	Disease
("	O
meth	Disease
mouth	Disease
"),	O
and	O
excessive	O
tooth	Disease
wear	Disease
.	O
Oral	O
rehabilitation	O
of	O
patients	O
using	O
methamphetamine	Chemical
can	O
be	O
challenging.	O
CASE	O
DESCRIPTION:	O
A	O
30-year-old	O
Caucasian	O
woman	O
presented	O
with	O
dental	O
pain	Disease
,	O
bad	Disease
breath	Disease
,	O
and	O
self-reported	O
poor	O
esthetics.	O
A	O
comprehensive	O
examination	O
including	O
her	O
medical	O
history,	O
panoramic	O
radiograph,	O
and	O
intraoral	O
examination	O
revealed	O
19	O
carious	Disease
lesions	Disease
,	O
which	O
is	O
not	O
very	O
common	O
for	O
a	O
healthy	O
adult.	O
She	O
reported	O
her	O
use	O
of	O
methamphetamine	Chemical
for	O
five	O
years	O
and	O
had	O
not	O
experienced	O
any	O
major	O
carious	Disease
episodes	Disease
before	O
she	O
started	O
using	O
the	O
drug.	O
SUMMARY:	O
The	O
patient's	O
medical	O
and	O
dental	O
histories	O
along	O
with	O
radiographic	O
and	O
clinical	O
findings	O
lead	O
to	O
a	O
diagnosis	O
of	O
"	O
meth	Disease
mouth	Disease
."	O
Although	O
three	O
different	O
dental	O
treatment	O
modalities	O
(either	O
conventional	O
or	O
implant-supported)	O
have	O
been	O
offered	O
to	O
the	O
patient	O
since	O
August	O
2007,	O
the	O
patient	O
has	O
yet	O
to	O
initiate	O
any	O
treatment.	O
CLINICAL	O
SIGNIFICANCE:	O
This	O
clinical	O
case	O
showing	O
oral	O
manifestations	O
of	O
meth	Disease
mouth	Disease
was	O
presented	O
to	O
help	O
dental	O
practitioners	O
recognize	O
and	O
manage	O
patients	O
who	O
may	O
be	O
abusing	O
methamphetamines	Chemical

Thyroxine	Chemical
abuse:	O
an	O
unusual	O
case	O
of	O
thyrotoxicosis	Disease
in	O
pregnancy.	O
Eating	Disease
disorders	Disease
and	O
the	O
associated	O
behavioural	O
problems	O
and	O
drug	Disease
abuse	Disease
are	O
uncommon	O
in	O
pregnancy.	O
When	O
they	O
do	O
occur	O
they	O
are	O
often	O
unrecognized	O
because	O
of	O
denial	O
but	O
when	O
significant	O
may	O
pose	O
a	O
risk	O
to	O
both	O
the	O
mother	O
and	O
her	O
fetus.	O
This	O
case	O
illustrates	O
a	O
number	O
of	O
problems	O
that	O
may	O
be	O
encountered	O
in	O
women	O
with	O
eating	Disease
disorders	Disease
in	O
pregnancy,	O
including	O
prolonged	O
and	O
recurrent	O
metabolic	O
disturbances	O
and	O
diuretic	O
abuse.	O
In	O
particular	O
it	O
illustrates	O
the	O
derangements	O
of	O
thyroid	O
function	O
seen	O
in	O
pregnant	O
women	O
with	O
eating	Disease
disorders	Disease
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyrotoxicosis	Disease
remains	O
obscure,	O
thyroxine	Chemical

Attenuation	O
of	O
methamphetamine	Chemical
-induced	O
nigrostriatal	O
dopaminergic	O
neurotoxicity	Disease
in	O
mice	O
by	O
lipopolysaccharide	Chemical
pretreatment.	O
Immunological	O
activation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methamphetamine	Chemical
-induced	O
dopaminergic	Disease
terminal	Disease
damage	Disease
.	O
In	O
this	O
study,	O
we	O
examined	O
the	O
roles	O
of	O
lipopolysaccharide	Chemical
,	O
a	O
pro-inflammatory	O
and	O
inflammatory	O
factor,	O
treatment	O
in	O
modulating	O
the	O
methamphetamine	Chemical
-induced	O
nigrostriatal	O
dopamine	Chemical
	O
neurotoxicity	Disease
.	O
Lipopolysaccharide	Chemical
pretreatment	O
did	O
not	O
affect	O
the	O
basal	O
body	O
temperature	O
or	O
methamphetamine	Chemical
-elicited	O
hyperthermia	Disease
three	O
days	O
later.	O
Such	O
systemic	O
lipopolysaccharide	Chemical
treatment	O
mitigated	O
methamphetamine	Chemical
-induced	O
striatal	O
dopamine	Chemical
and	O
3,4-dihydroxyphenylacetic	Chemical
acid	Chemical
depletions	O
in	O
a	O
dose-dependent	O
manner.	O
As	O
the	O
most	O
potent	O
dose	O
(1	O
mg/kg)	O
of	O
lipopolysaccharide	Chemical
was	O
administered	O
two	O
weeks,	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetamine	Chemical
dosing	O
regimen,	O
methamphetamine	Chemical
-induced	O
striatal	O
dopamine	Chemical
and	O
3,4-dihydroxyphenylacetic	Chemical
acid	Chemical
depletions	O
remained	O
unaltered.	O
Moreover,	O
systemic	O
lipopolysaccharide	Chemical
pretreatment	O
(1	O
mg/kg)	O
attenuated	O
local	O
methamphetamine	Chemical
infusion-produced	O
dopamine	Chemical
and	O
3,4-dihydroxyphenylacetic	Chemical
acid	Chemical
depletions	O
in	O
the	O
striatum,	O
indicating	O
that	O
the	O
protective	O
effect	O
of	O
lipopolysaccharide	Chemical
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peripheral	O
distribution	O
or	O
metabolism	O
of	O
methamphetamine	Chemical
.	O
We	O
concluded	O
a	O
critical	O
time	O
window	O
for	O
systemic	O
lipopolysaccharide	Chemical
pretreatment	O
in	O
exerting	O
effective	O
protection	O
against	O
methamphetamine	Chemical
-induced	O
nigrostriatal	O
dopamine	Chemical
	O
neurotoxicity	Disease

Effect	O
of	O
converting	O
enzyme	O
inhibition	O
on	O
the	O
course	O
of	O
adriamycin	Chemical
-induced	O
nephropathy	Disease
.	O
The	O
effect	O
of	O
the	O
converting	O
enzyme	O
inhibitor	O
(CEI)	O
enalapril	Chemical
was	O
assessed	O
in	O
Munich-Wistar	O
rats	O
with	O
established	O
adriamycin	Chemical
	O
nephrosis	Disease
.	O
Rats	O
were	O
given	O
a	O
single	O
dose	O
of	O
adriamycin	Chemical
and	O
one	O
month	O
later	O
divided	O
into	O
four	O
groups	O
matched	O
for	O
albuminuria	Disease
,	O
blood	O
pressure,	O
and	O
plasma	O
albumin	O
concentration.	O
Groups	O
1	O
and	O
3	O
remained	O
untreated	O
while	O
groups	O
2	O
and	O
4	O
received	O
enalapril	Chemical
.	O
Groups	O
1	O
and	O
2	O
underwent	O
micropuncture	O
studies	O
after	O
10	O
days.	O
These	O
short-term	O
studies	O
showed	O
that	O
enalapril	Chemical
reduced	O
arterial	O
blood	O
pressure	O
(101	O
+/-	O
2	O
vs.	O
124	O
+/-	O
3	O
mm	O
Hg,	O
group	O
2	O
vs.	O
1,	O
P	O
less	O
than	O
0.05)	O
and	O
glomerular	O
capillary	O
pressure	O
(54	O
+/-	O
1	O
vs.	O
61	O
+/-	O
2	O
mm	O
Hg,	O
P	O
less	O
than	O
0.05)	O
without	O
reducing	O
albuminuria	Disease
(617	O
+/-	O
50	O
vs.	O
570	O
+/-	O
47	O
mg/day)	O
or	O
GFR	O
(1.03	O
+/-	O
0.04	O
vs.	O
1.04	O
+/-	O
0.11	O
ml/min).	O
Groups	O
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
months	O
to	O
assess	O
the	O
effect	O
of	O
enalapril	Chemical
on	O
progression	O
of	O
renal	Disease
injury	Disease
in	O
adriamycin	Chemical
	O
nephrosis	Disease
.	O
Chronic	O
enalapril	Chemical
treatment	O
reduced	O
blood	O
pressure	O
without	O
reducing	O
albuminuria	Disease
in	O
group	O
4.	O
Untreated	O
group	O
3	O
rats	O
exhibited	O
a	O
progressive	O
reduction	O
in	O
GFR	O
(0.35	O
+/-	O
0.08	O
ml/min	O
at	O
4	O
months,	O
0.27	O
+/-	O
0.07	O
ml/min	O
at	O
6	O
months).	O
Enalapril	Chemical
treatment	O
blunted	O
but	O
did	O
not	O
prevent	O
reduction	O
in	O
GFR	O
in	O
group	O
4	O
(0.86	O
+/-	O
0.15	O
ml/min	O
at	O
4	O
months,	O
0.69	O
+/-	O
0.13	O
ml/min	O
at	O
6	O
months,	O
both	O
P	O
less	O
than	O
0.05	O
vs.	O
group	O
3).	O
Reduction	O
in	O
GFR	O
was	O
associated	O
with	O
the	O
development	O
of	O
glomerular	Disease
sclerosis	Disease

Butyrylcholinesterase	O
gene	O
mutations	O
in	O
patients	O
with	O
prolonged	O
apnea	Disease
after	O
succinylcholine	Chemical
for	O
electroconvulsive	O
therapy.	O
BACKGROUND:	O
patients	O
undergoing	O
electroconvulsive	O
therapy	O
(ECT)	O
often	O
receive	O
succinylcholine	Chemical
as	O
part	O
of	O
the	O
anesthetic	O
procedure.	O
The	O
duration	O
of	O
action	O
may	O
be	O
prolonged	O
in	O
patients	O
with	O
genetic	O
variants	O
of	O
the	O
butyrylcholinesterase	O
enzyme	O
(BChE),	O
the	O
most	O
common	O
being	O
the	O
K-	O
and	O
the	O
A-variants.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
significance	O
of	O
genetic	O
variants	O
in	O
butyrylcholinesterase	O
gene	O
(BCHE)	O
in	O
patients	O
with	O
a	O
suspected	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	Chemical
after	O
ECT.	O
METHODS:	O
a	O
total	O
of	O
13	O
patients	O
were	O
referred	O
to	O
the	O
Danish	O
Cholinesterase	O
Research	O
Unit	O
after	O
ECT	O
during	O
38	O
months.	O
We	O
determined	O
the	O
BChE	O
activity	O
and	O
the	O
BCHE	O
genotype	O
using	O
molecular	O
genetic	O
methods,	O
the	O
duration	O
of	O
apnea	Disease
,	O
time	O
to	O
sufficient	O
spontaneous	O
ventilation	O
and	O
whether	O
neuromuscular	O
monitoring	O
was	O
used.	O
The	O
duration	O
of	O
apnea	Disease
was	O
compared	O
with	O
published	O
data	O
on	O
normal	O
subjects.	O
RESULTS:	O
in	O
11	O
patients,	O
mutations	O
were	O
found	O
in	O
the	O
BCHE	O
gene,	O
the	O
K-variant	O
being	O
the	O
most	O
frequent.	O
The	O
duration	O
of	O
apnea	Disease
was	O
5-15	O
min	O
compared	O
with	O
3-5.3	O
min	O
from	O
the	O
literature.	O
Severe	O
distress	O
was	O
noted	O
in	O
the	O
recovery	O
phase	O
in	O
two	O
patients.	O
Neuromuscular	O
monitoring	O
was	O
used	O
in	O
two	O
patients.	O
CONCLUSION:	O
eleven	O
of	O
13	O
patients	O
with	O
a	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	Chemical
had	O
mutations	O
in	O
BCHE,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolonged	O
period	O
of	O
apnea	Disease

Ketamine	Chemical
sedation	O
for	O
the	O
reduction	O
of	O
children's	O
fractures	Disease
in	O
the	O
emergency	O
department.	O
BACKGROUND:	O
There	O
recently	O
has	O
been	O
a	O
resurgence	O
in	O
the	O
utilization	O
of	O
ketamine	Chemical
,	O
a	O
unique	O
anesthetic,	O
for	O
emergency-department	O
procedures	O
requiring	O
sedation.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
safety	O
and	O
efficacy	O
of	O
ketamine	Chemical
for	O
sedation	O
in	O
the	O
treatment	O
of	O
children's	O
fractures	Disease
in	O
the	O
emergency	O
department.	O
METHODS:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(average	O
age,	O
5.3	O
years;	O
range,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	Disease
or	O
dislocation	Disease
in	O
the	O
emergency	O
department	O
at	O
a	O
level-I	O
trauma	Disease
center	O
were	O
prospectively	O
evaluated.	O
Ketamine	Chemical
hydrochloride	Chemical
was	O
administered	O
intravenously	O
(at	O
a	O
dose	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight)	O
in	O
ninety-nine	O
of	O
the	O
patients	O
and	O
intramuscularly	O
(at	O
a	O
dose	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight)	O
in	O
the	O
other	O
fifteen.	O
A	O
board-certified	O
emergency	O
physician	O
skilled	O
in	O
airway	O
management	O
supervised	O
administration	O
of	O
the	O
anesthetic,	O
and	O
the	O
patients	O
were	O
monitored	O
by	O
a	O
registered	O
nurse.	O
Any	O
pain	Disease
during	O
the	O
reduction	O
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	O
according	O
to	O
the	O
Children's	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	Disease
Scale	O
(CHEOPS).	O
RESULTS:	O
The	O
average	O
time	O
from	O
intravenous	O
administration	O
of	O
ketamine	Chemical
to	O
manipulation	O
of	O
the	O
fracture	Disease
or	O
dislocation	Disease
was	O
one	O
minute	O
and	O
thirty-six	O
seconds	O
(range,	O
twenty	O
seconds	O
to	O
five	O
minutes),	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty-two	O
seconds	O
(range,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes).	O
The	O
average	O
score	O
according	O
to	O
the	O
Children's	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	Disease
Scale	O
was	O
6.4	O
points	O
(range,	O
5	O
to	O
10	O
points),	O
reflecting	O
minimal	O
or	O
no	O
pain	Disease
during	O
fracture	Disease
reduction.	O
Adequate	O
fracture	Disease
reduction	O
was	O
obtained	O
in	O
111	O
of	O
the	O
children.	O
Ninety-nine	O
percent	O
(sixty-eight)	O
of	O
the	O
sixty-nine	O
parents	O
present	O
during	O
the	O
reduction	O
were	O
pleased	O
with	O
the	O
sedation	O
and	O
would	O
allow	O
it	O
to	O
be	O
used	O
again	O
in	O
a	O
similar	O
situation.	O
Patency	O
of	O
the	O
airway	O
and	O
independent	O
respiration	O
were	O
maintained	O
in	O
all	O
of	O
the	O
patients.	O
Blood	O
pressure	O
and	O
heart	O
rate	O
remained	O
stable.	O
Minor	O
side	O
effects	O
included	O
nausea	Disease
(thirteen	O
patients),	O
emesis	Disease
(eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	Disease
),	O
clumsiness	Disease
(evident	O
as	O
ataxic	Disease
movements	Disease
in	O
ten	O
patients),	O
and	O
dysphoric	Disease
reaction	Disease
(one	O
patient).	O
No	O
long-term	O
sequelae	O
were	O
noted,	O
and	O
no	O
patients	O
had	O
hallucinations	Disease
or	O
nightmares.	O
CONCLUSIONS:	O
Ketamine	Chemical
reliably,	O
safely,	O
and	O
quickly	O
provided	O
adequate	O
sedation	O
to	O
effectively	O
facilitate	O
the	O
reduction	O
of	O
children's	O
fractures	Disease
in	O
the	O
emergency	O
department	O
at	O
our	O
institution.	O
Ketamine	Chemical

Prophylactic	O
use	O
of	O
lamivudine	Chemical
with	O
chronic	O
immunosuppressive	O
therapy	O
for	O
rheumatologic	Disease
disorders	Disease
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
report	O
our	O
experience	O
concerning	O
the	O
effectiveness	O
of	O
the	O
prophylactic	O
administration	O
of	O
lamivudine	Chemical
in	O
hepatitis	Chemical
B	Chemical
virus	Chemical
surface	Chemical
antigen	Chemical
(	O
HBs	Chemical
Ag	Chemical
)	O
positive	O
patients	O
with	O
rheumatologic	Disease
disease	Disease
.	O
From	O
June	O
2004	O
to	O
October	O
2006,	O
11	O
HBs	Chemical
Ag	Chemical
positive	O
patients	O
with	O
rheumatologic	Disease
diseases	Disease
,	O
who	O
were	O
on	O
both	O
immunosuppressive	O
and	O
prophylactic	O
lamivudine	Chemical
therapies,	O
were	O
retrospectively	O
assessed.	O
Liver	O
function	O
tests,	O
hepatitis	Disease
B	Disease
virus	O
(HBV)	O
serologic	O
markers,	O
and	O
HBV	O
DNA	O
levels	O
of	O
the	O
patients	O
during	O
follow-up	O
were	O
obtained	O
from	O
hospital	O
file	O
records.	O
Eleven	O
patients	O
(six	O
male)	O
with	O
median	O
age	O
47	O
years	O
(range	O
27-73),	O
median	O
disease	O
duration	O
50	O
months	O
(range	O
9-178)	O
and	O
median	O
follow-up	O
period	O
of	O
patients	O
13.8	O
months	O
(range	O
5-27)	O
were	O
enrolled	O
in	O
this	O
study.	O
Lamivudine	Chemical
therapy	O
was	O
started	O
3-7	O
days	O
prior	O
to	O
immunosuppressive	O
therapy	O
in	O
all	O
patients.	O
Baseline,	O
liver	O
function	O
tests	O
were	O
elevated	O
in	O
two	O
patients	O
(fourth	O
patient:	O
ALT:122	O
IU/l,	O
AST:111	O
IU/l,	O
tenth	O
patient:ALT:294	O
IU/l,	O
AST:274	O
IU/l,	O
with	O
minimal	O
changes	O
in	O
the	O
liver	O
biopsy	O
in	O
both).	O
Shortly	O
after	O
treatment	O
their	O
tests	O
normalized	O
and	O
during	O
follow-up	O
period	O
none	O
of	O
the	O
patients	O
had	O
abnormal	Disease
liver	Disease
function	Disease
tests.	O
In	O
four	O
patients	O
HBV	O
DNA	O
levels	O
were	O
higher	O
than	O
normal	O
at	O
baseline.	O
Two	O
of	O
these	O
normalized	O
and	O
the	O
others	O
increased	O
later.	O
In	O
three	O
additional	O
patients,	O
HBV	O
DNA	O
levels	O
were	O
increased	O
during	O
follow-up.	O
None	O
of	O
the	O
patients	O
had	O
significant	O
clinical	O
sings	O
of	O
HBV	O
activation.	O
Lamivudine	Chemical
was	O
well	O
tolerated	O
and	O
was	O
continued	O
in	O
all	O
patients.	O
Prophylactic	O
administration	O
of	O
lamivudine	Chemical

Safety	O
of	O
transesophageal	O
echocardiography	O
in	O
adults:	O
study	O
in	O
a	O
multidisciplinary	O
hospital.	O
BACKGROUND:	O
TEE	O
is	O
a	O
semi-invasive	O
tool	O
broadly	O
used	O
and	O
its	O
utilization	O
associated	O
to	O
sedatives	O
drugs	O
might	O
to	O
affect	O
the	O
procedure	O
safety.	O
OBJECTIVE:	O
to	O
analyze	O
aspects	O
of	O
TEE	O
safety	O
associated	O
to	O
the	O
use	O
of	O
Midazolan	Chemical
(	O
MZ	Chemical
)	O
and	O
Flumazenil	Chemical
(	O
FL	Chemical
)	O
and	O
the	O
influence	O
of	O
the	O
clinical	O
variables	O
on	O
the	O
event	O
rate.	O
METHOD:	O
prospective	O
study	O
with	O
137	O
patients	O
that	O
underwent	O
TEE	O
with	O
MZ	Chemical
associated	O
to	O
moderate	O
sedation.	O
We	O
analyzed	O
the	O
following	O
events:	O
complications	O
related	O
with	O
the	O
topical	O
anesthesia,	O
with	O
MZ	Chemical
use	O
and	O
with	O
the	O
procedure.	O
Uni-	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
test	O
the	O
influence	O
of	O
the	O
clinical	O
variables:	O
age,	O
sex,	O
stroke	Disease
,	O
myocardiopathy	Disease
(	O
MP	Disease
),	O
duration	O
of	O
the	O
test,	O
mitral	Disease
regurgitation	Disease
(	O
MR	Disease
)	O
and	O
the	O
MZ	Chemical
dose.	O
RESULTS:	O
All	O
patients	O
(65+/-16	O
yrs;	O
58%	O
males)	O
finished	O
the	O
examination.	O
The	O
mean	O
doses	O
of	O
MZ	Chemical
and	O
FL	Chemical
were	O
4.3+/-1.9	O
mg	O
and	O
0.28+/-0.2	O
mg,	O
respectively.	O
The	O
duration	O
of	O
the	O
examination	O
and	O
the	O
mean	O
ejection	O
fraction	O
(EF)	O
were	O
16.4+/-6.1	O
minutes	O
and	O
60+/-9%,	O
respectively.	O
Mild	O
hypoxia	Disease
(SO2<90%)	O
was	O
the	O
most	O
common	O
event	O
(11	O
patients);	O
3	O
patients	O
(2%)	O
presented	O
transient	O
hypoxia	Disease
due	O
to	O
upper	O
airway	Disease
obstruction	Disease
by	O
probe	O
introduction	O
and	O
8	O
(5.8%)	O
due	O
to	O
hypoxia	Disease
caused	O
by	O
MZ	Chemical
use.	O
Transient	O
hypotension	Disease
(SAP<90mmHg)	O
occurred	O
in	O
1	O
patient	O
(0.7%).	O
The	O
multivariate	O
analysis	O
showed	O
that	O
severe	O
MR	Disease
,	O
MP	Disease
(EF<45%)	O
and	O
high	O
doses	O
of	O
MZ	Chemical
(>5mg)	O
were	O
associated	O
with	O
events	O
(p<0.001).	O
The	O
EF	O
was	O
40%,	O
in	O
the	O
group	O
with	O
MP	Disease
and	O
44%	O
in	O
the	O
group	O
with	O
severe	O
MR	Disease

Effects	O
of	O
calcium	Chemical
channel	O
blockers	O
on	O
bupivacaine	Chemical
-induced	O
toxicity	Disease
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
influence	O
of	O
calcium	Chemical
channel	O
blockers	O
on	O
bupivacaine	Chemical
-induced	O
acute	O
toxicity	Disease
.	O
For	O
each	O
of	O
the	O
three	O
tested	O
calcium	Chemical
channel	O
blockers	O
(	O
diltiazem	Chemical
,	O
verapamil	Chemical
and	O
bepridil	Chemical
)	O
6	O
groups	O
of	O
mice	O
were	O
treated	O
by	O
two	O
different	O
doses,	O
i.e.	O
2	O
and	O
10	O
mg/kg/i.p.,	O
or	O
an	O
equal	O
volume	O
of	O
saline	O
for	O
the	O
control	O
group	O
(n	O
=	O
20);	O
15	O
minutes	O
later,	O
all	O
the	O
animals	O
were	O
injected	O
with	O
a	O
single	O
50	O
mg/kg/i.p.	O
dose	O
of	O
bupivacaine	Chemical
.	O
The	O
convulsant	O
activity,	O
the	O
time	O
of	O
latency	O
to	O
convulse	O
and	O
the	O
mortality	O
rate	O
were	O
assessed	O
in	O
each	O
group.	O
The	O
local	O
anesthetic-induced	O
mortality	O
was	O
significantly	O
increased	O
by	O
the	O
three	O
different	O
calcium	Chemical
channel	O
blockers.	O
The	O
convulsant	O
activity	O
of	O
bupivacaine	Chemical
was	O
not	O
significantly	O
modified	O
but	O
calcium	Chemical
channel	O
blockers	O
decreased	O
the	O
time	O
of	O
latency	O
to	O
obtain	O
bupivacaine	Chemical
-induced	O
convulsions	Disease
;	O
this	O
effect	O
was	O
less	O
pronounced	O
with	O
bepridil	Chemical

Selegiline	Chemical
-induced	O
postural	Disease
hypotension	Disease
in	O
Parkinson's	Disease
disease	Disease
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	O
withdrawal.	O
OBJECTIVES:	O
The	O
United	O
Kingdom	O
Parkinson's	Disease
Disease	Disease
Research	O
Group	O
(UKPDRG)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson's	Disease
disease	Disease
(	O
PD	Disease
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	Chemical
per	O
day	O
and	O
L-dopa	Chemical
compared	O
with	O
those	O
taking	O
L-dopa	Chemical
alone.	O
Recently,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	Chemical
and	O
L-dopa	Chemical
was	O
associated	O
with	O
selective	O
systolic	Disease
orthostatic	Disease
hypotension	Disease
which	O
was	O
abolished	O
by	O
withdrawal	O
of	O
selegiline	Chemical
.	O
This	O
unwanted	O
effect	O
on	O
postural	O
blood	O
pressure	O
was	O
not	O
the	O
result	O
of	O
underlying	O
autonomic	O
failure.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	O
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
stopping	O
selegiline	Chemical
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	O
causes	O
orthostatic	Disease
hypotension	Disease
.	O
METHODS:	O
The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head-up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	Disease
patients	O
receiving	O
selegiline	Chemical
and	O
as	O
the	O
drug	O
was	O
withdrawn.	O
RESULTS:	O
Head-up	O
tilt	O
caused	O
systolic	Disease
orthostatic	Disease
hypotension	Disease
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	Disease
patients	O
on	O
selegiline	Chemical
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures.	O
A	O
lesser	O
degree	O
of	O
orthostatic	Disease
hypotension	Disease
occurred	O
with	O
standing.	O
Orthostatic	Disease
hypotension	Disease
was	O
ameliorated	O
4	O
days	O
after	O
withdrawal	O
of	O
selegiline	Chemical
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug.	O
Stopping	O
selegiline	Chemical
also	O
significantly	O
reduced	Disease
the	Disease
supine	Disease
systolic	Disease
and	Disease
diastolic	Disease
blood	Disease
pressures	Disease
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action.	O
CONCLUSION:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	Chemical
in	O
combination	O
with	O
L-dopa	Chemical
is	O
associated	O
with	O
selective	O
orthostatic	Disease
hypotension	Disease
.	O
The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	O
be	O
the	O
result	O
of	O
non-selective	O
inhibition	O
of	O
monoamine	O
oxidase	O
or	O
of	O
amphetamine	Chemical
and	O
metamphetamine	Chemical

Explicit	O
episodic	O
memory	O
for	O
sensory-discriminative	O
components	O
of	O
capsaicin	Chemical
-induced	O
pain	Disease
:	O
immediate	O
and	O
delayed	O
ratings.	O
Pain	Disease
memory	O
is	O
thought	O
to	O
affect	O
future	O
pain	Disease
sensitivity	O
and	O
thus	O
contribute	O
to	O
clinical	O
pain	Disease
conditions.	O
Systematic	O
investigations	O
of	O
the	O
human	O
capacity	O
to	O
remember	O
sensory	O
features	O
of	O
experimental	O
pain	Disease
are	O
sparse.	O
In	O
order	O
to	O
address	O
long-term	O
pain	Disease
memory,	O
nine	O
healthy	O
male	O
volunteers	O
received	O
intradermal	O
injections	O
of	O
three	O
doses	O
of	O
capsaicin	Chemical
(0.05,	O
1	O
and	O
20	O
microg,	O
separated	O
by	O
15	O
min	O
breaks),	O
each	O
given	O
three	O
times	O
in	O
a	O
balanced	O
design	O
across	O
three	O
sessions	O
at	O
one	O
week	O
intervals.	O
Pain	Disease
rating	O
was	O
performed	O
using	O
a	O
computerized	O
visual	O
analogue	O
scale	O
(0-100)	O
digitized	O
at	O
1/s,	O
either	O
immediately	O
online	O
or	O
one	O
hour	O
or	O
one	O
day	O
after	O
injection.	O
Subjects	O
also	O
recalled	O
their	O
pains	Disease
one	O
week	O
later.	O
Capsaicin	Chemical
injection	O
reliably	O
induced	O
a	O
dose-dependent	O
flare	O
(p<0.001)	O
without	O
any	O
difference	O
within	O
or	O
across	O
sessions.	O
The	O
strong	O
burning	O
pain	Disease
decayed	O
exponentially	O
within	O
a	O
few	O
minutes.	O
Subjects	O
were	O
able	O
to	O
reliably	O
discriminate	O
pain	Disease
magnitude	O
and	O
duration	O
across	O
capsaicin	Chemical
doses	O
(both	O
p<0.001),	O
regardless	O
of	O
whether	O
first-time	O
ratings	O
were	O
requested	O
immediately,	O
after	O
one	O
hour	O
or	O
after	O
one	O
day.	O
Pain	Disease
recall	O
after	O
one	O
week	O
was	O
similarly	O
precise	O
(magnitude:	O
p<0.01,	O
duration:	O
p<0.05).	O
Correlation	O
with	O
rating	O
recall	O
after	O
one	O
week	O
was	O
best	O
when	O
first-time	O
ratings	O
were	O
requested	O
as	O
late	O
as	O
one	O
day	O
after	O
injection	O
(R(2)=0.79)	O
indicating	O
that	O
both	O
rating	O
retrievals	O
utilized	O
similar	O
memory	O
traces.	O
These	O
results	O
indicate	O
a	O
reliable	O
memory	O
for	O
magnitude	O
and	O
duration	O
of	O
experimentally	O
induced	O
pain	Disease

Reversibility	O
of	O
captopril	Chemical
-induced	O
renal	Disease
insufficiency	Disease
after	O
prolonged	O
use	O
in	O
an	O
unusual	O
case	O
of	O
renovascular	Disease
hypertension	Disease
.	O
We	O
report	O
a	O
case	O
of	O
severe	O
hypertension	Disease
with	O
an	O
occluded	O
renal	O
artery	O
to	O
a	O
solitary	O
kidney,	O
who	O
developed	O
sudden	Disease
deterioration	Disease
of	Disease
renal	Disease
function	Disease
following	O
treatment	O
with	O
captopril	Chemical
.	O
His	O
renal	O
function	O
remained	O
impaired	O
but	O
stable	O
during	O
2	O
years'	O
treatment	O
with	O
captopril	Chemical
but	O
returned	O
to	O
pre-treatment	O
levels	O
soon	O
after	O
cessation	O
of	O
the	O
drug.	O
This	O
indicates	O
reversibility	O
in	O
captopril	Chemical
-induced	O
renal	Disease
failure	Disease

Liver	Disease
disease	Disease
caused	O
by	O
propylthiouracil	Chemical
.	O
This	O
report	O
presents	O
the	O
clinical,	O
laboratory,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	O
a	O
patient	O
with	O
chronic	Disease
active	Disease
(aggressive)	Disease
hepatitis	Disease
caused	O
by	O
the	O
administration	O
of	O
propylthiouracil	Chemical
.	O
This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drugs	O
that	O
must	O
be	O
considered	O
in	O
the	O
evaluation	O
of	O
chronic	O
liver	Disease
disease	Disease

Capsaicin	Chemical
-induced	O
muscle	Disease
pain	Disease
alters	O
the	O
excitability	O
of	O
the	O
human	O
jaw-stretch	O
reflex.	O
The	O
pathophysiology	O
of	O
painful	O
temporomandibular	Disease
disorders	Disease
is	O
not	O
fully	O
understood,	O
but	O
evidence	O
suggests	O
that	O
muscle	Disease
pain	Disease
modulates	O
motor	O
function	O
in	O
characteristic	O
ways.	O
This	O
study	O
tested	O
the	O
hypothesis	O
that	O
activation	O
of	O
nociceptive	Disease
muscle	Disease
afferent	O
fibers	O
would	O
be	O
linked	O
to	O
an	O
increased	O
excitability	O
of	O
the	O
human	O
jaw-stretch	O
reflex	O
and	O
whether	O
this	O
process	O
would	O
be	O
sensitive	O
to	O
length	O
and	O
velocity	O
of	O
the	O
stretch.	O
Capsaicin	Chemical
(10	O
micro	O
g)	O
was	O
injected	O
into	O
the	O
masseter	O
muscle	O
to	O
induce	O
pain	Disease
in	O
11	O
healthy	O
volunteers.	O
Short-latency	O
reflex	O
responses	O
were	O
evoked	O
in	O
the	O
masseter	O
and	O
temporalis	O
muscles	O
by	O
a	O
stretch	O
device	O
with	O
different	O
velocities	O
and	O
displacements	O
before,	O
during,	O
and	O
after	O
the	O
pain	Disease
.	O
The	O
normalized	O
reflex	O
amplitude	O
increased	O
with	O
an	O
increase	O
in	O
velocity	O
at	O
a	O
given	O
displacement,	O
but	O
remained	O
constant	O
with	O
different	O
displacements	O
at	O
a	O
given	O
velocity.	O
The	O
normalized	O
reflex	O
amplitude	O
was	O
significantly	O
higher	O
during	O
pain	Disease
,	O
but	O
only	O
at	O
faster	O
stretches	O
in	O
the	O
painful	Disease
muscle	Disease
.	O
Increased	O
sensitivity	O
of	O
the	O
fusimotor	O
system	O
during	O
acute	O
muscle	Disease
pain	Disease

Repetitive	O
transcranial	O
magnetic	O
stimulation	O
for	O
levodopa	Chemical
-induced	O
dyskinesias	Disease
in	O
Parkinson's	Disease
disease	Disease
.	O
In	O
a	O
placebo-controlled,	O
single-blinded,	O
crossover	O
study,	O
we	O
assessed	O
the	O
effect	O
of	O
"real"	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(rTMS)	O
versus	O
"sham"	O
rTMS	O
(placebo)	O
on	O
peak	O
dose	O
dyskinesias	Disease
in	O
patients	O
with	O
Parkinson's	Disease
disease	Disease
(	O
PD	Disease
).	O
Ten	O
patients	O
with	O
PD	Disease
and	O
prominent	O
dyskinesias	Disease
had	O
rTMS	O
(1,800	O
pulses;	O
1	O
Hz	O
rate)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice,	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series.	O
Direct	O
comparison	O
between	O
sham	O
and	O
real	O
rTMS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinician-assessed	O
dyskinesia	Disease
severity.	O
However,	O
comparison	O
with	O
the	O
baseline	O
showed	O
small	O
but	O
significant	O
reduction	O
in	O
dyskinesia	Disease
severity	O
following	O
real	O
rTMS	O
but	O
not	O
placebo.	O
The	O
major	O
effect	O
was	O
on	O
dystonia	Disease
subscore.	O
Similarly,	O
in	O
patient	O
diaries,	O
although	O
both	O
treatments	O
caused	O
reduction	O
in	O
subjective	O
dyskinesia	Disease
scores	O
during	O
the	O
days	O
of	O
intervention,	O
the	O
effect	O
was	O
sustained	O
for	O
3	O
days	O
after	O
the	O
intervention	O
for	O
the	O
real	O
rTMS	O
only.	O
Following	O
rTMS,	O
no	O
side	O
effects	O
and	O
no	O
adverse	O
effects	O
on	O
motor	O
function	O
and	O
PD	Disease
symptoms	O
were	O
noted.	O
The	O
results	O
suggest	O
the	O
existence	O
of	O
residual	O
beneficial	O
clinical	O
aftereffects	O
of	O
consecutive	O
daily	O
applications	O
of	O
low-frequency	O
rTMS	O
on	O
dyskinesias	Disease
in	O
PD	Disease

Disulfiram	Chemical
-like	O
syndrome	O
after	O
hydrogen	Chemical
cyanamide	Chemical
professional	O
skin	O
exposure:	O
two	O
case	O
reports	O
in	O
France.	O
Hydrogen	Chemical
cyanamide	Chemical
is	O
a	O
plant	O
growth	O
regulator	O
used	O
in	O
agriculture	O
to	O
induce	O
bud	O
break	O
in	O
fruit	O
trees.	O
Contact	O
with	O
the	O
skin	O
can	O
result	O
in	O
percutaneous	O
absorption	O
of	O
the	O
substance	O
that	O
inhibits	O
aldehyde	Chemical
dehydrogenase	O
and	O
can	O
induce	O
acetaldehyde	Chemical
syndrome	O
in	O
case	O
of	O
alcohol	Chemical
use.	O
The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
two	O
cases	O
of	O
a	O
disulfiram	Chemical
-like	O
syndrome	O
following	O
occupational	O
exposure	O
to	O
hydrogen	Chemical
cyanamide	Chemical
.	O
The	O
first	O
case	O
involved	O
a	O
59-year-old	O
man	O
who	O
used	O
Dormex	Chemical
,	O
which	O
contains	O
hydrogen	Chemical
cyanamide	Chemical
,	O
without	O
protection	O
after	O
consuming	O
a	O
large	O
amount	O
of	O
alcohol	Chemical
during	O
a	O
meal.	O
In	O
less	O
than	O
1	O
hour	O
after	O
the	O
ingestion	O
of	O
alcohol	Chemical
,	O
he	O
developed	O
malaise	O
with	O
flushing	Disease
of	Disease
the	Disease
face	Disease
,	O
tachycardia	Disease
,	O
and	O
dyspnea	Disease
.	O
Manifestations	O
regressed	O
spontaneously	O
under	O
surveillance	O
in	O
the	O
hospital.	O
The	O
second	O
case	O
occurred	O
in	O
a	O
55-year-old	O
farmer	O
following	O
cutaneous	O
contact	O
with	O
Dormex	Chemical
.	O
Five	O
hours	O
after	O
exposure,	O
he	O
developed	O
disulfiram	Chemical
-like	O
syndrome	O
with	O
flushing	Disease
,	O
tachycardia	Disease
,	O
and	O
arterial	Disease
hypotension	Disease
after	O
consuming	O
three	O
glasses	O
of	O
wine.	O
The	O
patient	O
recovered	O
spontaneously	O
in	O
3	O
hours	O
under	O
surveillance	O
in	O
the	O
hospital.	O
These	O
cases	O
confirm	O
the	O
necessity	O
of	O
avoiding	O
alcohol	Chemical
consumption	O
as	O
recommended	O
in	O
the	O
instructions	O
for	O
use	O
of	O
Dormex	Chemical

Repeated	O
trimipramine	Chemical
induces	O
dopamine	Chemical
D2/D3	O
and	O
alpha1-adrenergic	O
up-regulation.	O
Trimipramine	Chemical
(	O
TRI	Chemical
),	O
which	O
shows	O
a	O
clinical	O
antidepressant	Chemical
activity,	O
is	O
chemically	O
related	O
to	O
imipramine	Chemical
but	O
does	O
not	O
inhibit	O
the	O
reuptake	O
of	O
noradrenaline	Chemical
and	O
5-hydroxytryptamine	Chemical
,	O
nor	O
does	O
it	O
induce	O
beta-adrenergic	O
down-regulation.	O
The	O
mechanism	O
of	O
its	O
antidepressant	Chemical
activity	O
is	O
still	O
unknown.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
out	O
whether	O
TRI	Chemical
given	O
repeatedly	O
was	O
able	O
to	O
induce	O
adaptive	O
changes	O
in	O
the	O
dopaminergic	O
and	O
alpha1-adrenergic	O
systems,	O
demonstrated	O
by	O
us	O
previously	O
for	O
various	O
antidepressants	Chemical
.	O
TRI	Chemical
was	O
given	O
to	O
male	O
Wistar	O
rats	O
and	O
male	O
Albino	O
Swiss	O
mice	O
perorally	O
twice	O
daily	O
for	O
14	O
days.	O
In	O
the	O
acute	O
experiment	O
TRI	Chemical
(given	O
i.p.)	O
does	O
not	O
antagonize	O
the	O
reserpine	Chemical
	O
hypothermia	Disease
in	O
mice	O
and	O
does	O
not	O
potentiate	O
the	O
5-hydroxytryptophan	Chemical
head	O
twitches	O
in	O
rats.	O
TRI	Chemical
given	O
repeatedly	O
to	O
rats	O
increases	O
the	O
locomotor	O
hyperactivity	Disease
induced	O
by	O
d-amphetamine	Chemical
,	O
quinpirole	Chemical
and	O
(+)-7-hydroxy-dipropyloaminotetralin	O
(	O
dopamine	Chemical
D2	O
and	O
D3	O
effects).	O
The	O
stereotypies	O
induced	O
by	O
d-amphetamine	Chemical
or	O
apomorphine	Chemical
are	O
not	O
potentiated	O
by	O
TRI	Chemical
.	O
It	O
increases	O
the	O
behaviour	O
stimulation	O
evoked	O
by	O
phenylephrine	Chemical
(given	O
intraventricularly)	O
in	O
rats,	O
evaluated	O
in	O
the	O
open	O
field	O
test	O
as	O
well	O
as	O
the	O
aggressiveness	Disease
evoked	O
by	O
clonidine	Chemical
in	O
mice,	O
both	O
these	O
effects	O
being	O
mediated	O
by	O
an	O
alpha1-adrenergic	O
receptor.	O
It	O
may	O
be	O
concluded	O
that,	O
like	O
other	O
tricyclic	O
antidepressants	Chemical
studied	O
previously,	O
TRI	Chemical
given	O
repeatedly	O
increases	O
the	O
responsiveness	O
of	O
brain	O
dopamine	Chemical
D2	O
and	O
D3	O
(locomotor	O
activity	O
but	O
not	O
stereotypy)	O
as	O
well	O
as	O
alpha1-adrenergic	O
receptors	O
to	O
their	O
agonists.	O
A	O
question	O
arises	O
whether	O
the	O
reuptake	O
inhibition	O
is	O
of	O
any	O
importance	O
to	O
the	O
adaptive	O
changes	O
induced	O
by	O
repeated	O
antidepressants	Chemical
,	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
antidepressant	Chemical

Ranitidine	Chemical
-induced	O
acute	O
interstitial	Disease
nephritis	Disease
in	O
a	O
cadaveric	O
renal	O
allograft.	O
Ranitidine	Chemical
frequently	O
is	O
used	O
for	O
preventing	O
peptic	O
ulceration	O
after	O
renal	O
transplantation.	O
This	O
drug	O
occasionally	O
has	O
been	O
associated	O
with	O
acute	O
interstitial	Disease
nephritis	Disease
in	O
native	O
kidneys.	O
There	O
are	O
no	O
similar	O
reports	O
with	O
renal	O
transplantation.	O
We	O
report	O
a	O
case	O
of	O
ranitidine	Chemical
-induced	O
acute	O
interstitial	Disease
nephritis	Disease

Late,	O
late	O
doxorubicin	Chemical
	O
cardiotoxicity	Disease
.	O
Cardiac	Disease
toxicity	Disease
is	O
a	O
major	O
complication	O
which	O
limits	O
the	O
use	O
of	O
adriamycin	Chemical
as	O
a	O
chemotherapeutic	O
agent.	O
Cardiomyopathy	Disease
is	O
frequent	O
when	O
the	O
total	O
dose	O
exceeds	O
600	O
mg/m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
months	O
after	O
cessation	O
of	O
therapy.	O
A	O
patient	O
is	O
reported	O
who	O
developed	O
progressive	O
cardiomyopathy	Disease
two	O
and	O
one-half	O
years	O
after	O
receiving	O
580	O
mg/m2	O
which	O
apparently	O
represents	O
late,	O
late	O
cardiotoxicity	Disease

Acetazolamide	Chemical
-induced	O
nephrolithiasis	Disease
:	O
implications	O
for	O
treatment	O
of	O
neuromuscular	Disease
disorders	Disease
.	O
Carbonic	O
anhydrase	O
inhibitors	O
can	O
cause	O
nephrolithiasis	Disease
.	O
We	O
studied	O
20	O
patients	O
receiving	O
long-term	O
carbonic	O
anhydrase	O
inhibitor	O
treatment	O
for	O
periodic	O
paralysis	Disease
and	O
myotonia	Disease
.	O
Three	O
patients	O
on	O
acetazolamide	Chemical
(15%)	O
developed	O
renal	Disease
calculi	Disease
.	O
Extracorporeal	O
lithotripsy	O
successfully	O
removed	O
a	O
renal	Disease
calculus	Disease
in	O
one	O
patient	O
and	O
surgery	O
removed	O
a	O
staghorn	O
calculus	Disease
in	O
another,	O
permitting	O
continued	O
treatment.	O
Renal	O
function	O
remained	O
normal	O
in	O
all	O
patients.	O
Nephrolithiasis	Disease
is	O
a	O
complication	O
of	O
acetazolamide	Chemical

Is	O
the	O
treatment	O
of	O
scabies	Disease
hazardous?	O
Treatment	O
for	O
scabies	Disease
is	O
usually	O
initiated	O
by	O
general	O
practitioners;	O
most	O
consider	O
lindane	Chemical
(	O
gamma	Chemical
benzene	Chemical
hexachloride	Chemical
)	O
the	O
treatment	O
of	O
choice.	O
Lindane	Chemical
is	O
also	O
widely	O
used	O
as	O
an	O
agricultural	O
and	O
industrial	O
pesticide,	O
and	O
as	O
a	O
result	O
the	O
toxic	O
profile	O
of	O
this	O
insecticide	O
is	O
well	O
understood.	O
Evidence	O
is	O
accumulating	O
that	O
lindane	Chemical
can	O
be	O
toxic	Disease
to	Disease
the	Disease
central	Disease
nervous	Disease
system	Disease
and	O
may	O
be	O
associated	O
with	O
aplastic	Disease
anaemia	Disease
.	O
Preparations	O
containing	O
lindane	Chemical
continue	O
to	O
be	O
sold	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hazard	O
to	O
poorly	O
informed	O
patients.	O
This	O
literature	O
review	O
suggests	O
that	O
general	O
practitioners	O
should	O
prescribe	O
scabicides	O
with	O
increased	O
caution	O
for	O
certain	O
at-risk	O
groups,	O
and	O
give	O
adequate	O
warnings	O
regarding	O
potential	O
toxicity	Disease

Anaesthetists'	O
nightmare:	O
masseter	Disease
spasm	Disease
after	O
induction	O
in	O
an	O
undiagnosed	O
case	O
of	O
myotonia	Disease
congenita	Disease
.	O
We	O
report	O
an	O
undiagnosed	O
case	O
of	O
myotonia	Disease
congenita	Disease
in	O
a	O
24-year-old	O
previously	O
healthy	O
primigravida,	O
who	O
developed	O
life	O
threatening	O
masseter	Disease
spasm	Disease
following	O
a	O
standard	O
dose	O
of	O
intravenous	O
suxamethonium	Chemical

Toxicity	Disease
in	O
rhesus	O
monkeys	O
following	O
administration	O
of	O
the	O
8-aminoquinoline	Chemical
	O
8-[(4-amino-l-methylbutyl)amino]-	Chemical
5-(l-hexyloxy)-6-methoxy-4-methylquinoline	Chemical
(	O
WR242511	Chemical
).	O
INTRODUCTION:	O
Many	O
substances	O
that	O
form	O
methemoglobin	O
(MHb)	O
effectively	O
counter	O
cyanide	O
(CN)	O
toxicity	Disease
.	O
Although	O
MHb	O
formers	O
are	O
generally	O
applied	O
as	O
treatments	O
for	O
CN	O
poisoning	Disease
,	O
it	O
has	O
been	O
proposed	O
that	O
a	O
stable,	O
long-acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	O
pretreatment.	O
Using	O
this	O
rationale,	O
the	O
8-aminoquinoline	Chemical
	O
WR242511	Chemical
,	O
a	O
potent	O
long-lasting	O
MHb	O
former	O
in	O
rodents	O
and	O
beagle	O
dogs,	O
was	O
studied	O
in	O
the	O
rhesus	O
monkey	O
for	O
advanced	O
development	O
as	O
a	O
potential	O
CN	O
pretreatment.	O
METHODS:	O
In	O
this	O
study,	O
WR242511	Chemical
was	O
administered	O
intravenously	O
(IV)	O
in	O
2	O
female	O
and	O
4	O
male	O
rhesus	O
monkeys	O
in	O
doses	O
of	O
3.5	O
and/or	O
7.0	O
mg/kg;	O
a	O
single	O
male	O
also	O
received	O
WR242511	Chemical
orally	O
(PO)	O
at	O
7.0	O
mg/kg.	O
Health	O
status	O
and	O
MHb	O
levels	O
were	O
monitored	O
following	O
exposure.	O
RESULTS:	O
The	O
selected	O
doses	O
of	O
WR242511	Chemical
,	O
which	O
produced	O
significant	O
methemoglobinemia	Disease
in	O
beagle	O
dogs	O
in	O
earlier	O
studies	O
conducted	O
elsewhere,	O
produced	O
very	O
little	O
MHb	O
(mean	O
<	O
2.0%)	O
in	O
the	O
rhesus	O
monkey.	O
Furthermore,	O
transient	O
hemoglobinuria	Disease
was	O
noted	O
approximately	O
60	O
minutes	O
postinjection	O
of	O
WR242511	Chemical
(3.5	O
or	O
7.0	O
mg/kg),	O
and	O
2	O
lethalities	O
occurred	O
(one	O
IV	O
and	O
one	O
PO)	O
following	O
the	O
7.0	O
mg/kg	O
dose.	O
Myoglobinuria	Disease
was	O
also	O
observed	O
following	O
the	O
7.0	O
mg/kg	O
dose.	O
Histopathology	O
analyses	O
in	O
the	O
2	O
animals	O
that	O
died	O
revealed	O
liver	Disease
and	Disease
kidney	Disease
toxicity	Disease
,	O
with	O
greater	O
severity	O
in	O
the	O
orally-treated	O
animal.	O
CONCLUSIONS:	O
These	O
data	O
demonstrate	O
direct	O
and/or	O
indirect	O
drug-induced	O
toxicity	Disease
.	O
It	O
is	O
concluded	O
that	O
WR242511	Chemical
should	O
not	O
be	O
pursued	O
as	O
a	O
pretreatment	O
for	O
CN	O
poisoning	Disease
unless	O
the	O
anti-CN	O
characteristics	O
of	O
this	O
compound	O
can	O
be	O
successfully	O
dissociated	O
from	O
those	O
producing	O
undesirable	O
toxicity	Disease

Neuroplasticity	O
of	O
the	O
adult	O
primate	O
auditory	O
cortex	O
following	O
cochlear	O
hearing	Disease
loss	Disease
.	O
Tonotopic	O
organization	O
is	O
an	O
essential	O
feature	O
of	O
the	O
primary	O
auditory	O
area	O
(A1)	O
of	O
primate	O
cortex.	O
In	O
A1	O
of	O
macaque	O
monkeys,	O
low	O
frequencies	O
are	O
represented	O
rostrolaterally	O
and	O
high	O
frequencies	O
are	O
represented	O
caudomedially.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
changes	O
occur	O
in	O
this	O
tonotopic	O
organization	O
following	O
cochlear	O
hearing	Disease
loss	Disease
.	O
Under	O
anesthesia,	O
the	O
superior	O
temporal	O
gyrus	O
of	O
adult	O
macaque	O
monkeys	O
was	O
exposed,	O
and	O
the	O
tonotopic	O
organization	O
of	O
A1	O
was	O
mapped	O
using	O
conventional	O
microelectrode	O
recording	O
techniques.	O
Following	O
recovery,	O
the	O
monkeys	O
were	O
selectively	O
deafened	O
for	O
high	O
frequencies	O
using	O
kanamycin	Chemical
and	O
furosemide	Chemical
.	O
The	O
actual	O
frequencies	O
deafened	O
were	O
determined	O
by	O
the	O
loss	O
of	O
tone-burst	O
elicited	O
auditory	O
brainstem	O
responses.	O
Three	O
months	O
after	O
deafening,	O
A1	O
was	O
remapped.	O
Postmortem	O
cytoarchitectural	O
features	O
identifying	O
A1	O
were	O
correlated	O
with	O
the	O
electrophysiologic	O
data.	O
The	O
results	O
indicate	O
that	O
the	O
deprived	O
area	O
of	O
A1	O
undergoes	O
extensive	O
reorganization	O
and	O
becomes	O
responsive	O
to	O
intact	O
cochlear	O
frequencies.	O
The	O
region	O
of	O
cortex	O
that	O
represents	O
the	O
low	O
frequencies	O
was	O
not	O
obviously	O
affected	O
by	O
the	O
cochlear	O
hearing	Disease
loss	Disease

The	O
site	O
of	O
common	O
side	O
effects	O
of	O
sumatriptan	Chemical
.	O
Atypical	Disease
sensations	Disease
following	O
the	O
use	O
of	O
subcutaneous	O
sumatriptan	Chemical
are	O
common,	O
but	O
of	O
uncertain	O
origin.	O
They	O
are	O
almost	O
always	O
benign,	O
but	O
can	O
be	O
mistaken	O
for	O
a	O
serious	O
adverse	O
event	O
by	O
the	O
patient.	O
Two	O
patients	O
are	O
presented	O
with	O
tingling	Disease
or	Disease
burning	Disease
sensations	Disease
limited	O
to	O
areas	O
of	O
heat	O
exposure	O
or	O
sunburn	Disease

Tremor	Disease
side	O
effects	O
of	O
salbutamol	Chemical
,	O
quantified	O
by	O
a	O
laser	O
pointer	O
technique.	O
OBJECTIVE:	O
To	O
study	O
tremor	Disease
side	O
effects	O
of	O
salbutamol	Chemical
an	O
easily	O
applicable,	O
quick	O
and	O
low-priced	O
method	O
is	O
needed.	O
A	O
new	O
method	O
using	O
a	O
commercially	O
available,	O
pen-shaped	O
laser	O
pointer	O
was	O
developed.	O
Aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
sensitivity,	O
reproducibility,	O
reference	O
values	O
and	O
the	O
agreement	O
with	O
a	O
questionnaire.	O
METHODS:	O
Tremor	Disease
was	O
measured	O
using	O
a	O
laser	O
pointer	O
technique.	O
To	O
determine	O
sensitivity	O
we	O
assessed	O
tremor	Disease
in	O
44	O
patients	O
with	O
obstructive	Disease
lung	Disease
disease	Disease
after	O
administration	O
of	O
cumulative	O
doses	O
of	O
salbutamol	Chemical
.	O
Subjects	O
were	O
asked	O
to	O
aim	O
at	O
the	O
centre	O
of	O
a	O
target,	O
subdivided	O
in	O
concentric	O
circles,	O
from	O
5	O
m	O
distance.	O
The	O
circle	O
in	O
which	O
the	O
participant	O
succeeded	O
to	O
aim	O
was	O
recorded	O
in	O
millimetres	O
radius.	O
In	O
another	O
series	O
of	O
measurements,	O
reproducibility	O
and	O
reference	O
values	O
of	O
the	O
tremor	Disease
was	O
assessed	O
in	O
65	O
healthy	O
subjects	O
in	O
three	O
sessions,	O
at	O
9	O
a.m.,	O
4	O
p.m.	O
and	O
9	O
a.m.,	O
respectively,	O
1	O
week	O
later.	O
Postural	O
tremor	Disease
was	O
measured	O
with	O
the	O
arm	O
horizontally	O
outstretched	O
rest	O
tremor	Disease
with	O
the	O
arm	O
supported	O
by	O
an	O
armrest	O
and	O
finally	O
tremor	Disease
was	O
measured	O
after	O
holding	O
a	O
2-kg	O
weight	O
until	O
exhaustion.	O
Inter-observer	O
variability	O
was	O
measured	O
in	O
a	O
series	O
of	O
10	O
healthy	O
subjects.	O
Tremor	Disease
was	O
measured	O
simultaneously	O
by	O
two	O
independent	O
observers.	O
RESULTS:	O
Salbutamol	Chemical
significantly	O
increased	O
tremor	Disease
severity	O
in	O
patients	O
in	O
a	O
dose-dependent	O
way.	O
Within	O
healthy	O
adults	O
no	O
age-dependency	O
could	O
be	O
found	O
(b	O
=	O
0.262	O
mm/year;	O
P	O
=	O
0.72).	O
There	O
was	O
no	O
agreement	O
between	O
the	O
questionnaire	O
and	O
tremor	Disease
severity	O
(r	O
=	O
0.093;	O
P	O
=	O
0.53).	O
Postural	O
tremor	Disease
showed	O
no	O
significant	O
difference	O
between	O
the	O
first	O
and	O
third	O
session	O
(P	O
=	O
0.07).	O
Support	O
of	O
the	O
arm	O
decreased	O
tremor	Disease
severity,	O
exhaustion	O
increased	O
tremor	Disease
severity	O
significantly.	O
A	O
good	O
agreement	O
was	O
found	O
between	O
two	O
independent	O
observers	O
(interclass	O
correlation	O
coefficient	O
0.72).	O
DISCUSSION:	O
Quantifying	O
tremor	Disease

Increased	O
frequency	O
of	O
venous	Disease
thromboembolism	Disease
with	O
the	O
combination	O
of	O
docetaxel	Chemical
and	O
thalidomide	Chemical
in	O
patients	O
with	O
metastatic	O
androgen-independent	O
prostate	Disease
cancer	Disease
.	O
STUDY	O
OBJECTIVE:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	Disease
thromboembolism	Disease
(	O
VTE	Disease
)	O
in	O
patients	O
with	O
advanced	O
androgen-independent	O
prostate	Disease
cancer	Disease
who	O
were	O
treated	O
with	O
docetaxel	Chemical
alone	O
or	O
in	O
combination	O
with	O
thalidomide	Chemical
.	O
DESIGN:	O
Retrospective	O
analysis	O
of	O
a	O
randomized	O
phase	O
II	O
trial.	O
SETTING:	O
National	O
Institutes	O
of	O
Health	O
clinical	O
research	O
center.	O
PATIENTS:	O
Seventy	O
men,	O
aged	O
50-80	O
years,	O
with	O
advanced	O
androgen-independent	O
prostate	Disease
cancer	Disease
.	O
INTERVENTION:	O
Each	O
patient	O
received	O
either	O
intravenous	O
docetaxel	Chemical
30	O
mg/m2/week	O
for	O
3	O
consecutive	O
weeks,	O
followed	O
by	O
1	O
week	O
off,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	Chemical
200	O
mg	O
every	O
evening	O
plus	O
the	O
same	O
docetaxel	Chemical
regimen.	O
This	O
4-week	O
cycle	O
was	O
repeated	O
until	O
there	O
was	O
evidence	O
of	O
excessive	O
toxicity	Disease
or	O
disease	O
progression.	O
MEASUREMENTS	O
AND	O
MAIN	O
RESULTS:	O
None	O
of	O
23	O
patients	O
who	O
received	O
docetaxel	Chemical
alone	O
developed	O
VTE	Disease
,	O
whereas	O
9	O
of	O
47	O
patients	O
(19%)	O
who	O
received	O
docetaxel	Chemical
plus	O
thalidomide	Chemical
developed	O
VTE	Disease
(p=0.025).	O
CONCLUSION:	O
The	O
addition	O
of	O
thalidomide	Chemical
to	O
docetaxel	Chemical
in	O
the	O
treatment	O
of	O
prostate	Disease
cancer	Disease
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	Disease
.	O
Clinicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
complication	O
when	O
adding	O
thalidomide	Chemical

Sublingual	O
absorption	O
of	O
the	O
quaternary	Chemical
ammonium	Chemical
antiarrhythmic	O
agent,	O
UM-272	Chemical
.	O
UM-272	Chemical
(	O
N,N-dimethylpropranolol	Chemical
),	O
a	O
quaternary	O
antiarrhythmic	O
agent,	O
was	O
administered	O
sublingually	O
to	O
dogs	O
with	O
ouabain	Chemical
-induced	O
ventricular	Disease
tachycardias	Disease
.	O
Both	O
anti-arrhythmic	O
efficacy	O
and	O
bioavailability	O
were	O
compared	O
to	O
oral	O
drug.	O
Sublingual	O
UM-272	Chemical
converted	O
ventricular	Disease
tachycardia	Disease

Severe	O
thrombocytopenia	Disease
and	O
haemolytic	Disease
anaemia	Disease
associated	O
with	O
ciprofloxacin	Chemical
:	O
a	O
case	O
report	O
with	O
fatal	O
outcome.	O
Haematological	O
adverse	O
reactions	O
associated	O
with	O
fatal	O
outcome	O
are	O
rare	O
during	O
treatment	O
with	O
ciprofloxacin	Chemical
.	O
A	O
30-year	O
old	O
Caucasian	O
man	O
reported	O
with	O
abdominal	Disease
pain	Disease
and	O
jaundice	Disease
after	O
3-day	O
administration	O
of	O
oral	O
ciprofloxacin	Chemical
for	O
a	O
suspect	O
of	O
urinary	Disease
tract	Disease
infection	Disease
.	O
Clinical	O
evaluations	O
suggested	O
an	O
initial	O
diagnosis	O
of	O
severe	O
thrombocytopenia	Disease
and	O
haemolysis	Disease
.	O
The	O
patient	O
progressively	O
developed	O
petechiae	Disease
and	O
purpura	Disease
on	O
thorax	O
and	O
lower	O
limbs.	O
Despite	O
pharmacological	O
and	O
supportive	O
interventions,	O
laboratory	O
parameters	O
worsened	O
and	O
the	O
patient	O
died	O
17	O
hours	O
after	O
admission.	O
An	O
accurate	O
autopsy	O
revealed	O
most	O
organs	O
with	O
diffuse	O
petechial	O
haemorrhages	Disease
.	O
No	O
signs	O
of	O
bone	Disease
marrow	Disease
depression	Disease
were	O
found.	O
No	O
thrombi	Disease
or	O
signs	O
of	O
microangiopathies	Disease
were	O
observed	O
in	O
arterial	O
vessels.	O
Blood	O
and	O
urine	O
cultures	O
did	O
not	O
show	O
any	O
bacterial	O
growth.	O
This	O
case	O
report	O
shows	O
that	O
ciprofloxacin	Chemical
may	O
precipitate	O
life-threatening	O
thrombocytopenia	Disease
and	O
haemolytic	Disease
anaemia	Disease

Simvastatin	Chemical
-induced	O
bilateral	O
leg	O
compartment	Disease
syndrome	Disease
and	O
myonecrosis	Disease
associated	O
with	O
hypothyroidism	Disease
.	O
A	O
54-year-old	O
hypothyroid	Disease
male	O
taking	O
thyroxine	Chemical
and	O
simvastatin	Chemical
presented	O
with	O
bilateral	O
leg	O
compartment	Disease
syndrome	Disease
and	O
myonecrosis	Disease
.	O
Urgent	O
fasciotomies	O
were	O
performed	O
and	O
the	O
patient	O
made	O
an	O
uneventful	O
recovery	O
with	O
the	O
withdrawal	O
of	O
simvastatin	Chemical
.	O
It	O
is	O
likely	O
that	O
this	O
complication	O
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
increased	O
worldwide	O
use	O
of	O
this	O
drug	O
and	O
its	O
approval	O
for	O
all	O
arteriopathic	Disease

Bile	Disease
duct	Disease
hamartoma	Disease
occurring	O
in	O
association	O
with	O
long-term	O
treatment	O
with	O
danazol	Chemical
.	O
We	O
report	O
a	O
case	O
of	O
bile	Disease
duct	Disease
hamartoma	Disease
which	O
developed	O
in	O
a	O
patient	O
who	O
had	O
been	O
on	O
long-term	O
danazol	Chemical
treatment.	O
Such	O
patients	O
should	O
be	O
under	O
close	O
follow-up,	O
preferably	O
with	O
periodic	O
ultrasound	O
examination	O
of	O
the	O
liver.	O
If	O
the	O
patient	O
develops	O
a	O
liver	Disease
mass	Disease

Granulomatous	Disease
hepatitis	Disease
due	O
to	O
combination	Chemical
of	Chemical
amoxicillin	Chemical
and	Chemical
clavulanic	Chemical
acid	Chemical
.	O
We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
amoxicillin-clavulanic	Chemical
acid	Chemical
-induced	O
hepatitis	Disease
with	O
histologic	O
multiple	O
granulomas	Disease
.	O
This	O
type	O
of	O
lesion	O
broadens	O
the	O
spectrum	O
of	O
liver	Disease
injury	Disease
due	O
to	O
this	O
drug	O
combination,	O
mainly	O
represented	O
by	O
a	O
benign	O
cholestatic	Disease
syndrome	Disease
.	O
The	O
association	O
of	O
granulomas	Disease
and	O
eosinophilia	Disease
favor	O
an	O
immunoallergic	O
mechanism.	O
As	O
penicillin	Chemical
derivatives	O
and	O
amoxicillin	Chemical
alone	O
are	O
known	O
to	O
induce	O
such	O
types	O
of	O
lesions,	O
the	O
amoxicillin	Chemical
component,	O
with	O
or	O
without	O
a	O
potentiating	O
effect	O
of	O
clavulanic	Chemical
acid	Chemical

Intracranial	Disease
aneurysms	Disease
and	O
cocaine	Disease
abuse	Disease
:	O
analysis	O
of	O
prognostic	O
indicators.	O
OBJECTIVE:	O
The	O
outcome	O
of	O
subarachnoid	Disease
hemorrhage	Disease
associated	O
with	O
cocaine	Disease
abuse	Disease
is	O
reportedly	O
poor.	O
However,	O
no	O
study	O
in	O
the	O
literature	O
has	O
reported	O
the	O
use	O
of	O
a	O
statistical	O
model	O
to	O
analyze	O
the	O
variables	O
that	O
influence	O
outcome.	O
METHODS:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6-year	O
period	O
revealed	O
14	O
patients	O
with	O
cocaine	Chemical
-related	O
aneurysms	Disease
.	O
This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
135	O
patients	O
with	O
ruptured	Disease
aneurysms	Disease
and	O
no	O
history	O
of	O
cocaine	Disease
abuse	Disease
.	O
Age	O
at	O
presentation,	O
time	O
of	O
ictus	O
after	O
intoxication,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	Disease
hemorrhage	Disease
,	O
size	O
of	O
the	O
aneurysm	Disease
,	O
location	O
of	O
the	O
aneurysm	Disease
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared.	O
RESULTS:	O
The	O
patients	O
in	O
the	O
study	O
group	O
were	O
significantly	O
younger	O
than	O
the	O
patients	O
in	O
the	O
control	O
group	O
(P	O
<	O
0.002).	O
In	O
patients	O
in	O
the	O
study	O
group,	O
all	O
aneurysms	Disease
were	O
located	O
in	O
the	O
anterior	O
circulation.	O
The	O
majority	O
of	O
these	O
aneurysms	Disease
were	O
smaller	O
than	O
those	O
of	O
the	O
control	O
group	O
(8	O
+/-	O
6.08	O
mm	O
versus	O
11	O
+/-	O
5.4	O
mm;	O
P	O
=	O
0.05).	O
The	O
differences	O
in	O
mortality	O
and	O
morbidity	O
between	O
the	O
two	O
groups	O
were	O
not	O
significant.	O
Hunt	O
and	O
Hess	O
grade	O
(P	O
<	O
0.005)	O
and	O
age	O
(P	O
<	O
0.007)	O
were	O
significant	O
predictors	O
of	O
outcome	O
for	O
the	O
patients	O
with	O
cocaine	Chemical
-related	O
aneurysms	Disease
.	O
CONCLUSION:	O
Cocaine	Chemical
use	O
predisposed	O
aneurysmal	Disease
rupture	Disease
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aneurysms	Disease

Anti-	O
epileptic	Disease
drugs-induced	O
de	O
novo	O
absence	Disease
seizures	Disease
.	O
The	O
authors	O
present	O
three	O
patients	O
with	O
de	O
novo	O
absence	Disease
epilepsy	Disease
after	O
administration	O
of	O
carbamazepine	Chemical
and	O
vigabatrin	Chemical
.	O
Despite	O
the	O
underlying	O
diseases,	O
the	O
prognosis	O
for	O
drug-induced	O
de	O
novo	O
absence	Disease
seizure	Disease
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuing	O
the	O
use	O
of	O
the	O
offending	O
drugs.	O
The	O
gamma-aminobutyric	Chemical
acid	Chemical
-transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophysiology	O
of	O
the	O
absence	Disease
epilepsy	Disease
.	O
Because	O
drug-induced	O
de	O
novo	O
absence	Disease
seizure	Disease
is	O
rare,	O
pro-absence	O
drugs	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
factor.	O
The	O
underlying	O
epileptogenecity	O
of	O
the	O
patients	O
or	O
the	O
synergistic	O
effects	O
of	O
the	O
accompanying	O
drugs	O
is	O
required	O
to	O
trigger	O
the	O
de	O
novo	O
absence	Disease
seizure	Disease
.	O
The	O
possibility	O
of	O
drug-induced	O
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	O
in	O
seizure	Disease
frequency	O
and/or	O
new	O
seizure	Disease
types	O
appear	O
following	O
a	O
change	O
in	O
drug	O
treatment.	O
By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	Disease
epilepsy	Disease
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	Disease
and	O
prevent	O
drug-induced	O
absence	Disease
seizures	Disease

Procainamide	Chemical
-induced	O
polymorphous	O
ventricular	Disease
tachycardia	Disease
.	O
Seven	O
cases	O
of	O
procainamide	Chemical
-induced	O
polymorphous	O
ventricular	Disease
tachycardia	Disease
are	O
presented.	O
In	O
four	O
patients,	O
polymorphous	O
ventricular	Disease
tachycardia	Disease
appeared	O
after	O
intravenous	O
administration	O
of	O
200	O
to	O
400	O
mg	O
of	O
procainamide	Chemical
for	O
the	O
treatment	O
of	O
sustained	O
ventricular	Disease
tachycardia	Disease
.	O
In	O
the	O
remaining	O
three	O
patients,	O
procainamide	Chemical
was	O
administered	O
orally	O
for	O
treatment	O
of	O
chronic	O
premature	Disease
ventricular	Disease
contractions	Disease
or	O
atrial	Disease
flutter	Disease
.	O
These	O
patients	O
had	O
Q-T	Disease
prolongation	Disease
and	O
recurrent	O
syncope	Disease
due	O
to	O
polymorphous	O
ventricular	Disease
tachycardia	Disease
.	O
In	O
four	O
patients,	O
the	O
arrhythmia	Disease
was	O
rapidly	O
diagnosed	O
and	O
treated	O
with	O
disappearance	O
of	O
further	O
episodes	O
of	O
the	O
arrhythmia	Disease
.	O
In	O
two	O
patients,	O
the	O
arrhythmia	Disease
degenerated	O
into	O
irreversible	O
ventricular	Disease
fibrillation	Disease
and	O
both	O
patients	O
died.	O
In	O
the	O
seventh	O
patient,	O
a	O
permanent	O
ventricular	O
pacemaker	O
was	O
inserted	O
and,	O
despite	O
continuation	O
of	O
procainamide	Chemical
therapy,	O
polymorphous	O
ventricular	Disease
tachycardia	Disease
did	O
not	O
reoccur.	O
These	O
seven	O
cases	O
demonstrate	O
that	O
procainamide	Chemical
can	O
produce	O
an	O
acquired	O
prolonged	Disease
Q-T	Disease
syndrome	Disease
with	O
polymorphous	O
ventricular	Disease
tachycardia	Disease

Role	O
of	O
activation	O
of	O
bradykinin	Chemical
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood-brain	O
barrier	O
during	O
acute	O
hypertension	Disease
.	O
Cellular	O
mechanisms	O
which	O
account	O
for	O
disruption	O
the	O
blood-brain	O
barrier	O
during	O
acute	O
hypertension	Disease
are	O
not	O
clear.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
synthesis/release	O
of	O
bradykinin	Chemical
to	O
activate	O
B2	O
receptors	O
in	O
disruption	O
of	O
the	O
blood-brain	O
barrier	O
during	O
acute	O
hypertension	Disease
.	O
Permeability	O
of	O
the	O
blood-brain	O
barrier	O
was	O
quantitated	O
by	O
clearance	O
of	O
fluorescent-labeled	O
dextran	Chemical
before	O
and	O
during	O
phenylephrine	Chemical
-induced	O
acute	O
hypertension	Disease
in	O
rats	O
treated	O
with	O
vehicle	O
and	O
Hoe-140	Chemical
(0.1	O
microM).	O
Phenylephrine	Chemical
infusion	O
increased	O
arterial	O
pressure,	O
arteriolar	O
diameter	O
and	O
clearance	O
of	O
fluorescent	O
dextran	Chemical
by	O
a	O
similar	O
magnitude	O
in	O
both	O
groups.	O
These	O
findings	O
suggest	O
that	O
disruption	O
of	O
the	O
blood-brain	O
barrier	O
during	O
acute	O
hypertension	Disease
is	O
not	O
related	O
to	O
the	O
synthesis/release	O
of	O
bradykinin	Chemical

5-azacytidine	Chemical
potentiates	O
initiation	Disease
induced	Disease
by	Disease
carcinogens	Disease
in	O
rat	O
liver.	O
To	O
test	O
the	O
validity	O
of	O
the	O
hypothesis	O
that	O
hypomethylation	O
of	O
DNA	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	Disease
of	Disease
carcinogenic	Disease
process	Disease
,	O
5-azacytidine	Chemical
(	O
5-AzC	Chemical
)	O
(10	O
mg/kg),	O
an	O
inhibitor	O
of	O
DNA	O
methylation,	O
was	O
given	O
to	O
rats	O
during	O
the	O
phase	O
of	O
repair	O
synthesis	O
induced	O
by	O
the	O
three	O
carcinogens,	O
benzo[a]-pyrene	Chemical
(200	O
mg/kg),	O
N-methyl-N-nitrosourea	Chemical
(60	O
mg/kg)	O
and	O
1,2-dimethylhydrazine	Chemical
(	O
1,2-DMH	Chemical
)	O
(100	O
mg/kg).	O
The	O
initiated	O
hepatocytes	O
in	O
the	O
liver	O
were	O
assayed	O
as	O
the	O
gamma-glutamyltransferase	O
(gamma-GT)	O
positive	O
foci	O
formed	O
following	O
a	O
2-week	O
selection	O
regimen	O
consisting	O
of	O
dietary	O
0.02%	O
2-acetylaminofluorene	Chemical
coupled	O
with	O
a	O
necrogenic	O
dose	O
of	O
CCl4	Chemical
.	O
The	O
results	O
obtained	O
indicate	O
that	O
with	O
all	O
three	O
carcinogens,	O
administration	O
of	O
5-AzC	Chemical
during	O
repair	O
synthesis	O
increased	O
the	O
incidence	O
of	O
initiated	O
hepatocytes,	O
for	O
example	O
10-20	O
foci/cm2	O
in	O
5-AzC	Chemical
and	O
carcinogen-treated	O
rats	O
compared	O
with	O
3-5	O
foci/cm2	O
in	O
rats	O
treated	O
with	O
carcinogen	O
only.	O
Administration	O
of	O
[3H]-5-azadeoxycytidine	Chemical
during	O
the	O
repair	O
synthesis	O
induced	O
by	O
1,2-DMH	Chemical
further	O
showed	O
that	O
0.019	O
mol	O
%	O
of	O
cytosine	Chemical
residues	O
in	O
DNA	O
were	O
substituted	O
by	O
the	O
analogue,	O
indicating	O
that	O
incorporation	O
of	O
5-AzC	Chemical
occurs	O
during	O
repair	O
synthesis.	O
In	O
the	O
absence	O
of	O
the	O
carcinogen,	O
5-AzC	Chemical

Withdrawal-emergent	Disease
rabbit	Disease
syndrome	Disease
during	O
dose	O
reduction	O
of	O
risperidone	Chemical
.	O
Rabbit	Disease
syndrome	Disease
(	O
RS	Disease
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	O
medication.	O
Here	O
we	O
present	O
a	O
case	O
of	O
withdrawal-emergent	Disease
RS	Disease
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported.	O
The	O
patient	O
developed	O
RS	Disease
during	O
dose	O
reduction	O
of	O
risperidone	Chemical
.	O
The	O
symptom	O
was	O
treated	O
successfully	O
with	O
trihexyphenidyl	Chemical
anticholinergic	O
therapy.	O
The	O
underlying	O
mechanism	O
of	O
withdrawal-emergent	Disease
RS	Disease
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	Chemical
,	O
a	O
serotonin	Chemical
-	O
dopamine	Chemical
antagonist,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	Chemical
system	O
in	O
the	O
development	O
of	O
RS	Disease

Verapamil	Chemical
withdrawal	O
as	O
a	O
possible	O
cause	O
of	O
myocardial	Disease
infarction	Disease
in	O
a	O
hypertensive	Disease
woman	O
with	O
a	O
normal	O
coronary	O
angiogram.	O
Verapamil	Chemical
is	O
an	O
effective	O
and	O
relatively-safe	O
antihypertensive	O
drug.	O
Serious	O
adverse	O
effects	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depression	Disease
of	O
cardiac	O
contractility	O
and	O
conduction,	O
especially	O
when	O
the	O
drug	O
is	O
combined	O
with	O
beta-blocking	O
agents.	O
We	O
report	O
a	O
case	O
in	O
which	O
myocardial	Disease
infarction	Disease
coincided	O
with	O
the	O
introduction	O
of	O
captopril	Chemical
and	O
the	O
withdrawal	O
of	O
verapamil	Chemical
in	O
a	O
previously	O
asymptomatic	O
woman	O
with	O
severe	O
hypertension	Disease
.	O
Possible	O
mechanisms	O
that	O
involve	O
a	O
verapamil	Chemical
-related	O
increase	O
in	O
platelet	O
and/or	O
vascular	O
alpha	O
2-adrenoreceptor	O
affinity	O
for	O
catecholamines	Chemical

Remission	O
induction	O
of	O
meningeal	Disease
leukemia	Disease
with	O
high-dose	O
intravenous	O
methotrexate	Chemical
.	O
Twenty	O
children	O
with	O
acute	Disease
lymphoblastic	Disease
leukemia	Disease
who	O
developed	O
meningeal	Disease
disease	Disease
were	O
treated	O
with	O
a	O
high-dose	O
intravenous	O
methotrexate	Chemical
regimen	O
that	O
was	O
designed	O
to	O
achieve	O
and	O
maintain	O
CSF	O
methotrexate	Chemical
concentrations	O
of	O
10(-5)	O
mol/L	O
without	O
the	O
need	O
for	O
concomitant	O
intrathecal	O
dosing.	O
The	O
methotrexate	Chemical
was	O
administered	O
as	O
a	O
loading	O
dose	O
of	O
6,000	O
mg/m2	O
for	O
a	O
period	O
of	O
one	O
hour	O
followed	O
by	O
an	O
infusion	O
of	O
1,200	O
mg/m2/h	O
for	O
23	O
hours.	O
Leucovorin	Chemical
rescue	O
was	O
initiated	O
12	O
hours	O
after	O
the	O
end	O
of	O
the	O
infusion	O
with	O
a	O
loading	O
dose	O
of	O
200	O
mg/m2	O
followed	O
by	O
12	O
mg/m2	O
every	O
three	O
hours	O
for	O
six	O
doses	O
and	O
then	O
every	O
six	O
hours	O
until	O
the	O
plasma	O
methotrexate	Chemical
level	O
decreased	O
to	O
less	O
than	O
1	O
X	O
10(-7)	O
mol/L.	O
The	O
mean	O
steady-state	O
plasma	O
and	O
CSF	O
methotrexate	Chemical
concentrations	O
achieved	O
were	O
1.1	O
X	O
10(-3)	O
mol/L	O
and	O
3.6	O
X	O
10(-5)	O
mol/L,	O
respectively.	O
All	O
20	O
patients	O
responded	O
to	O
this	O
regimen,	O
16/20	O
(80%)	O
achieved	O
a	O
complete	O
remission,	O
and	O
20%	O
obtained	O
a	O
partial	O
remission.	O
The	O
most	O
common	O
toxicities	Disease
encountered	O
were	O
transient	O
serum	O
transaminase	O
and	O
bilirubin	Chemical
elevations,	O
neutropenia	Disease
,	O
and	O
mucositis	Disease
.	O
One	O
patient	O
had	O
focal	O
seizures	Disease
and	O
transient	Disease
hemiparesis	Disease
but	O
recovered	O
completely.	O
High-dose	O
intravenous	O
methotrexate	Chemical
is	O
an	O
effective	O
treatment	O
for	O
the	O
induction	O
of	O
remission	O
after	O
meningeal	O
relapse	O
in	O
acute	Disease
lymphoblastic	Disease
leukemia	Disease

Hypersensitivity	Disease
to	O
carbamazepine	Chemical
presenting	O
with	O
a	O
leukemoid	Disease
reaction	Disease
,	O
eosinophilia	Disease
,	O
erythroderma	Disease
,	O
and	O
renal	Disease
failure	Disease
.	O
We	O
report	O
a	O
patient	O
in	O
whom	O
hypersensitivity	Disease
to	O
carbamazepine	Chemical
presented	O
with	O
generalized	O
erythroderma	Disease
,	O
a	O
severe	O
leukemoid	Disease
reaction	Disease
,	O
eosinophilia	Disease
,	O
hyponatremia	Disease
,	O
and	O
renal	Disease
failure	Disease
.	O
This	O
is	O
the	O
first	O
report	O
of	O
such	O
an	O
unusual	O
reaction	O
to	O
carbamazepine	Chemical

The	O
interpeduncular	O
nucleus	O
regulates	O
nicotine	Chemical
's	O
effects	O
on	O
free-field	O
activity.	O
Partial	O
lesions	O
were	O
made	O
with	O
kainic	Chemical
acid	Chemical
in	O
the	O
interpeduncular	O
nucleus	O
of	O
the	O
ventral	O
midbrain	O
of	O
the	O
rat.	O
Compared	O
with	O
sham-operated	O
controls,	O
lesions	O
significantly	O
(p	O
<	O
0.25)	O
blunted	O
the	O
early	O
(<60	O
min)	O
free-field	O
locomotor	Disease
hypoactivity	Disease
caused	O
by	O
nicotine	Chemical
(0.5	O
mg	O
kg(-1),	O
i.m.),	O
enhanced	O
the	O
later	O
(60-120	O
min)	O
nicotine	Chemical
-induced	O
hyperactivity	Disease
,	O
and	O
raised	O
spontaneous	O
nocturnal	O
activity.	O
Lesions	O
reduced	O
the	O
extent	O
of	O
immunohistological	O
staining	O
for	O
choline	Chemical
acetyltransferase	O
in	O
the	O
interpeduncular	O
nucleus	O
(p	O
<0.025),	O
but	O
not	O
for	O
tyrosine	Chemical
hydroxylase	O
in	O
the	O
surrounding	O
catecholaminergic	O
A10	O
region.	O
We	O
conclude	O
that	O
the	O
interpeduncular	O
nucleus	O
mediates	O
nicotinic	O
depression	Disease

Assessment	O
of	O
a	O
new	O
non-invasive	O
index	O
of	O
cardiac	O
performance	O
for	O
detection	O
of	O
dobutamine	Chemical
-induced	O
myocardial	Disease
ischemia	Disease
.	O
BACKGROUND:	O
Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine	Chemical
-induced	O
myocardial	Disease
ischemia	Disease
.	O
OBJECTIVES:	O
To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(dP/dtejc)	O
measurement,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes,	O
as	O
compared	O
to	O
standard	O
12-lead	O
ECG,	O
for	O
detecting	O
dobutamine	Chemical
-induced	O
myocardial	Disease
ischemia	Disease
,	O
using	O
Tc99m-Sestamibi	Chemical
single-photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	O
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	Disease
.	O
METHODS:	O
The	O
study	O
group	O
comprised	O
40	O
patients	O
undergoing	O
Sestamibi	Chemical
-SPECT/	O
dobutamine	Chemical
stress	O
test.	O
Simultaneous	O
measurements	O
of	O
ECG	O
and	O
brachial	O
artery	O
dP/dtejc	O
were	O
performed	O
at	O
each	O
dobutamine	Chemical
level.	O
In	O
19	O
of	O
the	O
40	O
patients	O
perfusion	O
defects	O
compatible	O
with	O
ischemia	Disease
were	O
detected	O
on	O
SPECT.	O
The	O
increase	O
in	O
dP/dtejc	O
during	O
infusion	O
of	O
dobutamine	Chemical
in	O
this	O
group	O
was	O
severely	O
impaired	O
as	O
compared	O
to	O
the	O
non-ischemic	O
group.	O
dP/dtejc	O
outcome	O
was	O
combined	O
with	O
the	O
ECG	O
results,	O
giving	O
an	O
ECG-enhanced	O
value,	O
and	O
compared	O
to	O
ECG	O
alone.	O
RESULTS:	O
The	O
sensitivity	O
improved	O
dramatically	O
from	O
16%	O
to	O
79%,	O
positive	O
predictive	O
value	O
increased	O
from	O
60%	O
to	O
68%	O
and	O
negative	O
predictive	O
value	O
from	O
54%	O
to	O
78%,	O
and	O
specificity	O
decreased	O
from	O
90%	O
to	O
67%.	O
CONCLUSIONS:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specificity,	O
the	O
combination	O
with	O
dP/dtejc	O
improved	O
the	O
sensitivity	O
of	O
the	O
test	O
and	O
could	O
be	O
a	O
cost-savings	O
alternative	O
to	O
cardiac	O
imaging	O
or	O
perfusion	O
studies	O
to	O
detect	O
myocardial	Disease
ischemia	Disease

Acute	Disease
liver	Disease
failure	Disease
in	O
two	O
patients	O
with	O
regular	O
alcohol	Chemical
consumption	O
ingesting	O
paracetamol	Chemical
at	O
therapeutic	O
dosage.	O
BACKGROUND:	O
The	O
possible	O
role	O
of	O
alcohol	Chemical
in	O
the	O
development	O
of	O
hepatotoxicity	Disease
associated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	Chemical
(	O
acetaminophen	Chemical
)	O
is	O
currently	O
debated.	O
CASE	O
REPORT:	O
We	O
describe	O
2	O
patients	O
who	O
were	O
regular	O
consumers	O
of	O
alcohol	Chemical
and	O
who	O
developed	O
liver	Disease
failure	Disease
within	O
3-5	O
days	O
after	O
hospitalization	O
and	O
stopping	O
alcohol	Chemical
consumption	O
while	O
being	O
treated	O
with	O
4	O
g	O
paracetamol	Chemical
/day.	O
A	O
paracetamol	Chemical
serum	O
level	O
obtained	O
in	O
one	O
of	O
these	O
patients	O
was	O
not	O
in	O
the	O
toxic	O
range.	O
Possible	O
risk	O
factors	O
for	O
the	O
development	O
of	O
hepatotoxicity	Disease
in	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
of	O
paracetamol	Chemical
are	O
discussed.	O
CONCLUSION:	O
In	O
patients	O
with	O
risk	O
factors,	O
e.g.	O
regular	O
consumption	O
of	O
alcohol	Chemical
,	O
liver	Disease
failure	Disease
is	O
possible	O
when	O
therapeutic	O
doses	O
are	O
ingested.	O
We	O
propose	O
that	O
the	O
paracetamol	Chemical
dose	O
should	O
not	O
exceed	O
2	O
g/day	O
in	O
such	O
patients	O
and	O
that	O
their	O
liver	O
function	O
should	O
be	O
monitored	O
closely	O
while	O
being	O
treated	O
with	O
paracetamol	Chemical

Cocaine	Chemical
related	O
chest	Disease
pain	Disease
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg?	O
The	O
recreational	O
use	O
of	O
cocaine	Chemical
is	O
on	O
the	O
increase.	O
The	O
emergency	O
nurse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
cocaine	Chemical
use.	O
In	O
particular,	O
the	O
tendency	O
of	O
cocaine	Chemical
to	O
produce	O
chest	Disease
pain	Disease
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	Disease
pain	Disease
who	O
is	O
otherwise	O
at	O
low	O
risk.	O
The	O
mechanism	O
of	O
chest	Disease
pain	Disease
related	O
to	O
cocaine	Chemical
use	O
is	O
discussed	O
and	O
treatment	O
dilemmas	O
are	O
discussed.	O
Finally,	O
moral	O
issues	O
relating	O
to	O
the	O
testing	O
of	O
potential	O
cocaine	Chemical

Severe	O
rhabdomyolysis	Disease
and	O
acute	Disease
renal	Disease
failure	Disease
secondary	O
to	O
concomitant	O
use	O
of	O
simvastatin	Chemical
,	O
amiodarone	Chemical
,	O
and	O
atazanavir	Chemical
.	O
OBJECTIVE:	O
To	O
report	O
a	O
case	O
of	O
a	O
severe	O
interaction	O
between	O
simvastatin	Chemical
,	O
amiodarone	Chemical
,	O
and	O
atazanavir	Chemical
resulting	O
in	O
rhabdomyolysis	Disease
and	O
acute	Disease
renal	Disease
failure	Disease
.	O
BACKGROUND:	O
A	O
72-year-old	O
white	O
man	O
with	O
underlying	O
human	Disease
immunodeficiency	Disease
virus	Disease
,	O
atrial	Disease
fibrillation	Disease
,	O
coronary	Disease
artery	Disease
disease	Disease
,	O
and	O
hyperlipidemia	Disease
presented	O
with	O
generalized	O
pain	Disease
,	O
fatigue	Disease
,	O
and	O
dark	O
orange	O
urine	O
for	O
3	O
days.	O
The	O
patient	O
was	O
taking	O
80	O
mg	O
simvastatin	Chemical
at	O
bedtime	O
(initiated	O
27	O
days	O
earlier);	O
amiodarone	Chemical
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
for	O
7	O
days,	O
then	O
200	O
mg	O
daily	O
(initiated	O
19	O
days	O
earlier);	O
and	O
400	O
mg	O
atazanavir	Chemical
daily	O
(initiated	O
at	O
least	O
2	O
years	O
previously).	O
Laboratory	O
evaluation	O
revealed	O
66,680	O
U/L	O
creatine	Chemical
kinase,	O
93	O
mg/dL	O
blood	Chemical
urea	Chemical
nitrogen	Chemical
,	O
4.6	O
mg/dL	O
creatinine	Chemical
,	O
1579	O
U/L	O
aspartate	Chemical
aminotransferase,	O
and	O
738	O
U/L	O
alanine	Chemical
aminotransferase.	O
Simvastatin	Chemical
,	O
amiodarone	Chemical
,	O
and	O
the	O
patient's	O
human	Disease
immunodeficiency	Disease
virus	Disease
medications	O
were	O
all	O
temporarily	O
discontinued	O
and	O
the	O
patient	O
was	O
given	O
forced	O
alkaline	O
diuresis	O
and	O
started	O
on	O
dialysis.	O
Nine	O
days	O
later	O
the	O
patient's	O
creatine	Chemical
kinase	O
had	O
dropped	O
to	O
1695	O
U/L	O
and	O
creatinine	Chemical
was	O
3.3	O
mg/dL.	O
The	O
patient	O
was	O
discharged	O
and	O
continued	O
outpatient	O
dialysis	O
for	O
1	O
month	O
until	O
his	O
renal	O
function	O
recovered.	O
DISCUSSION:	O
The	O
risk	O
of	O
rhabdomyolysis	Disease
is	O
increased	O
in	O
the	O
presence	O
of	O
concomitant	O
drugs	O
that	O
inhibit	O
simvastatin	Chemical
metabolism.	O
Simvastatin	Chemical
is	O
metabolized	O
by	O
CYP3A4.	O
Amiodarone	Chemical
and	O
atazanavir	Chemical
are	O
recognized	O
CYP3A4	O
inhibitors.	O
CONCLUSIONS:	O
Pharmacokinetic	O
differences	O
in	O
statins	Chemical
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
risk	O
of	O
potential	O
drug	O
interactions.	O
In	O
patients	O
requiring	O
the	O
concurrent	O
use	O
of	O
statins	Chemical
and	O
CYP3A4	O
inhibitors,	O
pravastatin	Chemical
,	O
fluvastatin	Chemical
,	O
and	O
rosuvastatin	Chemical
carry	O
the	O
lowest	O
risk	O
of	O
drug	O
interactions;	O
atorvastatin	Chemical
carries	O
moderate	O
risk,	O
whereas	O
simvastatin	Chemical
and	O
lovastatin	Chemical

Phase	O
II	O
trial	O
of	O
vinorelbine	Chemical
in	O
metastatic	O
squamous	Disease
cell	Disease
esophageal	Disease
carcinoma	Disease
.	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	Disease
Gastrointestinal	O
Treat	O
Cancer	Disease
Cooperative	O
Group.	O
PURPOSE:	O
To	O
evaluate	O
the	O
response	O
rate	O
and	O
toxic	O
effects	O
of	O
vinorelbine	Chemical
(	O
VNB	Chemical
)	O
administered	O
as	O
a	O
single	O
agent	O
in	O
metastatic	O
squamous	Disease
cell	Disease
esophageal	Disease
carcinoma	Disease
.	O
PATIENTS	O
AND	O
METHODS:	O
Forty-six	O
eligible	O
patients	O
with	O
measurable	O
lesions	O
were	O
included	O
and	O
were	O
stratified	O
according	O
to	O
previous	O
chemotherapy.	O
Thirty	O
patients	O
without	O
prior	O
chemotherapy	O
and	O
16	O
pretreated	O
with	O
cisplatin	Chemical
-based	O
chemotherapy	O
were	O
assessable	O
for	O
toxicity	Disease
and	O
response.	O
VNB	Chemical
was	O
administered	O
weekly	O
as	O
a	O
25-mg/m2	O
short	O
intravenous	O
(i.v.)	O
infusion.	O
RESULTS:	O
Six	O
of	O
30	O
patients	O
(20%)	O
without	O
prior	O
chemotherapy	O
achieved	O
a	O
partial	O
response	O
(PR)	O
(95%	O
confidence	O
interval	O
[CI],	O
8%	O
to	O
39%).	O
The	O
median	O
duration	O
of	O
response	O
was	O
21	O
weeks	O
(range,	O
17	O
to	O
28).	O
One	O
of	O
16	O
patients	O
(6%)	O
with	O
prior	O
chemotherapy	O
had	O
a	O
complete	O
response	O
(CR)	O
of	O
31	O
weeks'	O
duration	O
(95%	O
CI,	O
0%	O
to	O
30%).	O
The	O
overall	O
response	O
rate	O
(World	O
Health	O
Organization	O
[WHO]	O
criteria)	O
was	O
15%	O
(CR,	O
2%;	O
PR	O
13%;	O
95%	O
CI,	O
6%	O
to	O
29%).	O
The	O
median	O
dose-intensity	O
(DI)	O
was	O
20	O
mg/m2/wk.	O
VNB	Chemical
was	O
well	O
tolerated	O
and	O
zero	O
instances	O
of	O
WHO	O
grade	O
4	O
nonhematologic	O
toxicity	Disease
occurred.	O
At	O
least	O
one	O
episode	O
of	O
grade	O
3	O
or	O
4	O
granulocytopenia	Disease
was	O
seen	O
in	O
59%	O
of	O
patients.	O
A	O
grade	O
2	O
or	O
3	O
infection	Disease
occurred	O
in	O
16%	O
of	O
patients,	O
but	O
no	O
toxic	O
deaths	Disease
occurred.	O
Other	O
side	O
effects	O
were	O
rare,	O
and	O
peripheral	Disease
neurotoxicity	Disease
has	O
been	O
minor	O
(26%	O
grade	O
1).	O
CONCLUSION:	O
These	O
data	O
indicate	O
that	O
VNB	Chemical
is	O
an	O
active	O
agent	O
in	O
metastatic	O
esophageal	Disease
squamous	Disease
cell	Disease
carcinoma	Disease
.	O
Given	O
its	O
excellent	O
tolerance	O
profile	O
and	O
low	O
toxicity	Disease
,	O
further	O
evaluation	O
of	O
VNB	Chemical

Paclitaxel	Chemical
,	O
cisplatin	Chemical
,	O
and	O
gemcitabine	Chemical
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	Disease
cell	Disease
lung	Disease
carcinoma	Disease
.	O
BACKGROUND:	O
Cisplatin	Chemical
-based	O
chemotherapy	O
combinations	O
improve	O
quality	O
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	Disease
cell	Disease
lung	Disease
carcinoma	Disease
(	O
NSCLC	Disease
).	O
The	O
emergence	O
of	O
new	O
active	O
drugs	O
might	O
translate	O
into	O
more	O
effective	O
regimens	O
for	O
the	O
treatment	O
of	O
this	O
disease.	O
METHODS:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility,	O
response	O
rate,	O
and	O
toxicity	Disease
of	O
a	O
paclitaxel	Chemical
,	O
cisplatin	Chemical
,	O
and	O
gemcitabine	Chemical
combination	O
to	O
treat	O
metastatic	O
NSCLC	Disease
.	O
Thirty-five	O
consecutive	O
chemotherapy-naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	Disease
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0-2	O
were	O
treated	O
with	O
a	O
combination	O
of	O
paclitaxel	Chemical
(135	O
mg/m(2)	O
given	O
intravenously	O
in	O
3	O
hours)	O
on	O
Day	O
1,	O
cisplatin	Chemical
(120	O
mg/m(2)	O
given	O
intravenously	O
in	O
6	O
hours)	O
on	O
Day	O
1,	O
and	O
gemcitabine	Chemical
(800	O
mg/m(2)	O
given	O
intravenously	O
in	O
30	O
minutes)	O
on	O
Days	O
1	O
and	O
8,	O
every	O
4	O
weeks.	O
Although	O
responding	O
patients	O
were	O
scheduled	O
to	O
receive	O
consolidation	O
radiotherapy	O
and	O
24	O
patients	O
received	O
preplanned	O
second-line	O
chemotherapy	O
after	O
disease	O
progression,	O
the	O
response	O
and	O
toxicity	Disease
rates	O
reported	O
refer	O
only	O
to	O
the	O
chemotherapy	O
regimen	O
given.	O
RESULTS:	O
All	O
the	O
patients	O
were	O
examined	O
for	O
toxicity	Disease
;	O
34	O
were	O
examinable	O
for	O
response.	O
An	O
objective	O
response	O
was	O
observed	O
in	O
73.5%	O
of	O
the	O
patients	O
(95%	O
confidence	O
interval	O
[CI],	O
55.6-87.1%),	O
including	O
4	O
complete	O
responses	O
(11.7%).	O
According	O
to	O
intention-to-treat,	O
the	O
overall	O
response	O
rate	O
was	O
71.4%	O
(95%	O
CI,	O
53.	O
7-85.4%).	O
After	O
154	O
courses	O
of	O
therapy,	O
the	O
median	O
dose	O
intensity	O
was	O
131	O
mg/m(2)	O
for	O
paclitaxel	Chemical
(97.3%),	O
117	O
mg/m(2)	O
for	O
cisplatin	Chemical
(97.3%),	O
and	O
1378	O
mg/m(2)	O
for	O
gemcitabine	Chemical
(86.2%).	O
World	O
Health	O
Organization	O
Grade	O
3-4	O
neutropenia	Disease
and	O
thrombocytopenia	Disease
occurred	O
in	O
39.9%	O
and	O
11.4%	O
of	O
patients,	O
respectively.	O
There	O
was	O
one	O
treatment-related	O
death	Disease
.	O
Nonhematologic	O
toxicities	Disease
were	O
mild.	O
After	O
a	O
median	O
follow-up	O
of	O
22	O
months,	O
the	O
median	O
progression	O
free	O
survival	O
rate	O
was	O
7	O
months,	O
and	O
the	O
median	O
survival	O
time	O
was	O
16	O
months.	O
CONCLUSIONS:	O
The	O
combination	O
of	O
paclitaxel	Chemical
,	O
cisplatin	Chemical
,	O
and	O
gemcitabine	Chemical
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	Disease
.	O
This	O
treatment	O
merits	O
further	O
comparison	O
with	O
other	O
cisplatin	Chemical

Evaluation	O
of	O
adverse	O
reactions	O
of	O
aponidine	Chemical
hydrochloride	Chemical
ophthalmic	O
solution.	O
We	O
prospectively	O
evaluated	O
the	O
adverse	O
reactions	O
of	O
apraclonidine	Chemical
in	O
20	O
normal	O
volunteers	O
by	O
instilling	O
a	O
single	O
drop	O
of	O
1%	O
apraclonidine	Chemical
in	O
their	O
right	O
eyes.	O
Examinations,	O
including	O
blood	O
pressure,	O
pulse	O
rate,	O
conjunctiva	O
and	O
cornea,	O
intraocular	O
pressure	O
(IOP),	O
pupil	O
diameter,	O
basal	O
tear	O
secretion	O
and	O
margin	O
reflex	O
distance	O
of	O
both	O
upper	O
and	O
lower	O
eyelids,	O
were	O
performed	O
prior	O
to	O
entry	O
and	O
at	O
1,	O
3,	O
5	O
and	O
7	O
hours	O
after	O
instillation.	O
The	O
ocular	Disease
hypotensive	Disease
effects	O
were	O
statistically	O
significant	O
for	O
apraclonidine	Chemical
-treated	O
eyes	O
throughout	O
the	O
study	O
and	O
also	O
statistically	O
significant	O
for	O
contralateral	O
eyes	O
from	O
three	O
hours	O
after	O
topical	O
administration	O
of	O
1%	O
apraclonidine	Chemical
.	O
Decreases	Disease
in	Disease
systolic	Disease
blood	Disease
pressure	Disease
were	O
statistically,	O
but	O
not	O
clinically,	O
significant.	O
No	O
significant	O
changes	O
in	O
diastolic	O
blood	O
pressure,	O
pulse	O
rate	O
and	O
basal	O
tear	O
secretion	O
were	O
noted.	O
Conjunctival	Disease
blanching	Disease
and	O
mydriasis	Disease
were	O
commonly	O
found.	O
Upper	O
lid	O
retraction	O
was	O
frequently	O
noted.	O
While	O
the	O
elevations	O
of	O
the	O
upper	O
lid	O
margin	O
in	O
most	O
subjects	O
were	O
not	O
more	O
than	O
2	O
mm	O
and	O
did	O
not	O
cause	O
noticeable	O
change	O
in	O
appearance,	O
one	O
subject	O
suffered	O
from	O
mechanical	O
entropion	Disease
and	O
marked	O
corneal	Disease
abrasion	Disease

Carmofur	Chemical
-induced	O
organic	Disease
mental	Disease
disorders	Disease
.	O
Organic	Disease
mental	Disease
disorder	Disease
was	O
observed	O
in	O
a	O
29-year-old	O
female	O
in	O
the	O
prognostic	O
period	O
after	O
the	O
onset	O
of	O
carmofur	Chemical
-induced	O
leukoencephalopathy	Disease
.	O
Symptoms	O
such	O
as	O
euphoria,	O
emotional	O
lability	O
and	O
puerile	O
attitude	O
noted	O
in	O
the	O
patient	O
were	O
diagnosed	O
as	O
organic	Disease
personality	Disease
syndrome	Disease
according	O
to	O
the	O
criteria	O
defined	O
in	O
the	O
DSM-III-R.	O
It	O
is	O
referred	O
to	O
as	O
a	O
frontal	Disease
lobe	Disease
syndrome	Disease
.	O
Brain	O
CT	O
revealed	O
a	O
periventricular	O
low	O
density	O
area	O
in	O
the	O
frontal	O
white	O
matter	O
and	O
moderate	O
dilatation	O
of	O
the	O
lateral	O
ventricles	O
especially	O
at	O
the	O
bilateral	O
anterior	O
horns.	O
Consequently,	O
carmofur	Chemical
-induced	O
leukoencephalopathy	Disease
may	O
uncommonly	O
result	O
in	O
organic	Disease
personality	Disease
syndrome	Disease
in	O
the	O
residual	O
state.	O
It	O
may	O
be	O
attributed	O
to	O
the	O
structural	Disease
damage	Disease
to	Disease
the	Disease
frontal	Disease
lobe	Disease

International	O
mexiletine	Chemical
and	O
placebo	O
antiarrhythmic	O
coronary	O
trial:	O
I.	O
Report	O
on	O
arrhythmia	Disease
and	O
other	O
findings.	O
Impact	O
Research	O
Group.	O
The	O
antiarrhythmic	O
effects	O
of	O
the	O
sustained	O
release	O
form	O
of	O
mexiletine	Chemical
(	O
Mexitil-Perlongets	Chemical
)	O
were	O
evaluated	O
in	O
a	O
double-blind	O
placebo	O
trial	O
in	O
630	O
patients	O
with	O
recent	O
documented	O
myocardial	Disease
infarction	Disease
.	O
The	O
primary	O
response	O
variable	O
was	O
based	O
on	O
central	O
reading	O
of	O
24	O
hour	O
ambulatory	O
electrocardiographic	O
recordings	O
and	O
was	O
defined	O
as	O
the	O
occurrence	O
of	O
30	O
or	O
more	O
single	O
premature	O
ventricular	O
complexes	O
in	O
any	O
two	O
consecutive	O
30	O
minute	O
blocks	O
or	O
one	O
or	O
more	O
runs	O
of	O
two	O
or	O
more	O
premature	O
ventricular	O
complexes	O
in	O
the	O
entire	O
24	O
hour	O
electrocardiographic	O
recording.	O
Large	O
differences,	O
regarded	O
as	O
statistically	O
significant,	O
between	O
the	O
mexiletine	Chemical
and	O
placebo	O
groups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
months	O
1	O
and	O
4,	O
but	O
only	O
trends	O
were	O
observed	O
at	O
month	O
12.	O
These	O
differences	O
were	O
observed	O
even	O
though	O
the	O
serum	O
mexiletine	Chemical
levels	O
obtained	O
in	O
this	O
study	O
were	O
generally	O
lower	O
than	O
those	O
observed	O
in	O
studies	O
that	O
have	O
used	O
the	O
regular	O
form	O
of	O
the	O
drug.	O
There	O
were	O
more	O
deaths	Disease
in	O
the	O
mexiletine	Chemical
group	O
(7.6%)	O
than	O
in	O
the	O
placebo	O
group	O
(4.8%);	O
the	O
difference	O
was	O
not	O
statistically	O
significant.	O
The	O
incidence	O
of	O
coronary	O
events	O
was	O
similar	O
in	O
both	O
groups.	O
Previously	O
recognized	O
side	O
effects,	O
particularly	O
tremor	Disease
and	O
gastrointestinal	Disease
problems	Disease
,	O
were	O
more	O
frequent	O
in	O
the	O
mexiletine	Chemical

Regional	O
localization	O
of	O
the	O
antagonism	O
of	O
amphetamine	Chemical
-induced	O
hyperactivity	Disease
by	O
intracerebral	O
calcitonin	Chemical
injections.	O
Calcitonin	Chemical
receptors	O
are	O
found	O
in	O
the	O
brain,	O
and	O
intracerebral	O
infusions	O
of	O
calcitonin	Chemical
can	O
produce	O
behavioral	O
effects.	O
Among	O
these	O
behavioral	O
effects	O
are	O
decreases	O
in	O
food	O
intake	O
and	O
decreases	O
in	O
amphetamine	Chemical
-induced	O
locomotor	O
activity.	O
In	O
previous	O
experiments	O
we	O
found	O
that	O
decreases	O
in	O
food	O
intake	O
were	O
induced	O
by	O
local	O
administration	O
of	O
calcitonin	Chemical
into	O
several	O
hypothalamic	O
sites	O
and	O
into	O
the	O
nucleus	O
accumbens.	O
In	O
the	O
present	O
experiment	O
calcitonin	Chemical
decreased	O
locomotor	O
activity	O
when	O
locally	O
injected	O
into	O
the	O
same	O
sites	O
where	O
it	O
decreases	O
food	O
intake.	O
The	O
areas	O
where	O
calcitonin	Chemical
is	O
most	O
effective	O
in	O
decreasing	O
locomotor	O
activity	O
are	O
located	O
in	O
the	O
hypothalamus	O
and	O
nucleus	O
accumbens,	O
suggesting	O
that	O
these	O
areas	O
are	O
the	O
major	O
sites	O
of	O
action	O
of	O
calcitonin	Chemical
in	O
inhibiting	O
amphetamine	Chemical

Fatal	O
intracranial	Disease
bleeding	Disease
associated	O
with	O
prehospital	O
use	O
of	O
epinephrine	Chemical
.	O
We	O
present	O
a	O
case	O
of	O
paramedic	O
misjudgment	O
in	O
the	O
execution	O
of	O
a	O
protocol	O
for	O
the	O
treatment	O
of	O
allergic	Disease
reaction	Disease
in	O
a	O
case	O
of	O
pulmonary	Disease
edema	Disease
with	O
wheezing	Disease
.	O
The	O
sudden	O
onset	O
of	O
respiratory	Disease
distress	Disease
,	O
rash	Disease
,	O
and	O
a	O
history	O
of	O
a	O
new	O
medicine	O
led	O
the	O
two	O
paramedics	O
on	O
the	O
scene	O
to	O
administer	O
subcutaneous	O
epinephrine	Chemical
.	O
Subsequently,	O
acute	O
cardiac	Disease
arrest	Disease
and	O
fatal	O
subarachnoid	Disease
hemorrhage	Disease
occurred.	O
Epinephrine	Chemical
has	O
a	O
proven	O
role	O
in	O
cardiac	Disease
arrest	Disease
in	O
prehospital	O
care;	O
however,	O
use	O
by	O
paramedics	O
in	O
patients	O
with	O
suspected	O
allergic	Disease
reaction	Disease
and	O
severe	O
hypertension	Disease

A	O
case	O
of	O
massive	O
rhabdomyolysis	Disease
following	O
molindone	Chemical
administration.	O
Rhabdomyolysis	Disease
is	O
a	O
potentially	O
lethal	O
syndrome	O
that	O
psychiatric	Disease
patients	O
seem	O
predisposed	O
to	O
develop.	O
The	O
clinical	O
signs	O
and	O
symptoms,	O
typical	O
laboratory	O
features,	O
and	O
complications	O
of	O
rhabdomyolysis	Disease
are	O
presented.	O
The	O
case	O
of	O
a	O
schizophrenic	Disease
patient	O
is	O
reported	O
to	O
illustrate	O
massive	O
rhabdomyolysis	Disease
and	O
subsequent	O
acute	Disease
renal	Disease
failure	Disease
following	O
molindone	Chemical
administration.	O
Physicians	O
who	O
prescribe	O
molindone	Chemical

Cardiovascular	Disease
alterations	Disease
in	O
rat	O
fetuses	O
exposed	O
to	O
calcium	Chemical
channel	O
blockers.	O
Preclinical	O
toxicologic	O
investigation	O
suggested	O
that	O
a	O
new	O
calcium	Chemical
channel	O
blocker,	O
Ro	Chemical
40-5967	Chemical
,	O
induced	O
cardiovascular	Disease
alterations	Disease
in	O
rat	O
fetuses	O
exposed	O
to	O
this	O
agent	O
during	O
organogenesis.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
hypothesis	O
that	O
calcium	Chemical
channel	O
blockers	O
in	O
general	O
induce	O
cardiovascular	Disease
malformations	Disease
indicating	O
a	O
pharmacologic	O
class	O
effect.	O
We	O
studied	O
three	O
calcium	Chemical
channel	O
blockers	O
of	O
different	O
structure,	O
nifedipine	Chemical
,	O
diltiazem	Chemical
,	O
and	O
verapamil	Chemical
,	O
along	O
with	O
the	O
new	O
agent.	O
Pregnant	O
rats	O
were	O
administered	O
one	O
of	O
these	O
calcium	Chemical
channel	O
blockers	O
during	O
the	O
period	O
of	O
cardiac	O
morphogenesis	O
and	O
the	O
offspring	O
examined	O
on	O
day	O
20	O
of	O
gestation	O
for	O
cardiovascular	Disease
malformations	Disease
.	O
A	O
low	O
incidence	O
of	O
cardiovascular	Disease
malformations	Disease
was	O
observed	O
after	O
exposure	O
to	O
each	O
of	O
the	O
four	O
calcium	Chemical
channel	O
blockers,	O
but	O
this	O
incidence	O
was	O
statistically	O
significant	O
only	O
for	O
verapamil	Chemical
and	O
nifedipine	Chemical
.	O
All	O
four	O
agents	O
were	O
associated	O
with	O
aortic	O
arch	O
branching	O
variants,	O
although	O
significantly	O
increased	O
only	O
for	O
Ro	Chemical
40-5967	Chemical
and	O
verapamil	Chemical

Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	O
and	O
P120T	O
on	O
the	O
replication	O
of	O
lamivudine	Chemical
-resistant	O
hepatitis	Chemical
B	Chemical
virus	Chemical
e	Chemical
antigen	Chemical
-positive	O
and	O
-negative	O
strains.	O
Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	Disease
B	Disease
virus	O
(HBV)	O
represent	O
an	O
emerging	O
clinical	O
challenge,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape,	O
HBV	O
reactivation,	O
and	O
failure	O
of	O
diagnostic	O
tests.	O
Recent	O
data	O
suggest	O
a	O
preferential	O
selection	O
of	O
immune	O
escape	O
mutants	O
in	O
distinct	O
peripheral	O
blood	O
leukocyte	O
compartments	O
of	O
infected	O
individuals.	O
We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants,	O
the	O
sG145R	O
and	O
sP120T	O
mutants,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment-associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	Chemical
(	O
LAM	Chemical
)	O
and/or	O
HBeAg	Chemical
negativity.	O
Replication-competent	O
HBV	O
strains	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	Chemical
resistance	O
(rtM204I	O
or	O
rtL180M/rtM204V)	O
were	O
generated	O
on	O
an	O
HBeAg	Chemical
-positive	O
and	O
an	O
HBeAg	Chemical
-negative	O
background	O
with	O
precore	O
(PC)	O
and	O
basal	O
core	O
promoter	O
(BCP)	O
mutants.	O
The	O
sG145R	O
mutation	O
strongly	O
reduced	O
HBsAg	Chemical
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM	Chemical
-resistant	O
HBV	O
mutants	O
to	O
the	O
levels	O
of	O
wild-type	O
HBV,	O
and	O
PC	O
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication.	O
Although	O
the	O
sP120T	O
substitution	O
also	O
impaired	O
HBsAg	Chemical
secretion,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	Chemical
-resistant	O
clones.	O
However,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	Chemical
negativity	O
(PC/BCP),	O
sP120T,	O
and	O
LAM	Chemical
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild-type	O
HBV.	O
In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	Chemical
resistance	O
mutations,	O
the	O
nucleotide	Chemical
analogues	O
adefovir	Chemical
and	O
tenofovir	Chemical

The	O
effects	O
of	O
sevoflurane	Chemical
on	O
lidocaine	Chemical
-induced	O
convulsions	Disease
.	O
The	O
influence	O
of	O
sevoflurane	Chemical
on	O
lidocaine	Chemical
-induced	O
convulsions	Disease
was	O
studied	O
in	O
cats.	O
The	O
convulsive	Disease
threshold	O
(mean	O
+/-	O
SD)	O
was	O
41.4	O
+/-	O
6.5	O
mg.	O
l(-1)	O
with	O
lidocaine	Chemical
infusion	O
(6	O
mg.kg(-1).min(-1)),	O
increasing	O
significantly	O
to	O
66.6	O
+/-	O
10.9	O
mg.	O
l(-1)	O
when	O
the	O
end-tidal	O
concentration	O
of	O
sevoflurane	Chemical
was	O
0.8%.	O
However,	O
the	O
threshold	O
(61.6	O
+/-	O
8.7	O
mg.	O
l(-1))	O
during	O
1.6%	O
sevoflurane	Chemical
was	O
not	O
significant	O
from	O
that	O
during	O
0.8%	O
sevoflurane	Chemical
,	O
indicating	O
a	O
celling	O
effect.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsive	Disease
threshold	O
between	O
sevoflurane	Chemical
and	O
enflurane	Chemical
.	O
The	O
rise	O
in	O
blood	O
pressure	O
became	O
less	O
marked	O
when	O
higher	O
concentrations	O
of	O
sevoflurane	Chemical
or	O
enflurane	Chemical
were	O
administered	O
and	O
the	O
blood	O
pressure	O
at	O
convulsions	Disease
decreased	O
significantly	O
in	O
1.6%	O
sevoflurane	Chemical
,	O
and	O
in	O
0.8%	O
and	O
1.6%	O
enflurane	Chemical
.	O
However,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocaine	Chemical
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg.	O
Apamin	Chemical
,	O
a	O
selective	O
blocker	O
of	O
calcium	Chemical
-dependent	O
potassium	Chemical
channels,	O
was	O
administered	O
intracerebroventricularly	O
in	O
rats	O
anesthetized	O
with	O
0.8%	O
sevoflurane	Chemical
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
anticonvulsive	O
effects.	O
Apamin	Chemical
(10	O
ng)	O
had	O
a	O
tendency	O
to	O
decrease	O
the	O
convulsive	Disease
threshold	O
(21.6	O
+/-	O
2.2	O
to	O
19.9	O
+/-	O
2.5	O
mg.	O
l(-1))	O
but	O
this	O
was	O
not	O
statistically	O
significant.	O
It	O
is	O
suggested	O
that	O
sevoflurane	Chemical
reduces	O
the	O
convulsive	Disease
effect	O
of	O
lidocaine	Chemical
	O
toxicity	Disease
but	O
carries	O
some	O
risk	O
due	O
to	O
circulatory	O
depression	Disease

Anti-oxidant	O
effects	O
of	O
atorvastatin	Chemical
in	O
dexamethasone	Chemical
-induced	O
hypertension	Disease
in	O
the	O
rat.	O
1.	O
Dexamethasone	Chemical
(	O
Dex	Chemical
)-induced	O
hypertension	Disease
is	O
characterized	O
by	O
endothelial	O
dysfunction	O
associated	O
with	O
nitric	Chemical
oxide	Chemical
(	O
NO	Chemical
)	O
deficiency	O
and	O
increased	O
superoxide	Chemical
(	O
O2-	Chemical
)	O
production.	O
Atorvastatin	Chemical
(	O
Ato	Chemical
)	O
possesses	O
pleiotropic	O
properties	O
that	O
have	O
been	O
reported	O
to	O
improve	O
endothelial	O
function	O
through	O
increased	O
availability	O
of	O
NO	Chemical
and	O
reduced	O
O2-	Chemical
production	O
in	O
various	O
forms	O
of	O
hypertension	Disease
.	O
In	O
the	O
present	O
study,	O
we	O
investigated	O
whether	O
50	O
mg/kg	O
per	O
day,	O
p.o.,	O
Ato	Chemical
could	O
prevent	O
endothelial	O
NO	Chemical
synthase	O
(eNOS)	O
downregulation	O
and	O
the	O
increase	O
in	O
O2-	Chemical
in	O
Sprague-Dawley	O
(SD)	O
rats,	O
thereby	O
reducing	O
blood	O
pressure.	O
2.	O
Male	O
SD	O
rats	O
(n	O
=	O
30)	O
were	O
treated	O
with	O
Ato	Chemical
(50	O
mg/kg	O
per	O
day	O
in	O
drinking	O
water)	O
or	O
tap	O
water	O
for	O
15	O
days.	O
Dexamethasone	Chemical
(10	O
microg/kg	O
per	O
day,	O
s.c.)	O
or	O
saline	O
was	O
started	O
after	O
4	O
days	O
in	O
Ato	Chemical
-treated	O
and	O
non-treated	O
rats	O
and	O
continued	O
for	O
11-13	O
days.	O
Systolic	O
blood	O
pressure	O
(SBP)	O
was	O
measured	O
on	O
alternate	O
days	O
using	O
the	O
tail-cuff	O
method.	O
Endothelial	O
function	O
was	O
assessed	O
by	O
acetylcholine	Chemical
-induced	O
vasorelaxation	O
and	O
phenylephrine	Chemical
-induced	O
vasoconstriction	O
in	O
aortic	O
segments.	O
Vascular	O
eNOS	O
mRNA	O
was	O
assessed	O
by	O
semi-quantitative	O
reverse	O
transcription-polymerase	O
chain	O
reaction.	O
3.	O
In	O
rats	O
treated	O
with	O
Dex	Chemical
alone,	O
SBP	O
was	O
increased	O
from	O
109	O
+/-	O
2	O
to	O
133	O
+/-	O
2	O
mmHg	O
on	O
Days	O
4	O
and	O
Day	O
14,	O
respectively	O
(P	O
<	O
0.001).	O
In	O
the	O
Ato	Chemical
+	O
Dex	Chemical
group,	O
SBP	O
was	O
increased	O
from	O
113	O
+/-	O
2	O
to	O
119	O
+/-	O
2	O
mmHg	O
on	O
Days	O
4	O
to	O
14,	O
respectively	O
(P	O
<	O
0.001),	O
but	O
was	O
significantly	O
lower	O
than	O
SBP	O
in	O
the	O
group	O
treated	O
with	O
Dex	Chemical
alone	O
(P	O
<	O
0.05).	O
Endothelial-dependent	O
relaxation	O
and	O
eNOS	O
mRNA	O
expression	O
were	O
greater	O
in	O
the	O
Dex	Chemical
+	O
Ato	Chemical
group	O
than	O
in	O
the	O
Dex	Chemical
only	O
group	O
(P	O
<	O
0.05	O
and	O
P	O
<	O
0.0001,	O
respectively).	O
Aortic	O
superoxide	Chemical
production	O
was	O
lower	O
in	O
the	O
Dex	Chemical
+	O
Ato	Chemical
group	O
compared	O
with	O
the	O
group	O
treated	O
with	O
Dex	Chemical
alone	O
(P	O
<	O
0.0001).	O
4.	O
Treatment	O
with	O
Ato	Chemical
improved	O
endothelial	O
function,	O
reduced	O
superoxide	Chemical
production	O
and	O
reduced	O
SBP	O
in	O
Dex	Chemical

99mTc-glucarate	Chemical
for	O
detection	O
of	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
infarction	Disease
in	O
rats.	O
Infarct	Disease
-avid	O
radiopharmaceuticals	O
are	O
necessary	O
for	O
rapid	O
and	O
timely	O
diagnosis	O
of	O
acute	O
myocardial	Disease
infarction	Disease
.	O
The	O
animal	O
model	O
used	O
to	O
produce	O
infarction	Disease
implies	O
artery	O
ligation	O
but	O
chemical	O
induction	O
can	O
be	O
easily	O
obtained	O
with	O
isoproterenol	Chemical
.	O
A	O
new	O
infarct	Disease
-avid	O
radiopharmaceutical	O
based	O
on	O
glucaric	Chemical
acid	Chemical
was	O
prepared	O
in	O
the	O
hospital	O
radiopharmacy	O
of	O
the	O
INCMNSZ.	O
99mTc-glucarate	Chemical
was	O
easy	O
to	O
prepare,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol	Chemical
-induced	O
acute	O
myocardial	Disease
infarction	Disease
.	O
Histological	O
studies	O
demonstrated	O
that	O
the	O
rats	O
developed	O
an	O
infarct	Disease
18	O
h	O
after	O
isoproterenol	Chemical
administration.	O
The	O
rat	O
biodistribution	O
studies	O
showed	O
a	O
rapid	O
blood	O
clearance	O
via	O
the	O
kidneys.	O
Thirty	O
minutes	O
after	O
99mTc-glucarate	Chemical
administration	O
the	O
standardised	O
heart	O
uptake	O
value	O
S(h)UV	O
was	O
4.7	O
in	O
infarcted	O
rat	O
heart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
normal	O
rats.	O
ROIs	O
drawn	O
over	O
the	O
gamma	O
camera	O
images	O
showed	O
a	O
ratio	O
of	O
4.4.	O
The	O
high	O
image	O
quality	O
suggests	O
that	O
high	O
contrast	O
images	O
can	O
be	O
obtained	O
in	O
humans	O
and	O
the	O
96	O
h	O
stability	O
makes	O
it	O
an	O
ideal	O
agent	O
to	O
detect,	O
in	O
patients,	O
early	O
cardiac	Disease
infarction	Disease

A	O
randomized,	O
placebo-controlled	O
dose-comparison	O
trial	O
of	O
haloperidol	Chemical
for	O
psychosis	Disease
and	O
disruptive	Disease
behaviors	Disease
in	O
Alzheimer's	Disease
disease	Disease
.	O
OBJECTIVE:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
side	O
effects	O
of	O
two	O
doses	O
of	O
haloperidol	Chemical
and	O
placebo	O
in	O
the	O
treatment	O
of	O
psychosis	Disease
and	O
disruptive	Disease
behaviors	Disease
in	O
patients	O
with	O
Alzheimer's	Disease
disease	Disease
.	O
METHOD:	O
In	O
a	O
6-week	O
random-assignment,	O
double-blind,	O
placebo-controlled	O
trial	O
(phase	O
A),	O
haloperidol	Chemical
,	O
2-3	O
mg/day	O
(standard	O
dose),	O
and	O
haloperidol	Chemical
,	O
0.50-0.75	O
mg/day	O
(low	O
dose),	O
were	O
compared	O
in	O
71	O
outpatients	O
with	O
Alzheimer's	Disease
disease	Disease
.	O
For	O
the	O
subsequent	O
6-week	O
double-blind	O
crossover	O
phase	O
(phase	O
B),	O
patients	O
taking	O
standard-	O
or	O
low-dose	O
haloperidol	Chemical
were	O
switched	O
to	O
placebo,	O
and	O
patients	O
taking	O
placebo	O
were	O
randomly	O
assigned	O
to	O
standard-	O
or	O
low-dose	O
haloperidol	Chemical
.	O
RESULTS:	O
For	O
the	O
60	O
patients	O
who	O
completed	O
phase	O
A,	O
standard-dose	O
haloperidol	Chemical
was	O
efficacious	O
and	O
superior	O
to	O
both	O
low-dose	O
haloperidol	Chemical
and	O
placebo	O
for	O
scores	O
on	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
psychosis	Disease
factor	O
and	O
on	O
psychomotor	Disease
agitation	Disease
.	O
Response	O
rates	O
according	O
to	O
three	O
sets	O
of	O
criteria	O
were	O
greater	O
with	O
the	O
standard	O
dose	O
(55%-60%)	O
than	O
the	O
low	O
dose	O
(25%-35%)	O
and	O
placebo	O
(25%-30%).	O
The	O
advantage	O
of	O
standard	O
dose	O
over	O
low	O
dose	O
was	O
replicated	O
in	O
phase	O
B.	O
In	O
phase	O
A,	O
extrapyramidal	Disease
signs	Disease
tended	O
to	O
be	O
greater	O
with	O
the	O
standard	O
dose	O
than	O
in	O
the	O
other	O
two	O
conditions,	O
primarily	O
because	O
of	O
a	O
subgroup	O
(20%)	O
who	O
developed	O
moderate	O
to	O
severe	O
signs.	O
Low-dose	O
haloperidol	Chemical
did	O
not	O
differ	O
from	O
placebo	O
on	O
any	O
measure	O
of	O
efficacy	O
or	O
side	O
effects.	O
CONCLUSIONS:	O
The	O
results	O
indicated	O
a	O
favorable	O
therapeutic	O
profile	O
for	O
haloperidol	Chemical
in	O
doses	O
of	O
2-3	O
mg/day,	O
although	O
a	O
subgroup	O
developed	O
moderate	O
to	O
severe	O
extrapyramidal	Disease
signs	Disease
.	O
A	O
starting	O
dose	O
of	O
1	O
mg/day	O
with	O
gradual,	O
upward	O
dose	O
titration	O
is	O
recommended.	O
The	O
narrow	O
therapeutic	O
window	O
observed	O
with	O
haloperidol	Chemical
may	O
also	O
apply	O
to	O
other	O
neuroleptics	O
used	O
in	O
Alzheimer's	Disease
disease	Disease
patients	O
with	O
psychosis	Disease
and	O
disruptive	Disease
behaviors	Disease

Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
in	O
healthy	O
rats	O
predict	O
susceptibility	O
to	O
adriamycin	Chemical
-induced	O
renal	Disease
damage	Disease
.	O
BACKGROUND:	O
In	O
man,	O
differences	O
in	O
angiotensin	Chemical
-converting	O
enzyme	O
(ACE)	O
levels,	O
related	O
to	O
ACE	O
(I/D)	O
genotype,	O
are	O
associated	O
with	O
renal	O
prognosis.	O
This	O
raises	O
the	O
hypothesis	O
that	O
individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
are	O
involved	O
in	O
renal	O
susceptibility	O
to	O
inflicted	O
damage.	O
Therefore,	O
we	O
studied	O
the	O
predictive	O
effect	O
of	O
renal	O
ACE	O
activity	O
for	O
the	O
severity	O
of	O
renal	Disease
damage	Disease
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	Chemical
in	O
rats.	O
METHODS:	O
Renal	O
ACE	O
activity	O
(	O
Hip-His-Leu	Chemical
cleavage	O
by	O
cortical	O
homogenates)	O
was	O
determined	O
by	O
renal	O
biopsy	O
in	O
27	O
adult	O
male	O
Wistar	O
rats.	O
After	O
1	O
week	O
of	O
recovery,	O
proteinuria	Disease
was	O
induced	O
by	O
adriamycin	Chemical
[1.5	O
mg/kg	O
intravenously	O
(i.v.)	O
n	O
=	O
18;	O
controls,	O
saline	O
i.v.	O
n	O
=	O
9].	O
Proteinuria	Disease
was	O
measured	O
every	O
2	O
weeks.	O
After	O
12	O
weeks,	O
rats	O
were	O
sacrificed	O
and	O
their	O
kidneys	O
harvested.	O
RESULTS:	O
As	O
anticipated,	O
adriamycin	Chemical
elicited	O
nephrotic	Disease
range	O
proteinuria	Disease
,	O
renal	Disease
interstitial	Disease
damage	Disease
and	O
mild	O
focal	Disease
glomerulosclerosis	Disease
.	O
Baseline	O
renal	O
ACE	O
positively	O
correlated	O
with	O
the	O
relative	O
rise	O
in	O
proteinuria	Disease
after	O
adriamycin	Chemical
(r	O
=	O
0.62,	O
P<0.01),	O
renal	O
interstitial	O
alpha-smooth	O
muscle	O
actin	O
(r	O
=	O
0.49,	O
P<0.05),	O
interstitial	O
macrophage	O
influx	O
(r	O
=	O
0.56,	O
P<0.05),	O
interstitial	O
collagen	O
III	O
(r	O
=	O
0.53,	O
P<0.05),	O
glomerular	O
alpha-smooth	O
muscle	O
actin	O
(r	O
=	O
0.74,	O
P<0.01)	O
and	O
glomerular	O
desmin	O
(r	O
=	O
0.48,	O
P<0.05).	O
Baseline	O
renal	O
ACE	O
did	O
not	O
correlate	O
with	O
focal	Disease
glomerulosclerosis	Disease
(r	O
=	O
0.22,	O
NS).	O
In	O
controls,	O
no	O
predictive	O
values	O
for	O
renal	O
parameters	O
were	O
observed.	O
CONCLUSION:	O
Individual	O
differences	O
in	O
renal	O
ACE	O
activity	O
predict	O
the	O
severity	O
of	O
adriamycin	Chemical
-induced	O
renal	Disease
damage	Disease
in	O
this	O
outbred	O
rat	O
strain.	O
This	O
supports	O
the	O
assumption	O
that	O
differences	O
in	O
renal	O
ACE	O
activity	O
predispose	O
to	O
a	O
less	O
favourable	O
course	O
of	O
renal	Disease
damage	Disease

Clinical	O
nephrotoxicity	Disease
of	O
tobramycin	Chemical
and	O
gentamicin	Chemical
.	O
A	O
prospective	O
study.	O
Nearly	O
3.2	O
million	O
people	O
in	O
this	O
country	O
receive	O
aminoglycoside	Chemical
antibiotics	O
annually.	O
Gentamicin	Chemical
sulfate	Chemical
and	O
tobramycin	Chemical
sulfate	Chemical
continue	O
to	O
demonstrate	O
ototoxicity	Disease
and	O
nephrotoxicity	Disease
in	O
both	O
animal	O
and	O
clinical	O
studies.	O
In	O
this	O
study,	O
62	O
patients	O
with	O
confirmed	O
initial	O
normal	O
renal	O
function	O
and	O
treated	O
with	O
2	O
to	O
5	O
mg/kg/day	O
of	O
gentamicin	Chemical
sulfate	Chemical
or	O
tobramycin	Chemical
sulfate	Chemical
for	O
a	O
minimum	O
of	O
seven	O
days	O
were	O
followed	O
up	O
prospectively	O
for	O
the	O
development	O
of	O
aminoglycoside	Chemical
-related	O
renal	Disease
failure	Disease
,	O
defined	O
as	O
at	O
least	O
a	O
one-third	O
reduction	O
in	O
renal	O
function.	O
In	O
these	O
62	O
patients,	O
no	O
other	O
causes	O
for	O
renal	Disease
failure	Disease
could	O
be	O
identified.	O
Five	O
of	O
33	O
(15%)	O
of	O
the	O
tobramycin	Chemical
-treated	O
patients	O
and	O
16	O
of	O
29	O
(55.2%)	O
of	O
the	O
gentamicin	Chemical
-treated	O
patients	O
had	O
renal	Disease
failure	Disease
.	O
Thus,	O
gentamicin	Chemical
was	O
associated	O
with	O
renal	Disease
failure	Disease
more	O
than	O
three	O
times	O
as	O
often	O
as	O
was	O
tobramycin	Chemical

Neuroprotective	O
action	O
of	O
MPEP	Chemical
,	O
a	O
selective	O
mGluR5	O
antagonist,	O
in	O
methamphetamine	Chemical
-induced	O
dopaminergic	O
neurotoxicity	Disease
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	Chemical
outflow	O
and	O
inhibition	O
of	O
hyperthermia	Disease
in	O
rats.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	O
of	O
metabotropic	O
glutamate	Chemical
receptor	O
5	O
(mGluR5)	O
in	O
the	O
toxic	O
action	O
of	O
methamphetamine	Chemical
on	O
dopaminergic	O
neurones	O
in	O
rats.	O
Methamphetamine	Chemical
(10	O
mg/kg	O
sc),	O
administered	O
five	O
times,	O
reduced	O
the	O
levels	O
of	O
dopamine	Chemical
and	O
its	O
metabolites	O
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection.	O
A	O
selective	O
antagonist	O
of	O
mGluR5,	O
2-methyl-6-(phenylethynyl)pyridine	Chemical
(	O
MPEP	Chemical
;	O
5	O
mg/kg	O
ip),	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	Chemical
injection	O
reversed	O
the	O
above-mentioned	O
methamphetamine	Chemical
effects.	O
A	O
single	O
MPEP	Chemical
(5	O
mg/kg	O
ip)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	Chemical
level	O
in	O
the	O
striatum,	O
as	O
well	O
as	O
dopamine	Chemical
release	O
stimulated	O
either	O
by	O
methamphetamine	Chemical
(10	O
mg/kg	O
sc)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	Chemical
(100	O
microM).	O
Moreover,	O
it	O
transiently	O
diminished	O
the	O
methamphetamine	Chemical
(10	O
mg/kg	O
sc)-induced	O
hyperthermia	Disease
and	O
reduced	O
basal	O
body	O
temperature.	O
MPEP	Chemical
administered	O
into	O
the	O
striatum	O
at	O
high	O
concentrations	O
(500	O
microM)	O
increased	O
extracellular	O
dopamine	Chemical
levels,	O
while	O
lower	O
concentrations	O
(50-100	O
microM)	O
were	O
devoid	O
of	O
any	O
effect.	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	Chemical
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	Chemical
-induced	O
toxicity	Disease
.	O
Neuroprotection	O
rendered	O
by	O
MPEP	Chemical
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	Chemical
-induced	O
dopamine	Chemical
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	Disease

Pharmacokinetics	O
of	O
desipramine	Chemical
HCl	Chemical
when	O
administered	O
with	O
cinacalcet	Chemical
HCl	Chemical
.	O
OBJECTIVE:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalcet	Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P450	O
isoenzyme	O
(CYP)	O
2D6.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
cinacalcet	Chemical
on	O
CYP2D6	O
activity,	O
using	O
desipramine	Chemical
as	O
a	O
probe	O
substrate,	O
in	O
healthy	O
subjects.	O
METHODS:	O
Seventeen	O
subjects	O
who	O
were	O
genotyped	O
as	O
CYP2D6	O
extensive	O
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized,	O
open-label,	O
crossover	O
study	O
to	O
receive	O
a	O
single	O
oral	O
dose	O
of	O
desipramine	Chemical
(50	O
mg)	O
on	O
two	O
separate	O
occasions,	O
once	O
alone	O
and	O
once	O
after	O
multiple	O
doses	O
of	O
cinacalcet	Chemical
(90	O
mg	O
for	O
7	O
days).	O
Blood	O
samples	O
were	O
obtained	O
predose	O
and	O
up	O
to	O
72	O
h	O
postdose.	O
RESULTS:	O
Fourteen	O
subjects	O
completed	O
both	O
treatment	O
arms.	O
Relative	O
to	O
desipramine	Chemical
alone,	O
mean	O
AUC	O
and	O
C(max)	O
of	O
desipramine	Chemical
increased	O
3.6-	O
and	O
1.8-fold	O
when	O
coadministered	O
with	O
cinacalcet	Chemical
.	O
The	O
t	O
(1/2,z)	O
of	O
desipramine	Chemical
was	O
longer	O
when	O
desipramine	Chemical
was	O
coadministered	O
with	O
cinacalcet	Chemical
(21.0	O
versus	O
43.3	O
hs).	O
The	O
t	O
(max)	O
was	O
similar	O
between	O
the	O
regimens.	O
Fewer	O
subjects	O
reported	O
adverse	O
events	O
following	O
treatment	O
with	O
desipramine	Chemical
alone	O
than	O
when	O
receiving	O
desipramine	Chemical
with	O
cinacalcet	Chemical
(33	O
versus	O
86%),	O
the	O
most	O
frequent	O
of	O
which	O
(	O
nausea	Disease
and	O
headache	Disease
)	O
have	O
been	O
reported	O
for	O
patients	O
treated	O
with	O
either	O
desipramine	Chemical
or	O
cinacalcet	Chemical
.	O
CONCLUSION:	O
This	O
study	O
demonstrates	O
that	O
cinacalcet	Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
CYP2D6.	O
These	O
data	O
suggest	O
that	O
during	O
concomitant	O
treatment	O
with	O
cinacalcet	Chemical

Proteomic	O
analysis	O
of	O
striatal	O
proteins	O
in	O
the	O
rat	O
model	O
of	O
L-DOPA	Chemical
-induced	O
dyskinesia	Disease
.	O
L-DOPA	Chemical
-induced	O
dyskinesia	Disease
(	O
LID	Disease
)	O
is	O
among	O
the	O
motor	O
complications	O
that	O
arise	O
in	O
Parkinson's	Disease
disease	Disease
(	O
PD	Disease
)	O
patients	O
after	O
a	O
prolonged	O
treatment	O
with	O
L-DOPA	Chemical
.	O
To	O
this	O
day,	O
transcriptome	O
analysis	O
has	O
been	O
performed	O
in	O
a	O
rat	O
model	O
of	O
LID	Disease
[Neurobiol.	O
Dis.,	O
17	O
(2004),	O
219]	O
but	O
information	O
regarding	O
the	O
proteome	O
is	O
still	O
lacking.	O
In	O
the	O
present	O
study,	O
we	O
investigated	O
the	O
changes	O
occurring	O
at	O
the	O
protein	O
level	O
in	O
striatal	O
samples	O
obtained	O
from	O
the	O
unilaterally	O
6-hydroxydopamine	Chemical
-lesion	O
rat	O
model	O
of	O
PD	Disease
treated	O
with	O
saline,	O
L-DOPA	Chemical
or	O
bromocriptine	Chemical
using	O
two-dimensional	O
difference	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
(MS).	O
Rats	O
treated	O
with	O
L-DOPA	Chemical
were	O
allocated	O
to	O
two	O
groups	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
LID	Disease
.	O
Among	O
the	O
2000	O
spots	O
compared	O
for	O
statistical	O
difference,	O
67	O
spots	O
were	O
significantly	O
changed	O
in	O
abundance	O
and	O
identified	O
using	O
matrix-assisted	O
laser	O
desorption/ionization	O
time-of-flight	O
MS,	O
atmospheric	O
pressure	O
matrix-assisted	O
laser	O
desorption/ionization	O
and	O
HPLC	O
coupled	O
tandem	O
MS	O
(LC/MS/MS).	O
Out	O
of	O
these	O
67	O
proteins,	O
LID	Disease
significantly	O
changed	O
the	O
expression	O
level	O
of	O
five	O
proteins:	O
alphabeta-crystalin,	O
gamma-enolase,	O
guanidoacetate	O
methyltransferase,	O
vinculin,	O
and	O
proteasome	O
alpha-2	O
subunit.	O
Complementary	O
techniques	O
such	O
as	O
western	O
immunoblotting	O
and	O
immunohistochemistry	O
were	O
performed	O
to	O
investigate	O
the	O
validity	O
of	O
the	O
data	O
obtained	O
using	O
the	O
proteomic	O
approach.	O
In	O
conclusion,	O
this	O
study	O
provides	O
new	O
insights	O
into	O
the	O
protein	O
changes	O
occurring	O
in	O
LID	Disease

Pseudo-	O
allergic	Disease
reactions	Disease
to	O
corticosteroids	Chemical
:	O
diagnosis	O
and	O
alternatives.	O
Two	O
patients	O
treated	O
with	O
parenteral	O
paramethasone	Chemical
(Triniol)	O
and	O
dexamethasone	Chemical
(Sedionbel)	O
are	O
described.	O
A	O
few	O
minutes	O
after	O
administration	O
of	O
the	O
drugs,	O
they	O
presented	O
urticaria	Disease
(patients	O
1	O
and	O
2)	O
and	O
conjunctivitis	Disease
(patient	O
1).	O
The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
cause	O
of	O
the	O
patients'	O
reactions,	O
the	O
immunological	O
mechanisms	O
involved	O
and	O
whether	O
these	O
patients	O
would	O
be	O
able	O
to	O
tolerate	O
any	O
kind	O
of	O
corticoid.	O
Clinical	O
examinations	O
and	O
skin,	O
oral	O
and	O
parenteral	O
challenges	O
with	O
different	O
corticosteroids	Chemical
and	O
ELISA	O
tests	O
were	O
performed.	O
In	O
the	O
two	O
patients,	O
skin	O
and	O
ELISA	O
tests	O
with	O
paramethasone	Chemical
were	O
negative,	O
as	O
was	O
the	O
prick	O
test	O
with	O
each	O
of	O
its	O
excipients.	O
A	O
single-blind	O
parenteral	O
challenge	O
with	O
Triniol	O
was	O
positive	O
in	O
both	O
patients	O
after	O
the	O
administration	O
of	O
1	O
ml	O
of	O
the	O
drug,	O
and	O
negative	O
with	O
its	O
excipients.	O
We	O
also	O
carried	O
out	O
oral	O
and	O
parenteral	O
challenges	O
with	O
other	O
corticosteroids	Chemical
and	O
found	O
intolerance	O
to	O
some	O
of	O
them.	O
These	O
results	O
suggest	O
that	O
paramethasone	Chemical
caused	O
pseudoallergic	O
reactions	O
in	O
our	O
patients.	O
Corticosteroids	O
different	O
from	O
paramethasone	Chemical
also	O
produced	O
hypersensitivity	Disease
reactions	O
in	O
these	O
patients;	O
however,	O
a	O
few	O
of	O
them	O
were	O
tolerated.	O
The	O
basic	O
mechanisms	O
of	O
those	O
reactions	O
are	O
not	O
yet	O
fully	O
understood.	O
To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
pseudo-	O
allergy	Disease
caused	O
by	O
paramethasone	Chemical

Valproic	Chemical
acid	Chemical
induced	O
encephalopathy	Disease
--19	O
new	O
cases	O
in	O
Germany	O
from	O
1994	O
to	O
2003--a	O
side	O
effect	O
associated	O
to	O
VPA	Chemical
-therapy	O
not	O
only	O
in	O
young	O
children.	O
Valproic	Chemical
acid	Chemical
(	O
VPA	Chemical
)	O
is	O
a	O
broad-spectrum	O
antiepileptic	O
drug	O
and	O
is	O
usually	O
well-tolerated.	O
Rare	O
serious	O
complications	O
may	O
occur	O
in	O
some	O
patients,	O
including	O
haemorrhagic	O
pancreatitis	Disease
,	O
bone	Disease
marrow	Disease
suppression	Disease
,	O
VPA	Chemical
-induced	O
hepatotoxicity	Disease
and	O
VPA	Chemical
-induced	O
encephalopathy	Disease
.	O
The	O
typical	O
signs	O
of	O
VPA	Chemical
-induced	O
encephalopathy	Disease
are	O
impaired	Disease
consciousness	Disease
,	O
sometimes	O
marked	O
EEG	O
background	O
slowing,	O
increased	O
seizure	Disease
frequency,	O
with	O
or	O
without	O
hyperammonemia	Disease
.	O
There	O
is	O
still	O
no	O
proof	O
of	O
causative	O
effect	O
of	O
VPA	Chemical
in	O
patients	O
with	O
encephalopathy	Disease
,	O
but	O
only	O
of	O
an	O
association	O
with	O
an	O
assumed	O
causal	O
relation.	O
We	O
report	O
19	O
patients	O
with	O
VPA	Chemical
-associated	O
encephalopathy	Disease

Haemolytic-uraemic	Disease
syndrome	Disease
after	O
treatment	O
with	O
metronidazole	Chemical
.	O
This	O
paper	O
describes	O
the	O
clinical	O
features	O
of	O
six	O
children	O
who	O
developed	O
the	O
haemolytic-uraemic	Disease
syndrome	Disease
after	O
treatment	O
with	O
metronidazole	Chemical
.	O
These	O
children	O
were	O
older	O
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
recent	O
bowel	O
surgery	O
than	O
are	O
other	O
children	O
with	O
this	O
condition.	O
While	O
the	O
involvement	O
of	O
metronidazole	Chemical
in	O
the	O
aetiology	O
of	O
the	O
haemolytic-uraemic	Disease
syndrome	Disease
is	O
not	O
established	O
firmly,	O
the	O
action	O
of	O
this	O
drug	O
in	O
sensitizing	O
tissues	O
to	O
oxidation	O
injury	O
and	O
the	O
reported	O
evidence	O
of	O
oxidation	O
changes	O
in	O
the	O
haemolytic-uraemic	Disease
syndrome	Disease
suggest	O
a	O
possible	O
link	O
between	O
metronidazole	Chemical
treatment	O
and	O
some	O
cases	O
of	O
the	O
haemolytic-uraemic	Disease
syndrome	Disease

Risk	O
factors	O
of	O
sensorineural	Disease
hearing	Disease
loss	Disease
in	O
preterm	O
infants.	O
Among	O
547	O
preterm	O
infants	O
of	O
<	O
or	O
=	O
34	O
weeks	O
gestation	O
born	O
between	O
1987	O
and	O
1991,	O
8	O
children	O
(1.46%)	O
developed	O
severe	O
progressive	O
and	O
bilateral	O
sensorineural	Disease
hearing	Disease
loss	Disease
.	O
Perinatal	O
risk	O
factors	O
of	O
infants	O
with	O
hearing	Disease
loss	Disease
were	O
compared	O
with	O
those	O
of	O
two	O
control	O
groups	O
matched	O
for	O
gestation	O
and	O
birth	O
weight	O
and	O
for	O
perinatal	O
complications.	O
Our	O
observations	O
demonstrated	O
an	O
association	O
of	O
hearing	Disease
loss	Disease
with	O
a	O
higher	O
incidence	O
of	O
perinatal	O
complications.	O
Ototoxicity	Disease
appeared	O
closely	O
related	O
to	O
a	O
prolonged	O
administration	O
and	O
higher	O
total	O
dose	O
of	O
ototoxic	Disease
drugs,	O
particularly	O
aminoglycosides	Chemical
and	O
furosemide	Chemical
.	O
Finally,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
audiologic	O
assessment	O
in	O
sick	O
preterm	O
children	O
as	O
hearing	Disease
loss	Disease

Pharmacokinetic	O
and	O
clinical	O
studies	O
in	O
patients	O
with	O
cimetidine	Chemical
-associated	O
mental	O
confusion	Disease
.	O
15	O
cases	O
of	O
cimetidine	Chemical
-associated	O
mental	O
confusion	Disease
have	O
been	O
reported.	O
In	O
order	O
that	O
this	O
syndrome	O
might	O
be	O
investigated	O
changes	O
in	O
mental	O
status	O
(M.S.)	O
were	O
correlated	O
with	O
serum	O
concentrations	O
and	O
renal	O
and	O
hepatic	O
function	O
in	O
36	O
patients,	O
30	O
patients	O
had	O
no	O
M.S.	O
change	O
on	O
cimetidine	Chemical
and	O
6	O
had	O
moderate	O
to	O
severe	O
changes.	O
These	O
6	O
patients	O
had	O
both	O
renal	Disease
and	Disease
liver	Disease
dysfunction	Disease
(P	O
less	O
than	O
0.05),	O
as	O
well	O
as	O
cimetidine	Chemical
trough-concentrations	O
of	O
more	O
than	O
1.25	O
microgram/ml	O
(P	O
less	O
than	O
0.05).	O
The	O
severity	O
of	O
M.S.	O
changes	O
increased	O
as	O
trough-concentrations	O
rose,	O
5	O
patients	O
had	O
lumbar	O
puncture.	O
The	O
cerebrospinal	O
fluid:	O
serum	O
ratio	O
of	O
cimetidine	Chemical
concentrations	O
was	O
0.24:1	O
and	O
indicates	O
that	O
cimetidine	Chemical
passes	O
the	O
blood-brain	O
barrier;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M.S.	O
changes	O
are	O
due	O
to	O
blockade	O
of	O
histamine	Chemical
H2-receptors	O
in	O
the	O
central	O
nervous	O
system.	O
Patients	O
likely	O
to	O
have	O
both	O
raised	O
trough-concentrations	O
and	O
mental	O
confusion	Disease
are	O
those	O
with	O
both	O
severe	O
renal	Disease
and	Disease
hepatic	Disease
dysfunction	Disease
.	O
They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reduced	O
doses	O
of	O
cimetidine	Chemical

Different	O
lobular	O
distributions	O
of	O
altered	O
hepatocyte	O
tight	O
junctions	O
in	O
rat	O
models	O
of	O
intrahepatic	Disease
and	Disease
extrahepatic	Disease
cholestasis	Disease
.	O
Hepatocyte	O
tight	O
junctions	O
(TJs),	O
the	O
only	O
intercellular	O
barrier	O
between	O
the	O
sinusoidal	O
and	O
the	O
canalicular	O
spaces,	O
play	O
a	O
key	O
role	O
in	O
bile	O
formation.	O
Although	O
hepatocyte	O
TJs	O
are	O
impaired	O
in	O
cholestasis	Disease
,	O
attempts	O
to	O
localize	O
the	O
precise	O
site	O
of	O
hepatocyte	O
TJ	O
damage	O
by	O
freeze-fracture	O
electron	O
microscopy	O
have	O
produced	O
limited	O
information.	O
Recently,	O
several	O
TJ-associated	O
proteins	O
like	O
ZO-1	O
and	O
7H6	O
have	O
been	O
identified	O
and	O
characterized.	O
Immunolocalization	O
of	O
7H6	O
appears	O
to	O
closely	O
correlate	O
with	O
paracellular	O
permeability.	O
We	O
used	O
rat	O
models	O
of	O
intrahepatic	Disease
cholestasis	Disease
by	O
ethinyl	Chemical
estradiol	Chemical
(	O
EE	Chemical
)	O
treatment	O
and	O
extrahepatic	Disease
cholestasis	Disease
by	O
bile	O
duct	O
ligation	O
(BDL)	O
to	O
precisely	O
determine	O
the	O
site	O
of	O
TJ	O
damage.	O
Alterations	O
in	O
hepatocyte	O
TJs	O
were	O
assessed	O
by	O
double-immunolabeling	O
for	O
7H6	O
and	O
ZO-1	O
using	O
a	O
confocal	O
laser	O
scanning	O
microscope.	O
In	O
control	O
rats,	O
immunostaining	O
for	O
7H6	O
and	O
ZO-1	O
colocalized	O
to	O
outline	O
bile	O
canaliculi	O
in	O
a	O
continuous	O
fashion.	O
In	O
contrast,	O
7H6	O
and	O
ZO-1	O
immunostaining	O
was	O
more	O
discontinuous,	O
outlining	O
the	O
bile	O
canaliculi	O
after	O
BDL.	O
Immunostaining	O
for	O
7H6,	O
not	O
ZO-1,	O
decreased	O
and	O
predominantly	O
appeared	O
as	O
discrete	O
signals	O
in	O
the	O
submembranous	O
cytoplasm	O
of	O
periportal	O
hepatocytes	O
after	O
BDL.	O
After	O
EE	Chemical
treatment,	O
changes	O
in	O
immunostaining	O
for	O
7H6	O
and	O
ZO-1	O
were	O
similar	O
to	O
those	O
seen	O
in	O
periportal	O
hepatocytes	O
after	O
BDL,	O
but	O
distributed	O
more	O
diffusely	O
throughout	O
the	O
lobule.	O
This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impairment	O
of	O
hepatocyte	O
TJs	O
occurs	O
heterogenously	O
in	O
the	O
liver	O
lobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	Chemical

Long	O
term	O
audiological	O
evaluation	O
of	O
beta-thalassemic	Disease
patients.	O
OBJECTIVE:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
incidence	O
and	O
to	O
monitor	O
the	O
progression	O
of	O
hearing	Disease
loss	Disease
in	O
children	O
and	O
young	O
adults	O
with	O
beta-thalassemia	Disease
major.	O
METHODS:	O
One	O
hundred	O
and	O
four	O
(104)	O
patients	O
aged	O
6-35	O
years	O
(mean	O
17,2	O
years)	O
participated	O
in	O
the	O
study.	O
All	O
patients	O
were	O
on	O
a	O
regular	O
transfusion-chelation	O
program	O
maintaining	O
a	O
mean	O
hemoglobin	O
level	O
of	O
9.5	O
gr/dl.	O
Subjects	O
were	O
receiving	O
desferrioxamine	Chemical
(	O
DFO	Chemical
)	O
chelation	O
treatment	O
with	O
a	O
mean	O
daily	O
dose	O
of	O
50-60	O
mg/kg,	O
5-6	O
days	O
a	O
week	O
during	O
the	O
first	O
six	O
years	O
of	O
the	O
study,	O
which	O
was	O
then	O
reduced	O
to	O
40-50	O
mg/kg	O
for	O
the	O
following	O
eight	O
years.	O
Patients	O
were	O
followed	O
for	O
8-14	O
years.	O
RESULTS:	O
Overall,	O
21	O
out	O
of	O
104	O
patients	O
(20.2%)	O
presented	O
with	O
high	O
frequency	O
sensorineural	Disease
hearing	Disease
loss	Disease
(	O
SNHL	Disease
),	O
either	O
unilateral	O
or	O
bilateral.	O
No	O
ototoxic	Disease
factor,	O
other	O
than	O
DFO	Chemical
,	O
was	O
present	O
in	O
any	O
of	O
the	O
patients.	O
Patients	O
with	O
SNHL	Disease
presented	O
with	O
relatively	O
lower	O
serum	O
ferritin	O
levels	O
than	O
those	O
with	O
normal	O
hearing,	O
however,	O
no	O
statistically	O
significant	O
difference	O
was	O
observed.	O
Subjects	O
with	O
SNHL	Disease
were	O
submitted	O
to	O
DFO	Chemical
reduction	O
or	O
temporary	O
withdrawal.	O
Following	O
intervention,	O
7	O
out	O
of	O
21	O
affected	O
patients	O
recovered,	O
10	O
remained	O
stable	O
and	O
4	O
demonstrated	O
aggravation.	O
CONCLUSION:	O
The	O
findings	O
are	O
indicative	O
of	O
DFO	Chemical
's	O
contributing	O
role	O
in	O
the	O
development	O
of	O
hearing	Disease
impairment	Disease
.	O
Regular	O
audiologic	O
evaluation	O
is	O
imperative	O
in	O
all	O
thalassemic	Disease
patients	O
so	O
that	O
early	O
changes	O
may	O
be	O
recognized	O
and	O
treatment	O
may	O
be	O
judiciously	O
adjusted	O
in	O
order	O
to	O
prevent	O
or	O
reverse	O
hearing	Disease
impairment	Disease

Design	O
and	O
analysis	O
of	O
the	O
HYPREN-trial:	O
safety	O
of	O
enalapril	Chemical
and	O
prazosin	Chemical
in	O
the	O
initial	O
treatment	O
phase	O
of	O
patients	O
with	O
congestive	Disease
heart	Disease
failure	Disease
.	O
Since	O
the	O
introduction	O
of	O
angiotensin	Chemical
converting	Chemical
enzyme	Chemical
(ACE)	Chemical
inhibitors	Chemical
into	O
the	O
adjunctive	O
treatment	O
of	O
patients	O
with	O
congestive	Disease
heart	Disease
failure	Disease
,	O
cases	O
of	O
severe	O
hypotension	Disease
,	O
especially	O
on	O
the	O
first	O
day	O
of	O
treatment,	O
have	O
occasionally	O
been	O
reported.	O
To	O
assess	O
the	O
safety	O
of	O
the	O
ACE	Chemical
inhibitor	Chemical
	O
enalapril	Chemical
a	O
multicenter,	O
randomized,	O
prazosin	Chemical
-controlled	O
trial	O
was	O
designed	O
that	O
compared	O
the	O
incidence	O
and	O
severity	O
of	O
symptomatic	O
hypotension	Disease
on	O
the	O
first	O
day	O
of	O
treatment.	O
Trial	O
medication	O
was	O
2.5	O
mg	O
enalapril	Chemical
or	O
0.5	O
prazosin	Chemical
.	O
Subjects	O
were	O
1210	O
inpatients	O
with	O
New	O
York	O
Heart	O
Association	O
(NYHA)	O
functional	O
class	O
II	O
and	O
III.	O
Patients	O
who	O
received	O
enalapril	Chemical
experienced	O
clinically	O
and	O
statistically	O
significantly	O
less	O
symptomatic	O
hypotension	Disease
(5.2%)	O
than	O
the	O
patients	O
who	O
received	O
prazosin	Chemical
(12.9%).	O
All	O
patients	O
recovered.	O
It	O
was	O
concluded	O
that	O
treatment	O
with	O
enalapril	Chemical
was	O
well	O
tolerated	O
and	O
it	O
is,	O
therefore,	O
unreasonable	O
to	O
restrict	O
the	O
initiation	O
of	O
treatment	O
with	O
enalapril	Chemical

Antagonism	O
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	O
with	O
azidothymidine	Chemical
-induced	O
anemia	Disease
and	O
in	O
bone	O
marrow	O
endothelial	O
cells.	O
Azidothymidine	Chemical
(	O
AZT	Chemical
)-induced	O
anemia	Disease
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF-IL-3	O
(fusion	O
protein	O
of	O
insulin-like	O
growth	O
factor	O
II	O
(IGF	O
II)	O
and	O
interleukin	O
3).	O
Although	O
interleukin	O
3	O
(IL-3)	O
and	O
erythropoietin	O
(EPO)	O
are	O
known	O
to	O
act	O
synergistically	O
on	O
hematopoietic	O
cell	O
proliferation	O
in	O
vitro,	O
injection	O
of	O
IGF-IL-3	O
and	O
EPO	O
in	O
AZT	Chemical
-treated	O
mice	O
resulted	O
in	O
a	O
reduction	O
of	O
red	O
cells	O
and	O
an	O
increase	O
of	O
plasma	O
EPO	O
levels	O
as	O
compared	O
to	O
animals	O
treated	O
with	O
IGF-IL-3	O
or	O
EPO	O
alone.	O
We	O
tested	O
the	O
hypothesis	O
that	O
the	O
antagonistic	O
effect	O
of	O
IL-3	O
and	O
EPO	O
on	O
erythroid	O
cells	O
may	O
be	O
mediated	O
by	O
endothelial	O
cells.	O
Bovine	O
liver	O
erythroid	O
cells	O
were	O
cultured	O
on	O
monolayers	O
of	O
human	O
bone	O
marrow	O
endothelial	O
cells	O
previously	O
treated	O
with	O
EPO	O
and	O
IGF-IL-3.	O
There	O
was	O
a	O
significant	O
reduction	O
of	O
thymidine	Chemical
incorporation	O
into	O
both	O
erythroid	O
and	O
endothelial	O
cells	O
in	O
cultures	O
pre-treated	O
with	O
IGF-IL-3	O
and	O
EPO.	O
Endothelial	O
cell	O
culture	O
supernatants	O
separated	O
by	O
ultrafiltration	O
and	O
ultracentrifugation	O
from	O
cells	O
treated	O
with	O
EPO	O
and	O
IL-3	O
significantly	O
reduced	O
thymidine	Chemical

Interactive	O
effects	O
of	O
variations	O
in	O
[	O
Na	Chemical
]o	O
and	O
[	O
Ca	Chemical
]o	O
on	O
rat	O
atrial	O
spontaneous	O
frequency.	O
The	O
effects	O
of	O
varying	O
the	O
extracellular	O
concentrations	O
of	O
Na	Chemical
and	O
Ca	Chemical
([	O
Na	Chemical
]o	O
and	O
[	O
Ca	Chemical
]o)	O
on	O
both,	O
the	O
spontaneous	O
beating	O
and	O
the	O
negative	O
chronotropic	O
action	O
of	O
verapamil	Chemical
,	O
were	O
studied	O
in	O
the	O
isolated	O
rat	O
atria.	O
Basal	O
frequency	O
(BF)	O
evaluated	O
by	O
surface	O
electrogram	O
was	O
223	O
+/-	O
4	O
beats/min.	O
in	O
control	O
Krebs-Ringer	O
containing	O
137	O
mM	O
Na	Chemical
and	O
1.35	O
mM	O
Ca	Chemical
(N).	O
It	O
decreased	O
by	O
16	O
+/-	O
3%	O
by	O
lowering	O
[	O
Na	Chemical
]o	O
to	O
78	O
mM	O
(LNa),	O
23	O
+/-	O
2%	O
by	O
lowering	O
simultaneously	O
[	O
Na	Chemical
]o	O
to	O
78	O
mM	O
and	O
[	O
Ca	Chemical
]o	O
to	O
0.675	O
mM	O
(LNa+LCa)	O
and	O
31	O
+/-	O
5%	O
by	O
lowering	O
[	O
Na	Chemical
]o	O
to	O
78	O
mM	O
plus	O
increasing	O
[	O
Ca	Chemical
]o	O
to	O
3.6	O
mM	O
(LNa+HCa).	O
At	O
normal	O
[	O
Na	Chemical
]o,	O
decrease	O
(0.675	O
mM)	O
or	O
increase	O
(3.6	O
mM)	O
of	O
[	O
Ca	Chemical
]o	O
did	O
not	O
modify	O
BF;	O
a	O
reduction	O
of	O
ten	O
times	O
(0.135	O
mM	O
of	O
normal	O
[	O
Ca	Chemical
]o	O
was	O
effective	O
to	O
reduce	O
BF	O
by	O
40	O
+/-	O
13%.	O
All	O
negative	O
chronotropic	O
effects	O
were	O
BF-dependent.	O
Dose-dependent	O
bradycardia	Disease
induced	O
by	O
verapamil	Chemical
was	O
potentiated	O
by	O
LNa,	O
LCa,	O
and	O
HCa.	O
Independent	O
but	O
not	O
additive	O
effects	O
of	O
Na	Chemical
and	O
Ca	Chemical
are	O
shown	O
by	O
decreases	O
in	O
the	O
values	O
of	O
[	O
verapamil	Chemical
]o	O
needed	O
to	O
reduce	O
BF	O
by	O
30%	O
(IC30)	O
with	O
the	O
following	O
order	O
of	O
inhibitory	O
potency:	O
LNa	O
>	O
LCa	O
>	O
HCa	O
>	O
N,	O
resulting	O
LNa+HCa	O
similar	O
to	O
LNa.	O
The	O
[	O
verapamil	Chemical
]o	O
that	O
arrested	O
atrial	O
beating	O
(AC)	O
was	O
also	O
potentiated	O
with	O
the	O
order	O
LNa	O
=	O
LNa+LCa	O
=	O
LNa+HCa	O
=	O
LCa	O
>	O
HCa	O
=	O
N.	O
The	O
results	O
indicate	O
that	O
rat	O
atrial	O
spontaneous	O
beating	O
is	O
more	O
dependent	O
on	O
[	O
Na	Chemical
]o	O
than	O
on	O
[	O
Ca	Chemical
]o	O
in	O
a	O
range	O
of	O
+/-	O
50%	O
of	O
their	O
normal	O
concentration.	O
Also	O
the	O
enhancement	O
of	O
verapamil	Chemical

Sodium	Chemical
status	O
influences	O
chronic	O
amphotericin	Chemical
B	Chemical
	O
nephrotoxicity	Disease
in	O
rats.	O
The	O
nephrotoxic	Disease
potential	O
of	O
amphotericin	Chemical
B	Chemical
(5	O
mg/kg	O
per	O
day	O
intraperitoneally	O
for	O
3	O
weeks)	O
has	O
been	O
investigated	O
in	O
salt-depleted,	O
normal-salt,	O
and	O
salt-loaded	O
rats.	O
In	O
salt-depleted	O
rats,	O
amphotericin	Chemical
B	Chemical
decreased	O
creatinine	Chemical
clearance	O
linearly	O
with	O
time,	O
with	O
an	O
85%	O
reduction	O
by	O
week	O
3.	O
In	O
contrast,	O
in	O
normal-salt	O
rats	O
creatinine	Chemical
clearance	O
was	O
decreased	O
but	O
to	O
a	O
lesser	O
extent	O
at	O
week	O
2	O
and	O
3,	O
and	O
in	O
salt-loaded	O
rats	O
creatinine	Chemical
clearance	O
did	O
not	O
change	O
for	O
2	O
weeks	O
and	O
was	O
decreased	O
by	O
43%	O
at	O
week	O
3.	O
All	O
rats	O
in	O
the	O
sodium	Chemical
-depleted	O
group	O
had	O
histopathological	O
evidence	O
of	O
patchy	O
tubular	O
cytoplasmic	O
degeneration	O
in	O
tubules	O
that	O
was	O
not	O
observed	O
in	O
any	O
normal-salt	O
or	O
salt-loaded	O
rat.	O
Concentrations	O
of	O
amphotericin	Chemical
B	Chemical
in	O
plasma	O
were	O
not	O
significantly	O
different	O
among	O
the	O
three	O
groups	O
at	O
any	O
time	O
during	O
the	O
study.	O
However,	O
at	O
the	O
end	O
of	O
3	O
weeks,	O
amphotericin	Chemical
B	Chemical
levels	O
in	O
the	O
kidneys	O
and	O
liver	O
were	O
significantly	O
higher	O
in	O
salt-depleted	O
and	O
normal-salt	O
rats	O
than	O
those	O
in	O
salt-loaded	O
rats,	O
with	O
plasma/kidney	O
ratios	O
of	O
21,	O
14,	O
and	O
8	O
in	O
salt-depleted,	O
normal-salt,	O
and	O
salt-loaded	O
rats,	O
respectively.	O
In	O
conclusion,	O
reductions	O
in	O
creatinine	Chemical
clearance	O
and	O
renal	O
amphotericin	Chemical
B	Chemical
accumulation	O
after	O
chronic	O
amphotericin	Chemical
B	Chemical
administration	O
were	O
enhanced	O
by	O
salt	O
depletion	O
and	O
attenuated	O
by	O
sodium	Chemical

Reversible	O
inferior	Disease
colliculus	Disease
lesion	Disease
in	O
metronidazole	Chemical
-induced	O
encephalopathy	Disease
:	O
magnetic	O
resonance	O
findings	O
on	O
diffusion-weighted	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
imaging.	O
OBJECTIVE:	O
This	O
is	O
to	O
present	O
reversible	O
inferior	Disease
colliculus	Disease
lesions	Disease
in	O
metronidazole	Chemical
-induced	O
encephalopathy	Disease
,	O
to	O
focus	O
on	O
the	O
diffusion-weighted	O
imaging	O
(DWI)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
(FLAIR)	O
imaging.	O
MATERIALS	O
AND	O
METHODS:	O
From	O
November	O
2005	O
to	O
September	O
2007,	O
8	O
patients	O
(5	O
men	O
and	O
3	O
women)	O
were	O
diagnosed	O
as	O
having	O
metronidazole	Chemical
-induced	O
encephalopathy	Disease
(age	O
range;	O
43-78	O
years).	O
They	O
had	O
been	O
taking	O
metronidazole	Chemical
(total	O
dosage,	O
45-120	O
g;	O
duration,	O
30	O
days	O
to	O
2	O
months)	O
to	O
treat	O
the	O
infection	Disease
in	O
various	O
organs.	O
Initial	O
brain	O
magnetic	O
resonance	O
imaging	O
(MRI)	O
were	O
obtained	O
after	O
the	O
hospitalization,	O
including	O
DWI	O
(8/8),	O
apparent	O
diffusion	O
coefficient	O
(ADC)	O
map	O
(4/8),	O
FLAIR	O
(7/8),	O
and	O
T2-weighted	O
image	O
(8/8).	O
Follow-up	O
MRIs	O
were	O
performed	O
on	O
5	O
patients	O
from	O
third	O
to	O
14th	O
days	O
after	O
discontinuation	O
of	O
metronidazole	Chemical
administration.	O
Findings	O
of	O
initial	O
and	O
follow-up	O
MRIs	O
were	O
retrospectively	O
evaluated	O
by	O
2	O
neuroradiologists	O
by	O
consensus,	O
to	O
analyze	O
the	O
presence	O
of	O
abnormal	O
signal	O
intensities,	O
their	O
locations,	O
and	O
signal	O
changes	O
on	O
follow-up	O
images.	O
RESULTS:	O
Initial	O
MRIs	O
showed	O
abnormal	O
high	O
signal	O
intensities	O
on	O
DWI	O
and	O
FLAIR	O
(or	O
T2-weighted	O
image)	O
at	O
the	O
dentate	O
nucleus	O
(8/8),	O
inferior	O
colliculus	O
(6/8),	O
corpus	O
callosum	O
(2/8),	O
pons	O
(2/8),	O
medulla	O
(1/8),	O
and	O
bilateral	O
cerebral	O
white	O
matter	O
(1/8).	O
High-signal	O
intensity	O
lesions	O
on	O
DWI	O
tended	O
to	O
show	O
low	O
signal	O
intensity	O
on	O
ADC	O
map	O
(3/4),	O
but	O
in	O
one	O
patient,	O
high	O
signal	O
intensity	O
was	O
shown	O
at	O
bilateral	O
dentate	O
nuclei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map.	O
All	O
the	O
lesions	O
in	O
dentate,	O
inferior	O
colliculus,	O
pons,	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow-up	O
MRIs	O
in	O
5	O
patients,	O
but	O
in	O
1	O
patient	O
of	O
them,	O
corpus	O
callosal	Disease
lesion	Disease
persisted.	O
CONCLUSIONS:	O
Reversible	O
inferior	Disease
colliculus	Disease
lesions	Disease
could	O
be	O
considered	O
as	O
the	O
characteristic	O
for	O
metronidazole	Chemical
-induced	O
encephalopathy	Disease

Comparison	O
of	O
the	O
respiratory	O
effects	O
of	O
i.v.	O
infusions	O
of	O
morphine	Chemical
and	O
regional	O
analgesia	O
by	O
extradural	O
block.	O
The	O
incidence	O
of	O
postoperative	O
respiratory	O
apnoea	Disease
was	O
compared	O
between	O
five	O
patients	O
receiving	O
a	O
continuous	O
i.v.	O
infusion	O
of	O
morphine	Chemical
(mean	O
73.6	O
mg)	O
and	O
five	O
patients	O
receiving	O
a	O
continuous	O
extradural	O
infusion	O
of	O
0.25%	O
bupivacaine	Chemical
(mean	O
192	O
mg)	O
in	O
the	O
24-h	O
period	O
following	O
upper	O
abdominal	O
surgery.	O
Monitoring	O
consisted	O
of	O
airflow	O
detection	O
by	O
a	O
carbon	Chemical
dioxide	Chemical
analyser,	O
chest	O
wall	O
movement	O
detected	O
by	O
pneumatic	O
capsules,	O
and	O
continuous	O
electrocardiograph	O
recorded	O
with	O
a	O
Holter	O
ambulatory	O
monitor.	O
Both	O
obstructive	Disease
(P	Disease
less	Disease
than	Disease
0.05)	Disease
and	Disease
central	Disease
apnoea	Disease
(P	O
less	O
than	O
0.05)	O
occurred	O
more	O
frequently	O
in	O
patients	O
who	O
had	O
a	O
morphine	Chemical
infusion.	O
There	O
was	O
also	O
a	O
higher	O
incidence	O
of	O
tachyarrhythmias	Disease
(P	O
less	O
than	O
0.05)	O
and	O
ventricular	Disease
ectopic	Disease
beats	Disease
(P	O
less	O
than	O
0.05)	O
in	O
the	O
morphine	Chemical

Magnetic	O
resonance	O
volumetry	O
of	O
the	O
cerebellum	O
in	O
epileptic	Disease
patients	O
after	O
phenytoin	Chemical
	O
overdosages	Disease
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
phenytoin	Chemical
medication	O
and	O
cerebellar	Disease
atrophy	Disease
in	O
patients	O
who	O
had	O
experienced	O
clinical	O
intoxication.	O
Five	O
females	O
and	O
6	O
males,	O
21-59	O
years	O
of	O
age,	O
were	O
examined	O
with	O
a	O
1.5-T	O
whole-body	O
system	O
using	O
a	O
circular	O
polarized	O
head	O
coil.	O
Conventional	O
spin	O
echo	O
images	O
were	O
acquired	O
in	O
the	O
sagittal	O
and	O
transverse	O
orientation.	O
In	O
addition,	O
we	O
performed	O
a	O
high-resolution	O
3D	O
gradient	O
echo,	O
T1-weighted	O
sequences	O
at	O
a	O
1-mm	O
slice	O
thickness.	O
The	O
images	O
were	O
subsequently	O
processed	O
to	O
obtain	O
volumetric	O
data	O
for	O
the	O
cerebellum.	O
Cerebellar	O
volume	O
for	O
the	O
patient	O
group	O
ranged	O
between	O
67.66	O
and	O
131.08	O
ml	O
(mean	O
108.9	O
ml).	O
In	O
addition	O
3D	O
gradient	O
echo	O
data	O
sets	O
from	O
10	O
healthy	O
male	O
and	O
10	O
healthy	O
female	O
age-matched	O
volunteers	O
were	O
used	O
to	O
compare	O
cerebellar	O
volumes.	O
Using	O
linear	O
regression	O
we	O
found	O
that	O
no	O
correlation	O
exists	O
between	O
seizure	Disease
duration,	O
elevation	O
of	O
phenytoin	Chemical
serum	O
levels	O
and	O
cerebellar	O
volume.	O
However,	O
multiple	O
regression	O
for	O
the	O
daily	O
dosage,	O
duration	O
of	O
phenytoin	Chemical
treatment	O
and	O
cerebellar	O
volume	O
revealed	O
a	O
correlation	O
of	O
these	O
parameters.	O
We	O
conclude	O
that	O
phenytoin	Chemical
	O
overdosage	Disease
does	O
not	O
necessarily	O
result	O
in	O
cerebellar	Disease
atrophy	Disease
and	O
it	O
is	O
unlikely	O
that	O
phenytoin	Chemical
medication	O
was	O
the	O
only	O
cause	O
of	O
cerebellar	Disease
atrophy	Disease
in	O
the	O
remaining	O
patients.	O
Quantitative	O
morphometric	O
studies	O
of	O
the	O
cerebellum	O
provide	O
valuable	O
insights	O
into	O
the	O
pathogenesis	O
of	O
cerebellar	Disease
disorders	Disease

Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	Disease
damage	Disease
in	O
doxorubicin	Chemical
-induced	O
cardiomyopathy	Disease
rats,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings.	O
BACKGROUND:	O
Cardiac	O
troponins	O
I	O
(cTnI)	O
and	O
T	O
(cTnT)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sensitive	O
and	O
specific	O
markers	O
of	O
myocardial	Disease
cell	Disease
injury	Disease
.	O
We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	Disease
damage	Disease
in	O
a	O
rat	O
model	O
of	O
doxorubicin	Chemical
(	O
DOX	Chemical
)-induced	O
cardiomyopathy	Disease
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	Disease
disorders	Disease
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model.	O
METHODS:	O
Thirty-five	O
Wistar	O
rats	O
were	O
given	O
1.5	O
mg/kg	O
DOX	Chemical
,	O
i.v.,	O
weekly	O
for	O
up	O
to	O
8	O
weeks	O
for	O
a	O
total	O
cumulative	O
dose	O
of	O
12	O
mg/kg	O
BW.	O
Ten	O
rats	O
received	O
saline	O
as	O
a	O
control	O
group.	O
cTnI	O
was	O
measured	O
with	O
Access(R)	O
(ng/ml)	O
and	O
a	O
research	O
immunoassay	O
(pg/ml),	O
and	O
compared	O
with	O
cTnT,	O
CK-MB	O
mass	O
and	O
CK.	O
By	O
using	O
transthoracic	O
echocardiography,	O
anterior	O
and	O
posterior	O
wall	O
thickness,	O
LV	O
diameters	O
and	O
LV	O
fractional	O
shortening	O
(FS)	O
were	O
measured	O
in	O
all	O
rats	O
before	O
DOX	Chemical
or	O
saline,	O
and	O
at	O
weeks	O
6	O
and	O
9	O
after	O
treatment	O
in	O
all	O
surviving	O
rats.	O
Histology	O
was	O
performed	O
in	O
DOX	Chemical
-rats	O
at	O
6	O
and	O
9	O
weeks	O
after	O
the	O
last	O
DOX	Chemical
dose	O
and	O
in	O
all	O
controls.	O
RESULTS:	O
Eighteen	O
of	O
the	O
DOX	Chemical
rats	O
died	O
prematurely	O
of	O
general	O
toxicity	Disease
during	O
the	O
9-week	O
period.	O
End-diastolic	O
(ED)	O
and	O
end-systolic	O
(ES)	O
LV	O
diameters/BW	O
significantly	O
increased,	O
whereas	O
LV	O
FS	O
was	O
decreased	O
after	O
9	O
weeks	O
in	O
the	O
DOX	Chemical
group	O
(p<0.001).	O
These	O
parameters	O
remained	O
unchanged	O
in	O
controls.	O
Histological	O
evaluation	O
of	O
hearts	O
from	O
all	O
rats	O
given	O
DOX	Chemical
revealed	O
significant	O
slight	O
degrees	O
of	O
perivascular	O
and	O
interstitial	O
fibrosis	Disease
.	O
In	O
7	O
of	O
the	O
18	O
rats,	O
degeneration	O
and	O
myocyte	O
vacuolisation	O
were	O
found.	O
Only	O
five	O
of	O
the	O
controls	O
exhibited	O
evidence	O
of	O
very	O
slight	O
perivascular	O
fibrosis	Disease
.	O
A	O
significant	O
rise	O
in	O
cTnT	O
was	O
found	O
in	O
DOX	Chemical
rats	O
after	O
cumulative	O
doses	O
of	O
7.5	O
and	O
12	O
mg/kg	O
in	O
comparison	O
with	O
baseline	O
(p<0.05).	O
cTnT	O
found	O
in	O
rats	O
after	O
12	O
mg/kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7.5	O
mg/kg	O
DOX	Chemical
.	O
Maximal	O
cTnI	O
(pg/ml)	O
and	O
cTnT	O
levels	O
were	O
significantly	O
increased	O
in	O
DOX	Chemical
rats	O
compared	O
with	O
controls	O
(p=0.006,	O
0.007).	O
cTnI	O
(ng/ml),	O
CK-MB	O
mass	O
and	O
CK	O
remained	O
unchanged	O
in	O
DOX	Chemical
rats	O
compared	O
with	O
controls.	O
All	O
markers	O
remained	O
stable	O
in	O
controls.	O
Analysis	O
of	O
data	O
revealed	O
a	O
significant	O
correlation	O
between	O
maximal	O
cTnT	O
and	O
ED	O
and	O
ES	O
LV	O
diameters/BW	O
(r=0.81	O
and	O
0.65;	O
p<0.0001).	O
A	O
significant	O
relationship	O
was	O
observed	O
between	O
maximal	O
cTnT	O
and	O
the	O
extent	O
of	O
myocardial	O
morphological	O
changes,	O
and	O
between	O
LV	O
diameters/BW	O
and	O
histological	O
findings.	O
CONCLUSIONS:	O
Among	O
markers	O
of	O
ischemic	Disease
injury	Disease
after	O
DOX	Chemical
in	O
rats,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	Disease
damage	Disease
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes.	O
Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	Chemical
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross-reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	Chemical
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	Disease

Calcineurin-inhibitor	O
induced	O
pain	Disease
syndrome	O
(	O
CIPS	Disease
):	O
a	O
severe	O
disabling	O
complication	O
after	O
organ	O
transplantation.	O
Bone	O
pain	Disease
after	O
transplantation	O
is	O
a	O
frequent	O
complication	O
that	O
can	O
be	O
caused	O
by	O
several	O
diseases.	O
Treatment	O
strategies	O
depend	O
on	O
the	O
correct	O
diagnosis	O
of	O
the	O
pain	Disease
.	O
Nine	O
patients	O
with	O
severe	O
pain	Disease
in	O
their	O
feet,	O
which	O
was	O
registered	O
after	O
transplantation,	O
were	O
investigated.	O
Bone	O
scans	O
showed	O
an	O
increased	O
tracer	O
uptake	O
of	O
the	O
foot	O
bones.	O
Magnetic	O
resonance	O
imaging	O
demonstrated	O
bone	Disease
marrow	Disease
oedema	Disease
in	O
the	O
painful	O
bones.	O
Pain	Disease
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	Disease
,	O
like	O
reflex	Disease
sympathetic	Disease
dystrophy	Disease
,	O
polyneuropathy	Disease
,	O
Morton's	Disease
neuralgia	Disease
,	O
gout	Disease
,	O
osteoporosis	Disease
,	O
avascular	Disease
necrosis	Disease
,	O
intermittent	Disease
claudication	Disease
,	O
orthopaedic	O
foot	Disease
deformities	Disease
,	O
stress	Disease
fractures	Disease
,	O
and	O
hyperparathyroidism	Disease
.	O
The	O
reduction	O
of	O
cyclosporine	Chemical
-	O
or	O
tacrolimus	Chemical
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	Chemical
channel	O
blockers	O
led	O
to	O
relief	O
of	O
pain	Disease
.	O
The	O
Calcineurin-inhibitor	O
Induced	O
Pain	Disease
Syndrome	O
(	O
CIPS	Disease
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	Chemical
or	O
tacrolimus	Chemical
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans.	O
Incorrect	O
diagnosis	O
of	O
the	O
syndrome	O
will	O
lead	O
to	O
a	O
significant	O
reduction	O
of	O
life	O
quality	O
in	O
patients	O
suffering	O
from	O
CIPS	Disease

The	O
haemodynamic	O
effects	O
of	O
propofol	Chemical
in	O
combination	O
with	O
ephedrine	Chemical
in	O
elderly	O
patients	O
(ASA	O
groups	O
3	O
and	O
4).	O
The	O
marked	O
vasodilator	O
and	O
negative	O
inotropic	O
effects	O
of	O
propofol	Chemical
are	O
disadvantages	O
in	O
frail	O
elderly	O
patients.	O
We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	O
of	O
ephedrine	Chemical
to	O
propofol	Chemical
in	O
order	O
to	O
obtund	O
the	O
hypotensive	Disease
response.	O
The	O
haemodynamic	O
effects	O
of	O
adding	O
15,	O
20	O
or	O
25	O
mg	O
of	O
ephedrine	Chemical
to	O
200	O
mg	O
of	O
propofol	Chemical
were	O
compared	O
to	O
control	O
in	O
40	O
ASA	O
3/4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito-urinary	O
surgery.	O
The	O
addition	O
of	O
ephedrine	Chemical
to	O
propofol	Chemical
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	Disease
response	O
to	O
propofol	Chemical
at	O
all	O
doses	O
used	O
in	O
this	O
study.	O
However,	O
marked	O
tachycardia	Disease
associated	O
with	O
the	O
use	O
of	O
ephedrine	Chemical
in	O
combination	O
with	O
propofol	Chemical
occurred	O
in	O
the	O
majority	O
of	O
patients,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients.	O
Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	Disease
inducing	O
myocardial	Disease
ischemia	Disease
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	Chemical
/	O
propofol	Chemical

Neurotoxicity	Disease
of	O
halogenated	Chemical
hydroxyquinolines	Chemical
:	O
clinical	O
analysis	O
of	O
cases	O
reported	O
outside	O
Japan.	O
An	O
analysis	O
is	O
presented	O
of	O
220	O
cases	O
of	O
possible	O
neurotoxic	Disease
reactions	O
to	O
halogenated	Chemical
hydroxyquinolines	Chemical
reported	O
from	O
outside	O
Japan.	O
In	O
80	O
cases	O
insufficient	O
information	O
was	O
available	O
for	O
adequate	O
comment	O
and	O
in	O
29	O
a	O
relationship	O
to	O
the	O
administration	O
of	O
clioquinol	Chemical
could	O
be	O
excluded.	O
Of	O
the	O
remainder,	O
a	O
relationship	O
to	O
clioquinol	Chemical
was	O
considered	O
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
cases.	O
In	O
six	O
of	O
the	O
probable	O
cases	O
the	O
neurological	Disease
disturbance	Disease
consisted	O
of	O
an	O
acute	O
reversible	O
encephalopathy	Disease
usually	O
related	O
to	O
the	O
ingestion	O
of	O
a	O
high	O
dose	O
of	O
clioquinol	Chemical
over	O
a	O
short	O
period.	O
The	O
most	O
common	O
manifestation,	O
observed	O
in	O
15	O
further	O
cases,	O
was	O
isolated	O
optic	Disease
atrophy	Disease
.	O
This	O
was	O
most	O
frequently	O
found	O
in	O
children,	O
many	O
of	O
whom	O
had	O
received	O
clioquinol	Chemical
as	O
treatment	O
for	O
acrodermatitis	Disease
enteropathica	Disease
.	O
In	O
the	O
remaining	O
cases,	O
a	O
combination	O
of	O
myelopathy	Disease
,	O
visual	Disease
disturbance	Disease
,	O
and	O
peripheral	Disease
neuropathy	Disease
was	O
the	O
most	O
common	O
manifestation.	O
Isolated	O
myelopathy	Disease
or	O
peripheral	Disease
neuropathy	Disease
,	O
or	O
these	O
manifestations	O
occurring	O
together,	O
were	O
infrequent.	O
The	O
onset	O
of	O
all	O
manifestations	O
(except	O
toxic	O
encephalopathy	Disease
)	O
was	O
usually	O
subacute,	O
with	O
subsequent	O
partial	O
recovery.	O
Older	O
subjects	O
tended	O
to	O
display	O
more	O
side	O
effects.	O
The	O
full	O
syndrome	O
of	O
subacute	O
myelo-optic	Disease
neuropathy	Disease

Epileptic	Disease
seizures	Disease
following	O
cortical	O
application	O
of	O
fibrin	O
sealants	O
containing	O
tranexamic	Chemical
acid	Chemical
in	O
rats.	O
BACKGROUND:	O
Fibrin	O
sealants	O
(FS)	O
derived	O
from	O
human	O
plasma	O
are	O
frequently	O
used	O
in	O
neurosurgery.	O
In	O
order	O
to	O
increase	O
clot	O
stability,	O
FS	O
typically	O
contain	O
aprotinin,	O
a	O
natural	O
fibrinolysis	O
inhibitor.	O
Recently,	O
synthetic	O
fibrinolysis	O
inhibitors	O
such	O
as	O
tranexamic	Chemical
acid	Chemical
(	O
tAMCA	Chemical
)	O
have	O
been	O
considered	O
as	O
substitutes	O
for	O
aprotinin.	O
However,	O
tAMCA	Chemical
has	O
been	O
shown	O
to	O
cause	O
epileptic	Disease
seizures	Disease
.	O
We	O
wanted	O
to	O
study	O
whether	O
tAMCA	Chemical
retains	O
its	O
convulsive	Disease
action	O
if	O
incorporated	O
into	O
a	O
FS.	O
METHOD:	O
FS	O
containing	O
aprotinin	O
or	O
different	O
concentrations	O
of	O
tAMCA	Chemical
(0.5-47.5	O
mg/ml)	O
were	O
applied	O
to	O
the	O
pial	O
surface	O
of	O
the	O
cortex	O
of	O
anaesthetized	O
rats.	O
The	O
response	O
of	O
the	O
animals	O
was	O
evaluated	O
using	O
electroencephalography	O
and	O
by	O
monitoring	O
the	O
clinical	O
behaviour	O
during	O
and	O
after	O
recovery	O
from	O
anaesthesia.	O
FINDINGS:	O
FS	O
containing	O
tAMCA	Chemical
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	O
with	O
distinct	O
convulsive	Disease
behaviours.	O
The	O
degree	O
of	O
these	O
seizures	Disease
increased	O
with	O
increasing	O
concentration	O
of	O
tAMCA	Chemical
.	O
Thus,	O
FS	O
containing	O
47.5	O
mg/ml	O
tAMCA	Chemical
evoked	O
generalized	Disease
seizures	Disease
in	O
all	O
tested	O
rats	O
(n=6)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	Chemical
(0.5	O
mg/ml)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk-correlated	O
convulsive	Disease
potentials	O
in	O
1	O
of	O
6	O
rats.	O
In	O
contrast,	O
FS	O
containing	O
aprotinin	O
did	O
not	O
evoke	O
any	O
paroxysmal	O
activity.	O
INTERPRETATION:	O
Tranexamic	Chemical
acid	Chemical
retains	O
its	O
convulsive	Disease
action	O
within	O
FS.	O
Thus,	O
use	O
of	O
FS	O
containing	O
tAMCA	Chemical

A	O
diet	O
promoting	O
sugar	Disease
dependency	Disease
causes	O
behavioral	Disease
cross-sensitization	Disease
to	O
a	O
low	O
dose	O
of	O
amphetamine	Chemical
.	O
Previous	O
research	O
in	O
this	O
laboratory	O
has	O
shown	O
that	O
a	O
diet	O
of	O
intermittent	O
excessive	O
sugar	O
consumption	O
produces	O
a	O
state	O
with	O
neurochemical	O
and	O
behavioral	O
similarities	O
to	O
drug	Disease
dependency	Disease
.	O
The	O
present	O
study	O
examined	O
whether	O
female	O
rats	O
on	O
various	O
regimens	O
of	O
sugar	O
access	O
would	O
show	O
behavioral	Disease
cross-sensitization	Disease
to	O
a	O
low	O
dose	O
of	O
amphetamine	Chemical
.	O
After	O
a	O
30-min	O
baseline	O
measure	O
of	O
locomotor	O
activity	O
(day	O
0),	O
animals	O
were	O
maintained	O
on	O
a	O
cyclic	O
diet	O
of	O
12-h	O
deprivation	O
followed	O
by	O
12-h	O
access	O
to	O
10%	O
sucrose	Chemical
solution	O
and	O
chow	O
pellets	O
(12	O
h	O
access	O
starting	O
4	O
h	O
after	O
onset	O
of	O
the	O
dark	O
period)	O
for	O
21	O
days.	O
Locomotor	O
activity	O
was	O
measured	O
again	O
for	O
30	O
min	O
at	O
the	O
beginning	O
of	O
days	O
1	O
and	O
21	O
of	O
sugar	O
access.	O
Beginning	O
on	O
day	O
22,	O
all	O
rats	O
were	O
maintained	O
on	O
ad	O
libitum	O
chow.	O
Nine	O
days	O
later	O
locomotor	O
activity	O
was	O
measured	O
in	O
response	O
to	O
a	O
single	O
low	O
dose	O
of	O
amphetamine	Chemical
(0.5	O
mg/kg).	O
The	O
animals	O
that	O
had	O
experienced	O
cyclic	O
sucrose	Chemical
and	O
chow	O
were	O
hyperactive	Disease
in	O
response	O
to	O
amphetamine	Chemical
compared	O
with	O
four	O
control	O
groups	O
(ad	O
libitum	O
10%	O
sucrose	Chemical
and	O
chow	O
followed	O
by	O
amphetamine	Chemical
injection,	O
cyclic	O
chow	O
followed	O
by	O
amphetamine	Chemical
injection,	O
ad	O
libitum	O
chow	O
with	O
amphetamine	Chemical
,	O
or	O
cyclic	O
10%	O
sucrose	Chemical
and	O
chow	O
with	O
a	O
saline	O
injection).	O
These	O
results	O
suggest	O
that	O
a	O
diet	O
comprised	O
of	O
alternating	O
deprivation	O
and	O
access	O
to	O
a	O
sugar	O
solution	O
and	O
chow	O
produces	O
bingeing	O
on	O
sugar	O
that	O
leads	O
to	O
a	O
long	O
lasting	O
state	O
of	O
increased	O
sensitivity	O
to	O
amphetamine	Chemical
,	O
possibly	O
due	O
to	O
a	O
lasting	O
alteration	O
in	O
the	O
dopamine	Chemical

D-penicillamine	Chemical
-induced	O
angiopathy	Disease
in	O
rats.	O
The	O
effect	O
of	O
high	O
dose	O
D-penicillamine	Chemical
treatment	O
on	O
aortic	O
permeability	O
to	O
albumin	O
and	O
on	O
the	O
ultrastructure	O
of	O
the	O
vessel.	O
Male	O
Sprague-Dawley	O
rats	O
were	O
treated	O
with	O
D-penicillamine	Chemical
(	O
D-pen	Chemical
)	O
500	O
mg/kg/day	O
for	O
10	O
or	O
42	O
days.	O
Pair	O
fed	O
rats	O
served	O
as	O
controls.	O
Changes	O
in	O
aortic	O
morphology	O
were	O
examined	O
by	O
light-	O
and	O
transmission-electron	O
microscopy	O
(TEM).	O
In	O
addition,	O
the	O
endothelial	O
permeability	O
and	O
the	O
penetration	O
through	O
the	O
aortic	O
wall	O
of	O
albumin	O
were	O
studied	O
10	O
minutes,	O
24	O
and	O
48	O
hours	O
after	O
i.	O
v.	O
injection	O
of	O
human	O
serum	O
131I-albumin	O
(131I-HSA).	O
TEM	O
revealed	O
extensive	O
elastolysis	O
in	O
the	O
arterial	O
wall	O
of	O
D-pen	Chemical
-treated	O
rats,	O
consistent	O
with	O
an	O
inhibitory	O
effect	O
on	O
crosslink	O
formation.	O
In	O
experimental	O
animals	O
excess	O
deposition	O
of	O
collagen	O
and	O
glycoaminoglycans	O
was	O
observed	O
in	O
the	O
subendothelial	O
and	O
medial	O
layer	O
of	O
the	O
aortic	O
wall,	O
together	O
with	O
prominent	O
basal	O
membrane	O
substance	O
around	O
aortic	O
smooth	O
muscle	O
cells.	O
The	O
aorta/serum-ratio	O
and	O
the	O
radioactive	O
build-up	O
24	O
and	O
48	O
hours	O
after	O
injection	O
of	O
131I-HSA	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
D-pen	Chemical
for	O
42	O
days,	O
indicating	O
an	O
impeded	O
transmural	O
transport	O
of	O
tracer	O
which	O
may	O
be	O
caused	O
by	O
a	O
steric	O
exclusion	O
effect	O
of	O
abundant	O
hyaluronate	Chemical
.	O
The	O
endothelial	O
ultrastructure	O
was	O
unaffected	O
by	O
D-pen	Chemical
,	O
and	O
no	O
differences	O
in	O
aortic	O
131I-HSA	O
radioactivity	O
or	O
aorta/serum-ratio	O
were	O
recorded	O
between	O
experimental	O
and	O
control	O
groups	O
10	O
minutes	O
after	O
tracer	O
injection,	O
indicating	O
that	O
the	O
permeability	O
of	O
the	O
endothelial	O
barrier	O
to	O
albumin	O
remained	O
unaffected	O
by	O
D-pen	Chemical
treatment.	O
These	O
observations	O
support	O
the	O
hypothesis	O
that	O
treatment	O
with	O
high	O
doses	O
of	O
D-pen	Chemical

Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	O
of	O
anthracycline	Chemical
-induced	O
cardiotoxicity	Disease
.	O
Anthracyclines	Chemical
are	O
effective	O
antineoplastic	O
drugs,	O
but	O
they	O
frequently	O
cause	O
dose-related	O
cardiotoxicity	Disease
.	O
The	O
cardiotoxicity	Disease
of	O
conventional	O
anthracycline	Chemical
therapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	Disease
dysfunction	Disease
.	O
We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(BNP)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	Chemical
-induced	O
cardiotoxicity	Disease
in	O
patients	O
with	O
acute	Disease
leukemia	Disease
treated	O
with	O
a	O
daunorubicin	Chemical
(	O
DNR	Chemical
)-containing	O
regimen.	O
Thirteen	O
patients	O
with	O
acute	Disease
leukemia	Disease
were	O
treated	O
with	O
a	O
DNR	Chemical
-containing	O
regimen.	O
Cardiac	O
functions	O
were	O
evaluated	O
with	O
radionuclide	O
angiography	O
before	O
chemotherapies.	O
The	O
plasma	O
levels	O
of	O
atrial	O
natriuretic	O
peptide	O
(ANP)	O
and	O
BNP	O
were	O
measured	O
at	O
the	O
time	O
of	O
radionuclide	O
angiography.	O
Three	O
patients	O
developed	O
congestive	Disease
heart	Disease
failure	Disease
after	O
the	O
completion	O
of	O
chemotherapy.	O
Five	O
patients	O
were	O
diagnosed	O
as	O
having	O
subclinical	O
heart	Disease
failure	Disease
after	O
the	O
completion	O
of	O
chemotherapy.	O
The	O
plasma	O
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	Disease
failure	Disease
increased	O
above	O
the	O
normal	O
limit	O
(40	O
pg/ml)	O
before	O
the	O
detection	O
of	O
clinical	O
or	O
subclinical	O
heart	Disease
failure	Disease
by	O
radionuclide	O
angiography.	O
On	O
the	O
other	O
hand,	O
BNP	O
did	O
not	O
increase	O
in	O
the	O
patients	O
without	O
heart	Disease
failure	Disease
given	O
DNR	Chemical
,	O
even	O
at	O
more	O
than	O
700	O
mg/m(2).	O
The	O
plasma	O
level	O
of	O
ANP	O
did	O
not	O
always	O
increase	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	Disease
failure	Disease
.	O
These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	O
of	O
anthracycline	Chemical
-induced	O
cardiotoxicity	Disease

Antibacterial	O
medication	O
use	O
during	O
pregnancy	O
and	O
risk	O
of	O
birth	Disease
defects	Disease
:	O
National	O
Birth	Disease
Defects	Disease
Prevention	O
Study.	O
OBJECTIVE:	O
To	O
estimate	O
the	O
association	O
between	O
antibacterial	O
medications	O
and	O
selected	O
birth	Disease
defects	Disease
.	O
DESIGN,	O
SETTING,	O
AND	O
PARTICIPANTS:	O
Population-based,	O
multisite,	O
case-control	O
study	O
of	O
women	O
who	O
had	O
pregnancies	O
affected	O
by	O
1	O
of	O
more	O
than	O
30	O
eligible	O
major	O
birth	Disease
defects	Disease
identified	O
via	O
birth	Disease
defect	Disease
surveillance	O
programs	O
in	O
10	O
states	O
(n	O
=	O
13	O
155)	O
and	O
control	O
women	O
randomly	O
selected	O
from	O
the	O
same	O
geographical	O
regions	O
(n	O
=	O
4941).	O
MAIN	O
EXPOSURE:	O
Reported	O
maternal	O
use	O
of	O
antibacterials	O
(1	O
month	O
before	O
pregnancy	O
through	O
the	O
end	O
of	O
the	O
first	O
trimester).	O
MAIN	O
OUTCOME	O
MEASURE:	O
Odds	O
ratios	O
(ORs)	O
measuring	O
the	O
association	O
between	O
antibacterial	O
use	O
and	O
selected	O
birth	Disease
defects	Disease
adjusted	O
for	O
potential	O
confounders.	O
RESULTS:	O
The	O
reported	O
use	O
of	O
antibacterials	O
increased	O
during	O
pregnancy,	O
peaking	O
during	O
the	O
third	O
month.	O
Sulfonamides	Chemical
were	O
associated	O
with	O
anencephaly	Disease
(adjusted	O
OR	O
[AOR]	O
=	O
3.4;	O
95%	O
confidence	O
interval	O
[CI],	O
1.3-8.8),	O
hypoplastic	Disease
left	Disease
heart	Disease
syndrome	Disease
(AOR	O
=	O
3.2;	O
95%	O
CI,	O
1.3-7.6),	O
coarctation	Disease
of	Disease
the	Disease
aorta	Disease
(AOR	O
=	O
2.7;	O
95%	O
CI,	O
1.3-5.6),	O
choanal	Disease
atresia	Disease
(AOR	O
=	O
8.0;	O
95%	O
CI,	O
2.7-23.5),	O
transverse	Disease
limb	Disease
deficiency	Disease
(AOR	O
=	O
2.5;	O
95%	O
CI,	O
1.0-5.9),	O
and	O
diaphragmatic	Disease
hernia	Disease
(AOR	O
=	O
2.4;	O
95%	O
CI,	O
1.1-5.4).	O
Nitrofurantoins	Chemical
were	O
associated	O
with	O
anophthalmia	Disease
or	O
microphthalmos	Disease
(AOR	O
=	O
3.7;	O
95%	O
CI,	O
1.1-12.2),	O
hypoplastic	Disease
left	Disease
heart	Disease
syndrome	Disease
(AOR	O
=	O
4.2;	O
95%	O
CI,	O
1.9-9.1),	O
atrial	Disease
septal	Disease
defects	Disease
(AOR	O
=	O
1.9;	O
95%	O
CI,	O
1.1-3.4),	O
and	O
cleft	Disease
lip	Disease
with	O
cleft	Disease
palate	Disease
(AOR	O
=	O
2.1;	O
95%	O
CI,	O
1.2-3.9).	O
Other	O
antibacterial	O
agents	O
that	O
showed	O
associations	O
included	O
erythromycins	Chemical
(2	O
defects),	O
penicillins	Chemical
(1	O
defect),	O
cephalosporins	Chemical
(1	O
defect),	O
and	O
quinolones	Chemical
(1	O
defect).	O
CONCLUSIONS:	O
Reassuringly,	O
penicillins	Chemical
,	O
erythromycins	Chemical
,	O
and	O
cephalosporins	Chemical
,	O
although	O
used	O
commonly	O
by	O
pregnant	O
women,	O
were	O
not	O
associated	O
with	O
many	O
birth	Disease
defects	Disease
.	O
Sulfonamides	Chemical
and	O
nitrofurantoins	Chemical
were	O
associated	O
with	O
several	O
birth	Disease
defects	Disease

Incidence	O
of	O
neoplasms	Disease
in	O
patients	O
with	O
rheumatoid	Disease
arthritis	Disease
exposed	O
to	O
different	O
treatment	O
regimens.	O
Immunosuppressive	O
drugs	O
have	O
been	O
used	O
during	O
the	O
last	O
30	O
years	O
in	O
treatment	O
of	O
patients	O
with	O
severe	O
rheumatoid	Disease
arthritis	Disease
.	O
The	O
drugs	O
commonly	O
used	O
are	O
cyclophosphamide	Chemical
and	O
chlorambucil	Chemical
(	O
alkylating	Chemical
agents	Chemical
),	O
azathioprine	Chemical
(	O
purine	Chemical
analogue),	O
and	O
methotrexate	Chemical
(	O
folic	Chemical
acid	Chemical
analogue).	O
There	O
is	O
evidence	O
that	O
all	O
four	O
immunosuppressive	O
drugs	O
can	O
reduce	O
synovitis	Disease
,	O
but	O
disease	O
activity	O
almost	O
always	O
recurs	O
after	O
therapy	O
is	O
stopped.	O
Since	O
adverse	O
reactions	O
are	O
frequent,	O
less	O
than	O
50	O
percent	O
of	O
patients	O
are	O
able	O
to	O
continue	O
a	O
particular	O
drug	O
for	O
more	O
than	O
one	O
year.	O
Since	O
it	O
takes	O
three	O
to	O
12	O
months	O
to	O
achieve	O
maximal	O
effects,	O
those	O
patients	O
who	O
are	O
unable	O
to	O
continue	O
the	O
drug	O
receive	O
little	O
benefit	O
from	O
it.	O
Patients	O
treated	O
with	O
alkylating	Chemical
agents	Chemical
have	O
an	O
increased	O
risk	O
of	O
development	O
of	O
acute	Disease
nonlymphocytic	Disease
leukemia	Disease
,	O
and	O
both	O
alkylating	Chemical
agents	Chemical
and	O
azathioprine	Chemical
are	O
associated	O
with	O
the	O
development	O
of	O
non-Hodgkin's	Disease
lymphoma	Disease
.	O
Cyclophosphamide	Chemical
therapy	O
increases	O
the	O
risk	O
of	O
carcinoma	Disease
of	Disease
the	Disease
bladder	Disease
.	O
There	O
have	O
been	O
several	O
long-term	O
studies	O
of	O
patients	O
with	O
rheumatoid	Disease
arthritis	Disease
treated	O
with	O
azathioprine	Chemical
and	O
cyclophosphamide	Chemical
and	O
the	O
incidence	O
of	O
most	O
of	O
the	O
common	O
cancers	Disease
is	O
not	O
increased.	O
Data	O
on	O
the	O
possible	O
increased	O
risk	O
of	O
malignancy	Disease
in	O
rheumatoid	Disease
arthritis	Disease
are	O
still	O
being	O
collected,	O
and	O
until	O
further	O
information	O
is	O
available,	O
the	O
use	O
of	O
immunosuppressive	O
drugs,	O
particularly	O
alkylating	Chemical
agents	Chemical
,	O
in	O
the	O
treatment	O
of	O
rheumatoid	Disease
arthritis	Disease

Patterns	O
of	O
hepatic	Disease
injury	Disease
induced	O
by	O
methyldopa	Chemical
.	O
Twelve	O
patients	O
with	O
liver	Disease
disease	Disease
related	O
to	O
methyldopa	Chemical
were	O
seen	O
between	O
1967	O
and	O
1977.	O
Illness	O
occurred	O
within	O
1--9	O
weeks	O
of	O
commencement	O
of	O
therapy	O
in	O
9	O
patients,	O
the	O
remaining	O
3	O
patients	O
having	O
received	O
the	O
drug	O
for	O
13	O
months,	O
15	O
months	O
and	O
7	O
years	O
before	O
experiencing	O
symptoms.	O
Jaundice	Disease
with	O
tender	O
hepatomegaly	Disease
,	O
usually	O
preceded	O
by	O
symptoms	O
of	O
malaise,	O
anorexia	Disease
,	O
nausea	Disease
and	O
vomiting	Disease
,	O
and	O
associated	O
with	O
upper	O
abdominal	Disease
pain	Disease
,	O
was	O
an	O
invariable	O
finding	O
in	O
all	O
patients.	O
Biochemical	O
liver	O
function	O
tests	O
indicated	O
hepatocellular	O
necrosis	Disease
and	O
correlated	O
with	O
histopathological	O
evidence	O
of	O
hepatic	Disease
injury	Disease
,	O
the	O
spectrum	O
of	O
which	O
ranged	O
from	O
fatty	Disease
change	Disease
and	O
focal	O
hepatocellular	O
necrosis	Disease
to	O
massive	Disease
hepatic	Disease
necrosis	Disease
.	O
Most	O
patients	O
showed	O
moderate	O
to	O
severe	O
acute	Disease
hepatitis	Disease
or	O
chronic	Disease
active	Disease
hepatitis	Disease
with	O
associated	O
cholestasis	Disease
.	O
The	O
drug	O
was	O
withdrawn	O
on	O
presentation	O
to	O
hospital	O
in	O
11	O
patients,	O
with	O
rapid	O
clinical	O
improvement	O
in	O
9.	O
One	O
patient	O
died,	O
having	O
presented	O
in	O
hepatic	Disease
failure	Disease
,	O
and	O
another,	O
who	O
had	O
been	O
taking	O
methyldopa	Chemical
for	O
7	O
years,	O
showed	O
slower	O
clinical	O
and	O
biochemical	O
resolution	O
over	O
a	O
period	O
of	O
several	O
months.	O
The	O
remaining	O
patient	O
in	O
the	O
series	O
developed	O
fulminant	Disease
hepatitis	Disease
when	O
the	O
drug	O
was	O
accidentally	O
recommenced	O
1	O
year	O
after	O
a	O
prior	O
episode	O
of	O
methyldopa	Chemical
-induced	O
hepatitis	Disease
.	O
In	O
this	O
latter	O
patient,	O
and	O
in	O
2	O
others,	O
the	O
causal	O
relationship	O
between	O
methyldopa	Chemical
and	O
hepatic	Disease
dysfunction	Disease
was	O
proved	O
with	O
the	O
recurrence	O
of	O
hepatitis	Disease

A	O
phase	O
I/II	O
study	O
of	O
paclitaxel	Chemical
plus	O
cisplatin	Chemical
as	O
first-line	O
therapy	O
for	O
head	Disease
and	Disease
neck	Disease
cancers	Disease
:	O
preliminary	O
results.	O
Improved	O
outcomes	O
among	O
patients	O
with	O
head	Disease
and	Disease
neck	Disease
carcinomas	Disease
require	O
investigations	O
of	O
new	O
drugs	O
for	O
induction	O
therapy.	O
Preliminary	O
results	O
of	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
of	O
single-agent	O
paclitaxel	Chemical
(	O
Taxol	Chemical
;	O
Bristol-Myers	O
Squibb	O
Company,	O
Princeton,	O
NJ)	O
reported	O
a	O
37%	O
response	O
rate	O
in	O
patients	O
with	O
head	Disease
and	Disease
neck	Disease
cancer	Disease
,	O
and	O
the	O
paclitaxel	Chemical
/	O
cisplatin	Chemical
combination	O
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	O
improved	O
median	O
response	O
duration	O
in	O
ovarian	Disease
cancer	Disease
patients.	O
We	O
initiated	O
a	O
phase	O
I/II	O
trial	O
to	O
determine	O
the	O
response	O
and	O
toxicity	Disease
of	O
escalating	O
paclitaxel	Chemical
doses	O
combined	O
with	O
fixed-dose	O
cisplatin	Chemical
with	O
granulocyte	O
colony-stimulating	O
factor	O
support	O
in	O
patients	O
with	O
untreated	O
locally	O
advanced	O
inoperable	O
head	Disease
and	Disease
neck	Disease
carcinoma	Disease
.	O
To	O
date,	O
23	O
men	O
with	O
a	O
median	O
age	O
of	O
50	O
years	O
and	O
good	O
performance	O
status	O
have	O
entered	O
the	O
trial.	O
Primary	O
tumor	Disease
sites	O
were	O
oropharynx,	O
10	O
patients;	O
hypopharynx,	O
four;	O
larynx,	O
two;	O
oral	O
cavity,	O
three;	O
unknown	O
primary,	O
two;	O
and	O
nasal	O
cavity	O
and	O
parotid	O
gland,	O
one	O
each.	O
Of	O
20	O
patients	O
evaluable	O
for	O
toxicity	Disease
,	O
four	O
had	O
stage	O
III	O
and	O
16	O
had	O
stage	O
IV	O
disease.	O
Treatment,	O
given	O
every	O
21	O
days	O
for	O
a	O
maximum	O
of	O
three	O
cycles,	O
consisted	O
of	O
paclitaxel	Chemical
by	O
3-hour	O
infusion	O
followed	O
the	O
next	O
day	O
by	O
a	O
fixed	O
dose	O
of	O
cisplatin	Chemical
(75	O
mg/m2).	O
The	O
dose	O
levels	O
incorporate	O
escalating	O
paclitaxel	Chemical
doses,	O
and	O
intrapatient	O
escalations	O
within	O
a	O
given	O
dose	O
level	O
are	O
permitted	O
if	O
toxicity	Disease
permits.	O
At	O
the	O
time	O
of	O
this	O
writing,	O
dose	O
level	O
4	O
(260,	O
270,	O
and	O
280	O
mg/m2)	O
is	O
being	O
evaluated;	O
three	O
patients	O
from	O
this	O
level	O
are	O
evaluable.	O
With	O
paclitaxel	Chemical
doses	O
of	O
200	O
mg/m2	O
and	O
higher,	O
granulocyte	O
colony-stimulating	O
factor	O
5	O
micrograms/kg/d	O
is	O
given	O
(days	O
4	O
through	O
12).	O
Of	O
18	O
patients	O
evaluable	O
for	O
response,	O
seven	O
(39%)	O
achieved	O
a	O
complete	O
response	O
and	O
six	O
(33%)	O
achieved	O
a	O
partial	O
response.	O
Three	O
patients	O
had	O
no	O
change	O
and	O
disease	O
progressed	O
in	O
two.	O
The	O
overall	O
response	O
rate	O
is	O
72%.	O
Eleven	O
responding	O
patients	O
had	O
subsequent	O
surgery/radiotherapy	O
or	O
radical	O
radiotherapy.	O
Two	O
pathologic	O
complete	O
responses	O
were	O
observed	O
in	O
patients	O
who	O
had	O
achieved	O
clinical	O
complete	O
responses.	O
Alopecia	Disease
,	O
paresthesias	Disease
,	O
and	O
arthralgias	Disease
/	O
myalgias	Disease
have	O
occurred	O
frequently,	O
but	O
with	O
one	O
exception	O
(a	O
grade	O
3	O
myalgia	Disease
)	O
they	O
have	O
been	O
grade	O
1	O
or	O
2.	O
No	O
dose-limiting	O
hematologic	O
toxicity	Disease
has	O
been	O
seen.	O
Paclitaxel	Chemical
/	O
cisplatin	Chemical
is	O
an	O
effective	O
first-line	O
regimen	O
for	O
locoregionally	O
advanced	O
head	Disease
and	Disease
neck	Disease
cancer	Disease
and	O
continued	O
study	O
is	O
warranted.	O
Results	O
thus	O
far	O
suggest	O
no	O
dose-response	O
effect	O
for	O
paclitaxel	Chemical

A	O
phase	O
I	O
study	O
of	O
4'-0-tetrahydropyranyladriamycin	Chemical
.	O
Clinical	O
pharmacology	O
and	O
pharmacokinetics.	O
A	O
Phase	O
I	O
study	O
of	O
intravenous	O
(IV)	O
bolus	O
4'-0-tetrahydropyranyladriamycin	Chemical
(	O
Pirarubicin	Chemical
)	O
was	O
done	O
in	O
55	O
patients	O
in	O
good	O
performance	O
status	O
with	O
refractory	O
tumors	Disease
.	O
Twenty-six	O
had	O
minimal	O
prior	O
therapy	O
(good	O
risk),	O
23	O
had	O
extensive	O
prior	O
therapy	O
(poor	O
risk),	O
and	O
six	O
had	O
renal	Disease
and/or	Disease
hepatic	Disease
dysfunction	Disease
.	O
A	O
total	O
of	O
167	O
courses	O
at	O
doses	O
of	O
15	O
to	O
70	O
mg/m2	O
were	O
evaluable.	O
Maximum	O
tolerated	O
dose	O
in	O
good-risk	O
patients	O
was	O
70	O
mg/m2,	O
and	O
in	O
poor-risk	O
patients,	O
60	O
mg/m2.	O
The	O
dose-limiting	O
toxic	O
effect	O
was	O
transient	O
noncumulative	O
granulocytopenia	Disease
.	O
Granulocyte	O
nadir	O
was	O
on	O
day	O
14	O
(range,	O
4-22).	O
Less	O
frequent	O
toxic	O
effects	O
included	O
thrombocytopenia	Disease
,	O
anemia	Disease
,	O
nausea	Disease
,	O
mild	O
alopecia	Disease
,	O
phlebitis	Disease
,	O
and	O
mucositis	Disease
.	O
Myelosuppression	Disease
was	O
more	O
in	O
patients	O
with	O
hepatic	Disease
dysfunction	Disease
.	O
Pharmacokinetic	O
analyses	O
in	O
21	O
patients	O
revealed	O
Pirarubicin	Chemical
plasma	O
T	O
1/2	O
alpha	O
(+/-	O
SE)	O
of	O
2.5	O
+/-	O
0.85	O
minutes,	O
T	O
beta	O
1/2	O
of	O
25.6	O
+/-	O
6.5	O
minutes,	O
and	O
T	O
1/2	O
gamma	O
of	O
23.6	O
+/-	O
7.6	O
hours.	O
The	O
area	O
under	O
the	O
curve	O
was	O
537	O
+/-	O
149	O
ng/ml	O
x	O
hours,	O
volume	O
of	O
distribution	O
(Vd)	O
3504	O
+/-	O
644	O
l/m2,	O
and	O
total	O
clearance	O
(ClT)	O
was	O
204	O
+	O
39.3	O
l/hour/m2.	O
Adriamycinol	Chemical
,	O
doxorubicin	Chemical
,	O
adriamycinone	Chemical
,	O
and	O
tetrahydropyranyladriamycinol	Chemical
were	O
the	O
metabolites	O
detected	O
in	O
plasma	O
and	O
the	O
amount	O
of	O
doxorubicin	Chemical
was	O
less	O
than	O
or	O
equal	O
to	O
10%	O
of	O
the	O
total	O
metabolites.	O
Urinary	O
excretion	O
of	O
Pirarubicin	Chemical
in	O
the	O
first	O
24	O
hours	O
was	O
less	O
than	O
or	O
equal	O
to	O
10%.	O
Activity	O
was	O
noted	O
in	O
mesothelioma	Disease
,	O
leiomyosarcoma	Disease
,	O
and	O
basal	Disease
cell	Disease
carcinoma	Disease

Differential	O
effects	O
of	O
gamma-hexachlorocyclohexane	Chemical
(	O
lindane	Chemical
)	O
on	O
pharmacologically-induced	O
seizures	Disease
.	O
Gamma-hexachlorocyclohexane	Chemical
(	O
gamma-HCH	Chemical
),	O
the	O
active	O
ingredient	O
of	O
the	O
insecticide	O
lindane	Chemical
,	O
has	O
been	O
shown	O
to	O
decrease	O
seizure	Disease
threshold	O
to	O
pentylenetrazol	O
(	O
PTZ	Chemical
)	O
3	O
h	O
after	O
exposure	O
to	O
gamma-HCH	Chemical
and	O
conversely	O
increase	O
threshold	O
to	O
PTZ	Chemical
-induced	O
seizures	Disease
24	O
h	O
after	O
exposure	O
to	O
gamma-HCH	Chemical
(Vohland	O
et	O
al.	O
1981).	O
In	O
this	O
study,	O
the	O
severity	O
of	O
response	O
to	O
other	O
seizure	Disease
-inducing	O
agents	O
was	O
tested	O
in	O
mice	O
1	O
and	O
24	O
h	O
after	O
intraperitoneal	O
administration	O
of	O
80	O
mg/kg	O
gamma-HCH	Chemical
.	O
One	O
hour	O
after	O
the	O
administration	O
of	O
gamma-HCH	Chemical
,	O
the	O
activity	O
of	O
seizure	Disease
-inducing	O
agents	O
was	O
increased,	O
regardless	O
of	O
their	O
mechanism,	O
while	O
24	O
h	O
after	O
gamma-HCH	Chemical
a	O
differential	O
response	O
was	O
observed.	O
Seizure	Disease
activity	O
due	O
to	O
PTZ	Chemical
and	O
picrotoxin	Chemical
(	O
PTX	Chemical
)	O
was	O
significantly	O
decreased;	O
however,	O
seizure	Disease
activity	O
due	O
to	O
3-mercaptopropionic	Chemical
acid	Chemical
(	O
MPA	Chemical
),	O
bicuculline	Chemical
(	O
BCC	Chemical
),	O
methyl	Chemical
6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate	Chemical
(	O
DMCM	Chemical
),	O
or	O
strychnine	Chemical
(	O
STR	Chemical
)	O
was	O
not	O
different	O
from	O
control.	O
In	O
vitro,	O
gamma-HCH	Chemical
,	O
pentylenetetrazol	Chemical
and	O
picrotoxin	Chemical
were	O
shown	O
to	O
inhibit	O
3H-TBOB	Chemical
binding	O
in	O
mouse	O
whole	O
brain,	O
with	O
IC50	O
values	O
of	O
4.6,	O
404	O
and	O
9.4	O
microM,	O
respectively.	O
MPA	Chemical
,	O
BCC	Chemical
,	O
DMCM	Chemical
,	O
and	O
STR	Chemical
showed	O
no	O
inhibition	O
of	O
3H-TBOB	Chemical
(	O
t-butyl	Chemical
bicyclo-orthobenzoate	Chemical
)	O
binding	O
at	O
concentrations	O
of	O
100	O
micron.	O
The	O
pharmacological	O
challenge	O
data	O
suggest	O
that	O
tolerance	O
may	O
occur	O
to	O
seizure	Disease
activity	O
induced	O
by	O
PTZ	Chemical
and	O
PTX	Chemical
24	O
h	O
after	O
gamma-HCH	Chemical
,	O
since	O
the	O
response	O
to	O
only	O
these	O
two	O
seizure	Disease
-inducing	O
agents	O
is	O
decreased.	O
The	O
in	O
vitro	O
data	O
suggest	O
that	O
the	O
site	O
responsible	O
for	O
the	O
decrease	O
in	O
seizure	Disease
activity	O
24	O
h	O
after	O
gamma-HCH	Chemical
may	O
be	O
the	O
GABA	Chemical

Severe	O
ocular	Disease
and	Disease
orbital	Disease
toxicity	Disease
after	O
intracarotid	O
injection	O
of	O
carboplatin	Chemical
for	O
recurrent	O
glioblastomas	Disease
.	O
BACKGROUND:	O
Glioblastoma	Disease
is	O
a	O
malignant	Disease
tumor	Disease
that	O
occurs	O
in	O
the	O
cerebrum	O
during	O
adulthood.	O
With	O
current	O
treatment	O
regimens	O
including	O
combined	O
surgery,	O
radiation	O
and	O
chemotherapy,	O
the	O
average	O
life	O
expectancy	O
of	O
the	O
patients	O
is	O
limited	O
to	O
approximately	O
1	O
year.	O
Therefore,	O
patients	O
with	O
glioblastoma	Disease
sometimes	O
have	O
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen.	O
Generally,	O
carboplatin	Chemical
is	O
said	O
to	O
have	O
milder	O
side	O
effects	O
than	O
cisplatin	Chemical
,	O
whose	O
ocular	Disease
and	Disease
orbital	Disease
toxicity	Disease
are	O
well	O
known.	O
However,	O
we	O
experienced	O
a	O
case	O
of	O
severe	O
ocular	Disease
and	Disease
orbital	Disease
toxicity	Disease
after	O
intracarotid	O
injection	O
of	O
carboplatin	Chemical
,	O
which	O
is	O
infrequently	O
reported.	O
CASE:	O
A	O
58-year-old	O
man	O
received	O
an	O
intracarotid	O
injection	O
of	O
carboplatin	Chemical
for	O
recurrent	O
glioblastomas	Disease
in	O
his	O
left	O
temporal	O
lobe.	O
He	O
complained	O
of	O
pain	Disease
and	Disease
visual	Disease
disturbance	Disease
in	Disease
the	Disease
ipsilateral	Disease
eye	Disease
30	O
h	O
after	O
the	O
injection.	O
Various	O
ocular	O
symptoms	O
and	O
findings	O
caused	O
by	O
carboplatin	Chemical
	O
toxicity	Disease
were	O
seen.	O
RESULTS:	O
He	O
was	O
treated	O
with	O
intravenous	O
administration	O
of	O
corticosteroids	O
and	O
glycerin	Chemical
for	O
6	O
days	O
after	O
the	O
injection.	O
Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	O
angle-closure	O
glaucoma	Disease
decreased	O
and	O
ocular	Disease
pain	Disease
diminished,	O
inexorable	O
papilledema	Disease
and	O
exudative	O
retinal	Disease
detachment	Disease
continued	O
for	O
3	O
weeks.	O
Finally,	O
6	O
weeks	O
later,	O
diffuse	O
chorioretinal	Disease
atrophy	Disease
with	O
optic	Disease
atrophy	Disease
occurred	O
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost.	O
CONCLUSION:	O
When	O
performing	O
intracarotid	O
injection	O
of	O
carboplatin	Chemical
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	O
ocular	Disease
toxicity	Disease

Phase	O
II	O
study	O
of	O
the	O
amsacrine	Chemical
analogue	O
CI-921	Chemical
(	O
NSC	Chemical
343499	Chemical
)	O
in	O
non-small	Disease
cell	Disease
lung	Disease
cancer	Disease
.	O
CI-921	Chemical
(	O
NSC	Chemical
343499	Chemical
;	O
9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino]	Chemical
-N,5-dimethyl-	Chemical
4-acridinecarboxamide	Chemical
)	O
is	O
a	O
topoisomerase	O
II	O
poison	O
with	O
high	O
experimental	O
antitumour	O
activity.	O
It	O
was	O
administered	O
by	O
15	O
min	O
infusion	O
to	O
16	O
evaluable	O
patients	O
with	O
non-small	Disease
cell	Disease
lung	Disease
cancer	Disease
(	O
NSCLC	Disease
)	O
(7	O
with	O
no	O
prior	O
treatment,	O
9	O
patients	O
in	O
relapse	O
following	O
surgery/radiotherapy)	O
at	O
a	O
dose	O
(648	O
mg/m2	O
divided	O
over	O
3	O
days,	O
repeated	O
every	O
3	O
weeks)	O
determined	O
by	O
phase	O
I	O
trial.	O
Patients	O
had	O
a	O
median	O
performance	O
status	O
of	O
1	O
(WHO),	O
and	O
median	O
age	O
of	O
61	O
years.	O
The	O
histology	O
comprised	O
squamous	Disease
carcinoma	Disease
(11),	O
adenocarcinoma	Disease
(1),	O
mixed	O
histology	O
(2),	O
bronchio-alveolar	Disease
carcinoma	Disease
(1)	O
and	O
large	O
cell	O
undifferentiated	Disease
carcinoma	Disease
(1).	O
Neutropenia	Disease
grade	O
greater	O
than	O
or	O
equal	O
to	O
3	O
was	O
seen	O
in	O
15	O
patients,	O
infections	Disease
with	O
recovery	O
in	O
3,	O
and	O
grand	O
mal	O
seizures	Disease
in	O
1	O
patient.	O
Grade	O
less	O
than	O
or	O
equal	O
to	O
2	O
nausea	Disease
and	O
vomiting	Disease
occurred	O
in	O
66%	O
courses	O
and	O
phlebitis	Disease
in	O
the	O
infusion	O
arm	O
in	O
37%.	O
1	O
patient	O
with	O
squamous	Disease
cell	Disease
carcinoma	Disease
achieved	O
a	O
partial	O
response	O
lasting	O
5	O
months.	O
Further	O
testing	O
in	O
this	O
and	O
other	O
tumour	Disease

Alpha-lipoic	Chemical
acid	Chemical
prevents	O
mitochondrial	Disease
damage	Disease
and	O
neurotoxicity	Disease
in	O
experimental	O
chemotherapy	O
neuropathy	Disease
.	O
The	O
study	O
investigates	O
if	O
alpha-lipoic	Chemical
acid	Chemical
is	O
neuroprotective	O
against	O
chemotherapy	O
induced	O
neurotoxicity	Disease
,	O
if	O
mitochondrial	Disease
damage	Disease
plays	O
a	O
critical	O
role	O
in	O
toxic	Disease
neurodegenerative	Disease
cascade	Disease
,	O
and	O
if	O
neuroprotective	O
effects	O
of	O
alpha-lipoic	Chemical
acid	Chemical
depend	O
on	O
mitochondria	O
protection.	O
We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	Disease
neuropathy	Disease
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(DRG)	O
sensory	O
neurons	O
to	O
paclitaxel	Chemical
and	O
cisplatin	Chemical
,	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs.	O
This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	O
of	O
alpha-lipoic	Chemical
acid	Chemical
in	O
preventing	O
axonal	Disease
damage	Disease
and	O
apoptosis	O
and	O
the	O
function	O
and	O
ultrastructural	O
morphology	O
of	O
mitochondria	O
after	O
exposure	O
to	O
toxic	O
agents	O
and	O
alpha-lipoic	Chemical
acid	Chemical
.	O
Our	O
results	O
demonstrate	O
that	O
both	O
cisplatin	Chemical
and	O
paclitaxel	Chemical
cause	O
early	O
mitochondrial	Disease
impairment	Disease
with	O
loss	O
of	O
membrane	O
potential	O
and	O
induction	O
of	O
autophagic	O
vacuoles	O
in	O
neurons.	O
Alpha-lipoic	Chemical
acid	Chemical
exerts	O
neuroprotective	O
effects	O
against	O
chemotherapy	O
induced	O
neurotoxicity	Disease
in	O
sensory	O
neurons:	O
it	O
rescues	O
the	O
mitochondrial	Disease
toxicity	Disease
and	O
induces	O
the	O
expression	O
of	O
frataxin,	O
an	O
essential	O
mitochondrial	O
protein	O
with	O
anti-oxidant	O
and	O
chaperone	O
properties.	O
In	O
conclusion	O
mitochondrial	Disease
toxicity	Disease
is	O
an	O
early	O
common	O
event	O
both	O
in	O
paclitaxel	Chemical
and	O
cisplatin	Chemical
induced	O
neurotoxicity	Disease
.	O
Alpha-lipoic	Chemical
acid	Chemical
protects	O
sensory	O
neurons	O
through	O
its	O
anti-oxidant	O
and	O
mitochondrial	O
regulatory	O
functions,	O
possibly	O
inducing	O
the	O
expression	O
of	O
frataxin.	O
These	O
findings	O
suggest	O
that	O
alpha-lipoic	Chemical
acid	Chemical
might	O
reduce	O
the	O
risk	O
of	O
developing	O
peripheral	Disease
nerve	Disease
toxicity	Disease

Optimising	O
stroke	Disease
prevention	O
in	O
non-valvular	O
atrial	Disease
fibrillation	Disease
.	O
Atrial	Disease
fibrillation	Disease
is	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality.	O
Pooled	O
data	O
from	O
trials	O
comparing	O
antithrombotic	O
treatment	O
with	O
placebo	O
have	O
shown	O
that	O
warfarin	Chemical
reduces	O
the	O
risk	O
of	O
stroke	Disease
by	O
62%,	O
and	O
that	O
aspirin	Chemical
alone	O
reduces	O
the	O
risk	O
by	O
22%.	O
Overall,	O
in	O
high-risk	O
patients,	O
warfarin	Chemical
is	O
superior	O
to	O
aspirin	Chemical
in	O
preventing	O
strokes	Disease
,	O
with	O
a	O
relative	O
risk	O
reduction	O
of	O
36%.	O
Ximelagatran	Chemical
,	O
an	O
oral	O
direct	O
thrombin	O
inhibitor,	O
was	O
found	O
to	O
be	O
as	O
efficient	O
as	O
vitamin	Chemical
K	Chemical
antagonist	O
drugs	O
in	O
the	O
prevention	O
of	O
embolic	Disease
events	Disease
,	O
but	O
has	O
been	O
recently	O
withdrawn	O
because	O
of	O
abnormal	Disease
liver	Disease
function	Disease
tests.	O
The	O
ACTIVE-W	O
(	O
Atrial	Disease
Fibrillation	Disease
	O
Clopidogrel	Chemical
Trial	O
with	O
Irbesartan	Chemical
for	O
Prevention	O
of	O
Vascular	O
Events)	O
study	O
has	O
demonstrated	O
that	O
warfarin	Chemical
is	O
superior	O
to	O
platelet	O
therapy	O
(	O
clopidogrel	Chemical
plus	O
aspirin	Chemical
)	O
in	O
the	O
prevention	O
af	O
embolic	Disease
events	Disease
.	O
Idraparinux	Chemical
,	O
a	O
Factor	O
Xa	O
inhibitor,	O
is	O
being	O
evaluated	O
in	O
patients	O
with	O
atrial	Disease
fibrillation	Disease
.	O
Angiotensin	Chemical
-converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	Chemical
II	Chemical
receptor-blocking	O
drugs	O
hold	O
promise	O
in	O
atrial	Disease
fibrillation	Disease
through	O
cardiac	Disease
remodelling	Disease
.	O
Preliminary	O
studies	O
suggest	O
that	O
statins	Chemical

Interaction	O
of	O
cyclosporin	Chemical
A	Chemical
with	O
antineoplastic	O
agents.	O
A	O
synergistic	O
effect	O
of	O
etoposide	Chemical
and	O
cyclosporin	Chemical
A	Chemical
was	O
observed	O
in	O
a	O
patient	O
with	O
acute	Disease
T-lymphocytic	Disease
leukemia	Disease
in	O
relapse.	O
The	O
concomitant	O
administration	O
of	O
etoposide	Chemical
and	O
cyclosporin	Chemical
A	Chemical
resulted	O
in	O
eradication	O
of	O
hitherto	O
refractory	O
leukemic	Disease
infiltration	Disease
of	O
bone	O
marrow.	O
Severe	O
side	O
effects	O
in	O
terms	O
of	O
mental	O
confusion	Disease
and	O
progressive	O
hyperbilirubinemia	Disease
,	O
however,	O
point	O
to	O
an	O
enhancement	O
not	O
only	O
of	O
antineoplastic	O
effects	O
but	O
also	O
of	O
toxicity	Disease
in	O
normal	O
tissues.	O
This	O
report	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
pharmacodynamic	O
properties	O
of	O
cyclosporin	Chemical
A	Chemical

The	O
hematologic	O
effects	O
of	O
cefonicid	Chemical
and	O
cefazedone	Chemical
in	O
the	O
dog:	O
a	O
potential	O
model	O
of	O
cephalosporin	Chemical
	O
hematotoxicity	Disease
in	O
man.	O
Cephalosporin	Chemical
antibiotics	O
cause	O
a	O
variety	O
of	O
hematologic	Disease
disturbances	Disease
in	O
man,	O
the	O
pathogeneses	O
and	O
hematopathology	O
of	O
which	O
remain	O
poorly	O
characterized.	O
There	O
is	O
a	O
need	O
for	O
a	O
well-defined	O
animal	O
model	O
in	O
which	O
these	O
blood	Disease
dyscrasias	Disease
can	O
be	O
studied.	O
In	O
four	O
subacute	O
toxicity	Disease
studies,	O
the	O
intravenous	O
administration	O
of	O
cefonicid	Chemical
or	O
cefazedone	Chemical
to	O
beagle	O
dogs	O
caused	O
a	O
dose-dependent	O
incidence	O
of	O
anemia	Disease
,	O
neutropenia	Disease
,	O
and	O
thrombocytopenia	Disease
after	O
1-3	O
months	O
of	O
treatment.	O
A	O
nonregenerative	O
anemia	Disease
was	O
the	O
most	O
compromising	O
of	O
the	O
cytopenias	Disease
and	O
occurred	O
in	O
approximately	O
50%	O
of	O
dogs	O
receiving	O
400-500	O
mg/kg	O
cefonicid	Chemical
or	O
540-840	O
mg/kg	O
cefazedone	Chemical
.	O
All	O
three	O
cytopenias	Disease
were	O
completely	O
reversible	O
following	O
cessation	O
of	O
treatment;	O
the	O
time	O
required	O
for	O
recovery	O
of	O
the	O
erythron	O
(approximately	O
1	O
month)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
granulocytes	O
and	O
platelets	O
(hours	O
to	O
a	O
few	O
days).	O
Upon	O
rechallenge	O
with	O
either	O
cephalosporin	Chemical
,	O
the	O
hematologic	Disease
syndrome	Disease
was	O
reproduced	O
in	O
most	O
dogs	O
tested;	O
cefonicid	Chemical
(but	O
not	O
cefazedone	Chemical
)-treated	O
dogs	O
showed	O
a	O
substantially	O
reduced	O
induction	O
period	O
(15	O
+/-	O
5	O
days)	O
compared	O
to	O
that	O
of	O
the	O
first	O
exposure	O
to	O
the	O
drug	O
(61	O
+/-	O
24	O
days).	O
This	O
observation,	O
along	O
with	O
the	O
rapid	O
rate	O
of	O
decline	O
in	O
red	O
cell	O
mass	O
parameters	O
of	O
affected	O
dogs,	O
suggests	O
that	O
a	O
hemolytic	Disease
component	O
complicated	O
the	O
red	O
cell	O
production	O
problem	O
and	O
that	O
multiple	O
toxicologic	O
mechanisms	O
contributed	O
to	O
the	O
cytopenia	Disease
.	O
We	O
conclude	O
that	O
the	O
administration	O
of	O
high	O
doses	O
of	O
cefonicid	Chemical
or	O
cefazedone	Chemical
to	O
dogs	O
can	O
induce	O
hematotoxicity	Disease
similar	O
to	O
the	O
cephalosporin	Chemical
-induced	O
blood	Disease
dyscrasias	Disease

A	O
pyridoxine	Chemical
-dependent	O
behavioral	Disease
disorder	Disease
unmasked	O
by	O
isoniazid	Chemical
.	O
A	O
3-year-old	O
girl	O
had	O
behavioral	Disease
deterioration	Disease
,	O
with	O
hyperkinesis	Disease
,	O
irritability	Disease
,	O
and	O
sleeping	Disease
difficulties	Disease
after	O
the	O
therapeutic	O
administration	O
of	O
isoniazid	Chemical
.	O
The	O
administration	O
of	O
pharmacologic	O
doses	O
of	O
pyridoxine	Chemical
hydrochloride	Chemical
led	O
to	O
a	O
disappearance	O
of	O
symptoms.	O
After	O
discontinuing	O
isoniazid	Chemical
therapy	O
a	O
similar	O
pattern	O
of	O
behavior	O
was	O
noted	O
that	O
was	O
controlled	O
by	O
pyridoxine	Chemical
.	O
A	O
placebo	O
had	O
no	O
effect,	O
but	O
niacinamide	Chemical
was	O
as	O
effective	O
as	O
pyridoxine	Chemical
.	O
Periodic	O
withdrawal	O
of	O
pyridoxine	Chemical
was	O
associated	O
with	O
return	O
of	O
the	O
hyperkinesis	Disease
.	O
The	O
level	O
of	O
pyridoxal	Chemical
in	O
the	O
blood	O
was	O
normal	O
during	O
the	O
periods	O
of	O
relapse.	O
Metabolic	O
studies	O
suggested	O
a	O
block	O
in	O
the	O
kynurenine	Chemical
pathway	O
of	O
tryptophan	Chemical
metabolism.	O
The	O
patient	O
has	O
been	O
followed	O
for	O
six	O
years	O
and	O
has	O
required	O
pharmacologic	O
doses	O
of	O
pyridoxine	Chemical

A	O
selective	O
dopamine	Chemical
D4	O
receptor	O
antagonist,	O
NRA0160	Chemical
:	O
a	O
preclinical	O
neuropharmacological	O
profile.	O
NRA0160	Chemical
,	O
5	Chemical
-	Chemical
[2-	Chemical
(	Chemical
4-	Chemical
(	Chemical
3	Chemical
-	Chemical
fluorobenzylidene)	Chemical
piperidin-1-yl)	Chemical
ethyl]	Chemical
-	Chemical
4	Chemical
-(4-fluorophenyl)	Chemical
thiazole-2-carboxamide	Chemical
,	O
has	O
a	O
high	O
affinity	O
for	O
human	O
cloned	O
dopamine	Chemical
D4.2,	O
D4.4	O
and	O
D4.7	O
receptors,	O
with	O
Ki	O
values	O
of	O
0.5,	O
0.9	O
and	O
2.7	O
nM,	O
respectively.	O
NRA0160	Chemical
is	O
over	O
20,000fold	O
more	O
potent	O
at	O
the	O
dopamine	Chemical
D4.2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	Chemical
D2L	O
receptor.	O
NRA0160	Chemical
has	O
negligible	O
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	Chemical
D3	O
receptor	O
(Ki=39	O
nM),	O
rat	O
serotonin	Chemical
(	O
5-HT	Chemical
)2A	O
receptors	O
(Ki=180	O
nM)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(Ki=237	O
nM).	O
NRA0160	Chemical
and	O
clozapine	Chemical
antagonized	O
locomotor	O
hyperactivity	Disease
induced	O
by	O
methamphetamine	Chemical
(	O
MAP	Chemical
)	O
in	O
mice.	O
NRA0160	Chemical
and	O
clozapine	Chemical
antagonized	O
MAP	Chemical
-induced	O
stereotyped	O
behavior	O
in	O
mice,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50%	O
inhibition,	O
even	O
at	O
the	O
highest	O
dose	O
given.	O
NRA0160	Chemical
and	O
clozapine	Chemical
significantly	O
induced	O
catalepsy	Disease
in	O
rats,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50%	O
induction	O
even	O
at	O
the	O
highest	O
dose	O
given.	O
NRA0160	Chemical
and	O
clozapine	Chemical
significantly	O
reversed	O
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(PPI)	O
in	O
rats	O
produced	O
by	O
apomorphine	Chemical
.	O
NRA0160	Chemical
and	O
clozapine	Chemical
significantly	O
shortened	O
the	O
phencyclidine	Chemical
(	O
PCP	Chemical
)-induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task.	O
These	O
findings	O
suggest	O
that	O
NRA0160	Chemical

Prolonged	O
cholestasis	Disease
after	O
troleandomycin	Chemical
-induced	O
acute	O
hepatitis	Disease
.	O
We	O
report	O
the	O
case	O
of	O
a	O
patient	O
in	O
whom	O
troleandomycin	Chemical
-induced	O
hepatitis	Disease
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	Disease
.	O
Jaundice	Disease
occurred	O
after	O
administration	O
of	O
troleandomycin	Chemical
for	O
7	O
days	O
and	O
was	O
associated	O
with	O
hypereosinophilia	Disease
.	O
Jaundice	Disease
disappeared	O
within	O
3	O
months	O
but	O
was	O
followed	O
by	O
prolonged	O
anicteric	O
cholestasis	Disease
marked	O
by	O
pruritus	Disease
and	O
high	O
levels	O
of	O
alkaline	O
phosphatase	O
and	O
gammaglutamyltransferase	O
activities.	O
Finally,	O
pruritus	Disease
disappeared	O
within	O
19	O
months,	O
and	O
liver	O
tests	O
returned	O
to	O
normal	O
27	O
months	O
after	O
the	O
onset	O
of	O
hepatitis	Disease
.	O
This	O
observation	O
demonstrates	O
that	O
prolonged	O
cholestasis	Disease
can	O
follow	O
troleandomycin	Chemical
-induced	O
acute	O
hepatitis	Disease

HMG	O
CoA	O
reductase	O
inhibitors.	O
Current	O
clinical	O
experience.	O
Lovastatin	Chemical
and	O
simvastatin	Chemical
are	O
the	O
2	O
best-known	O
members	O
of	O
the	O
class	O
of	O
hypolipidaemic	O
agents	O
known	O
as	O
HMG	O
CoA	O
reductase	O
inhibitors.	O
Clinical	O
experience	O
with	O
lovastatin	Chemical
includes	O
over	O
5000	O
patients,	O
700	O
of	O
whom	O
have	O
been	O
treated	O
for	O
2	O
years	O
or	O
more,	O
and	O
experience	O
with	O
simvastatin	Chemical
includes	O
over	O
3500	O
patients,	O
of	O
whom	O
350	O
have	O
been	O
treated	O
for	O
18	O
months	O
or	O
more.	O
Lovastatin	Chemical
has	O
been	O
marketed	O
in	O
the	O
United	O
States	O
for	O
over	O
6	O
months.	O
Both	O
agents	O
show	O
substantial	O
clinical	O
efficacy,	O
with	O
reductions	O
in	O
total	O
cholesterol	Chemical
of	O
over	O
30%	O
and	O
in	O
LDL-	O
cholesterol	Chemical
of	O
40%	O
in	O
clinical	O
studies.	O
Modest	O
increases	O
in	O
HDL-	O
cholesterol	Chemical
levels	O
of	O
about	O
10%	O
are	O
also	O
reported.	O
Clinical	O
tolerability	O
of	O
both	O
agents	O
has	O
been	O
good,	O
with	O
fewer	O
than	O
3%	O
of	O
patients	O
withdrawn	O
from	O
treatment	O
because	O
of	O
clinical	O
adverse	O
experiences.	O
Ophthalmological	O
examinations	O
in	O
over	O
1100	O
patients	O
treated	O
with	O
one	O
or	O
the	O
other	O
agent	O
have	O
revealed	O
no	O
evidence	O
of	O
significant	O
short	O
term	O
(up	O
to	O
2	O
years)	O
cataractogenic	O
potential.	O
One	O
to	O
2%	O
of	O
patients	O
have	O
elevations	O
of	O
serum	O
transaminases	O
to	O
greater	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal.	O
These	O
episodes	O
are	O
asymptomatic	O
and	O
reversible	O
when	O
therapy	O
is	O
discontinued.	O
Minor	O
elevations	O
of	O
creatine	Chemical
kinase	O
levels	O
are	O
reported	O
in	O
about	O
5%	O
of	O
patients.	O
Myopathy	Disease
,	O
associated	O
in	O
some	O
cases	O
with	O
myoglobinuria	Disease
,	O
and	O
in	O
2	O
cases	O
with	O
transient	O
renal	Disease
failure	Disease
,	O
has	O
been	O
rarely	O
reported	O
with	O
lovastatin	Chemical
,	O
especially	O
in	O
patients	O
concomitantly	O
treated	O
with	O
cyclosporin	Chemical
,	O
gemfibrozil	Chemical
or	O
niacin	Chemical
.	O
Lovastatin	Chemical
and	O
simvastatin	Chemical
are	O
both	O
effective	O
and	O
well-tolerated	O
agents	O
for	O
lowering	O
elevated	O
levels	O
of	O
serum	O
cholesterol	Chemical
.	O
As	O
wider	O
use	O
confirms	O
their	O
safety	O
profile,	O
they	O
will	O
gain	O
increasing	O
importance	O
in	O
the	O
therapeutic	O
approach	O
to	O
hypercholesterolaemia	Disease

Sulfasalazine	Chemical
-induced	O
lupus	Disease
erythematosus	Disease
.	O
Pneumonitis	Disease
,	O
bilateral	O
pleural	Disease
effusions	Disease
,	O
echocardiographic	O
evidence	O
of	O
cardiac	Disease
tamponade	Disease
,	O
and	O
positive	O
autoantibodies	O
developed	O
in	O
a	O
43-year-old	O
man,	O
who	O
was	O
receiving	O
long-term	O
sulfasalazine	Chemical
therapy	O
for	O
chronic	O
ulcerative	Disease
colitis	Disease
.	O
After	O
cessation	O
of	O
the	O
sulfasalazine	Chemical
and	O
completion	O
of	O
a	O
six-week	O
course	O
of	O
corticosteroids,	O
these	O
problems	O
resolved	O
over	O
a	O
period	O
of	O
four	O
to	O
six	O
months.	O
It	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine	Chemical
-induced	O
lupus	Disease
,	O
which	O
manifested	O
with	O
serositis	Disease
and	O
pulmonary	O
parenchymal	O
involvement	O
in	O
the	O
absence	O
of	O
joint	O
symptoms.	O
Physicians	O
who	O
use	O
sulfasalazine	Chemical
to	O
treat	O
patients	O
with	O
inflammatory	Disease
bowel	Disease
disease	Disease
should	O
be	O
aware	O
of	O
the	O
signs	O
of	O
sulfasalazine	Chemical
-induced	O
lupus	Disease
syndrome	Disease

Optimization	O
of	O
levodopa	Chemical
therapy.	O
While	O
there	O
is	O
no	O
single	O
correct	O
starting	O
dose	O
for	O
levodopa	Chemical
therapy,	O
many	O
individuals	O
can	O
be	O
started	O
on	O
either	O
the	O
25/100	O
or	O
controlled-release	O
formula,	O
following	O
the	O
general	O
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidopa	Chemical
-	O
levodopa	Chemical
to	O
the	O
point	O
of	O
"normality,"	O
which	O
can	O
lead	O
to	O
toxicity	Disease
.	O
The	O
physician	O
should	O
also	O
determine	O
the	O
proper	O
use	O
of	O
any	O
adjunctive	O
medications;	O
such	O
combined	O
therapy	O
has	O
become	O
the	O
standard	O
approach	O
to	O
treatment.	O
Following	O
the	O
initial	O
period	O
of	O
therapy,	O
emerging	O
difficulties	O
require	O
a	O
reassessment	O
of	O
therapeutic	O
approaches,	O
such	O
as	O
dosage	O
adjustment	O
or	O
introduction	O
of	O
a	O
dopamine	Chemical
agonist.	O
Other	O
possible	O
adverse	O
effects--such	O
as	O
gastrointestinal	Disease
disorders	Disease
,	O
orthostatic	Disease
hypotension	Disease
,	O
levodopa	Chemical
-induced	O
psychosis	Disease
,	O
sleep	Disease
disturbances	Disease
or	O
parasomnias	Disease
,	O
or	O
drug	O
interactions--also	O
require	O
carefully	O
monitored	O
individual	O
treatment.	O
Nonpharmacologic	O
concerns	O
can	O
help	O
the	O
Parkinson's	Disease
disease	Disease

Alpha	O
and	O
beta	O
coma	Disease
in	O
drug	O
intoxication	O
uncomplicated	O
by	O
cerebral	Disease
hypoxia	Disease
.	O
Four	O
patients	O
who	O
were	O
rendered	O
comatose	Disease
or	O
stuporous	Disease
by	O
drug	O
intoxication,	O
but	O
who	O
were	O
not	O
hypoxic,	O
are	O
described.	O
Three	O
patients	O
received	O
high	O
doses	O
of	O
chlormethiazole	Chemical
for	O
alcohol	Chemical
	O
withdrawal	Disease
symptoms	Disease
,	O
and	O
one	O
took	O
a	O
suicidal	O
overdose	Disease
of	O
nitrazepam	Chemical
.	O
The	O
patient	O
with	O
nitrazepam	Chemical
	O
overdose	Disease
and	O
two	O
of	O
those	O
with	O
chlormethiazole	Chemical
intoxication	O
conformed	O
to	O
the	O
criteria	O
of	O
'alpha	O
coma	Disease
',	O
showing	O
non-reactive	O
generalized	O
or	O
frontally	O
predominant	O
alpha	O
activity	O
in	O
the	O
EEG.	O
The	O
fourth	O
patient	O
who	O
was	O
unconscious	O
after	O
chlormethiazole	Chemical
administration	O
exhibite	O
generalized	O
non-reactive	O
activity	O
in	O
the	O
slow	O
beta	O
range.	O
All	O
four	O
recovered	O
completely	O
without	O
neurological	Disease
sequelae	Disease
following	O
the	O
withdrawal	O
of	O
the	O
offending	O
agents.	O
The	O
similarities	O
between	O
the	O
effects	O
of	O
structural	O
lesions	O
and	O
pharmacological	O
depression	Disease
of	O
the	O
brain	O
stem	O
reticular	O
formation	O
are	O
discussed.	O
It	O
is	O
suggested	O
that	O
in	O
both	O
situations	O
disturbed	O
reticulo-thalamic	O
interactions	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
alpha	O
coma	Disease
.	O
It	O
is	O
concluded	O
that	O
when	O
this	O
electroencephalographic	O
and	O
behavioural	O
picture	O
is	O
seen	O
in	O
drug	O
intoxication,	O
in	O
the	O
absence	O
of	O
significant	O
hypoxaemia	Disease

Omitting	O
fentanyl	Chemical
reduces	O
nausea	Disease
and	O
vomiting	Disease
,	O
without	O
increasing	O
pain	Disease
,	O
after	O
sevoflurane	Chemical
for	O
day	O
surgery.	O
BACKGROUND	O
AND	O
OBJECTIVE:	O
Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	Chemical
,	O
postoperative	Disease
nausea	Disease
and	Disease
vomiting	Disease
occurs	O
frequently.	O
Fentanyl	Chemical
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this,	O
although	O
it	O
may	O
also	O
improve	O
analgesia.	O
METHODS:	O
This	O
double-blind	O
study	O
examined	O
the	O
incidence	O
and	O
severity	O
of	O
postoperative	Disease
nausea	Disease
and	Disease
vomiting	Disease
and	O
pain	Disease
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	Chemical
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients.	O
Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	Chemical
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	Chemical
in	O
addition	O
to	O
fentanyl	Chemical
.	O
RESULTS:	O
Omission	O
of	O
fentanyl	Chemical
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	Disease
nausea	Disease
and	Disease
vomiting	Disease
,	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	Disease
and/or	O
moderate	O
to	O
severe	O
nausea	Disease
prior	O
to	O
discharge	O
from	O
20%	O
and	O
17%	O
with	O
fentanyl	Chemical
and	O
fentanyl	Chemical
-	O
dexamethasone	Chemical
,	O
respectively,	O
to	O
5%	O
(P	O
=	O
0.013).	O
Antiemetic	O
requirements	O
were	O
reduced	O
from	O
24%	O
and	O
31%	O
to	O
7%	O
(P	O
=	O
0.0012).	O
Dexamethasone	Chemical
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	Disease
nausea	Disease
and	Disease
vomiting	Disease
.	O
Combining	O
the	O
two	O
fentanyl	Chemical
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids,	O
reducing	O
postoperative	Disease
nausea	Disease
and	Disease
vomiting	Disease
and	O
nausea	Disease
prior	O
to	O
discharge	O
from	O
35%	O
and	O
33%	O
to	O
22%	O
and	O
19%	O
(P	O
=	O
0.049	O
and	O
P	O
=	O
0.035),	O
respectively,	O
while	O
nausea	Disease
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42%	O
to	O
27%	O
(P	O
=	O
0.034).	O
Pain	Disease
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	Chemical
.	O
Fentanyl	Chemical
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane	Chemical
-sparing	O
effect	O
and	O
increased	O
respiratory	Disease
depression	Disease
,	O
hypotension	Disease
and	O
bradycardia	Disease
.	O
CONCLUSION:	O
As	O
fentanyl	Chemical
exacerbated	O
postoperative	Disease
nausea	Disease
and	Disease
vomiting	Disease
without	O
an	O
improvement	O
in	O
postoperative	Disease
pain	Disease
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	Chemical

Renal	Disease
Fanconi	Disease
syndrome	Disease
and	O
myopathy	Disease
after	O
liver	O
transplantation:	O
drug-related	O
mitochondrial	Disease
cytopathy	Disease
?	O
Advances	O
in	O
the	O
field	O
of	O
transplantation	O
provide	O
a	O
better	O
quality	O
of	O
life	O
and	O
allow	O
more	O
favorable	O
conditions	O
for	O
growth	O
and	O
development	O
in	O
children.	O
However,	O
combinations	O
of	O
different	O
therapeutic	O
regimens	O
require	O
consideration	O
of	O
potential	O
adverse	O
reactions.	O
We	O
describe	O
a	O
15-yr-old	O
girl	O
who	O
had	O
orthotopic	O
liver	O
transplantation	O
because	O
of	O
Wilson's	Disease
disease	Disease
.	O
Tacrolimus	Chemical
,	O
MMF	Chemical
,	O
and	O
steroids	Chemical
were	O
given	O
as	O
immunosuppressant.	O
Lamivudine	Chemical
was	O
added	O
because	O
of	O
de	O
nova	O
hepatitis	Disease
B	Disease
infection	Disease
during	O
her	O
follow-up.	O
Three	O
yr	O
after	O
transplantation	O
she	O
developed	O
renal	Disease
Fanconi	Disease
syndrome	Disease
with	O
severe	O
metabolic	Disease
acidosis	Disease
,	O
hypophosphatemia	Disease
,	O
glycosuria	Disease
,	O
and	O
aminoaciduria	Disease
.	O
Although	O
tacrolimus	Chemical
was	O
suspected	O
to	O
be	O
the	O
cause	O
of	O
late	O
post-transplant	O
renal	O
acidosis	Disease
and	O
was	O
replaced	O
by	O
sirolimus	Chemical
,	O
acidosis	Disease
,	O
and	O
electrolyte	O
imbalance	O
got	O
worse.	O
Proximal	O
muscle	Disease
weakness	Disease
has	O
developed	O
during	O
her	O
follow-up.	O
Fanconi	Disease
syndrome	Disease
,	O
as	O
well	O
as	O
myopathy	Disease
,	O
is	O
well	O
recognized	O
in	O
patients	O
with	O
mitochondrial	Disease
disorders	Disease
and	O
caused	O
by	O
depletion	O
of	O
mtDNA.	O
We	O
suggest	O
that	O
our	O
patient's	O
tubular	Disease
dysfunction	Disease
and	O
myopathy	Disease
may	O
have	O
resulted	O
from	O
mitochondrial	Disease
dysfunction	Disease
which	O
is	O
triggered	O
by	O
tacrolimus	Chemical
and	O
augmented	O
by	O
lamivudine	Chemical

Antipsychotic-like	O
profile	O
of	O
thioperamide	Chemical
,	O
a	O
selective	O
H3-receptor	O
antagonist	O
in	O
mice.	O
Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	Disease
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
study	O
the	O
effect	O
of	O
histamine	Chemical
H(3)-receptor	O
ligands	O
on	O
neuroleptic-induced	O
catalepsy	Disease
,	O
apomorphine	Chemical
-induced	O
climbing	O
behavior	O
and	O
amphetamine	Chemical
-induced	O
locomotor	O
activities	O
in	O
mice.	O
Catalepsy	Disease
was	O
induced	O
by	O
haloperidol	Chemical
(2	O
mg/kg	O
p.o.),	O
while	O
apomorphine	Chemical
(1.5	O
mg/kg	O
s.c.)	O
and	O
amphetamine	Chemical
(2	O
mg/kg	O
s.c.)	O
were	O
used	O
for	O
studying	O
climbing	O
behavior	O
and	O
locomotor	O
activities,	O
respectively.	O
(R)-alpha-methylhistamine	Chemical
(	O
RAMH	Chemical
)	O
(5	O
microg	O
i.c.v.)	O
and	O
thioperamide	Chemical
(	O
THP	Chemical
)	O
(15	O
mg/kg	O
i.p.),	O
per	O
se	O
did	O
not	O
cause	O
catalepsy	Disease
.	O
Administration	O
of	O
THP	Chemical
(3.75,	O
7.5	O
and	O
15	O
mg/kg	O
i.p.)	O
1	O
h	O
prior	O
to	O
haloperidol	Chemical
resulted	O
in	O
a	O
dose-dependent	O
increase	O
in	O
the	O
catalepsy	Disease
times	O
(P	O
<	O
0.05).	O
However,	O
pretreatment	O
with	O
RAMH	Chemical
significantly	O
reversed	O
such	O
an	O
effect	O
of	O
THP	Chemical
(15	O
mg/kg	O
i.p.).	O
RAMH	Chemical
per	O
se	O
showed	O
significant	O
reduction	O
in	O
locomotor	O
time,	O
distance	O
traveled	O
and	O
average	O
speed	O
but	O
THP	Chemical
(15	O
mg/kg	O
i.p.)	O
per	O
se	O
had	O
no	O
effect	O
on	O
these	O
parameters.	O
On	O
amphetamine	Chemical
-induced	O
hyperactivity	Disease
,	O
THP	Chemical
(3.75	O
and	O
7.5	O
mg/kg	O
i.p.)	O
reduced	O
locomotor	O
time,	O
distance	O
traveled	O
and	O
average	O
speed	O
(P	O
<	O
0.05).	O
Pretreatment	O
with	O
RAMH	Chemical
(5	O
microg	O
i.c.v.)	O
could	O
partially	O
reverse	O
such	O
effects	O
of	O
THP	Chemical
(3.75	O
mg/kg	O
i.p.).	O
Climbing	O
behavior	O
induced	O
by	O
apomorphine	Chemical
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	Chemical
.	O
Such	O
an	O
effect	O
was,	O
however,	O
reversed	O
in	O
presence	O
of	O
RAMH	Chemical
.	O
THP	Chemical
exhibited	O
an	O
antipsychotic-like	O
profile	O
by	O
potentiating	O
haloperidol	Chemical
-induced	O
catalepsy	Disease
,	O
reducing	O
amphetamine	Chemical
-induced	O
hyperactivity	Disease
and	O
reducing	O
apomorphine	Chemical
-induced	O
climbing	O
in	O
mice.	O
Such	O
effects	O
of	O
THP	Chemical
were	O
reversed	O
by	O
RAMH	Chemical
indicating	O
the	O
involvement	O
of	O
histamine	Chemical
H(3)-receptors.	O
Findings	O
suggest	O
a	O
potential	O
for	O
H(3)-receptor	O
antagonists	O
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	Disease

Transient	O
platypnea-orthodeoxia-like	Disease
syndrome	Disease
induced	O
by	O
propafenone	Chemical
	O
overdose	Disease
in	O
a	O
young	O
woman	O
with	O
Ebstein's	Disease
anomaly	Disease
.	O
In	O
this	O
report	O
we	O
describe	O
the	O
case	O
of	O
a	O
37-year-old	O
white	O
woman	O
with	O
Ebstein's	Disease
anomaly	Disease
,	O
who	O
developed	O
a	O
rare	O
syndrome	O
called	O
platypnea-orthodeoxia	Disease
,	O
characterized	O
by	O
massive	O
right-to-left	O
interatrial	O
shunting	O
with	O
transient	O
profound	O
hypoxia	Disease
and	O
cyanosis	Disease
.	O
This	O
shunt	O
of	O
blood	O
via	O
a	O
patent	Disease
foramen	Disease
ovale	Disease
occurred	O
in	O
the	O
presence	O
of	O
a	O
normal	O
pulmonary	O
artery	O
pressure,	O
and	O
was	O
probably	O
precipitated	O
by	O
a	O
propafenone	Chemical
	O
overdose	Disease
.	O
This	O
drug	O
caused	O
biventricular	Disease
dysfunction	Disease
,	O
due	O
to	O
its	O
negative	O
inotropic	O
effect,	O
and	O
hypotension	Disease

A	O
Phase	O
II	O
trial	O
of	O
cisplatin	Chemical
plus	O
WR-2721	Chemical
(	O
amifostine	Chemical
)	O
for	O
metastatic	O
breast	Disease
carcinoma	Disease
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(E8188).	O
BACKGROUND:	O
Cisplatin	Chemical
has	O
minimal	O
antitumor	O
activity	O
when	O
used	O
as	O
second-	O
or	O
third-line	O
treatment	O
of	O
metastatic	O
breast	Disease
carcinoma	Disease
.	O
Older	O
reports	O
suggest	O
an	O
objective	O
response	O
rate	O
of	O
8%	O
when	O
60-120	O
mg/m2	O
of	O
cisplatin	Chemical
is	O
administered	O
every	O
3-4	O
weeks.	O
Although	O
a	O
dose-response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	Chemical
,	O
the	O
dose-limiting	O
toxicities	Disease
associated	O
with	O
cisplatin	Chemical
(e.g.,	O
nephrotoxicity	Disease
,	O
ototoxicity	Disease
,	O
and	O
neurotoxicity	Disease
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	Disease
carcinoma	Disease
.	O
WR-2721	Chemical
or	O
amifostine	Chemical
initially	O
was	O
developed	O
to	O
protect	O
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war.	O
Amifostine	Chemical
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	O
effects	O
of	O
alkylating	Chemical
agents	Chemical
and	O
cisplatin	Chemical
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy.	O
Early	O
trials	O
of	O
cisplatin	Chemical
and	O
amifostine	Chemical
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	Chemical
-induced	O
nephrotoxicity	Disease
,	O
ototoxicity	Disease
,	O
and	O
neuropathy	Disease
were	O
reduced.	O
METHODS:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	O
of	O
cisplatin	Chemical
plus	O
amifostine	Chemical
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
metastatic	O
breast	Disease
carcinoma	Disease
who	O
had	O
received	O
one,	O
but	O
not	O
more	O
than	O
one,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease.	O
Patients	O
received	O
amifostine	Chemical
,	O
910	O
mg/m2	O
intravenously	O
over	O
15	O
minutes.	O
After	O
completion	O
of	O
the	O
amifostine	Chemical
infusion,	O
cisplatin	Chemical
120	O
mg/m2	O
was	O
administered	O
over	O
30	O
minutes.	O
Intravenous	O
hydration	O
and	O
mannitol	Chemical
was	O
administered	O
before	O
and	O
after	O
cisplatin	Chemical
.	O
Treatment	O
was	O
administered	O
every	O
3	O
weeks	O
until	O
disease	O
progression.	O
RESULTS:	O
Forty-four	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
of	O
which	O
7	O
(16%)	O
were	O
ineligible.	O
A	O
median	O
of	O
2	O
cycles	O
of	O
therapy	O
was	O
administered	O
to	O
the	O
37	O
eligible	O
patients.	O
Six	O
partial	O
responses	O
were	O
observed	O
for	O
an	O
overall	O
response	O
rate	O
of	O
16%.	O
Most	O
patients	O
(57%)	O
stopped	O
treatment	O
because	O
of	O
disease	O
progression.	O
Neurologic	Disease
toxicity	Disease
was	O
reported	O
in	O
52%	O
of	O
patients.	O
Seven	O
different	O
life-threatening	O
toxicities	Disease
were	O
observed	O
in	O
patients	O
while	O
receiving	O
treatment.	O
CONCLUSIONS:	O
The	O
combination	O
of	O
cisplatin	Chemical
and	O
amifostine	Chemical
in	O
this	O
study	O
resulted	O
in	O
an	O
overall	O
response	O
rate	O
of	O
16%.	O
Neither	O
a	O
tumor	Disease
-protective	O
effect	O
nor	O
reduced	O
toxicity	Disease
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifostine	Chemical
to	O
cisplatin	Chemical

Warfarin	Chemical
-induced	O
iliopsoas	O
hemorrhage	Disease
with	O
subsequent	O
femoral	Disease
nerve	Disease
palsy	Disease
.	O
We	O
present	O
the	O
case	O
of	O
a	O
28-year-old	O
man	O
on	O
chronic	O
warfarin	Chemical
therapy	O
who	O
sustained	O
a	O
minor	O
muscle	Disease
tear	Disease
and	O
developed	O
increasing	O
pain	Disease
and	O
a	O
flexure	O
contracture	Disease
of	O
the	O
right	O
hip.	O
Surgical	O
exploration	O
revealed	O
an	O
iliopsoas	O
hematoma	Disease
and	O
femoral	O
nerve	Disease
entrapment	Disease
,	O
resulting	O
in	O
a	O
femoral	Disease
nerve	Disease
palsy	Disease
and	O
partial	Disease
loss	Disease
of	Disease
quadriceps	Disease
functions	Disease
.	O
Anticoagulant-induced	O
femoral	Disease
nerve	Disease
palsy	Disease
represents	O
the	O
most	O
common	O
form	O
of	O
warfarin	Chemical
-induced	O
peripheral	Disease
neuropathy	Disease
;	O
it	O
is	O
characterized	O
by	O
severe	O
pain	Disease
in	O
the	O
inguinal	O
region,	O
varying	O
degrees	O
of	O
motor	Disease
and	Disease
sensory	Disease
impairment	Disease
,	O
and	O
flexure	O
contracture	Disease

Myasthenia	Disease
gravis	Disease
caused	O
by	O
penicillamine	Chemical
and	O
chloroquine	Chemical
therapy	O
for	O
rheumatoid	Disease
arthritis	Disease
.	O
We	O
have	O
described	O
a	O
unique	O
patient	O
who	O
had	O
reversible	O
and	O
dose-related	O
myasthenia	Disease
gravis	Disease
after	O
penicillamine	Chemical
and	O
chloroquine	Chemical
therapy	O
for	O
rheumatoid	Disease
arthritis	Disease
.	O
Although	O
acetylcholine	Chemical

Nephrotoxicity	Disease
of	O
combined	O
cephalothin	Chemical
-	O
gentamicin	Chemical
regimen.	O
Two	O
patients	O
developed	O
acute	Disease
tubular	Disease
necrosis	Disease
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	Disease
renal	Disease
failure	Disease
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	O
of	O
cephalothin	Chemical
sodium	Chemical
and	O
gentamicin	Chemical
sulfate	Chemical
therapy.	O
Patients	O
who	O
are	O
given	O
this	O
drug	O
regimen	O
should	O
be	O
observed	O
very	O
carefully	O
for	O
early	O
signs	O
of	O
nephrotoxicity	Disease
.	O
High	O
doses	O
of	O
this	O
antibiotic	O
combination	O
should	O
be	O
avoided	O
especially	O
in	O
elderly	O
patients.	O
Patients	O
with	O
renal	Disease
insufficiency	Disease

Components	O
of	O
lemon	O
essential	O
oil	O
attenuate	O
dementia	Disease
induced	O
by	O
scopolamine	Chemical
.	O
The	O
anti-	O
dementia	Disease
effects	O
of	O
s-limonene	Chemical
and	O
s-perillyl	Chemical
alcohol	Chemical
were	O
observed	O
using	O
the	O
passive	O
avoidance	O
test	O
(PA)	O
and	O
the	O
open	O
field	O
habituation	O
test	O
(OFH).	O
These	O
lemon	O
essential	O
oils	O
showed	O
strong	O
ability	O
to	O
improve	O
memory	Disease
impaired	Disease
by	O
scopolamine	Chemical
;	O
however,	O
s-perillyl	Chemical
alcohol	Chemical
relieved	O
the	O
deficit	Disease
of	Disease
associative	Disease
memory	Disease
in	O
PA	O
only,	O
and	O
did	O
not	O
improve	O
non-associative	O
memory	O
significantly	O
in	O
OFH.	O
Analysis	O
of	O
neurotransmitter	O
concentration	O
in	O
some	O
brain	O
regions	O
on	O
the	O
test	O
day	O
showed	O
that	O
dopamine	Chemical
concentration	O
of	O
the	O
vehicle/	O
scopolamine	Chemical
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
vehicle/vehicle	O
group,	O
but	O
this	O
phenomenon	O
was	O
reversed	O
when	O
s-limonene	Chemical
or	O
s-perillyl	Chemical
alcohol	Chemical
were	O
administered	O
before	O
the	O
injection	O
of	O
scopolamine	Chemical

The	O
selective	O
5-HT6	O
receptor	O
antagonist	O
Ro4368554	Chemical
restores	O
memory	O
performance	O
in	O
cholinergic	O
and	O
serotonergic	O
models	O
of	O
memory	Disease
deficiency	Disease
in	O
the	O
rat.	O
Antagonists	O
at	O
serotonin	Chemical
type	O
6	O
(	O
5-HT	Chemical
(6))	O
receptors	O
show	O
activity	O
in	O
models	O
of	O
learning	O
and	O
memory.	O
Although	O
the	O
underlying	O
mechanism(s)	O
are	O
not	O
well	O
understood,	O
these	O
effects	O
may	O
involve	O
an	O
increase	O
in	O
acetylcholine	Chemical
(	O
ACh	Chemical
)	O
levels.	O
The	O
present	O
study	O
sought	O
to	O
characterize	O
the	O
cognitive-enhancing	O
effects	O
of	O
the	O
5-HT	Chemical
(6)	O
antagonist	O
Ro4368554	Chemical
(	O
3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole	Chemical
)	O
in	O
a	O
rat	O
object	O
recognition	O
task	O
employing	O
a	O
cholinergic	O
(	O
scopolamine	Chemical
pretreatment)	O
and	O
a	O
serotonergic-	O
(	O
tryptophan	Chemical
(	O
TRP	Chemical
)	O
depletion)	O
deficient	O
model,	O
and	O
compared	O
its	O
pattern	O
of	O
action	O
with	O
that	O
of	O
the	O
acetylcholinesterase	O
inhibitor	O
metrifonate	Chemical
.	O
Initial	O
testing	O
in	O
a	O
time-dependent	O
forgetting	O
task	O
employing	O
a	O
24-h	O
delay	O
between	O
training	O
and	O
testing	O
showed	O
that	O
metrifonate	Chemical
improved	O
object	O
recognition	O
(at	O
10	O
and	O
30	O
mg/kg,	O
p.o.),	O
whereas	O
Ro4368554	Chemical
was	O
inactive.	O
Both,	O
Ro4368554	Chemical
(3	O
and	O
10	O
mg/kg,	O
intraperitoneally	O
(i.p.))	O
and	O
metrifonate	Chemical
(10	O
mg/kg,	O
p.o.,	O
respectively)	O
reversed	O
memory	Disease
deficits	Disease
induced	O
by	O
scopolamine	Chemical
and	O
TRP	Chemical
depletion	O
(10	O
mg/kg,	O
i.p.,	O
and	O
3	O
mg/kg,	O
p.o.,	O
respectively).	O
In	O
conclusion,	O
although	O
Ro4368554	Chemical
did	O
not	O
improve	O
a	O
time-related	O
retention	O
deficit,	O
it	O
reversed	O
a	O
cholinergic	O
and	O
a	O
serotonergic	O
memory	Disease
deficit	Disease
,	O
suggesting	O
that	O
both	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
facilitation	O
of	O
object	O
memory	O
by	O
Ro4368554	Chemical
and,	O
possibly,	O
other	O
5-HT	Chemical

Lone	O
atrial	Disease
fibrillation	Disease
associated	O
with	O
creatine	Chemical
monohydrate	O
supplementation.	O
Atrial	Disease
fibrillation	Disease
in	O
young	O
patients	O
without	O
structural	O
heart	Disease
disease	Disease
is	O
rare.	O
Therefore,	O
when	O
the	O
arrhythmia	Disease
is	O
present	O
in	O
this	O
population,	O
reversible	O
causes	O
must	O
be	O
identified	O
and	O
resolved.	O
Thyroid	Disease
disorders	Disease
,	O
illicit	O
drug	O
or	O
stimulant	O
use,	O
and	O
acute	Disease
alcohol	Disease
intoxication	Disease
are	O
among	O
these	O
causes.	O
We	O
report	O
the	O
case	O
of	O
a	O
30-year-old	O
Caucasian	O
man	O
who	O
came	O
to	O
the	O
emergency	O
department	O
in	O
atrial	Disease
fibrillation	Disease
with	O
rapid	O
ventricular	O
response.	O
His	O
medical	O
history	O
was	O
unremarkable,	O
except	O
for	O
minor	O
fractures	Disease
of	O
the	O
fingers	O
and	O
foot.	O
Thyroid-stimulating	O
hormone,	O
magnesium	Chemical
,	O
and	O
potassium	Chemical
levels	O
were	O
within	O
normal	O
limits,	O
urine	O
drug	O
screen	O
was	O
negative,	O
and	O
alcohol	Chemical
use	O
was	O
denied.	O
However,	O
when	O
the	O
patient	O
was	O
questioned	O
about	O
use	O
of	O
herbal	O
products	O
and	O
supplements,	O
the	O
use	O
of	O
creatine	Chemical
monohydrate	O
was	O
revealed.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital,	O
anticoagulated	O
with	O
unfractionated	O
heparin	Chemical
,	O
and	O
given	O
intravenous	O
diltiazem	Chemical
for	O
rate	O
control	O
and	O
intravenous	O
amiodarone	Chemical
for	O
rate	O
and	O
rhythm	O
control.	O
When	O
discharged	O
less	O
than	O
24	O
hours	O
later,	O
he	O
was	O
receiving	O
metoprolol	Chemical
and	O
aspirin	Chemical
,	O
with	O
follow-up	O
plans	O
for	O
echocardiography	O
and	O
nuclear	O
imaging	O
to	O
assess	O
perfusion.	O
Exogenous	O
creatine	Chemical
is	O
used	O
by	O
athletes	O
to	O
theoretically	O
improve	O
exercise	O
performance.	O
Vegetarians	O
may	O
also	O
take	O
creatine	Chemical
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
meat,	O
fish,	O
and	O
other	O
animal	O
products.	O
Previous	O
anecdotal	O
reports	O
have	O
linked	O
creatine	Chemical
to	O
the	O
development	O
of	O
arrhythmia	Disease

Comparison	O
of	O
developmental	O
toxicity	Disease
of	O
selective	O
and	O
non-selective	O
cyclooxygenase-2	O
inhibitors	O
in	O
CRL:(WI)WUBR	O
Wistar	O
rats--	O
DFU	Chemical
and	O
piroxicam	Chemical
study.	O
BACKGROUND:	O
Cyclooxygenase	O
(COX)	O
inhibitors	O
are	O
one	O
of	O
the	O
most	O
often	O
ingested	O
drugs	O
during	O
pregnancy.	O
Unlike	O
general	O
toxicity	Disease
data,	O
their	O
prenatal	O
toxic	O
effects	O
were	O
not	O
extensively	O
studied	O
before.	O
The	O
aim	O
of	O
the	O
experiment	O
was	O
to	O
evaluate	O
the	O
developmental	O
toxicity	Disease
of	O
the	O
non-selective	O
(	O
piroxicam	Chemical
)	O
and	O
selective	O
(	O
DFU	Chemical
;	O
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)	Chemical
phenyl-2(5H)-furanon	Chemical
)	O
COX-2	O
inhibitors.	O
METHODS:	O
Drugs	O
were	O
separately,	O
orally	O
once	O
daily	O
dosed	O
to	O
pregnant	O
rats	O
from	O
day	O
8	O
to	O
21	O
(GD1=plug	O
day).	O
Doses	O
were	O
set	O
at	O
0.3,	O
3.0	O
and	O
30.0mg/kg	O
for	O
piroxicam	Chemical
and	O
0.2,	O
2.0	O
and	O
20.0mg/kg	O
for	O
DFU	Chemical
.	O
Fetuses	O
were	O
delivered	O
on	O
GD	O
21	O
and	O
routinely	O
examined.	O
Comprehensive	O
clinical	O
and	O
developmental	O
measurements	O
were	O
done.	O
The	O
pooled	O
statistical	O
analysis	O
for	O
ventricular	Disease
septal	Disease
(VSD)	Disease
and	Disease
midline	Disease
(MD)	Disease
defects	Disease
was	O
performed	O
for	O
rat	O
fetuses	O
exposed	O
to	O
piroxicam	Chemical
,	O
selective	O
and	O
non-selective	O
COX-2	O
inhibitor	O
based	O
on	O
present	O
and	O
historic	O
data.	O
RESULTS:	O
Maternal	O
toxicity	Disease
,	O
intrauterine	Disease
growth	Disease
retardation	Disease
,	O
and	O
increase	Disease
of	Disease
external	Disease
and	Disease
skeletal	Disease
variations	Disease
were	O
found	O
in	O
rats	O
treated	O
with	O
the	O
highest	O
dose	O
of	O
piroxicam	Chemical
.	O
Decrease	O
of	O
fetal	O
length	O
was	O
the	O
only	O
signs	O
of	O
the	O
DFU	Chemical
developmental	O
toxicity	Disease
observed	O
in	O
pups	O
exposed	O
to	O
the	O
highest	O
compound	O
dose.	O
Lack	O
of	O
teratogenicity	O
was	O
found	O
in	O
piroxicam	Chemical
and	O
DFU	Chemical
-exposed	O
groups.	O
Prenatal	O
exposure	O
to	O
non-selective	O
COX	O
inhibitors	O
increases	O
the	O
risk	O
of	O
VSD	O
and	O
MD	O
when	O
compared	O
to	O
historic	O
control	O
but	O
not	O
with	O
selective	O
COX-2	O
inhibitors.	O
CONCLUSION:	O
Both	O
selective	O
and	O
non-selective	O
COX-2	O
inhibitors	O
were	O
toxic	O
for	O
rats	O
fetuses	O
when	O
administered	O
in	O
the	O
highest	O
dose.	O
Unlike	O
DFU	Chemical
,	O
piroxicam	Chemical
was	O
also	O
highly	O
toxic	O
to	O
the	O
dams.	O
Prenatal	O
exposure	O
to	O
selective	O
COX-2	O
inhibitors	O
does	O
not	O
increase	O
the	O
risk	O
of	O
ventricular	Disease
septal	Disease
and	Disease
midline	Disease
defects	Disease

Protective	O
efficacy	O
of	O
neuroactive	O
steroids	Chemical
against	O
cocaine	Chemical
kindled-	O
seizures	Disease
in	O
mice.	O
Neuroactive	O
steroids	Chemical
demonstrate	O
pharmacological	O
actions	O
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	Disease
and	Disease
psychiatric	Disease
disorders	Disease
.	O
They	O
offer	O
protection	O
against	O
seizures	Disease
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	O
certain	O
stages	O
of	O
drug	Disease
dependence	Disease
in	O
preclinical	O
assessments.	O
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	Chemical
that	O
positively	O
modulate	O
the	O
gamma-aminobutyric	Chemical
acid	Chemical
(	O
GABA	Chemical
(A))	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	Chemical
engendered	O
by	O
repeated	O
cocaine	Chemical
administration	O
(	O
seizure	Disease
kindling).	O
Allopregnanolone	Chemical
(	O
3alpha-hydroxy-5alpha-pregnan-20-one	Chemical
),	O
pregnanolone	Chemical
(	O
3alpha-hydroxy-5beta-pregnan-20-one	Chemical
)	O
and	O
ganaxolone	Chemical
(a	O
synthetic	O
derivative	O
of	O
allopregnanolone	Chemical
	O
3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one	Chemical
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(anticonvulsant	O
effect)	O
and	O
development	O
(antiepileptogenic	O
effect)	O
of	O
cocaine	Chemical
-kindled	O
seizures	Disease
in	O
male,	O
Swiss-Webster	O
mice.	O
Kindled	O
seizures	Disease
were	O
induced	O
by	O
daily	O
administration	O
of	O
60	O
mg/kg	O
cocaine	Chemical
for	O
5	O
days.	O
All	O
of	O
these	O
positive	O
GABA	Chemical
(A)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	Disease
,	O
whereas	O
only	O
allopregnanolone	Chemical
and	O
ganaxolone	Chemical
inhibited	O
the	O
development	O
of	O
kindling.	O
Allopregnanolone	Chemical
and	O
pregnanolone	Chemical
,	O
but	O
not	O
ganaxolone	Chemical
,	O
also	O
reduced	O
cumulative	O
lethality	O
associated	O
with	O
kindling.	O
These	O
findings	O
demonstrate	O
that	O
some	O
neuroactive	O
steroids	Chemical
attenuate	O
convulsant	O
and	O
sensitizing	O
properties	O
of	O
cocaine	Chemical

Kidney	O
function	O
and	O
morphology	O
after	O
short-term	O
combination	O
therapy	O
with	O
cyclosporine	Chemical
A	Chemical
,	O
tacrolimus	Chemical
and	O
sirolimus	Chemical
in	O
the	O
rat.	O
BACKGROUND:	O
Sirolimus	Chemical
(	O
SRL	Chemical
)	O
may	O
supplement	O
calcineurin	O
inhibitors	O
in	O
clinical	O
organ	O
transplantation.	O
These	O
are	O
nephrotoxic	Disease
,	O
but	O
SRL	Chemical
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	O
nephrotoxic	Disease
effects,	O
although	O
this	O
question	O
is	O
still	O
open.	O
In	O
a	O
number	O
of	O
treatment	O
protocols	O
where	O
SRL	Chemical
was	O
combined	O
with	O
a	O
calcineurin	O
inhibitor	O
indications	O
of	O
a	O
synergistic	O
nephrotoxic	Disease
effect	O
were	O
described.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague-Dawley	O
rats	O
treated	O
with	O
either	O
cyclosporine	Chemical
A	Chemical
(	O
CsA	Chemical
),	O
tacrolimus	Chemical
(	O
FK506	Chemical
)	O
or	O
SRL	Chemical
as	O
monotherapies	O
or	O
in	O
different	O
combinations.	O
METHODS:	O
For	O
a	O
period	O
of	O
2	O
weeks,	O
CsA	Chemical
15	O
mg/kg/day	O
(given	O
orally),	O
FK506	Chemical
3.0	O
mg/kg/day	O
(given	O
orally)	O
or	O
SRL	Chemical
0.4	O
mg/kg/day	O
(given	O
intraperitoneally)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague-Dawley	O
rats.	O
In	O
the	O
'conscious	O
catheterized	O
rat'	O
model,	O
the	O
glomerular	O
filtration	O
rate	O
(GFR)	O
was	O
measured	O
as	O
the	O
clearance	O
of	O
Cr(EDTA).	O
The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi-quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	O
of	O
striped	O
fibrosis	Disease
,	O
subcapsular	O
fibrosis	Disease
and	O
the	O
number	O
of	O
basophilic	O
tubules,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	Disease
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red.	O
RESULTS:	O
CsA	Chemical
,	O
FK506	Chemical
and	O
SRL	Chemical
all	O
significantly	O
decreased	O
the	O
GFR.	O
A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	Chemical
was	O
combined	O
with	O
either	O
FK506	Chemical
or	O
SRL	Chemical
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	Chemical
plus	O
SRL	Chemical
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances.	O
The	O
morphological	O
changes	O
presented	O
a	O
similar	O
pattern.	O
The	O
semi-quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	O
with	O
CsA	Chemical
plus	O
SRL	Chemical
(P<0.001	O
compared	O
with	O
controls)	O
and	O
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	Disease
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(P<0.02).	O
The	O
FK506	Chemical
plus	O
SRL	Chemical
combination	O
showed	O
only	O
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	Disease
as	O
compared	O
with	O
controls	O
(P=0.05).	O
CONCLUSION:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	Disease
effect	O
of	O
CsA	Chemical
plus	O
SRL	Chemical
,	O
whereas	O
FK506	Chemical
plus	O
SRL	Chemical

Effect	O
of	O
fucoidan	Chemical
treatment	O
on	O
collagenase-induced	O
intracerebral	Disease
hemorrhage	Disease
in	O
rats.	O
Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
brain	Disease
damage	Disease
following	O
ischemic	Disease
stroke	Disease
.	O
Intracerebral	Disease
hemorrhage	Disease
is	O
associated	O
with	O
more	O
inflammation	Disease
than	O
ischemic	Disease
stroke	Disease
.	O
We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	Chemical
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	O
inflammatory	O
brain	Disease
damage	Disease
,	O
in	O
a	O
rat	O
model	O
of	O
intracerebral	Disease
hemorrhage	Disease
induced	O
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus.	O
Rats	O
were	O
treated	O
with	O
seven	O
day	O
intravenous	O
infusion	O
of	O
fucoidan	Chemical
(30	O
micrograms	O
h-1)	O
or	O
vehicle.	O
The	O
hematoma	Disease
was	O
assessed	O
in	O
vivo	O
by	O
magnetic	O
resonance	O
imaging.	O
Motor	O
behavior,	O
passive	O
avoidance,	O
and	O
skilled	O
forelimb	O
function	O
were	O
tested	O
repeatedly	O
for	O
six	O
weeks.	O
Fucoidan	Chemical
-treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	Disease
blood	Disease
clotting	Disease
and	O
hemodilution	Disease
,	O
had	O
larger	O
hematomas	Disease
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	Disease
in	O
the	O
vicinity	O
of	O
the	O
hematoma	Disease
after	O
three	O
days.	O
They	O
showed	O
significantly	O
more	O
rapid	O
improvement	O
of	O
motor	O
function	O
in	O
the	O
first	O
week	O
following	O
hemorrhage	Disease
and	O
better	O
memory	O
retention	O
in	O
the	O
passive	O
avoidance	O
test.	O
Acute	O
white	Disease
matter	Disease
edema	Disease
and	O
eventual	O
neuronal	Disease
loss	Disease
in	O
the	O
striatum	O
adjacent	O
to	O
the	O
hematoma	Disease
did	O
not	O
differ	O
between	O
the	O
two	O
groups.	O
Investigation	O
of	O
more	O
specific	O
anti-inflammatory	O
agents	O
and	O
hemodiluting	O
agents	O
are	O
warranted	O
in	O
intracerebral	Disease
hemorrhage	Disease

Paracetamol	Chemical
-associated	O
coma	Disease
,	O
metabolic	Disease
acidosis	Disease
,	O
renal	Disease
and	Disease
hepatic	Disease
failure	Disease
.	O
A	O
case	O
of	O
metabolic	Disease
acidosis	Disease
,	O
acute	Disease
renal	Disease
failure	Disease
and	Disease
hepatic	Disease
failure	Disease
following	O
paracetamol	Chemical

Hepatic	O
reactions	O
associated	O
with	O
ketoconazole	Chemical
in	O
the	O
United	O
Kingdom.	O
Ketoconazole	Chemical
was	O
introduced	O
in	O
the	O
United	O
Kingdom	O
in	O
1981.	O
By	O
November	O
1984	O
the	O
Committee	O
on	O
Safety	O
of	O
Medicines	O
had	O
received	O
82	O
reports	O
of	O
possible	O
hepatotoxicity	Disease
associated	O
with	O
the	O
drug,	O
including	O
five	O
deaths	Disease
.	O
An	O
analysis	O
of	O
the	O
75	O
cases	O
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	O
that	O
16,	O
including	O
three	O
deaths	Disease
,	O
were	O
probably	O
related	O
to	O
treatment	O
with	O
the	O
drug.	O
Of	O
the	O
remainder,	O
48	O
were	O
possibly	O
related	O
to	O
treatment,	O
five	O
were	O
unlikely	O
to	O
be	O
so,	O
and	O
six	O
were	O
unclassifiable.	O
The	O
mean	O
age	O
of	O
patients	O
in	O
the	O
16	O
probable	O
cases	O
was	O
57.9,	O
with	O
hepatotoxicity	Disease
being	O
more	O
common	O
in	O
women.	O
The	O
average	O
duration	O
of	O
treatment	O
before	O
the	O
onset	O
of	O
jaundice	Disease
was	O
61	O
days.	O
None	O
of	O
these	O
well	O
validated	O
cases	O
occurred	O
within	O
the	O
first	O
10	O
days	O
after	O
treatment.	O
The	O
results	O
of	O
serum	O
liver	O
function	O
tests	O
suggested	O
hepatocellular	Disease
injury	Disease
in	O
10	O
(63%);	O
the	O
rest	O
showed	O
a	O
mixed	O
pattern.	O
In	O
contrast,	O
the	O
results	O
of	O
histological	O
examination	O
of	O
the	O
liver	O
often	O
showed	O
evidence	O
of	O
cholestasis	Disease
.	O
The	O
characteristics	O
of	O
the	O
48	O
patients	O
in	O
the	O
possible	O
cases	O
were	O
similar.	O
Allergic	O
manifestations	O
such	O
as	O
rash	Disease
and	O
eosinophilia	Disease
were	O
rare.	O
Hepatitis	Disease
was	O
usually	O
reversible	O
when	O
treatment	O
was	O
stopped,	O
with	O
the	O
results	O
of	O
liver	O
function	O
tests	O
returning	O
to	O
normal	O
after	O
an	O
average	O
of	O
3.1	O
months.	O
In	O
two	O
of	O
the	O
three	O
deaths	Disease
probably	O
associated	O
with	O
ketoconazole	Chemical
treatment	O
the	O
drug	O
had	O
been	O
continued	O
after	O
the	O
onset	O
of	O
jaundice	Disease
and	O
other	O
symptoms	O
of	O
hepatitis	Disease
.	O
Clinical	O
and	O
biochemical	O
monitoring	O
at	O
regular	O
intervals	O
for	O
evidence	O
of	O
hepatitis	Disease
is	O
advised	O
during	O
long	O
term	O
treatment	O
with	O
ketoconazole	Chemical
to	O
prevent	O
possible	O
serious	O
hepatic	Disease
injury	Disease

Combined	O
effects	O
of	O
prolonged	O
prostaglandin	Chemical
E1	Chemical
-induced	O
hypotension	Disease
and	O
haemodilution	Disease
on	O
human	O
hepatic	O
function.	O
Combined	O
effects	O
of	O
prolonged	O
prostaglandin	Chemical
E1	Chemical
(	O
PGE1	Chemical
)-induced	O
hypotension	Disease
and	O
haemodilution	Disease
on	O
hepatic	O
function	O
were	O
studied	O
in	O
30	O
patients	O
undergoing	O
hip	O
surgery.	O
The	O
patients	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups;	O
those	O
in	O
group	O
A	O
(n	O
=	O
10)	O
were	O
subjected	O
to	O
controlled	O
hypotension	Disease
alone,	O
those	O
in	O
group	O
B	O
(n	O
=	O
10)	O
to	O
haemodilution	Disease
alone	O
and	O
those	O
in	O
group	O
C	O
(n	O
=	O
10)	O
to	O
both	O
controlled	O
hypotension	Disease
and	O
haemodilution	Disease
.	O
Haemodilution	Disease
in	O
groups	O
B	O
and	O
C	O
was	O
produced	O
by	O
withdrawing	O
approximately	O
1000	O
mL	O
of	O
blood	O
and	O
replacing	O
it	O
with	O
the	O
same	O
amount	O
of	O
dextran	Chemical
solution,	O
and	O
final	O
haematocrit	O
values	O
were	O
21	O
or	O
22%.	O
Controlled	O
hypotension	Disease
in	O
groups	O
A	O
and	O
C	O
was	O
induced	O
with	O
PGE1	Chemical
to	O
maintain	O
mean	O
arterial	O
blood	O
pressure	O
at	O
55	O
mmHg	O
for	O
180	O
min.	O
Measurements	O
included	O
arterial	O
ketone	O
body	O
ratio	O
(AKBR,	O
aceto-acetate	Chemical
/	O
3-hydroxybutyrate	Chemical
)	O
and	O
clinical	O
hepatic	O
function	O
parameters.	O
AKBR	O
and	O
biological	O
hepatic	O
function	O
tests	O
showed	O
no	O
change	O
throughout	O
the	O
time	O
course	O
in	O
groups	O
A	O
and	O
B.	O
In	O
group	O
C,	O
AKBR	O
showed	O
a	O
significant	O
decrease	O
at	O
120	O
min	O
(-40%)	O
and	O
at	O
180	O
min	O
(-49%)	O
after	O
the	O
start	O
of	O
hypotension	Disease
and	O
at	O
60	O
min	O
(-32%)	O
after	O
recovery	O
of	O
normotension,	O
and	O
SGOT,	O
SGPT,	O
LDH	O
and	O
total	O
bilirubin	Chemical
showed	O
significant	O
increases	O
after	O
operation.	O
The	O
results	O
suggest	O
that	O
a	O
prolonged	O
combination	O
of	O
more	O
than	O
120	O
min	O
of	O
PGE1	Chemical
-induced	O
hypotension	Disease
and	O
moderate	O
haemodilution	Disease
would	O
cause	O
impairment	Disease
of	Disease
hepatic	Disease
function	Disease

Levodopa	Chemical
-induced	O
dyskinesias	Disease
in	O
patients	O
with	O
Parkinson's	Disease
disease	Disease
:	O
filling	O
the	O
bench-to-bedside	O
gap.	O
Levodopa	Chemical
is	O
the	O
most	O
effective	O
drug	O
for	O
the	O
treatment	O
of	O
Parkinson's	Disease
disease	Disease
.	O
However,	O
the	O
long-term	O
use	O
of	O
this	O
dopamine	Chemical
precursor	O
is	O
complicated	O
by	O
highly	O
disabling	O
fluctuations	O
and	O
dyskinesias	Disease
.	O
Although	O
preclinical	O
and	O
clinical	O
findings	O
suggest	O
pulsatile	O
stimulation	O
of	O
striatal	O
postsynaptic	O
receptors	O
as	O
a	O
key	O
mechanism	O
underlying	O
levodopa	Chemical
-induced	O
dyskinesias	Disease
,	O
their	O
pathogenesis	O
is	O
still	O
unclear.	O
In	O
recent	O
years,	O
evidence	O
from	O
animal	O
models	O
of	O
Parkinson's	Disease
disease	Disease
has	O
provided	O
important	O
information	O
to	O
understand	O
the	O
effect	O
of	O
specific	O
receptor	O
and	O
post-receptor	O
molecular	O
mechanisms	O
underlying	O
the	O
development	O
of	O
dyskinetic	Disease
movements	Disease
.	O
Recent	O
preclinical	O
and	O
clinical	O
data	O
from	O
promising	O
lines	O
of	O
research	O
focus	O
on	O
the	O
differential	O
role	O
of	O
presynaptic	O
versus	O
postsynaptic	O
mechanisms,	O
dopamine	Chemical
receptor	O
subtypes,	O
ionotropic	O
and	O
metabotropic	O
glutamate	Chemical
receptors,	O
and	O
non-dopaminergic	O
neurotransmitter	O
systems	O
in	O
the	O
pathophysiology	O
of	O
levodopa	Chemical
-induced	O
dyskinesias	Disease

Prevention	O
of	O
seizures	Disease
and	O
reorganization	O
of	O
hippocampal	O
functions	O
by	O
transplantation	O
of	O
bone	O
marrow	O
cells	O
in	O
the	O
acute	O
phase	O
of	O
experimental	O
epilepsy	Disease
.	O
In	O
this	O
study,	O
we	O
investigated	O
the	O
therapeutic	O
potential	O
of	O
bone	O
marrow	O
mononuclear	O
cells	O
(BMCs)	O
in	O
a	O
model	O
of	O
epilepsy	Disease
induced	O
by	O
pilocarpine	Chemical
in	O
rats.	O
BMCs	O
obtained	O
from	O
green	O
fluorescent	O
protein	O
(GFP)	O
transgenic	O
mice	O
or	O
rats	O
were	O
transplanted	O
intravenously	O
after	O
induction	O
of	O
status	Disease
epilepticus	Disease
(	O
SE	Disease
).	O
Spontaneous	Disease
recurrent	Disease
seizures	Disease
(	O
SRS	Disease
)	O
were	O
monitored	O
using	O
Racine's	O
seizure	Disease
severity	O
scale.	O
All	O
of	O
the	O
rats	O
in	O
the	O
saline-treated	O
epileptic	Disease
control	O
group	O
developed	O
SRS	Disease
,	O
whereas	O
none	O
of	O
the	O
BMC-treated	O
epileptic	Disease
animals	O
had	O
seizures	Disease
in	O
the	O
short	O
term	O
(15	O
days	O
after	O
transplantation),	O
regardless	O
of	O
the	O
BMC	O
source.	O
Over	O
the	O
long-term	O
chronic	O
phase	O
(120	O
days	O
after	O
transplantation),	O
only	O
25%	O
of	O
BMC-treated	O
epileptic	Disease
animals	O
had	O
seizures	Disease
,	O
but	O
with	O
a	O
lower	O
frequency	O
and	O
duration	O
compared	O
to	O
the	O
epileptic	Disease
control	O
group.	O
The	O
density	O
of	O
hippocampal	O
neurons	O
in	O
the	O
brains	O
of	O
animals	O
treated	O
with	O
BMCs	O
was	O
markedly	O
preserved.	O
At	O
hippocampal	O
Schaeffer	O
collateral-CA1	O
synapses,	O
long-term	O
potentiation	O
was	O
preserved	O
in	O
BMC-transplanted	O
rats	O
compared	O
to	O
epileptic	Disease
controls.	O
The	O
donor-derived	O
GFP(+)	O
cells	O
were	O
rarely	O
found	O
in	O
the	O
brains	O
of	O
transplanted	O
epileptic	Disease
rats.	O
In	O
conclusion,	O
treatment	O
with	O
BMCs	O
can	O
prevent	O
the	O
development	O
of	O
chronic	O
seizures	Disease
,	O
reduce	O
neuronal	Disease
loss	Disease

Cardioprotective	O
effect	O
of	O
salvianolic	Chemical
acid	Chemical
A	Chemical
on	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
infarction	Disease
in	O
rats.	O
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
cardioprotective	O
potential	O
of	O
salvianolic	Chemical
acid	Chemical
A	Chemical
on	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
infarction	Disease
in	O
rats.	O
Hemodynamic	O
parameters	O
and	O
lead	O
II	O
electrocardiograph	O
were	O
monitored	O
and	O
recorded	O
continuously.	O
Cardiac	O
marker	O
enzymes	O
and	O
antioxidative	O
parameters	O
in	O
serum	O
and	O
heart	O
tissues	O
were	O
measured.	O
Assay	O
for	O
mitochondrial	O
respiratory	O
function	O
and	O
histopathological	O
examination	O
of	O
heart	O
tissues	O
were	O
performed.	O
Isoproterenol	Chemical
-treated	O
rats	O
showed	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
lactate	Chemical
dehydrogenase,	O
aspartate	Chemical
transaminase,	O
creatine	Chemical
kinase	O
and	O
malondialdehyde	Chemical
and	O
significant	O
decreases	O
in	O
the	O
activities	O
of	O
superoxide	Chemical
dismutase,	O
catalase	O
and	O
glutathione	Chemical
peroxidase	O
in	O
serum	O
and	O
heart.	O
These	O
rats	O
also	O
showed	O
declines	O
in	O
left	O
ventricular	O
systolic	O
pressure,	O
maximum	O
and	O
minimum	O
rate	O
of	O
developed	O
left	O
ventricular	O
pressure,	O
and	O
elevation	O
of	O
left	O
ventricular	O
end-diastolic	O
pressure	O
and	O
ST-segment.	O
In	O
addition,	O
mitochondrial	O
respiratory	Disease
dysfunction	Disease
characterized	O
by	O
decreased	O
respiratory	O
control	O
ratio	O
and	O
ADP	Chemical
/O	O
was	O
observed	O
in	O
isoproterenol	Chemical
-treated	O
rats.	O
Administration	O
of	O
salvianolic	Chemical
acid	Chemical
A	Chemical
for	O
a	O
period	O
of	O
8	O
days	O
significantly	O
attenuated	O
isoproterenol	Chemical
-induced	O
cardiac	Disease
dysfunction	Disease
and	O
myocardial	Disease
injury	Disease
and	O
improved	O
mitochondrial	O
respiratory	O
function.	O
The	O
protective	O
role	O
of	O
salvianolic	Chemical
acid	Chemical
A	Chemical
against	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
damage	Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination.	O
The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
salvianolic	Chemical
acid	Chemical
A	Chemical
possessing	O
antioxidant	O
activity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isoproterenol	Chemical
-induced	O
myocardial	Disease
infarction	Disease

Acute	O
effects	O
of	O
N-(2-propylpentanoyl)urea	Chemical
on	O
hippocampal	O
amino	Chemical
acid	Chemical
neurotransmitters	O
in	O
pilocarpine	Chemical
-induced	O
seizure	Disease
in	O
rats.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
anticonvulsant	O
activity	O
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	O
of	O
hippocampal	O
amino	Chemical
acid	Chemical
neurotransmitters	O
(	O
glutamate	Chemical
,	O
aspartate	Chemical
,	O
glycine	Chemical
and	O
GABA	Chemical
)	O
of	O
N-(2-propylpentanoyl)urea	Chemical
(	O
VPU	Chemical
)	O
in	O
comparison	O
to	O
its	O
parent	O
compound,	O
valproic	Chemical
acid	Chemical
(	O
VPA	Chemical
).	O
VPU	Chemical
was	O
more	O
potent	O
than	O
VPA	Chemical
,	O
exhibiting	O
the	O
median	O
effective	O
dose	O
(ED(50))	O
of	O
49	O
mg/kg	O
in	O
protecting	O
rats	O
against	O
pilocarpine	Chemical
-induced	O
seizure	Disease
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	Chemical
was	O
322	O
mg/kg.	O
In	O
vivo	O
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	O
administration	O
of	O
pilocarpine	Chemical
induced	O
a	O
pronounced	O
increment	O
of	O
hippocampal	O
glutamate	Chemical
and	O
aspartate	Chemical
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
level	O
of	O
glycine	Chemical
and	O
GABA	Chemical
.	O
Pretreatment	O
with	O
either	O
VPU	Chemical
(50	O
and	O
100	O
mg/kg)	O
or	O
VPA	Chemical
(300	O
and	O
600	O
mg/kg)	O
completely	O
abolished	O
pilocarpine	Chemical
-evoked	O
increases	O
in	O
extracellular	O
glutamate	Chemical
and	O
aspartate	Chemical
.	O
In	O
addition,	O
a	O
statistically	O
significant	O
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	O
of	O
GABA	Chemical
and	O
glycine	Chemical
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	Chemical
and	O
aspartate	Chemical
level.	O
Based	O
on	O
the	O
finding	O
that	O
VPU	Chemical
and	O
VPA	Chemical
could	O
protect	O
the	O
animals	O
against	O
pilocarpine	Chemical
-induced	O
seizure	Disease
it	O
is	O
suggested	O
that	O
the	O
reduction	O
of	O
inhibitory	O
amino	Chemical
acid	Chemical
neurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduction	O
of	O
glutamate	Chemical
and	O
aspartate	Chemical
.	O
Therefore,	O
like	O
VPA	Chemical
,	O
the	O
finding	O
that	O
VPU	Chemical
could	O
drastically	O
reduce	O
pilocarpine	Chemical
-induced	O
increases	O
in	O
glutamate	Chemical
and	O
aspartate	Chemical
should	O
account,	O
at	O
least	O
partly,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine	Chemical
-induced	O
seizure	Disease

Acute	O
hepatitis	Disease
attack	O
after	O
exposure	O
to	O
telithromycin	Chemical
.	O
INTRODUCTION:	O
Antibiotic-associated	O
hepatotoxicity	Disease
is	O
rare.	O
With	O
widespread	O
use	O
of	O
antimicrobial	O
agents,	O
however,	O
hepatic	Disease
injury	Disease
occurs	O
frequently,	O
and	O
among	O
adverse	Disease
drug	Disease
reactions	Disease
,	O
idiosyncratic	O
reactions	O
are	O
the	O
most	O
serious.	O
CASE	O
SUMMARY:	O
A	O
25-year-old	O
male	O
patient,	O
with	O
a	O
height	O
of	O
175	O
cm	O
and	O
weight	O
of	O
72	O
kg	O
presented	O
to	O
Marmara	O
University	O
Hospital	O
Emergency	O
Department,	O
Istanbul,	O
Turkey,	O
with	O
5	O
days'	O
history	O
of	O
jaundice	Disease
,	O
malaise,	O
nausea	Disease
,	O
and	O
vomiting	Disease
.	O
He	O
had	O
been	O
prescribed	O
telithromycin	Chemical
400	O
mg/d	O
PO	O
to	O
treat	O
an	O
upper	Disease
respiratory	Disease
tract	Disease
infection	Disease
7	O
days	O
prior.	O
Admission	O
laboratory	O
tests	O
were	O
as	O
follows:	O
alanine	Chemical
aminotransferase,	O
67	O
U/L	O
(reference	O
range,	O
10-37	O
U/L);	O
aspartate	Chemical
aminotransferase,	O
98	O
U/L	O
(10-40	O
U/L);	O
alkaline	O
phosphatase,	O
513	O
U/L	O
(0-270	O
U/L);	O
gamma-glutamyltransferase,	O
32	O
U/L	O
(7-49	O
U/L);	O
amylase,	O
46	O
U/L	O
(0-220	O
U/L);	O
total	O
bilirubin	Chemical
,	O
20.1	O
mg/dL	O
(0.2-1.0	O
mg/dL);	O
direct	O
bilirubin	Chemical
,	O
14.8	O
mg/dL	O
(0-0.3	O
mg/dL);	O
and	O
albumin,	O
4.7	O
mg/dL	O
(3.5-5.4	O
mg/dL).	O
No	O
toxin,	O
alcohol	Chemical
,	O
or	O
other	O
drugs	O
were	O
reported.	O
The	O
patient	O
had	O
suffered	O
a	O
previous	O
episode	O
of	O
"acute	O
hepatitis	Disease
of	O
unknown	O
origin,"	O
that	O
occurred	O
after	O
telithromycin	Chemical
usage.	O
Both	O
incidents	O
occurred	O
within	O
a	O
year.	O
DISCUSSION:	O
Telithromycin	Chemical
is	O
the	O
first	O
of	O
the	O
ketolide	O
antibacterials	O
to	O
receive	O
US	O
Food	O
and	O
Drug	O
Administration	O
approval	O
for	O
clinical	O
use.	O
It	O
has	O
been	O
associated	O
with	O
infrequent	O
and	O
usually	O
reversible	O
severe	O
hepatic	Disease
dysfunction	Disease
.	O
Based	O
on	O
a	O
score	O
of	O
8	O
on	O
the	O
Naranjo	O
adverse	Disease
drug	Disease
reaction	Disease
probability	O
scale,	O
telithromycin	Chemical
was	O
the	O
probable	O
cause	O
of	O
acute	O
hepatitis	Disease
in	O
this	O
patient,	O
and	O
pathological	O
findings	O
suggested	O
drug-induced	O
toxic	Disease
hepatitis	Disease
.	O
Recurrence	O
of	O
hepatitis	Disease
attack	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incident	O
had	O
been	O
communicated	O
to	O
the	O
attending	O
physician	O
who	O
prescribed	O
telithromycin	Chemical
the	O
second	O
time.	O
CONCLUSION:	O
Here	O
we	O
report	O
a	O
case	O
of	O
acute	O
hepatitis	Disease
probably	O
associated	O
with	O
the	O
administration	O
of	O
telithromycin	Chemical

Spironolactone	Chemical
-induced	O
renal	Disease
insufficiency	Disease
and	O
hyperkalemia	Disease
in	O
patients	O
with	O
heart	Disease
failure	Disease
.	O
BACKGROUND:	O
A	O
previous	O
randomized	O
controlled	O
trial	O
evaluating	O
the	O
use	O
of	O
spironolactone	Chemical
in	O
heart	Disease
failure	Disease
patients	O
reported	O
a	O
low	O
risk	O
of	O
hyperkalemia	Disease
(2%)	O
and	O
renal	Disease
insufficiency	Disease
(0%).	O
Because	O
treatments	O
for	O
heart	Disease
failure	Disease
have	O
changed	O
since	O
the	O
benefits	O
of	O
spironolactone	Chemical
were	O
reported,	O
the	O
prevalence	O
of	O
these	O
complications	O
may	O
differ	O
in	O
current	O
clinical	O
practice.	O
We	O
therefore	O
sought	O
to	O
determine	O
the	O
prevalence	O
and	O
clinical	O
associations	O
of	O
hyperkalemia	Disease
and	O
renal	Disease
insufficiency	Disease
in	O
heart	Disease
failure	Disease
patients	O
treated	O
with	O
spironolactone	Chemical
.	O
METHODS:	O
We	O
performed	O
a	O
case	O
control	O
study	O
of	O
heart	Disease
failure	Disease
patients	O
treated	O
with	O
spironolactone	Chemical
in	O
our	O
clinical	O
practice.	O
Cases	O
were	O
patients	O
who	O
developed	O
hyperkalemia	Disease
(	O
K	Chemical
(+)	O
>5.0	O
mEq/L)	O
or	O
renal	Disease
insufficiency	Disease
(	O
Cr	Chemical
>or=2.5	O
mg/dL),	O
and	O
they	O
were	O
compared	O
to	O
2	O
randomly	O
selected	O
controls	O
per	O
case.	O
Clinical	O
characteristics,	O
medications,	O
and	O
serum	O
chemistries	O
at	O
baseline	O
and	O
follow-up	O
time	O
periods	O
were	O
compared.	O
RESULTS:	O
Sixty-seven	O
of	O
926	O
patients	O
(7.2%)	O
required	O
discontinuation	O
of	O
spironolactone	Chemical
due	O
to	O
hyperkalemia	Disease
(n	O
=	O
33)	O
or	O
renal	Disease
failure	Disease
(n	O
=	O
34).	O
Patients	O
who	O
developed	O
hyperkalemia	Disease
were	O
older	O
and	O
more	O
likely	O
to	O
have	O
diabetes	Disease
,	O
had	O
higher	O
baseline	O
serum	O
potassium	Chemical
levels	O
and	O
lower	O
baseline	O
potassium	Chemical
supplement	O
doses,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
beta-blockers	O
than	O
controls	O
(n	O
=	O
134).	O
Patients	O
who	O
developed	O
renal	Disease
insufficiency	Disease
had	O
lower	O
baseline	O
body	O
weight	O
and	O
higher	O
baseline	O
serum	O
creatinine	Chemical
,	O
required	O
higher	O
doses	O
of	O
loop	O
diuretics,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
thiazide	Chemical
diuretics	O
than	O
controls.	O
CONCLUSIONS:	O
Spironolactone	Chemical
-induced	O
hyperkalemia	Disease
and	O
renal	Disease
insufficiency	Disease

End-stage	Disease
renal	Disease
disease	Disease
(	O
ESRD	Disease
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(OLTX)	O
using	O
calcineurin-based	O
immunotherapy:	O
risk	O
of	O
development	O
and	O
treatment.	O
BACKGROUND:	O
The	O
calcineurin	O
inhibitors	O
cyclosporine	Chemical
and	O
tacrolimus	Chemical
are	O
both	O
known	O
to	O
be	O
nephrotoxic	Disease
.	O
Their	O
use	O
in	O
orthotopic	O
liver	O
transplantation	O
(OLTX)	O
has	O
dramatically	O
improved	O
success	O
rates.	O
Recently,	O
however,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	O
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end-stage	Disease
renal	Disease
disease	Disease
(	O
ESRD	Disease
).	O
This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	Disease
and	O
chronic	Disease
renal	Disease
failure	Disease
(	O
CRF	Disease
)	O
in	O
OLTX	O
patients.	O
METHODS:	O
Patients	O
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
months	O
postoperatively	O
were	O
studied	O
(n=834).	O
Our	O
prospectively	O
collected	O
database	O
was	O
the	O
source	O
of	O
information.	O
Patients	O
were	O
divided	O
into	O
three	O
groups:	O
Controls,	O
no	O
CRF	Disease
or	O
ESRD	Disease
,	O
n=748;	O
CRF	Disease
,	O
sustained	O
serum	O
creatinine	Chemical
>2.5	O
mg/dl,	O
n=41;	O
and	O
ESRD	Disease
,	O
n=45.	O
Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables,	O
diagnosis,	O
postoperative	O
variables,	O
survival,	O
type	O
of	O
ESRD	Disease
therapy,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	Disease
.	O
RESULTS:	O
At	O
13	O
years	O
after	O
OLTX,	O
the	O
incidence	O
of	O
severe	O
renal	Disease
dysfunction	Disease
was	O
18.1%	O
(	O
CRF	Disease
8.6%	O
and	O
ESRD	Disease
9.5%).	O
Compared	O
with	O
control	O
patients,	O
CRF	Disease
and	O
ESRD	Disease
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	Chemical
levels,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	Disease
syndrome	Disease
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively,	O
and	O
a	O
higher	O
1-year	O
serum	O
creatinine	Chemical
.	O
Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	Chemical
compared	O
with	O
average	O
at	O
1	O
year,	O
3	O
months,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	Disease
or	O
ESRD	Disease
with	O
odds	O
ratios	O
of	O
2.6,	O
2.2,	O
and	O
1.6,	O
respectively.	O
Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups,	O
but	O
by	O
year	O
13,	O
the	O
survival	O
of	O
the	O
patients	O
who	O
had	O
ESRD	Disease
was	O
only	O
28.2%	O
compared	O
with	O
54.6%	O
in	O
the	O
control	O
group.	O
Patients	O
developing	O
ESRD	Disease
had	O
a	O
6-year	O
survival	O
after	O
onset	O
of	O
ESRD	Disease
of	O
27%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71.4%	O
for	O
the	O
patients	O
developing	O
ESRD	Disease
who	O
subsequently	O
received	O
kidney	O
transplants.	O
CONCLUSIONS:	O
Patients	O
who	O
are	O
more	O
than	O
10	O
years	O
post-OLTX	O
have	O
CRF	Disease
and	O
ESRD	Disease
at	O
a	O
high	O
rate.	O
The	O
development	O
of	O
ESRD	Disease
decreases	O
survival,	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only.	O
Patients	O
who	O
develop	O
ESRD	Disease
have	O
a	O
higher	O
preoperative	O
and	O
1-year	O
serum	O
creatinine	Chemical
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	Disease
syndrome	Disease
.	O
However,	O
an	O
increase	O
of	O
serum	O
creatinine	Chemical
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	Disease
or	O
ESRD	Disease

Effect	O
of	O
intravenous	O
nimodipine	Chemical
on	O
blood	O
pressure	O
and	O
outcome	O
after	O
acute	Disease
stroke	Disease
.	O
BACKGROUND	O
AND	O
PURPOSE:	O
The	O
Intravenous	O
Nimodipine	Chemical
West	O
European	O
Stroke	Disease
Trial	O
(INWEST)	O
found	O
a	O
correlation	O
between	O
nimodipine	Chemical
-induced	O
reduction	Disease
in	Disease
blood	Disease
pressure	Disease
(BP)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	Disease
stroke	Disease
.	O
We	O
sought	O
to	O
confirm	O
this	O
correlation	O
with	O
and	O
without	O
adjustment	O
for	O
prognostic	O
variables	O
and	O
to	O
investigate	O
outcome	O
in	O
subgroups	O
with	O
increasing	O
levels	O
of	O
BP	Disease
reduction	Disease
.	O
METHODS:	O
Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	Disease
stroke	Disease
(within	O
24	O
hours)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placebo	O
(n=100),	O
1	O
mg/h	O
(low-dose)	O
nimodipine	Chemical
(n=101),	O
or	O
2	O
mg/h	O
(high-dose)	O
nimodipine	Chemical
(n=94).	O
The	O
correlation	O
between	O
average	O
BP	O
change	O
during	O
the	O
first	O
2	O
days	O
and	O
the	O
outcome	O
at	O
day	O
21	O
was	O
analyzed.	O
RESULTS:	O
Two	O
hundred	O
sixty-five	O
patients	O
were	O
included	O
in	O
this	O
analysis	O
(n=92,	O
93,	O
and	O
80	O
for	O
placebo,	O
low	O
dose,	O
and	O
high	O
dose,	O
respectively).	O
Nimodipine	Chemical
treatment	O
resulted	O
in	O
a	O
statistically	O
significant	O
reduction	Disease
in	Disease
systolic	Disease
BP	Disease
(SBP)	O
and	O
diastolic	O
BP	O
(DBP)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days.	O
In	O
multivariate	O
analysis,	O
a	O
significant	O
correlation	O
between	O
DBP	Disease
reduction	Disease
and	O
worsening	O
of	O
the	O
neurological	O
score	O
was	O
found	O
for	O
the	O
high-dose	O
group	O
(beta=0.49,	O
P=0.	O
048).	O
Patients	O
with	O
a	O
DBP	Disease
reduction	Disease
of	O
>	O
or	O
=20%	O
in	O
the	O
high-dose	O
group	O
had	O
a	O
significantly	O
increased	O
adjusted	O
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	Disease
or	O
dependency	O
(Barthel	O
Index	O
<60)	O
(n/N=25/26,	O
OR	O
10.	O
16,	O
95%	O
CI	O
1.02	O
to	O
101.74)	O
and	O
death	Disease
alone	O
(n/N=9/26,	O
OR	O
4.336,	O
95%	O
CI	O
1.131	O
16.619)	O
compared	O
with	O
all	O
placebo	O
patients	O
(n/N=62/92	O
and	O
14/92,	O
respectively).	O
There	O
was	O
no	O
correlation	O
between	O
SBP	O
change	O
and	O
outcome.	O
CONCLUSIONS:	O
DBP,	O
but	O
not	O
SBP,	O
reduction	O
was	O
associated	O
with	O
neurological	O
worsening	O
after	O
the	O
intravenous	O
administration	O
of	O
high-dose	O
nimodipine	Chemical
after	O
acute	Disease
stroke	Disease
.	O
For	O
low-dose	O
nimodipine	Chemical
,	O
the	O
results	O
were	O
not	O
conclusive.	O
These	O
results	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroprotective	O
property	O
of	O
nimodipine	Chemical

Transient	Disease
neurologic	Disease
symptoms	Disease
after	O
spinal	O
anesthesia:	O
a	O
lower	O
incidence	O
with	O
prilocaine	Chemical
and	O
bupivacaine	Chemical
than	O
with	O
lidocaine	Chemical
.	O
BACKGROUND:	O
Recent	O
evidence	O
suggests	O
that	O
transient	Disease
neurologic	Disease
symptoms	Disease
(	O
TNSs	Disease
)	O
frequently	O
follow	O
lidocaine	Chemical
spinal	O
anesthesia	O
but	O
are	O
infrequent	O
with	O
bupivacaine	Chemical
.	O
However,	O
identification	O
of	O
a	O
short-acting	O
local	O
anesthetic	O
to	O
substitute	O
for	O
lidocaine	Chemical
for	O
brief	O
surgical	O
procedures	O
remains	O
an	O
important	O
goal.	O
Prilocaine	Chemical
is	O
an	O
amide	O
local	O
anesthetic	O
with	O
a	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
lidocaine	Chemical
.	O
Accordingly,	O
the	O
present,	O
prospective	O
double-blind	O
study	O
compares	O
prilocaine	Chemical
with	O
lidocaine	Chemical
and	O
bupivacaine	Chemical
with	O
respect	O
to	O
duration	O
of	O
action	O
and	O
relative	O
risk	O
of	O
TNSs	Disease
.	O
METHODS:	O
Ninety	O
patients	O
classified	O
as	O
American	O
Society	O
of	O
Anesthesiologists	O
physical	O
status	O
I	O
or	O
II	O
who	O
were	O
scheduled	O
for	O
short	O
gynecologic	O
procedures	O
under	O
spinal	O
anesthesia	O
were	O
randomly	O
allocated	O
to	O
receive	O
2.5	O
ml	O
2%	O
lidocaine	Chemical
in	O
7.5%	O
glucose	Chemical
,	O
2%	O
prilocaine	Chemical
in	O
7.5%	O
glucose	Chemical
,	O
or	O
0.5%	O
bupivacaine	Chemical
in	O
7.5%	O
glucose	Chemical
.	O
All	O
solutions	O
were	O
provided	O
in	O
blinded	O
vials	O
by	O
the	O
hospital	O
pharmacy.	O
Details	O
of	O
spinal	O
puncture,	O
extension	O
and	O
regression	O
of	O
spinal	O
block,	O
and	O
the	O
times	O
to	O
reach	O
discharge	O
criteria	O
were	O
noted.	O
In	O
the	O
evening	O
of	O
postoperative	O
day	O
1,	O
patients	O
were	O
evaluated	O
for	O
TNSs	Disease
by	O
a	O
physician	O
unaware	O
of	O
the	O
drug	O
administered	O
and	O
the	O
details	O
of	O
the	O
anesthetic	O
procedure.	O
RESULTS:	O
Nine	O
of	O
30	O
patients	O
receiving	O
lidocaine	Chemical
experienced	O
TNSs	Disease
,	O
1	O
of	O
30	O
patients	O
receiving	O
prilocaine	Chemical
(P	O
=	O
0.03)	O
had	O
them,	O
and	O
none	O
of	O
30	O
patients	O
receiving	O
bupivacaine	Chemical
had	O
TNSs	Disease
.	O
Times	O
to	O
ambulate	O
and	O
to	O
void	O
were	O
similar	O
after	O
lidocaine	Chemical
and	O
prilocaine	Chemical
(150	O
vs.	O
165	O
min	O
and	O
238	O
vs.	O
253	O
min,	O
respectively)	O
but	O
prolonged	O
after	O
bupivacaine	Chemical
(200	O
and	O
299	O
min,	O
respectively;	O
P	O
<	O
0.05).	O
CONCLUSIONS:	O
Prilocaine	Chemical
may	O
be	O
preferable	O
to	O
lidocaine	Chemical
for	O
short	O
surgical	O
procedures	O
because	O
it	O
has	O
a	O
similar	O
duration	O
of	O
action	O
but	O
a	O
lower	O
incidence	O
of	O
TNSs	Disease

The	O
role	O
of	O
nicotine	Chemical
in	O
smoking-related	O
cardiovascular	Disease
disease	Disease
.	O
Nicotine	Chemical
activates	O
the	O
sympathetic	O
nervous	O
system	O
and	O
in	O
this	O
way	O
could	O
contribute	O
to	O
cardiovascular	Disease
disease	Disease
.	O
Animal	O
studies	O
and	O
mechanistic	O
studies	O
indicate	O
that	O
nicotine	Chemical
could	O
play	O
a	O
role	O
in	O
accelerating	O
atherosclerosis	Disease
,	O
but	O
evidence	O
among	O
humans	O
is	O
too	O
inadequate	O
to	O
be	O
definitive	O
about	O
such	O
an	O
effect.	O
Almost	O
certainly,	O
nicotine	Chemical
via	O
its	O
hemodynamic	O
effects	O
contributes	O
to	O
acute	O
cardiovascular	O
events,	O
although	O
current	O
evidence	O
suggests	O
that	O
the	O
effects	O
of	O
nicotine	Chemical
are	O
much	O
less	O
important	O
than	O
are	O
the	O
prothrombotic	O
effects	O
of	O
cigarette	O
smoking	O
or	O
the	O
effects	O
of	O
carbon	Chemical
monoxide	Chemical
.	O
Nicotine	Chemical
does	O
not	O
appear	O
to	O
enhance	O
thrombosis	Disease
among	O
humans.	O
Clinical	O
studies	O
of	O
pipe	O
smokers	O
and	O
people	O
using	O
transdermal	O
nicotine	Chemical
support	O
the	O
idea	O
that	O
toxins	O
other	O
than	O
nicotine	Chemical
are	O
the	O
most	O
important	O
causes	O
of	O
acute	O
cardiovascular	O
events.	O
Finally,	O
the	O
dose	O
response	O
for	O
cardiovascular	O
events	O
of	O
nicotine	Chemical
appears	O
to	O
be	O
flat,	O
suggesting	O
that	O
if	O
nicotine	Chemical

Seizure	Disease
resulting	O
from	O
a	O
venlafaxine	Chemical
	O
overdose	Disease
.	O
OBJECTIVE:	O
To	O
report	O
a	O
case	O
of	O
venlafaxine	Chemical
	O
overdose	Disease
.	O
CASE	O
SUMMARY:	O
A	O
40-year-old	O
woman	O
with	O
major	Disease
depression	Disease
took	O
an	O
overdose	Disease
of	O
venlafaxine	Chemical
in	O
an	O
apparent	O
suicide	O
attempt.	O
After	O
the	O
ingestion	O
of	O
26	O
venlafaxine	Chemical
50-mg	O
tablets,	O
the	O
patient	O
experienced	O
a	O
witnessed	O
generalized	O
seizure	Disease
.	O
She	O
was	O
admitted	O
to	O
the	O
medical	O
intensive	O
care	O
unit,	O
venlafaxine	Chemical
was	O
discontinued,	O
and	O
no	O
further	O
sequelae	O
were	O
seen.	O
DISCUSSION:	O
To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
venlafaxine	Chemical
	O
overdose	Disease
that	O
resulted	O
in	O
a	O
generalized	O
seizure	Disease
.	O
Based	O
on	O
nonoverdose	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
venlafaxine	Chemical
and	O
the	O
potential	O
risks	O
of	O
available	O
interventions,	O
no	O
emergent	O
therapy	O
was	O
instituted.	O
CONCLUSIONS:	O
The	O
venlafaxine	Chemical
	O
overdose	Disease
in	O
our	O
patient	O
resulted	O
in	O
a	O
single	O
episode	O
of	O
generalized	O
seizure	Disease

Effect	O
of	O
nifedipine	Chemical
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
receiving	O
tacrolimus	Chemical
.	O
The	O
effect	O
of	O
nifedipine	Chemical
on	O
renal	O
function	O
in	O
liver	O
transplant	O
recipients	O
who	O
were	O
receiving	O
tacrolimus	Chemical
was	O
evaluated	O
between	O
January	O
1992	O
and	O
January	O
1996.	O
Two	O
groups	O
of	O
patients	O
receiving	O
tacrolimus	Chemical
were	O
compared	O
over	O
a	O
period	O
of	O
1	O
year,	O
one	O
group	O
comprising	O
hypertensive	Disease
patients	O
who	O
were	O
receiving	O
nifedipine	Chemical
,	O
and	O
the	O
other	O
comprising	O
nonhypertensive	O
patients	O
not	O
receiving	O
nifedipine	Chemical
.	O
The	O
time	O
from	O
transplant	O
to	O
baseline	O
was	O
similar	O
in	O
all	O
patients.	O
Nifedipine	Chemical
significantly	O
improved	O
kidney	O
function	O
as	O
indicated	O
by	O
a	O
significant	O
lowering	O
of	O
serum	O
creatinine	Chemical
levels	O
at	O
6	O
and	O
12	O
months.	O
The	O
observed	O
positive	O
impact	O
of	O
nifedipine	Chemical
on	O
reducing	O
the	O
nephrotoxicity	Disease
associated	O
with	O
tacrolimus	Chemical
in	O
liver	O
transplant	O
recipients	O
should	O
be	O
an	O
important	O
factor	O
in	O
selecting	O
an	O
agent	O
to	O
treat	O
hypertension	Disease

Sinus	Disease
arrest	Disease
associated	O
with	O
continuous-infusion	O
cimetidine	Chemical
.	O
The	O
administration	O
of	O
intermittent	O
intravenous	O
infusions	O
of	O
cimetidine	Chemical
is	O
infrequently	O
associated	O
with	O
the	O
development	O
of	O
bradyarrhythmias	Disease
.	O
A	O
40-year-old	O
man	O
with	O
leukemia	Disease
and	O
no	O
history	O
of	O
cardiac	Disease
disease	Disease
developed	O
recurrent,	O
brief	O
episodes	O
of	O
apparent	O
sinus	Disease
arrest	Disease
while	O
receiving	O
continuous-infusion	O
cimetidine	Chemical
50	O
mg/hour.	O
The	O
arrhythmias	Disease
were	O
temporally	O
related	O
to	O
cimetidine	Chemical
administration,	O
disappeared	O
after	O
dechallenge,	O
and	O
did	O
not	O
recur	O
during	O
ranitidine	Chemical
treatment.	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
sinus	Disease
arrest	Disease
associated	O
with	O
continuous-infusion	O
cimetidine	Chemical

Composition	O
of	O
gall	Disease
bladder	Disease
stones	Disease
associated	O
with	O
octreotide	Chemical
:	O
response	O
to	O
oral	O
ursodeoxycholic	Chemical
acid	Chemical
.	O
Octreotide	Chemical
,	O
an	O
effective	O
treatment	O
for	O
acromegaly	Disease
,	O
induces	O
gall	Disease
bladder	Disease
stones	Disease
in	O
13-60%	O
of	O
patients.	O
Because	O
knowledge	O
of	O
stone	O
composition	O
is	O
essential	O
for	O
studies	O
of	O
their	O
pathogenesis,	O
treatment,	O
and	O
prevention,	O
this	O
was	O
investigated	O
by	O
direct	O
and	O
indirect	O
methods	O
in	O
14	O
octreotide	Chemical
treated	O
acromegalic	Disease
patients	O
with	O
gall	Disease
stones	Disease
.	O
Chemical	O
analysis	O
of	O
gall	Disease
stones	Disease
retrieved	O
at	O
cholecystectomy	O
from	O
two	O
patients,	O
showed	O
that	O
they	O
contained	O
71%	O
and	O
87%	O
cholesterol	Chemical
by	O
weight.	O
In	O
the	O
remaining	O
12	O
patients,	O
localised	O
computed	O
tomography	O
of	O
the	O
gall	O
bladder	O
showed	O
that	O
eight	O
had	O
stones	O
with	O
maximum	O
attenuation	O
scores	O
of	O
<	O
100	O
Hounsfield	O
units	O
(values	O
of	O
<	O
100	O
HU	O
predict	O
cholesterol	Chemical
rich,	O
dissolvable	O
stones).	O
Gall	O
bladder	O
bile	O
was	O
obtained	O
by	O
ultrasound	O
guided,	O
fine	O
needle	O
puncture	O
from	O
six	O
patients.	O
All	O
six	O
patients	O
had	O
supersaturated	O
bile	O
(mean	O
(SEM)	O
cholesterol	Chemical
saturation	O
index	O
of	O
1.19	O
(0.08)	O
(range	O
1.01-1.53))	O
and	O
all	O
had	O
abnormally	O
rapid	O
cholesterol	Chemical
microcrystal	O
nucleation	O
times	O
(<	O
4	O
days	O
(range	O
1-4)),	O
whilst	O
in	O
four,	O
the	O
bile	O
contained	O
cholesterol	Chemical
microcrystals	O
immediately	O
after	O
sampling.	O
Of	O
the	O
12	O
patients	O
considered	O
for	O
oral	O
ursodeoxycholic	Chemical
acid	Chemical
(	O
UDCA	Chemical
)	O
treatment,	O
two	O
had	O
a	O
blocked	O
cystic	O
duct	O
and	O
were	O
not	O
started	O
on	O
UDCA	Chemical
while	O
one	O
was	O
lost	O
to	O
follow	O
up.	O
After	O
one	O
year	O
of	O
treatment,	O
five	O
of	O
the	O
remaining	O
nine	O
patients	O
showed	O
either	O
partial	O
(n	O
=	O
3)	O
or	O
complete	O
(n	O
=	O
2)	O
gall	Disease
stone	Disease
dissolution,	O
suggesting	O
that	O
their	O
stones	O
were	O
cholesterol	Chemical
rich.	O
This	O
corresponds,	O
by	O
actuarial	O
(life	O
table)	O
analysis,	O
to	O
a	O
combined	O
gall	Disease
stone	Disease
dissolution	O
rate	O
of	O
58.3	O
(15.9%).	O
In	O
conclusion,	O
octreotide	Chemical
induced	O
gall	Disease
stones	Disease
are	O
generally	O
small,	O
multiple,	O
and	O
cholesterol	Chemical
rich	O
although,	O
in	O
common	O
with	O
spontaneous	O
gall	Disease
stone	Disease
disease	Disease
,	O
at	O
presentation	O
some	O
patients	O
will	O
have	O
a	O
blocked	O
cystic	O
duct	O
and	O
some	O
gall	Disease
stones	Disease
containing	O
calcium	Chemical

Cardiovascular	Disease
complications	Disease
associated	O
with	O
terbutaline	Chemical
treatment	O
for	O
preterm	Disease
labor	Disease
.	O
Severe	O
cardiovascular	Disease
complications	Disease
occurred	O
in	O
eight	O
of	O
160	O
patients	O
treated	O
with	O
terbutaline	Chemical
for	O
preterm	Disease
labor	Disease

Neurologic	O
effects	O
of	O
subarachnoid	O
administration	O
of	O
2-chloroprocaine-CE	Chemical
,	O
bupivacaine	Chemical
,	O
and	O
low	O
pH	O
normal	O
saline	O
in	O
dogs.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
neurologic	O
consequences	O
of	O
deliberate	O
subarachnoid	O
injection	O
of	O
large	O
volumes	O
of	O
2-chloroprocaine-CE	Chemical
in	O
experimental	O
animals.	O
The	O
possible	O
role	O
of	O
low	O
pH	O
as	O
well	O
as	O
total	O
volume	O
as	O
potential	O
factors	O
in	O
causing	O
neurotoxicity	Disease
was	O
evaluated.	O
The	O
65	O
dogs	O
in	O
the	O
study	O
received	O
injections	O
in	O
the	O
subarachnoid	O
space	O
as	O
follows:	O
6	O
to	O
8	O
ml	O
of	O
bupivacaine	Chemical
(N	O
=	O
15),	O
2-chloroprocaine-CE	Chemical
(N	O
=	O
20),	O
low	O
pH	O
normal	O
saline	O
(pH	O
3.0)	O
(N	O
=	O
20),	O
or	O
normal	O
saline	O
(N	O
=	O
10).	O
Of	O
the	O
20	O
animals	O
that	O
received	O
subarachnoid	O
injection	O
of	O
2-chloroprocaine-CE	Chemical
seven	O
(35%)	O
developed	O
hind-limb	O
paralysis	Disease
.	O
None	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	Chemical
,	O
normal	O
saline,	O
or	O
normal	O
saline	O
titrated	O
to	O
a	O
pH	O
3.0	O
developed	O
hind-limb	O
paralysis	Disease
.	O
Of	O
the	O
15	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
2-chloroprocaine-CE	Chemical
,	O
13	O
showed	O
subpial	Disease
necrosis	Disease
;	O
the	O
nerve	O
roots	O
and	O
subarachnoid	O
vessels	O
were	O
normal.	O
The	O
spinal	O
cords	O
of	O
the	O
animals	O
that	O
received	O
bupivacaine	Chemical

Early	O
adjuvant	O
adriamycin	Chemical
in	O
superficial	O
bladder	Disease
carcinoma	Disease
.	O
A	O
multicenter	O
study	O
was	O
performed	O
in	O
110	O
patients	O
with	O
superficial	O
transitional	O
cell	O
carcinoma	Disease
of	Disease
the	Disease
bladder	Disease
.	O
Adriamycin	Chemical
(50	O
mg/50	O
ml)	O
was	O
administered	O
intravesically	O
within	O
24	O
h	O
after	O
transurethral	O
resection	O
of	O
TA-T1	O
(O-A)	O
bladder	Disease
tumors	Disease
.	O
Instillation	O
was	O
repeated	O
twice	O
during	O
the	O
first	O
week,	O
then	O
weekly	O
during	O
the	O
first	O
month	O
and	O
afterwards	O
monthly	O
for	O
1	O
year.	O
The	O
tolerance	O
was	O
evaluated	O
in	O
these	O
110	O
patients,	O
and	O
29	O
patients	O
presented	O
with	O
local	O
side-effects.	O
In	O
24	O
of	O
these	O
patients	O
chemical	O
cystitis	Disease
was	O
severe	O
enough	O
for	O
them	O
to	O
drop	O
out	O
of	O
the	O
study.	O
No	O
systemic	O
side-effects	O
were	O
observed.	O
Recurrence	O
was	O
studied	O
in	O
82	O
evaluable	O
patients	O
after	O
1	O
year	O
of	O
follow-up	O
and	O
in	O
72	O
patients	O
followed	O
for	O
2-3	O
years	O
(mean	O
32	O
months).	O
Of	O
the	O
82	O
patients	O
studied	O
after	O
1	O
year,	O
23	O
had	O
primary	O
and	O
59	O
recurrent	O
disease.	O
Of	O
the	O
82	O
evaluable	O
patients,	O
50	O
did	O
not	O
show	O
any	O
recurrence	O
after	O
1	O
year	O
(61%),	O
while	O
32	O
presented	O
with	O
one	O
or	O
more	O
recurrences	O
(39%).	O
Of	O
these	O
recurrences,	O
27	O
were	O
T1	O
tumors	Disease
while	O
five	O
progressed	O
to	O
more	O
highly	O
invasive	O
lesions.	O
In	O
patients	O
that	O
were	O
free	O
of	O
recurrence	O
during	O
the	O
first	O
year,	O
80%	O
remained	O
tumor	Disease
-free	O
during	O
the	O
2-	O
to	O
3-year	O
follow-up	O
period.	O
Of	O
the	O
patients	O
developing	O
one	O
or	O
more	O
recurrences	O
during	O
the	O
first	O
year,	O
only	O
50%	O
presented	O
with	O
further	O
recurrence	O
once	O
the	O
instillations	O
were	O
stopped.	O
The	O
beneficial	O
effect	O
of	O
Adriamycin	Chemical

Hyperkalemia	Disease
associated	O
with	O
sulindac	Chemical
therapy.	O
Hyperkalemia	Disease
has	O
recently	O
been	O
recognized	O
as	O
a	O
complication	O
of	O
nonsteroidal	O
antiinflammatory	O
agents	O
(NSAID)	O
such	O
as	O
indomethacin	Chemical
.	O
Several	O
recent	O
studies	O
have	O
stressed	O
the	O
renal	O
sparing	O
features	O
of	O
sulindac	Chemical
,	O
owing	O
to	O
its	O
lack	O
of	O
interference	O
with	O
renal	O
prostacyclin	Chemical
synthesis.	O
We	O
describe	O
4	O
patients	O
in	O
whom	O
hyperkalemia	Disease
ranging	O
from	O
6.1	O
to	O
6.9	O
mEq/l	O
developed	O
within	O
3	O
to	O
8	O
days	O
of	O
sulindac	Chemical
administration.	O
In	O
all	O
of	O
them	O
normal	O
serum	O
potassium	Chemical
levels	O
reached	O
within	O
2	O
to	O
4	O
days	O
of	O
stopping	O
sulindac	Chemical
.	O
As	O
no	O
other	O
medications	O
known	O
to	O
effect	O
serum	O
potassium	Chemical
had	O
been	O
given	O
concomitantly,	O
this	O
course	O
of	O
events	O
is	O
suggestive	O
of	O
a	O
cause-and-effect	O
relationship	O
between	O
sulindac	Chemical
and	O
hyperkalemia	Disease
.	O
These	O
observations	O
indicate	O
that	O
initial	O
hopes	O
that	O
sulindac	Chemical

Ventricular	Disease
tachyarrhythmias	Disease
during	O
cesarean	O
section	O
after	O
ritodrine	Chemical
therapy:	O
interaction	O
with	O
anesthetics.	O
This	O
case	O
illustrates	O
that	O
patients	O
receiving	O
ritodrine	Chemical
for	O
preterm	Disease
labor	Disease
may	O
risk	O
interactions	O
between	O
the	O
residual	O
betamimetic	O
effects	O
of	O
ritodrine	Chemical
and	O
the	O
effects	O
of	O
anesthetics	O
during	O
cesarean	O
section.	O
Such	O
interactions	O
may	O
result	O
in	O
serious	O
cardiovascular	Disease
complications	Disease
even	O
after	O
cessation	O
of	O
an	O
infusion	O
of	O
ritodrine	Chemical
.	O
Preoperative	O
assessment	O
should	O
focus	O
on	O
cardiovascular	O
status	O
and	O
serum	O
potassium	Chemical
level.	O
Delaying	O
induction	O
of	O
anesthesia	O
should	O
be	O
considered	O
whenever	O
possible.	O
Careful	O
fluid	O
administration	O
and	O
cautious	O
use	O
of	O
titrated	O
doses	O
of	O
ephedrine	Chemical
are	O
advised.	O
After	O
delivery	O
of	O
the	O
infant,	O
there	O
should	O
be	O
no	O
contraindication	O
to	O
the	O
use	O
of	O
an	O
alpha-adrenergic	O
vasopressor	O
such	O
as	O
phenylephrine	Chemical
to	O
treat	O
hypotensive	Disease
patients	O
with	O
tachycardia	Disease

Immunohistochemical,	O
electron	O
microscopic	O
and	O
morphometric	O
studies	O
of	O
estrogen	Chemical
-induced	O
rat	O
prolactinomas	Disease
after	O
bromocriptine	Chemical
treatment.	O
To	O
clarify	O
the	O
effects	O
of	O
bromocriptine	Chemical
on	O
prolactinoma	Disease
cells	O
in	O
vivo,	O
immunohistochemical,	O
ultrastructural	O
and	O
morphometrical	O
analyses	O
were	O
applied	O
to	O
estrogen	Chemical
-induced	O
rat	O
prolactinoma	Disease
cells	O
1	O
h	O
and	O
6	O
h	O
after	O
injection	O
of	O
bromocriptine	Chemical
(3	O
mg/kg	O
of	O
body	O
weight).	O
One	O
h	O
after	O
treatment,	O
serum	O
prolactin	O
levels	O
decreased	O
markedly.	O
Electron	O
microscopy	O
disclosed	O
many	O
secretory	O
granules,	O
slightly	O
distorted	O
rough	O
endoplasmic	O
reticulum,	O
and	O
partially	O
dilated	O
Golgi	O
cisternae	O
in	O
the	O
prolactinoma	Disease
cells.	O
Morphometric	O
analysis	O
revealed	O
that	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
increased,	O
while	O
the	O
volume	O
density	O
of	O
cytoplasmic	O
microtubules	O
decreased.	O
These	O
findings	O
suggest	O
that	O
lowered	O
serum	O
prolactin	O
levels	O
in	O
the	O
early	O
phase	O
of	O
bromocriptine	Chemical
treatment	O
may	O
result	O
from	O
an	O
impaired	O
secretion	O
of	O
prolactin	O
due	O
to	O
decreasing	O
numbers	O
of	O
cytoplasmic	O
microtubules.	O
At	O
6	O
h	O
after	O
injection,	O
serum	O
prolactin	O
levels	O
were	O
still	O
considerably	O
lower	O
than	O
in	O
controls.	O
The	O
prolactinoma	Disease
cells	O
at	O
this	O
time	O
were	O
well	O
granulated,	O
with	O
vesiculated	O
rough	O
endoplasmic	O
reticulum	O
and	O
markedly	O
dilated	O
Golgi	O
cisternae.	O
Electron	O
microscopical	O
immunohistochemistry	O
revealed	O
positive	O
reaction	O
products	O
noted	O
on	O
the	O
secretory	O
granules,	O
Golgi	O
cisternae,	O
and	O
endoplasmic	O
reticulum	O
of	O
the	O
untreated	O
rat	O
prolactinoma	Disease
cells.	O
However,	O
only	O
secretory	O
granules	O
showed	O
the	O
positive	O
reaction	O
products	O
for	O
prolactin	O
6	O
h	O
after	O
bromocriptine	Chemical
treatment	O
of	O
the	O
adenoma	Disease
cells.	O
An	O
increase	O
in	O
the	O
volume	O
density	O
of	O
secretory	O
granules	O
and	O
a	O
decrease	O
in	O
the	O
volume	O
densities	O
of	O
rough	O
endoplasmic	O
reticulum	O
and	O
microtubules	O
was	O
determined	O
by	O
morphometric	O
analysis,	O
suggesting	O
that	O
bromocriptine	Chemical

On	O
two	O
paradoxical	O
side-effects	O
of	O
prednisolone	Chemical
in	O
rats,	O
ribosomal	O
RNA	O
biosyntheses,	O
and	O
a	O
mechanism	O
of	O
action.	O
Liver	Disease
enlargement	Disease
and	O
muscle	Disease
wastage	Disease
occurred	O
in	O
Wistar	O
rats	O
following	O
the	O
subcutaneous	O
administration	O
of	O
prednisolone	Chemical
.	O
In	O
the	O
liver	O
both	O
the	O
content	O
of	O
RNA	O
and	O
the	O
biosynthesis	O
of	O
ribosomal	O
RNA	O
increased	O
while	O
both	O
the	O
RNA	O
content	O
and	O
ribosomal	O
RNA	O
biosynthesis	O
were	O
reduced	O
in	O
the	O
gastrocnemius	O
muscle.	O
It	O
is	O
suggested	O
that	O
the	O
drug	O
acted	O
in	O
a	O
selective	O
and	O
tissue-specific	O
manner	O
to	O
enhance	O
ribosomal	O
RNA	O
synthesis	O
in	O
the	O
liver	O
and	O
depress	O
such	O
synthesis	O
in	O
the	O
muscle.	O
This	O
view	O
supports	O
the	O
contention	O
that	O
the	O
liver	O
and	O
muscle	O
are	O
independent	O
sites	O
of	O
prednisolone	Chemical

Possible	O
intramuscular	O
midazolam	Chemical
-associated	O
cardiorespiratory	Disease
arrest	Disease
and	O
death	Disease
.	O
Midazolam	Chemical
hydrochloride	Chemical
is	O
commonly	O
used	O
for	O
dental	O
or	O
endoscopic	O
procedures.	O
Although	O
generally	O
consisted	O
safe	O
when	O
given	O
intramuscularly,	O
intravenous	O
administration	O
is	O
known	O
to	O
cause	O
respiratory	Disease
and	Disease
cardiovascular	Disease
depression	Disease
.	O
This	O
report	O
describes	O
the	O
first	O
published	O
case	O
of	O
cardiorespiratory	Disease
arrest	Disease
and	O
death	Disease
associated	O
with	O
intramuscular	O
administration	O
of	O
midazolam	Chemical
.	O
Information	O
regarding	O
midazolam	Chemical

Serial	O
epilepsy	Disease
caused	O
by	O
levodopa/carbidopa	Chemical
administration	O
in	O
two	O
patients	O
on	O
hemodialysis.	O
Two	O
patients	O
with	O
similar	O
clinical	O
features	O
are	O
presented:	O
both	O
patients	O
had	O
chronic	Disease
renal	Disease
failure	Disease
,	O
on	O
hemodialysis	O
for	O
many	O
years	O
but	O
recently	O
begun	O
on	O
a	O
high-flux	O
dialyzer;	O
both	O
had	O
been	O
receiving	O
a	O
carbidopa/levodopa	Chemical
preparation;	O
and	O
both	O
had	O
the	O
onset	O
of	O
hallucinosis	Disease
and	O
recurrent	O
seizures	Disease
,	O
which	O
were	O
refractory	O
to	O
anticonvulsants.	O
The	O
first	O
patient	O
died	O
without	O
a	O
diagnosis;	O
the	O
second	O
patient	O
had	O
a	O
dramatic	O
recovery	O
following	O
the	O
administration	O
of	O
vitamin	Chemical
B6	Chemical

Effect	O
of	O
L-alpha-glyceryl-phosphorylcholine	Chemical
on	O
amnesia	Disease
caused	O
by	O
scopolamine	Chemical
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
test	O
the	O
effects	O
of	O
L-alpha-glycerylphosphorylcholine	Chemical
(	O
L-alpha-GFC	Chemical
)	O
on	O
memory	Disease
impairment	Disease
induced	O
by	O
scopolamine	Chemical
in	O
man.	O
Thirty-two	O
healthy	O
young	O
volunteers	O
were	O
randomly	O
allocated	O
to	O
four	O
different	O
groups.	O
They	O
were	O
given	O
a	O
ten	O
day	O
pretreatment	O
with	O
either	O
L-alpha-GFC	Chemical
or	O
placebo,	O
p.o.,	O
and	O
on	O
the	O
eleventh	O
day	O
either	O
scopolamine	Chemical
or	O
placebo,	O
i.m.	O
Before	O
and	O
0.5,	O
1,	O
2,	O
3,	O
and	O
6	O
h	O
after	O
injection	O
the	O
subjects	O
were	O
given	O
attention	O
and	O
mnemonic	O
tests.	O
The	O
findings	O
of	O
this	O
study	O
indicate	O
that	O
the	O
drug	O
is	O
able	O
to	O
antagonize	O
impairment	Disease
of	Disease
attention	Disease
and	Disease
memory	Disease
induced	O
by	O
scopolamine	Chemical

Seizures	Disease
induced	O
by	O
the	O
cocaine	Chemical
metabolite	O
benzoylecgonine	Chemical
in	O
rats.	O
The	O
half-life	O
(t1/2)	O
of	O
cocaine	Chemical
is	O
relatively	O
short,	O
but	O
some	O
of	O
the	O
consequences	O
of	O
its	O
use,	O
such	O
as	O
seizures	Disease
and	O
strokes	Disease
,	O
can	O
occur	O
hours	O
after	O
exposure.	O
This	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
metabolite	O
of	O
cocaine	Chemical
may	O
be	O
responsible	O
for	O
some	O
of	O
those	O
delayed	O
sequelae.	O
We	O
evaluated	O
the	O
potential	O
of	O
the	O
major	O
metabolite	O
of	O
cocaine	Chemical
,	O
benzoylecgonine	Chemical
(	O
BE	Chemical
),	O
to	O
cause	O
seizures	Disease
.	O
Two	O
separate	O
equimolar	O
doses	O
(0.2	O
and	O
0.4	O
mumol)	O
of	O
either	O
cocaine	Chemical
or	O
BE	Chemical
were	O
injected	O
ventricularly	O
in	O
unanesthetized	O
juvenile	O
rats.	O
Treated	O
rats	O
were	O
then	O
evaluated	O
for	O
incidence,	O
latency,	O
and	O
seizure	Disease
pattern	O
or	O
for	O
locomotor	O
activity	O
in	O
animals	O
without	O
seizures	Disease
.	O
BE	Chemical
-Induced	O
seizures	Disease
occurred	O
more	O
frequently	O
and	O
had	O
significantly	O
longer	O
latencies	O
than	O
those	O
induced	O
by	O
equimolar	O
amounts	O
of	O
cocaine	Chemical
.	O
Whereas	O
cocaine	Chemical
-induced	O
seizures	Disease
were	O
best	O
characterized	O
as	O
brief,	O
generalized,	O
and	O
tonic	O
and	O
resulted	O
in	O
death	Disease
,	O
those	O
induced	O
by	O
BE	Chemical
were	O
prolonged,	O
often	O
multiple	O
and	O
mixed	O
in	O
type,	O
and	O
rarely	O
resulted	O
in	O
death	Disease
.	O
Electrical	O
recordings	O
from	O
the	O
hippocampus	O
showed	O
a	O
rhythmic	O
progression	O
in	O
EEG	O
frequency	O
and	O
voltage	O
with	O
clinical	O
seizure	Disease
expression.	O
BE	Chemical
-Injected	O
rats	O
that	O
did	O
not	O
have	O
seizures	Disease
had	O
significantly	O
more	O
locomotor	O
activity	O
than	O
cocaine	Chemical
-injected	O
animals	O
without	O
seizures	Disease
.	O
The	O
finding	O
that	O
cocaine	Chemical
-	O
and	O
BE	Chemical
-induced	O
seizures	Disease
differ	O
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mechanism	O
for	O
cocaine	Chemical
-induced	O
seizures	Disease
and	O
emphasizes	O
the	O
importance	O
of	O
a	O
cocaine	Chemical
metabolite,	O
BE	Chemical

Protection	O
against	O
amphetamine	Chemical
-induced	O
neurotoxicity	Disease
toward	O
striatal	O
dopamine	Chemical
neurons	O
in	O
rodents	O
by	O
LY274614	Chemical
,	O
an	O
excitatory	O
amino	Chemical
acid	Chemical
antagonist.	O
LY274614	Chemical
,	O
3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr	Chemical
oisoquinoline-3-	Chemical
carboxylic	Chemical
acid	Chemical
,	O
has	O
been	O
described	O
as	O
a	O
potent	O
antagonist	O
of	O
the	O
N-methyl-D-aspartate	Chemical
(	O
NMDA	Chemical
)	O
subtype	O
of	O
glutamate	Chemical
receptor.	O
Here	O
its	O
ability	O
to	O
antagonize	O
the	O
prolonged	O
depletion	O
of	O
dopamine	Chemical
in	O
the	O
striatum	O
by	O
amphetamine	Chemical
in	O
iprindole	Chemical
-treated	O
rats	O
is	O
reported.	O
A	O
single	O
18.4	O
mg/kg	O
(i.p.)	O
dose	O
of	O
(+/-)-	O
amphetamine	Chemical
hemisulfate,	O
given	O
to	O
rats	O
pretreated	O
with	O
iprindole	Chemical
,	O
resulted	O
in	O
persistent	O
depletion	O
of	O
dopamine	Chemical
in	O
the	O
striatum	O
1	O
week	O
later.	O
This	O
prolonged	O
depletion	O
of	O
dopamine	Chemical
in	O
the	O
striatum	O
was	O
antagonized	O
by	O
dizocilpine	Chemical
(	O
MK-801	Chemical
,	O
a	O
non-competitive	O
antagonist	O
of	O
NMDA	Chemical
receptors)	O
or	O
by	O
LY274614	Chemical
(a	O
competitive	O
antagonist	O
of	O
NMDA	Chemical
receptors).	O
The	O
protective	O
effect	O
of	O
LY274614	Chemical
was	O
dose-dependent,	O
being	O
maximum	O
at	O
10-40	O
mgkg	O
(i.p.).	O
A	O
10	O
mg/kg	O
dose	O
of	O
LY274614	Chemical
was	O
effective	O
in	O
antagonizing	O
the	O
depletion	O
of	O
dopamine	Chemical
in	O
the	O
striatum,	O
when	O
given	O
as	O
long	O
as	O
8	O
hr	O
prior	O
to	O
amphetamine	Chemical
but	O
not	O
when	O
given	O
24	O
hr	O
prior	O
to	O
amphetamine	Chemical
.	O
Depletion	O
of	O
dopamine	Chemical
in	O
the	O
striatum	O
was	O
also	O
antagonized	O
when	O
LY274614	Chemical
was	O
given	O
after	O
the	O
injection	O
of	O
amphetamine	Chemical
;	O
LY274614	Chemical
protected	O
when	O
given	O
up	O
to	O
4	O
hr	O
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	O
after	O
amphetamine	Chemical
.	O
The	O
prolonged	O
depletion	O
of	O
dopamine	Chemical
in	O
the	O
striatum	O
in	O
mice,	O
given	O
multiple	O
injections	O
of	O
methamphetamine	Chemical
,	O
was	O
also	O
antagonized	O
dose-dependently	O
and	O
completely	O
by	O
LY274614	Chemical
.	O
The	O
data	O
strengthen	O
the	O
evidence	O
that	O
the	O
neurotoxic	Disease
effect	O
of	O
amphetamine	Chemical
and	O
related	O
compounds	O
toward	O
nigrostriatal	O
dopamine	Chemical
neurons	O
involves	O
NMDA	Chemical
receptors	O
and	O
that	O
LY274614	Chemical
is	O
an	O
NMDA	Chemical

Neonatal	O
pyridoxine	Chemical
responsive	O
convulsions	Disease
due	O
to	O
isoniazid	Chemical
therapy.	O
A	O
17-day-old	O
infant	O
on	O
isoniazid	Chemical
therapy	O
13	O
mg/kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	Disease
was	O
admitted	O
after	O
4	O
days	O
of	O
clonic	Disease
fits	Disease
.	O
No	O
underlying	O
infective	O
or	O
biochemical	O
cause	O
could	O
be	O
found.	O
The	O
fits	Disease
ceased	O
within	O
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	Chemical
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	Chemical
deficiency	O
secondary	O
to	O
isoniazid	Chemical

Reversal	O
by	O
phenylephrine	Chemical
of	O
the	O
beneficial	O
effects	O
of	O
intravenous	O
nitroglycerin	Chemical
in	O
patients	O
with	O
acute	Disease
myocardial	Disease
infarction	Disease
.	O
Nitroglycerin	Chemical
has	O
been	O
shown	O
to	O
reduce	O
ST-segment	O
elevation	O
during	O
acute	Disease
myocardial	Disease
infarction	Disease
,	O
an	O
effect	O
potentiated	O
in	O
the	O
dog	O
by	O
agents	O
that	O
reverse	O
nitroglycerin	Chemical
-induced	O
hypotension	Disease
.	O
Our	O
study	O
was	O
designed	O
to	O
determine	O
the	O
effects	O
of	O
combined	O
nitroglycerin	Chemical
and	O
phenylephrine	Chemical
therapy.	O
Ten	O
patients	O
with	O
acute	O
transmural	O
myocardial	Disease
infarctions	Disease
received	O
intravenous	O
nitroglycerin	Chemical
,	O
sufficient	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
from	O
107	O
+/-	O
6	O
to	O
85	O
+/-	O
6	O
mm	O
Hg	O
(P	O
less	O
than	O
0.001),	O
for	O
60	O
minutes.	O
Left	O
ventricular	O
filling	O
pressure	O
decreased	O
from	O
19	O
+/-	O
2	O
to	O
11	O
+/-	O
2	O
mm	O
Hg	O
(P	O
less	O
than	O
0.001).	O
SigmaST,	O
the	O
sum	O
of	O
ST-segment	O
elevations	O
in	O
16	O
precordial	O
leads,	O
decreased	O
(P	O
less	O
than	O
0.02)	O
with	O
intravenous	O
nitroglycerin	Chemical
.	O
Subsequent	O
addition	O
of	O
phenylephrine	Chemical
infusion,	O
sufficient	O
to	O
re-elevate	O
mean	O
arterial	O
pressure	O
to	O
106	O
+/-	O
4	O
mm	O
Hg	O
(P	O
less	O
than	O
0.001)	O
for	O
30	O
minutes,	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
to	O
17	O
+/-	O
2	O
mm	O
Hg	O
(P	O
less	O
than	O
0.05)	O
and	O
also	O
significantly	O
increased	O
sigmaST	O
(P	O
less	O
than	O
0.05).	O
Our	O
results	O
suggest	O
that	O
addition	O
of	O
phenylephrine	Chemical
to	O
nitroglycerin	Chemical
is	O
not	O
beneficial	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
acute	Disease
myocardial	Disease
infarction	Disease

Elevation	O
of	O
ADAM10,	O
ADAM17,	O
MMP-2	O
and	O
MMP-9	O
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2	Chemical
-induced	O
thoracic	Disease
aortic	Disease
aneurysm	Disease
in	O
a	O
rat	O
model.	O
PURPOSE:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
model	O
of	O
thoracic	Disease
aortic	Disease
aneurysm	Disease
(	O
TAA	Disease
)	O
by	O
calcium	Chemical
chloride	Chemical
(	O
CaCl(2)	Chemical
)-induced	O
arterial	Disease
injury	Disease
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	O
disintegrin	O
and	O
metalloproteinase	O
(ADAM),	O
matrix	O
metalloproteinases	O
(MMPs)	O
and	O
their	O
endogenous	O
inhibitors	O
(TIMPs)	O
in	O
TAA	Disease
formation.	O
METHODS:	O
Thoracic	O
aorta	O
of	O
male	O
Sprague-Dawley	O
rats	O
was	O
exposed	O
to	O
0.5M	O
CaCl(2)	Chemical
or	O
normal	O
saline	O
(	O
NaCl	Chemical
).	O
After	O
12weeks,	O
animals	O
were	O
euthanized,	O
and	O
CaCl(2)	Chemical
-treated,	O
CaCl(2)	Chemical
-untreated	O
(n=12)	O
and	O
NaCl	Chemical
-treated	O
aortic	O
segments	O
(n=12)	O
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments.	O
MMP-TIMP	O
and	O
ADAM	O
mRNAs	O
were	O
semi-quantitatively	O
analyzed	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
immunohistochemistry.	O
RESULTS:	O
Despite	O
similar	O
external	O
diameters	O
among	O
CaCl(2)	Chemical
-treated,	O
non-	O
CaCl(2)	Chemical
-treated	O
and	O
NaCl	Chemical
-treated	O
segments,	O
aneurymal	O
alteration	O
(n=6,	O
50%),	O
media	O
degeneration	O
with	O
regional	O
disruption,	O
fragmentation	O
of	O
elastic	O
fiber,	O
and	O
increased	O
collagen	O
deposition	O
(n=12,	O
100%)	O
were	O
demonstrated	O
in	O
CaCl(2)	Chemical
-treated	O
segments.	O
MMP-2,	O
MMP-9,	O
ADAM-10	O
and	O
ADAM-17	O
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl(2)	Chemical
-treated	O
segments	O
(all	O
p<0.01),	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl(2)	Chemical
-untreated	O
segments,	O
as	O
compared	O
with	O
NaCl	Chemical
-treated	O
segments.	O
Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP-2,	O
MMP-9,	O
ADAM-10	O
and	O
ADAM-17	O
(all	O
p<0.01)	O
in	O
intima	O
and	O
media	O
for	O
CaCl(2)	Chemical
-treated	O
segments.	O
TIMP	O
mRNA	O
and	O
tissue	O
levels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aortic	O
segments.	O
CONCLUSION:	O
This	O
study	O
establishes	O
a	O
TAA	Disease
model	O
by	O
periarterial	O
CaCl(2)	Chemical

When	O
drugs	O
disappear	O
from	O
the	O
patient:	O
elimination	O
of	O
intravenous	O
medication	O
by	O
hemodiafiltration.	O
Twenty-three	O
hours	O
after	O
heart	O
transplantation,	O
life-threatening	O
acute	O
right	Disease
heart	Disease
failure	Disease
was	O
diagnosed	O
in	O
a	O
patient	O
requiring	O
continuous	O
venovenous	O
hemodiafiltration	O
(CVVHDF).	O
Increasing	O
doses	O
of	O
catecholamines	Chemical
,	O
sedatives,	O
and	O
muscle	O
relaxants	O
administered	O
through	O
a	O
central	O
venous	O
catheter	O
were	O
ineffective.	O
However,	O
a	O
bolus	O
of	O
epinephrine	Chemical
injected	O
through	O
an	O
alternative	O
catheter	O
provoked	O
a	O
hypertensive	Disease
crisis.	O
Thus,	O
interference	O
with	O
the	O
central	O
venous	O
infusion	O
by	O
the	O
dialysis	O
catheter	O
was	O
suspected.	O
The	O
catheters	O
were	O
changed,	O
and	O
hemodynamics	O
stabilized	O
at	O
lower	O
catecholamine	Chemical

Long-term	O
glutamate	Chemical
supplementation	O
failed	O
to	O
protect	O
against	O
peripheral	Disease
neurotoxicity	Disease
of	O
paclitaxel	Chemical
.	O
Toxic	O
peripheral	Disease
neuropathy	Disease
is	O
still	O
a	O
significant	O
limiting	O
factor	O
for	O
chemotherapy	O
with	O
paclitaxel	Chemical
(	O
PAC	Chemical
),	O
although	O
glutamate	Chemical
and	O
its	O
closely	O
related	O
amino	Chemical
acid	Chemical
	O
glutamine	Chemical
were	O
claimed	O
to	O
ameliorate	O
PAC	Chemical
	O
neurotoxicity	Disease
.	O
This	O
pilot	O
trial	O
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
glutamate	Chemical
supplementation	O
for	O
preventing	O
PAC	Chemical
-induced	O
peripheral	Disease
neuropathy	Disease
in	O
a	O
randomized,	O
placebo-controlled,	O
double-blinded	O
clinical	O
and	O
electro-diagnostic	O
study.	O
Forty-three	O
ovarian	Disease
cancer	Disease
patients	O
were	O
available	O
for	O
analysis	O
following	O
six	O
cycles	O
of	O
the	O
same	O
PAC	Chemical
-containing	O
regimen:	O
23	O
had	O
been	O
supplemented	O
by	O
glutamate	Chemical
all	O
along	O
the	O
treatment	O
period,	O
at	O
a	O
daily	O
dose	O
of	O
three	O
times	O
500	O
mg	O
(group	O
G),	O
and	O
20	O
had	O
received	O
a	O
placebo	O
(group	O
P).	O
Patients	O
were	O
evaluated	O
by	O
neurological	O
examinations,	O
questionnaires	O
and	O
sensory-motor	O
nerve	O
conduction	O
studies.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
signs	O
or	O
symptoms	O
between	O
the	O
two	O
groups	O
although	O
neurotoxicity	Disease
symptoms	O
presented	O
mostly	O
with	O
lower	O
scores	O
of	O
severity	O
in	O
group	O
G.	O
However,	O
this	O
difference	O
reached	O
statistical	O
significance	O
only	O
with	O
regard	O
to	O
reported	O
pain	Disease
sensation	O
(P	O
=	O
0.011).	O
Also	O
the	O
frequency	O
of	O
abnormal	O
electro-diagnostic	O
findings	O
showed	O
similarity	O
between	O
the	O
two	O
groups	O
(G:	O
7/23	O
=	O
30.4%;	O
P:	O
6/20	O
=	O
30%).	O
This	O
pilot	O
study	O
leads	O
to	O
the	O
conclusion	O
that	O
glutamate	Chemical
supplementation	O
at	O
the	O
chosen	O
regimen	O
fails	O
to	O
protect	O
against	O
peripheral	Disease
neurotoxicity	Disease
of	O
PAC	Chemical

Attentional	O
modulation	O
of	O
perceived	O
pain	Disease
intensity	O
in	O
capsaicin	Chemical
-induced	O
secondary	O
hyperalgesia	Disease
.	O
Perceived	O
pain	Disease
intensity	O
is	O
modulated	O
by	O
attention.	O
However,	O
it	O
is	O
not	O
known	O
that	O
how	O
pain	Disease
intensity	O
ratings	O
are	O
affected	O
by	O
attention	O
in	O
capsaicin	Chemical
-induced	O
secondary	O
hyperalgesia	Disease
.	O
Here	O
we	O
show	O
that	O
perceived	O
pain	Disease
intensity	O
in	O
secondary	O
hyperalgesia	Disease
is	O
decreased	O
when	O
attention	O
is	O
distracted	O
away	O
from	O
the	O
painful	O
pinprick	O
stimulus	O
with	O
a	O
visual	O
task.	O
Furthermore,	O
it	O
was	O
found	O
that	O
the	O
magnitude	O
of	O
attentional	O
modulation	O
in	O
secondary	O
hyperalgesia	Disease
is	O
very	O
similar	O
to	O
that	O
of	O
capsaicin	Chemical
-untreated,	O
control	O
condition.	O
Our	O
findings,	O
showing	O
no	O
interaction	O
between	O
capsaicin	Chemical
treatment	O
and	O
attentional	O
modulation	O
suggest	O
that	O
capsaicin	Chemical
-induced	O
secondary	O
hyperalgesia	Disease
and	O
attention	O
might	O
affect	O
mechanical	O
pain	Disease

Testosterone	Chemical
-dependent	O
hypertension	Disease
and	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
in	O
Dahl	O
salt	Chemical
-sensitive	O
rats.	O
Blood	O
pressure	O
(BP)	O
is	O
more	O
salt	Chemical
sensitive	O
in	O
men	O
than	O
in	O
premenopausal	O
women.	O
In	O
Dahl	O
salt	Chemical
-sensitive	O
rats	O
(DS),	O
high-	O
salt	Chemical
(HS)	O
diet	O
increases	O
BP	O
more	O
in	O
males	O
than	O
females.	O
In	O
contrast	O
to	O
the	O
systemic	O
renin-	O
angiotensin	Chemical
system,	O
which	O
is	O
suppressed	O
in	O
response	O
to	O
HS	O
in	O
male	O
DS,	O
intrarenal	O
angiotensinogen	O
expression	O
is	O
increased,	O
and	O
intrarenal	O
levels	O
of	O
ANG	O
II	O
are	O
not	O
suppressed.	O
In	O
this	O
study,	O
the	O
hypothesis	O
was	O
tested	O
that	O
there	O
is	O
a	O
sexual	O
dimorphism	O
in	O
HS-induced	O
upregulation	O
of	O
intrarenal	O
angiotensinogen	O
mediated	O
by	O
testosterone	Chemical
that	O
also	O
causes	O
increases	O
in	O
BP	O
and	O
renal	Disease
injury	Disease
.	O
On	O
a	O
low-	O
salt	Chemical
(LS)	O
diet,	O
male	O
DS	O
had	O
higher	O
levels	O
of	O
intrarenal	O
angiotensinogen	O
mRNA	O
than	O
females.	O
HS	O
diet	O
for	O
4	O
wk	O
increased	O
renal	O
cortical	O
angiotensinogen	O
mRNA	O
and	O
protein	O
only	O
in	O
male	O
DS,	O
which	O
was	O
prevented	O
by	O
castration.	O
Ovariectomy	O
of	O
female	O
DS	O
had	O
no	O
effect	O
on	O
intrarenal	O
angiotensinogen	O
expression	O
on	O
either	O
diet.	O
Radiotelemetric	O
BP	O
was	O
similar	O
between	O
males	O
and	O
castrated	O
rats	O
on	O
LS	O
diet.	O
HS	O
diet	O
for	O
4	O
wk	O
caused	O
a	O
progressive	O
increase	O
in	O
BP,	O
protein	O
and	O
albumin	O
excretion,	O
and	O
glomerular	Disease
sclerosis	Disease
in	O
male	O
DS	O
rats,	O
which	O
were	O
attenuated	O
by	O
castration.	O
Testosterone	Chemical
replacement	O
in	O
castrated	O
DS	O
rats	O
increased	O
BP,	O
renal	Disease
injury	Disease
,	O
and	O
upregulation	O
of	O
renal	O
angiotensinogen	O
associated	O
with	O
HS	O
diet.	O
Testosterone	Chemical
contributes	O
to	O
the	O
development	O
of	O
hypertension	Disease
and	O
renal	Disease
injury	Disease
in	O
male	O
DS	O
rats	O
on	O
HS	O
diet	O
possibly	O
through	O
upregulation	O
of	O
the	O
intrarenal	O
renin-	O
angiotensin	Chemical

Prenatal	O
protein	O
deprivation	O
alters	O
dopamine	Chemical
-mediated	O
behaviors	O
and	O
dopaminergic	O
and	O
glutamatergic	O
receptor	O
binding.	O
Epidemiological	O
evidence	O
indicates	O
that	O
prenatal	O
nutritional	O
deprivation	O
may	O
increase	O
the	O
risk	O
of	O
schizophrenia	Disease
.	O
The	O
goal	O
of	O
these	O
studies	O
was	O
to	O
use	O
an	O
animal	O
model	O
to	O
examine	O
the	O
effects	O
of	O
prenatal	O
protein	O
deprivation	O
on	O
behaviors	O
and	O
receptor	O
binding	O
with	O
relevance	O
to	O
schizophrenia	Disease
.	O
We	O
report	O
that	O
prenatally	O
protein	O
deprived	O
(PD)	O
female	O
rats	O
showed	O
an	O
increased	O
stereotypic	O
response	O
to	O
apomorphine	Chemical
and	O
an	O
increased	O
locomotor	O
response	O
to	O
amphetamine	Chemical
in	O
adulthood.	O
These	O
differences	O
were	O
not	O
observed	O
during	O
puberty.	O
No	O
changes	O
in	O
haloperidol	Chemical
-induced	O
catalepsy	Disease
or	O
MK-801	Chemical
-induced	O
locomotion	O
were	O
seen	O
following	O
PD.	O
In	O
addition,	O
PD	O
female	O
rats	O
showed	O
increased	O
(3)	O
H	Chemical
-	O
MK-801	Chemical
binding	O
in	O
the	O
striatum	O
and	O
hippocampus,	O
but	O
not	O
in	O
the	O
cortex.	O
PD	O
female	O
rats	O
also	O
showed	O
increased	O
(3)	O
H	Chemical
-	O
haloperidol	Chemical
binding	O
and	O
decreased	O
dopamine	Chemical
transporter	O
binding	O
in	O
striatum.	O
No	O
statistically	O
significant	O
changes	O
in	O
behavior	O
or	O
receptor	O
binding	O
were	O
found	O
in	O
PD	O
males	O
with	O
the	O
exception	O
of	O
increased	O
(3)	O
H	Chemical
-	O
MK-801	Chemical
binding	O
in	O
cortex.	O
This	O
animal	O
model	O
may	O
be	O
useful	O
to	O
explore	O
the	O
mechanisms	O
by	O
which	O
prenatal	O
nutritional	Disease
deficiency	Disease
enhances	O
risk	O
for	O
schizophrenia	Disease

mToR	O
inhibitors-induced	O
proteinuria	Disease
:	O
mechanisms,	O
significance,	O
and	O
management.	O
Massive	O
urinary	O
protein	O
excretion	O
has	O
been	O
observed	O
after	O
conversion	O
from	O
calcineurin	O
inhibitors	O
to	O
mammalian	O
target	O
of	O
rapamycin	Chemical
(mToR)	O
inhibitors,	O
especially	O
sirolimus	Chemical
,	O
in	O
renal	O
transplant	O
recipients	O
with	O
chronic	Disease
allograft	Disease
nephropathy	Disease
.	O
Because	O
proteinuria	Disease
is	O
a	O
major	O
predictive	O
factor	O
of	O
poor	O
transplantation	O
outcome,	O
many	O
studies	O
focused	O
on	O
this	O
adverse	O
event	O
during	O
the	O
past	O
years.	O
Whether	O
proteinuria	Disease
was	O
due	O
to	O
sirolimus	Chemical
or	O
only	O
a	O
consequence	O
of	O
calcineurin	O
inhibitors	O
withdrawal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinuria	Disease
has	O
been	O
observed	O
during	O
sirolimus	Chemical
therapy	O
in	O
islet	O
transplantation	O
and	O
in	O
patients	O
who	O
received	O
sirolimus	Chemical
de	O
novo.	O
Podocyte	O
injury	O
and	O
focal	O
segmental	O
glomerulosclerosis	Disease
have	O
been	O
related	O
to	O
mToR	O
inhibition	O
in	O
some	O
patients,	O
but	O
the	O
pathways	O
underlying	O
these	O
lesions	O
remain	O
hypothetic.	O
We	O
discuss	O
herein	O
the	O
possible	O
mechanisms	O
and	O
the	O
significance	O
of	O
mToR	O
blockade-induced	O
proteinuria	Disease

Hypothalamic	O
prolactin	O
receptor	O
messenger	O
ribonucleic	Chemical
acid	Chemical
levels,	O
prolactin	O
signaling,	O
and	O
hyperprolactinemic	Disease
inhibition	O
of	O
pulsatile	O
luteinizing	O
hormone	O
secretion	O
are	O
dependent	O
on	O
estradiol	Chemical
.	O
Hyperprolactinemia	Disease
can	O
reduce	O
fertility	O
and	O
libido.	O
Although	O
central	O
prolactin	O
actions	O
are	O
thought	O
to	O
contribute	O
to	O
this,	O
the	O
mechanisms	O
are	O
poorly	O
understood.	O
We	O
first	O
tested	O
whether	O
chronic	O
hyperprolactinemia	Disease
inhibited	O
two	O
neuroendocrine	O
parameters	O
necessary	O
for	O
female	O
fertility:	O
pulsatile	O
LH	O
secretion	O
and	O
the	O
estrogen	Chemical
-induced	O
LH	O
surge.	O
Chronic	O
hyperprolactinemia	Disease
induced	O
by	O
the	O
dopamine	Chemical
antagonist	O
sulpiride	Chemical
caused	O
a	O
40%	O
reduction	O
LH	O
pulse	O
frequency	O
in	O
ovariectomized	O
rats,	O
but	O
only	O
in	O
the	O
presence	O
of	O
chronic	O
low	O
levels	O
of	O
estradiol	Chemical
.	O
Sulpiride	Chemical
did	O
not	O
affect	O
the	O
magnitude	O
of	O
a	O
steroid	Chemical
-induced	O
LH	O
surge	O
or	O
the	O
percentage	O
of	O
GnRH	O
neurons	O
activated	O
during	O
the	O
surge.	O
Estradiol	Chemical
is	O
known	O
to	O
influence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prolactin	O
receptors	O
(PRL-R)	O
and	O
components	O
of	O
prolactin's	O
signaling	O
pathway.	O
To	O
test	O
the	O
hypothesis	O
that	O
estrogen	Chemical
increases	O
PRL-R	O
expression	O
and	O
sensitivity	O
to	O
prolactin,	O
we	O
next	O
demonstrated	O
that	O
estradiol	Chemical
greatly	O
augments	O
prolactin-induced	O
STAT5	O
activation.	O
Lastly,	O
we	O
measured	O
PRL-R	O
and	O
suppressor	O
of	O
cytokine	O
signaling	O
(SOCS-1	O
and	O
-3	O
and	O
CIS,	O
which	O
reflect	O
the	O
level	O
of	O
prolactin	O
signaling)	O
mRNAs	O
in	O
response	O
to	O
sulpiride	Chemical
and	O
estradiol	Chemical
.	O
Sulpiride	Chemical
induced	O
only	O
SOCS-1	O
in	O
the	O
medial	O
preoptic	O
area,	O
where	O
GnRH	O
neurons	O
are	O
regulated,	O
but	O
in	O
the	O
arcuate	O
nucleus	O
and	O
choroid	O
plexus,	O
PRL-R,	O
SOCS-3,	O
and	O
CIS	O
mRNA	O
levels	O
were	O
also	O
induced.	O
Estradiol	Chemical
enhanced	O
these	O
effects	O
on	O
SOCS-3	O
and	O
CIS.	O
Interestingly,	O
estradiol	Chemical
also	O
induced	O
PRL-R,	O
SOCS-3,	O
and	O
CIS	O
mRNA	O
levels	O
independently.	O
These	O
data	O
show	O
that	O
GnRH	O
pulse	O
frequency	O
is	O
inhibited	O
by	O
chronic	O
hyperprolactinemia	Disease
in	O
a	O
steroid	Chemical
-dependent	O
manner.	O
They	O
also	O
provide	O
evidence	O
for	O
estradiol	Chemical

Estrogen	O
prevents	O
cholesteryl	Chemical
ester	Chemical
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	Chemical
.	O
Individuals	O
with	O
HIV	O
can	O
now	O
live	O
long	O
lives	O
with	O
drug	O
therapy	O
that	O
often	O
includes	O
protease	O
inhibitors	O
such	O
as	O
ritonavir	Chemical
.	O
Many	O
patients,	O
however,	O
develop	O
negative	O
long-term	O
side	O
effects	O
such	O
as	O
premature	Disease
atherosclerosis	Disease
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
ritonavir	Chemical
treatment	O
increases	O
atherosclerotic	Disease
lesion	Disease
formation	O
in	O
male	O
mice	O
to	O
a	O
greater	O
extent	O
than	O
in	O
female	O
mice.	O
Furthermore,	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
ritonavir	Chemical
-treated	O
females	O
had	O
less	O
cholesteryl	Chemical
ester	Chemical
accumulation.	O
In	O
the	O
present	O
study,	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
female	O
hormones	O
influence	O
cholesterol	Chemical
metabolism	O
in	O
macrophages	O
in	O
response	O
to	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	Chemical
.	O
We	O
have	O
utilized	O
the	O
human	O
monocyte	O
cell	O
line,	O
THP-1	O
as	O
a	O
model	O
to	O
address	O
this	O
question.	O
Briefly,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage-like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta-estradiol	Chemical
(	O
E2	Chemical
),	O
100	O
nM	O
progesterone	Chemical
or	O
vehicle	O
(0.01%	O
ethanol	Chemical
).	O
Cells	O
were	O
then	O
treated	O
with	O
30	O
ng/ml	O
ritonavir	Chemical
or	O
vehicle	O
in	O
the	O
presence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h.	O
Cell	O
extracts	O
were	O
harvested,	O
and	O
lipid	O
or	O
total	O
RNA	O
was	O
isolated.	O
E2	Chemical
decreased	O
the	O
accumulation	O
of	O
cholesteryl	Chemical
esters	Chemical
in	O
macrophages	O
following	O
ritonavir	Chemical
treatment.	O
Ritonavir	Chemical
increased	O
the	O
expression	O
of	O
the	O
scavenger	O
receptor,	O
CD36	O
mRNA,	O
responsible	O
for	O
the	O
uptake	O
of	O
LDL.	O
Additionally,	O
ritonavir	Chemical
treatment	O
selectively	O
increased	O
the	O
relative	O
levels	O
of	O
PPARgamma	O
mRNA,	O
a	O
transcription	O
factor	O
responsible	O
for	O
the	O
regulation	O
of	O
CD36	O
mRNA	O
expression.	O
Treatment	O
with	O
E2	Chemical
,	O
however,	O
failed	O
to	O
prevent	O
these	O
increases	O
at	O
the	O
mRNA	O
level.	O
E2	Chemical
did,	O
however,	O
significantly	O
suppress	O
CD36	O
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry.	O
This	O
data	O
suggests	O
that	O
E2	Chemical
modifies	O
the	O
expression	O
of	O
CD36	O
at	O
the	O
level	O
of	O
protein	O
expression	O
in	O
monocyte-derived	O
macrophages	O
resulting	O
in	O
reduced	O
cholesteryl	Chemical
ester	Chemical
accumulation	O
following	O
ritonavir	Chemical

Upregulation	O
of	O
brain	O
expression	O
of	O
P-glycoprotein	O
in	O
MRP2-deficient	O
TR(-)	O
rats	O
resembles	O
seizure	Disease
-induced	O
up-regulation	O
of	O
this	O
drug	O
efflux	O
transporter	O
in	O
normal	O
rats.	O
PURPOSE:	O
The	O
multidrug	O
resistance	O
protein	O
2	O
(MRP2)	O
is	O
a	O
drug	O
efflux	O
transporter	O
that	O
is	O
expressed	O
predominantly	O
at	O
the	O
apical	O
domain	O
of	O
hepatocytes	O
but	O
seems	O
also	O
to	O
be	O
expressed	O
at	O
the	O
apical	O
membrane	O
of	O
brain	O
capillary	O
endothelial	O
cells	O
that	O
form	O
the	O
blood-brain	O
barrier	O
(BBB).	O
MRP2	O
is	O
absent	O
in	O
the	O
transport-deficient	O
(TR(-))	O
Wistar	O
rat	O
mutant,	O
so	O
that	O
this	O
rat	O
strain	O
was	O
very	O
helpful	O
in	O
defining	O
substrates	O
of	O
MRP2	O
by	O
comparing	O
tissue	O
concentrations	O
or	O
functional	O
activities	O
of	O
compounds	O
in	O
MRP2-deficient	O
rats	O
with	O
those	O
in	O
transport-competent	O
Wistar	O
rats.	O
By	O
using	O
this	O
strategy	O
to	O
study	O
the	O
involvement	O
of	O
MRP2	O
in	O
brain	O
access	O
of	O
antiepileptic	O
drugs	O
(AEDs),	O
we	O
recently	O
reported	O
that	O
phenytoin	Chemical
is	O
a	O
substrate	O
for	O
MRP2	O
in	O
the	O
BBB.	O
However,	O
one	O
drawback	O
of	O
such	O
studies	O
in	O
genetically	O
deficient	O
rats	O
is	O
the	O
fact	O
that	O
compensatory	O
changes	O
with	O
upregulation	O
of	O
other	O
transporters	O
can	O
occur.	O
This	O
prompted	O
us	O
to	O
study	O
the	O
brain	O
expression	O
of	O
P-glycoprotein	O
(Pgp),	O
a	O
major	O
drug	O
efflux	O
transporter	O
in	O
many	O
tissues,	O
including	O
the	O
BBB,	O
in	O
TR(-)	O
rats	O
compared	O
with	O
nonmutant	O
(wild-type)	O
Wistar	O
rats.	O
METHODS:	O
The	O
expression	O
of	O
MRP2	O
and	O
Pgp	O
in	O
brain	O
and	O
liver	O
sections	O
of	O
TR(-)	O
rats	O
and	O
normal	O
Wistar	O
rats	O
was	O
determined	O
with	O
immunohistochemistry,	O
by	O
using	O
a	O
novel,	O
highly	O
selective	O
monoclonal	O
MRP2	O
antibody	O
and	O
the	O
monoclonal	O
Pgp	O
antibody	O
C219,	O
respectively.	O
RESULTS:	O
Immunofluorescence	O
staining	O
with	O
the	O
MRP2	O
antibody	O
was	O
found	O
to	O
label	O
a	O
high	O
number	O
of	O
microvessels	O
throughout	O
the	O
brain	O
in	O
normal	O
Wistar	O
rats,	O
whereas	O
such	O
labeling	O
was	O
absent	O
in	O
TR(-)	O
rats.	O
TR(-)	O
rats	O
exhibited	O
a	O
significant	O
up-regulation	O
of	O
Pgp	O
in	O
brain	O
capillary	O
endothelial	O
cells	O
compared	O
with	O
wild-type	O
controls.	O
No	O
such	O
obvious	O
upregulation	O
of	O
Pgp	O
was	O
observed	O
in	O
liver	O
sections.	O
A	O
comparable	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
was	O
obtained	O
after	O
pilocarpine	Chemical
-induced	O
seizures	Disease
in	O
wild-type	O
Wistar	O
rats.	O
Experiments	O
with	O
systemic	O
administration	O
of	O
the	O
Pgp	O
substrate	O
phenobarbital	Chemical
and	O
the	O
selective	O
Pgp	O
inhibitor	O
tariquidar	Chemical
in	O
TR(-)	O
rats	O
substantiated	O
that	O
Pgp	O
is	O
functional	O
and	O
compensates	O
for	O
the	O
lack	O
of	O
MRP2	O
in	O
the	O
BBB.	O
CONCLUSIONS:	O
The	O
data	O
on	O
TR(-)	O
rats	O
indicate	O
that	O
Pgp	O
plays	O
an	O
important	O
role	O
in	O
the	O
compensation	O
of	O
MRP2	O
deficiency	O
in	O
the	O
BBB.	O
Because	O
such	O
a	O
compensatory	O
mechanism	O
most	O
likely	O
occurs	O
to	O
reduce	O
injury	Disease
to	Disease
the	Disease
brain	Disease
from	O
cytotoxic	O
compounds,	O
the	O
present	O
data	O
substantiate	O
the	O
concept	O
that	O
MRP2	O
performs	O
a	O
protective	O
role	O
in	O
the	O
BBB.	O
Furthermore,	O
our	O
data	O
suggest	O
that	O
TR(-)	O
rats	O
are	O
an	O
interesting	O
tool	O
to	O
study	O
consequences	O
of	O
overexpression	O
of	O
Pgp	O
in	O
the	O
BBB	O
on	O
access	O
of	O
drugs	O
in	O
the	O
brain,	O
without	O
the	O
need	O
of	O
inducing	O
seizures	Disease

Use	O
of	O
chromosome	O
substitution	O
strains	O
to	O
identify	O
seizure	Disease
susceptibility	O
loci	O
in	O
mice.	O
Seizure	Disease
susceptibility	O
varies	O
among	O
inbred	O
mouse	O
strains.	O
Chromosome	O
substitution	O
strains	O
(CSS),	O
in	O
which	O
a	O
single	O
chromosome	O
from	O
one	O
inbred	O
strain	O
(donor)	O
has	O
been	O
transferred	O
onto	O
a	O
second	O
strain	O
(host)	O
by	O
repeated	O
backcrossing,	O
may	O
be	O
used	O
to	O
identify	O
quantitative	O
trait	O
loci	O
(QTLs)	O
that	O
contribute	O
to	O
seizure	Disease
susceptibility.	O
QTLs	O
for	O
susceptibility	O
to	O
pilocarpine	Chemical
-induced	O
seizures	Disease
,	O
a	O
model	O
of	O
temporal	Disease
lobe	Disease
epilepsy	Disease
,	O
have	O
not	O
been	O
reported,	O
and	O
CSS	O
have	O
not	O
previously	O
been	O
used	O
to	O
localize	O
seizure	Disease
susceptibility	O
genes.	O
We	O
report	O
QTLs	O
identified	O
using	O
a	O
B6	O
(host)	O
x	O
A/J	O
(donor)	O
CSS	O
panel	O
to	O
localize	O
genes	O
involved	O
in	O
susceptibility	O
to	O
pilocarpine	Chemical
-induced	O
seizures	Disease
.	O
Three	O
hundred	O
fifty-five	O
adult	O
male	O
CSS	O
mice,	O
58	O
B6,	O
and	O
39	O
A/J	O
were	O
tested	O
for	O
susceptibility	O
to	O
pilocarpine	Chemical
-induced	O
seizures	Disease
.	O
Highest	O
stage	O
reached	O
and	O
latency	O
to	O
each	O
stage	O
were	O
recorded	O
for	O
all	O
mice.	O
B6	O
mice	O
were	O
resistant	O
to	O
seizures	Disease
and	O
slower	O
to	O
reach	O
stages	O
compared	O
to	O
A/J	O
mice.	O
The	O
CSS	O
for	O
Chromosomes	O
10	O
and	O
18	O
progressed	O
to	O
the	O
most	O
severe	O
stages,	O
diverging	O
dramatically	O
from	O
the	O
B6	O
phenotype.	O
Latencies	O
to	O
stages	O
were	O
also	O
significantly	O
shorter	O
for	O
CSS10	O
and	O
CSS18	O
mice.	O
CSS	O
mapping	O
suggests	O
seizure	Disease
susceptibility	O
loci	O
on	O
mouse	O
Chromosomes	O
10	O
and	O
18.	O
This	O
approach	O
provides	O
a	O
framework	O
for	O
identifying	O
potentially	O
novel	O
homologous	O
candidate	O
genes	O
for	O
human	O
temporal	Disease
lobe	Disease
epilepsy	Disease

Investigation	O
of	O
mitochondrial	O
involvement	O
in	O
the	O
experimental	O
model	O
of	O
epilepsy	Disease
induced	O
by	O
pilocarpine	Chemical
.	O
Mitochondrial	Disease
abnormalities	Disease
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epileptogenesis,	O
such	O
as	O
energy	O
generation,	O
control	O
of	O
cell	O
death	Disease
,	O
neurotransmitter	O
synthesis,	O
and	O
free	O
radical	O
(FR)	O
production.	O
Increased	O
production	O
of	O
FRs	O
may	O
cause	O
mtDNA	O
damage	O
leading	O
to	O
decreased	O
activities	O
of	O
oxidative	O
phosphorylation	O
complexes	O
containing	O
mtDNA-encoded	O
subunits.	O
In	O
this	O
study,	O
we	O
investigated	O
whether	O
increased	O
generation	O
of	O
FR	O
during	O
status	Disease
epilepticus	Disease
would	O
be	O
sufficient	O
to	O
provoke	O
abnormalities	O
in	O
mtDNA	O
and	O
in	O
the	O
expression	O
and	O
activity	O
of	O
cytochrome	O
c	O
oxidase	O
(CCO),	O
complex	O
IV	O
of	O
the	O
respiratory	O
chain,	O
in	O
the	O
chronic	O
phase	O
of	O
the	O
pilocarpine	Chemical
model	O
of	O
temporal	Disease
lobe	Disease
epilepsy	Disease
.	O
DNA	O
analysis	O
revealed	O
low	O
amounts	O
of	O
a	O
4.8	O
kb	O
mtDNA	O
deletion	O
but	O
with	O
no	O
differences	O
in	O
frequency	O
or	O
quantity	O
in	O
the	O
control	O
and	O
experimental	O
groups.	O
We	O
did	O
not	O
find	O
abnormalities	O
in	O
the	O
expression	O
and	O
distribution	O
of	O
an	O
mtDNA-encoded	O
subunit	O
of	O
CCO	O
(CCO-I)	O
or	O
a	O
relative	O
decrease	O
in	O
CCO-I	O
when	O
compared	O
with	O
nuclear-encoded	O
subunits	O
(CCO-IV	O
and	O
SDH-fp).	O
No	O
abnormality	O
in	O
CCO	O
activity	O
was	O
observed	O
through	O
histochemistry.	O
Although	O
evidences	O
of	O
mitochondrial	Disease
abnormalities	Disease

Causes	O
of	O
acute	O
thrombotic	Disease
microangiopathy	Disease
in	O
patients	O
receiving	O
kidney	O
transplantation.	O
OBJECTIVES:	O
Thrombotic	Disease
microangiopathy	Disease
is	O
a	O
well-known	O
problem	O
in	O
patients	O
following	O
renal	O
transplantation.	O
In	O
postrenal	O
transplantation,	O
thrombotic	Disease
microangiopathy	Disease
is	O
often	O
a	O
reflection	O
of	O
hemolytic	Disease
uremic	Disease
syndrome	Disease
.	O
We	O
aimed	O
to	O
determine	O
the	O
causes	O
of	O
thrombotic	Disease
microangiopathy	Disease
in	O
a	O
population	O
of	O
renal	O
transplantation	O
recipients	O
and	O
discuss	O
the	O
literature.	O
MATERIALS	O
AND	O
METHODS:	O
We	O
investigated	O
the	O
causes	O
of	O
thrombotic	Disease
microangiopathy	Disease
during	O
a	O
1-year	O
period,	O
from	O
June	O
2003	O
to	O
June	O
2004,	O
at	O
the	O
King	O
Fahad	O
National	O
Guard	O
Hospital	O
in	O
Riyadh,	O
Saudi	O
Arabia,	O
by	O
reviewing	O
the	O
slides	O
of	O
all	O
transplant	O
biopsies	O
(n=25)	O
performed	O
during	O
this	O
interval.	O
Pre-	O
and	O
posttransplant	O
crossmatching	O
was	O
done	O
when	O
possible.	O
RESULTS:	O
Five	O
cases	O
of	O
thrombotic	Disease
microangiopathy	Disease
were	O
found.	O
Three	O
of	O
these	O
cases	O
were	O
from	O
the	O
25	O
transplantations	O
performed	O
at	O
King	O
Fahad	O
National	O
Guard	O
Hospital,	O
while	O
the	O
other	O
2	O
transplantations	O
had	O
been	O
performed	O
abroad	O
and	O
were	O
referred	O
to	O
us	O
for	O
follow-up.	O
Three	O
cases	O
were	O
related	O
to	O
cyclosporine	Chemical
,	O
and	O
1	O
case	O
was	O
secondary	O
to	O
both	O
cyclosporine	Chemical
and	O
tacrolimus	Chemical
.	O
The	O
fifth	O
case	O
had	O
features	O
of	O
thrombotic	Disease
microangiopathy	Disease
related	O
to	O
an	O
antiphospholipid	Disease
syndrome	Disease
in	O
a	O
patient	O
with	O
systemic	Disease
lupus	Disease
erythematosus	Disease
.	O
CONCLUSIONS:	O
In	O
the	O
literature,	O
the	O
most-frequent	O
cause	O
of	O
hemolytic	Disease
uremic	Disease
syndrome	Disease
in	O
patients	O
following	O
renal	O
transplantation	O
is	O
recurrence	O
of	O
the	O
hemolytic	Disease
uremic	Disease
syndrome	Disease
.	O
Other	O
causes	O
include	O
drug-related	O
(	O
cyclosporine	Chemical
,	O
tacrolimus	Chemical
)	O
toxicity	Disease
,	O
procoagulant	O
status,	O
and	O
antibody-mediated	O
rejection.	O
We	O
found	O
that	O
the	O
most-frequent	O
cause	O
of	O
thrombotic	Disease
microangiopathy	Disease
was	O
drug	O
related,	O
secondary	O
mainly	O
to	O
cyclosporine	Chemical
.	O
In	O
the	O
current	O
study,	O
the	O
frequency	O
of	O
thrombotic	Disease
microangiopathy	Disease

Severe	O
reversible	O
left	Disease
ventricular	Disease
systolic	Disease
and	Disease
diastolic	Disease
dysfunction	Disease
due	O
to	O
accidental	O
iatrogenic	O
epinephrine	Chemical
	O
overdose	Disease
.	O
Catecholamine	Chemical
-induced	O
cardiomyopathy	Disease
due	O
to	O
chronic	O
excess	O
of	O
endogenous	O
catecholamines	Chemical
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	O
phenomenon.	O
In	O
contrast,	O
reports	O
of	O
myocardial	Disease
dysfunction	Disease
due	O
to	O
acute	O
iatrogenic	O
overdose	Disease
are	O
rare.	O
A	O
35-year-old	O
woman	O
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	Chemical
developed	O
myocardial	Disease
stunning	Disease
that	O
was	O
characterized	O
by	O
severe	O
hemodynamic	O
compromise,	O
profound,	O
albeit	O
transient,	O
left	Disease
ventricular	Disease
systolic	Disease
and	Disease
diastolic	Disease
dysfunction	Disease
,	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	O
of	O
myocardial	Disease
necrosis	Disease

Urinary	Disease
bladder	Disease
cancer	Disease
in	O
Wegener's	Disease
granulomatosis	Disease
:	O
risks	O
and	O
relation	O
to	O
cyclophosphamide	Chemical
.	O
OBJECTIVE:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	Disease
cancer	Disease
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	Chemical
,	O
in	O
patients	O
with	O
Wegener's	Disease
granulomatosis	Disease
.	O
METHODS:	O
In	O
the	O
population	O
based,	O
nationwide	O
Swedish	O
Inpatient	O
Register	O
a	O
cohort	O
of	O
1065	O
patients	O
with	O
Wegener's	Disease
granulomatosis	Disease
,	O
1969-95,	O
was	O
identified.	O
Through	O
linkage	O
with	O
the	O
Swedish	O
Cancer	Disease
Register,	O
all	O
subjects	O
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	Disease
cancer	Disease
were	O
identified.	O
Nested	O
within	O
the	O
cohort,	O
a	O
matched	O
case-control	O
study	O
was	O
performed	O
to	O
estimate	O
the	O
association	O
between	O
cyclophosphamide	Chemical
and	O
bladder	Disease
cancer	Disease
using	O
odds	O
ratios	O
(ORs)	O
as	O
relative	O
risk.	O
In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	Disease
cancer	Disease
after	O
Wegener's	Disease
granulomatosis	Disease
,	O
and	O
the	O
relative	O
prevalence	O
of	O
a	O
history	O
of	O
bladder	Disease
cancer	Disease
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener's	Disease
granulomatosis	Disease
,	O
were	O
also	O
estimated.	O
RESULTS:	O
The	O
median	O
cumulative	O
doses	O
of	O
cyclophosphamide	Chemical
among	O
cases	O
(n	O
=	O
11)	O
and	O
controls	O
(n	O
=	O
25)	O
were	O
113	O
g	O
and	O
25	O
g,	O
respectively.	O
The	O
risk	O
of	O
bladder	Disease
cancer	Disease
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	Chemical
(OR	O
=	O
2.0,	O
95%	O
confidence	O
interval	O
(CI)	O
0.8	O
to	O
4.9).	O
Treatment	O
duration	O
longer	O
than	O
1	O
year	O
was	O
associated	O
with	O
an	O
eightfold	O
increased	O
risk	O
(OR	O
=	O
7.7,	O
95%	O
CI	O
0.9	O
to	O
69).	O
The	O
absolute	O
risk	O
for	O
bladder	Disease
cancer	Disease
in	O
the	O
cohort	O
reached	O
10%	O
16	O
years	O
after	O
diagnosis	O
of	O
Wegener's	Disease
granulomatosis	Disease
,	O
and	O
a	O
history	O
of	O
bladder	Disease
cancer	Disease
was	O
(non-significantly)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener's	Disease
granulomatosis	Disease
.	O
CONCLUSION:	O
The	O
results	O
indicate	O
a	O
dose-response	O
relationship	O
between	O
cyclophosphamide	Chemical
and	O
the	O
risk	O
of	O
bladder	Disease
cancer	Disease
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener's	Disease
granulomatosis	Disease

L-arginine	Chemical
transport	O
in	O
humans	O
with	O
cortisol	Chemical
-induced	O
hypertension	Disease
.	O
A	O
deficient	O
L-arginine	Chemical
-	O
nitric	Chemical
oxide	Chemical
system	O
is	O
implicated	O
in	O
cortisol	Chemical
-induced	O
hypertension	Disease
.	O
We	O
investigate	O
whether	O
abnormalities	O
in	O
L-arginine	Chemical
uptake	O
contribute	O
to	O
this	O
deficiency.	O
Eight	O
healthy	O
men	O
were	O
recruited.	O
Hydrocortisone	Chemical
acetate	Chemical
(50	O
mg)	O
was	O
given	O
orally	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5-day	O
fixed-salt	O
diet	O
(150	O
mmol/d).	O
Crossover	O
studies	O
were	O
performed	O
2	O
weeks	O
apart.	O
Thirty	O
milliliters	O
of	O
blood	O
was	O
obtained	O
for	O
isolation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
after	O
each	O
treatment	O
period.	O
L-arginine	Chemical
uptake	O
was	O
assessed	O
in	O
mononuclear	O
cells	O
incubated	O
with	O
L-arginine	Chemical
(1	O
to	O
300	O
micromol/L),	O
incorporating	O
100	O
nmol/L	O
[3H]-l-arginine	Chemical
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C.	O
Forearm	O
[3H]-L-arginine	Chemical
extraction	O
was	O
calculated	O
after	O
infusion	O
of	O
[3H]-L-arginine	Chemical
into	O
the	O
brachial	O
artery	O
at	O
a	O
rate	O
of	O
100	O
nCi/min	O
for	O
80	O
minutes.	O
Deep	O
forearm	O
venous	O
samples	O
were	O
collected	O
for	O
determination	O
of	O
L-arginine	Chemical
extraction.	O
Plasma	O
cortisol	Chemical
concentrations	O
were	O
significantly	O
raised	O
during	O
the	O
active	O
phase	O
(323+/-43	O
to	O
1082+/-245	O
mmol/L,	O
P<0.05).	O
Systolic	O
blood	O
pressure	O
was	O
elevated	O
by	O
an	O
average	O
of	O
7	O
mm	O
Hg.	O
Neither	O
L-arginine	Chemical
transport	O
into	O
mononuclear	O
cells	O
(placebo	O
vs	O
active,	O
26.3+/-3.6	O
vs	O
29.0+/-2.1	O
pmol/10	O
000	O
cells	O
per	O
5	O
minutes,	O
respectively,	O
at	O
an	O
l-arginine	Chemical
concentration	O
of	O
300	O
micromol/L)	O
nor	O
L-arginine	Chemical
extraction	O
in	O
the	O
forearm	O
(at	O
80	O
minutes,	O
placebo	O
vs	O
active,	O
1	O
868	O
904+/-434	O
962	O
vs	O
2	O
013	O
910+/-770	O
619	O
disintegrations	O
per	O
minute)	O
was	O
affected	O
by	O
cortisol	Chemical
treatment;	O
ie,	O
that	O
L-arginine	Chemical
uptake	O
is	O
not	O
affected	O
by	O
short-term	O
cortisol	Chemical
treatment.	O
We	O
conclude	O
that	O
cortisol	Chemical
-induced	O
increases	Disease
in	Disease
blood	Disease
pressure	Disease
are	O
not	O
associated	O
with	O
abnormalities	O
in	O
the	O
l-arginine	Chemical

MR	O
imaging	O
with	O
quantitative	O
diffusion	O
mapping	O
of	O
tacrolimus	Chemical
-induced	O
neurotoxicity	Disease
in	O
organ	O
transplant	O
patients.	O
Our	O
objective	O
was	O
to	O
investigate	O
brain	O
MR	O
imaging	O
findings	O
and	O
the	O
utility	O
of	O
diffusion-weighted	O
(DW)	O
imaging	O
in	O
organ	O
transplant	O
patients	O
who	O
developed	O
neurologic	O
symptoms	O
during	O
tacrolimus	Chemical
therapy.	O
Brain	O
MR	O
studies,	O
including	O
DW	O
imaging,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	O
receiving	O
tacrolimus	Chemical
who	O
developed	O
neurologic	Disease
complications	Disease
.	O
In	O
each	O
patient	O
who	O
had	O
abnormalities	O
on	O
the	O
initial	O
MR	O
study,	O
a	O
follow-up	O
MR	O
study	O
was	O
performed	O
1	O
month	O
later.	O
Apparent	O
diffusion	O
coefficient	O
(ADC)	O
values	O
on	O
the	O
initial	O
MR	O
study	O
were	O
correlated	O
with	O
reversibility	O
of	O
the	O
lesions.	O
Of	O
the	O
14	O
patients,	O
5	O
(35.7%)	O
had	O
white	Disease
matter	Disease
abnormalities	Disease
,	O
1	O
(7.1%)	O
had	O
putaminal	Disease
hemorrhage	Disease
,	O
and	O
8	O
(57.1%)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images.	O
Among	O
the	O
5	O
patients	O
with	O
white	Disease
matter	Disease
abnormalities	Disease
,	O
4	O
patients	O
(80.0%)	O
showed	O
higher	O
than	O
normal	O
ADC	O
values	O
on	O
initial	O
MR	O
images,	O
and	O
all	O
showed	O
complete	O
resolution	O
on	O
follow-up	O
images.	O
The	O
remaining	O
1	O
patient	O
(20.0%)	O
showed	O
lower	O
than	O
normal	O
ADC	O
value	O
and	O
showed	O
incomplete	O
resolution	O
with	O
cortical	Disease
laminar	Disease
necrosis	Disease
.	O
Diffusion-weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	O
of	O
tacrolimus	Chemical
-induced	O
neurotoxicity	Disease

Octreotide	Chemical
-induced	O
hypoxemia	Disease
and	O
pulmonary	Disease
hypertension	Disease
in	O
premature	O
neonates.	O
The	O
authors	O
report	O
2	O
cases	O
of	O
premature	O
neonates	O
who	O
had	O
enterocutaneous	O
fistula	Disease
complicating	O
necrotizing	Disease
enterocolitis	Disease
.	O
Pulmonary	Disease
hypertension	Disease
developed	O
after	O
administration	O
of	O
a	O
somatostatin	O
analogue,	O
octreotide	Chemical
,	O
to	O
enhance	O
resolution	O
of	O
the	O
fistula	Disease

Sequential	O
observations	O
of	O
exencephaly	Disease
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system:	O
analysis	O
of	O
the	O
mechanism	O
of	O
transformation	O
from	O
exencephaly	Disease
to	O
anencephaly	Disease
.	O
Anencephaly	Disease
has	O
been	O
suggested	O
to	O
develop	O
from	O
exencephaly	Disease
;	O
however,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear.	O
We	O
examined	O
this	O
theory	O
using	O
the	O
exo	O
utero	O
development	O
system	O
that	O
allows	O
direct	O
and	O
sequential	O
observations	O
of	O
mid-	O
to	O
late-gestation	O
mouse	O
embryos.	O
We	O
observed	O
the	O
exencephaly	Disease
induced	O
by	O
5-azacytidine	Chemical
at	O
embryonic	O
day	O
13.5	O
(E13.5),	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18.5,	O
and	O
re-observed	O
the	O
same	O
embryos	O
at	O
E18.5.	O
We	O
confirmed	O
several	O
cases	O
of	O
transformation	O
from	O
exencephaly	Disease
to	O
anencephaly	Disease
.	O
However,	O
in	O
many	O
cases,	O
the	O
exencephalic	Disease
brain	O
tissue	O
was	O
preserved	O
with	O
more	O
or	O
less	O
reduction	O
during	O
this	O
period.	O
To	O
analyze	O
the	O
transformation	O
patterns,	O
we	O
classified	O
the	O
exencephaly	Disease
by	O
size	O
and	O
shape	O
of	O
the	O
exencephalic	Disease
tissue	O
into	O
several	O
types	O
at	O
E13.5	O
and	O
E18.5.	O
It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	Disease
tissue	O
was	O
not	O
simply	O
size-dependent,	O
and	O
all	O
cases	O
of	O
anencephaly	Disease
at	O
E18.5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	Disease
tissue	O
at	O
E13.5.	O
Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	Disease
at	O
E13.5,	O
frequent	O
hemorrhaging	Disease
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	Disease
head	O
at	O
E15.5,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	Disease
tissue	O
at	O
E18.5.	O
From	O
observations	O
of	O
the	O
vasculature,	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
were	O
identified	O
in	O
the	O
exencephalic	Disease
head.	O
These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	Disease
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels,	O
subsequent	O
peripheral	O
circulatory	Disease
failure	Disease
and/or	O
hemorrhaging	Disease
in	O
various	O
parts	O
of	O
the	O
exencephalic	Disease
head,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	Disease
to	O
anencephaly	Disease

Acute	O
cocaine	Chemical
-induced	O
seizures	Disease
:	O
differential	O
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains.	O
Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	O
for	O
susceptibility	O
to	O
behavioral	O
seizures	Disease
induced	O
by	O
a	O
single	O
injection	O
of	O
cocaine	Chemical
.	O
Cocaine	Chemical
was	O
injected	O
ip	O
over	O
a	O
range	O
of	O
doses	O
(50-100	O
mg/kg)	O
and	O
behavior	O
was	O
monitored	O
for	O
20	O
minutes.	O
Seizure	Disease
end	O
points	O
included	O
latency	O
to	O
forelimb	O
or	O
hindlimb	O
clonus,	O
latency	O
to	O
clonic	O
running	O
seizure	Disease
and	O
latency	O
to	O
jumping	O
bouncing	O
seizure	Disease
.	O
A	O
range	O
of	O
strain	O
specific	O
sensitivities	O
was	O
documented	O
with	O
A/J	O
and	O
SJL	O
mice	O
being	O
most	O
sensitive	O
and	O
C57BL/6J	O
most	O
resistant.	O
DBA/2J,	O
BALB/cByJ	O
and	O
NZW/LacJ	O
strains	O
exhibited	O
intermediate	O
sensitivity.	O
EEG	O
recordings	O
were	O
made	O
in	O
SJL,	O
A/J	O
and	O
C57BL/6J	O
mice	O
revealing	O
a	O
close	O
correspondence	O
between	O
electrical	O
activity	O
and	O
behavior.	O
Additionally,	O
levels	O
of	O
cocaine	Chemical
determined	O
in	O
hippocampus	O
and	O
cortex	O
were	O
not	O
different	O
between	O
sensitive	O
and	O
resistant	O
strains.	O
Additional	O
studies	O
of	O
these	O
murine	O
strains	O
may	O
be	O
useful	O
for	O
investigating	O
genetic	O
influences	O
on	O
cocaine	Chemical
-induced	O
seizures	Disease

Microangiopathic	Disease
hemolytic	Disease
anemia	Disease
complicating	O
FK506	Chemical
(	O
tacrolimus	Chemical
)	O
therapy.	O
We	O
describe	O
3	O
episodes	O
of	O
microangiopathic	Disease
hemolytic	Disease
anemia	Disease
(	O
MAHA	Disease
)	O
in	O
2	O
solid	O
organ	O
recipients	O
under	O
FK506	Chemical
(	O
tacrolimus	Chemical
)	O
therapy.	O
In	O
both	O
cases,	O
discontinuation	O
of	O
FK506	Chemical
and	O
treatment	O
with	O
plasma	O
exchange,	O
fresh	O
frozen	O
plasma	O
replacement,	O
corticosteroids	Chemical
,	O
aspirin	Chemical
,	O
and	O
dipyridamole	Chemical
led	O
to	O
resolution	O
of	O
MAHA	Disease
.	O
In	O
one	O
patient,	O
reintroduction	O
of	O
FK506	Chemical
led	O
to	O
rapid	O
recurrence	O
of	O
MAHA	Disease
.	O
FK506	Chemical
-associated	O
MAHA	Disease
is	O
probably	O
rare	O
but	O
physicians	O
must	O
be	O
aware	O
of	O
this	O
severe	O
complication.	O
In	O
our	O
experience	O
and	O
according	O
to	O
the	O
literature,	O
FK506	Chemical
does	O
not	O
seem	O
to	O
cross-react	O
with	O
cyclosporin	Chemical
A	Chemical
(	O
CyA	Chemical
),	O
an	O
immuno-suppressive	O
drug	O
already	O
known	O
to	O
induce	O
MAHA	Disease

Variant	O
ventricular	Disease
tachycardia	Disease
in	O
desipramine	Chemical
	O
toxicity	Disease
.	O
We	O
report	O
a	O
case	O
of	O
variant	O
ventricular	Disease
tachycardia	Disease
induced	O
by	O
desipramine	Chemical
	O
toxicity	Disease
.	O
Unusual	O
features	O
of	O
the	O
arrhythmia	Disease
are	O
repetitive	O
group	O
beating,	O
progressive	O
shortening	O
of	O
the	O
R-R	O
interval,	O
progressive	O
widening	O
of	O
the	O
QRS	O
complex	O
with	O
eventual	O
failure	O
of	O
intraventricular	O
conduction,	O
and	O
changes	O
in	O
direction	O
of	O
the	O
QRS	O
axis.	O
Recognition	O
of	O
variant	O
ventricular	Disease
tachycardia	Disease
is	O
important	O
because	O
therapy	O
differs	O
from	O
that	O
of	O
classic	O
ventricular	Disease
tachycardia	Disease

Desipramine	Chemical
-induced	O
delirium	Disease
at	O
"subtherapeutic"	O
concentrations:	O
a	O
case	O
report.	O
An	O
elderly	O
patient	O
treated	O
with	O
low	O
dose	O
Desipramine	Chemical
developed	O
a	O
delirium	Disease
while	O
her	O
plasma	O
level	O
was	O
in	O
the	O
"subtherapeutic"	O
range.	O
Delirium	Disease
,	O
which	O
may	O
be	O
induced	O
by	O
tricyclic	O
drug	O
therapy	O
in	O
the	O
elderly,	O
can	O
be	O
caused	O
by	O
tricyclics	O
with	O
low	O
anticholinergic	O
potency.	O
Therapeutic	O
ranges	O
for	O
antidepressants	Chemical

Mouse	O
strain-dependent	O
effect	O
of	O
amantadine	Chemical
on	O
motility	O
and	O
brain	O
biogenic	O
amines	Chemical
.	O
The	O
effect	O
of	O
amantadine	Chemical
hydrochloride	Chemical
,	O
injected	O
i.p.	O
in	O
6	O
increments	O
of	O
100	O
mg/kg	O
each	O
over	O
30	O
hr,	O
on	O
mouse	O
motility	O
and	O
whole	O
brain	O
content	O
of	O
selected	O
biogenic	O
amines	Chemical
and	O
major	O
metabolites	O
was	O
studied	O
in	O
4	O
strains	O
of	O
mice.	O
These	O
were	O
the	O
albino	O
Sprague-Dawley	O
ICR	O
and	O
BALB/C,	O
the	O
black	O
C57BL/6	O
and	O
the	O
brown	O
CDF-I	O
mouse	O
strains.	O
Amantadine	Chemical
treatment	O
produced	O
a	O
biphasic	O
effect	O
on	O
mouse	O
motility.	O
The	O
initial	O
dose	O
of	O
amantadine	Chemical
	O
depressed	Disease
locomotor	O
activity	O
in	O
all	O
mouse	O
strains	O
studied	O
with	O
the	O
BALB/C	O
mice	O
being	O
the	O
most	O
sensitive.	O
Subsequent	O
amantadine	Chemical
treatments	O
produced	O
enhancement	O
of	O
motility	O
from	O
corresponding	O
control	O
in	O
all	O
mouse	O
strains	O
with	O
the	O
BALB/C	O
mice	O
being	O
the	O
least	O
sensitive.	O
The	O
locomotor	O
activity	O
was	O
decreased	O
from	O
corresponding	O
controls	O
in	O
all	O
strains	O
studied,	O
except	O
for	O
the	O
ICR	O
mice,	O
during	O
an	O
overnight	O
drug-free	O
period	O
following	O
the	O
fourth	O
amantadine	Chemical
treatment.	O
Readministration	O
of	O
amantadine	Chemical
,	O
after	O
a	O
drug-free	O
overnight	O
period,	O
increased	O
motility	O
from	O
respective	O
saline	O
control	O
in	O
all	O
strains	O
with	O
exception	O
of	O
the	O
BALB/C	O
mice	O
where	O
suppression	Disease
of	Disease
motility	Disease
occurred.	O
Treatment	O
with	O
amantadine	Chemical
did	O
not	O
alter	O
whole	O
brain	O
dopamine	Chemical
levels	O
but	O
decreased	O
the	O
amounts	O
of	O
3,4-dihydroxyphenylacetic	Chemical
acid	Chemical
in	O
the	O
BALB/C	O
mice	O
compared	O
to	O
saline	O
control.	O
Conversely,	O
brain	O
normetanephrine	Chemical
concentration	O
was	O
increased	O
from	O
saline	O
control	O
by	O
amantadine	Chemical
in	O
the	O
BALB/C	O
mice.	O
The	O
results	O
suggest	O
a	O
strain-dependent	O
effect	O
of	O
amantadine	Chemical
on	O
motility	O
and	O
indicate	O
a	O
differential	O
response	O
to	O
the	O
acute	O
and	O
multiple	O
dose	O
regimens	O
used.	O
The	O
BALB/C	O
mouse	O
was	O
the	O
most	O
sensitive	O
strain	O
and	O
could	O
serve	O
as	O
the	O
strain	O
of	O
choice	O
for	O
evaluating	O
the	O
side	O
effects	O
of	O
amantadine	Chemical
.	O
The	O
biochemical	O
results	O
of	O
brain	O
biogenic	O
amines	Chemical
of	O
BALB/C	O
mouse	O
strain	O
suggest	O
a	O
probable	O
decrease	O
of	O
catecholamine	Chemical
turnover	O
rate	O
and/or	O
metabolism	O
by	O
monoamine	O
oxidase	O
and	O
a	O
resulting	O
increase	O
in	O
O-methylation	O
of	O
norepinephrine	Chemical
which	O
may	O
account	O
for	O
a	O
behavioral	Disease
depression	Disease
caused	O
by	O
amantadine	Chemical

No	O
enhancement	O
by	O
phenobarbital	Chemical
of	O
the	O
hepatocarcinogenicity	O
of	O
a	O
choline	Chemical
-devoid	O
diet	O
in	O
the	O
rat.	O
An	O
experiment	O
was	O
performed	O
to	O
test	O
whether	O
inclusion	O
of	O
phenobarbital	Chemical
in	O
a	O
choline	Chemical
-devoid	O
diet	O
would	O
increase	O
the	O
hepatocarcinogenicity	O
of	O
the	O
diet.	O
Groups	O
of	O
5-week	O
old	O
male	O
Fischer-344	O
rats	O
were	O
fed	O
for	O
7-25	O
months	O
semipurified	O
choline	Chemical
-devoid	O
or	O
choline	Chemical
-supplemented	O
diets,	O
containing	O
or	O
not	O
0.06%	O
phenobarbital	Chemical
.	O
No	O
hepatic	O
preneoplastic	O
nodules	O
or	O
hepatocellular	Disease
carcinomas	Disease
developed	O
in	O
rats	O
fed	O
the	O
plain	O
choline	Chemical
-supplemented	O
diet,	O
while	O
one	O
preneoplastic	O
nodule	O
and	O
one	O
hepatocellular	Disease
carcinoma	Disease
developed	O
in	O
two	O
rats	O
fed	O
the	O
same	O
diet	O
containing	O
phenobarbital	Chemical
.	O
The	O
incidence	O
of	O
preneoplastic	O
nodules	O
and	O
of	O
hepatocellular	Disease
carcinomas	Disease
was	O
10%	O
and	O
37%,	O
respectively,	O
in	O
rats	O
fed	O
the	O
plain	O
choline	Chemical
-devoid	O
diet,	O
and	O
17%	O
and	O
30%,	O
in	O
rats	O
fed	O
the	O
phenobarbital	Chemical
-containing	O
choline	Chemical
-devoid	O
diet.	O
The	O
results	O
evinced	O
no	O
enhancement	O
of	O
the	O
hepatocarcinogenicity	O
of	O
the	O
choline	Chemical
-devoid	O
diet	O
by	O
phenobarbital	Chemical

Effect	O
of	O
direct	O
intracoronary	O
administration	O
of	O
methylergonovine	Chemical
in	O
patients	O
with	O
and	O
without	O
variant	Disease
angina	Disease
.	O
The	O
effects	O
of	O
intracoronary	O
administration	O
of	O
methylergonovine	Chemical
were	O
studied	O
in	O
21	O
patients	O
with	O
variant	Disease
angina	Disease
and	O
22	O
patients	O
with	O
atypical	O
chest	Disease
pain	Disease
and	O
in	O
others	O
without	O
angina	Disease
pectoris	Disease
(control	O
group).	O
Methylergonovine	Chemical
was	O
administered	O
continuously	O
at	O
a	O
rate	O
of	O
10	O
micrograms/min	O
up	O
to	O
50	O
micrograms.	O
In	O
all	O
patients	O
with	O
variant	Disease
angina	Disease
,	O
coronary	Disease
spasm	Disease
was	O
provoked	O
at	O
a	O
mean	O
dose	O
of	O
28	O
+/-	O
13	O
micrograms	O
(mean	O
+/-	O
SD).	O
In	O
the	O
control	O
group	O
neither	O
ischemic	O
ST	O
change	O
nor	O
localized	O
spasm	Disease
occurred.	O
The	O
basal	O
tone	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
left	O
coronary	O
artery.	O
The	O
percentage	O
of	O
vasoconstriction	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
left	O
coronary	O
artery.	O
These	O
results	O
suggest	O
that	O
spasm	Disease
provocation	O
tests,	O
which	O
use	O
an	O
intracoronary	O
injection	O
of	O
a	O
relatively	O
low	O
dose	O
of	O
methylergonovine	Chemical
,	O
have	O
a	O
high	O
sensitivity	O
in	O
variant	Disease
angina	Disease

Dobutamine	Chemical
stress	O
echocardiography:	O
a	O
sensitive	O
indicator	O
of	O
diminished	O
myocardial	O
function	O
in	O
asymptomatic	O
doxorubicin	Chemical
-treated	O
long-term	O
survivors	O
of	O
childhood	O
cancer	Disease
.	O
Doxorubicin	Chemical
is	O
an	O
effective	O
anticancer	O
chemotherapeutic	O
agent	O
known	O
to	O
cause	O
acute	O
and	O
chronic	O
cardiomyopathy	Disease
.	O
To	O
develop	O
a	O
more	O
sensitive	O
echocardiographic	O
screening	O
test	O
for	O
cardiac	Disease
damage	Disease
due	O
to	O
doxorubicin	Chemical
,	O
a	O
cohort	O
study	O
was	O
performed	O
using	O
dobutamine	Chemical
infusion	O
to	O
differentiate	O
asymptomatic	O
long-term	O
survivors	O
of	O
childhood	O
cancer	Disease
treated	O
with	O
doxorubicin	Chemical
from	O
healthy	O
control	O
subjects.	O
Echocardiographic	O
data	O
from	O
the	O
experimental	O
group	O
of	O
21	O
patients	O
(mean	O
age	O
16	O
+/-	O
5	O
years)	O
treated	O
from	O
1.6	O
to	O
14.3	O
years	O
(median	O
5.3)	O
before	O
this	O
study	O
with	O
27	O
to	O
532	O
mg/m2	O
of	O
doxorubicin	Chemical
(mean	O
196)	O
were	O
compared	O
with	O
echocardiographic	O
data	O
from	O
12	O
normal	O
age-matched	O
control	O
subjects.	O
Graded	O
dobutamine	Chemical
infusions	O
of	O
0.5,	O
2.5,	O
5	O
and	O
10	O
micrograms/kg	O
per	O
min	O
were	O
administered.	O
Echocardiographic	O
Doppler	O
studies	O
were	O
performed	O
before	O
infusion	O
and	O
after	O
15	O
min	O
of	O
infusion	O
at	O
each	O
rate.	O
Dobutamine	Chemical
infusion	O
at	O
10	O
micrograms/kg	O
per	O
min	O
was	O
discontinued	O
after	O
six	O
studies	O
secondary	O
to	O
a	O
50%	O
incidence	O
rate	O
of	O
adverse	O
symptoms.	O
The	O
most	O
important	O
findings	O
were	O
that	O
compared	O
with	O
values	O
in	O
control	O
subjects,	O
end-systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
and	O
percent	O
of	O
left	O
ventricular	O
posterior	O
wall	O
thickening	O
in	O
doxorubicin	Chemical
-treated	O
patients	O
were	O
decreased	O
at	O
baseline	O
study	O
and	O
these	O
findings	O
were	O
more	O
clearly	O
delineated	O
with	O
dobutamine	Chemical
stimulation.	O
End-systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
baseline	O
for	O
the	O
doxorubicin	Chemical
-treated	O
group	O
was	O
11	O
+/-	O
1.9	O
mm	O
versus	O
13.1	O
+/-	O
1.5	O
mm	O
for	O
control	O
subjects	O
(p	O
less	O
than	O
0.01).	O
End-systolic	O
left	O
ventricular	O
posterior	O
wall	O
dimension	O
at	O
the	O
5-micrograms/kg	O
per	O
min	O
dobutamine	Chemical
infusion	O
for	O
the	O
doxorubicin	Chemical

Effects	O
of	O
aminophylline	Chemical
on	O
the	O
threshold	O
for	O
initiating	O
ventricular	Disease
fibrillation	Disease
during	O
respiratory	Disease
failure	Disease
.	O
Cardiac	Disease
arrhythmias	Disease
have	O
frequently	O
been	O
reported	O
in	O
association	O
with	O
respiratory	Disease
failure	Disease
.	O
The	O
possible	O
additive	O
role	O
of	O
pharmacologic	O
agents	O
in	O
precipitating	O
cardiac	Disease
disturbances	Disease
in	O
patients	O
with	O
respiratory	Disease
failure	Disease
has	O
only	O
recently	O
been	O
emphasized.	O
The	O
effects	O
of	O
aminophylline	Chemical
on	O
the	O
ventricular	Disease
fibrillation	Disease
threshold	O
during	O
normal	O
acid-base	O
conditions	O
and	O
during	O
respiratory	Disease
failure	Disease
were	O
studied	O
in	O
anesthetized	O
open	O
chest	O
dogs.	O
The	O
ventricular	Disease
fibrillation	Disease
threshold	O
was	O
measured	O
by	O
passing	O
a	O
gated	O
train	O
of	O
12	O
constant	O
current	O
pulses	O
through	O
the	O
ventricular	O
myocardium	O
during	O
the	O
vulnerable	O
period	O
of	O
the	O
cardiac	O
cycle.	O
During	O
the	O
infusion	O
of	O
aminophylline	Chemical
,	O
the	O
ventricular	Disease
fibrillation	Disease
threshold	O
was	O
reduced	O
by	O
30	O
to	O
40	O
percent	O
of	O
the	O
control	O
when	O
pH	O
and	O
partial	O
pressures	O
of	O
oxygen	Chemical
(	O
PO2	Chemical
)	O
and	O
carbon	Chemical
dioxide	Chemical
(	O
CO2	Chemical
)	O
were	O
kept	O
within	O
normal	O
limits.	O
When	O
respiratory	Disease
failure	Disease
was	O
produced	O
by	O
hypoventilation	Disease
(pH	O
7.05	O
to	O
7.25;	O
PC02	O
70	O
to	O
100	O
mm	O
Hg:	O
P02	O
20	O
to	O
40	O
mm	O
Hg),	O
infusion	O
of	O
aminophylline	Chemical
resulted	O
in	O
an	O
even	O
greater	O
decrease	O
in	O
ventricular	Disease
fibrillation	Disease
threshold	O
to	O
60	O
percent	O
of	O
the	O
control	O
level.	O
These	O
experiments	O
suggest	O
that	O
although	O
many	O
factors	O
may	O
contribute	O
to	O
the	O
increased	O
incidence	O
of	O
ventricular	Disease
arrhythmias	Disease
in	O
respiratory	Disease
failure	Disease
,	O
pharmacologic	O
agents,	O
particularly	O
aminophylline	Chemical

Case	O
report:	O
acute	O
unintentional	O
carbachol	Chemical
intoxication.	O
INTRODUCTION:	O
Intoxications	O
with	O
carbachol	Chemical
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
agonist	O
are	O
rare.	O
We	O
report	O
an	O
interesting	O
case	O
investigating	O
a	O
(near)	O
fatal	O
poisoning	Disease
.	O
METHODS:	O
The	O
son	O
of	O
an	O
84-year-old	O
male	O
discovered	O
a	O
newspaper	O
report	O
stating	O
clinical	O
success	O
with	O
plant	O
extracts	O
in	O
Alzheimer's	Disease
disease	Disease
.	O
The	O
mode	O
of	O
action	O
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synthetic	O
compound	O
'	O
carbamylcholin	Chemical
';	O
that	O
is,	O
carbachol	Chemical
.	O
He	O
bought	O
25	O
g	O
of	O
carbachol	Chemical
as	O
pure	O
substance	O
in	O
a	O
pharmacy,	O
and	O
the	O
father	O
was	O
administered	O
400	O
to	O
500	O
mg.	O
Carbachol	Chemical
concentrations	O
in	O
serum	O
and	O
urine	O
on	O
day	O
1	O
and	O
2	O
of	O
hospital	O
admission	O
were	O
analysed	O
by	O
HPLC-mass	O
spectrometry.	O
RESULTS:	O
Minutes	O
after	O
oral	O
administration,	O
the	O
patient	O
developed	O
nausea	Disease
,	O
sweating	O
and	O
hypotension	Disease
,	O
and	O
finally	O
collapsed.	O
Bradycardia	Disease
,	O
cholinergic	O
symptoms	O
and	O
asystole	Disease
occurred.	O
Initial	O
cardiopulmonary	O
resuscitation	O
and	O
immediate	O
treatment	O
with	O
adrenaline	Chemical
(	O
epinephrine	Chemical
),	O
atropine	Chemical
and	O
furosemide	Chemical
was	O
successful.	O
On	O
hospital	O
admission,	O
blood	O
pressure	O
of	O
the	O
intubated,	O
bradyarrhythmic	O
patient	O
was	O
100/65	O
mmHg.	O
Further	O
signs	O
were	O
hyperhidrosis	Disease
,	O
hypersalivation	Disease
,	O
bronchorrhoea	Disease
,	O
and	O
severe	O
miosis	Disease
;	O
the	O
electrocardiographic	O
finding	O
was	O
atrio-ventricular	Disease
dissociation	Disease
.	O
High	O
doses	O
of	O
atropine	Chemical
(up	O
to	O
50	O
mg	O
per	O
24	O
hours),	O
adrenaline	Chemical
and	O
dopamine	Chemical
were	O
necessary.	O
The	O
patient	O
was	O
extubated	O
1	O
week	O
later.	O
However,	O
increased	O
dyspnoea	Disease
and	O
bronchospasm	Disease
necessitated	O
reintubation.	O
Respiratory	Disease
insufficiency	Disease
was	O
further	O
worsened	O
by	O
Proteus	Disease
mirabilis	Disease
infection	Disease
and	O
severe	O
bronchoconstriction.	O
One	O
week	O
later,	O
the	O
patient	O
was	O
again	O
extubated	O
and	O
3	O
days	O
later	O
was	O
transferred	O
to	O
a	O
peripheral	O
ward.	O
On	O
the	O
next	O
day	O
he	O
died,	O
probably	O
as	O
a	O
result	O
of	O
heart	Disease
failure	Disease
.	O
Serum	O
samples	O
from	O
the	O
first	O
and	O
second	O
days	O
contained	O
3.6	O
and	O
1.9	O
mg/l	O
carbachol	Chemical
,	O
respectively.	O
The	O
corresponding	O
urine	O
concentrations	O
amounted	O
to	O
374	O
and	O
554	O
mg/l.	O
CONCLUSION:	O
This	O
case	O
started	O
with	O
a	O
media	O
report	O
in	O
a	O
popular	O
newspaper,	O
initiated	O
by	O
published,	O
peer-reviewed	O
research	O
on	O
herbals,	O
and	O
involved	O
human	O
failure	O
in	O
a	O
case	O
history,	O
medical	O
examination	O
and	O
clinical	O
treatment.	O
For	O
the	O
first	O
time,	O
an	O
analytical	O
method	O
for	O
the	O
determination	O
of	O
carbachol	Chemical
in	O
plasma	O
and	O
urine	O
has	O
been	O
developed.	O
The	O
analysed	O
carbachol	Chemical
concentration	O
exceeded	O
the	O
supposed	O
serum	O
level	O
resulting	O
from	O
a	O
therapeutic	O
dose	O
by	O
a	O
factor	O
of	O
130	O
to	O
260.	O
Especially	O
in	O
old	O
patients,	O
intensivists	O
should	O
consider	O
intoxications	O
(with	O
cholinergics)	O
as	O
a	O
cause	O
of	O
acute	Disease
cardiovascular	Disease
failure	Disease

Crossover	O
comparison	O
of	O
efficacy	O
and	O
preference	O
for	O
rizatriptan	Chemical
10	O
mg	O
versus	O
ergotamine	Chemical
/	O
caffeine	Chemical
in	O
migraine	Disease
.	O
Rizatriptan	Chemical
is	O
a	O
selective	O
5-HT	Chemical
(1B/1D)	O
receptor	O
agonist	O
with	O
rapid	O
oral	O
absorption	O
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	Disease
.	O
This	O
randomized	O
double-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	O
for	O
1	O
rizatriptan	Chemical
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	Chemical
1	O
mg/	O
caffeine	Chemical
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	Disease
attack	O
with	O
each	O
therapy.	O
Of	O
patients	O
expressing	O
a	O
preference	O
(89.1%),	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatriptan	Chemical
to	O
ergotamine	Chemical
/	O
caffeine	Chemical
(69.9	O
vs.	O
30.1%,	O
p	O
<	O
or	O
=	O
0.001).	O
Faster	O
relief	O
of	O
headache	Disease
was	O
the	O
most	O
important	O
reason	O
for	O
preference,	O
cited	O
by	O
67.3%	O
of	O
patients	O
preferring	O
rizatriptan	Chemical
and	O
54.2%	O
of	O
patients	O
who	O
preferred	O
ergotamine	Chemical
/	O
caffeine	Chemical
.	O
The	O
co-primary	O
endpoint	O
of	O
being	O
pain	Disease
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptan	Chemical
.	O
Forty-nine	O
percent	O
of	O
patients	O
were	O
pain	Disease
free	O
2	O
h	O
after	O
rizatriptan	Chemical
,	O
compared	O
with	O
24.3%	O
treated	O
with	O
ergotamine	Chemical
/	O
caffeine	Chemical
(p	O
<	O
or	O
=	O
0.001),	O
rizatriptan	Chemical
being	O
superior	O
within	O
1	O
h	O
of	O
treatment.	O
Headache	Disease
relief	O
at	O
2	O
h	O
was	O
75.9%	O
for	O
rizatriptan	Chemical
and	O
47.3%	O
for	O
ergotamine	Chemical
/	O
caffeine	Chemical
(p	O
<	O
or	O
=	O
0.001),	O
with	O
rizatriptan	Chemical
being	O
superior	O
to	O
ergotamine	Chemical
/	O
caffeine	Chemical
within	O
30	O
min	O
of	O
dosing.	O
Almost	O
36%	O
of	O
patients	O
taking	O
rizatriptan	Chemical
were	O
pain	Disease
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	O
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h,	O
compared	O
to	O
20%	O
of	O
patients	O
on	O
ergotamine	Chemical
/	O
caffeine	Chemical
(p	O
<	O
or	O
=	O
0.001).	O
Rizatriptan	Chemical
was	O
also	O
superior	O
to	O
ergotamine	Chemical
/	O
caffeine	Chemical
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	Disease
,	O
vomiting	Disease
,	O
phonophobia	Disease
or	O
photophobia	Disease
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(p	O
<	O
or	O
=	O
0.001).	O
More	O
patients	O
were	O
(completely,	O
very	O
or	O
somewhat)	O
satisfied	O
2	O
h	O
after	O
treatment	O
with	O
rizatriptan	Chemical
(69.8%)	O
than	O
at	O
2	O
h	O
after	O
treatment	O
with	O
ergotamine	Chemical
/	O
caffeine	Chemical
(38.6%,	O
p	O
<	O
or	O
=	O
0.001).	O
Recurrence	O
rates	O
were	O
31.4%	O
with	O
rizatriptan	Chemical
and	O
15.3%	O
with	O
ergotamine	Chemical
/	O
caffeine	Chemical
.	O
Both	O
active	O
treatments	O
were	O
well	O
tolerated.	O
The	O
most	O
common	O
adverse	O
events	O
(incidence	O
>	O
or	O
=	O
5%	O
in	O
one	O
group)	O
after	O
rizatriptan	Chemical
and	O
ergotamine	Chemical
/	O
caffeine	Chemical
,	O
respectively,	O
were	O
dizziness	Disease
(6.7	O
and	O
5.3%),	O
nausea	Disease
(4.2	O
and	O
8.5%)	O
and	O
somnolence	Disease

Thrombotic	Disease
microangiopathy	Disease
and	O
renal	Disease
failure	Disease
associated	O
with	O
antineoplastic	O
chemotherapy.	O
Five	O
patients	O
with	O
carcinoma	Disease
developed	O
thrombotic	Disease
microangiopathy	Disease
(characterized	O
by	O
renal	Disease
insufficiency	Disease
,	O
microangiopathic	Disease
hemolytic	Disease
anemia	Disease
,	O
and	O
usually	O
thrombocytopenia	Disease
)	O
after	O
treatment	O
with	O
cisplatin	Chemical
,	O
bleomycin	Chemical
,	O
and	O
a	O
vinca	Chemical
alkaloid	Chemical
.	O
One	O
patient	O
had	O
thrombotic	Disease
thrombocytopenic	Disease
purpura	Disease
,	O
three	O
the	O
hemolytic-uremic	Disease
syndrome	Disease
,	O
and	O
one	O
an	O
apparent	O
forme	O
fruste	O
of	O
one	O
of	O
these	O
disorders.	O
Histologic	O
examination	O
of	O
the	O
renal	O
tissue	O
showed	O
evidence	O
of	O
intravascular	Disease
coagulation	Disease
,	O
primarily	O
affecting	O
the	O
small	O
arteries,	O
arterioles,	O
and	O
glomeruli.	O
Because	O
each	O
patient	O
was	O
tumor	Disease
-free	O
or	O
had	O
only	O
a	O
small	O
tumor	Disease
at	O
the	O
onset	O
of	O
this	O
syndrome,	O
the	O
thrombotic	Disease
microangiopathy	Disease
may	O
have	O
been	O
induced	O
by	O
chemotherapy.	O
Diagnosis	O
of	O
this	O
potentially	O
fatal	O
complication	O
may	O
be	O
delayed	O
or	O
missed	O
if	O
renal	O
tissue	O
or	O
the	O
peripheral	O
blood	O
smear	O
is	O
not	O
examined,	O
because	O
renal	Disease
failure	Disease
may	O
be	O
ascribed	O
to	O
cisplatin	Chemical
	O
nephrotoxicity	Disease
and	O
the	O
anemia	Disease
and	O
thrombocytopenia	Disease
to	O
drug-induced	O
bone	Disease
marrow	Disease
suppression	Disease

Salvage	O
therapy	O
with	O
nelarabine	Chemical
,	O
etoposide	Chemical
,	O
and	O
cyclophosphamide	Chemical
in	O
relapsed/refractory	O
paediatric	O
T-cell	Disease
lymphoblastic	Disease
leukaemia	Disease
and	Disease
lymphoma	Disease
.	O
A	O
combination	O
of	O
5	O
d	O
of	O
nelarabine	Chemical
(	O
AraG	Chemical
)	O
with	O
5	O
d	O
of	O
etoposide	Chemical
(	O
VP	Chemical
)	O
and	O
cyclophosphamide	Chemical
(	O
CPM	Chemical
)	O
and	O
prophylactic	O
intrathecal	O
chemotherapy	O
was	O
used	O
as	O
salvage	O
therapy	O
in	O
seven	O
children	O
with	O
refractory	O
or	O
relapsed	O
T-cell	Disease
leukaemia	Disease
or	Disease
lymphoma	Disease
.	O
The	O
most	O
common	O
side	O
effects	O
attributable	O
to	O
the	O
AraG	Chemical
included	O
Grade	O
2	O
and	O
3	O
sensory	O
and	O
motor	O
neuropathy	Disease
and	O
musculoskeletal	Disease
pain	Disease
.	O
Haematological	Disease
toxicity	Disease
was	O
greater	O
for	O
the	O
combination	O
than	O
AraG	Chemical
alone,	O
although	O
median	O
time	O
to	O
neutrophil	O
and	O
platelet	O
recovery	O
was	O
consistent	O
with	O
other	O
salvage	O
therapies.	O
All	O
patients	O
had	O
some	O
response	O
to	O
the	O
combined	O
therapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remission	O
after	O
one	O
or	O
two	O
courses	O
of	O
AraG	Chemical
/	O
VP	Chemical
/	O
CPM	Chemical
.	O
Our	O
experience	O
supports	O
the	O
safety	O
of	O
giving	O
AraG	Chemical
as	O
salvage	O
therapy	O
in	O
synchrony	O
with	O
etoposide	Chemical
and	O
cyclophosphamide	Chemical
,	O
although	O
neurological	Disease
toxicity	Disease

The	O
3-week	O
sulphasalazine	Chemical
syndrome	O
strikes	O
again.	O
A	O
34-year-old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	Disease
,	O
fever	Disease
,	O
lymphadenopathy	Disease
and	O
hepatitis	Disease
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	Chemical
for	O
sero-negative	O
rheumatoid	Disease
arthritis	Disease
.	O
Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	Disease
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates,	O
without	O
viral	O
inclusion	O
bodies,	O
suggestive	O
of	O
an	O
adverse	Disease
drug	Disease
reaction	Disease
.A	O
week	O
later,	O
fulminant	O
drug-induced	Disease
hepatitis	Disease
,	O
associated	O
with	O
the	O
presence	O
of	O
anti-nuclear	O
autoantibodies	O
(but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	Disease
),	O
and	O
accompanied	O
by	O
multi-organ	Disease
failure	Disease
and	O
sepsis	Disease
,	O
supervened.	O
She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy.Post-mortem	O
examination	O
showed	O
evidence	O
of	O
massive	Disease
hepatocellular	Disease
necrosis	Disease
,	O
acute	O
hypersensitivity	O
myocarditis	Disease
,	O
focal	O
acute	O
tubulo-interstitial	O
nephritis	Disease
and	O
extensive	O
bone	Disease
marrow	Disease
necrosis	Disease
,	O
with	O
no	O
evidence	O
of	O
malignancy	Disease
.	O
It	O
is	O
thought	O
that	O
the	O
clinico-pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so-called	O
"3-week	O
sulphasalazine	Chemical
syndrome",	O
a	O
rare,	O
but	O
often	O
fatal,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	Chemical

Bupropion	Chemical
(	O
Zyban	Chemical
)	O
toxicity	Disease
.	O
Bupropion	Chemical
is	O
a	O
monocyclic	O
antidepressant	Chemical
structurally	O
related	O
to	O
amphetamine	Chemical
.	O
Zyban	Chemical
,	O
a	O
sustained-release	O
formulation	O
of	O
bupropion	Chemical
hydrochloride	Chemical
,	O
was	O
recently	O
released	O
in	O
Ireland,	O
as	O
a	O
smoking	O
cessation	O
aid.	O
In	O
the	O
initial	O
6	O
months	O
since	O
it's	O
introduction,	O
12	O
overdose	Disease
cases	O
have	O
been	O
reported	O
to	O
The	O
National	O
Poisons	O
Information	O
Centre.	O
8	O
patients	O
developed	O
symptoms	O
of	O
toxicity	Disease
.	O
Common	O
features	O
included	O
tachycardia	Disease
,	O
drowsiness,	O
hallucinations	Disease
and	O
convulsions	Disease
.	O
Two	O
patients	O
developed	O
severe	O
cardiac	Disease
arrhythmias	Disease
,	O
including	O
one	O
patient	O
who	O
was	O
resuscitated	O
following	O
a	O
cardiac	Disease
arrest	Disease
.	O
All	O
patients	O
recovered	O
without	O
sequelae.	O
We	O
report	O
a	O
case	O
of	O
a	O
31	O
year	O
old	O
female	O
who	O
required	O
admission	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
ventilation	O
and	O
full	O
supportive	O
therapy,	O
following	O
ingestion	O
of	O
13.5g	O
bupropion	Chemical
.	O
Recurrent	O
seizures	Disease
were	O
treated	O
with	O
diazepam	Chemical
and	O
broad	O
complex	O
tachycardia	Disease
was	O
successfully	O
treated	O
with	O
adenosine	Chemical
.	O
Zyban	Chemical
caused	O
significant	O
neurological	Disease
and	Disease
cardiovascular	Disease
toxicity	Disease
in	O
overdose	Disease

Survey	O
of	O
complications	O
of	O
indocyanine	Chemical
green	Chemical
angiography	O
in	O
Japan.	O
PURPOSE:	O
We	O
evaluated	O
the	O
safety	O
of	O
indocyanine	Chemical
green	Chemical
for	O
use	O
in	O
fundus	O
angiography.	O
METHODS:	O
We	O
sent	O
a	O
questionnaire	O
concerning	O
complications	O
of	O
indocyanine	Chemical
green	Chemical
to	O
32	O
institutions	O
in	O
Japan,	O
which	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
client	O
list	O
from	O
the	O
Topcon	O
Company,	O
which	O
manufactures	O
the	O
indocyanine	Chemical
green	Chemical
fundus	O
camera.	O
RESULTS:	O
Ophthalmologists	O
at	O
15	O
institutions	O
responded,	O
reporting	O
a	O
total	O
of	O
3,774	O
indocyanine	Chemical
green	Chemical
angiograms	O
performed	O
on	O
2,820	O
patients	O
between	O
June	O
1984	O
and	O
September	O
1992.	O
Before	O
angiography,	O
intradermal	O
or	O
intravenous	O
indocyanine	Chemical
green	Chemical
testing,	O
or	O
both	O
was	O
performed	O
at	O
13	O
of	O
15	O
institutions.	O
For	O
three	O
patients,	O
the	O
decision	O
was	O
made	O
not	O
to	O
proceed	O
with	O
angiography	O
after	O
positive	O
preangiographic	O
testing.	O
The	O
dosage	O
of	O
indocyanine	Chemical
green	Chemical
used	O
for	O
angiography	O
varied	O
from	O
25	O
to	O
75	O
mg,	O
depending	O
upon	O
the	O
institution.	O
There	O
were	O
13	O
cases	O
of	O
adverse	O
reactions	O
(0.34%),	O
ten	O
of	O
which	O
were	O
mild	O
reactions	O
such	O
as	O
nausea	Disease
,	O
exanthema	Disease
,	O
urtication	Disease
,	O
itchiness	Disease
,	O
and	O
urgency	O
to	O
defecate,	O
and	O
did	O
not	O
require	O
treatment.	O
Also	O
recorded	O
were	O
one	O
case	O
of	O
pain	Disease
of	O
the	O
vein,	O
which	O
required	O
treatment,	O
and	O
two	O
cases	O
of	O
hypotension	Disease
.	O
The	O
two	O
hypotensive	Disease
patients	O
required	O
treatment	O
for	O
shock	Disease
.	O
CONCLUSIONS:	O
A	O
comparison	O
of	O
frequency	O
of	O
adverse	O
reactions	O
to	O
indocyanine	Chemical
green	Chemical
with	O
the	O
previously	O
reported	O
frequency	O
of	O
such	O
reactions	O
to	O
fluorescein	Chemical
sodium	Chemical
indicated	O
that	O
indocyanine	Chemical
green	Chemical
is	O
a	O
safe	O
as	O
fluorescein	Chemical

Bradykinin	Chemical
receptors	O
antagonists	O
and	O
nitric	Chemical
oxide	Chemical
synthase	O
inhibitors	O
in	O
vincristine	Chemical
and	O
streptozotocin	Chemical
induced	O
hyperalgesia	Disease
in	O
chemotherapy	O
and	O
diabetic	Disease
neuropathy	Disease
rat	O
model.	O
PURPOSE:	O
The	O
influence	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
constitutive	O
NO	Chemical
synthase	O
(L-NOArg;	O
1.0	O
mg/kg	O
ip),	O
a	O
relatively	O
selective	O
inhibitor	O
of	O
inducible	O
NO	Chemical
synthase	O
(L-NIL;	O
1.0	O
mg/kg	O
ip)	O
and	O
a	O
relatively	O
specific	O
inhibitor	O
of	O
neuronal	O
NO	Chemical
synthase	O
(7-NI;	O
0.1	O
mg/kg	O
ip),	O
on	O
antihyperalgesic	O
action	O
of	O
selective	O
antagonists	O
of	O
B2	O
and	O
B1	O
receptors:	O
D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]	O
bradykinin	Chemical
(	O
HOE	Chemical
140	Chemical
;	O
70	O
nmol/kg	O
ip)	O
or	O
des	Chemical
Arg10	Chemical
HOE	Chemical
140	Chemical
(70	O
nmol/kg	O
ip)	O
respectively,	O
in	O
model	O
of	O
diabetic	Disease
(streptozotocin-induced)	Disease
and	Disease
toxic	Disease
(vincristine-induced)	Disease
neuropathy	Disease
was	O
investigated.	O
METHODS:	O
The	O
changes	O
in	O
pain	Disease
thresholds	O
were	O
determined	O
using	O
mechanical	O
stimuli--the	O
modification	O
of	O
the	O
classic	O
paw	O
withdrawal	O
test	O
described	O
by	O
Randall-Selitto.	O
RESULTS:	O
The	O
results	O
of	O
this	O
paper	O
confirm	O
that	O
inhibition	O
of	O
bradykinin	Chemical
receptors	O
and	O
inducible	O
NO	Chemical
synthase	O
but	O
not	O
neuronal	O
NO	Chemical
synthase	O
activity	O
reduces	O
diabetic	Disease
hyperalgesia	Disease
.	O
Pretreatment	O
with	O
L-NOArg	O
and	O
L-NIL	O
but	O
not	O
7-NI,	O
significantly	O
increases	O
antihyperalgesic	O
activity	O
both	O
HOE	Chemical
140	Chemical
and	O
des	Chemical
Arg10	Chemical
HOE	Chemical
140	Chemical
.	O
It	O
was	O
also	O
shown	O
that	O
both	O
products	O
of	O
inducible	O
NO	Chemical
synthase	O
and	O
neuronal	O
NO	Chemical
synthase	O
activation	O
as	O
well	O
as	O
bradykinin	Chemical
are	O
involved	O
in	O
hyperalgesia	Disease
produced	O
by	O
vincristine	Chemical
.	O
Moreover,	O
L-NOArg	O
and	O
7-NI	O
but	O
not	O
L-NIL	O
intensify	O
antihyperalgesic	O
activity	O
of	O
HOE	Chemical
140	Chemical
or	O
des-Arg10HOE	Chemical
140	Chemical
in	O
toxic	Disease
neuropathy	Disease
.	O
CONCLUSIONS:	O
Results	O
of	O
these	O
studies	O
suggest	O
that	O
B1	O
and	O
B2	O
receptors	O
are	O
engaged	O
in	O
transmission	O
of	O
nociceptive	O
stimuli	O
in	O
both	O
diabetic	Disease
and	Disease
toxic	Disease
neuropathy	Disease
.	O
In	O
streptozotocin	Chemical
-induced	O
hyperalgesia	Disease
,	O
inducible	O
NO	Chemical
synthase	O
participates	O
in	O
pronociceptive	O
activity	O
of	O
bradykinin	Chemical
,	O
whereas	O
in	O
vincristine	Chemical
-induced	O
hyperalgesia	Disease
	O
bradykinin	Chemical
seemed	O
to	O
activate	O
neuronal	O
NO	Chemical
synthase	O
pathway.	O
Therefore,	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	Chemical
receptor	O
antagonists	O
and	O
NO	Chemical
synthase	O
inhibitors	O
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	Disease
pain	Disease

Cardiac	Disease
toxicity	Disease
observed	O
in	O
association	O
with	O
high-dose	O
cyclophosphamide	Chemical
-based	O
chemotherapy	O
for	O
metastatic	O
breast	Disease
cancer	Disease
.	O
INTRODUCTION:	O
Cyclophosphamide	Chemical
is	O
an	O
alkylating	O
agent	O
given	O
frequently	O
as	O
a	O
component	O
of	O
many	O
conditioning	O
regimens.	O
In	O
high	O
doses,	O
its	O
nonhematological	O
dose-limiting	O
toxicity	Disease
is	O
cardiomyopathy	Disease
.	O
STUDY	O
DESIGN:	O
We	O
combined	O
paclitaxel	Chemical
,	O
melphalan	Chemical
and	O
high-dose	O
cyclophosphamide	Chemical
,	O
thiotepa	Chemical
,	O
and	O
carboplatin	Chemical
in	O
a	O
triple	O
sequential	O
high-dose	O
regimen	O
for	O
patients	O
with	O
metastatic	O
breast	Disease
cancer	Disease
.	O
Analysis	O
was	O
performed	O
on	O
61	O
women	O
with	O
chemotherapy-responsive	O
metastatic	O
breast	Disease
cancer	Disease
receiving	O
96-h	O
infusional	O
cyclophosphamide	Chemical
as	O
part	O
of	O
a	O
triple	O
sequential	O
high-dose	O
regimen	O
to	O
assess	O
association	O
between	O
presence	O
of	O
peritransplant	O
congestive	Disease
heart	Disease
failure	Disease
(	O
CHF	Disease
)	O
and	O
the	O
following	O
pretreatment	O
characteristics:	O
presence	O
of	O
electrocardiogram	O
(EKG)	O
abnormalities,	O
age,	O
hypertension	Disease
,	O
prior	O
cardiac	O
history,	O
smoking,	O
diabetes	Disease
mellitus	Disease
,	O
prior	O
use	O
of	O
anthracyclines	Chemical
,	O
and	O
left-sided	O
chest	O
irradiation.	O
RESULTS:	O
Six	O
of	O
61	O
women	O
(10%)	O
developed	O
clinically	O
reversible	O
grade	O
3	O
CHF	Disease
following	O
infusional	O
cyclophosphamide	Chemical
with	O
a	O
median	O
percent	O
decline	O
in	O
ejection	O
fraction	O
of	O
31%.	O
Incidence	O
of	O
transient	O
cyclophosphamide	Chemical
-related	O
cardiac	Disease
toxicity	Disease
(10%)	O
is	O
comparable	O
to	O
previous	O
recorded	O
literature.	O
Older	O
age	O
was	O
significantly	O
correlated	O
with	O
the	O
CHF	Disease
development;	O
with	O
median	O
ages	O
for	O
the	O
entire	O
group	O
and	O
for	O
patients	O
developing	O
CHF	Disease
of	O
45	O
and	O
59,	O
respectively.	O
No	O
association	O
was	O
found	O
with	O
other	O
pretreatment	O
characteristics.	O
CONCLUSIONS:	O
As	O
a	O
result	O
of	O
these	O
findings,	O
oncologists	O
should	O
carefully	O
monitor	O
fluid	O
balance	O
in	O
older	O
patients.	O
Routine	O
EKG	O
monitoring	O
during	O
infusional	O
cyclophosphamide	Chemical
did	O
not	O
predict	O
CHF	Disease

Inappropriate	O
use	O
of	O
carbamazepine	Chemical
and	O
vigabatrin	Chemical
in	O
typical	O
absence	Disease
seizures	Disease
.	O
Carbamazepine	Chemical
and	O
vigabatrin	Chemical
are	O
contraindicated	O
in	O
typical	O
absence	Disease
seizures	Disease
.	O
Of	O
18	O
consecutive	O
referrals	O
of	O
children	O
with	O
resistant	O
typical	O
absences	O
only,	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	Chemical
either	O
as	O
monotherapy	O
or	O
as	O
an	O
add-on.	O
Vigabatrin	Chemical
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children.	O
Frequency	O
of	O
absences	O
increased	O
in	O
four	O
children	O
treated	O
with	O
carbamazepine	Chemical
and	O
two	O
of	O
these	O
developed	O
myoclonic	Disease
jerks	Disease
,	O
which	O
resolved	O
on	O
withdrawal	O
of	O
carbamazepine	Chemical
.	O
Absences	O
were	O
aggravated	O
in	O
both	O
cases	O
where	O
vigabatrin	Chemical
was	O
added	O
on	O
to	O
concurrent	O
treatment.	O
Optimal	O
control	O
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	Chemical
valproate	Chemical
,	O
lamotrigine	Chemical
,	O
or	O
ethosuximide	Chemical

Hemolytic	Disease
anemia	Disease
associated	O
with	O
the	O
use	O
of	O
omeprazole	Chemical
.	O
Omeprazole	Chemical
is	O
the	O
first	O
drug	O
designed	O
to	O
block	O
the	O
final	O
step	O
in	O
the	O
acid	O
secretory	O
process	O
within	O
the	O
parietal	O
cell.	O
It	O
has	O
been	O
shown	O
to	O
be	O
extremely	O
effective	O
in	O
the	O
treatment	O
of	O
peptic	Disease
ulcer	Disease
disease	Disease
,	O
reflux	Disease
esophagitis	Disease
,	O
and	O
the	O
Zollinger-Ellison	Disease
syndrome	Disease
.	O
Although	O
clinical	O
experience	O
with	O
omeprazole	Chemical
is	O
still	O
limited,	O
many	O
controlled	O
studies	O
have	O
established	O
the	O
short-term	O
safety	O
of	O
this	O
drug.	O
We	O
report	O
the	O
first	O
case	O
of	O
a	O
serious	O
short-term	O
adverse	O
reaction	O
with	O
the	O
use	O
of	O
omeprazole	Chemical
:	O
hemolytic	Disease
anemia	Disease
.	O
The	O
patient	O
developed	O
weakness,	O
lethargy	Disease
,	O
and	O
shortness	Disease
of	Disease
breath	Disease
2	O
days	O
after	O
starting	O
therapy	O
with	O
omeprazole	Chemical
.	O
Two	O
weeks	O
after	O
the	O
initiation	O
of	O
therapy,	O
her	O
hematocrit	O
had	O
decreased	O
from	O
44.1%	O
to	O
20.4%,	O
and	O
she	O
had	O
a	O
positive	O
direct	O
Coombs	O
antiglobulin	O
test	O
and	O
an	O
elevated	O
indirect	O
bilirubin	Chemical
.	O
After	O
she	O
discontinued	O
the	O
omeprazole	Chemical
,	O
her	O
hemoglobin	O
and	O
hematocrit	O
gradually	O
returned	O
to	O
normal.	O
The	O
mechanism	O
by	O
which	O
omeprazole	Chemical
caused	O
the	O
patient's	O
hemolytic	Disease
anemia	Disease

The	O
use	O
and	O
toxicity	Disease
of	O
didanosine	Chemical
(	O
ddI	Chemical
)	O
in	O
HIV	Disease
antibody-positive	Disease
individuals	O
intolerant	O
to	O
zidovudine	Chemical
(	O
AZT	Chemical
)	O
One	O
hundred	O
and	O
fifty-one	O
patients	O
intolerant	O
to	O
zidovudine	Chemical
(	O
AZT	Chemical
)	O
received	O
didanosine	Chemical
(	O
ddI	Chemical
)	O
to	O
a	O
maximum	O
dose	O
of	O
12.5	O
mg/kg/day.	O
Patient	O
response	O
was	O
assessed	O
using	O
changes	O
in	O
CD4+	O
lymphocyte	O
subset	O
count,	O
HIV	O
p24	O
antigen,	O
weight,	O
and	O
quality	O
of	O
life.	O
Seventy	O
patients	O
developed	O
major	O
opportunistic	Disease
infections	Disease
whilst	O
on	O
therapy;	O
this	O
was	O
the	O
first	O
AIDS	Disease
diagnosis	O
in	O
17.	O
Only	O
minor	O
changes	O
in	O
CD4+	O
lymphocyte	O
subset	O
count	O
were	O
observed	O
in	O
AIDS	Disease
patients,	O
although	O
a	O
more	O
significant	O
rise	O
occurred	O
in	O
those	O
with	O
earlier	O
stages	O
of	O
disease.	O
Of	O
those	O
positive	O
for	O
p24	O
antigen	O
at	O
the	O
commencement	O
of	O
the	O
study	O
67%	O
showed	O
a	O
positive	O
response,	O
and	O
this	O
was	O
most	O
likely	O
in	O
those	O
with	O
CD4+	O
lymphocyte	O
subset	O
counts	O
above	O
100	O
mm3.	O
A	O
positive	O
weight	O
response	O
was	O
seen	O
in	O
16%	O
of	O
patients.	O
Most	O
patients	O
showed	O
improvement	O
in	O
individual	O
parameters	O
and	O
global	O
score	O
of	O
quality	O
of	O
life.	O
Adverse	O
reactions	O
possibly	O
attributable	O
to	O
didanosine	Chemical
were	O
common.	O
The	O
most	O
common	O
side-effect	O
was	O
diarrhoea	Disease
,	O
which	O
resulted	O
in	O
cessation	O
of	O
therapy	O
in	O
19	O
individuals.	O
Peripheral	Disease
neuropathy	Disease
occurred	O
in	O
12	O
patients	O
and	O
pancreatitis	Disease
in	O
six.	O
Thirteen	O
patients	O
developed	O
a	O
raised	O
serum	O
amylase	O
without	O
abdominal	Disease
pain	Disease
.	O
Seven	O
patients	O
developed	O
glucose	Disease
tolerance	Disease
curves	Disease
characteristic	O
of	O
diabetes	Disease
but	O
these	O
were	O
mild,	O
did	O
not	O
require	O
treatment	O
and	O
returned	O
to	O
normal	O
on	O
ceasing	O
didanosine	Chemical

Can	O
angiogenesis	O
be	O
a	O
target	O
of	O
treatment	O
for	O
ribavirin	Chemical
associated	O
hemolytic	Disease
anemia	Disease
?	O
BACKGROUND/AIMS:	O
Recently	O
ribavirin	Chemical
has	O
been	O
found	O
to	O
inhibit	O
angiogenesis	O
and	O
a	O
number	O
of	O
angiogenesis	O
inhibitors	O
such	O
as	O
sunitinib	Chemical
and	O
sorafenib	Chemical
have	O
been	O
found	O
to	O
cause	O
acute	O
hemolysis	Disease
.	O
We	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
a	O
relation	O
between	O
hemoglobin,	O
haptoglobin	O
and	O
angiogenesis	O
soluble	O
markers	O
which	O
are	O
modifiable	O
and	O
can	O
help	O
in	O
developing	O
strategies	O
against	O
anemia	Disease
.	O
METHODS:	O
Fourteen	O
patients	O
chronically	Disease
infected	Disease
with	Disease
hepatitis	Disease
C	Disease
virus	Disease
were	O
treated	O
by	O
pegylated	Chemical
interferon	Chemical
alpha	Chemical
2a	Chemical
and	O
ribavirin	Chemical
.	O
Serum	O
hemoglobin,	O
haptoglobin	O
and	O
angiogenesis	O
markers	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
angiopoetin-2	O
were	O
investigated	O
before	O
and	O
after	O
therapy.	O
RESULTS:	O
We	O
observed	O
a	O
significant	O
decrease	O
in	O
haptoglobin	O
levels	O
at	O
the	O
end	O
of	O
the	O
treatment	O
period.	O
Hemoglobin	O
levels	O
also	O
decreased	O
but	O
insignificantly	O
by	O
treatment.	O
In	O
contrast	O
with	O
the	O
literature,	O
serum	O
levels	O
of	O
angiogenesis	O
factors	O
did	O
not	O
change	O
significantly	O
by	O
pegylated	Chemical
interferon	Chemical
and	O
ribavirin	Chemical
therapy.	O
We	O
found	O
no	O
correlation	O
of	O
angiogenesis	O
soluble	O
markers	O
with	O
either	O
hemoglobin	O
or	O
haptoglobin.	O
CONCLUSION:	O
This	O
is	O
the	O
first	O
study	O
in	O
the	O
literature	O
investigating	O
a	O
link	O
between	O
angiogenesis	O
soluble	O
markers	O
and	O
ribavirin	Chemical
induced	O
anemia	Disease
in	O
patients	O
with	O
hepatitis	Disease
C	Disease
and	O
we	O
could	O
not	O
find	O
any	O
relation.	O
Future	O
research	O
with	O
larger	O
number	O
of	O
patients	O
is	O
needed	O
to	O
find	O
out	O
modifiable	O
factors	O
that	O
will	O
improve	O
the	O
safety	O
of	O
ribavirin	Chemical

Cocaine	Chemical
causes	O
memory	Disease
and	Disease
learning	Disease
impairments	Disease
in	O
rats:	O
involvement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
oxidative	O
stress,	O
and	O
prevention	O
by	O
topiramate	Chemical
.	O
Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	Chemical
	O
toxicity	Disease
including	O
an	O
increase	O
in	O
oxidative	O
stress	O
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	Chemical
induced-behaviour	O
is	O
poorly	O
understood.	O
Nuclear	O
factor	O
kappa	O
B	O
(NFkappaB)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	O
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	O
toxicity	Disease
and	O
addiction	O
mechanisms.	O
Therefore	O
NFkappaB	O
activity,	O
oxidative	O
stress,	O
neuronal	O
nitric	Chemical
oxide	Chemical
synthase	O
(nNOS)	O
activity,	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	Chemical
,	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	Disease
addiction	Disease
,	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	Chemical
administration	O
in	O
rats.	O
NFkappaB	O
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	Chemical
treated	O
rats,	O
as	O
well	O
as	O
GSH	Chemical
concentration	O
and	O
glutathione	Chemical
peroxidase	O
activity	O
in	O
the	O
hippocampus,	O
whereas	O
nNOS	O
activity	O
in	O
the	O
hippocampus	O
was	O
increased.	O
Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	Chemical
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	O
activity	O
in	O
the	O
frontal	O
cortex.	O
In	O
contrast,	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	O
activity	O
and	O
the	O
decrease	O
of	O
glutathione	Chemical
peroxidase.	O
These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
NFkappaB	O
in	O
the	O
alterations	O
induced	O
by	O
cocaine	Chemical
.	O
Topiramate	Chemical

Antinociceptive	O
and	O
antiamnesic	O
properties	O
of	O
the	O
presynaptic	O
cholinergic	O
amplifier	O
PG-9	Chemical
.	O
The	O
antinociceptive	O
effect	O
of	O
3	Chemical
alpha-tropyl	Chemical
2-(p-bromophenyl)propionate	Chemical
[(+/-)-	O
PG-9	Chemical
]	O
(10-40	O
mg	O
kg-1	O
s.c.;	O
30-60	O
mg	O
kg-1	O
p.o.;	O
10-30	O
mg	O
kg-1	O
i.v.;	O
10-30	O
micrograms/mouse	O
i.c.v.)	O
was	O
examined	O
in	O
mice,	O
rats	O
and	O
guinea	O
pigs	O
by	O
use	O
of	O
the	O
hot-plate,	O
abdominal-constriction,	O
tail-flick	O
and	O
paw-pressure	O
tests.	O
(+/-)-	O
PG-9	Chemical
antinociception	O
peaked	O
15	O
min	O
after	O
injection	O
and	O
then	O
slowly	O
diminished.	O
The	O
antinociception	O
produced	O
by	O
(+/-)-	O
PG-9	Chemical
was	O
prevented	O
by	O
the	O
unselective	O
muscarinic	O
antagonist	O
atropine	Chemical
,	O
the	O
M1-selective	O
antagonists	O
pirenzepine	Chemical
and	O
dicyclomine	Chemical
and	O
the	O
acetylcholine	Chemical
depletor	O
hemicholinium-3	Chemical
,	O
but	O
not	O
by	O
the	O
opioid	O
antagonist	O
naloxone	Chemical
,	O
the	O
gamma-aminobutyric	Chemical
acidB	Chemical
antagonist	O
3-aminopropyl-diethoxy-methyl-phosphinic	Chemical
acid	Chemical
,	O
the	O
H3	O
agonist	O
R-(alpha)-methylhistamine	Chemical
,	O
the	O
D2	O
antagonist	O
quinpirole	Chemical
,	O
the	O
5-hydroxytryptamine4	Chemical
antagonist	O
2-methoxy-4-amino-5-chlorobenzoic	Chemical
acid	Chemical
2-(diethylamino)ethyl	Chemical
ester	Chemical
hydrochloride,	O
the	O
5-hydroxytryptamin1A	Chemical
antagonist	O
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine	Chemical
hydrobromide	O
and	O
the	O
polyamines	O
depletor	O
reserpine	Chemical
.	O
Based	O
on	O
these	O
data,	O
it	O
can	O
be	O
postulated	O
that	O
(+/-)-	O
PG-9	Chemical
exerted	O
an	O
antinociceptive	O
effect	O
mediated	O
by	O
a	O
central	O
potentiation	O
of	O
cholinergic	O
transmission.	O
(+/-)-	O
PG-9	Chemical
(10-40	O
mg	O
kg-1	O
i.p.)	O
was	O
able	O
to	O
prevent	O
amnesia	Disease
induced	O
by	O
scopolamine	Chemical
(1	O
mg	O
kg-1	O
i.p.)	O
and	O
dicyclomine	Chemical
(2	O
mg	O
kg-1	O
i.p.)	O
in	O
the	O
mouse	O
passive-avoidance	O
test.	O
Affinity	O
profiles	O
of	O
(+/-)-	O
PG-9	Chemical
for	O
muscarinic	O
receptor	O
subtypes,	O
determined	O
by	O
functional	O
studies	O
(rabbit	O
vas	O
deferens	O
for	O
M1,	O
guinea	O
pig	O
atrium	O
for	O
M2,	O
guinea	O
pig	O
ileum	O
for	O
M3	O
and	O
immature	O
guinea	O
pig	O
uterus	O
for	O
putative	O
M4),	O
have	O
shown	O
an	O
M4/M1	O
selectivity	O
ratio	O
of	O
10.2	O
that	O
might	O
be	O
responsible	O
for	O
the	O
antinociception	O
and	O
the	O
anti-	O
amnesic	Disease
effect	O
induced	O
by	O
(+/-)-	O
PG-9	Chemical
through	O
an	O
increase	O
in	O
acetylcholine	Chemical
extracellular	O
levels.	O
In	O
the	O
antinociceptive	O
and	O
antiamnesic	O
dose	O
range,	O
(+/-)-	O
PG-9	Chemical

Hyperbaric	O
oxygen	Chemical
therapy	O
for	O
control	O
of	O
intractable	O
cyclophosphamide	Chemical
-induced	O
hemorrhagic	Disease
cystitis	Disease
.	O
We	O
report	O
a	O
case	O
of	O
intractable	O
hemorrhagic	Disease
cystitis	Disease
due	O
to	O
cyclophosphamide	Chemical
therapy	O
for	O
Wegener's	Disease
granulomatosis	Disease
.	O
Conservative	O
treatment,	O
including	O
bladder	O
irrigation	O
with	O
physiological	O
saline	O
and	O
instillation	O
of	O
prostaglandin	Chemical
F2	Chemical
alpha	Chemical
,	O
failed	O
to	O
totally	O
control	O
hemorrhage	Disease
.	O
We	O
then	O
used	O
hyperbaric	O
oxygen	Chemical
at	O
an	O
absolute	O
pressure	O
of	O
2	O
atm,	O
5	O
days	O
a	O
week	O
for	O
8	O
consecutive	O
weeks.	O
The	O
bleeding	Disease
ceased	O
completely	O
by	O
the	O
end	O
of	O
treatment	O
and	O
the	O
patient	O
remained	O
free	O
of	O
hematuria	Disease
thereafter.	O
No	O
side	O
effect	O
was	O
noted	O
during	O
the	O
course	O
of	O
therapy.	O
In	O
future,	O
this	O
form	O
of	O
therapy	O
can	O
offer	O
a	O
safe	O
alternative	O
in	O
the	O
treatment	O
of	O
cyclophosphamide	Chemical
-induced	O
hemorrhagic	Disease
cystitis	Disease

Further	O
studies	O
on	O
effects	O
of	O
irrigation	O
solutions	O
on	O
rat	O
bladders.	O
Further	O
studies	O
on	O
the	O
effects	O
of	O
certain	O
irrigating	O
fluids	O
on	O
the	O
rat	O
bladder	O
for	O
18	O
hours	O
are	O
reported.	O
The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	O
p-choloroaniline	Chemical
is	O
not	O
a	O
significant	O
factor	O
in	O
chlorhexidine-digluconate	Chemical
associated	O
erosive	O
cystitis	Disease
.	O
A	O
high	O
percentage	O
of	O
kanamycin	Chemical
-	O
colistin	Chemical
and	O
povidone-iodine	Chemical
irrigations	O
were	O
associated	O
with	O
erosive	O
cystitis	Disease
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage.	O
Picloxydine	Chemical
irrigations	O
appeared	O
to	O
have	O
a	O
lower	O
incidence	O
of	O
erosive	O
cystitis	Disease

Clinical	O
experiences	O
in	O
an	O
open	O
and	O
a	O
double-blind	O
trial.	O
A	O
total	O
of	O
sixty	O
patients	O
were	O
trated	O
with	O
bromperidol	Chemical
first	O
in	O
open	O
conditions	O
(20	O
patients),	O
then	O
on	O
a	O
double	O
blind	O
basis	O
(40	O
patients)	O
with	O
haloperidol	Chemical
as	O
the	O
reference	O
substance.	O
The	O
open	O
study	O
lasted	O
for	O
four	O
weeks;	O
the	O
drug	O
was	O
administrated	O
in	O
the	O
form	O
of	O
1	O
mg	O
tablets.	O
The	O
daily	O
dose	O
(initial	O
dose:	O
1	O
mg;	O
mean	O
dose	O
at	O
the	O
end	O
of	O
the	O
trial:	O
4.47	O
mg)	O
was	O
always	O
administered	O
in	O
one	O
single	O
dose.	O
Nineteen	O
patients	O
finished	O
the	O
trial,	O
and	O
in	O
18	O
cases	O
the	O
therapeutic	O
result	O
was	O
considered	O
very	O
good	O
to	O
good.	O
These	O
results	O
were	O
confirmed	O
by	O
statistical	O
analysis.	O
Nine	O
patients	O
exhibited	O
mild	O
to	O
moderate	O
extrapyramidal	Disease
concomitant	Disease
symptoms	Disease
;	O
no	O
other	O
side	O
effects	O
were	O
observed.	O
The	O
results	O
of	O
detailed	O
laboratory	O
tests	O
and	O
evaluations	O
of	O
various	O
quantitative	O
and	O
qualitative	O
tolerability	O
parameters	O
were	O
not	O
indicative	O
of	O
toxic	O
effects.	O
In	O
the	O
double	O
blind	O
study	O
with	O
haloperidol	Chemical
,	O
both	O
substances	O
were	O
found	O
to	O
be	O
highly	O
effective	O
in	O
the	O
treatment	O
of	O
psychotic	Disease
syndromes	Disease
belonging	Disease
predominantly	Disease
to	Disease
the	Disease
schizophrenia	Disease
group	Disease
.	O
Certain	O
clues,	O
including	O
the	O
onset	O
of	O
action,	O
seem	O
to	O
be	O
indicative	O
of	O
the	O
superiority	O
of	O
bromperidol	Chemical

Curcumin	Chemical
ameliorates	O
cognitive	Disease
dysfunction	Disease
and	O
oxidative	O
damage	O
in	O
phenobarbitone	Chemical
and	O
carbamazepine	Chemical
administered	O
rats.	O
The	O
antiepileptic	O
drugs,	O
phenobarbitone	Chemical
and	O
carbamazepine	Chemical
are	O
well	O
known	O
to	O
cause	O
cognitive	Disease
impairment	Disease
on	O
chronic	O
use.	O
The	O
increase	O
in	O
free	O
radical	O
generation	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanisms	O
of	O
cognitive	Disease
impairment	Disease
by	O
antiepileptic	O
drugs.	O
Curcumin	Chemical
has	O
shown	O
antioxidant,	O
anti-inflammatory	O
and	O
neuro-protective	O
properties.	O
Therefore,	O
the	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
effect	O
of	O
chronic	O
curcumin	Chemical
administration	O
on	O
phenobarbitone	Chemical
-	O
and	O
carbamazepine	Chemical
-induced	O
cognitive	Disease
impairment	Disease
and	O
oxidative	O
stress	O
in	O
rats.	O
Pharmacokinetic	O
interactions	O
of	O
curcumin	Chemical
with	O
phenobarbitone	Chemical
and	O
carbamazepine	Chemical
were	O
also	O
studied.	O
Vehicle/drugs	O
were	O
administered	O
daily	O
for	O
21days	O
to	O
male	O
Wistar	O
rats.	O
Passive	O
avoidance	O
paradigm	O
and	O
elevated	O
plus	O
maze	O
test	O
were	O
used	O
to	O
assess	O
cognitive	O
function.	O
At	O
the	O
end	O
of	O
study	O
period,	O
serum	O
phenobarbitone	Chemical
and	O
carbamazepine	Chemical
,	O
whole	O
brain	O
malondialdehyde	Chemical
and	O
reduced	O
glutathione	Chemical
levels	O
were	O
estimated.	O
The	O
administration	O
of	O
phenobarbitone	Chemical
and	O
carbamazepine	Chemical
for	O
21days	O
caused	O
a	O
significant	O
impairment	Disease
of	Disease
learning	Disease
and	Disease
memory	Disease
as	O
well	O
as	O
an	O
increased	O
oxidative	O
stress.	O
Concomitant	O
curcumin	Chemical
administration	O
prevented	O
the	O
cognitive	Disease
impairment	Disease
and	O
decreased	O
the	O
increased	O
oxidative	O
stress	O
induced	O
by	O
these	O
antiepileptic	O
drugs.	O
Curcumin	Chemical
co-administration	O
did	O
not	O
cause	O
any	O
significant	O
alteration	O
in	O
the	O
serum	O
concentrations	O
of	O
both	O
phenobarbitone	Chemical
as	O
well	O
as	O
carbamazepine	Chemical
.	O
These	O
results	O
show	O
that	O
curcumin	Chemical
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deterioration	Disease
of	Disease
cognitive	Disease
functions	Disease
and	O
oxidative	O
damage	O
in	O
rats	O
treated	O
with	O
phenobarbitone	Chemical
and	O
carbamazepine	Chemical
without	O
significantly	O
altering	O
their	O
serum	O
concentrations.	O
The	O
findings	O
suggest	O
that	O
curcumin	Chemical
can	O
be	O
considered	O
as	O
a	O
potential	O
safe	O
and	O
effective	O
adjuvant	O
to	O
phenobarbitone	Chemical
and	O
carbamazepine	Chemical
therapy	O
in	O
preventing	O
cognitive	Disease
impairment	Disease

Pyrrolidine	Chemical
dithiocarbamate	Chemical
protects	O
the	O
piriform	O
cortex	O
in	O
the	O
pilocarpine	Chemical
	O
status	Disease
epilepticus	Disease
model.	O
Pyrrolidine	Chemical
dithiocarbamate	Chemical
(	O
PDTC	Chemical
)	O
has	O
a	O
dual	O
mechanism	O
of	O
action	O
as	O
an	O
antioxidant	O
and	O
an	O
inhibitor	O
of	O
the	O
transcription	O
factor	O
kappa-beta.	O
Both,	O
production	O
of	O
reactive	O
oxygen	Chemical
species	O
as	O
well	O
as	O
activation	O
of	O
NF-kappaB	O
have	O
been	O
implicated	O
in	O
severe	O
neuronal	Disease
damage	Disease
in	O
different	O
sub-regions	O
of	O
the	O
hippocampus	O
as	O
well	O
as	O
in	O
the	O
surrounding	O
cortices.	O
The	O
effect	O
of	O
PDTC	Chemical
on	O
status	Disease
epilepticus	Disease
-associated	O
cell	O
loss	O
in	O
the	O
hippocampus	O
and	O
piriform	O
cortex	O
was	O
evaluated	O
in	O
the	O
rat	O
fractionated	O
pilocarpine	Chemical
model.	O
Treatment	O
with	O
150	O
mg/kg	O
PDTC	Chemical
before	O
and	O
following	O
status	Disease
epilepticus	Disease
significantly	O
increased	O
the	O
mortality	O
rate	O
to	O
100%.	O
Administration	O
of	O
50	O
mg/kg	O
PDTC	Chemical
(low-dose)	O
did	O
not	O
exert	O
major	O
effects	O
on	O
the	O
development	O
of	O
a	O
status	Disease
epilepticus	Disease
or	O
the	O
mortality	O
rate.	O
In	O
vehicle-treated	O
rats,	O
status	Disease
epilepticus	Disease
caused	O
pronounced	O
neuronal	Disease
damage	Disease
in	O
the	O
piriform	O
cortex	O
comprising	O
both	O
pyramidal	O
cells	O
and	O
interneurons.	O
Low-dose	O
PDTC	Chemical
treatment	O
almost	O
completely	O
protected	O
from	O
lesions	O
in	O
the	O
piriform	O
cortex.	O
A	O
significant	O
decrease	O
in	O
neuronal	O
density	O
of	O
the	O
hippocampal	O
hilar	O
formation	O
was	O
identified	O
in	O
vehicle-	O
and	O
PDTC	Chemical
-treated	O
rats	O
following	O
status	Disease
epilepticus	Disease
.	O
In	O
conclusion,	O
the	O
NF-kappaB	O
inhibitor	O
and	O
antioxidant	O
PDTC	Chemical
protected	O
the	O
piriform	O
cortex,	O
whereas	O
it	O
did	O
not	O
affect	O
hilar	O
neuronal	Disease
loss	Disease
.	O
These	O
data	O
might	O
indicate	O
that	O
the	O
generation	O
of	O
reactive	O
oxygen	Chemical
species	O
and	O
activation	O
of	O
NF-kappaB	O
plays	O
a	O
more	O
central	O
role	O
in	O
seizure	Disease
-associated	O
neuronal	Disease
damage	Disease
in	O
the	O
temporal	O
cortex	O
as	O
compared	O
to	O
the	O
hippocampal	O
hilus.	O
However,	O
future	O
investigations	O
are	O
necessary	O
to	O
exactly	O
analyze	O
the	O
biochemical	O
mechanisms	O
by	O
which	O
PDTC	Chemical

Safety	O
profile	O
of	O
a	O
nicotine	Chemical
lozenge	O
compared	O
with	O
that	O
of	O
nicotine	Chemical
gum	O
in	O
adult	O
smokers	O
with	O
underlying	O
medical	O
conditions:	O
a	O
12-week,	O
randomized,	O
open-label	O
study.	O
BACKGROUND:	O
Nicotine	Chemical
polacrilex	O
lozenges	O
deliver	O
25%	O
to	O
27%	O
more	O
nicotine	Chemical
compared	O
with	O
equivalent	O
doses	O
of	O
nicotine	Chemical
polacrilex	O
gum.	O
The	O
increased	O
nicotine	Chemical
exposure	O
from	O
the	O
lozenge	O
has	O
raised	O
questions	O
about	O
the	O
relative	O
safety	O
of	O
the	O
lozenge	O
and	O
gum.	O
OBJECTIVE:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
safety	O
profiles	O
of	O
the	O
4-mg	O
nicotine	Chemical
lozenge	O
and	O
4-mg	O
nicotine	Chemical
gum	O
in	O
smokers	O
with	O
selected	O
label-restricted	O
diseases.	O
METHODS:	O
This	O
was	O
a	O
multicenter,	O
randomized,	O
open-label	O
study	O
in	O
adult	O
smokers	O
with	O
heart	Disease
disease	Disease
,	O
hypertension	Disease
not	O
controlled	O
by	O
medication,	O
and/or	O
diabetes	Disease
mellitus	Disease
.	O
Patients	O
were	O
randomized	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
the	O
4-mg	O
nicotine	Chemical
lozenge	O
or	O
4-mg	O
nicotine	Chemical
gum.	O
Safety	O
assessments	O
were	O
made	O
at	O
baseline	O
and	O
at	O
2,	O
4,	O
6,	O
and	O
12	O
weeks	O
after	O
the	O
start	O
of	O
product	O
use.	O
RESULTS:	O
Nine	O
hundred	O
one	O
patients	O
were	O
randomized	O
to	O
treatment,	O
447	O
who	O
received	O
the	O
lozenge	O
and	O
454	O
who	O
received	O
the	O
gum	O
(safety	O
population).	O
The	O
majority	O
were	O
women	O
(52.7%).	O
Patients'	O
mean	O
age	O
was	O
53.9	O
years,	O
their	O
mean	O
weight	O
was	O
193.9	O
pounds,	O
and	O
they	O
smoked	O
a	O
mean	O
of	O
25.2	O
cigarettes	O
per	O
day	O
at	O
baseline.	O
Five	O
hundred	O
fifty-three	O
patients,	O
264	O
taking	O
the	O
lozenge	O
and	O
289	O
taking	O
the	O
gum,	O
used	O
the	O
study	O
product	O
for	O
>	O
or	O
=4	O
days	O
per	O
week	O
during	O
the	O
first	O
2	O
weeks	O
(evaluable	O
population).	O
The	O
nicotine	Chemical
lozenge	O
and	O
nicotine	Chemical
gum	O
were	O
equally	O
well	O
tolerated,	O
despite	O
increased	O
nicotine	Chemical
exposure	O
from	O
the	O
lozenge.	O
The	O
incidence	O
of	O
adverse	O
events	O
in	O
the	O
2	O
groups	O
was	O
similar	O
during	O
the	O
first	O
2	O
weeks	O
of	O
product	O
use	O
(evaluation	O
population:	O
55.3%	O
lozenge,	O
54.7%	O
gum),	O
as	O
well	O
as	O
during	O
the	O
entire	O
study	O
(safety	O
population:	O
63.8%	O
and	O
58.6%,	O
respectively).	O
Stratification	O
of	O
patients	O
by	O
sex,	O
age,	O
extent	O
of	O
concurrent	O
smoking,	O
extent	O
of	O
product	O
use,	O
and	O
severity	O
of	O
adverse	O
events	O
revealed	O
no	O
clinically	O
significant	O
differences	O
between	O
the	O
lozenge	O
and	O
gum.	O
The	O
most	O
common	O
adverse	O
events	O
were	O
nausea	Disease
(17.2%	O
and	O
16.1%;	O
95%	O
CI,	O
-3.7	O
to	O
6.0),	O
hiccups	Disease
(10.7%	O
and	O
6.6%;	O
95%	O
CI,	O
0.5	O
to	O
7.8),	O
and	O
headache	Disease
(8.7%	O
and	O
9.9%;	O
95%	O
Cl,	O
-5.0	O
to	O
2.6).	O
Serious	O
adverse	O
events	O
were	O
reported	O
in	O
11	O
and	O
13	O
patients	O
in	O
the	O
respective	O
groups.	O
Fewer	O
than	O
6%	O
of	O
patients	O
in	O
either	O
group	O
were	O
considered	O
by	O
the	O
investigator	O
to	O
have	O
a	O
worsening	O
of	O
their	O
overall	O
disease	O
condition	O
during	O
the	O
study.	O
The	O
majority	O
of	O
patients	O
(>60%)	O
experienced	O
no	O
change	O
in	O
their	O
disease	O
status	O
from	O
baseline.	O
CONCLUSION:	O
The	O
4-mg	O
nicotine	Chemical
lozenge	O
and	O
4-mg	O
nicotine	Chemical

Development	O
of	O
levodopa	Chemical
-induced	O
dyskinesias	Disease
in	O
parkinsonian	Disease
monkeys	O
may	O
depend	O
upon	O
rate	O
of	O
symptom	O
onset	O
and/or	O
duration	O
of	O
symptoms.	O
Levodopa	Chemical
-induced	O
dyskinesias	Disease
(	O
LIDs	Disease
)	O
present	O
a	O
major	O
problem	O
for	O
the	O
long-term	O
management	O
of	O
Parkinson's	Disease
disease	Disease
(	O
PD	Disease
)	O
patients.	O
Due	O
to	O
the	O
interdependence	O
of	O
risk	O
factors	O
in	O
clinical	O
populations,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	O
factors	O
that	O
may	O
influence	O
the	O
development	O
of	O
LIDs	Disease
.	O
Using	O
macaque	O
monkeys	O
with	O
different	O
types	O
of	O
MPTP	Chemical
-induced	O
parkinsonism	Disease
,	O
the	O
current	O
study	O
evaluated	O
the	O
degree	O
to	O
which	O
rate	O
of	O
symptom	O
progression,	O
symptom	O
severity,	O
and	O
response	O
to	O
and	O
duration	O
of	O
levodopa	Chemical
therapy	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
LIDs	Disease
.	O
Monkeys	O
with	O
acute	O
(short-term)	O
MPTP	Chemical
exposure,	O
rapid	O
symptom	O
onset	O
and	O
short	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	Chemical
therapy	O
developed	O
dyskinesia	Disease
between	O
11	O
and	O
24	O
days	O
of	O
daily	O
levodopa	Chemical
administration.	O
In	O
contrast,	O
monkeys	O
with	O
long-term	O
MPTP	Chemical
exposure,	O
slow	O
symptom	O
progression	O
and/or	O
long	O
symptom	O
duration	O
prior	O
to	O
initiation	O
of	O
levodopa	Chemical
therapy	O
were	O
more	O
resistant	O
to	O
developing	O
LIDs	Disease
(e.g.,	O
dyskinesia	Disease
developed	O
no	O
sooner	O
than	O
146	O
days	O
of	O
chronic	O
levodopa	Chemical
administration).	O
All	O
animals	O
were	O
similarly	O
symptomatic	O
at	O
the	O
start	O
of	O
levodopa	Chemical
treatment	O
and	O
had	O
similar	O
therapeutic	O
responses	O
to	O
the	O
drug.	O
These	O
data	O
suggest	O
distinct	O
differences	O
in	O
the	O
propensity	O
to	O
develop	O
LIDs	Disease
in	O
monkeys	O
with	O
different	O
rates	O
of	O
symptom	O
progression	O
or	O
symptom	O
durations	O
prior	O
to	O
levodopa	Chemical
and	O
demonstrate	O
the	O
value	O
of	O
these	O
models	O
for	O
further	O
studying	O
the	O
pathophysiology	O
of	O
LIDs	Disease

Propylthiouracil	Chemical
-induced	O
perinuclear-staining	O
antineutrophil	O
cytoplasmic	O
autoantibody-positive	O
vasculitis	Disease
in	O
conjunction	O
with	O
pericarditis	Disease
.	O
OBJECTIVE:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil	Chemical
-induced	O
vasculitis	Disease
manifesting	O
with	O
pericarditis	Disease
.	O
METHODS:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	Disease
treated	O
with	O
propylthiouracil	Chemical
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	Disease
,	O
fever	Disease
,	O
and	O
glomerulonephritis	Disease
developed.	O
Serologic	O
testing	O
and	O
immunologic	O
studies	O
were	O
done,	O
and	O
a	O
pericardial	O
biopsy	O
was	O
performed.	O
RESULTS:	O
A	O
25-year-old	O
woman	O
with	O
Graves'	Disease
disease	Disease
had	O
a	O
febrile	Disease
illness	Disease
and	O
evidence	O
of	O
pericarditis	Disease
,	O
which	O
was	O
confirmed	O
by	O
biopsy.	O
Serologic	O
evaluation	O
revealed	O
the	O
presence	O
of	O
perinuclear-staining	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
(pANCA)	O
against	O
myeloperoxidase	O
(MPO).	O
Propylthiouracil	Chemical
therapy	O
was	O
withdrawn,	O
and	O
she	O
was	O
treated	O
with	O
a	O
1-month	O
course	O
of	O
prednisone	Chemical
,	O
which	O
alleviated	O
her	O
symptoms.	O
A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	Disease
in	O
anti-MPO	O
pANCA-positive	O
vasculitis	Disease
associated	O
with	O
propylthio-	Chemical
uracil	Chemical
therapy.	O
CONCLUSION:	O
Pericarditis	Disease
may	O
be	O
the	O
initial	O
manifestation	O
of	O
drug-induced	O
vasculitis	Disease
attributable	O
to	O
propylthio-	Chemical
uracil	Chemical

Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta-carboline	Chemical
-induced	O
seizures	Disease
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA	Chemical
(A)	O
receptor	O
ligands.	O
Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(BS	O
line)	O
or	O
resistance	O
(BR	O
line)	O
to	O
seizures	Disease
induced	O
by	O
a	O
single	O
i.p.	O
injection	O
of	O
methyl	Chemical
beta-carboline-3-carboxylate	Chemical
(	O
beta-CCM	Chemical
),	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	Chemical
(A)	O
receptor	O
benzodiazepine	Chemical
site.	O
Our	O
aim	O
was	O
to	O
characterize	O
both	O
lines'	O
sensitivities	O
to	O
various	O
physiological	O
effects	O
of	O
other	O
ligands	O
of	O
the	O
GABA	Chemical
(A)	O
receptor.	O
We	O
measured	O
diazepam	Chemical
-induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus-maze	O
test,	O
diazepam	Chemical
-induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states,	O
and	O
picrotoxin	Chemical
-	O
and	O
pentylenetetrazol	Chemical
-induced	O
seizures	Disease
after	O
i.p.	O
injections.	O
Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta-CCM	Chemical
can	O
be	O
extended	O
to	O
diazepam	Chemical
,	O
picrotoxin	Chemical
,	O
and	O
pentylenetetrazol	Chemical
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	Chemical

Analgesic	O
effect	O
of	O
intravenous	O
ketamine	Chemical
in	O
cancer	Disease
patients	O
on	O
morphine	Chemical
therapy:	O
a	O
randomized,	O
controlled,	O
double-blind,	O
crossover,	O
double-dose	O
study.	O
Pain	Disease
not	O
responsive	O
to	O
morphine	Chemical
is	O
often	O
problematic.	O
Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N-methyl-D-aspartate	Chemical
(	O
NMDA	Chemical
)	O
antagonists,	O
such	O
as	O
ketamine	Chemical
,	O
may	O
be	O
effective	O
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	Disease
syndromes,	O
such	O
as	O
neuropathic	Disease
pain	Disease
.	O
A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	Chemical
(0.25	O
mg/kg	O
or	O
0.50	O
mg/kg)	O
was	O
given	O
to	O
10	O
cancer	Disease
patients	O
whose	O
pain	Disease
was	O
unrelieved	O
by	O
morphine	Chemical
in	O
a	O
randomized,	O
double-blind,	O
crossover,	O
double-dose	O
study.	O
Pain	Disease
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale;	O
nausea	Disease
and	O
vomiting	Disease
,	O
drowsiness,	O
confusion	Disease
,	O
and	O
dry	Disease
mouth	Disease
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(not	O
at	O
all,	O
slight,	O
a	O
lot,	O
awful);	O
Mini-Mental	O
State	O
Examination	O
(MMSE)	O
(0-30);	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(T0)	O
and	O
after	O
30	O
minutes	O
(T30),	O
60	O
minutes	O
(T60),	O
120	O
minutes	O
(T120),	O
and	O
180	O
minutes	O
(T180).	O
Ketamine	Chemical
,	O
but	O
not	O
saline	O
solution,	O
significantly	O
reduced	O
the	O
pain	Disease
intensity	O
in	O
almost	O
all	O
the	O
patients	O
at	O
both	O
doses.	O
This	O
effect	O
was	O
more	O
relevant	O
in	O
patients	O
treated	O
with	O
higher	O
doses.	O
Hallucinations	Disease
occurred	O
in	O
4	O
patients,	O
and	O
an	O
unpleasant	O
sensation	O
("empty	O
head")	O
was	O
also	O
reported	O
by	O
2	O
patients.	O
These	O
episodes	O
reversed	O
after	O
the	O
administration	O
of	O
diazepam	Chemical
1	O
mg	O
intravenously.	O
Significant	O
increases	O
in	O
drowsiness	O
were	O
reported	O
in	O
patients	O
treated	O
with	O
ketamine	Chemical
in	O
both	O
groups	O
and	O
were	O
more	O
marked	O
with	O
ketamine	Chemical
0.50	O
mg/kg.	O
A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	O
who	O
received	O
0.50	O
mg/kg	O
of	O
ketamine	Chemical
.	O
Ketamine	Chemical
can	O
improve	O
morphine	Chemical
analgesia	O
in	O
difficult	O
pain	Disease
syndromes,	O
such	O
as	O
neuropathic	Disease
pain	Disease
.	O
However,	O
the	O
occurrence	O
of	O
central	O
adverse	O
effects	O
should	O
be	O
taken	O
into	O
account,	O
especially	O
when	O
using	O
higher	O
doses.	O
This	O
observation	O
should	O
be	O
tested	O
in	O
studies	O
of	O
prolonged	O
ketamine	Chemical

Endocrine	O
screening	O
in	O
1,022	O
men	O
with	O
erectile	Disease
dysfunction	Disease
:	O
clinical	O
significance	O
and	O
cost-effective	O
strategy.	O
PURPOSE:	O
We	O
reviewed	O
the	O
results	O
of	O
serum	O
testosterone	Chemical
and	O
prolactin	O
determination	O
in	O
1,022	O
patients	O
referred	O
because	O
of	O
erectile	Disease
dysfunction	Disease
and	O
compared	O
the	O
data	O
with	O
history,	O
results	O
of	O
physical	O
examination,	O
other	O
etiological	O
investigations	O
and	O
effects	O
of	O
endocrine	O
therapy	O
to	O
refine	O
the	O
rules	O
of	O
cost-effective	O
endocrine	O
screening	O
and	O
to	O
pinpoint	O
actual	O
responsibility	O
for	O
hormonal	O
abnormalities.	O
MATERIALS	O
AND	O
METHODS:	O
Testosterone	Chemical
and	O
prolactin	O
were	O
determined	O
by	O
radioimmunoassay.	O
Every	O
patient	O
was	O
screened	O
for	O
testosterone	Chemical
and	O
451	O
were	O
screened	O
for	O
prolactin	O
on	O
the	O
basis	O
of	O
low	Disease
sexual	Disease
desire	Disease
,	O
gynecomastia	Disease
or	O
testosterone	Chemical
less	O
than	O
4	O
ng./ml.	O
Determination	O
was	O
repeated	O
in	O
case	O
of	O
abnormal	O
first	O
results.	O
Prolactin	O
results	O
were	O
compared	O
with	O
those	O
of	O
a	O
previous	O
personal	O
cohort	O
of	O
1,340	O
patients	O
with	O
erectile	Disease
dysfunction	Disease
and	O
systematic	O
prolactin	O
determination.	O
Main	O
clinical	O
criteria	O
tested	O
regarding	O
efficiency	O
in	O
hormone	O
determination	O
were	O
low	Disease
sexual	Disease
desire	Disease
,	O
small	O
testes	O
and	O
gynecomastia	Disease
.	O
Endocrine	O
therapy	O
consisted	O
of	O
testosterone	Chemical
heptylate	Chemical
or	O
human	O
chorionic	O
gonadotropin	O
for	O
hypogonadism	Disease
and	O
bromocriptine	Chemical
for	O
hyperprolactinemia	Disease
.	O
RESULTS:	O
Testosterone	Chemical
was	O
less	O
than	O
3	O
ng./ml.	O
in	O
107	O
patients	O
but	O
normal	O
in	O
40%	O
at	O
repeat	O
determination.	O
The	O
prevalence	O
of	O
repeatedly	O
low	O
testosterone	Chemical
increased	O
with	O
age	O
(4%	O
before	O
age	O
50	O
years	O
and	O
9%	O
50	O
years	O
or	O
older).	O
Two	O
pituitary	Disease
tumors	Disease
were	O
discovered	O
after	O
testosterone	Chemical
determination.	O
Most	O
of	O
the	O
other	O
low	O
testosterone	Chemical
levels	O
seemed	O
to	O
result	O
from	O
nonorganic	O
hypothalamic	Disease
dysfunction	Disease
because	O
of	O
normal	O
serum	O
luteinizing	O
hormone	O
and	O
prolactin	O
and	O
to	O
have	O
only	O
a	O
small	O
role	O
in	O
erectile	Disease
dysfunction	Disease
(definite	O
improvement	O
in	O
only	O
16	O
of	O
44	O
[36%]	O
after	O
androgen	O
therapy,	O
normal	O
morning	O
or	O
nocturnal	O
erections	O
in	O
30%	O
and	O
definite	O
vasculogenic	O
contributions	O
in	O
42%).	O
Determining	O
testosterone	Chemical
only	O
in	O
cases	O
of	O
low	Disease
sexual	Disease
desire	Disease
or	O
abnormal	O
physical	O
examination	O
would	O
have	O
missed	O
40%	O
of	O
the	O
cases	O
with	O
low	O
testosterone	Chemical
,	O
including	O
37%	O
of	O
those	O
subsequently	O
improved	O
by	O
androgen	O
therapy.	O
Prolactin	O
exceeded	O
20	O
ng./ml.	O
in	O
5	O
men	O
and	O
was	O
normal	O
in	O
2	O
at	O
repeat	O
determination.	O
Only	O
1	O
prolactinoma	Disease
was	O
discovered.	O
These	O
data	O
are	O
lower	O
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(overall	O
prolactin	O
greater	O
than	O
20	O
ng./ml.	O
in	O
1.86%	O
of	O
1,821	O
patients,	O
prolactinomas	Disease
in	O
7,	O
0.38%).	O
Bromocriptine	Chemical
was	O
definitely	O
effective	O
in	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng./ml.	O
(8	O
of	O
12	O
compared	O
to	O
only	O
9	O
of	O
22	O
cases	O
with	O
prolactin	O
between	O
20	O
and	O
35	O
ng./ml.).	O
Testosterone	Chemical
was	O
low	O
in	O
less	O
than	O
50%	O
of	O
cases	O
with	O
prolactin	O
greater	O
than	O
35	O
ng./ml.	O
CONCLUSIONS:	O
Low	O
prevalences	O
and	O
effects	O
of	O
low	O
testosterone	Chemical
and	O
high	O
prolactin	O
in	O
erectile	Disease
dysfunction	Disease
cannot	O
justify	O
their	O
routine	O
determination.	O
However,	O
cost-effective	O
screening	O
strategies	O
recommended	O
so	O
far	O
missed	O
40	O
to	O
50%	O
of	O
cases	O
improved	O
with	O
endocrine	O
therapy	O
and	O
the	O
pituitary	Disease
tumors	Disease
.	O
We	O
now	O
advocate	O
that	O
before	O
age	O
50	O
years	O
testosterone	Chemical
be	O
determined	O
only	O
in	O
cases	O
of	O
low	Disease
sexual	Disease
desire	Disease
and	O
abnormal	O
physical	O
examination	O
but	O
that	O
it	O
be	O
measured	O
in	O
all	O
men	O
older	O
than	O
50	O
years.	O
Prolactin	O
should	O
be	O
determined	O
only	O
in	O
cases	O
of	O
low	Disease
sexual	Disease
desire	Disease
,	O
gynecomastia	Disease
and/or	O
testosterone	Chemical

Thiopentone	Chemical
pretreatment	O
for	O
propofol	Chemical
injection	O
pain	Disease
in	O
ambulatory	O
patients.	O
This	O
study	O
investigated	O
propofol	Chemical
injection	O
pain	Disease
in	O
patients	O
undergoing	O
ambulatory	O
anaesthesia.	O
In	O
a	O
randomized,	O
double-blind	O
trial,	O
90	O
women	O
were	O
allocated	O
to	O
receive	O
one	O
of	O
three	O
treatments	O
prior	O
to	O
induction	O
of	O
anaesthesia	O
with	O
propofol	Chemical
.	O
Patients	O
in	O
Group	O
C	O
received	O
2	O
ml	O
normal	O
saline,	O
Group	O
L,	O
2	O
ml,	O
lidocaine	Chemical
2%	O
(40	O
mg)	O
and	O
Group	O
T,	O
2	O
ml	O
thiopentone	Chemical
2.5%	O
(50	O
mg).	O
Venous	O
discomfort	O
was	O
assessed	O
with	O
a	O
visual	O
analogue	O
scale	O
(VAS)	O
5-15	O
sec	O
after	O
commencing	O
propofol	Chemical
administration	O
using	O
an	O
infusion	O
pump	O
(rate	O
1000	O
micrograms.kg-1.min-1).	O
Loss	Disease
of	Disease
consciousness	Disease
occurred	O
in	O
60-90	O
sec.	O
Visual	O
analogue	O
scores	O
(mean	O
+/-	O
SD)	O
during	O
induction	O
were	O
lower	O
in	O
Groups	O
L	O
(3.3	O
+/-	O
2.5)	O
and	O
T	O
(4.1	O
+/-	O
2.7)	O
than	O
in	O
Group	O
C	O
(5.6	O
+/-	O
2.3);	O
P	O
=	O
0.0031.	O
The	O
incidence	O
of	O
venous	O
discomfort	O
was	O
lower	O
in	O
Group	O
L	O
(76.6%;	O
P	O
<	O
0.05)	O
than	O
in	O
Group	O
C	O
(100%)	O
but	O
not	O
different	O
from	O
Group	O
T	O
(90%).	O
The	O
VAS	O
scores	O
for	O
recall	O
of	O
pain	Disease
in	O
the	O
recovery	O
room	O
were	O
correlated	O
with	O
the	O
VAS	O
scores	O
during	O
induction	O
(r	O
=	O
0.7045;	O
P	O
<	O
0.0001).	O
Recovery	O
room	O
discharge	O
times	O
were	O
similar:	O
C	O
(75.9	O
+/-	O
19.4	O
min);	O
L	O
73.6	O
+/-	O
21.6	O
min);	O
T	O
(77.1	O
+/-	O
18.9	O
min).	O
Assessing	O
their	O
overall	O
satisfaction,	O
89.7%	O
would	O
choose	O
propofol	Chemical
anaesthesia	O
again.	O
We	O
conclude	O
that	O
lidocaine	Chemical
reduces	O
the	O
incidence	O
and	O
severity	O
of	O
propofol	Chemical
injection	O
pain	Disease
in	O
ambulatory	O
patients	O
whereas	O
thiopentone	Chemical

Comparison	O
of	O
i.v.	O
glycopyrrolate	Chemical
and	O
atropine	Chemical
in	O
the	O
prevention	O
of	O
bradycardia	Disease
and	O
arrhythmias	Disease
following	O
repeated	O
doses	O
of	O
suxamethonium	Chemical
in	O
children.	O
The	O
effectiveness	O
of	O
administration	O
of	O
glycopyrrolate	Chemical
5	O
and	O
10	O
micrograms	O
kg-1	O
and	O
atropine	Chemical
10	O
and	O
20	O
micrograms	O
kg-1	O
i.v.	O
immediately	O
before	O
the	O
induction	O
of	O
anaesthesia,	O
to	O
prevent	O
arrhythmia	Disease
and	O
bradycardia	Disease
following	O
repeated	O
doses	O
of	O
suxamethonium	Chemical
in	O
children,	O
was	O
studied.	O
A	O
control	O
group	O
was	O
included	O
for	O
comparison	O
with	O
the	O
lower	O
dose	O
range	O
of	O
glycopyrrolate	Chemical
and	O
atropine	Chemical
.	O
A	O
frequency	O
of	O
bradycardia	Disease
of	O
50%	O
was	O
noted	O
in	O
the	O
control	O
group,	O
but	O
this	O
was	O
not	O
significantly	O
different	O
from	O
the	O
frequency	O
with	O
the	O
active	O
drugs.	O
Bradycardia	Disease
(defined	O
as	O
a	O
decrease	O
in	O
heart	O
rate	O
to	O
less	O
than	O
50	O
beat	O
min-1)	O
was	O
prevented	O
when	O
the	O
larger	O
dose	O
of	O
either	O
active	O
drug	O
was	O
used.	O
It	O
is	O
recommended	O
that	O
either	O
glycopyrrolate	Chemical
10	O
micrograms	O
kg-1	O
or	O
atropine	Chemical
20	O
micrograms	O
kg-1	O
i.v.	O
should	O
immediately	O
precede	O
induction	O
of	O
anaesthesia,	O
in	O
children,	O
if	O
the	O
repeated	O
administration	O
of	O
suxamethonium	Chemical

Reduction	O
in	O
caffeine	Chemical
	O
toxicity	Disease
by	O
acetaminophen	Chemical
.	O
A	O
patient	O
who	O
allegedly	O
consumed	O
100	O
tablets	O
of	O
an	O
over-the-counter	O
analgesic	O
containing	O
sodium	Chemical
acetylsalicylate	Chemical
,	O
caffeine	Chemical
,	O
and	O
acetaminophen	Chemical
displayed	O
no	O
significant	O
CNS	O
stimulation	O
despite	O
the	O
presence	O
of	O
175	O
micrograms	O
of	O
caffeine	Chemical
per	O
mL	O
of	O
serum.	O
Because	O
salicylates	O
have	O
been	O
reported	O
to	O
augment	O
the	O
stimulatory	O
effects	O
of	O
caffeine	Chemical
on	O
the	O
CNS,	O
attention	O
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
presence	O
of	O
acetaminophen	Chemical
(52	O
micrograms/mL)	O
reduced	O
the	O
CNS	O
toxicity	Disease
of	O
caffeine	Chemical
.	O
Studies	O
in	O
DBA/2J	O
mice	O
showed	O
that:	O
1)	O
pretreatment	O
with	O
acetaminophen	Chemical
(100	O
mg/kg)	O
increased	O
the	O
interval	O
between	O
the	O
administration	O
of	O
caffeine	Chemical
(300	O
to	O
450	O
mg/kg	O
IP)	O
and	O
the	O
onset	O
of	O
fatal	O
convulsions	Disease
by	O
a	O
factor	O
of	O
about	O
two;	O
and	O
2)	O
pretreatment	O
with	O
acetaminophen	Chemical
(75	O
mg/kg)	O
reduced	O
the	O
incidence	O
of	O
audiogenic	O
seizures	Disease
produced	O
in	O
the	O
presence	O
of	O
caffeine	Chemical
(12.5	O
to	O
75	O
mg/kg	O
IP).	O
The	O
frequency	O
of	O
sound-induced	O
seizures	Disease
after	O
12.5	O
or	O
25	O
mg/kg	O
caffeine	Chemical
was	O
reduced	O
from	O
50	O
to	O
5%	O
by	O
acetaminophen	Chemical
.	O
In	O
the	O
absence	O
of	O
caffeine	Chemical
,	O
acetaminophen	Chemical
(up	O
to	O
300	O
mg/kg)	O
did	O
not	O
modify	O
the	O
seizures	Disease
induced	O
by	O
maximal	O
electroshock	O
and	O
did	O
not	O
alter	O
the	O
convulsant	O
dose	O
of	O
pentylenetetrezol	Chemical
in	O
mice	O
(tests	O
performed	O
by	O
the	O
Anticonvulsant	O
Screening	O
Project	O
of	O
NINCDS).	O
Acetaminophen	Chemical
(up	O
to	O
150	O
micrograms/mL)	O
did	O
not	O
retard	O
the	O
incorporation	O
of	O
radioactive	O
adenosine	Chemical
into	O
ATP	Chemical
in	O
slices	O
of	O
rat	O
cerebral	O
cortex.	O
Thus	O
the	O
mechanism	O
by	O
which	O
acetaminophen	Chemical
antagonizes	O
the	O
actions	O
of	O
caffeine	Chemical

Flestolol	Chemical
:	O
an	O
ultra-short-acting	O
beta-adrenergic	O
blocking	O
agent.	O
Flestolol	Chemical
(	O
ACC-9089	Chemical
)	O
is	O
a	O
nonselective,	O
competitive,	O
ultra-short-acting	O
beta-adrenergic	O
blocking	O
agent,	O
without	O
any	O
intrinsic	O
sympathomimetic	O
activity.	O
Flestolol	Chemical
is	O
metabolized	O
by	O
plasma	O
esterases	O
and	O
has	O
an	O
elimination	O
half-life	O
of	O
approximately	O
6.5	O
minutes.	O
This	O
agent	O
was	O
well	O
tolerated	O
in	O
healthy	O
volunteers	O
at	O
doses	O
up	O
to	O
100	O
micrograms/kg/min.	O
In	O
long-term	O
infusion	O
studies,	O
flestolol	Chemical
was	O
well	O
tolerated	O
at	O
the	O
effective	O
beta-blocking	O
dose	O
(5	O
micrograms/kg/min)	O
for	O
up	O
to	O
seven	O
days.	O
Flestolol	Chemical
blood	O
concentrations	O
increased	O
linearly	O
with	O
increasing	O
dose	O
and	O
good	O
correlation	O
exists	O
between	O
blood	O
concentrations	O
of	O
flestolol	Chemical
and	O
beta-adrenergic	O
blockade.	O
Flestolol	Chemical
produced	O
a	O
dose-dependent	O
attenuation	O
of	O
isoproterenol	Chemical
-induced	O
tachycardia	Disease
.	O
Electrophysiologic	O
and	O
hemodynamic	O
effects	O
of	O
flestolol	Chemical
are	O
similar	O
to	O
those	O
of	O
other	O
beta	O
blockers.	O
In	O
contrast	O
with	O
other	O
beta	O
blockers,	O
flestolol	Chemical
-induced	O
effects	O
reverse	O
rapidly	O
(within	O
30	O
minutes)	O
following	O
discontinuation	O
because	O
of	O
its	O
short	O
half-life.	O
Flestolol	Chemical
effectively	O
reduced	O
heart	O
rate	O
in	O
patients	O
with	O
supraventricular	Disease
tachyarrhythmia	Disease
.	O
In	O
patients	O
with	O
unstable	Disease
angina	Disease
,	O
flestolol	Chemical
infusion	O
was	O
found	O
to	O
be	O
safe	O
and	O
effective	O
in	O
controlling	O
chest	Disease
pain	Disease
.	O
It	O
is	O
concluded	O
that	O
flestolol	Chemical
is	O
a	O
potent,	O
well-tolerated,	O
ultra-short-acting	O
beta-adrenergic	O
blocking	O
agent.	O
Use	O
of	O
flestolol	Chemical

Adverse	O
effect	O
of	O
the	O
calcium	Chemical
channel	O
blocker	O
nitrendipine	Chemical
on	O
nephrosclerosis	Disease
in	O
rats	O
with	O
renovascular	Disease
hypertension	Disease
.	O
The	O
effect	O
of	O
a	O
6-week	O
treatment	O
with	O
the	O
calcium	Chemical
channel	O
blocker	O
nitrendipine	Chemical
or	O
the	O
angiotensin	Chemical
converting	O
enzyme	O
inhibitor	O
enalapril	Chemical
on	O
blood	O
pressure,	O
albuminuria	Disease
,	O
renal	O
hemodynamics,	O
and	O
morphology	O
of	O
the	O
nonclipped	O
kidney	O
was	O
studied	O
in	O
rats	O
with	O
two-kidney,	O
one	O
clip	O
renovascular	Disease
hypertension	Disease
.	O
Six	O
weeks	O
after	O
clipping	O
of	O
one	O
renal	O
artery,	O
hypertensive	Disease
rats	O
(178	O
+/-	O
4	O
mm	O
Hg)	O
were	O
randomly	O
assigned	O
to	O
three	O
groups:	O
untreated	O
hypertensive	Disease
controls	O
(n	O
=	O
8),	O
enalapril	Chemical
-treated	O
(n	O
=	O
8),	O
or	O
nitrendipine	Chemical
-treated	O
(n	O
=	O
10).	O
Sham-operated	O
rats	O
served	O
as	O
normotensive	O
controls	O
(128	O
+/-	O
3	O
mm	O
Hg,	O
n	O
=	O
8).	O
After	O
6	O
weeks	O
of	O
treatment,	O
renal	O
hemodynamics	O
(glomerular	O
filtration	O
rate	O
and	O
renal	O
plasma	O
flow)	O
were	O
measured	O
in	O
the	O
anesthetized	O
rats.	O
Renal	O
tissue	O
was	O
obtained	O
for	O
determination	O
of	O
glomerular	O
size	O
and	O
sclerosis.	O
Enalapril	Chemical
but	O
not	O
nitrendipine	Chemical
reduced	O
blood	O
pressure	O
significantly.	O
After	O
6	O
weeks	O
of	O
therapy,	O
glomerular	O
filtration	O
rate	O
was	O
not	O
different	O
among	O
the	O
studied	O
groups.	O
Renal	O
plasma	O
flow	O
increased,	O
but	O
albumin	O
excretion	O
and	O
glomerulosclerosis	Disease
did	O
not	O
change	O
after	O
enalapril	Chemical
treatment.	O
In	O
contrast,	O
in	O
the	O
nitrendipine	Chemical
-treated	O
group	O
albuminuria	Disease
increased	O
from	O
12.8	O
+/-	O
2	O
progressively	O
to	O
163	O
+/-	O
55	O
compared	O
with	O
19.2	O
+/-	O
9	O
mg/24	O
hr	O
in	O
the	O
hypertensive	Disease
controls.	O
Furthermore,	O
glomerulosclerosis	Disease
index	O
was	O
significantly	O
increased	O
in	O
the	O
nitrendipine	Chemical
-treated	O
group	O
compared	O
with	O
the	O
hypertensive	Disease
controls	O
(0.38	O
+/-	O
0.1	O
versus	O
0.13	O
+/-	O
0.04).	O
In	O
addition,	O
glomerular	O
size	O
was	O
higher	O
in	O
the	O
nitrendipine	Chemical
-treated	O
group	O
(14.9	O
+/-	O
0.17	O
10(-3)	O
mm2)	O
but	O
lower	O
in	O
the	O
enalapril	Chemical
-treated	O
group	O
(11.5	O
+/-	O
0.15	O
10(-3)	O
mm2)	O
compared	O
with	O
the	O
hypertensive	Disease

Treatment	O
of	O
tinnitus	Disease
by	O
intratympanic	O
instillation	O
of	O
lignocaine	Chemical
(	O
lidocaine	Chemical
)	O
2	O
per	O
cent	O
through	O
ventilation	O
tubes.	O
Idiopathic	Disease
subjective	Disease
tinnitus	Disease
(	O
IST	Disease
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otological	O
pathologies.	O
This	O
paper	O
presents	O
the	O
results	O
of	O
treating	O
IST	Disease
by	O
intratympanic	O
instillation	O
of	O
lignocaine	Chemical
(	O
lidocaine	Chemical
)	O
2	O
per	O
cent	O
through	O
a	O
grommet,	O
for	O
five	O
weekly	O
courses.	O
Fifty-two	O
patients	O
suffering	O
from	O
intractable	O
tinnitus	Disease
entered	O
this	O
therapeutic	O
trial,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
courses.	O
In	O
one	O
patient,	O
the	O
tinnitus	Disease
was	O
almost	O
completely	O
abolished,	O
but	O
in	O
all	O
the	O
nine	O
patients	O
the	O
decompensated	O
tinnitus	Disease
changed	O
to	O
a	O
compensated	O
one.	O
We	O
suggest	O
this	O
mode	O
of	O
treatment	O
for	O
patients	O
that	O
were	O
previously	O
treated	O
by	O
drugs,	O
acupuncture	O
and	O
biofeedback,	O
with	O
disappointing	O
results.	O
Patients	O
should	O
be	O
warned	O
about	O
the	O
side	O
effects	O
of	O
vertigo	Disease
and	O
vomiting	Disease
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillation,	O
and	O
that	O
the	O
tinnitus	Disease

Perhexiline	Chemical
maleate	Chemical
and	O
peripheral	Disease
neuropathy	Disease
.	O
Peripheral	Disease
neuropathy	Disease
has	O
been	O
noted	O
as	O
a	O
complication	O
of	O
therapy	O
with	O
perhexiline	Chemical
maleate	Chemical
,	O
a	O
drug	O
widely	O
used	O
in	O
France	O
(and	O
in	O
clinical	O
trials	O
in	O
the	O
United	O
States)	O
for	O
the	O
prophylactic	O
treatment	O
of	O
angina	Disease
pectoris	Disease
.	O
In	O
24	O
patients	O
with	O
this	O
complication,	O
the	O
marked	O
slowing	O
of	O
motor	O
nerve	O
conduction	O
velocity	O
and	O
the	O
electromyographic	O
changes	O
imply	O
mainly	O
a	O
demyelinating	Disease
disorder	Disease
.	O
Improvement	O
was	O
noted	O
with	O
cessation	O
of	O
therapy.	O
In	O
a	O
few	O
cases	O
the	O
presence	O
of	O
active	O
denervation	O
signified	O
a	O
poor	O
prognosis,	O
with	O
only	O
slight	O
improvement.	O
The	O
underlying	O
mechanism	O
causing	O
the	O
neuropathy	Disease

Effect	O
of	O
humoral	O
modulators	O
of	O
morphine	Chemical
-induced	O
increase	Disease
in	Disease
locomotor	Disease
activity	Disease
of	O
mice.	O
The	O
effect	O
of	O
humoral	O
modulators	O
on	O
the	O
morphine	Chemical
-induced	O
increase	Disease
in	Disease
locomotor	Disease
activity	Disease
of	O
mice	O
was	O
studied.	O
The	O
subcutaneous	O
administration	O
of	O
10	O
mg/kg	O
of	O
morphine	Chemical
-HC1	O
produced	O
a	O
marked	O
increase	Disease
in	Disease
locomotor	Disease
activity	Disease
in	O
mice.	O
The	O
morphine	Chemical
-induced	O
hyperactivity	Disease
was	O
potentiated	O
by	O
scopolamine	Chemical
and	O
attenuated	O
by	O
physostigmine	Chemical
.	O
In	O
contrast,	O
both	O
methscopolamine	Chemical
and	O
neostigmine	Chemical
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood-brain	O
barrier,	O
had	O
no	O
effect	O
on	O
the	O
hyperactivity	Disease
produced	O
by	O
morphine	Chemical
.	O
Pretreatment	O
of	O
mice	O
with	O
alpha-methyltyrosine	Chemical
(20	O
mg/kg	O
i.p.,	O
one	O
hour),	O
an	O
inhibitor	O
of	O
tyrosine	Chemical
hydroxylase,	O
significantly	O
decreased	O
the	O
activity-increasing	O
effects	O
of	O
morphine	Chemical
.	O
On	O
the	O
other	O
hand,	O
pretreatment	O
with	O
p-chlorophenylalamine	Chemical
(3	O
X	O
320	O
mg/kg	O
i.p.,	O
24	O
hr),	O
a	O
serotonin	Chemical
depletor,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	Disease
.	O
The	O
study	O
suggests	O
that	O
the	O
activity-increasing	O
effects	O
of	O
morphine	Chemical
are	O
mediated	O
by	O
the	O
release	O
of	O
catecholamines	Chemical
from	O
adrenergic	O
neurons	O
in	O
the	O
brain.	O
And	O
the	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
morphine	Chemical
acts	O
by	O
retarding	O
the	O
release	O
of	O
acetylcholine	Chemical
at	O
some	O
central	O
cholinergic	O
synapses.	O
It	O
is	O
also	O
suggested	O
from	O
collected	O
evidence	O
that	O
the	O
activity-increasing	O
effects	O
of	O
morphine	Chemical
in	O
mice	O
are	O
mediated	O
by	O
mechanisms	O
different	O
from	O
those	O
which	O
mediate	O
the	O
activity-increasing	O
effects	O
of	O
morphine	Chemical

Mechanisms	O
of	O
FK	Chemical
506	Chemical
-induced	O
hypertension	Disease
in	O
the	O
rat.	O
-	O
Tacrolimus	Chemical
(	O
FK	Chemical
506	Chemical
)	O
is	O
a	O
powerful,	O
widely	O
used	O
immunosuppressant.	O
The	O
clinical	O
utility	O
of	O
FK	Chemical
506	Chemical
is	O
complicated	O
by	O
substantial	O
hypertension	Disease
and	O
nephrotoxicity	Disease
.	O
To	O
clarify	O
the	O
mechanisms	O
of	O
FK	Chemical
506	Chemical
-induced	O
hypertension	Disease
,	O
we	O
studied	O
the	O
chronic	O
effects	O
of	O
FK	Chemical
506	Chemical
on	O
the	O
synthesis	O
of	O
endothelin-1	O
(ET-1),	O
the	O
expression	O
of	O
mRNA	O
of	O
ET-1	O
and	O
endothelin-converting	O
enzyme-1	O
(ECE-1),	O
the	O
endothelial	O
nitric	Chemical
oxide	Chemical
synthase	O
(eNOS)	O
activity,	O
and	O
the	O
expression	O
of	O
mRNA	O
of	O
eNOS	O
and	O
C-type	O
natriuretic	O
peptide	O
(CNP)	O
in	O
rat	O
blood	O
vessels.	O
In	O
addition,	O
the	O
effect	O
of	O
the	O
specific	O
endothelin	O
type	O
A	O
receptor	O
antagonist	O
FR	Chemical
139317	Chemical
on	O
FK	Chemical
506	Chemical
-induced	O
hypertension	Disease
in	O
rats	O
was	O
studied.	O
FK	Chemical
506	Chemical
,	O
5	O
mg.	O
kg-1.	O
d-1	O
given	O
for	O
4	O
weeks,	O
elevated	O
blood	O
pressure	O
from	O
102+/-13	O
to	O
152+/-15	O
mm	O
Hg	O
and	O
increased	O
the	O
synthesis	O
of	O
ET-1	O
and	O
the	O
levels	O
of	O
ET-1	O
mRNA	O
in	O
the	O
mesenteric	O
artery	O
(240%	O
and	O
230%,	O
respectively).	O
Little	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
ECE-1	O
mRNA	O
and	O
CNP	O
mRNA.	O
FK	Chemical
506	Chemical
decreased	O
eNOS	O
activity	O
and	O
the	O
levels	O
of	O
eNOS	O
mRNA	O
in	O
the	O
aorta	O
(48%	O
and	O
55%,	O
respectively).	O
The	O
administration	O
of	O
FR	Chemical
139317	Chemical
(10	O
mg.	O
kg-1.	O
d-1)	O
prevented	O
FK	Chemical
506	Chemical
-induced	O
hypertension	Disease
in	O
rats.	O
These	O
results	O
indicate	O
that	O
FK	Chemical
506	Chemical
may	O
increase	O
blood	O
pressure	O
not	O
only	O
by	O
increasing	O
ET-1	O
production	O
but	O
also	O
by	O
decreasing	O
NO	Chemical

Suxamethonium	Chemical
induced	O
prolonged	O
apnea	Disease
in	O
a	O
patient	O
receiving	O
electroconvulsive	O
therapy.	O
Suxamethonium	Chemical
causes	O
prolonged	O
apnea	Disease
in	O
patients	O
in	O
whom	O
pseudocholinesterase	O
enzyme	O
gets	O
deactivated	O
by	O
organophosphorus	Chemical
(OP)	Chemical
poisons	Chemical
.	O
Here,	O
we	O
present	O
a	O
similar	O
incident	O
in	O
a	O
severely	O
depressed	Disease
patient	O
who	O
received	O
electroconvulsive	O
therapy	O
(ECT).	O
Prolonged	O
apnea	Disease
in	O
our	O
case	O
ensued	O
because	O
the	O
information	O
about	O
suicidal	O
attempt	O
by	O
OP	Chemical
compound	Chemical

The	O
effects	O
of	O
the	O
adjunctive	O
bupropion	Chemical
on	O
male	O
sexual	Disease
dysfunction	Disease
induced	O
by	O
a	O
selective	Chemical
serotonin	Chemical
reuptake	Chemical
inhibitor	Chemical
:	O
a	O
double-blind	O
placebo-controlled	O
and	O
randomized	O
study.	O
OBJECTIVE:	O
To	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
adjunctive	O
bupropion	Chemical
sustained-release	O
(SR)	O
on	O
male	O
sexual	Disease
dysfunction	Disease
(	O
SD	Disease
)	O
induced	O
by	O
a	O
selective	Chemical
serotonin	Chemical
reuptake	Chemical
inhibitor	Chemical
(	O
SSRI	Chemical
),	O
as	O
SD	Disease
is	O
a	O
common	O
side-effect	O
of	O
SSRIs	Chemical
and	O
the	O
most	O
effective	O
treatments	O
have	O
yet	O
to	O
be	O
determined.	O
PATIENTS	O
AND	O
METHODS:	O
The	O
randomized	O
sample	O
consisted	O
of	O
234	O
euthymic	O
men	O
who	O
were	O
receiving	O
some	O
type	O
of	O
SSRI	Chemical
.	O
The	O
men	O
were	O
randomly	O
assigned	O
to	O
bupropion	Chemical
SR	O
(150	O
mg	O
twice	O
daily,	O
117)	O
or	O
placebo	O
(twice	O
daily,	O
117)	O
for	O
12	O
weeks.	O
Efficacy	O
was	O
evaluated	O
using	O
the	O
Clinical	O
Global	O
Impression-Sexual	O
Function	O
(CGI-SF;	O
the	O
primary	O
outcome	O
measure),	O
the	O
International	O
Index	O
of	O
Erectile	O
Function	O
(IIEF),	O
Arizona	O
Sexual	O
Experience	O
Scale	O
(ASEX),	O
and	O
Erectile	Disease
Dysfunction	Disease
Inventory	O
of	O
Treatment	O
Satisfaction	O
(EDITS)	O
(secondary	O
outcome	O
measures).	O
Participants	O
were	O
followed	O
biweekly	O
during	O
study	O
period.	O
RESULTS:	O
After	O
12	O
weeks	O
of	O
treatment,	O
the	O
mean	O
(sd)	O
scores	O
for	O
CGI-SF	O
were	O
significantly	O
lower,	O
i.e.	O
better,	O
in	O
patients	O
on	O
bupropion	Chemical
SR,	O
at	O
2.4	O
(1.2),	O
than	O
in	O
the	O
placebo	O
group,	O
at	O
3.9	O
(1.1)	O
(P=	O
0.01).	O
Men	O
who	O
received	O
bupropion	Chemical
had	O
a	O
significant	O
increase	O
in	O
the	O
total	O
IIEF	O
score	O
(54.4%	O
vs	O
1.2%;	O
P=	O
0.003),	O
and	O
in	O
the	O
five	O
different	O
domains	O
of	O
the	O
IIEF.	O
Total	O
ASEX	O
scores	O
were	O
significantly	O
lower,	O
i.e.	O
better,	O
among	O
men	O
who	O
received	O
bupropion	Chemical
than	O
placebo,	O
at	O
15.5	O
(4.3)	O
vs	O
21.5	O
(4.7)	O
(P=	O
0.002).	O
The	O
EDITS	O
scores	O
were	O
67.4	O
(10.2)	O
for	O
the	O
bupropion	Chemical
and	O
36.3	O
(11.7)	O
for	O
the	O
placebo	O
group	O
(P=	O
0.001).	O
The	O
ASEX	O
score	O
and	O
CGI-SF	O
score	O
were	O
correlated	O
(P=	O
0.003).	O
In	O
linear	O
regression	O
analyses	O
the	O
CGI-SF	O
score	O
was	O
not	O
affected	O
significantly	O
by	O
the	O
duration	O
of	O
SD	Disease
,	O
type	O
of	O
SSRI	Chemical
used	O
and	O
age.	O
CONCLUSIONS:	O
Bupropion	Chemical
is	O
an	O
effective	O
treatment	O
for	O
male	O
SD	Disease
induced	O
by	O
SSRIs	Chemical
.	O
These	O
results	O
provide	O
empirical	O
support	O
for	O
conducting	O
a	O
further	O
study	O
of	O
bupropion	Chemical

Lamivudine	Chemical
for	O
the	O
prevention	O
of	O
hepatitis	Disease
B	Disease
virus	O
reactivation	O
in	O
hepatitis-B	Chemical
surface	Chemical
antigen	Chemical
(	O
HBSAG	Chemical
)	O
seropositive	O
cancer	Disease
patients	O
undergoing	O
cytotoxic	O
chemotherapy.	O
Hepatitis	Disease
B	Disease
virus	O
(HBV)	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
chronic	O
liver	Disease
disease	Disease
worldwide.	O
Cancer	Disease
patients	O
who	O
are	O
chronic	O
carriers	O
of	O
HBV	O
have	O
a	O
higher	O
hepatic	Disease
complication	Disease
rate	O
while	O
receiving	O
cytotoxic	O
chemotherapy	O
(CT)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	O
to	O
HBV	O
reactivation.	O
In	O
this	O
study,	O
cancer	Disease
patients	O
who	O
have	O
solid	O
and	O
hematological	Disease
malignancies	Disease
with	O
chronic	O
HBV	Disease
infection	Disease
received	O
the	O
antiviral	O
agent	O
lamivudine	Chemical
prior	O
and	O
during	O
CT	O
compared	O
with	O
historical	O
control	O
group	O
who	O
did	O
not	O
receive	O
lamivudine	Chemical
.	O
The	O
objectives	O
were	O
to	O
assess	O
the	O
efficacy	O
of	O
lamivudine	Chemical
in	O
reducing	O
the	O
incidence	O
of	O
HBV	O
reactivation,	O
and	O
diminishing	O
morbidity	O
and	O
mortality	O
during	O
CT.	O
Two	O
groups	O
were	O
compared	O
in	O
this	O
study.	O
The	O
prophylactic	O
lamivudin	Chemical
group	O
consisted	O
of	O
37	O
patients	O
who	O
received	O
prophylactic	O
lamivudine	Chemical
treatment.	O
The	O
historical	O
controls	O
consisted	O
of	O
50	O
consecutive	O
patients	O
who	O
underwent	O
CT	O
without	O
prophylactic	O
lamivudine	Chemical
.	O
They	O
were	O
followed	O
up	O
during	O
and	O
for	O
8	O
weeks	O
after	O
CT.	O
The	O
outcomes	O
were	O
compared	O
for	O
both	O
groups.	O
Of	O
our	O
control	O
group	O
(n=	O
50),	O
21	O
patients	O
(42%)	O
were	O
established	O
hepatitis	Disease
.	O
Twelve	O
(24%)	O
of	O
them	O
were	O
evaluated	O
as	O
severe	O
hepatitis	Disease
.	O
In	O
the	O
prophylactic	O
lamivudine	Chemical
group	O
severe	O
hepatitis	Disease
were	O
observed	O
only	O
in	O
1	O
patient	O
(2.7%)	O
of	O
37	O
patients	O
(p	O
<	O
0.006).	O
Comparison	O
of	O
the	O
mean	O
ALT	O
values	O
revealed	O
significantly	O
higher	O
mean	O
alanine	Chemical
aminotransferase	O
(ALT)	O
values	O
in	O
the	O
control	O
group	O
than	O
the	O
prophylactic	O
lamivudine	Chemical
group;	O
154:64	O
(p	O
<	O
0.32).	O
Our	O
study	O
suggests	O
that	O
prophylactic	O
lamivudine	Chemical
significantly	O
decreases	O
the	O
incidence	O
of	O
HBV	O
reactivation	O
and	O
overall	O
morbidity	O
in	O
cancer	Disease
patients	O
during	O
and	O
after	O
immunosuppressive	O
therapy.	O
Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
nucleoside	Chemical
or	O
nucleotide	Chemical

Ginsenoside	Chemical
Rg1	Chemical
restores	O
the	O
impairment	Disease
of	Disease
learning	Disease
induced	O
by	O
chronic	O
morphine	Chemical
administration	O
in	O
rats.	O
Rg1	Chemical
,	O
as	O
a	O
ginsenoside	Chemical
extracted	O
from	O
Panax	O
ginseng,	O
could	O
ameliorate	O
spatial	O
learning	Disease
impairment	Disease
.	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
Rg1	Chemical
might	O
be	O
a	O
useful	O
agent	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
adverse	O
effects	O
of	O
morphine	Chemical
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
Rg1	Chemical
on	O
learning	Disease
impairment	Disease
by	O
chronic	O
morphine	Chemical
administration	O
and	O
the	O
mechanism	O
responsible	O
for	O
this	O
effect.	O
Male	O
rats	O
were	O
subcutaneously	O
injected	O
with	O
morphine	Chemical
(10	O
mg/kg)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intervals	O
for	O
10	O
days,	O
and	O
Rg1	Chemical
(30	O
mg/kg)	O
was	O
intraperitoneally	O
injected	O
2	O
hours	O
after	O
the	O
second	O
injection	O
of	O
morphine	Chemical
once	O
a	O
day	O
for	O
10	O
days.	O
Spatial	O
learning	O
capacity	O
was	O
assessed	O
in	O
the	O
Morris	O
water	O
maze.	O
The	O
results	O
showed	O
that	O
rats	O
treated	O
with	O
Morphine	Chemical
/	O
Rg1	Chemical
decreased	O
escape	O
latency	O
and	O
increased	O
the	O
time	O
spent	O
in	O
platform	O
quadrant	O
and	O
entering	O
frequency.	O
By	O
implantation	O
of	O
electrodes	O
and	O
electrophysiological	O
recording	O
in	O
vivo,	O
the	O
results	O
showed	O
that	O
Rg1	Chemical
restored	O
the	O
long-term	O
potentiation	O
(LTP)	O
impaired	O
by	O
morphine	Chemical
in	O
both	O
freely	O
moving	O
and	O
anaesthetised	O
rats.	O
The	O
electrophysiological	O
recording	O
in	O
vitro	O
showed	O
that	O
Rg1	Chemical
restored	O
the	O
LTP	O
in	O
slices	O
from	O
the	O
rats	O
treated	O
with	O
morphine	Chemical
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slices	O
from	O
normal	O
saline-	O
or	O
morphine	Chemical
/	O
Rg1	Chemical
-treated	O
rats;	O
this	O
restoration	O
could	O
be	O
inhibited	O
by	O
N-methyl-D-aspartate	Chemical
(	O
NMDA	Chemical
)	O
receptor	O
antagonist	O
MK801	Chemical
.	O
We	O
conclude	O
that	O
Rg1	Chemical
may	O
significantly	O
improve	O
the	O
spatial	O
learning	O
capacity	O
impaired	O
by	O
chonic	O
morphine	Chemical
administration	O
and	O
restore	O
the	O
morphine	Chemical
-inhibited	O
LTP.	O
This	O
effect	O
is	O
NMDA	Chemical

A	O
study	O
on	O
the	O
effect	O
of	O
the	O
duration	O
of	O
subcutaneous	O
heparin	Chemical
injection	O
on	O
bruising	Disease
and	O
pain	Disease
.	O
AIM:	O
This	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
bruising	Disease
and	O
pain	Disease
following	O
the	O
administration	O
of	O
the	O
subcutaneous	O
injection	O
of	O
heparin	Chemical
.	O
BACKGROUND:	O
Although	O
different	O
methods	O
to	O
prevent	O
bruising	Disease
and	O
pain	Disease
following	O
the	O
subcutaneous	O
injection	O
of	O
heparin	Chemical
have	O
been	O
widely	O
studied	O
and	O
described,	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
the	O
occurrence	O
of	O
bruising	Disease
and	O
pain	Disease
is	O
little	O
documented.	O
DESIGN:	O
This	O
study	O
was	O
designed	O
as	O
within-subject,	O
quasi-experimental	O
research.	O
METHOD:	O
The	O
sample	O
for	O
the	O
study	O
consisted	O
of	O
50	O
patients	O
to	O
whom	O
subcutaneous	O
heparin	Chemical
was	O
administered.	O
Heparin	Chemical
was	O
injected	O
over	O
10	O
seconds	O
on	O
the	O
right	O
abdominal	O
site	O
and	O
30	O
seconds	O
on	O
the	O
left	O
abdominal	O
site.	O
Injections	O
areas	O
were	O
assessed	O
for	O
the	O
presence	O
of	O
bruising	Disease
at	O
48	O
and	O
72	O
hours	O
after	O
each	O
injection.	O
Dimensions	O
of	O
the	O
bruising	Disease
on	O
the	O
heparin	Chemical
applied	O
areas	O
were	O
measured	O
using	O
transparent	O
millimetric	O
measuring	O
paper.	O
The	O
visual	O
analog	O
scale	O
(VAS)	O
was	O
used	O
to	O
measure	O
pain	Disease
intensity	O
and	O
a	O
stop-watch	O
was	O
used	O
to	O
time	O
the	O
pain	Disease
period.	O
Data	O
were	O
analysed	O
using	O
chi-square	O
test,	O
Mann-Whitney	O
U,	O
Wilcoxon	O
signed	O
ranks	O
tests	O
and	O
correlation.	O
RESULTS:	O
The	O
percentage	O
of	O
bruising	Disease
occurrence	O
was	O
64%	O
with	O
the	O
injection	O
of	O
10	O
seconds	O
duration	O
and	O
42%	O
in	O
the	O
30-second	O
injection.	O
It	O
was	O
determined	O
that	O
the	O
size	O
of	O
the	O
bruising	Disease
was	O
smaller	O
in	O
the	O
30-second	O
injection.	O
Pain	Disease
intensity	O
and	O
pain	Disease
period	O
were	O
statistically	O
significantly	O
lower	O
for	O
the	O
30-second	O
injection	O
than	O
for	O
the	O
10-second	O
injection.	O
CONCLUSIONS:	O
It	O
was	O
determined	O
that	O
injection	O
duration	O
had	O
an	O
effect	O
on	O
bruising	Disease
and	O
pain	Disease
following	O
the	O
subcutaneous	O
administration	O
of	O
heparin	Chemical
.	O
This	O
study	O
should	O
be	O
repeated	O
on	O
a	O
larger	O
sample.	O
RELEVANCE	O
TO	O
CLINICAL	O
PRACTICE:	O
When	O
administering	O
subcutaneous	O
heparin	Chemical

Acute	O
reserpine	Chemical
and	O
subchronic	O
haloperidol	Chemical
treatments	O
change	O
synaptosomal	O
brain	O
glutamate	Chemical
uptake	O
and	O
elicit	O
orofacial	Disease
dyskinesia	Disease
in	O
rats.	O
Reserpine	Chemical
-	O
and	O
haloperidol	Chemical
-induced	O
orofacial	Disease
dyskinesia	Disease
are	O
putative	O
animal	O
models	O
of	O
tardive	Disease
dyskinesia	Disease
(	O
TD	Disease
)	O
whose	O
pathophysiology	O
has	O
been	O
related	O
to	O
free	O
radical	O
generation	O
and	O
oxidative	O
stress.	O
In	O
the	O
present	O
study,	O
the	O
authors	O
induced	O
orofacial	Disease
dyskinesia	Disease
by	O
acute	O
reserpine	Chemical
and	O
subchronic	O
haloperidol	Chemical
administration	O
to	O
rats.	O
Reserpine	Chemical
injection	O
(one	O
dose	O
of	O
1	O
mg/kg	O
s.c.)	O
every	O
other	O
day	O
for	O
3	O
days	O
caused	O
a	O
significant	O
increase	O
in	O
vacuous	O
chewing,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching,	O
compared	O
to	O
the	O
control.	O
Haloperidol	Chemical
administration	O
(one	O
dose	O
of	O
12	O
mg/kg	O
once	O
a	O
week	O
s.c.)	O
for	O
4	O
weeks	O
caused	O
an	O
increase	O
in	O
vacuous	O
chewing,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
observed	O
in	O
four	O
weekly	O
evaluations.	O
After	O
the	O
treatments	O
and	O
behavioral	O
observation,	O
glutamate	Chemical
uptake	O
by	O
segments	O
of	O
the	O
brain	O
was	O
analyzed.	O
A	O
decreased	O
glutamate	Chemical
uptake	O
was	O
observed	O
in	O
the	O
subcortical	O
parts	O
of	O
animals	O
treated	O
with	O
reserpine	Chemical
and	O
haloperidol	Chemical
,	O
compared	O
to	O
the	O
control.	O
Importantly,	O
a	O
decrease	O
in	O
glutamate	Chemical
uptake	O
correlates	O
negatively	O
with	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
orofacial	Disease
diskinesia	Disease
.	O
These	O
results	O
indicate	O
that	O
early	O
changes	O
in	O
glutamate	Chemical

Acute	Disease
psychosis	Disease
due	O
to	O
treatment	O
with	O
phenytoin	Chemical
in	O
a	O
nonepileptic	O
patient.	O
The	O
development	O
of	O
psychosis	Disease
related	O
to	O
antiepileptic	O
drug	O
treatment	O
is	O
usually	O
attributed	O
to	O
the	O
interaction	O
between	O
the	O
epileptic	Disease
brain	O
substratum	O
and	O
the	O
antiepileptic	O
drugs.	O
The	O
case	O
of	O
a	O
nonepileptic	O
patient	O
who	O
developed	O
psychosis	Disease
following	O
phenytoin	Chemical
treatment	O
for	O
trigeminal	Disease
neuralgia	Disease
is	O
described.	O
This	O
case	O
suggests	O
that	O
the	O
psychotic	Disease
symptoms	Disease
that	O
occur	O
following	O
phenytoin	Chemical
treatment	O
in	O
some	O
epileptic	Disease
patients	O
may	O
be	O
the	O
direct	O
result	O
of	O
medication,	O
unrelated	O
to	O
seizures	Disease

The	O
effect	O
of	O
treatment	O
with	O
gum	Chemical
Arabic	Chemical
on	O
gentamicin	Chemical
	O
nephrotoxicity	Disease
in	O
rats:	O
a	O
preliminary	O
study.	O
In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	Chemical
Arabic	Chemical
on	O
acute	Disease
renal	Disease
failure	Disease
induced	O
by	O
gentamicin	Chemical
(	O
GM	Chemical
)	O
nephrotoxicity	Disease
.	O
Rats	O
were	O
treated	O
with	O
the	O
vehicle	O
(2	O
mL/kg	O
of	O
distilled	O
water	O
and	O
5%	O
w/v	O
cellulose,	O
10	O
days),	O
gum	Chemical
Arabic	Chemical
(2	O
mL/kg	O
of	O
a	O
10%	O
w/v	O
aqueous	O
suspension	O
of	O
gum	Chemical
Arabic	Chemical
powder,	O
orally	O
for	O
10	O
days),	O
or	O
gum	Chemical
Arabic	Chemical
concomitantly	O
with	O
GM	Chemical
(80mg/kg/day	O
intramuscularly,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period).	O
Nephrotoxicity	Disease
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	Chemical
and	O
urea	Chemical
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	Chemical
(	O
GSH	Chemical
)	O
in	O
the	O
kidney	O
cortex,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections.	O
The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	Chemical
Arabic	Chemical
and	O
GM	Chemical
significantly	O
increased	O
creatinine	Chemical
and	O
urea	Chemical
by	O
about	O
183	O
and	O
239%,	O
respectively	O
(compared	O
to	O
432	O
and	O
346%,	O
respectively,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	Chemical
),	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	Chemical
by	O
21%	O
(compared	O
to	O
27%	O
in	O
the	O
cellulose	O
plus	O
GM	Chemical
group)	O
The	O
GM	Chemical
-induced	O
proximal	O
tubular	Disease
necrosis	Disease
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	Chemical
together	O
with	O
gum	Chemical
Arabic	Chemical
than	O
in	O
those	O
given	O
GM	Chemical
and	O
cellulose.	O
It	O
could	O
be	O
inferred	O
that	O
gum	Chemical
Arabic	Chemical
treatment	O
has	O
induced	O
a	O
modest	O
amelioration	O
of	O
some	O
of	O
the	O
histological	O
and	O
biochemical	O
indices	O
of	O
GM	Chemical
	O
nephrotoxicity	Disease
.	O
Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treatments	O
on	O
renal	O
functional	O
aspects	O
in	O
models	O
of	O
chronic	Disease
renal	Disease
failure	Disease

Visual	Disease
hallucinations	Disease
associated	O
with	O
zonisamide	Chemical
.	O
Zonisamide	Chemical
is	O
a	O
broad-spectrum	O
antiepileptic	O
drug	O
used	O
to	O
treat	O
various	O
types	O
of	O
seizures	Disease
.	O
Although	O
visual	Disease
hallucinations	Disease
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	O
visual	Disease
hallucinations	Disease
and	O
altered	O
mental	O
status	O
after	O
zonisamide	Chemical
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased.	O
All	O
three	O
had	O
been	O
diagnosed	O
earlier	O
with	O
epilepsy	Disease
,	O
and	O
their	O
electroencephalogram	O
(EEG)	O
findings	O
were	O
abnormal.	O
During	O
monitoring,	O
visual	Disease
hallucinations	Disease
did	O
not	O
correlate	O
with	O
EEG	O
readings,	O
nor	O
did	O
video	O
recording	O
capture	O
any	O
of	O
the	O
described	O
events.	O
None	O
of	O
the	O
patients	O
had	O
experienced	O
visual	Disease
hallucinations	Disease
before	O
this	O
event.	O
The	O
only	O
recent	O
change	O
in	O
their	O
treatment	O
was	O
the	O
introduction	O
or	O
increased	O
dosage	O
of	O
zonisamide	Chemical
.	O
With	O
either	O
discontinuation	O
or	O
decreased	O
dosage	O
of	O
the	O
drug	O
the	O
symptoms	O
disappeared	O
and	O
did	O
not	O
recur.	O
Further	O
observations	O
and	O
reports	O
will	O
help	O
clarify	O
this	O
adverse	O
effect.	O
Until	O
then,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	O
complication	O
associated	O
with	O
zonisamide	Chemical

GLEPP1	O
receptor	O
tyrosine	Chemical
phosphatase	O
(Ptpro)	O
in	O
rat	O
PAN	Chemical
	O
nephrosis	Disease
.	O
A	O
marker	O
of	O
acute	O
podocyte	O
injury.	O
Glomerular	O
epithelial	O
protein	O
1	O
(GLEPP1)	O
is	O
a	O
podocyte	O
receptor	O
membrane	O
protein	O
tyrosine	Chemical
phosphatase	O
located	O
on	O
the	O
apical	O
cell	O
membrane	O
of	O
visceral	O
glomerular	O
epithelial	O
cell	O
and	O
foot	O
processes.	O
This	O
receptor	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
structure	O
and	O
function	O
of	O
podocyte	O
foot	O
process.	O
To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
marker	O
of	O
glomerular	Disease
injury	Disease
,	O
the	O
amount	O
and	O
distribution	O
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat.	O
Puromycin	Chemical
aminonucleoside	Chemical
	O
nephrosis	Disease
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	O
of	O
puromycin	Chemical
aminonucleoside	Chemical
(	O
PAN	Chemical
,	O
20	O
mg/100g	O
BW).	O
Tissues	O
were	O
analyzed	O
at	O
0,	O
5,	O
7,	O
11,	O
21,	O
45,	O
80	O
and	O
126	O
days	O
after	O
PAN	Chemical
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	Disease
associated	O
with	O
foot	O
process	O
effacement	O
(days	O
5-11)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	Disease
associated	O
with	O
glomerulosclerosis	Disease
(days	O
45-126).	O
At	O
day	O
5,	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
reduced	O
from	O
the	O
normal	O
range	O
(265.2	O
+/-	O
79.6	O
x	O
10(6)	O
moles/glomerulus	O
and	O
100%)	O
to	O
15%	O
of	O
normal	O
(41.8	O
+/-	O
4.8	O
x	O
10(6)	O
moles/glomerulus,	O
p	O
<	O
0.005).	O
This	O
occurred	O
in	O
association	O
with	O
an	O
increase	O
in	O
urinary	O
protein	O
content	O
from	O
1.8	O
+/-	O
1	O
to	O
99.0	O
+/-	O
61	O
mg/day	O
(p	O
<	O
0.001).	O
In	O
contrast,	O
podocalyxin	O
did	O
not	O
change	O
significantly	O
at	O
this	O
time.	O
By	O
day	O
11,	O
GLEPP1	O
protein	O
and	O
mRNA	O
had	O
begun	O
to	O
return	O
towards	O
baseline.	O
By	O
day	O
45-126,	O
at	O
a	O
time	O
when	O
glomerular	O
scarring	O
was	O
present,	O
GLEPP1	O
was	O
absent	O
from	O
glomerulosclerotic	O
areas	O
although	O
the	O
total	O
glomerular	O
content	O
of	O
GLEPP1	O
was	O
not	O
different	O
from	O
normal.	O
We	O
conclude	O
that	O
GLEPP1	O
expression,	O
unlike	O
podocalyxin,	O
reflects	O
podocyte	O
injury	O
induced	O
by	O
PAN	Chemical

Ticlopidine	Chemical
-induced	O
aplastic	Disease
anemia	Disease
:	O
report	O
of	O
three	O
Chinese	O
patients	O
and	O
review	O
of	O
the	O
literature.	O
In	O
this	O
study,	O
three	O
Chinese	O
patients	O
with	O
ticlopidine	Chemical
-induced	O
aplastic	Disease
anemia	Disease
were	O
reported	O
and	O
another	O
13	O
patients	O
in	O
the	O
English	O
literature	O
were	O
reviewed.	O
We	O
attempted	O
to	O
find	O
underlying	O
similarities,	O
evaluate	O
the	O
risk	O
factors,	O
and	O
identify	O
appropriate	O
treatment	O
for	O
this	O
complication.	O
All	O
but	O
one	O
of	O
the	O
patients	O
were	O
over	O
60	O
years	O
old,	O
and	O
the	O
6	O
who	O
died	O
were	O
all	O
older	O
than	O
65.	O
Therefore,	O
old	O
age	O
may	O
be	O
a	O
risk	O
factor	O
for	O
developing	O
this	O
complication.	O
Agranulocytosis	Disease
occurred	O
3-20	O
weeks	O
after	O
initiation	O
of	O
ticlopidine	Chemical
,	O
so	O
frequent	O
examination	O
of	O
white	O
cell	O
count	O
during	O
treatment	O
is	O
recommended.	O
There	O
seemed	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
the	O
dose	O
or	O
duration	O
used	O
and	O
the	O
severity	O
of	O
bone	Disease
marrow	Disease
suppression	Disease
.	O
Treatment	O
for	O
ticlopidine	Chemical
-induced	O
aplastic	Disease
anemia	Disease
with	O
colony-stimulating	O
factors	O
seemed	O
to	O
have	O
little	O
effect.	O
The	O
fact	O
that	O
5	O
of	O
the	O
6	O
patients	O
who	O
received	O
concurrent	O
calcium	Chemical

Facilitation	O
of	O
memory	O
retrieval	O
by	O
pre-test	O
morphine	Chemical
and	O
its	O
state	O
dependency	O
in	O
the	O
step-through	O
type	O
passive	O
avoidance	O
learning	O
test	O
in	O
mice.	O
Amnesia	Disease
produced	O
by	O
scopolamine	Chemical
and	O
cycloheximide	Chemical
were	O
reversed	O
by	O
morphine	Chemical
given	O
30	O
min	O
before	O
the	O
test	O
trial	O
(pre-test),	O
and	O
pre-test	O
morphine	Chemical
also	O
facilitated	O
the	O
memory	O
retrieval	O
in	O
the	O
animals	O
administered	O
naloxone	Chemical
during	O
the	O
training	O
trial.	O
Similarly,	O
pre-test	O
scopolamine	Chemical
partially	O
reversed	O
the	O
scopolamine	Chemical
-induced	O
amnesia	Disease
,	O
but	O
not	O
significantly;	O
and	O
pre-test	O
cycloheximide	Chemical
failed	O
to	O
reverse	O
the	O
cycloheximide	Chemical
-induced	O
amnesia	Disease
.	O
These	O
results	O
suggest	O
that	O
the	O
facilitation	O
of	O
memory	O
retrieval	O
by	O
pre-test	O
morphine	Chemical
might	O
be	O
the	O
direct	O
action	O
of	O
morphine	Chemical

Test	O
conditions	O
influence	O
the	O
response	O
to	O
a	O
drug	O
challenge	O
in	O
rodents.	O
These	O
studies	O
were	O
conducted	O
to	O
examine	O
the	O
differential	O
response	O
to	O
a	O
drug	O
challenge	O
under	O
varied	O
experimental	O
test	O
conditions	O
routinely	O
employed	O
to	O
study	O
drug-induced	O
behavioral	O
and	O
neurophysiological	O
responses	O
in	O
rodents.	O
Apomorphine	Chemical
,	O
a	O
nonselective	O
dopamine	Chemical
agonist	Chemical
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects,	O
its	O
ability	O
to	O
induce	O
hypothermia	Disease
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	Chemical
turnover	O
in	O
the	O
rodent	O
brain.	O
From	O
such	O
experiments	O
there	O
is	O
evidence	O
that	O
characterization	O
and	O
detection	O
of	O
apomorphine	Chemical
-induced	O
activity	O
in	O
rodents	O
critically	O
depends	O
upon	O
the	O
test	O
conditions	O
employed.	O
In	O
rats,	O
detection	O
of	O
apomorphine	Chemical
-induced	O
hyperactivity	Disease
was	O
facilitated	O
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions.	O
Moreover,	O
test	O
conditions	O
can	O
impact	O
upon	O
other	O
physiological	O
responses	O
to	O
apomorphine	Chemical
such	O
as	O
drug-induced	O
hypothermia	Disease
.	O
In	O
mice,	O
apomorphine	Chemical
produced	O
qualitatively	O
different	O
responses	O
under	O
novel	O
conditions	O
when	O
compared	O
to	O
those	O
behaviors	O
elicited	O
in	O
the	O
home	O
test	O
cage.	O
Drug-induced	O
gross	O
activity	O
counts	O
were	O
increased	O
in	O
the	O
novel	O
exploratory	O
box	O
only,	O
while	O
measures	O
of	O
stereotypic	O
behavior	O
were	O
similar	O
in	O
both.	O
By	O
contrast,	O
apomorphine	Chemical
-induced	O
locomotion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
exploratory	O
box.	O
Dopamine	Chemical
turnover	O
ratios	O
(	O
DOPAC	Chemical
:	O
DA	Chemical
and	O
HVA	Chemical
:	O
DA	Chemical
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts.	O
However,	O
apomorphine	Chemical
-induced	O
reductions	O
in	O
striatal	O
dopamine	Chemical

